VOLUME 4.3 TABLE OF CONTENTS

Section 8: Clinical Data

Section			<u>Page</u>				
8.8	Integrated Summary of Efficacy and Safety and Risk to Benefit Assessment (continued)						
	9	List of Efficacy Tables Referred To But Not Included in Text	001				
		1 Summary of Patient Disposition by Randomized Group (Phase III)	002				
		2 Summary of Patient Disposition by Randomized Group					
		(Phase IIb)	003				
		3 Summary of Baseline Patient Characteristics (Phase III)	004				
		4 Summary of Baseline Patient Characteristics (Phase IIb)	005				
		5 Summary of History of Vitreous Hemorrhage (Study Eye)					
		(Phase III)	006				
		6 Summary of History of Vitreous Hemorrhage (Study Eye) (Phase IIb)	007				
		7 Proportion of Patients with Efficacy Outcome by Month 2 Based on Monthly Assessment (Phase III)	008				
		8 Endpoint Evaluation: Incidence of Hemorrhage Clearance					
		on or Prior to Week 8 (Phase IIb)	009				
		9 Summary of "Improvement" Rates in Hemorrhage Density from Baseline on or Prior to Month 2 (Study Eye (Phase III)	010				
		10 Cumulative Percentage of Reduction in Vitreous Hemorrhage Density (Phase III)	011				
		11 Life Table Analysis: Time to BCVA Improvement on or Prior to Month 3 (Phase III)	012				
		12 Cumulative Percentages of BCVA Improvement (Phase III)	013				
		13 Cumulative Percentages of BCVA Improvement (Phase III)	014				
		14 Cumulative Percentages of BCVA Improvement (Phase IIb)	015				
		15 Cumulative Percentages of BCVA Improvement, Read Letters As					
		Is (Phase III)	016				
	10	List of Safety Tables Referred To But Not Included in the Text	017				
		1 Enrollment Status	021				
		2 Summary of Enrollment Status and Completion Status by					
		Treatment	022				
		3 Summary of Extent of Exposure and Follow-up Duration	023				
		4 Summary of Demographics and Baseline Characteristics	027				
		5 Incidence of Serious Adverse Events by System Organ Class	031				
		6 Incidence of Serious Ocular Adverse Events Affecting the Eye by	050				
		System Organ Class	058				
		7 Incidence of Adverse Events by System Organ Class	064				

			Page
8.8		egrated Summary of Efficacy and Safety and Risk to Benefit	
	As	sessment (continued)	
	10	Safety Tables (continued)	
		8 Incidence of Related Adverse Events by System Organ Class	121
		9 Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class	125
		10 Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class	134
		11 Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class (by Time Period of Onset)	138
		12 Incidence of Related Ocular Adverse Events Affecting the	4 # 4
		Study Eye by System Organ Class (by Time Period of Onset)	151
		13 Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class (by Time Period When Event was Present)	161
		14 Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class (by Time Period When	174
		Event was Present)	174
		15 Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class (by Treatment and Severity)	184
		16 Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class (by Treatment and Severity)	201
		17 Incidence of Ocular Adverse Events Affecting the Study Eye	
		by System Organ Class (by Treatment and Sex)	213
		18 Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class (by Treatment and Sex)	218
			210
		19 Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class (by Treatment and Age)	222
		20 Incidence of Related Ocular Adverse Events Affecting the	
		Study Eye by System Organ Class (by Treatment and Age)	227
		21 Incidence of Ocular Adverse Events Affecting the Study Eye	
		by System Organ Class (by Treatment and Race)	231
		22 Incidence of Related Ocular Adverse Events Affecting the	
		Study Eye by System Organ Class (by Treatment and Race)	248
		23 Incidence of Ocular Adverse Events Affecting the Study Eye	
		by System Organ Class (by Treatment and Diabetic Status)	260
		24 Incidence of Related Ocular Adverse Events Affecting the Study	
		Eye by System Organ Class (by Treatment and Diabetic Status)	277
		25 Analysis of Selected Ocular Adverse Events Affecting the Study	
		Eye by System Organ Class	289
		26 Analysis of Related Selected Ocular Adverse Events Affecting the Study Eye by System Organ Class	290
		~	

8.8	Integrated Summary of Efficacy and Safety and Risk to Benefit	Page
	Assessment (continued)	
	10 Safety Tables (continued)	
	27 Duration of Selected Ocular Adverse Events Affecting the Study Eye by System Organ Class	291
	28 Duration of Related Selected Ocular Adverse Events Affecting the Study Eye by System Organ Class	301
	29 Duration of Selected Ocular Adverse Events Affecting the Study Eye that Required Medication	311
	30 Duration of Related Selected Ocular Adverse Events Affecting the Study Eye that Required Medication	315
	31 Incidence of Cataract Affecting the Study Eye	319
	32 Summary of Ocular Symptoms Post-Treatment	320
	33 Summary of Ocular Symptoms Maximum Severity Post-Treatment	324
	34 Summary of Ocular Symptoms Maximum Severity Post-Treatment, Stratified by Baseline Severity	325
	35 Summary of Ocular Symptoms Change from Baseline at Specified Visits	329
	36 Summary of Anterior Chamber Signs Post-Treatment	337
	37 Summary of Anterior Chamber Signs Maximum Severity Post-Treatment	341
	38 Summary of Anterior Chamber Signs Maximum Severity Post-Treatment Stratified by Baseline Severity	342
	39 Summary of Anterior Chamber Signs Change from Baseline at Specified Visits	344
	40 Summary of Minimum and Maximum Intraocular Pressure Post-Treatment	346
	41 Summary of Minimum and Maximum Intraocular Pressure Post-Treatment Change from Baseline	350
	42 Summary of Intraocular Pressure at Specified Visits	354
	43 Summary of Intraocular Pressure Change from Baseline at Specified Visits	355
	44 Summary of Intraocular Pressure at Specified Visits (Study V-01-VIT-08961X)	356
	45 Summary of Intraocular Pressure Change from Baseline at Specified Visits (Study V-01-VIT-08961X)	357
	46 Incidence of Deaths	358
	47 Incidence of Deaths by Treatment	359

9.0 EFFICACY TABLES REFERRED TO BUT NOT INCLUDED IN THE TEXT

Table No.	Title
1	Summary of Patient Disposition by Randomized Group Phase III: VIT-02-08961X and VIT-03-08961X All Patients
2	Summary of Patient Disposition by Randomized Group Phase IIb: ACS202-HYA-001A (US) and ACS203-HYA-001MEX All Patients
3	Summary of Baseline Patient Characteristics Phase III: VIT-02-08961X and VIT-03-08961X Intent-to-Treat Population
4	Summary of Baseline Patient Characteristics Phase IIb: ACS202-HYA-001A (US) and ACS203-HYA-001MEX All Patients
5	Summary of History of Vitreous Hemorrhage (Study Eye) Phase III: VIT-02-08961X and VIT-03-08961X Intent-to-Treat Population
6	Summary of History of Vitreous Hemorrhage (Study Eye) Phase IIb: ACS202-HYA-001A (US) and ACS203-HYA-001MEX All Patients
7	Proportion of Patients with Efficacy Outcome by Month 2 based on Monthly Assessment (1, 2, 3) Phase III: VIT-02-08961X and VIT-03-08961X Intent-to-Treat Population
8	Endpoint Evaluation: Incidence of Hemorrhage Clearance on or Prior to Week 8 Phase IIb: ACS202-HYA-001A (US) and ACS203-HYA-001MEX All Patients
9	Summary of 'Improvement' Rates in Hemorrhage Density from Baseline on or Prior to Month 2 (Study Eye) Phase III: VIT-02-08961X and VIT-03-08961X Intent-to-Treat Population
10	Cumulative Percentage of Reduction in Hemorrhage Density Phase III: VIT-02-08961X and VIT-03-08961X Intent-to-Treat Population
11	Life Table Analysis: Time to BCVA Improvement on or Prior to Month 3 Phase III: VIT-02-08961X and VIT-03-08961X Intent-to-Treat Population
12	Cumulative Percentages of BCVA Improvement Phase III: VIT-02-08961X and VIT-03-08961X Intent-to-Treat Population
13	Cumulative Percentages of BCVA Improvement Phase III: VIT-02-08961X and VIT-03-08961X Intent to Treat Population
14	Cumulative Percentages of BCVA Improvement Phase IIb: ACS202-HYA-001A (US) and ACS203-HYA-001MEX All Patients
15	Cumulative Percentages of BCVA Improvement - Read Letters As Is Phase III: VIT-02-08961X and VIT-03-08961X Intent-to-Treat Population

Table 1: Summary of Patient Disposition by Randomized Group (Phase III: VIT-02-08961X and VIT-03-08961X, All Patients)

Number of Patients:	Saline Control	55 IU Vitrase	75 IU Vitrase	Overall
RANDOMIZED	385	368	383	1136
SCREENED	383	365	377	1125
INTENT-TO-TREAT POPULATION	383	365	377 374	1125
RECEIVED STUDY INJECTION	378	359	3/4	1111
COMPLETED VISIT:				
1 DAY POST TREATMENT	373 (96.9%)	354 (96.2%)	369 (96.3%)	1096 (96.5%)
WEEK 1			359 (93.7%)	
MONTH 1		294 (79.9%)		942 (82.9%)
MONTH 2				979 (86.2%)
MONTH 3	348 (90.4%)	315 (85.6%) 320 (87.0%)	342 (89.3%)	1010 (88.9%)
MONTH 6	239 (62.1%)	239 (64.9%)	250 (65.3%)	728 (64.1%)
MONTH 12			148 (38.6%)	
		,		
REASON FOR DISCONTINUATION BEFORE 3 MONTHS				
PATIENT WITHDREW CONSENT	9 (2.3%)	7 (1.9%)	4 (1.0%) 3 (0.8%) 1 (0.3%)	20 (1.8%)
LOST TO FOLLOW-UP	0 (0.0%)	5 (1.4%)	3 (0.8%)	8 (0.7%)
NON-COMPLIANCE	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.1%)
·	0 (0.0%)			
DEATH			6 (1.6%)	
OTHER	3 (0.8%)	6 (1.6%)	2 (0.5%)	11 (1.0%)
REASON FOR DISCONTINUATION BEFORE 12 MONTHS				
PATIENT WITHDREW CONSENT	20 (5 2%)	12 (3 3%)	12 (3.1%)	44 (3.9%)
LOST TO FOLLOW-UP			14 (3.7%)	
NON-COMPLIANCE			2 (0.5%)	
(SERIOUS) ADVERSE EVENT	0 (0 0%)	2 (0.5%)	4 (1 0%)	6 (0.5%)
DEATH	14 (3.6%)	15 (4 1%)	19 (5 0%)	48 (4.2%)
OTHER	4 (1.0%)	7 (1.9%)	4 (1.0%) 19 (5.0%) 6 (1.6%)	17 (1.5%)
~	- (,	,	0 (2000,	_, ,,
REASON FOR DISCONTINUATION AFTER 12 MONTHS				
PATIENT WITHDREW CONSENT	3 (0.8%)			
LOST TO FOLLOW-UP	5 (1.3%)	3 (0.8%)	5 (1.3%)	13 (1.1%)
LOST TO FOLLOW-UP NON-COMPLIANCE (SERIOUS) ADVERSE EVENT	0 (0.0%)	1 (0.3%)	0 (0.0%) 1 (0.3%) 2 (0.5%)	1 (0.1%)
(SERIOUS) ADVERSE EVENT	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.1%)
DEATH	2 (0.5%)	2 (0.5%)	2 (0.5%)	6 (0.5%)
OTHER	0 (0.0%)	1 (0.3%)	4 (1.0%)	5 (0.4%)

Table 2: Summary of Patient Disposition by Randomized Group (Phase IIb: ACS202-HYA-001A (US) and ACS203-HYA-001MEX, All Patients)

Number of Patients:		37.5 IU Vitrase	75 IU Vitrase	Overall
SCREENED	129	124	125	378
RANDOMIZED	129	124	125	378
RECEIVED STUDY INJECTION	129	124	125	378
RECEIVED STUDY INSECTION	129	124	123	370
COMPLETED VISIT:				
1 DAY POST TREATMENT	129 (100.0%)	124 (100.0%)	125 (100.0%)	378 (100.0%)
WEEK 1 (DAY 7)	125 (96.9%)	118 (95.2%)	124 (99.2%)	367 (97.1%)
MONTH 1 (DAY 28)	82 (63.6%)	92 (74.2%)	93 (74.4%)	267 (70.6%)
MONTH 2 (DAY 56)	66 (51.2%)	68 (54.8%)	54 (43.2%)	188 (49.7%)
FOLLOW-UP MONTH 3	13 (10.1%)	17 (13.7%)	17 (13.6%)	47 (12.4%)
FOLLOW-UP MONTH 6	11 (8.5%)	8 (6.5%)	10 (8.0%)	29 (7.7%)
FOLLOW-UP 1 YEAR	52 (40.3%)	53 (42.7%)	61 (48.8%)	166 (43.9%)
REASON FOR DISCONTINUATION				
ADVERSE EXPERIENCE	1 (0.8%)	2 (1.6%)	1 (0.8%)	4 (1.1%)
SUBJECT'S REQUEST TO END PARTICIPATION	0 (0.0%)	2 (1.6%)	0 (0.0%)	2 (0.5%)
NONCOMPLIANCE	4 (3.1%)	5 (4.0%)	2 (1.6%)	11 (2.9%)
LOST TO FOLLOW-UP	5 (3.9%)	3 (2.4%)	5 (4.0%)	13 (3.4%)
OTHER	2 (1.6%)	4 (3.2%)	1 (0.8%)	7 (1.9%)

Table 3: Summary of Baseline Patient Characteristics (Phase III: VIT-02-08961X and VIT-03-08961X, Intent-to-Treat Population)

Variable		Saline Control		75 IU Vitrase	Overall
GENDER	MALE	185 (48.3%) 198 (51.7%)	185 (50.7%)	211 (56.0%) 165 (43.8%)	
AGE (YRS)	31-50	4 (1.0%) 51 (13.3%) 230 (60.1%) 95 (24.8%)	58 (15.9%) 211 (57.8%)	214 (56.8%)	164 (14.6%) 655 (58.2%)
	SD	26 - 93	12.2	12.5 23 - 91	12.4
ETHNICITY	CAUCASIAN BLACK ASIAN OTHER	78 (20.4%)	15 (4.1%)	10 (2.7%) 79 (21.0%)	39 (3.5%)
DIABETIC STATUS	DIABETIC		263 (72.1%) 161 (44.1%)	77 (20.4%) 300 (79.6%) 178 (47.2%) 122 (32.4%)	858 (76.3%) 510 (45.3%)

Note: Patients 168-4629 (Vit-02, Saline Control), 334-6502 (Vit-03, Saline Control), 348-6540 (Vit-03, Saline Control), and 351-8117 (Vit-03,55 IU Vitrase) had calculated ages resolving to zero due to incorrect birth years recorded on the Demographics Case Report Form. Patient 146-3559 (Vit-02, 55 IU Vitrase) has no birth date value. These observations are not in the age calculations. Misrandomized Patient 146-3559 (Vit-02, 55 IU Vitrase) has no ethnicity value.

⁽a) Cochran-Mantel-Haenszel ('row mean scores differ') test, stratified by study

⁽b) two-way ANOVA (effects for study and treatment)

⁽c) Cochran-Mantel-Haenszel ('general association') test, stratified by study

⁽d) Cochran-Mantel-Haenszel ('general association') test, stratified by study (non-diabetic vs. Type I vs. Type II)

Table 4: Summary of Baseline Patient Characteristics (Phase IIb: ACS202-HYA-001A (US) and ACS203-HYA-001MEX, All Patients)

Variable	Value	7.5 IU Vitrase	37.5 IU Vitrase	75 IU Vitrase	Overall
GENDER	MALE FEMALE	70 (54.3%)	59 (47.6%) 65 (52.4%) 0.9488 (a)	66 (52.8%)	
AGE (YRS)	18-30 31-50 51-70 >70	22 (17.1%) 83 (64.3%)	0 (0.0%) 19 (15.3%) 87 (70.2%) 18 (14.5%)	23 (18.4%) 83 (66.4%)	64 (16.9%) 253 (66.9%)
	Mean (N) SD Min-Max	11.8 29 - 83	59.6 (124) 9.9 36 - 88 0.9591 (b)	11.2 27 - 89	11.0
ETHNICITY	CAUCASIAN BLACK ASIAN OTHER	10 (7.8%) 2 (1.6%) 85 (65.9%)	25 (20.2%) 7 (5.6%) 0 (0.0%) 92 (74.2%)	11 (8.8%) 1 (0.8%) 84 (67.2%)	28 (7.4%) 3 (0.8%)
DIABETIC STATUS	NON-DIABETIC DIABETIC	113 (87.6%)	19 (15.3%) 105 (84.7%) 0.4754 (a)	112 (89.6%)	

005

NOTE: MEX patient 1-117 (7.5 IU VITRASE) had 'Unknown' check for Diabetes at baseline and therefore excluded from the calculations under 'Diabetic Status'.

(a) Cochran-Mantel-Haenszel ('row mean scores differ') test, stratified by study

⁽b) two-way ANOVA (effects for study and treatment)

⁽c) Cochran-Mantel-Haenszel ('general association') test, stratified by study

Table 5: Summary of History of Vitreous Hemorrhage (Study Eye) (Phase III: VIT-02-08961X and VIT-03-08961X, Intent-to-Treat Population)

Measurement			55 IU Vitrase	75 IU Vitrase	Overall
	NUMBER OF PATIENTS	383	365	377	1125
VITREOUS HEMORRHAGE					
PROBABLE CAUSE	PROLIFERATIVE DIABETIC RETINOPATHY	278 (72.6%)	250 (68.5%)	281 (74.5%)	809 (71.9%)
	CENTRAL RETINAL VEIN OCCLUSION	20 (5.2%)	17 (4.7%)	17 (4.5%)	54 (4.8%)
	BRANCH RETINAL VEIN OCCLUSION EXUDATIVE MACULAR	18 (4.7%)	25 (6.8%)	10 (2.7%)	53 (4.7%)
	EXUDATIVE MACULAR DEGENERATION WITH CHOROIDAL NEOVASCULAR MEMBRANE	20 (5.2%)	14 (3.8%)	15 (4.0%)	49 (4.4%)
	MACROANEURYSM	1 (0.3%)	2 (0.5%)	1 (0.3%)	4 (0.4%)
	MACROANEURYSM HEMORRHAGIC POSTERIOR VITREOUS DETACHMENT				
	OTHER	6 (1.6%)	10 (2.7%)	11 (2.9%)	27 (2.4%)
	missing or NA		36 (9.9%) -Value = 0.3817	34 (9.0%) (a)	104 (9.2%)
DURATION (DAYS) AT ENTRY	<= 28	2 (0.5%)	0 (0.0%)	2 (0.5%)	4 (0.4%)
	29 - 90	195 (50.9%)	193 (52.9%)	182 (48.3%)	570 (50.7%)
				187 (49.6%)	
	missing or NA	7 (1.8%)	4 (1.1%)	6 (1.6%)	17 (1.5%)
	Mean (N)			124.3 (371)	
	SD Min-Max			112.4 6 - 997	
	Min-Max		-Value = 0.6650		6 ~ 1383
		р	-varue = 0.0050	(1)	

⁽a) Cochran-Mantel-Haenszel('general association') test, stratified by study(excluding 'missing or NA')
(b) two-way ANOVA(effects for study and treatment)
s:\dat\acs\nda2002\sas\programs\t_hemhist3 26SEP2002 11:00

Measurement		7.5 IU Vitrase	37.5 IU Vitrase	75 IU Vitrase	Overall
	NUMBER OF PATIENTS	129	124	125	378
VITREOUS HEMORRHAGE					
PROBABLE CAUSE	DIABETIC RETINOPATHY OTHER ETIOLOGY both YES (a) missing or NA (b)	17 (13.2%) 1 (0.8%) 0 (0.0%)	106 (85.5%) 15 (12.1%) 0 (0.0%) 3 (2.4%) p-Value = 0.5877 (11 (8.8%) 2 (1.6%) 4 (3.2%)	3 (0.8%)
DURATION (MONTHS) AT ENTRY	< 1 1 - 3 > 3 missing or NA			66 (52.8%) 59 (47.2%)	213 (56.3%) 165 (43.7%)
	Mean (N) SD Min-Max	3.3 1 - 25	3.9 (124) 3.4 1 - 24 p-Value = 0.7732 (3.5 I - 24	3.4

⁽a) US Patients 19-13 (7.5 IU VITRASE), 11-1 (75 IU VITRASE) and 19-1 (75 IU VITRASE)

⁽b) MEX Patients 1-65 (37.5 IU VITRASE), 2-35 (37.5 IU VITRASE), 1-75 (75 IU VITRASE), 2-87 (75 IU VITRASE), 2-99 (75 IU VITRASE), 2-102 (75 IU VITRASE), and US Patient 26-2 (37.5 IU VITRASE)

⁽c) Cochran-Mantel-Haenszel('row mean scores differ') test, stratified by study (excluding 'both YES' and 'missing or NA')

⁽d) two-way ANOVA (effects for study and treatment)

s:\dat\acs\nda2002\sas\programs\t_hemhist2 26SEP2002 13:56

Table 7: Proportion of Patients with Efficacy Outcome by Month 2 based on Monthly Assessment (1, 2, 3)
(Phase III: VIT-02-08961X and VIT-03-08961X, Intent-to-Treat Population)

	Saline Control	55 IU Vitrase	75 IU Vitrase
NUMBER OF PATIENTS	383	365	377
NO. (%) OF PATIENTS WITH OUTCOME OF EFFICACY 'SUCCESS'	106 (27.7%)	143 (39.2%)	144 (38.2%)
p-Values FOR PAIRWISE COMPARISONS WITH SALINE (a)		0.0008	0.0023
Homogeneity p-value (b)		0.9443	0.7398
NO. (%) OF PATIENTS WITH OUTCOME OF EFFICACY 'FAILURE'	277 (72.3%)	222 (60.8%)	233 (61.8%)
p-Values FOR PAIRWISE COMPARISONS WITH SALINE (c)		0.0008	0.0023
Homogeneity p-value (b)		0.9443	0.7398

008

^{&#}x27;Success' indicates investigator marked box 1, 2, or 3 on the efficacy CRF page at any visit on or prior to 2 months post-treatment. A patient that does not meet this criteria is considered an efficacy 'Failure'.

Pairwise comparison p-Values are based on the Cochran-Mantel-Haenszel (CMH) test, stratified by study (active dose vs. saline control) with no multiplicity adjustments.

⁽a) Cochran-Mantel-Haenszel test on the binary outcome of 'efficacy success' or 'non-success'. 'Non-success' includes 'treatment failure' and 'indeterminate'

⁽b) Breslow-Day test of homogeneity across studies

⁽c) Cochran-Mantel-Haenszel test on the binary outcome of 'efficacy failure' or 'non-failure'. 'Non-failure' includes 'treatment success' and 'indeterminate'

s:\dat\acs\nda2002\sas\programs\t_outcome1233 26SEP2002 11:01

Table 8: Endpoint Evaluation: Incidence of Hemorrhage Clearance on or Prior to Week 8 (Phase IIb: ACS202-HYA-001A (US) and ACS203-HYA-001MEX, All Patients)

Posttreatment Visit	7.5 IU Vitrase	37.5 IU Vitrase	75 IU Vitrase
ALL PATIENTS	***	124	125
NUMBER OF PATIENTS NO. (%) OF PATIENTS WITH OUTCOME OF EFFICACY 'SUCCESS'		124 49 (39.5%) p-Value = 0.0465 (a)	69 (55.2%)
PATIENTS WITH MILD OR MODERATE HEMORRHAGE NUMBER OF PATIENTS	34	25	26
NO. (%) OF PATIENTS WITH OUTCOME OF EFFICACY 'SUCCESS'	25 (73.5%)	15 (60.0%) p-Value = 0.2712 (a)	14 (53.8%)
PATIENTS WITH SEVERE HEMORRHAGE NUMBER OF PATIENTS	95	99	99
NO. (%) OF PATIENTS WITH OUTCOME OF EFFICACY 'SUCCESS'	35 (36.8%)	34 (34.3%) p-Value = 0.0051 (a)	

⁰⁰⁹

^{&#}x27;Success' indicates investigator marked box 1 on the Study Exit CRF page on or prior to 8 weeks post-treatment. A patient that does not meet this criteria is considered an efficacy 'Failure'.

⁽a) Cochran-Mantel-Haenszel ('row mean scores differ') test on the binary outcome of efficacy 'success' or 'failure', stratified by study.

Table 9: Summary of 'Improvement' Rates in Hemorrhage Density from Baseline on or Prior to Month 2 (Study Eye) (Phase III: VIT-02-08961X and VIT-03-08961X, Intent-to-Treat Population)

Hemorrhage Density on or Prior to Month 2	Saline Control	55 IU Vitrase	75 IU Vitrase	p-Value
NUMBER OF PATIENTS	383	365	377	
"MARKED IMPROVEMENT"				
NO. OF CLOCK HOURS WITH GRADE 0 OR 1:				
YES >= 6	80 (20.9%)	119 (32.6%)	114 (30.2%)	0.0007
NO < 6	297 (77.5%)	240 (65.8%)	260 (69.0%)	
"IMPROVEMENT"				
NO. OF CLOCK HOURS WITH GRADE 0, 1, OR 2:				
YES >= 6	137 (35.8%)	176 (48.2%)	169 (44.8%)	0.0016
NO < 6	240 (62.7%)	183 (50.1%)	205 (54.4%)	

Table 10: Cumulative Percentage of Reduction in Vitreous Hemorrhage Density (Phase III: VIT-02-08961X and VIT-03-08961X, Intent-to-Treat Population)

Posttreatment Visit		Saline Control	55 IU Vitrase	75 IU Vitrase
	NUMBER OF PATIENTS	383	365	377
	NOMBER OF FAITENTS	303	303	7,,
MONTH 1	NO. (%) OF PATIENTS WITH HEMORRHAGE DENSITY IMPROVEMENT	42 (11.0%)	74 (20.3%)	72 (19.1%)
	p-Value(a)		0.0004	0.0019
	Homogeneity p-Value(b)		0.9213	0.1274
MONTH 2	NO. (%) OF PATIENTS WITH HEMORRHAGE DENSITY IMPROVEMENT	82 (21.4%)	120 (32.9%)	114 (30.2%)
	p-Value(a)		0.0004	0.0061
	Homogeneity p-Value(b)		0.9461	0.2935
MONTH 3	NO. (%) OF PATIENTS WITH HEMORRHAGE DENSITY IMPROVEMENT	109 (28.5%)	141 (38.6%)	144 (38.2%)
	p-Value(a)		0.0030	0.0049
	Homogeneity p-Value(b)		0.6677	0.7883

Reduction of Hemorrhage Density is defined as at least 6 clock hours with density grades 0-1 (or at least 3 hours with grades 0-1 for patients that have BRVO recorded as causative condition for study hemorrhage) at a given posttreatment visit (prior to vitrectomy or recurrent vitreous hemorrhage).

(a) Cochran-Mantel-Haenszel test, stratified by study (active dose vs. saline control) with no multiplicity adjustments

(b) Breslow-Day test of homogeneity across studies

s:\dat\acs\nda2002\sas\programs\t hemclr cumu3 26SEP2002 11:01

Page 1 of 1

ISTA Integrated Summary of Efficacy

Table 11: Life Table Analysis: Time to BCVA Improvement (a) on or Prior to Month 3 (Phase III: VIT-02-08961X and VIT-03-08961X, Intent-to-Treat Population)

	Saline Control	55 IU Vitrase	75 IU Vitrase
NUMBER OF PATIENTS	383	365	377
SURVIVAL FUNCTION FOR TIME TO BCVA IMPROVEMENT			
ON OR PRIOR TO MONTH 3 (b)	r	o-Value = 0.0167	(c)

710

Note: Survival Function is defined as the probability that a patient improves prior to the given time point

- (a) Time to BCVA Improvement is defined as first evidence of post-Vitrase BCVA improvement from baseline of at least 0.3 LogMAR
- (b) Patients that do not show BCVA improvement are censored at the days to first Vitrectomy surgery or Recurrent Vitreous Hemorrhage. Patients that do not show BCVA improvement with no Vitrectomy or Recurrent Hemorrhage are censored at 123 days (92 days +/- 31 days) for the Month 3 analysis.
- (c) p-Value for time to BCVA Improvement is based on log rank test stratified by study
- s:\dat\acs\nda2002\sas\programs\t_bcva_life3 26SEP2002 11:02

Table 12: Cumulative Percentages of BCVA Improvement (a) (Phase III: VIT-02-08961X and VIT-03-08961X, Intent-to-Treat Population)

Posttreatment Visit		Saline Control	55 IU Vitrase	75 IU Vitrase
	NUMBER OF PATIENTS	383	365	377
MONTH 1	NO. (%) OF PATIENTS WITH BCVA	77 (20.1%)	112 (30.7%)	105 (27.9%)
	IMPROVEMEN I		p-value=0.0029 (b)	
MONTH 2	NO. (%) OF PATIENTS WITH BCVA	105 (27.4%)	150 (41.1%)	144 (38.2%)
	IMPROVEMENT		p-value=0.0002 (b)	
MONTH 3	NO. (%) OF PATIENTS WITH BCVA	132 (34.5%)	164 (44.9%)	164 (43.5%)
	THE NO VERIDIA I		p-value=0.0065 (b)	

013

Note: Cell entries represent the number (%) of patients achieving BCVA improvement on or before the indicated visit

(a) BCVA Improvement is defined as first evidence of post-Vitrase BCVA improvement at Months 1, 2, and 3 from baseline of at least 0.3 LogMAR (prior to vitrectomy or recurrent vitreous hemorrhage). Count fingers to any letters read is one line improvement, to 20/800 is a second line of improvement.

(b) Cochran-Mantel-Haenszel('row mean scores differ') test, stratified by study

Table 13: Cumulative Percentages of BCVA Improvement (a) (Phase III: VIT-02-08961X and VIT-03-08961X, Intent-to-Treat Population)

Posttreatment Visit		Saline Control	55 IU Vitrase	75 IU Vitrase
	NUMBER OF PATIENTS	383	365	377
MONTH 1	NO. (%) OF PATIENTS WITH BCVA IMPROVEMENT	77 (20.1%)	112 (30.7%)	105 (27.9%)
	p-Value (b)	- -	0.0009	0.0127
	Homogeneity p-Value (c)		0.8642	0.0445
MONTH 2	NO. (%) OF PATIENTS WITH BCVA IMPROVEMENT	105 (27.4%)	150 (41.1%)	144 (38 2%)
	p-Value (b)		0.0001	0.0016
	Homogeneity p-Value (c)		0.8452	0.3883
MONTH 3	NO. (%) OF PATIENTS WITH BCVA IMPROVEMENT	132 (34.5%)	164 (44.9%)	164 (43.5%)
	p-Value (b)		0.0035	0.0113
	Homogeneity p-Value (c)		0.3720	0.9515

Note: Cell entries represent the number (%) of patients achieving BCVA improvement on or before the indicated visit

(a) BCVA Improvement is defined as first evidence of post-Vitrase BCVA improvement at Months 1, 2, and 3 from baseline of at least 0.3 LogMAR (prior to vitrectomy or recurrent vitreous hemorrhage). Count fingers to any letters read is one line improvement, to 20/800 is a second line of improvement.

(b) Cochran-Mantel-Haenszel test, stratified by study (active dose vs. saline control) with no multiplicity adjustments

⁽c) Breslow-Day test of homogeneity across studies

Table 14: Cumulative Percentages of BCVA Improvement (a) (Phase IIb: ACS202-HYA-001A (US) and ACS203-HYA-001MEX, All Patients)

Posttreatment Visit	•	7.5 IU Vitrase	37.5 IU Vitrase	75 IU Vitrase
	NUMBER OF PATIENTS	129	124	125
MONTH 1 (DAY 28)	NO. (%) OF PATIENTS WITH BCVA IMPROVEMENT	40 (31.0%)	30 (24.2%)	29 (23.2%)
			p-Value = 0.3106 (b)	
MONTH 2 (DAY 56)	NO. (%) OF PATIENTS WITH BCVA IMPROVEMENT	49 (38.0%)	38 (30.6%)	36 (28.8%)
	district Andrew Transportation		p-Value = 0.2600 (b)	

013

Note: Cell entries represent the number (%) of patients achieving BCVA improvement on or before the indicated visit
(a) Time to BCVA Improvement is defined as first evidence of post-Vitrase BCVA improvement from baseline of at least 0.3 LogMAR (prior to vitrectomy).
Count fingers to any letters read is one line improvement, to 20/800 is a second line of improvement.
(b) Cochran-Mantel-Haenszel('row mean scores differ') test, stratified by study

Table 15: Cumulative Percentages of BCVA Improvement (a)
Read Letters As Is
(Phase III: VIT-02-08961X and VIT-03-08961X, Intent-to-Treat Population)

Posttreatment Visit		Saline Control	55 IU Vitrase	75 IU Vitrase
	NUMBER OF PATIENTS	383	365	377
MONTH 1	NO. (%) OF PATIENTS WITH BCVA	78 (20.4%)	112 (30.7%)	105 (27.9%)
	p-Value (b)		0.0013	0.0163
	Homogeneity p-Value (c)		0.9455	0.0557
MONTH 2	NO. (%) OF PATIENTS WITH BCVA IMPROVEMENT	106 (27.7%)	150 (41.1%)	144 (38.2%)
	p-Value (b)		0.0001	0.0021
	Homogeneity \hat{p} -Value (c)		0.7792	0.4358
MONTH 3	NO. (%) OF PATIENTS WITH BCVA IMPROVEMENT	131 (34.2%)	164 (44.9%)	164 (43.5%)
	p-Value (b)		0.0027	0.0091
	Homogeneity p-Value (c)		0.4137	0.9887

016

Note: Cell entries represent the number (%) of patients achieving BCVA improvement on or before the indicated visit
(a) Time to BCVA Improvement is defined as first evidence of post-Vitrase BCVA improvement from baseline of at least 0.3 LogMAR (prior to vitrectomy or recurrent vitreous hemorrhage). When determining improvement, LogMAR records worse than 1.6 (20/800) are left as is.

⁽b) Cochran-Mantel-Haenszel test, stratified by study (active dose vs. saline control) with no multiplicity adjustments

⁽c) Breslow-Day test of homogeneity across studies

s:\dat\acs\nda2002\sas\programs\t bcva_cumu3_asis 26SEP2002 11:03

10.0 SAFETY TABLES REFERRED TO BUT NOT INCLUDED IN THE TEXT

Table No.	Title
1	Enrollment Status All Studies
2	Summary of Enrollment Status and Completion Status by Treatment All Studies
3.1	Summary of Extent of Exposure and Follow-up Duration All Studies by Treatment
3.2	Summary of Extent of Exposure and Follow-up Duration All Studies by Study for Vitrase Groups Only
3.3	Summary of Extent of Exposure and Follow-up Duration Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
3.4	Summary of Extent of Exposure and Follow-up Duration PVD Study (PVD-01-08961x) by Treatment
4.1	Summary of Demographics and Baseline Characteristics All Studies by Treatment
4.2	Summary of Demographics and Baseline Characteristics All Studies by Study for Vitrase Groups Only
4.3	Summary of Demographics and Baseline Characteristics Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
4.4	Summary of Demographics and Baseline Characteristics PVD Study (PVD-01-08961X) by Treatment
5.1	Incidence of Serious Adverse Events by System Organ Class All Studies by Treatment
5.2	Incidence of Serious Adverse Events by System Organ Class All Studies by Study for Vitrase Groups Only
5.3	Incidence of Serious Adverse Events by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
5.4	Incidence of Serious Adverse Events by System Organ Class PVD Study (PVD-01-08961X) by Treatment
6	Incidence of Serious Ocular Adverse Events Affecting the Study Eye by System Organ Class – Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period of Onset
7.1	Incidence of Adverse Events by System Organ Class All Studies by Treatment
7.2	Incidence of Adverse Events by System Organ Class All Studies by Study for Vitrase Groups Only
7.3	Incidence of Adverse Events by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
7.4	Incidence of Adverse Events by System Organ Class PVD Study (PVD-01-08961X) by Treatment
8	Incidence of Related Adverse Events by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment

Table No.	Title
9	Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class – Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
9.a	Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class for Saline and 55 IU and 75 IU Vitrase Combined – Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
10	Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class – Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
11	Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class – Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period of Onset
12	Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class – Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period of Onset
13	Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class – Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period During Which Event was Present
14	Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class – Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period During Which Event was Present
15	Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class – Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Severity
16	Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class – Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Severity
17	Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class – Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Sex
18	Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class – Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Sex
19	Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class - Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Age
20	Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class – Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Age
21	Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class – Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Race
22	Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class – Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Race
23	Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class – Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Diabetic Status
24	Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class – Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Diabetic Status
25	Analysis of Selected Ocular Adverse Events Affecting the Study Eye by System Organ Class – Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
26	Analysis of Related Selected Ocular Adverse Events Affecting the Study Eye by System Organ Class – Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment

Table No.	Title
27	Duration of Selected Ocular Adverse Events Affecting the Study Eye – Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
28	Duration of Related Selected Ocular Adverse Events Affecting the Study Eye Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
29	Duration of Selected Ocular Adverse Events Affecting the Study Eye that Required Medication – Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
30	Duration of Related Selected Ocular Adverse Events Affecting the Study Eye that Required Medication – Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
31	Incidence of Cataract Affecting the Study Eye – Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period of Onset
32.1	Summary of Ocular Symptoms Post-Treatment All Studies by Treatment
32.2	Summary of Ocular Symptoms Post-Treatment All Studies by Study for Vitrase Groups Only
32.3	Summary of Ocular Symptoms Post-Treatment – Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
32.4	Summary of Ocular Symptoms Post-Treatment PVD Study (PVD-01-08961X) by Treatment
33	Summary of Ocular Symptoms Maximum Severity Post-Treatment Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
34	Summary of Ocular Symptoms Maximum Severity Post-Treatment, Stratified by Baseline Severity – Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
35	Summary of Ocular Symptoms Change from Baseline at Specified Visits Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
36.1	Summary of Anterior Chamber Signs Post-Treatment All Studies by Treatment
36.2	Summary of Anterior Chamber Signs Post-Treatment All Studies by Study for Vitrase Groups Only
36.3	Summary of Anterior Chamber Signs Post-Treatment Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
36.4	Summary of Anterior Chamber Signs Post-Treatment PVD Study (PVD-01-08961X) by Treatment
37	Summary of Anterior Chamber Signs Maximum Severity Post-Treatment Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
38	Summary of Anterior Chamber Signs Maximum Severity Post-Treatment Stratified by Baseline Severity – Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
39	Summary of Anterior Chamber Signs Change from Baseline at Specified Visits – Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
40.1	Summary of Minimum and Maximum Intraocular Pressure Post-Treatment All Studies by Treatment
40.2	Summary of Minimum and Maximum Intraocular Pressure Post-Treatment All Studies by Study for Vitrase Groups Only
40.3	Summary of Minimum and Maximum Intraocular Pressure Post-Treatment Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
40.4	Summary of Minimum and Maximum Intraocular Pressure Post-Treatment PVD Study (PVD-01-08961X) by Treatment

Table No.	Title
41.1	Summary of Minimum and Maximum Intraocular Pressure Post-Treatment Change from Baseline – All Studies by Treatment
41.2	Summary of Minimum and Maximum Intraocular Pressure Post-Treatment Change from Baseline – All Studies by Study for Vitrase Groups Only
41.3	Summary of Minimum and Maximum Intraocular Pressure Post-Treatment Change from Baseline – Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
41.4	Summary of Minimum and Maximum Intraocular Pressure Post-Treatment Change from Baseline – All Studies by Treatment
42	Summary of Intraocular Pressure at Specified Visits Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
43	Summary of Intraocular Pressure Change from baseline at Specified Visits Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
44	Summary of Intraocular Pressure at Specified Visits - Study V-01-VIT-08961X by Treatment
45	Summary of Intraocular Pressure Change from Baseline at Specified Visits Study V-01-VIT-08961X by Treatment
46	Incidence of Deaths All Studies
47	Incidence of Deaths by Treatment Primary Phase III Studies: VIT-02-08961X and VIT-03-08961X

Table 1 Enrollment Status All Studies

Study	Indication	Treatment Regimen	ITT [1]	Safety [2]
ACS201-HYA-001A	CLEARANCE OF VITREOUS HEMORRHAGE	SALINE, VITRASE: 37.5 IU, 75 IU	14	14
ACS201-HYA-002A	CLEARANCE OF VITREOUS HEMORRHAGE	SALINE, 75 IU VITRASE	28	28
PROBE STUDY	CLEARANCE OF VITREOUS HEMORRHAGE	75 IU VITRASE	34	34
V-01-VIT-08961X	CLEARANCE OF VITREOUS HEMORRHAGE	SALINE, 75 IU VITRASE	61	61
ACS202-HYA-001US	CLEARANCE OF VITREOUS HEMORRHAGE	VITRASE: 7.5 IU, 37.5 IU, 75 IU	153	153
ACS203-HYA-001MEX	CLEARANCE OF VITREOUS HEMORRHAGE	VITRASE: 7.5 IU, 37.5 IU, 75 IU	225	225
VIT-02-08961X (WW)	CLEARANCE OF VITREOUS HEMORRHAGE	CONTROL, VITRASE: 7.5 IU, 55 IU, 75 IU	71	71
VIT-02-08961X	CLEARANCE OF VITREOUS HEMORRHAGE	SALINE, VITRASE: 7.5 IU, 55 IU, 75 IU	750	740
VIT-03-08961X	CLEARANCE OF VITREOUS HEMORRHAGE	SALINE, VITRASE: 55 IU, 75 IU	556	551
PVD-01-08961X	INDUCING POSTERIOR VITREOUS DETACHMENT	SALINE, 75 IU VITRASE, SF6, 75 IU VITRASE + SF6	60	60
COR-01-08961X	CORRECTION OF MYOPIA	50 IU VITRASE + ACS-101C, 500 IU VITRASE + ACS-101C, ACS-101C	41	41
COP-01-08961X	CLEARANCE OF CORNEAL OPACITIES	SALINE, VITRASE: 50 IU, 100 IU, 200 IU, 400 IU, 500 IU	30	30

120

^[1] For studies VIT-02-08961X and VIT-03-08961X, the Intent-to-Treat Population consists of all patients randomized to receive treatment and have a screening visit. For all other studies, Intent-to-Treat population consists of all patients randomized to receive treatment with any available data in the individual databases.

^[2] Safety population consists of all patients randomized to receive treatment and had at least one post-treatment assessment.

		Hemorrhage Clearance Studies								Other Indications		
	Con	trol			Vitrase							
	ww	Saline [4]	7.5 IU	37.5 IU	55 IU	75 IU [5]	Total Vitrase	Vitrase 50-500 IU	Saline Control	Other Active [1]		
TOTAL ITT POPULATION	18	422	328	130	383	612	1453	84	21	70		
TOTAL SAFETY POPULATION	18	417	327	130	377	609	1443	84	21	70		
NUMBER COMPLETED [2]	5 (27.8%)	59 (14.1%)	153 (46.8%)	114 (87.7%)	34 (9.0%)	193 (31.7%)	494 (34.2%)	75 (89.3%)	20 (95.2%)	56 (80.0%)		
NUMBER DISCONTINUED DUE TO ADVERSE EVENT [3]	0 (0.0%)	1 (0.2%)	3 (0.9%)	2 (1.5%)	2 (0.5%)	8 (1.3%)	15 (1.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
NUMBER DISCONTINUED DUE TO DEATH	6 (33.3%)	17 (4.1%)	8 (2.4%)	0 (0.0%)	17 (4.5%)	23 (3.8%)	48 (3.3%)	0 (0.0%)	1 (4.8%)	0 (0.0%)		

720

Percents are based on the number of patients in the Safety Population.

Note: One patient in the study ACS201-HYA-002A received byth 75 IU Vitrase and Saline. This patient is included in both groups here. Twelve Patients in the "Probe Study" received two injections of 75 IU Vitrase. These patients are only counted once here.

- [1] Other Active treatments include SF6 (PVD-01-08961X) and ACS-101C (COR-01-08961X). 44 patients who received both Vitrase and another active study treatment are included in both groups.
- [2] Studies ACS201-HYA-002A and the Probe Study did not have a termination page or sufficient visit information to determine whether a patient completed the study. Patients in study ACS-201-HYA-001A where considered to have completed the study if they completed the Day 56 Visit.
- [3] Patients in studies VIT-02-08961X and VIT-03-08961X were only considered discontinued if due to a Serious Adverse Event.
- [4] Patient 01-024 (Study V-01-VIT-08961X, Saline Control) did not have a reason for discontinuation recorded. However, this patient was noted as dying 284 days post-treatment (See Listing of Deaths).
- [5] Patient 149-3702 (Study VIT-02-08961X , 75.0 IU Vitrase) died 450 days after discontinuing due to Lost to Follow-up. This patient is not included here.

Table 3.1 Summary of Extent of Exposure and Follow-up Duration All Studies by Treatment Safety Population

			Hemorrh		Ot	her Indicatio	ns			
	Con	trol			Vitrase	,				
	ww	Saline	7.5 IU	37.5 IU	55 IU	75 IU [2]	Total Vitrase	Vitrase 50-500 IU	Saline Control	Other Active [3]
NUMBER OF PATIENTS RECEIVING TREATMENT	0	417	327	130	377	609	1443	84	21	70
DURATION OF FOLLOW-UP (DAYS) [1] n Mean (SD) Median Range	18 469.6 (259) 373.0 34 - 966	417 312.0 (193) 346.0 5 - 784	327 361.3 (255) 364.0 1 - 964	130 380.3 (288) 455.5 2 - 811	377 327.4 (215) 352.0 7 - 972	605 316.7 (227) 343.0 6 - 1412	1439 335.4 (238) 358.0 1 - 1412	84 286.5 (134) 243.0 21 - 511	21 386.3 (147) 483.0 81 - 511	70 294.7 (138) 252.5 0 - 511
NUMBER AND PERCENT OF						(To (00 00)		<i>5</i> 2 (0 2 -0)
MONTH 6 MONTH 12	16 (88.9%) 15 (83.3%)						1026 (71.1%) 785 (54.4%)			

023

Note: One patient in study ACS201-HYA-002A received both 75 IU Vitrase and Saline. This patient is included in both groups here. Twelve patients in the "Probe Study" received two injections of 75 IU Vitrase. These patients are only counted once here.

"Watchful Waiting - Control" patients did not receive study injection.

^[1] Follow-up is defined as days from treatment to last visit completed for each patient.

^[2] Treatment date for 4 patients from study ACS201-HYA-002A could not be determined. Duration of follow-up could not be calculated.

^[3] Other Active treatments include SF6 (PVD-01-08961X) and ACS-101C (COR-01-08961X). Patients who received both Vitrase and another active study treatment are included in both groups.

Table 3.2

Summary of Extent of Exposure and Follow-up Duration
All Studies by Study for Vitrase Groups Only
Safety Population

	Phase I [2]	V-01-VIT-08961X	ACS202-HYA-001US	ACS203-HYA-001MEX	VIT-02-08961X	VIT-03-08961X	Other Indications [3]
NUMBER OF PATIENTS RECEIVING TREATMENT	68	31	153	225	602	364	84
DURATION OF FOLLOW-UP (DAYS) [1]							
n	64	31	153	225	602	364	84
Mean (SD)	200.9 (278.6)	362.0 (37.4)	97.2 (110.8)	530.6 (215.2)	355.3 (229.5)	303.4 (191.2)	286.5 (134.2)
Median	85.0	365.0	56.0	584.0	363.0	343.0	243.0
Range	28 - 1412	190 - 470	1 - 470	6 - 829	7 - 972	7 - 790	21 - 511
NUMBER AND PERCENT OF PATIENTS WITH:							
MONTH 6 FOLLOW-UP DATA	18 (26.5%)	31 (100%)	34 (22.2%)	201 (89.3%)	474 (78.7%)	268 (73.6%)	78 (92.9%)
MONTH 12 FOLLOW-UP DATA	11 (16.2%)	30 (96.8%)	18 (11.8%)	191 (84.9%)	347 (57.6%)	188 (51.6%)	25 (29.8%)

024

Note: One patient in study ACS201-HYA-002A received both 75 IU Vitrase and Saline. This patient is included here. Twelve patients in the "Probe Study" received two injections of 75 IU Vitrase. These patients are only counted once here.

^[1] Follow-up is defined as days from treatment to last visit completed for each patient.

^[2] Includes ACS201-HYA-001A, ACS201-HYA-002A, Probe Study

Note: Treatment date for 4 patients from study ACS201-HYA-002A could not be determined. Duration of follow-up could not be calculated.

^[3] Includes PVD-01-08961X, COR-01-08961X, COP-01-08961X

Table 3.3

Summary of Extent of Exposure and Follow-up Duration

Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment

Safety Population

	Con	trol			
	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
NUMBER OF PATIENTS RECEIVING TREATMENT	0	378	198	377	391
DURATION OF FOLLOW-UP (DAYS) [1]				200	201
n Maria (OD)	18	378	198 372.4 (232.5)	377 327.4 (215.5)	391 325.2 (209.5)
Mean (SD) Median	469.6 (258.9) 3 7 3.0	307.0 (196.3) 319.5	372.4 (232.5)	352.0	343.0
Range	34 - 966	5 - 784	8 - 964	7 - 972	7 - 965
NUMBER AND PERCENT OF PATIENTS WITH:					
MONTH 6 FOLLOW-UP DATA	16 (88.9%)	278 (73.5%)	159 (80.3%)	285 (75.6%)	298 (76.2%)
MONTH 12 FOLLOW-IIP DATA	15 (83.3%)	187 (49.5%)	121 (61.1%)	205 (54.4%)	209 (53.5%)

Table 3.4

Summary of Extent of Exposure and Follow-up Duration
PVD Study (PVD-01-08961X) by Treatment
Safety Population

			Vitrase 75 IU	
	Vitrase 75 IU	SF6	+ SF6	Saline
NUMBER OF PATIENTS RECEIVING TREATMENT	15	15	14	16
DURATION OF FOLLOW-UP (DAYS) [1]				
n	15	15	14	16
Mean (SD)	452.5 (109)	392.7 (151)	401.0 (147)	449.3 (105)
Median	483.0	483.0	483.0	483.0
Range	84 - 511	112 - 511	84 - 511	81 - 511
NUMBER AND PERCENT OF PATIENTS WITH:				
MONTH 6 FOLLOW-UP DATA	14 (93.3%)	12 (80.0%)	12 (85.7%)	15 (93.8%)
MONTH 12 FOLLOW-UP DATA	14 (93.3%)	12 (80.0%)	11 (78.6%)	15 (93.8%)

⁰²⁶

^[1] Follow-up is defined as days from treatment to last visit completed for each patient.

s:\dat\acs\iss2002\sas\programs\t_exposure_treat_PVD 17SEP2002 10:24

Table 4.1
Summary of Demographics and Baseline Characteristics
All Studies by Treatment
Safety Population

		Hemorrhage Clearance Studies							Other Indications			
	Con	trol			Vitrase					_		
	ww	Saline	7.5 IU	37.5 IU	55 IU	75 IU	Total Vitrase	Vitrase 50-500 IU	Saline Control	Other Active [1]		
NUMBER OF PATIENTS	18	417	327	130	377	609	1443	84	21	70		
GENDER												
MALE	13 (72.2%)	198 (47.5%)	159 (48.6%)	61 (46.9%)	193 (51.2%)	323 (53.0%)	736 (51.0%)	39 (46.4%)	14 (66.7%)	29 (41.4%)		
FEMALE	5 (27.8%)	219 (52.5%)	168 (51.4%)	69 (53.1%)	184 (48.8%)	285 (46.8%)	706 (48.9%)	45 (53.6%)	7 (33.3%)	41 (58.6%)		
MISSING OR N/A	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	1 (0.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
RACE												
CAUCASIAN	7 (38.9%)	255 (61.2%)	129 (39.4%)	25 (19.2%)	250 (66.3%)	294 (48.3%)	698 (48.4%)	1 (1.2%)	0 (0.0%)	1 (1.4%)		
HISPANIC	5 (27.8%)	65 (15.6%)	131 (40.1%)	60 (46.2%)	73 (19.4%)	158 (25.9%)	422 (29.2%)	83 (98.8%)	21 (100%)	69 (98.6%)		
BLACK	3 (16.7%)	31 (7.4%)	21 (6.4%)	7 (5.4%)	26 (6.9%)	43 (7.1%)	97 (6.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
OTHER	3 (16.7%)	57 (13.7%)	46 (14.1%)	32 (24.6%)	28 (7.4%)	85 (14.0%)	191 (13.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
MISSING OR N/A	0 (0.0%)	9 (2.2%)	0 (0.0%)	6 (4.6%)	0 (0.0%)	29 (4.8%)	35 (2.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
AGE (YEARS)												
n	18	406	327	130	376	601	1434	84	21	70		
Mean (SD)	66.2 (9.3)	61.5 (12.9)	60.1 (12.9)	59.6 (10.5)	61.6 (12.2)	60.9 (12.7)	60.8 (12.4)	39.7 (16.1)	50.5 (9.6)	39.6 (15.3)		
Median	67.5	62.0	61.0	58.0	62.0	61.0	61.0	35.0	51.0	36.0		
Range	48 ~ 81	18 - 93	25 - 97	36 - 91	23 - 90	7 - 91	7 - 97	18 - 77	33 - 66	18 - 68		
STUDY EYE												
OD	9 (50.0%)	214 (51.3%)	178 (54.4%)	69 (53.1%)	184 (48.8%)	295 (48.4%)	726 (50.3%)	47 (56.0%)	11 (52.4%)	36 (51.4%)		
os	9 (50.0%)	202 (48.4%)	149 (45.6%)		193 (51.2%)	310 (50.9%)	713 (49.4%)	37 (44.0%)	10 (47.6%)	34 (48.6%)		
OU	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	2 (0.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
MISSING OR N/A	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	2 (0.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		

027

Note: One patient in study ACS201-HYA-002A received both 75 IU Vitrase and Saline. This patient is included in both groups here. Twelve patients in the "Probe Study" received two injections of 75 IU Vitrase. These patients are only counted once here.

One patient in study VIT-02-08961X (Saline) and three patients (two Saline and one 55 IU) in study VIT-03-08961X had calculated ages resolving to zero due to incorrect birth dates recorded. These values are not included in the age calculation. In addition, patients with a missing DOB were not included in the age calculation.

^[1] Other Active treatments include SF6 (PVD-01-08961X) and ACS-101C (COR-01-08961X). Patients who received both Vitrase and another active study treatment are included in both groups.

Table 4.2
Summary of Demographics and Baseline Characteristics
All Studies by Study for Vitrase Groups Only
Safety Population

	Phase I [1]	V-01-VIT-08961X	ACS202-HYA-001US	ACS203-HYA-001MEX	VIT-02-08961X	VIT-03-08961X	Other Indications [2]
NUMBER OF PATIENTS	68	31	153	225	602	364	84
GENDER							
MALE	32 (47.1%)	19 (61.3%)	79 (51.6%)	98 (43.6%)	313 (52.0%)	195 (53.6%)	39 (46.4%)
FEMALE	36 (52.9%)	12 (38.7%)	74 (48.4%)	127 (56.4%)	289 (48.0%)	168 (46.2%)	45 (53.6%)
MISSING OR N/A	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
RACE							
CAUCASIAN	0 (0.0%)	0 (0.0%)	76 (49.7%)	10 (4.4%)	307 (51.0%)	305 (83.8%)	1 (1.2%)
HISPANIC	33 (48.5%)	0 (0.0%)	36 (23.5%)	136 (60.4%)	217 (36.0%)	0 (0.0%)	83 (98.8%)
BLACK	0 (0.0%)	0 (0.0%)	28 (18.3%)	0 (0.0%)	35 (5.8%)	34 (9.3%)	0 (0.0%)
OTHER	0 (0.0%)	31 (100%)	13 (8.5%)	79 (35.1%)	43 (7.1%)	25 (6.9%)	0 (0.0%)
MISSING OR N/A	35 (51.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
AGE (YEARS)							
n	65	26	153	225	602	363	84
Mean (SD)	56.3 (14.5)	54.0 (11.0)	61.8 (12.9)	58.3 (9.2)	61.3 (13.2)	62.3 (11.9)	39.7 (16.1)
Median	58.0	56.0	63.0	58.0	61.0	64.0	35.0
Range	7 - 91	22 - 71	29 - 88	27 - 89	25 - 97	23 - 91	18 - 77
STUDY EYE							
OD	32 (47.1%)	16 (51.6%)	75 (49.0%)	126 (56.0%)	307 (51.0%)	170 (46.7%)	47 (56.0%)
os	32 (47.1%)	15 (48.4%)	78 (51.0%)	99 (44.0%)	295 (49.0%)	194 (53.3%)	37 (44.0%)
OU	2 (2.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
MISSING OR N/A	2 (2.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

028

Note: One patient in study VIT-03-08961X (55 IU) had a calculated age resolving to zero. This record is not included in the age calculation. In addition, patients with a missing DOB were not included in the age calculation.

^[1] Includes ACS201-HYA-001A, ACS201-HYA-002A, Probe Study

^[2] Includes PVD-01-08961X, COR-01-08961X, COP-01-08961X

Table 4.3

Summary of Demographics and Baseline Characteristics

Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment

Safety Population

		Control			
	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
	-				201
NUMBER OF PATIENTS	18	378	198	377	391
GENDER					
MALE	13 (72.2	183 (48.4%) 100 (50.5%)	193 (51.2%)	215 (55.0%)
FEMALE	5 (27.8	195 (51.6%) 98 (49.5%)	184 (48.8%)	175 (44.8%)
MISSING OR N/A	0 (0.0	k) 0 (0.0%	0 (0.0%)	0 (0.0%)	1 (0.3%)
RACE					
CAUCASIAN	7 (38.9	3) 255 (67.5%	97 (49.0%)		
HISPANIC	5 (27.8				
BLACK	3 (16.7) 11 (5.6%)		
other	3 (16.7	s) 27 (7.1%) 16 (8.1%)	28 (7.4%)	24 (6.1%)
AGE (YEARS)					
n	18	375	198 60.2 (13.7)	376	391
Mean (SD)	66.2 (9.3				
Median	67.5	63.0	60.0	62.0	63.0
Range	48 - 81	26 - 93	25 - 97	23 - 90	23 - 91
STUDY EYE					
OD	9 (50.0	k) 194 (51.3%) 104 (52.5%)	184 (48.8%)	189 (48.3%)
OS	9 (50.0	ኔ) 184 (48.7%) 94 (47.5%)	193 (51.2%)	202 (51.7%)
DIABETIC STATUS [1]					
NUMBER OF PATIENTS	18	378		377	391
TYPE I DIABETES	5 (27.8			164 (43.5%)	
TYPE II DIABETES	11 (61.1			109 (28.9%)	
NON-DIABETIC	2 (11.1	86 (22.8 %) 25 (12.6%)	104 (27.6%)	80 (20.5%)

⁰²⁰

Note: One patient in study VIT-02-08961X (Saline) and three patients (two Saline and one 55 IU) in study VIT-03-08961X had calculated ages resolving to zero due to incorrect birth dates recorded. This record is not included in the age calculation.

In addition, patients with a missing DOB were not included in the age calculation.

^[1] Diabetic status is only summarized for studies VIT-02-08961X and VIT-03-08961X. Percents are based on total number of patients in those studies.

Type I diabetes includes all insulin-dependent diabetics.

Table 4.4

Summary of Demographics and Baseline Characteristics

PVD Study (PVD-01-08961X) by Treatment

Safety Population

	Vitrase 75 IU	SF6	Vitrase 75 IU + SF6	Saline
NUMBER OF PATIENTS	15	15	14	16
GENDER				
MALE	8 (53.3%)	5 (33.3%)	11 (78.6%)	10 (62.5%)
FEMALE	7 (46.7%)	10 (66.7%)	3 (21.4%)	6 (37.5%)
RACE				
HISPANIC	15 (100%)	15 (100%)	14 (100%)	16 (100%)
AGE (YEARS)				1
n	15	15	14	16
Mean (SD)	53.7 (8.6)	53.3 (11.1)	55.3 (8.5)	54.3 (7.5)
Median	54.0	57.0	53.0	53.5
Range	40 - 65	32 - 68	44 - 68	39 - 66
STUDY EYE				
OD	12 (80.0%)	8 (53.3%)	12 (85.7%)	11 (68.8%)
os	3 (20.0%)	7 (46.7%)	2 (14.3%)	5 (31.3%)

Table 5.1 Incidence of Serious Adverse Events by System Organ Class All Studies by Treatment Safety Population

			Other Indications							
	Cont	rol		ge Clearance	Vitrase_			_		
System Organ Class / Preferred Term	ww	Saline	7.5 IU	37.5 IU		75 IU	Total Vitrase	Vitrase 50-500 IU	Saline Control	Other Active [1]
NUMBER OF PATIENTS	18	417	327	130	377	609	1443	84	21	70
NUMBER OF PATIENTS WITH AT LEAST ONE SERIOUS ADVERSE EVENT	12 (67%)	159 (38%)	114 (35%)	11 (8%)	158 (42%)	199 (33%)	482 (33%)	27 (32%)	15 (71%)	16 (23%)
EYE DISORDERS VITREOUS HEMORRHAGE RETINAL DETACHMENT RUBEOSIS IRIDIS CATARACT SUBCAPSULAR VISUAL ACUITY REDUCED BLINDNESS NEC IRIS ADHESIONS CATARACT NUCLEAR CATARACT TUCLEAR CATARACT TORTICAL GLAUCOMA NOS CATARACT NEC VITREOUS FLOATERS VITREOUS HAEMORRHAGE VITREOUS DETACHMENT EYE PAIN INTRAOCULAR PRESSURE INCREASED HYPHEMA CATARACT NOS AGGRAVATED MACULAR EDEMA HYPOPYON IRITIS MACULAR OEDEMA EYE DEGENERATIVE DISORDER NOS MACULOPATHY	7 (39%) 2 (11%) 3 (17%) 1 (6%) 1 (6%) 2 (11%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (6%) 1 (6%) 0 (0%) 1 (6%) 1 (6%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)	102 (24%) 54 (13%) 26 (6%) 15 (4%) 5 (1%) 6 (1%) 4 (1%) 2 (<1%) 5 (1%) 5 (1%) 6 (1%) 6 (1%) 7 (1%) 7 (1%) 8 (1%) 9 (0%) 9 (0%) 9 (0%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (82 (25%) 50 (15%) 17 (5%) 13 (4%) 6 (2%) 1 (<1%) 5 (2%) 2 (1%) 4 (1%) 1 (<1%) 1 (<1%) 1 (<1%) 0 (0%) 5 (2%) 2 (1%) 0 (0%) 5 (2%) 2 (1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 2 (1%) 2 (1%) 3 (1%) 4 (1%) 4 (1%) 5 (2%) 6 (0%) 7 (0%)	9 (7%) 0 (0%) 5 (4%) 0 (0%)	119 (32%) 67 (18%) 30 (8%) 13 (3%) 12 (3%) 4 (1%) 6 (2%) 7 (2%) 4 (1%) 0 (0%) 4 (1%) 0 (0%) 1 (<1%) 2 (1%) 2 (1%) 3 (1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)	141 (23%) 71 (12%) 38 (6%) 12 (2%) 14 (2%) 0 (0%) 8 (1%) 9 (1%) 7 (1%) 5 (1%) 5 (1%) 0 (0%) 3 (<1%) 0 (0%) 3 (<1%) 2 (<1%) 1 (<1%) 2 (<1%) 1 (<1%) 2 (<1%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%)	351 (24%) 188 (13%) 90 (6%) 38 (3%) 32 (2%) 5 (<1%) 19 (1%) 18 (1%) 15 (1%) 10 (1%) 2 (<1%) 8 (1%) 0 (0%) 9 (1%) 6 (<1%) 6 (<1%) 6 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1	26 (31%) 0 (0%) 0 (0%) 1 (1%) 5 (6%) 11 (13%) 0 (0%) 1 (1%) 2 (2%) 0 (0%) 1 (1%) 4 (5%) 3 (4%) 1 (1%) 4 (5%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (1%) 2 (2%) 3 (4%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (1%) 2 (2%) 3 (4%) 0 (0%) 0 (0%)	14 (67%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 6 (29%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 3 (14%) 0 (0%) 0 (0%) 0 (0%) 3 (14%) 0 (0%)	16 (23%) 0 (0%) 0 (0%) 0 (0%) 3 (4%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (3%) 1 (1%) 2 (3%) 1 (1%) 0 (0%) 0 (0%) 1 (1%) 0 (0%)
PHOTOPHOBIA AGGRAVATED RETINOPATHY DIABETIC PSEUDOPHAKIA PHOTOPSIA PUPILLARY REFLEX IMPAIRED ABNORMAL SENSATION IN EYE CORNEAL EDEMA EYE IRRITATION HYPOTONY OF EYE	0 (0%) 1 (6%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 3 (1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%)	0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)	1 (<1%) 2 (1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)	3 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (<1%) 2 (<1%)	5 (<1%) 2 (<1%) 0 (0%) 0 (0%) 0 (0%) 3 (<1%) 0 (0%) 2 (<1%)	0 (0%) 0 (0%) 2 (2%) 4 (5%) 1 (1%) 0 (0%) 3 (4%) 0 (0%)	0 (0%) 0 (0%) 1 (5%) 0 (0%) 2 (10%) 0 (0%) 0 (0%)	0 (0% 0 (0% 1 (1% 1 (1% 0 (0% 0 (0% 0 (0%

Note: One patient in study ACS201-HYA-002A received both 75 IU Vitrase and Saline. This patient is included in both groups here. Twelve patients in the "Probe Study" received two injections of 75 IU Vitrase. These patients are only counted once here.

[1] Other Active transments include SF6 (PVD-01-08961X) and ACS-101C (COR-01-08961X). Patients who received both Vitrase and another active study

-

treatment are included in both groups.

Table 5.1 Incidence of Serious Adverse Events by System Organ Class All Studies by Treatment Safety Population

			Other Indications							
	Conti	rol.		ge Clearance	Vitrase					_
							Total	Vitrase	Saline	Other
System Organ Class / Preferred Term	ww	Saline	7.5 IU	37.5 IU	55 IU	75 IU	Vitrase	50-500 IU	Control	Active [1]
			0 (* 05)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	2 (10%)	0 (0%)
LACRIMATION INCREASED	0 (0%)	0 (0%) 0 (0%)	0 (0%) 0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	3 (4%)	0 (0%)	0 (0%)
OCULAR HYPERAEMIA	0 (0%) 0 (0%)		0 (0%) 0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
RETINAL HEMORRHAGE	0 (0%) 0 (0%)	1 (<1%) 0 (0%)	1 (<1%)	0 (0%)	2 (1%)	0 (0%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)
RETINAL ISCHEMIA	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	2 (<1%)	1 (1%)	0 (0%)	0 (0%)
VITREOUS DISORDER NOS CHOROIDAL DETACHMENT	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
CONJUNCTIVAL HEMORRHAGE CORNEAL OEDEMA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (2%)	0 (0%)	0 (0%)
	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	1 (5%)	0 (0%)
PHOTOPHOBIA POSTERIOR CAPSULE OPACIFICATION	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
RETINAL DEGENERATION RETINAL TEAR (EXC DETACHMENT)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
ACCOMMODATION DISORDER	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)
	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
CHORIORETINAL DISORDER NOS CHOROIDAL HEMORRHAGE	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
CONJUNCTIVAL EDEMA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)
CORECTOPIA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)
CORNEAL DISORDER NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)
CORNEAL EROSION CORNEAL GRAFT REJECTION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)
	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)
CORNEAL INFILTRATES CORNEAL OPACITY	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
CORNEAL ULCER NEC	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
EYE DISCHARGE	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)
EYE INFECTION FUNGAL NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
INTRAOCULAR PRESSURE DECREASED	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
IRIS VASCULAR DISORDER NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)
KERATITIS NEC	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
KERATOCONJUNCTIVITIS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)
OCULAR HYPEREMIA	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
OPEN ANGLE GLAUCOMA NOS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
OPTIC ATROPHY	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
OPTIC AIROFHI OPTIC DISC HEMORRHAGE	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
RETINAL ARTERY EMBOLISM	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
RETINAL DISORDER NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
RETINAL DISORDER NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
VISION BLURRED	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
CARDIAC DISORDERS	7 (39%)	21 (5%)	19 (6%)	0 (0%)	21 (6%)	35 (6%)	75 (5%)	0 (0%)	0 (0%)	0 (0%)

Note: One patient in study ACS201-HYA-002A received both 75 IU Vitrase and Saline. This patient is included in both groups here. Twelve patients in the "Probe Study" received two injections of 75 IU Vitrase. These patients are only counted once here.

^[1] Other Active treatments include SF6 (PVD-01-08961X) and ACS-101C (COR-01-08961X). Patients who received both Vitrase and another active study treatment are included in both groups.

s:\dat\acs\iss2002\sas\programs\t_sae_treat 06SEP2002 17:33

Table 5.1 Incidence of Serious Adverse Events by System Organ Class All Studies by Treatment Safety Population

			Other Indications							
	Contr	ol		ge Clearance	Vitrase					
System Organ Class / Preferred Term	ww	Saline	7.5 IU	37.5 IU	55 IU	75 IU	Total Vitrase	Vitrase 50-500 IU	Saline Control	Other Active [1]
MYOCARDIAL INFARCTION	3 (17%)	5 (1%)	7 (2%)	0 (0%)	3 (1%)	12 (2%)	22 (2%)	0 (0%)	0 (0%)	0 (0%)
CARDIAC FAILURE CONGESTIVE	2 (11%)	4 (1%)	5 (2%)	0 (0%)	5 (1%)	6 (1%)	16 (1%)	0 (0%)	0 (0%)	0 (0%)
CARDIAC ARREST	0 (0%)	2 (<1%)	1 (<1%)	0 (0%)	5 (1%)	2 (<1%)	8 (1%)	0 (0%)	0 (0%)	0 (0%)
ANGINA UNSTABLE	0 (0%)	0 (0%)	2 (1%)	0 (0%)	3 (1%)	3 (<1%)	8 (1%)	0 (0%)	0 (0%)	0 (0%)
CORONARY ARTERY OCCLUSION	0 (0%)	2 (<1%)	2 (1%)	0 (0%)	1 (<1%)	0 (0%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)
ANGINA PECTORIS	0 (0%)	3 (1%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
ARRHYTHMIA NOS	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	2 (1%)	0 (0%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)
ATRIAL FIBRILLATION	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	2 (1%)	1 (<1%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)
CARDIAC FAILURE NOS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	2 (<1%)	4 (<1%)	0 (0%)	0 (0%)	0 (0%)
CARDIOVASCULAR DISORDER NOS	1 (6%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
PULMONARY EDEMA NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	2 (1%)	1 (<1%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)
CORONARY ARTERY DISEASE NOS	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
LEFT VENTRICULAR FAILURE	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	2 (1%)	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	
AORTIC VALVE STENOSIS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (<1%)	2 (<1%)	0 (0%)	0 (0%)	
CARDIO-RESPIRATORY ARREST	1 (6%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	
MYOCARDIAL ISCHEMIA	0 (0%)	1 (<1%) .	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	- • • • •
ATRIOVENTRICULAR BLOCK NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	
BRADYCARDIA NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	
CARDIAC DISORDER NOS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	
CARDIOGENIC SHOCK	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	
CARDIOMYOPATHY NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	
DYSPNEA PAROXYSMAL NOCTURNAL	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	
DYSPNOEA NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	
HYPERTROPHIC CARDIOMYOPATHY	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
ISCHEMIC CARDIOMYOPATHY	1 (6%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
PALPITATIONS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	
PULMONARY CONGESTION	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
VENTRICULAR TACHYCARDIA	1 (6%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
INVESTIGATIONS	1 (6%)	13 (3%)	23 (7%)	0 (0%)	19 (5%)	23 (4%)	65 (5%)	1 (1%)	0 (0%)	
INTRAOCULAR PRESSURE INCREASED	0 (0%).	13 (3%)	23 (7%)	0 (0%)	17 (5%)	22 (4%)	62 (4%)	1 (1%)	0 (0%)	
BLOOD GLUCOSE FLUCTUATION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	
BLOOD GLUCOSE INCREASED	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	
HEMATOCRIT DECREASED	1 (6%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
INTRACCULAR PRESSURE ABNORMAL	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	
WEIGHT DECREASED	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	Ū (0%)	0 (0%)	0 (0%)
INFECTIONS AND INFESTATIONS	1 (6%)	11 (3%)	8 (2%)	0 (0%)	14 (4%)	14 (2%)	36 (2%)	2 (2%)	1 (5%)	
PNEUMONIA NOS	0 (0%)	2 (<1%)	2 (1%)	0 (0%)	4 (1%)	3 (<1%)	9 (1%)	0 (0%)	0 (0%)) 0 (0-5)

Note: One patient in study ACS201-HYA-002A received both 75 IU Vitrase and Saline. This patient is included in both groups here. Twelve patients in the "Probe Study" received two injections of 75 IU Vitrase. These patients are only counted once here.

^[1] Other Active treatments include SF6 (PVD-01-08961X) and ACS-101C (COR-01-08961X). Patients who received both Vitrase and another active study treatment are included in both groups.

Table 5.1 Incidence of Serious Adverse Events by System Organ Class All Studies by Treatment Safety Population

			Hemorrha	ge Clearance	Studies			Other Indications_		ons
	Con	trol		•	Vitrase					
							Total	Vitrase	Saline	Other
System Organ Class / Preferred Term	WW	Saline	7.5 IU	37.5 IU	55 IU	75 IU	Vitrase	50-500 IU	Control	Active [1]
CELLULITIS	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	2 (1%)	4 (1%)	6 (<1%)	0 (0%)	0 (0%)	0 (0%)
OSTEOMYELITIS NOS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	3 (1%)	2 (<1%)	6 (<1%)	0 (0%)	0 (0%)	0 (0%)
LOCALISED INFECTION	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	2 (1%)	1 (<1%)	4 (<1%)	0 (0%)	0 (0%)	0 (0%)
SEPSIS NOS	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	2 (1%)	1 (<1%)	4 (<1%)	0 (0%)	0 (0%)	0 (0%)
BRONCHITIS NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	2 (<1%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)
INFECTED SKIN ULCER	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
PYELONEPHRITIS NOS	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
STAPHYLOCOCCAL INFECTION NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (1%)	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
AMERICAN TRYPANOSOMIASIS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
BACTERIAL INFECTION NOS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
BLEPHARITIS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (5%)	0 (0%)
BRONCHITIS ACUTE NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
BRONCHOPNEUMONIA NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
CELLULITIS STAPHYLOCOCCAL	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
INFLUENZA	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
KERATITIS HERPETIC	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)
KIDNEY INFECTION NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)
LUNG INFECTION NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
OSTEOMYELITIS CHRONIC NOS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
PULMONARY TUBERCULOSIS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
SEPTIC ARTHRITIS NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
SEPTICEMIA STAPHYLOCOCCAL	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
SKIN INFECTION NOS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
URINARY TRACT INFECTION NOS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
UROSEPSIS	1 (6%)	0 (0%)	० (०%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
SURGICAL AND MEDICAL PROCEDURES	1 (6%)	15 (4%)	11 (3%)	0 (0%)	11 (3%)	11 (2%)	33 (2%)	0 (0%)	0 (0%)	0 (0%)
VITRECTOMY	0 (0%)	7 (2%)	2 (1%)	0 (0%)	3 (1%)	3 (<1%)	8 (1%)	0 (0%)	0 (0%)	0 (0%)
POST-OPERATIVE COMPLICATIONS NOS	0 (0%)	2 (<1%)	2 (1%)	0 (0%)	3 (1%)	2 (<1%)	7 (<1%)	0 (0%)	0 (0%)	0 (0%)
UNSPECIFIED COMPLICATION OF	0 (0%)	1 (<1%)	2 (1%)	0 (0%)	1 (<1%)	1 (<1%)	4 (<1%)	0 (0%)	0 (0%)	0 (0%)
PROCEDURE NEC	,	- ,,	_ ,	,						
CORONARY ARTERY SURGERY	1 (6%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	3 (<1%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)
FOOT AMPUTATION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
LEG AMPUTATION	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
TOE AMPUTATION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (1%)	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
ARTERIAL BYPASS OPERATION (EXC	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
CORONARY ARTERY)	5 , 507	- ,	- (/	- , /	- • •	/		. ,		
BLOOD PRODUCT TRANSFUSION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
CARDIAC OPERATION NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

Note: One patient in study ACS201-HYA-002A received both 75 IU Vitrase and Saline. This patient is included in both groups here. Twelve patients in the "Probe Study" received two injections of 75 IU Vitrase. These patients are only counted once here.

^[1] Other Active treatments include SF6 (PVD-01-08961X) and ACS-101C (COR-01-08961X). Patients who received both Vitrase and another active study treatment are included in both groups.

Table 5.1

Incidence of Serious Adverse Events by System Organ Class

All Studies by Treatment
Safety Population

				Hemorrhage Clearance Studies						Other Indications		
	Contr	rol		J	Vitrase			•				
							Total	Vitrase	Saline Control	Other Active [1]		
System Organ Class / Preferred Term		Saline	7.5 IU	37.5 IU	55 IU	75 IU 	Vitrase	50-500 IU	CONCIOI	ACCIVE [I,		
CARDIAC PACEMAKER INSERTION	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)		
CAROTID ENDARTERECTOMY	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)		
CRYOTHERAPY NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)		
DEVICE FAILURE NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)		
FOOT OPERATION NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)		
HIP ARTHROPLASTY	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)		
HOSPITALIZATION NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)		
KNEE ARTHROPLASTY	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)		
LIMB OPERATION NOS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)		
METATARSAL EXCISION	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0多)		
POST PROCEDURAL HEMORRHAGE	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)		
WOUND DEBRIDEMENT	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)		
			. ()	1 (1%)	8 (2%)	12 (2%)	29 (2%)	3 (4%)	0 (0%)	1 (1%)		
NERVOUS SYSTEM DISORDERS	1 (6%)	8 (2%)	8 (2%)		5 (1%)	7 (1%)	16 (1%)	0 (0%)	0 (0%)	0 (0%)		
CEREBROVASCULAR ACCIDENT NOS	1 (6%)	5 (1%)	4 (1%)		1 (<1%)	2 (<1%)	4 (<1%)	0 (0%)	0 (0%)	0 (0%)		
SYNCOPE	0 (0%)	1 (<1%)	1 (<1%)		0 (0%)	0 (0%)	1 (<1%)	2 (2%)	0 (0%)	0 (0%)		
HEADACHE NOS	0 (0%)	0 (0%)	0 (0%)	- ,	1 (<1%)	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)		
DIZZINESS (EXC VERTIGO)	0 (0%)	0 (0%)	1 (<1%)	* 1 *	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)		
HEMORRHAGIC STROKE	0 (0%)	1 (<1%)	0 (0%)	- ,	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)		
COMA NEC	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)		
CONVULSIONS NOS	0 (0%)	0 (0%)	0 (0%)	- 1 - 1	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)		
DEPRESSED LEVEL OF CONSCIOUSNESS	0 (0%)	1 (<1%)	0 (0%)		0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)		
HEMIPARESIS	0 (0%)	0 (0%)	1 (<1%)	- ' '	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)		
HYPOAESTHESIA	0 (0%)	0 (0%)	1 (<1%)		0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	1 (1%)		
IIIRD NERVE PARALYSIS	0 (0%)	0 (0%)	0 (0%)		0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)		
LACUNAR INFARCTION	0 (0%)	0 (0%)	0 (0%)		1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)		
PUPILLARY DISORDER NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	± (1±0/					
RENAL AND URINARY DISORDERS	4 (22%)	13 (3%)	7 (2%)	1 (1%)	6 (2%)	8 (1%)	22 (2%)	1 (1%)	0 (0%) 0 (0%)	0 (0%) 0 (0%)		
RENAL FAILURE NOS	1 (6%)	5 (1%)	4 (1%)	1 (1%)	3 (1%)	5 (1%)	13 (1%)	1 (1%)	0 (0%)	0 (0%)		
RENAL FAILURE ACUTE	3 (17%)	3 (1%)	2 (1%)	0 (0%) "	2 (1%)	2 (<1%)	6 (<1%)	- ,,	0 (0%)	0 (0%)		
RENAL FAILURE CHRONIC	1 (6%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)		0 (0%)	0 (0%)		
RENAL ARTERY STENOSIS	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)		0 (0%)		
CALCULUS RENAL NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	- :	0 (0%)		
CALCULUS URINARY	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	- '		
GLOMERULONEPHRITIS CHRONIC	0 (0%) -	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)		
RENAL FAILURE CHRONIC AGGRAVATED	1 (6%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)		
RENAL IMPAIRMENT NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)		
	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)		
RENAL VASCULAR DISORDER NOS	0 (0%)	T (~T.9)	0 \ 50/	- ,,								

Note: One patient in study ACS201-HYA-002A received both 75 IU Vitrase and Saline. This patient is included in both groups here. Twelve patients in the "Probe Study" received two injections of 75 IU Vitrase. These patients are only counted once here.

^[1] Other Active treatments include SF6 (PVD-01-08961X) and ACS-101C (COR-01-08961X). Patients who received both Vitrase and another active study treatment are included in both groups.

s:\dat\acs\iss2002\sas\programs\t_sae_treat 06SEP2002 17:33

Table 5.1 Incidence of Serious Adverse Events by System Organ Class All Studies by Treatment Safety Population

-			Hemorrhage Clearance Studies					Other Indications		
	Cont	rol		J	Vitrase					
System Organ Class / Preferred Term	ww	Saline	7.5 IÜ	37.5 IU		75 IU	Total Vitrase	Vitrase 50-500 IU	Saline Control	Other Active [1]
VASCULAR DISORDERS	0 (0%)	15 (4%)	7 (2%)	0 (0%)	8 (2%)	8 (1%)	23 (2%)	0 (0%)	0 (0%)	0 (0%)
GANGRENE NOS	0 (0%)	1 (<1%)	2 (1%)	0 (0%)	1 (<1%)	1 (<1%)	4 (<1%)	0 (0%)	0 (0%)	0 (0%)
HYPERTENSION NOS	0 (0%)	3 (1%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
PERIPHERAL VASCULAR DISEASE NOS	0 (0%)	3 (1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
TRANSIENT ISCHEMIC ATTACK	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
HYPERTENSION AGGRAVATED	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
HYPOTENSION NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
THROMBOEMBOLISM NOS	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
ARTERIAL ANEURYSM NOS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
ARTERIAL OCCLUSION NOS	- ::	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
CEREBRAL INFARCTION	•		0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
CEREBRAL ISCHEMIA		1 (<1%) 0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
CEREBROVASCULAR ACCIDENT NOS	- :	+ 1 + -,	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
COLLAPSE	• , ,			0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
HEMATOMA NOS	0 (0%)	0 (0%)		0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
ISCHEMIC FOOT	0 (0%)	0 (0%)		- ''	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
POSTURAL HYPOTENSION	0 (0%)	0 (0%)	0 (0%)			0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
PULMONARY EMBOLISM	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	•	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
PULMONARY HYPERTENSION NOS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
SUBARACHNOID HEMORRHAGE NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)			0 (0%)	0 (0%)	0 (0%)
VENOUS THROMBOSIS DEEP LIMB	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0.
METABOLISM AND NUTRITION DISORDERS	2 (11%)	8 (2%)	3 (1%)	0 (0%)	4 (1%)	11 (2%)	18 (1%)	1 (1%)	0 (0%)	1 (1%)
HYPOGLYCAEMIA NOS	0 (0%)	3 (1%)	0 (0%)	0 (0%)	0 (0%)	5 (1%)	5 (<1%)	1 (1%)	0 (0%)	1 (1%)
HYPERGLYCEMIA NOS	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	2 (1%)	0 (0%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)
DEHYDRATION	1 (6%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%) 0 (0%)
DIABETIC COMA NOS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	2 (<1%)	3 (<1%)	0 (0%)	0 (0%)	- •
HYPERKALEMIA	1 (6%)	1 (<1%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
DIABETIC COMPLICATION NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
DIABETIC NEUROPATHY NEC	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
DIABETES MELLITUS AGGRAVATED	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
DIABETIC AMYOTROPHY	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
DIABETIC EYE DISEASE NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
DIABETIC KETOACIDOSIS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
HYPOGLYCAEMIC COMA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
NONKETOTIC	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%,
HYPERGLYCEMIC-HYPEROSMOLAR COMA RETINOPATHY DIABETIC	0 (0%)	0 (0%)	0. (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)

Note: One patient in study ACS201-HYA-002A received both 75 IU Vitrase and Saline. This patient is included in both groups here. Twelve patients in the "Probe Study" received two injections of 75 IU Vitrase. These patients are only counted once here.

[1] Other Active treatments include SF6 (PVD-01-08961X) and ACS-101C (COR-01-08961X). Patients who received both Vitrase and another active study

treatment are included in both groups.

s:\dat\acs\iss2002\sas\programs\t_sae_treat 06SEP2002 17:33

Table 5.1 Incidence of Serious Adverse Events by System Organ Class All Studies by Treatment Safety Population

			Hemorrha	ge Clearance	Studies			Oth	er Indicati	ons
	Cont	rol			Vitrase					
			•				Total	Vitrase	Saline	Other
System Organ Class / Preferred Term	ww	Saline	7.5 IU	37.5 IU	55 IV	75 IU	Vitrase	50-500 IU	Control	Active [1]
GASTROINTESTINAL DISORDERS	0 (0%)	3 (1%)	1 (<1%)	0 (0%)	9 (2%)	7 (1%)	17 (1%)	0 (0%)	0 (0%)	0 (0%)
GASTROINTESTINAL HEMORRHAGE NOS	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	3 (1%)	2 (<1%)	6 (<1%)	0 (0%)	0 (0%)	0 (0%)
DIARRHEA NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	3 (1%)	0 (0%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)
ABDOMINAL PAIN UPPER	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (1%)	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
DUODENITIS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
ESOPHAGITIS NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
ABDOMINAL PAIN NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
DIVERTICULUM INTESTINAL	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
DUODENAL ULCER	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
GASTRIC ULCER	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
GASTRITIS NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
INGUINAL HERNIA NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
PEPTIC ULCER	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
PEPTIC ULCER HEMORRHAGE	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
PERITONEAL DISORDER NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
PERITONITIS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	O (O%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0왕)
RECTAL PROLAPSE	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
VOLVULUS OF BOWEL	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
VOMITING NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
RESPIRATORY, THORACIC AND	0 (0%)	3 (1%)	4 (1%)	0 (0%)	6 (2%)	4 (1%)	14 (1%)	1 (1%)	0 (0%)	0 (0%)
MEDIASTINAL DISORDERS										
DYSPNEA NOS	0 (0%)	1 (<1%)	4 (1%)	0 (0%)	1 (<1%)	2 (<1%)	7 (<1%)	0 (0%)	0 (0%)	0 (0%)
CHRONIC OBSTRUCTIVE AIRWAYS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (1%)	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
DISEASE										
ASTHMA NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
DYSPNEA EXACERBATED	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
EMPHYSEMA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
EPISTAXIS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
PLEURAL EFFUSION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
PNEUMONIA VIRAL NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
PULMONARY CONGESTION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)
RESPIRATORY FAILURE (EXC	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	O (0%)	0 (0%)
NEONATAL)	· , · ,	- ,,	- ,,							
GENERAL DISORDERS AND	1 (6%)	5 (1%)	2 (1%)	1 (1%)	1 (<1%)	6 (1%)	10 (1%)	0 (0%)	1 (5%)	0 (0%)
ADMINISTRATION SITE CONDITIONS						- 4 - 4.5	<i>- (</i>	0 / 071	0 / 001	0 (0%)
CHEST PAIN NEC	0 (0%)	2 (<1%)	2 (1%)	0 (0%)	0 (0%)	3 (<1%)	5 (<1%)	0 (0%)	0 (0%)	0 (0%)
DEATH NOS	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	1 (5%)	0 (0%)

Note: One patient in study ACS201-HYA-002A received both 75 IU Vitrase and Saline. This patient is included in both groups here. Twelve patients in the "Probe Study" received two injections of 75 IU Vitrase. These patients are only counted once here.

[1] Other Active treatments include SF6 (PVD-01-08961X) and ACS-101C (COR-01-08961X). Patients who received both Vitrase and another active study

treatment are included in both groups.

Table 5.1 Incidence of Serious Adverse Events by System Organ Class All Studies by Treatment Safety Population

			Hemorrha	ge Clearance	Studies			Oth	er Indicatio	ons
	Cont	rol			Vitrase					A. 1
System Organ Class / Preferred Term	ww	Saline	7.5 IU	37.5 IU	55 IV	75 IU	Total Vitrase	Vitrase 50-500 IU	Saline Control	Other Active [1]
NUMBER ORGAN PARTIES	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
MULTI-ORGAN FAILURE FALL	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
MASS NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	O (0%)
PYREXIA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
RIGORS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
SENSATION OF PRESSURE NOS	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
WEAKNESS	1 (6%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
INJURY AND POISONING	0 (0%)	4 (1%)	2 (1%)	0 (0%)	2 (1%)	8 (1%)	12 (1%)	0 (0%)	0 (0%)	0 (0%) 0 (0%)
HIP FRACTURE	0 (0%)	2 (<1%)	1 (<1%)	0 (0%)	0 (0%)	3 (<1%)	4 (<1%)	0 (0%)	0 (0%)	0 (0%)
FEMUR FRACTURE NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
LACERATION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (<1%)	2 (<1%)	0 (0%) 0 (0%)	0 (0%)	0 (0%)
ACCIDENTAL OVERDOSE (THERAPEUTIC	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (00)	0 (00)
AGENT)						0 (00)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
FOOT FRACTURE	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
INJURY NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%) 1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
LEG FRACTURE	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%) 0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
MEDICATION ERROR	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%) 0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	
TIBIA FRACTURE	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (04)	7 (<1.9)	1 (110)			
NEOPLASMS BENIGN AND MALIGNANT (INCLUDING CYSTS AND POLYPS)	0 (0%)	3 (1%)	2 (1%)	0 (0%)	1 (<1%)	4 (1%)	7 (<1%)	0 (0%)	0 (0%)	
BREAST CANCER FEMALE NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
CHRONIC LEUKEMIA NOS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	
COLON CANCER NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	
METASTASES TO LUNG	0 (0%)	0 (0%)	1 (<1%)	⊖ (ਹ%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	7 1 2
MYELODYSPLASTIC SYNDROME NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	
NONHODGKIN'S LYMPHOMA NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	• i i i i	
PROSTATE CANCER NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%) 0 (0%)	0 (0%)	- ' ' '
RADIOACTIVE IODINE THERAPY	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	- 1 - 1	0 (0%)	
RESPIRATORY TRACT NEOPLASM NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%) 1 (<1%)	0 (0%) 0 (0%)	0 (0%)	
SKIN NEOPLASM NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (00)	0 (50,
ENDOCRINE DISORDERS	0 (0%)	4 (1%)	0 (0%)	0 (0%)	1 (<1%)	3 (<1%)	4 (<1%)	0 (0%)	0 (0%)	
DIABETES MELLITUS INADEQUATE CONTROL	0 (0%)	4 (1%)	0 (0%)	0 (0%)	1 (<1%)	3 (<1%)	4 (<1%)	0 (0%)	0 (0%)	0 (0%)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	1 (<1%)	4 (1%)	6 (<1%)	0 (0%)	0 (0%)	0 (0%)

Note: One patient in study ACS201-HYA-002A received both 75 IU Vitrase and Saline. This patient is included in both groups here. Twelve patients in the "Probe Study" received two injections of 75 IU Vitrase. These patients are only counted once here.

^[1] Other Active treatments include SF6 (PVD-01-08961X) and ACS-101C (COR-01-08961X). Patients who received both Vitrase and another active study treatment are included in both groups.

s:\dat\acs\iss2002\sas\programs\t_sae_treat 06SEP2002 17:33

Table 5.1 Incidence of Serious Adverse Events by System Organ Class All Studies by Treatment Safety Population

			Hemorrha	ge Clearance	Studies			Other Indications		
	Contr	ol			Vitrase					
System Organ Class / Preferred Term	ww	Saline	7.5 IU	37.5 IU	55 IU	75 IU	Total Vitrase	Vitrase 50-500 IU	Saline Control	Other Active [1]
ANEMIA NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	1 (<1%)	2 (<1%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)
ANAEMIA NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
ANEMIA NOS AGGRAVATED	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
DISSEMINATED INTRAVASCULAR COAGULATION	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
SKIN & SUBCUTANEOUS TISSUE DISORDERS	0 (0%)	3 (1%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	2 (<1%)	1 (1%)	1 (5%)	1 (1%)
DERMATITIS ALLERGIC	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	O (0%)	0 (0%)	0 (0%)
DIABETIC FOOT ULCER	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
ECCHYMOSIS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
ERYTHEMA NEC	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (5%)	0 (0%)
FOOT ULCER	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	1 (1%) 0 (0%)
SKIN LESION NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
URTICARIA NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
MUSCULOSKELETAL, CONNECTIVE TISSUE AND BONE DISORDERS	0 (0%)	0 (0%)	4 (1%)	0 (0%)	1 (<1%)	1 (<1%)	6 (<1%)	0 (0%)	0 (0%)	0 (0%)
PAIN IN LIMB	0 (0%)	0 (0%)	3 (1%)	0 (0%)	1 (<1%)	0 (0%)	4 (<1%)	0 (0%)	0 (0%)	0 (0%)
ARTHRALGIA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%) 0 (0%)
ROTATOR CUFF SYNDROME	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	O (0%)	0 (0%)	0 (0%)
PSYCHIATRIC DISORDERS	0 (0%)	3 (1%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%) 0 (0%)
CONFUSION	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
DELIRIUM	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
DEPRESSION NEC	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%) 0 (0%)	0 (0%)	0 (0%)	0 (0%)
DISORIENTATION	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%) 0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
HALLUCINATION NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
SCHIZOPHRENIA NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (04)	0 (0%)	0 (0%)	0 (00,		
GENERAL DISORDERS AND ADMINISTRATIVE SITE CONDITIONS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	2 (1%)	0 (0%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)
AXILLARY MASS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%) 0 (0%)	0 (0%)
LOWER EXTREMITY MASS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%) 0 (0%)	0 (0%) 0 (0%)	0 (0%)
WEAKNESS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (04)	0 (0%)
HEPATO-BILIARY DISORDERS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%) 0 (0%)	0 (0%) 0 (0%)
CHOLELITHIASIS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%) 0 (0%)	0 (0%)	0 (0%)
HEPATITIS NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)

Note: One patient in study ACS201-HYA-002A received both 75 IU Vitrase and Saline. This patient is included in both groups here. Twelve patients in the "Probe Study" received two injections of 75 IU Vitrase. These patients are only counted once here.

[1] Other Active treatments include SF6 (PVD-01-08961X) and ACS-101C (COR-01-08961X). Patients who received both Vitrase and another active study

treatment are included in both groups.

s:\dat\acs\iss2002\sas\programs\t_sae_treat 06SEP2002 17:33

Page 10 of 10

ISTA Pharmaceuticals, Inc. Integrated Summary of Safety

Table 5.1 Incidence of Serious Adverse Events by System Organ Class All Studies by Treatment Safety Population

	Hemorrhage Clearance Studies							Other Indications		
	Conti	rol			Vitrase_					·
System Organ Class / Preferred Term	WW	Saline	7.5 IU	37.5 IU	55 IU	75 IU	Total Vitrase	Vitrase 50-500 IU	Saline Control	Other Active [1]
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
PYREXIA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
IMMUNE SYSTEM DISORDERS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
KIDNEY TRANSPLANT REJECTION	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
REPRODUCTIVE AND BREAST DISORDERS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
PROSTATITIS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
REPRODUCTIVE SYSTEM AND BREAST DISORDERS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
PROSTATITIS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

Note: One patient in study ACS201-HYA-002A received both 75 IU Vitrase and Saline. This patient is included in both groups here. Twelve patients in the "Probe Study" received two injections of 75 IU Vitrase. These patients are only counted once here.

^[1] Other Active treatments include SF6 (PVD-01-08961X) and ACS-101C (COR-01-08961X). Patients who received both Vitrase and another active study treatment are included in both groups.

Table 5.2 Incidence of Serious Adverse Events by System Organ Class All Studies by Study for Vitrase Groups Only Safety Population

System Organ Class / Preferred Term	Phase I [1]	V-01-VIT-08961X	ACS202-HYA-001US	ACS203-HYA-001MEX	VIT-02-08961X	VIT-03-08961X	Other Indications [2]
NUMBER OF PATIENTS	68	31	153	225	602	364	84
NUMBER OF PATIENTS WITH AT LEAST ONE SERIOUS ADVERSE EVENT	0 (0.0%)	10 (32.3%)	30 (19.6%)	1 (0.4%)	322 (53.5%)	119 (32.7%)	27 (32.1%)
EYE DISORDERS VITREOUS HEMORRHAGE RETINAL DETACHMENT RUBEOSIS IRIDIS CATARACT SUBCAPSULAR CATARACT NUCLEAR IRIS ADHESIONS BLINDNESS NEC CATARACT CORTICAL VISUAL ACUITY REDUCED GLAUCOMA NOS CATARACT NEC VITREOUS HAEMORRHAGE INTRAOCULAR PRESSURE INCREASED VITREOUS DETACHMENT HYPOPYON EYE DEGENERATIVE DISORDER NOS HYPHEMA MACULAR EDEMA VITREOUS FLOATERS CATARACT NOS AGGRAVATED IRITIS RETINOPATHY DIABETIC EYE PAIN MACULAR OEDEMA MACULOPATHY PUPILLARY REPLEX IMPAIRED CORNEAL EDEMA EYE IRRITATION OCULAR HYPERAEMIA PHOTOPHOBIA AGGRAVATED RETINAL ISCHEMIA VITREOUS DISORDER NOS CHOROIDAL DETACHMENT CORNEAL OEDEMA HYPOTONY OF EYE PHOTOPSIA POSTERIOR CAPSULE OPACIFICATION	0 (0.0%)	2 (6.5%)	17 (11.1%)	1 (0.4%)	240 (39.9%)	91 (25.0%)	26 (31.0%)
VITREOUS HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	143 (23.8%)	45 (12.4%)	0 (0.0%)
RETINAL DETACHMENT	0 (0.0%)	2 (6.5%)	7 (4.6%)	1 (0.4%)	53 (8.8%)	27 (7.4%)	0 (0.0%)
RUBEOSIS IRIDIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	35 (5.8%)	3 (0.8%)	1 (1.2%)
CATARACT SUBCAPSULAR	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	26 (4.3%)	6 (1.6%)	5 (6.0%)
CATARACT NUCLEAR	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	16 (2.7%)	2 (0.5%)	2 (2.4%)
IRIS ADHESIONS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	13 (2.2%)	6 (1.6%)	1 (1.2%)
BLINDNESS NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	15 (2.5%)	4 (1.1%)	0 (0.0%)
CATARACT CORTICAL	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	9 (1.5%)	5 (1.4%)	2 (2.4%)
VISUAL ACUITY REDUCED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.5%)	2 (0.5%)	11 (13 1%)
GLAUCOMA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	10 (1.7%)	3 (0.8%)	0 (0.0%)
CATARACT NEC	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	4 (0.7%)	5 (1.4%)	1 (1.2%)
VITREOUS HAEMORRHAGE	0 (0.0%)	1 (3.2%)	7 (4.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (3.6%)
INTRAOCULAR PRESSURE INCREASED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (1.0%)	3 (0.8%)	0 (0.0%)
VITREOUS DETACHMENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	8 (1.3%)	0 (0.0%)	1 (1.2%)
HYPOPYON	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (0.8%)	1 (0.3%)	1 (1.2%)
EYE DEGENERATIVE DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (1.0%)	0 (0.0%)	0 (0.0%)
НУРНЕМА	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (1.0%)	0 (0.0%)	0 (0.0%)
MACULAR EDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (0.8%)	1 (0.3%)	0 (0.0%)
VITREOUS FLOATERS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	4 (4.8%)
CATARACT NOS AGGRAVATED	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	3 (0.5%)	1 (0.3%)	0 (0.0%)
IRITIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.5%)	0 (0.0%)	2 (2.4%)
RETINOPATHY DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	3 (0.8%)	0 (0.0%)
EYE PAIN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (4.8%)
MACULAR OEDEMA	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (3.6%)
MACULOPATHY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (0.7%)	0 (0.0%)	0 (0.0%)
PUPILLARY REFLEX IMPAIRED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (4.8%)
CORNEAL EDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	1 (0.3%)	0 (0.0%)
EYE IRRITATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (3.6%)
OCULAR HYPERAEMIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (3.6%)
PHOTOPHOBIA AGGRAVATED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (3.6%)
RETINAL ISCHEMIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.5%)	0 (0.0%)	0 (0.0%)
VITREOUS DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	1 (1.2%)
CHOROIDAL DETACHMENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	1 (0.3%)	0 (0.0%)
CORNEAL OEDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
HYPOTONY OF EYE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
PHOTOPSIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
POSTERIOR CAPSULE OPACIFICATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)

^[1] Includes ACS201-HYA-001A, ACS201-HYA-002A, Probe Study [2] Includes PVD-01-08961X, COR-01-08961X, COP-01-08961X

s:\dat\acs\iss2002\sas\programs\t_sae_study 06SEP2002 17:33

Table 5.2 Incidence of Serious Adverse Events by System Organ Class All Studies by Study for Vitrase Groups Only Safety Population

System Organ Class / Preferred Term	Phase I [1]	V-01-VIT-08961X	ACS202-HYA-001US	ACS203-HYA-001MEX	VIT-02-08961X	VIT-03-08961X	Other Indications [2]
		0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	1 (0.3%)	0 (0.0%)
PSEUDOPHAKIA RETINAL DEGENERATION RETINAL HEMORRHAGE RETINAL TEAR (EXC DETACHMENT) ABNORMAL SENSATION IN EYE	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
RETINAL HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
RETINAL TEAR (EXC DETACHMENT)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
ABNORMAL SENSATION IN EYE	0 (0.0%)	0 (0.0%)	0 (0,0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
ACCOMMODATION DISORDER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
ACCOMMODATION DISORDER CHORIORETINAL DISORDER NOS CHOROIDAL HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
CHOROIDAL HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
CONJUNCTIVAL EDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
CONJUNCTIVAL HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
CORECTOPIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
CONJUNCTIVAL EDEMA CONJUNCTIVAL HEMORRHAGE CORECTOPIA CORNEAL DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
CORNEAL EROSION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
CORNEAL EROSION CORNEAL GRAFT REJECTION	0 (0.0%)	0 (0,0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
CORNEAL INFILTRATES	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
CORNEAL OPACITY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
CORNEAL ULCER NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
EYE DISCHARGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
EYE INFECTION FUNGAL NOS	0 (0.0%)	0 (0.0%)	0 (.0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
INTRAOCULAR PRESSURE DECREASED		0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
IRIS VASCULAR DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
KERATITIS NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
KERATOCONJUNCTIVITIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
LACRIMATION INCREASED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
OCULAR HYPEREMIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
OPEN ANGLE GLAUCOMA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
OPTIC DISC HEMORRHAGE	0 (0.0%)	0 (0,0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
PHOTOPHOBIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
RETINAL ARTERY EMBOLISM	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
		0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
RETINAL NEOVASCULARIZATION NOS VISION BLURRED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
CARDIAC DISORDERS	0 (0.0%)	2 (6.5%)	7 (4.6%)	0 (0.0%)	55 (9.1%)	11 (3.0%)	0 (0.0%)
MYOCARDIAL INFARCTION	0 (0.0%)	2 (6.5%)	3 (2.0%)	0 (0.0%)	14 (2.3%)	3 (0.8%)	0 (0.0%)
CARDIAC FAILURE CONGESTIVE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	13 (2.2%)	3 (0.8%)	0 (0.0%)
ANGINA UNSTABLE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	8 (1.3%)	0 (0.0%)	0 (0.0%)
CARDIAC ARREST	0 (0,0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	7 (1.2%)	1 (0.3%)	0 (0.0%)
CARDIAC FAILURE NOS	0 (0.0%)	0 (0 0%)	1 (0 7%)	0 (0.0%)	2 (0.3%)	1 (0.3%)	0 (0.0%)
ARRHYTHMIA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	1 (0.3%)	0 (0.0%)
ATRIAL FIBRILLATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	2 (0.5%)	0 (0.0%)
CORONARY ARTERY OCCLUSION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.5%)	0 (0.0%)	0 (0.0%)
PULMONARY EDEMA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	2 (0.5%)	0 (0.0%)
AORTIC VALVE STENOSIS	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.7%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)

^[1] Includes ACS201-HYA-001A, ACS201-HYA-002A, Probe Study [2] Includes PVD-01-08961X, COR-01-08961X, COP-01-08961X

Table 5.2
Incidence of Serious Adverse Events by System Organ Class
All Studies by Study for Vitrase Groups Only
Safety Population

System Organ Class / Preferred Term	Phase I [1]	V-01-VIT-08961X		ACS203-HYA-001MEX		VIT-03-08961X	Other Indications [2]
-1							
CORONARY ARTERY DISEASE NOS	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
LEFT VENTRICULAR FAILURE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	1 (0.3%)	0 (0.0%)
ANGINA PECTORIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
ATRIOVENTRICULAR BLOCK NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
BRADYCARDIA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
CARDIAC DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
CARDIO-RESPIRATORY ARREST	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
CARDIOGENIC SHOCK	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
CARDIOMYOPATHY NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
CARDIOVASCULAR DISORDER NOS	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
DYSPNEA PAROXYSMAL NOCTURNAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
DYSPNOEA NOS	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
MYOCARDIAL ISCHEMIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
PALPITATIONS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
INVESTIGATIONS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	56 (9.3%)	9 (2.5%)	1 (1.2%)
INTRAOCULAR PRESSURE INCREASED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	54 (9.0%)	8 (2.2%)	1 (1.2%)
BLOOD GLUCOSE FLUCTUATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
INTRACCIILAR PRESSIRE ARNORMAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
BLOOD GLUCOSE INCREASED INTRAOCULAR PRESSURE ABNORMAL WEIGHT DECREASED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
INFECTIONS AND INFESTATIONS	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	27 (4.5%)	8 (2.2%)	2 (2.4%)
PNEUMONIA NOS	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	7 (1.2%)	1 (0.3%)	0 (0.0%)
CELLULITIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (0.8%)	1 (0.3%)	0 (0.0%)
OSTEOMYELITIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (1.0%)	0 (0.0%)	0 (0.0%)
LOCALISED INFECTION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.5%)	1 (0.3%)	0 (0.0%)
SEPSIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	2 (0.5%)	0 (0.0%)
BRONCHITIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.5%)	0 (0.0%)	0 (0.0%)
STAPHYLOCOCCAL INFECTION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
AMERICAN TRYPANOSOMIASIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
BACTERIAL INFECTION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
BRONCHITIS ACUTE NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
CELLULITIS STAPHYLOCOCCAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
KERATITIS HERPETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
KIDNEY INFECTION NOS	0 (0 0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
LUNG INFECTION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
LUNG INFECTION NOS OSTEOMYELITIS CHRONIC NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
PULMONARY TUBERCULOSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
SEPTIC ARTHRITIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
SEPTICEMIA STAPHYLOCOCCAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
SKIN INFECTION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
URINARY TRACT INFECTION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)

^[1] Includes ACS201-HYA-001A, ACS201-HYA-002A, Probe Study

^[2] Includes PVD-01-08961X, COR-01-08961X, COP-01-08961X

s:\dat\acs\iss2002\sas\programs\t_sae_study 06SEP2002 17:33

Table 5.2 Incidence of Serious Adverse Events by System Organ Class All Studies by Study for Vitrase Groups Only Safety Population

System Organ Class / Preferred Term	Phase I [1]	V-01-VIT-08961X	ACS202-HYA-001US	ACS203-HYA-001MEX	VIT-02-08961X	VIT-03-08961X	Other Indications [2]
SURGICAL AND MEDICAL PROCEDURES	0 (0.0%)	2 (6.5%)	0 (0.0%)	0 (0.0%)	31 (5.1%)	0 (0.0%)	0 (0.0%)
VITRECTOMY	0 (0.0%)	2 (6.5%)	0 (0.0%)	0 (0.0%)	6 (1.0%)	0 (0.0%)	0 (0.0%)
POST-OPERATIVE COMPLICATIONS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	7 (1.2%)	0 (0.0%)	0 (0.0%)
UNSPECIFIED COMPLICATION OF PROCEDURE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (0.7%)	0 (0.0%)	0 (0.0%)
NEC							
CORONARY ARTERY SURGERY	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%)	3 (0.5%)	0 (0.0%)	0 (0.0%)
FOOT AMPUTATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
TOE AMPUTATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
ARTERIAL BYPASS OPERATION (EXC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
BLOOD PRODUCT TRANSFUSION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
CARDIAC PACEMAKER INSERTION	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
CAROTID ENDARTERECTOMY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
FOOT OPERATION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
HIP ARTHROPLASTY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
KNEE ARTHROPLASTY	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	0 (0.0%)	1 (0.2%) 1 (0.2%) 1 (0.2%) 1 (0.2%)	0 (0.0%)	0 (0.0%)
LEG AMPUTATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
LIMB OPERATION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
CORONARY ARTERY) BLOOD PRODUCT TRANSFUSION CARDIAC PACEMAKER INSERTION CAROTID ENDARTERECTOMY FOOT OPERATION NOS HIP ARTHROPLASTY KNEE ARTHROPLASTY LEG AMPUTATION LIMB OPERATION NOS POST PROCEDURAL HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
NERVOUS SYSTEM DISORDERS CEREBROVASCULAR ACCIDENT NOS SYNCOPE		0 (0.0%)	2 (1.3%)	0 (0.0%)	21 (3.5%)	6 (1.6%)	3 (3.6%)
CEREBROVASCULAR ACCIDENT NOS	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	9 (1.5%)	6 (1.6%)	0 (0.0%)
SYNCOPE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (0.7%) 0 (0.0%)	0 (0.0%)	0 (0.0%)
HEADACHE NOS DIZZINESS (EXC VERTIGO)	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
DIZZINESS (EXC VERTIGO)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0 0%)	0 (0.0%)
CONVULSIONS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%) 1 (0.2%)	Q (O.O%)	0 (0.0%)
HEMIPARESIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
CONVULSIONS NOS HEMIPARESIS HEMORRHAGIC STROKE HYDOAPERTUSIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
HYPOAESTHESIA IIIRD NERVE PARALYSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
IIIRD NERVE PARALYSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
LACUNAR INFARCTION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
PUPILLARY DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
RENAL AND URINARY DISORDERS	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	15 (2.5%)	6 (1.6%)	1 (1.2%)
RENAL FAILURE NOS	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	11 (1.8%)	1 (0.3%)	1 (1.2%)
RENAL FAILURE ACUTE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	4 (1.1%)	0 (0.0%)
CALCULUS RENAL NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
GLOMERULONEPHRITIS CHRONIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
RENAL ARTERY STENOSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
RENAL AND URINARY DISORDERS RENAL FAILURE NOS RENAL FAILURE ACUTE CALCULUS RENAL NOS GLOMERULONEPHRITIS CHRONIC RENAL ARTERY STENOSIS RENAL IMPAIRMENT NOS	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
VASCULAR DISORDERS GANGRENE NOS	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	17 (2.8%)	5 (1.4%)	0 (0.0%)
GANGRENE NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.5%)	1 (0.3%)	0 (0.0%)

^[1] Includes ACS201-HYA-001A, ACS201-HYA-002A, Probe Study [2] Includes PVD-01-08961X, COR-01-08961X, COP-01-08961X

Table 5.2 Incidence of Serious Adverse Events by System Organ Class All Studies by Study for Vitrase Groups Only Safety Population

System Organ Class Preferred Term Phase [1] V-01-VIT-09913 ACS202-HFA-001US ACS203-HFA-001HE VIT-02-09912 VIT-03-09913 Indications [2]	System Organ Class / Preferred Term	Phase I [1]	V-01-VIT-08961X	ACS202-HYA-001US	ACS203-HYA-001MEX	VIT-02-08961X	VIT-03-08961X	Other Indications [2]
TRANSIENT ISCHEMIC ATTACK 0 (0,0\$)		·			·			
TRANSIENT ISCHEMIC ATTACK 0 (0,0\$)	HYPERTENSION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	0 (0.0%)
TRANSIENT ISCHEMIC ATTACK 0 (0,0\$)	HYPOTENSION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
ARTERIAL AMEURYSM NOS 0 (0.0%)	TRANSIENT ISCHEMIC ATTACK	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
PERIPHERAL VASCULAR DISEASE NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.2%) 0 (0.0%			0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
PERIPHERAL VASCULAR DISEASE NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.2%) 0 (0.0%	ARTERIAL OCCLUSION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
PERIPHERAL VASCULAR DISEASE NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.2%) 0 (0.0%	CEREBROVASCULAR ACCIDENT NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
PERIPHERAL VASCULAR DISEASE NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.2%) 0 (0.0%	COLLAPSE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
PERIPHERAL VASCULAR DISEASE NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.2%) 0 (0.0%	HEMATOMA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
PERIPHERAL VASCULAR DISEASE NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.2%) 0 (0.0%	HYPERTENSION AGGRAVATED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
POSTURAL HYPOTENSION 0 (0.0\$) 1 (1.2\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 1 (1.2\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 1 (1.2\$) 0 (0.0\$) 0 (0.0\$) 1 (1.2\$) 0 (0.0\$)	ISCHEMIC FOOT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
POSTURAL HYPOTENSION 0 (0.0\$) 1 (1.2\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 1 (1.2\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 1 (1.2\$) 0 (0.0\$) 0 (0.0\$) 1 (1.2\$) 0 (0.0\$)	PERIPHERAL VASCULAR DISEASE NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
METABOLISM AND NUTRITION DISORDERS 0 (0.0%) 1 (3.2%) 1 (0.7%) 0 (0.0%) 11 (1.8%) 5 (1.4%) 1 (1.2%) HYPOGLYCAEMIA NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 5 (0.8%) 0 (0.0%) 1 (1.2%) DIABETIC COMA NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 1 (0.3%) 0 (0.0%) HYPERCLYCEMIA NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETIC NEUROPATHY NEC 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETIC AMYOTROPHY 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETIC COMPLICATION NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETIC EYE DISEASE NOS 0 (0.0%) 1 (3.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETIC KETOACIDOSIS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) HYPOGLYCAEMIA O (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) HYPOGLYCAEMIC COMA CETINOPATHY DIABETIC GASTROINTESTINAL DISORDERS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETINAL HEMORRHAGE NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETIC STINAL HEMORRHAGE NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	POSTURAL HYPOTENSION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
METABOLISM AND NUTRITION DISORDERS 0 (0.0%) 1 (3.2%) 1 (0.7%) 0 (0.0%) 11 (1.8%) 5 (1.4%) 1 (1.2%) HYPOGLYCAEMIA NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 5 (0.8%) 0 (0.0%) 1 (1.2%) DIABETIC COMA NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) HYPERCLYCEMIA NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETIC NEUROPATHY NEC 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETIC AMYOTROPHY 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETIC COMPLICATION NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETIC EYE DISEASE NOS 0 (0.0%) 1 (3.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETIC KETOACIDOSIS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) HYPERCALEMIA 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) HYPOGLYCAEMIC COMA RETINOPATHY DIABETIC GASTROINTESTINAL DISORDERS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETINAL HEMORRHAGE NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETINAL HEMORRHAGE NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETIC DIABETICAL DISORDERS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	PULMONARY EMBOLISM	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 / n 2%)		0 (0.0%)
METABOLISM AND NUTRITION DISORDERS 0 (0.0%) 1 (3.2%) 1 (0.7%) 0 (0.0%) 11 (1.8%) 5 (1.4%) 1 (1.2%) HYPOGLYCAEMIA NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 5 (0.8%) 0 (0.0%) 1 (1.2%) DIABETIC COMA NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) HYPERCLYCEMIA NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETIC NEUROPATHY NEC 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETIC AMYOTROPHY 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETIC COMPLICATION NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETIC EYE DISEASE NOS 0 (0.0%) 1 (3.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETIC KETOACIDOSIS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) HYPERCALEMIA 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) HYPOGLYCAEMIC COMA RETINOPATHY DIABETIC GASTROINTESTINAL DISORDERS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETINAL HEMORRHAGE NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETINAL HEMORRHAGE NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETIC DIABETICAL DISORDERS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	PULMONARY HYPERTENSION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
METABOLISM AND NUTRITION DISORDERS 0 (0.0%) 1 (3.2%) 1 (0.7%) 0 (0.0%) 11 (1.8%) 5 (1.4%) 1 (1.2%) HYPOGLYCAEMIA NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 5 (0.8%) 0 (0.0%) 1 (1.2%) DIABETIC COMA NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 1 (0.3%) 0 (0.0%) HYPERCLYCEMIA NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETIC NEUROPATHY NEC 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETIC AMYOTROPHY 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETIC COMPLICATION NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETIC EYE DISEASE NOS 0 (0.0%) 1 (3.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETIC KETOACIDOSIS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) HYPOGLYCAEMIA O (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) HYPOGLYCAEMIC COMA CETINOPATHY DIABETIC GASTROINTESTINAL DISORDERS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETINAL HEMORRHAGE NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETIC STINAL HEMORRHAGE NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	THROMBOEMBOLISM NOS	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	0 (0.0%)		0 (0.0%)
METABOLISM AND NUTRITION DISORDERS 0 (0.0%) 1 (3.2%) 1 (0.7%) 0 (0.0%) 11 (1.8%) 5 (1.4%) 1 (1.2%) HYPOGLYCAEMIA NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 5 (0.8%) 0 (0.0%) 1 (1.2%) DIABETIC COMA NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 1 (0.0%)	VENOUS THROMBOSIS DEEP LIMB	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
GASTROINTESTINAL DISORDERS 0 (0.0%) 1 (3.2%) 0 (0.0%) 0 (0.0%) 13 (2.2%) 3 (0.8%) 0 (0.0%) GASTROINTESTINAL HEMORRHAGE NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 5 (0.8%) 1 (0.3%) 0 (0.0%) DIAPPHEA NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)			1 (3.2%)	1 (0.7%)	0 (0.0%)	11 (1.8%)	5 (1.4%)	1 (12%)
GASTROINTESTINAL DISORDERS 0 (0.0%) 1 (3.2%) 0 (0.0%) 0 (0.0%) 13 (2.2%) 3 (0.8%) 0 (0.0%) GASTROINTESTINAL HEMORRHAGE NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 5 (0.8%) 1 (0.3%) 0 (0.0%) DIAPPHEA NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	HYPOGLYCAEMIA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (0.8%)	0 (0.0%)	1 (1.2%)
GASTROINTESTINAL DISORDERS 0 (0.0%) 1 (3.2%) 0 (0.0%) 0 (0.0%) 13 (2.2%) 3 (0.8%) 0 (0.0%) GASTROINTESTINAL HEMORRHAGE NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 5 (0.8%) 1 (0.3%) 0 (0.0%) DIAPPHEA NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	DIABETIC COMA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	1 (0.3%)	0 (0.0%)
GASTROINTESTINAL DISORDERS 0 (0.0%) 1 (3.2%) 0 (0.0%) 0 (0.0%) 13 (2.2%) 3 (0.8%) 0 (0.0%) GASTROINTESTINAL HEMORRHAGE NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 5 (0.8%) 1 (0.3%) 0 (0.0%) DIAPPHEA NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	HYPERGLYCEMIA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.5%)	0 (0.0%)	0 (0.0%)
GASTROINTESTINAL DISORDERS 0 (0.0%) 1 (3.2%) 0 (0.0%) 0 (0.0%) 13 (2.2%) 3 (0.8%) 0 (0.0%) GASTROINTESTINAL HEMORRHAGE NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 5 (0.8%) 1 (0.3%) 0 (0.0%) DIAPPHEA NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	DIABETIC NEUROPATHY NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	0 (0.0%)
GASTROINTESTINAL DISORDERS 0 (0.0%) 1 (3.2%) 0 (0.0%) 0 (0.0%) 13 (2.2%) 3 (0.8%) 0 (0.0%) GASTROINTESTINAL HEMORRHAGE NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 5 (0.8%) 1 (0.3%) 0 (0.0%) DIAPPHEA NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	DIABETES MELLITUS AGGRAVATED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
GASTROINTESTINAL DISORDERS 0 (0.0%) 1 (3.2%) 0 (0.0%) 0 (0.0%) 13 (2.2%) 3 (0.8%) 0 (0.0%) GASTROINTESTINAL HEMORRHAGE NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 5 (0.8%) 1 (0.3%) 0 (0.0%) DIAPPHEA NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	DIABETIC AMYOTROPHY	0 (0.0%)		0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
GASTROINTESTINAL DISORDERS 0 (0.0%) 1 (3.2%) 0 (0.0%) 0 (0.0%) 13 (2.2%) 3 (0.8%) 0 (0.0%) GASTROINTESTINAL HEMORRHAGE NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 5 (0.8%) 1 (0.3%) 0 (0.0%) DIAPPHEA NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	DIABETIC COMPLICATION NOS	0 (0.0%)	· · · · · · · · · · · · · · · · · · ·	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
GASTROINTESTINAL DISORDERS 0 (0.0%) 1 (3.2%) 0 (0.0%) 0 (0.0%) 13 (2.2%) 3 (0.8%) 0 (0.0%) GASTROINTESTINAL HEMORRHAGE NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 5 (0.8%) 1 (0.3%) 0 (0.0%) DIAPPHEA NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	DIABETIC EYE DISEASE NOS	0 (0.0%)	· ·	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
GASTROINTESTINAL DISORDERS 0 (0.0%) 1 (3.2%) 0 (0.0%) 0 (0.0%) 13 (2.2%) 3 (0.8%) 0 (0.0%) GASTROINTESTINAL HEMORRHAGE NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 5 (0.8%) 1 (0.3%) 0 (0.0%) DIAPPHEA NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	DIABETIC KETOACIDOSIS	0 (0.0%)		0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
GASTROINTESTINAL DISORDERS 0 (0.0%) 1 (3.2%) 0 (0.0%) 0 (0.0%) 13 (2.2%) 3 (0.8%) 0 (0.0%) GASTROINTESTINAL HEMORRHAGE NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 5 (0.8%) 1 (0.3%) 0 (0.0%) DIAPPHEA NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	HYPERKALEMIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
GASTROINTESTINAL DISORDERS 0 (0.0%) 1 (3.2%) 0 (0.0%) 0 (0.0%) 13 (2.2%) 3 (0.8%) 0 (0.0%) GASTROINTESTINAL HEMORRHAGE NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 5 (0.8%) 1 (0.3%) 0 (0.0%) DIAPPHEA NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	HYPOGI.YCAEMIC COMA	0 (0.0%)	0 (0.00)	0 (0.0%)	0 (0.0%)	0 (0.0%)		0 (0.0%)
GASTROINTESTINAL DISORDERS 0 (0.0%) 1 (3.2%) 0 (0.0%) 0 (0.0%) 13 (2.2%) 3 (0.8%) 0 (0.0%) GASTROINTESTINAL HEMORRHAGE NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 5 (0.8%) 1 (0.3%) 0 (0.0%) DIAPPHEA NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	RETINOPATHY DIABETIC	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	0 (0.0%)		
0.009 0.00						12 (2 22)	2 (0 00)	0 / 0 00)
0.009 0.009	GASTROINTESTINAL DISORDERS	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)			
DIARRHEA NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (0.3%) 1 (0.3%) 0 (0.0%) ABDOMINAL PAIN UPPER 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.2%) 1 (0.3%) 0 (0.0%) ESOPHAGITIS NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.2%) 1 (0.3%) 0 (0.0%) 0 (0.0%) ABDOMINAL PAIN NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.2%) 0 (0.0%)	GASTROINTESTINAL HEMORRHAGE NOS	0 (0.0%)		0 (0.0%)	0 (0.0%)			
ABDOMINAL PAIN UPPER 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.2%) 1 (0.3%) 0 (0.0%) ESOPHAGITIS NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.2%) 1 (0.3%) 0 (0.0%) ABDOMINAL PAIN NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.2%) 0 (0.0%) 0 (0.0%) DIVERTICULUM INTESTINAL 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.2%) 0 (0.0%)	DIARRHEA NOS	0 (0.0%)		0 (0.0%)	0 (0.0%)	2 (0.3%)	1 (0.3%)	0 (0.0%)
ESOPHAGITIS NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.2%) 1 (0.3%) 0 (0.0%) ABDOMINAL PAIN NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.2%) 0 (0.0%) 0 (0.0%) DIVERTICULUM INTESTINAL 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.2%) 0 (0.0%) DUODENAL ULCER 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.2%) 0 (0.0%) 0 (0.0%) DUODENITIS 0 0 (0.0%) 1 (3.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) GASTRITIS NOS 0 (0.0%) 1 (3.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) INGUINAL HERNIA NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) PEPTIC ULCER 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.2%) 0 (0.0%)	ABDOMINAL PAIN UPPER	0 (0.0%)		0 (0.0%)	0 (0.0%)	1 (0.2%)	1 (0.3%)	0 (0.0%)
ABDOMINAL PAIN NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.2%) 0 (0.0%)	ESOPHAGITIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	1 (0.3%)	0 (0 0%)
DIVERTICULUM INTESTINAL 0 (0.0%)	ABDOMINAL PAIN NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	ి 0 (0.0%)	0 (0.0%)
DUODENIAL ULCER 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.2%) 0 (0.0%) 0 (0.0%) DUODENITIS 0 (0.0%) 1 (3.2%) 0 (0.0%)	DIVERTICULUM INTESTINAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
DUODENITIS 0 (0.0%) 1 (3.2%) 0 (0.0%) <	DUODENAL ULCER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
GASTRITIS NOS 0 (0.0%) 1 (3.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	DUODENITIS	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
INGUINAL HERNIA NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) PEPTIC ULCER 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.2%) 0 (0.0%)	GASTRITIS NOS	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PEPTIC ULCER 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.2%) 0 (0.0%) 0 (0.0%)	INGUINAL HERNIA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0 0%)
	PEPTIC ULCER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)

^[1] Includes ACS201-HYA-001A, ACS201-HYA-002A, Probe Study
[2] Includes PVD-01-08961X, COR-01-08961X, COP-01-08961X

s:\dat\acs\iss2002\sas\programs\t_sae_study 06SEP2002 17:33

Table 5.2 Incidence of Serious Adverse Events by System Organ Class All Studies by Study for Vitrase Groups Only Safety Population

	Phase I [1]		ACS202-HYA-001US	ACS203-HYA-001MEX	VIT-02-08961X	VIT-03-08961X	Other Indications [2]
PEPTIC ULCER HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (.0.0%)
PERITONEAL DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
PERITONITIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
RECTAL PROLAPSE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
VOMITING NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	13 (2.2%)	1 (0.3%)	1 (1.2%)
DYSPNEA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	7 · (1.2%)	0 (0.0%)	0 (0.0%)
CHRONIC OBSTRUCTIVE AIRWAYS DISEASE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
DYSPNEA EXACERBATED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
EMPHYSEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
EPISTAXIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
PLEURAL EFFUSION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
PULMONARY CONGESTION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
RESPIRATORY FAILURE (EXC NEONATAL)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
INJURY AND POISONING	0 (0.0%)	1 (3.2%)	2 (1.3%)	0 (0.0%)	5 (0.8%)	4 (1.1%)	0 (0.0%)
HIP FRACTURE	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	2 (0.3%)	1 (0.3%)	0 (0.0%)
LACERATION	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
ACCIDENTAL OVERDOSE (THERAPEUTIC AGENT)	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
FEMUR FRACTURE NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
FOOT FRACTURE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
INJURY NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
LEG FRACTURE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
TIBIA FRACTURE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	0 (0.0%)	2 (6.5%)	1 (0.7%)	0 (0.0%)	7 (1.2%)	0 (0.0%)	0 (0.0%)
CHEST PAIN NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (0.8%)	0 (0.0%)	0 (0.0%)
DEATH NOS	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
FALL	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
MASS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
MULTI-ORGAN FAILURE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
PYREXIA	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
RIGORS	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
SENSATION OF PRESSURE NOS	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
NEOPLASMS BENIGN AND MALIGNANT (INCLUDING CYSTS AND POLYPS)	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)	4 (0.7%)	2 (0.5%)	0 (0.0%)
CHRONIC LEUKEMIA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
COLON CANCER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)

^[1] Includes ACS201-HYA-001A, ACS201-HYA-002A, Probe Study [2] Includes PVD-01-08961X, COR-01-08961X, COP-01-08961X

s:\dat\acs\iss2002\sas\programs\t_sae_study 06SEP2002 17:33

Table 5.2 Incidence of Serious Adverse Events by System Organ Class All Studies by Study for Vitrase Groups Only Safety Population

System Organ Class / Preferred Term	Phase I [1]	V-01-VIT-08961X	ACS202-HYA-001US	ACS203-HYA-001MEX	VIT-02-08961X	VIT-03-08961X	Other Indications [2]
METASTASES TO LUNG	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
MYELODYSPLASTIC SYNDROME NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
PROSTATE CANCER NOS	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
RESPIRATORY TRACT NEOPLASM NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
SKIN NEOPLASM NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	5 (0.8%)	0 (0.0%)	0 (0.0%)
ANEMIA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.5%)	0 (0.0%)	0 (0.0%)
ANAEMIA NOS	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
ANEMIA NOS AGGRAVATED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
DISSEMINATED INTRAVASCULAR COAGULATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
MUSCULOSKELETAL, CONNECTIVE TISSUE AND BONE DISORDERS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (1.0%)	0 (0.0%)	0 (0.0%)
PAIN IN LIMB	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (0.7%)	0 (0.0%)	0 (0.0%)
ARTHRALGIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
ROTATOR CUFF SYNDROME	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
ENDOCRINE DISORDERS	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	1 (0.3%)	0 (0.0%)
DIABETES MELLITUS INADEQUATE CONTROL	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	1 (0 3%)	0 (0.0%)
GENERAL DISORDERS AND ADMINISTRATIVE SITE CONDITIONS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	1 (0.3%)	0 (0.0%)
AXILLARY MASS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
LOWER EXTREMITY MASS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
WEAKNESS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
SKIN & SUBCUTANEOUS TISSUE DISORDERS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	1 (1.2%)
DIABETIC FOOT ULCER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
FOOT ULCER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	.0 (0.0%)	0 (0.0%)	1 (1.2%)
SKIN LESION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
PSYCHIATRIC DISORDERS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
DELIRIUM	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
DEPRESSION NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
PYREXIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
HEPATO-BILIARY DISORDERS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
HEPATITIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0:0%)	1 (0.3%)	0 (0.0%)
UDEWITITO NOS	0 (0.0%)	0 (0.0%)	0 (0.04)	3 (3.53)	3 (3.207	= • • • • •	•

^[1] Includes ACS201-HYA-001A, ACS201-HYA-002A, Probe Study [2] Includes PVD-01-08961X, COR-01-08961X, COP-01-08961X

s:\dat\acs\iss2002\sas\programs\t_sae_study 06SEP2002 17:33

Page 8 of 8

Table 5.2 Incidence of Serious Adverse Events by System Organ Class All Studies by Study for Vitrase Groups Only Safety Population

System Organ Class / Preferred Term	Phase I [1]	V-01-VIT-08961X	ACS202-HYA-001US	ACS203-HYA-001MEX	VIT-02-08961X	VIT-03-08961X	Other Indications (2)
IMMUNE SYSTEM DISORDERS KIDNEY TRANSPLANT REJECTION	0 (0.0%) 0 (0.0%)	1 (0.2%) 1 (0.2%)	0 (0.0%)	0 (0.0%) 0 (0.0%)			
REPRODUCTIVE AND BREAST DISORDERS PROSTATITIS	0 (0.0%) 0 (0.0%)	1 (0.2%) 1 (0.2%)	0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%)			

^[1] Includes ACS201-HYA-001A, ACS201-HYA-002A, Probe Study [2] Includes PVD-01-08961X, COR-01-08961X, COP-01-08961X

Table 5.3
Incidence of Serious Adverse Events by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Con	trol			
System Organ Class / Preferred Term	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
NUMBER OF PATIENTS	18	378	198	377	391
NUMBER OF PATIENTS WITH AT LEAST ONE SERIOUS ADVERSE EVENT	12 (66.7%)	151 (39.9%)	105 (53.0%)	158 (41.9%)	178 (45.5%)
EYE DISORDERS	7 (38.9%)	100 (26.5%)	79 (39.9%)	119 (31.6%)	133 (34.0%)
VITREOUS HEMORRHAGE	2 (11.1%)	54 (14.3%)	50 (25.3%)	67 (17.8%)	71 (18.2%)
RETINAL DETACHMENT	3 (16.7%)	24 (6.3%)	16 (8.1%)	30 (8.0%)	34 (8.7%)
RUBEOSIS IRIDIS	1 (5.6%)	15 (4.0%)	13 (6.6%)	13 (3.4%)	12 (3.1%)
CATARACT SUBCAPSULAR	1 (5.6%)	5 (1.3%)	6 (3.0%)	12 (3.2%)	14 (3.6%)
BLINDNESS NEC	1 (5.6%)	6 (1.6%)	5 (2.5%)	6 (1.6%)	8 (2.0%)
IRIS ADHESIONS	2 (11.1%)	4 (1.1%)	5 (2.5%)	5 (1.3%)	9 (2.3%)
CATARACT NUCLEAR	0 (0.0%)	2 (0.5%)	5 (2.5%)	6 (1.6%)	7 (1.8%)
GLAUCOMA NOS	0 (0.0%)	5 (1.3%)	4 (2.0%)	4 (1.1%)	5 (1.3%)
CATARACT CORTICAL	0 (0.0%)	2 (0.5%)	2 (1.0%)	7 (1.9%)	5 (1.3%)
CATARACT NEC	0 (0.0%)	5 (1.3%)	1 (0.5%)	4 (1.1%)	4 (1.0%)
INTRAOCULAR PRESSURE INCREASED	0 (0.0%)	1 (0.3%)	5 (2.5%)	1 (0.3%)	3 (0.8%)
НУРНЕМА	0 (0.0%)	3 (0.8%)	2 (1.0%)	2 (0.5%)	2 (0.5%)
MACULAR EDEMA	1 (5.6%)	1 (0.3%)	0 (0.0%)	4 (1.1%)	2 (0.5%)
VISUAL ACUITY REDUCED	0 (0.0%)	3 (0.8%)	1 (0.5%)	4 (1.1%)	0 (0.0%)
VITREOUS DETACHMENT	0 (0.0%)	0 (0.0%)	1 (0.5%)	4 (1.1%)	3 (0.8%)
CATARACT NOS AGGRAVATED	1 (5.6%)	2 (0.5%)	1 (0.5%)	2 (0.5%)	1 (0.3%)
EYE DEGENERATIVE DISORDER NOS	0 (0.0%)	0 (0.0%)	3 (1.5%)	3 (0.8%)	0 (0.0%)
HYPOPYON	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.8%)	3 (0.8%)
	0 (0.0%)	2 (0.5%)	2 (1.0%)	1 (0.3%)	1 (0.3%)
MACULOPATHY	1 (5.6%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	3 (0.8%)
RETINOPATHY DIABETIC	0 (0.0%)	3 (0.8%)	0 (0.0%)	2 (0.5%)	0 (0.0%)
PSEUDOPHAKIA		· · · · · · · · · · · · · · · · · · ·	1 (0.5%)	0 (0.0%)	2 (0.5%)
IRITIS	0 (0.0%)	1 (0.3%)	1 (0.5%)	0 (0.0%)	2 (0.5%)
CORNEAL EDEMA	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)
EYE PAIN	1 (5.6%)	2 (0.5%)	0 (0.0%)		
HYPOTONY OF EYE	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	2 (0.5%)
RETINAL HEMORRHAGE	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
RETINAL ISCHEMIA	0 (0.0%)	0 (0.0%)	1 (0.5%)	2 (0.5%)	0 (0.0%)
VITREOUS FLOATERS	0 (0.0%)	1 (0.3%)	1 (0.5%)	1 (0.3%)	0 (0.0%)
CHOROIDAL DETACHMENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
CONJUNCTIVAL HEMORRHAGE	0 (0.0%)	1 (0.3%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
POSTERIOR CAPSULE OPACIFICATION	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	0 (0.0%)
RETINAL TEAR (EXC DETACHMENT)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
VITREOUS DISORDER NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	0 (0.0%)
CHORIORETINAL DISORDER NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
CHOROIDAL HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
CONJUNCTIVAL EDEMA	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
CORNEAL OPACITY	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
CORNEAL ULCER NEC	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
EYE INFECTION FUNGAL NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
INTRACCULAR PRESSURE DECREASED	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
KERATITIS NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
		, ,			

Table 5.3
Incidence of Serious Adverse Events by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Control				
System Organ Class / Preferred Term			7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
	a / a as.	0 / 0 05)	1 (0.5%)	0 (0.0%)	0 (0.0%)
OCULAR HYPEREMIA	0 (0.0%)	0 (0.0%) 0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
OPEN ANGLE GLAUCOMA NOS	0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)
OPTIC ATROPHY	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
OPTIC DISC HEMORRHAGE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	
RETINAL ARTERY EMBOLISM	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	1 (0.3%) 0 (0.0%)
RETINAL DEGENERATION	0 (0.0%)	0 (0.0%)	1 (0.5%) 0 (0.0%)	0 (0.0%)	
RETINAL DISORDER NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
RETINAL NEOVASCULARIZATION NOS	0 (0.0%)	0 (0.0%)	0 (0.04)	0 (0.0%)	1 (0.3%)
VISION BLURRED	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
CARDIAC DISORDERS	7 (38.9%)	19 (5.0%)	16 (8.1%)	21 (5.6%)	29 (7.4%)
MYOCARDIAL INFARCTION	3 (16.7%)	5 (1.3%)	5 (2.5%)	3 (0.8%)	9 (2.3%)
CARDIAC FAILURE CONGESTIVE	2 (11.1%)	3 (0.8%)	5 (2.5%)	5 (1.3%)	6 (1.5%)
CARDIAC ARREST	0 (0.0%)	2 (0.5%)	1 (0.5%)	5 (1.3%)	2 (0.5%)
ANGINA UNSTABLE	0 (0.0%)	0 (0.0%)	2 (1.0%)	3 (0.8%)	3 (0.8%)
CORONARY ARTERY OCCLUSION	0 (0.0%)	2 (0.5%)	2 (1.0%)	1 (0.3%)	0 (0.0%)
ANGINA PECTORIS	0 (0.0%)	3 (0.8%)		1 (0.3%)	0 (0.0%)
ARRHYTHMIA NOS	0 (0.0%)	1 (0.3%)	0 (0.0%) 1 (0.5%)	2 (0.5%)	0 (0.0%)
ATRIAL FIBRILLATION	0 (0.0%)	1 (0.3%)	0 (0.0%)	2 (0.5%)	1 (0.3%)
PULMONARY EDEMA NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	2 (0.5%)	1 (0.3%)
CARDIAC FAILURE NOS	0 (0.0%)	0 (0.0%)		1 (0.3%)	1 (0.3%)
CARDIAC FAILURE NOS	1 (5.6%)	2 (0.5%)	1 (0.5%) 0 (0.0%)	0 (0.0%)	0 (0.0%)
LEFT VENTRICULAR FAILURE	0 (0.0%)	1 (0.3%)	0 (0.0%)	2 (0.5%)	0 (0.0%)
CARDIO-RESPIRATORY ARREST	1 (5.6%)	0 (0.0%)	0 (0.0%) 0 (0.0%)	2 (0.5%) 0 (0.0%)	1 (0.3%)
CORONARY ARTERY DISEASE NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
MYOCARDIAL ISCHEMIA	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
AORTIC VALVE STENOSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
ATRIOVENTRICULAR BLOCK NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
BRADYCARDIA NOS		•	1 (0.5%)	0 (0.0%)	0 (0.0%)
CARDIAC DISORDER NOS	0 (0.0%)	0 (0.0%)		1 (0.3%)	0 (0.0%)
CARDIOGENIC SHOCK	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
CARDIOMYOPATHY NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)		· · · · · · · · · · · · · · · · · · ·
DYSPNEA PAROXYSMAL NOCTURNAL	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%)	1 (0.3%)
HYPERTROPHIC CARDIOMYOPATHY	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
ISCHEMIC CARDIOMYOPATHY	1 (5.6%)	0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%)	0 (0.0%)
PALPITATIONS	0 (0.0%)	0 (0.0%)	- ,	0 (0.0%)	1 (0.3%)
VENTRICULAR TACHYCARDIA	1 (5.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
INVESTIGATIONS	1 (5.6%)	13 (3.4%)	23 (11.6%)	19 (5.0%)	23 (5.9%)
INTRAOCULAR PRESSURE INCREASED	0 (0.0%)	13 (3.4%)	23 (11.6%)	17 (4.5%)	22 (5.6%)
BLOOD GLUCOSE FLUCTUATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
BLOOD GLUCOSE INCREASED	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
HEMATOCRIT DECREASED	1 (5.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
INTRAOCULAR PRESSURE ABNORMAL	0 (0.0%)	0 (0.0%)	0 (0.0%) 1 (0.5%)	0 (0.0%)	0 (0.0%)
WEIGHT DECREASED	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
	- , ,	•	•		

Table 5.3
Incidence of Serious Adverse Events by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Contr	ol.			
System Organ Class / Preferred Term	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
INFECTIONS AND INFESTATIONS	1 (5.6%)	10 (2.6%)	8 (4.0%)	14 (3.7%)	13 (3.3%)
PNEUMONIA NOS	0 (0.0%)	2 (0.5%)	2 (1.0%)	4 (1.1%)	2 (0.5%)
CELLULITIS	0 (0.0%)	2 (0.5%)	0 (0.0%)	2 (0.5%)	4 (1.0%)
OSTEOMYELITIS NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	3 (0.8%)	2 (0.5%)
LOCALISED INFECTION	0 (0.0%)	1 (0.3%)	1 (0.5%)	2 (0.5%)	1 (0.3%)
SEPSIS NOS	0 (0.0%)	1 (0.3%)	1 (0.5%)	2 (0.5%)	1 (0.3%)
BRONCHITIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	2 (0.5%)
INFECTED SKIN ULCER	0 (0.0%)	2 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
STAPHYLOCOCCAL INFECTION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	0 (0.0%)
AMERICAN TRYPANOSOMIASIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
BACTERIAL INFECTION NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
BRONCHITIS ACUTE NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
BRONCHOPNEUMONIA NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CELLULITIS STAPHYLOCOCCAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
INFLUENZA	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
LUNG INFECTION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
OSTEOMYELITIS CHRONIC NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
PULMONARY TUBERCULOSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
PYELONEPHRITIS NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
SEPTIC ARTHRITIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
SEPTICEMIA STAPHYLOCOCCAL	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
SKIN INFECTION NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
URINARY TRACT INFECTION NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
UROSEPSIS	1 (5.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
SURGICAL AND MEDICAL PROCEDURES	1 (5.6%)	13 (3.4%)	11 (5.6%)	11 (2.9%)	9 (2.3%)
VITRECTOMY	0 (0.0%)	6 (1.6%)	2 (1.0%)	3 (0.8%)	1 (0.3%)
	0 (0.0%)	- ,	2 (1.0%)	3 (0.8%)	2 (0.5%)
POST-OPERATIVE COMPLICATIONS NOS	0 (0.0%)	2 (0.5%) 1 (0.3%)	2 (1.0%)	1 (0.3%)	1 (0.3%)
UNSPECIFIED COMPLICATION OF PROCEDURE NEC		•	0 (0.0%)	0 (0.0%)	3 (0.8%)
CORONARY ARTERY SURGERY	1 (5.6%) 0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
FOOT AMPUTATION		•	0 (0.0%)	2 (0.5%)	0 (0.0%)
TOE AMPUTATION	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
ARTERIAL BYPASS OPERATION (EXC CORONARY ARTERY)	0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
BLOOD PRODUCT TRANSFUSION	0 (0.0%)	•		0 (0.0%)	0 (0.0%)
CARDIAC OPERATION NOS	0 (0.0%)	1 (0.3%)	0 (0.0%) 1 (0.5%)	0 (0.0%)	0 (0.0%)
CARDIAC PACEMAKER INSERTION	0 (0.0%)	0 (0.0%)	· · · · · · · · · · · · · · · · · · ·	0 (0.0%)	0 (0.0%)
CAROTID ENDARTERECTOMY	0 (0.0%)	0 (0.0%)	1 (0.5%)		0 (0.0%)
DEVICE FAILURE NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%) 0 (0.0%)	1 (0.3%)
FOOT OPERATION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)		= 1 7 17
HIP ARTHROPLASTY	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%) 0 (0.0%)
HOSPITALIZATION NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	
KNEE ARTHROPLASTY	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
LEG AMPUTATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
LIMB OPERATION NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
METATARSAL EXCISION	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
POST PROCEDURAL HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)

Table 5.3

Incidence of Serious Adverse Events by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Contr	rol			
System Organ Class / Preferred Term	WW		7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
WOUND DEBRIDEMENT	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
RENAL AND URINARY DISORDERS	4 (22.2%)	12 (3.2%)	7 (3.5%)	6 (1.6%)	8 (2.0%)
RENAL FAILURE NOS	1 (5.6%)	5 (1.3%)	4 (2.0%)	3 (0.8%)	5 (1.3%)
RENAL FAILURE ACUTE	3 (16.7%)	3 (0.8%)	2 (1.0%)	2 (0.5%) 0 (0.0%)	2 (0.5%)
RENAL FAILURE CHRONIC	1 (5.6%)	2 (0.5%)	2 (1.0%) 0 (0.0%)	0 (0.0%)	0 (0.0%)
RENAL ARTERY STENOSIS	0 (0.0%)	1 (0.3%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
CALCULUS RENAL NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
GLOMERULONEPHRITIS CHRONIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%) 0 (0.0%)	0 (0.0%)
RENAL FAILURE CHRONIC AGGRAVATED	1 (5.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
RENAL IMPAIRMENT NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
RENAL VASCULAR DISORDER NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
VASCULAR DISORDERS	0 (0.0%)	14 (3.7%)	6 (3.0%)	8 (2.1%)	8 (2.0%)
HYPERTENSION NOS	0 (0.0%)	3 (0.8%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
GANGRENE NOS	0 (0.0%)	0 (0.0%)	2 (1.0%) 0 (0.0%)	1 (0.3%)	1 (0.3%)
PERIPHERAL VASCULAR DISEASE NOS	0 (0.0%)	3 (0.8%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
TRANSIENT ISCHEMIC ATTACK	0 (0.0%)	2 (0.5%)	0 (0.0%) 0 (0.0%)	1 (0.3%)	1 (0.3%)
HYPERTENSION AGGRAVATED	0 (0.0%)	2 (0.5%)		1 (0.3%)	0 (0.0%)
HYPOTENSION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%) 1 (0.5%)	1 (0.3%)	1 (0.3%)
ARTERIAL ANEURYSM NOS	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%) 0 (0.0%)
ARTERIAL OCCLUSION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%) 0 (0.0%)	0 (0.0%)
CEREBRAL INFARCTION	0 (0.0%)	1 (0.3%)	0 (0.0%) 0 (0.0%)	0 (0.0%)	0 (0.0%)
CEREBRAL ISCHEMIA	0 (0.0%)	1 (0.3%) 0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
CEREBROVASCULAR ACCIDENT NOS	0 (0.0%) 0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
COLLAPSE	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)
HEMATOMA NOS ISCHEMIC FOOT	0 (0.0%)	0 (0.0%)	1 (0.5%) 0 (0.0%)	1 (0.3%)	0 (0.0%)
POSTURAL HYPOTENSION	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
PULMONARY EMBOLISM	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
PULMONARY HYPERTENSION NOS	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)
SUBARACHNOID HEMORRHAGE NOS	0 (0.0%)	1 (0.3%)	1 (0.5%) 0 (0.0%)	0 (0.0%)	0 (0.0%)
THROMBOEMBOLISM NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
VENOUS THROMBOSIS DEEP LIMB	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
NERVOUS SYSTEM DISORDERS	1 (5.6%)	7 (1.9%)	7 (3.5%)	8 (2.1%)	12 (3.1%)
CEREBROVASCULAR ACCIDENT NOS	1 (5.6%)	4 (1.1%)	3 (1.5%)	5 (1.3%)	7 (1.8%)
SYNCOPE	0 (0.0%)	1 (0.3%)	1 (0.5%)	1 (0.3%)	2 (0.5%)
DIZZINESS (EXC VERTIGO)	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	0 (0.0%)
HEMORRHAGIC STROKE	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
COMA NEC	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CONVULSIONS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
DEPRESSED LEVEL OF CONSCIOUSNESS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
HEMIPARESIS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
HYPOAESTHESIA	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
LACUNAR INFARCTION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)

s:\dat\acs\iss2002\sas\programs\t_sae_dose 06SEP2002 17:33

Table 5.3
Incidence of Serious Adverse Events by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Contro	ol				
System Organ Class / Preferred Term	<u> </u>	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase	
PUPILLARY DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	
METABOLISM AND NUTRITION DISORDERS	2 (11.1%)	7 (1.9%)	3 (1.5%)	4 (1.1%)	9 (2.3%)	
HYPOGLYCAEMIA NOS	0 (0.0%)	2 (0.5%)	0 (0.0%)	0 (0.0%)	5 (1.3%)	
HYPERGLYCEMIA NOS	0 (0.0%)	1 (0.3%)	1 (0.5%)	2 (0.5%)	0 (0.0%)	
DEHYDRATION	1 (5.6%)	2 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
DIABETIC COMA NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	2 (0.5%)	
HYPERKALEMIA	1 (5.6%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	
DIABETIC COMPLICATION NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
DIABETIC NEUROPATHY NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	
DIABETES MELLITUS AGGRAVATED	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	
DIABETIC AMYOTROPHY	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	
DIABETIC KETOACIDOSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
HYPOGLYCAEMIC COMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	
NONKETOTIC HYPERGLYCEMIC-HYPEROSMOLAR COMA	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
GASTROINTESTINAL DISORDERS	0 (0.0%)	3 (0.8%)	1 (0.5%)	9 (2.4%)	6 (1.5%)	
GASTROINTESTINAL HEMORRHAGE NOS	0 (0.0%)	1 (0.3%)	1 (0.5%)	3 (0.8%)	2 (0.5%)	
DIARRHEA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.8%)	0 (0.0%)	
ABDOMINAL PAIN UPPER	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	0 (0.0%)	
ESOPHAGITIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	
ABDOMINAL PAIN NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
DIVERTICULUM INTESTINAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	
DUODENAL ULCER	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	
DUODENITIS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
GASTRIC ULCER	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
INGUINAL HERNIA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	
PEPTIC ULCER	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	
PEPTIC ULCER HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
PERITONEAL DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
PERITONITIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
RECTAL PROLAPSE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	
VOLVULUS OF BOWEL	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
VOMITING NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	0 (0.0%)	3 (0.8%)	4 (2.0%)	6 (1.6%)	4 (1.0%)	
DYSPNEA NOS	0 (0.0%)	1 (0.3%)	4 (2.0%)	1 (0.3%)	2 (0.5%)	
CHRONIC OBSTRUCTIVE AIRWAYS DISEASE	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	0 (0.0%)	
ASTHMA NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
DYSPNEA EXACERBATED	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	
EMPHYSEMA	0 (0.0%)	0 (0.0%)	0 (0 0%)	1 (0.3%)	0 (0.0%)	
EPISTAXIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	
PLEURAL EFFUSION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
PNEUMONIA VIRAL NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	

Table 5.3
Incidence of Serious Adverse Events by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Contro	ol			
System Organ Class / Preferred Term	ww -	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	1 (5.6%)	4 (1.1%)	2 (1.0%)	1 (0.3%)	4 (1.0%)
CHEST PAIN NEC	0 (0.0%)	2 (0.5%)	2 (1.0%)	0 (0.0%)	3 (0.8%)
MULTI-ORGAN FAILURE	0 (0.0%)	1 (0.3%)		0 (0.0%)	1 (0.3%)
DEATH NOS	0 (0.0%)	1 (0.3%)	0 (0.0%) 0 (0.0%) 0 (0.0%)	0 (0.0%)	0 (0.0%)
FALL	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
MASS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%)	1 (0.3%)	0 (0.0%)
WEAKNESS	1 (5.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
INJURY AND POISONING	0 (0.0%)	3 (0.8%)	0 (0.0%)	2 (0.5%)	7 (1.8%)
HIP FRACTURE	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	3 (0.8%)
FEMUR FRACTURE NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
FOOT FRACTURE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
INJURY NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
LACERATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%)	1 (0.3%) 1 (0.3%)
LEG FRACTURE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
MEDICATION ERROR	0 (0.0%) 0 (0.0%)	1 (0.3%) 0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%)	1 (0.3%)
TIBIA FRACTURE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.50)
NEOPLASMS BENIGN AND MALIGNANT (INCLUDING CYSTS AND POLYPS)	0 (0.0%)	2 (0.5%)	2 (1.0%)	1 (0.3%)	3 (0.8%)
CHRONIC LEUKEMIA NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
COLON CANCER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
METASTASES TO LUNG	0 (0.0%)	0 (0.0%)	1 (0.5%) 0 (0.0%)	0 (0.0%)	0 (0.0%)
MYELODYSPLASTIC SYNDROME NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
NONHODGKIN'S LYMPHOMA NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
RADIOACTIVE IODINE THERAPY	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%) 1 (0.3%)
RESPIRATORY TRACT NEOPLASM NOS	0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%)	1 (0.3%)	0 (0.0%)
SKIN NEOPLASM NOS	0 (0.0%)	0 (0.04)	0 (0.0%)	1 (0.3%)	0 (0.0%)
ENDOCRINE DISORDERS	0 (0.0%)	4 (1.1%)	0 (0.0%)	1 (0.3%)	2 (0.5%)
DIABETES MELLITUS INADEQUATE CONTROL	0 (0.0%)	4 (1.1%)	0 (0.0%)	1 (0.3%)	2 (0.5%)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	0 (0.0%)	1 (0.3%)	1 (0.5%)	1 (0.3%)	
ANEMIA NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	2 (0.5%)
ANEMIA NOS AGGRAVATED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
DISSEMINATED INTRAVASCULAR COAGULATION	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
MUSCULOSKELETAL, CONNECTIVE TISSUE AND BONE DISORDERS	0 (0.0%)	0 (0.0%)	4 (2.0%)	1 (0.3%)	1 (0.3%)
PAIN IN LIMB	0 (0.0%)	0 (0.0%)	3 (1.5%)	1 (0.3%)	0 (0.0%)
ARTHRALGIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
ROTATOR CUFF SYNDROME	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
PSYCHIATRIC DISORDERS	0 (0.0%)	3 (0.8%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
CONFUSION	0 (0.0%)	2 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
DELIRIUM	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
DEPRESSION NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
DISORIENTATION	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Table 5.3
Incidence of Serious Adverse Events by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Contro	ol			
System Organ Class / Preferred Term	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
HALLUCINATION NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	O (0.0%)
SCHIZOPHRENIA NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
GENERAL DISORDERS AND ADMINISTRATIVE SITE CONDITIONS	0 (0.0%)	0 (0.0%)	1 (0.5%)	2 (0.5%)	0 (0.0%)
AXILLARY MASS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
LOWER EXTREMITY MASS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
WEAKNESS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
SKIN & SUBCUTANEOUS TISSUE DISORDERS	0 (0.0%)	1 (0.3%)	1 (0.5%)	1 (0.3%)	0 (0.0%)
DIABETIC FOOT ULCER	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
SKIN LESION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
URTICARIA NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
HEPATO-BILIARY DISORDERS	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
CHOLELITHIASIS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
HEPATITIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
PYREXIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
IMMUNE SYSTEM DISORDERS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
KIDNEY TRANSPLANT REJECTION	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
REPRODUCTIVE AND BREAST DISORDERS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
PROSTATITIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
REPRODUCTIVE SYSTEM AND BREAST DISORDERS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PROSTATITIS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Table 5.4
Incidence of Serious Adverse Events by System Organ Class
PVD Study (PVD-01-08961X) by Treatment
Safety Population

System Organ Class / Preferred Term	Vitrase 75 IU	SF6	Vitrase 75 IU + SF6	Saline
NUMBER OF PATIENTS	15	15	14	16
NUMBER OF PATIENTS WITH AT LEAST ONE SERIOUS ADVERSE EVENT	9 (60%)	7 (47%)	9 (64%)	14 (88%)
EYE DISORDERS	9 (60%)	7 (47%)	9 (64%)	13 (81%)
VISUAL ACUITY REDUCED	6 (40%)	3 (20%)	4 (29%)	6 (38%)
VITREOUS FLOATERS	4 (27%)	2 (13%)	0 (0%)	5 (31%)
CATARACT SUBCAPSULAR	2 (13%)	1 (7%)	2 (14%)	4 (25%)
EYE PAIN	2 (13%) 2 (13%)	0 (0%)	1 (7%)	3 (19%)
MACULAR OEDEMA	1 (7%)	0 (0%)	2 (14%)	3 (19%)
PHOTOPHOBIA AGGRAVATED	3 (20%)	0 (0%)	0 (0%)	3 (19%)
VITREOUS HAEMORRHAGE	2 (13%)	0 (0%)	1 (7%)	3 (19%)
PHOTOPSIA	2 (13%)	0 (0%) 1 (7%)	0 (0%)	1 (6%)
PUPILLARY REFLEX IMPAIRED	3 (20%)	0 (0%)	1 (7%)	0 (0%)
VITREOUS DETACHMENT	3 (20%) 1 (7%)	3 (20%)	0 (0%)	0 (0%)
ABNORMAL SENSATION IN EYE	1 (7%)	0 (0%)	0 (0%)	2 (13%)
CATARACT CORTICAL	0 (0%)	1 (7%)	0 (0%) 2 (14%)	0 (0%)
LACRIMATION INCREASED	1 (7%)	0 (0%)	0 (0%)	2 (13%)
CATARACT NUCLEAR	2 (13%)	0 (0%)	0 (0%)	0 (0%)
IRITIS	1 / 7%	1 (7%)	0 (0%)	
EYE IRRITATION	1 (7%)	ር (0%)	0 (0%) 0 (0%)	0 (0%)
HYPOPYON	1 (7%)		0 (0%)	0 (0%)
IRIS VASCULAR DISORDER NOS	1 (/8)	0 (0%)	0 (0%)	0 (0%)
The state of the s	1 (7%)	0 (0%)	0 (0%)	0 (0%)
RUBEOSIS IRIDIS	1 (7%)	0 (0%)		
VITREOUS DISORDER NOS	1 (/6)	0 (01)	0 (0%)	0 (0%)
INFECTIONS AND INFESTATIONS	1 (7%)	0 (0%)	0 (0%)	1 (6%)
BLEPHARITIS	0 (0%)	0 (0%)	0 (0%)	1 (6%)
KIDNEY INFECTION NOS	1 (7%)	0 (0%)	0 (0%)	0 (0%)
SKIN & SUBCUTANEOUS TISSUE	0 (0%)	0 (0%)	1 (7%)	1 (6%)
ERYTHEMA NEC	ዕ (ዕ%)	0 (0%)	0 (0%)	1 (6%)
FOOT ULCER	0 (0%)	0 (0%)	1 (7%)	0 (0%)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	0 (0%)	0 (0%)	0 (0%)	1 (6%)
DEATH NOS	0 (0%)	0 (0%)	0 (0%)	1 (6%)
METABOLISM AND NUTRITION DISORDERS	0 (0%)	0 (0%)	1 (7%)	0 (0%)
HYPOGLYCAEMIA NOS	0 (0%)	0 (0%)		0 (0%)
Manager and manager and	0 / 0%)	D 1 0%\	7 / 7%\	0 (0%)
NERVOUS SYSTEM DISORDERS IIIRD NERVE PARALYSIS	0 (0%) 0 (0%)	0 (0%) 0 (0%)	1 (7%) 1 (7%)	0 (0%)

Table 5.4 Incidence of Serious Adverse Events by System Organ Class PVD Study (PVD-01-08961X) by Treatment Safety Population

			Vitrase 75 IU	
System Organ Class / Preferred Term	Vitrase 75 IU	SF6	+ SF6	Saline

RENAL AND URINARY DISORDERS	1 (7%)	0 (0%)	0 (0%)	0 (0%)
RENAL FAILURE NOS	1 (7%)	0 (0%)	0 { 0%}	0 (0%)

Page 1 of 6

ISTA Pharmaceuticals, Inc. Integrated Summary of Safety

Table 6

Incidence of Serious Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period of Onset

Safety Population
Treatment: WW Control (n = 18)

System Organ Class / Preferred Term	Day 0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
NUMBER OF PATIENTS WITH AT LEAST ONE SERIOUS ADVERSE EVENT	0 (0.0%)	0 (0.0%)	1 (5.6%)	2 (11.1%)	1 (5.6%)	4 (22.2%)	2 (11.1%)
EYE DISORDERS	0 (0.0%)	0 (0.0%)	1 (5,6%)	2 (11.1%)	1 (5.6%)	4 (22.2%)	2 (11.1%)
RETINAL DETACHMENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (16.7%)	0 (0.0%)
IRIS ADHESIONS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)	1 (5.6%)
BLINDNESS NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)
CATARACT NOS AGGRAVATED	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CATARACT SUBCAPSULAR	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)
MACULAR EDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)
RUBEOSIS IRIDIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
VITREOUS HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Table 6
Incidence of Serious Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period of Onset
Safety Population

Treatment: Saline Control (n = 378)

System Organ Class / Preferred Term	Day 0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
NUMBER OF PATIENTS WITH AT LEAST ONE SERIOUS ADVERSE EVENT	5 (1.3%)	3 (0.8%)	5 (1.3%)	8 (2.1%)	20 (5.3%)	32 (8.5%)	40 (10.6%)
EYE DISORDERS	2 (0.5%)	1 (0.3%)	4 (1.1%)	7 (1.9%)	18 (4.8%)	24 (6.3%)	39 (10.3%)
VITREOUS HEMORRHAGE	0 (0.0%)	0 (0.0%)	1 (0.3%)	5 (1.3%)	9 (2.4%)	14 (3.7%)	10 (2.6%)
RETINAL DETACHMENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	4 (1.1%)	4 (1.1%)	9 (2.4%)
RUBEOSIS IRIDIS	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	4 (1.1%)	1 (0.3%)	6 (1.6%)
CATARACT SUBCAPSULAR	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (1.1%)
BLINDNESS NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	2 (0.5%)
CATARACT NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	3 (0.8%)
GLAUCOMA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	3 (0.8%)
IRIS ADHESIONS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (1.1%)
НУРНЕМА	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	0 (0.0%)
PSEUDOPHAKIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	1 (0.3%)
VISUAL ACUITY REDUCED	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	1 (0.3%)
CATARACT CORTICAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)
CATARACT CONTICAL CATARACT NOS AGGRAVATED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
CATARACT NUCLEAR	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)
EYE PAIN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	0 (0.0%)
CONJUNCTIVAL HEMORRHAGE	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
HYPOTONY OF EYE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
INTRAOCULAR PRESSURE INCREASED		0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
	0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
IRITIS	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
MACULAR EDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
MACULOPATHY	0 (0.0%)	0 (0.0%)			, ,	0 (0.0%)	1 (0.3%)
OPTIC ATROPHY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
RETINAL DISORDER NOS	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
INVESTIGATIONS	2 (0.5%)	2 (0.5%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	5 (1.3%)	1 (0.3%)
INTRAOCULAR PRESSURE INCREASED	2 (0.5%)	2 (0.5%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	5 (1.3%)	1 (0.3%)
SURGICAL AND MEDICAL PROCEDURES	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	5 (1.3%)	0 (0.0%)
VITRECTOMY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	3 (0.8%)	0 (0.0%)
POST-OPERATIVE COMPLICATIONS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	0 (0.0%)
UNSPECIFIED COMPLICATION OF PROCEDURE NEC	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
NEOPLASMS BENIGN AND MALIGNANT (INCLUDING CYSTS AND POLYPS)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
RADIOACTIVE IODINE THERAPY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)

59

Events are included in the period in which they began.

Table 6
Incidence of Serious Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period of Onset
Safety Population
Treatment: 7.5 IU Vitrase (n = 198)

System Organ Class / Preferred Term	Day 0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
NUMBER OF PATIENTS WITH AT LEAST ONE SERIOUS ADVERSE EVENT	6 (3.0%)	5 (2.5%)	13 (6.6%)	18 (9.1%)	15 (7.6%)	35 (17.7%)	34 (17.29
EYE DISORDERS	1 (0.5%)	3 (1.5%)	9 (4.5%)	14 (7.1%)	15 (7.6%)	31 (15.7%)	33 (16.79
VITREOUS HEMORRHAGE	0 (0.0%)	1 (0.5%)	5 (2.5%)	7 (3.5%)	6 (3.0%)	16 (8.1%)	16 (8.1%
RETINAL DETACHMENT	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.5%)	4 (2.0%)	4 (2.0%)	6 (3.0
RUBEOSIS IRIDIS	0 (0.0%)	0 (0.0%)	3 (1.5%)	3 (1.5%)	3 (1.5%)	1 (0.5%)	6 (3.0
CATARACT SUBCAPSULAR	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	4 (2.0%)	1 (0.5
INTRAOCULAR PRESSURE INCREASED	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.0%)	0 (0.0%)	2 (1.0%)	2 (1.0
IRIS ADHESIONS	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.5%)	2 (1.0
BLINDNESS NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	3 (1.5
CATARACT NUCLEAR	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (2.0
GLAUCOMA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (1.5%)	1 (0.5
EYE DEGENERATIVE DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (1.5
CATARACT CORTICAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.0
HYPHEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.5
	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.5
MACULOPATHY		0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9
CATARACT NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
CATARACT NOS AGGRAVATED	1 (0.5%)				0 (0.0%)	0 (0.0%)	1 (0.9
CHORIORETINAL DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9
CONJUNCTIVAL EDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)		1 (0.5%)		•
CONJUNCTIVAL HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0
CORNEAL EDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5
CORNEAL ULCER NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5
INTRAOCULAR PRESSURE DECREASED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.
IRITIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.
OCULAR HYPEREMIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
OPEN ANGLE GLAUCOMA NOS	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.
OPTIC DISC HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.
POSTERIOR CAPSULE OPACIFICATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.
RETINAL DEGENERATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
RETINAL ISCHEMIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
VISION BLURRED	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.
VISUAL ACUITY REDUCED	0 (0.0%)	0 (0.0%)	0 (0.0%)	. 0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.
VITREOUS DETACHMENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.
VITREOUS DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
VITREOUS FLOATERS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.
INVESTIGATIONS INTRAOCULAR PRESSURE INCREASED	3 (1.5%)	2 (1.0%)	3 (1.5%)	3 (1.5%)	1 (0.5%)	8 (4.0%)	5 (2.5
INTRAOCULAR PRESSURE INCREASED	3 (1.5%)	2 (1.0%)	3 (1.5%)	3 (1.5%)	1 (0.5%)	8 (4.0%)	5 (2.5
SURGICAL AND MEDICAL PROCEDURES POST-OPERATIVE COMPLICATIONS NOS UNSPECIFIED COMPLICATION OF PROCEDURE NEC	2 (1.0%)		1 (0.5%)	1 (0.5%)	0 (0.0%)	2 (1.0%)	0 (0.0
POST-OPERATIVE COMPLICATIONS NOS	0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.0%)	0 (0.0
UNSPECIFIED COMPLICATION OF PROCEDURE NEC	2 (1.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0

Events are included in the period in which they began.

s:\dat\acs\iss2002\sas\programs\t_ocsae_onset 06SEP2002 17:33

Page 4 of 6

ISTA Pharmaceuticals, Inc. Integrated Summary of Safety

Table 6

Incidence of Serious Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period of Onset Safety Population

Treatment: 7.5 IU Vitrase (n = 198)

System Organ Class / Preferred Term	Day 0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
VITRECTOMY	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Table 6 Incidence of Serious Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period of Onset Safety Population

Treatment: 55 IU Vitrase (n = 377)

System Organ Class / Preferred Term	Day 0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
NUMBER OF PATIENTS WITH AT LEAST ONE SERIOUS ADVERSE EVENT	7 (1.9%)	7 (1.9%)	14 (3.7%)	18 (4.8%)	21 (5.6%)	39 (10.3%)	38 (10.1%)
EYE DISORDERS	5 (1.3%)	7 (1.9%)	13 (3.4%)	16 (4.2%)	21 (5.6%)	35 (9.3%)	34 (9.0%)
VITREOUS HEMORRHAGE	0 (0.0%)	0 (0.0%)	5 (1.3%)	8 (2.1%)	13 (3.4%)	17 (4.5%)	12 (3.2%)
RETINAL DETACHMENT	0 (0.0%)	3 (0.8%)	4 (1.1%)	3 (0.8%)	5 (1.3%)	9 (2.4%)	8 (2.1%)
CATARACT SUBCAPSULAR	0 (0.0%)	2 (0.5%)	0 (0.0%)	2 (0.5%)	0 (0.0%)	3 (0.8%)	5 (1.3%)
RUBEOSIS IRIDIS	1 (0.3%)	0 (0.0%)	2 (0.5%)	2 (0.5%)	1 (0.3%)	2 (0.5%)	4 (1.1%)
CATARACT CORTICAL	1 (0.3%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	4 (1.1%)
CATARACT NUCLEAR	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	4 (1.1%)
IRIS ADHESIONS	2 (0.5%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)
BLINDNESS NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	2 (0.5%)
VISUAL ACUITY REDUCED	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	2 (0.5%)	1 (0.3%)	0 (0.0%)
VITREOUS DETACHMENT	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	1 (0.3%)
CATARACT NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	2 (0.5%)
GLAUCOMA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	1 (0.3%)
HYPOPYON	2 (0.5%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CATARACT NOS AGGRAVATED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)
EYE DEGENERATIVE DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)
HYPHEMA	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)
MACULAR EDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
RETINAL ISCHEMIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	0 (0.0%)
CHOROIDAL DETACHMENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)
CORNEAL OPACITY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
EYE INFECTION FUNGAL NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
INTRACCULAR PRESSURE INCREASED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
MACULOPATHY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
POSTERIOR CAPSULE OPACIFICATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
PSEUDOPHAKIA RETINAL HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
RETINAL HEMORRHAGE RETINAL TEAR (EXC DETACHMENT)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
INVESTIGATIONS	1 (0.3%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	6 (1.6%)	6 (1.6%)
INTRAOCULAR PRESSURE INCREASED	1 (0.3%)		1 (0.3%)	1 (0.3%)	1 (0.3%)	6 (1.6%)	6 (1.6%)
SURGICAL AND MEDICAL PROCEDURES	1 (0.3%)	0 (0.0%)		1 (0.3%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
POST-OPERATIVE COMPLICATIONS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
UNSPECIFIED COMPLICATION OF PROCEDURE NEC	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
VITRECTOMY	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
NERVOUS SYSTEM DISORDERS	0 (0.0%)			1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PUPILLARY DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Events are included in the period in which they began.

s:\dat\acs\iss2002\sas\programs\t_ocsae_onset 06SEP2002 17:33

Table 6
Incidence of Serious Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period of Onset
Safety Population

Treatment: 75 IU Vitrase (n = 391)

System Organ Class / Preferred Term	Day 0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
NUMBER OF PATIENTS WITH AT LEAST ONE SERIOUS ADVERSE EVENT	14 (3.6%)	7 (1.8%)	13 (3.3%)	16 (4.1%)	21 (5.4%)	50 (12.8%)	51 (13.0%)
EYE DISORDERS	8 (2.0%)	6 (1.5%)	10 (2.6%)	16 (4.1%)	20 (5.1%)	47 (12.0%)	50 (12.8%)
VITREOUS HEMORRHAGE	0 (0.0%)	1 (0.3%)	3 (0.8%)	4 (1.0%)	5 (1.3%)	24 (6.1%)	30 (7.7%)
RETINAL DETACHMENT	0 (0.0%)	0 (0.0%)	2 (0.5%)	4 (1.0%)	6 (1.5%)	17 (4.3%)	8 (2.0%)
CATARACT SUBCAPSULAR	2 (0.5%)	1 (0.3%)	1 (0.3%)	2 (0.5%)	0 (0.0%)	2 (0.5%)	6 (1.5%)
IRIS ADHESIONS	1 (0.3%)	1 (0.3%)	2 (0.5%)	2 (0.5%)	0 (0.0%)	0 (0.0%)	3 (0.8%)
BLINDNESS NEC	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	3 (0.8%)	0 (0.0%)	5 (1.3%)
RUBEOSIS IRIDIS	1 (0.3%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	1 (0.3%)	1 (0.3%)	4 (1.0%)
CATARACT NUCLEAR	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	1 (0.3%)	3 (0.8%)
CATARACT CORTICAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	4 (1.0%)	0 (0.0%)
GLAUCOMA NOS	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	1 (0.3%)	0 (0.0%)
HYPOPYON	2 (0.5%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
INTRAOCULAR PRESSURE INCREASED	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	2 (0.5%)
VITREOUS DETACHMENT	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)
CATARACT NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)
НУРНЕМА	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
HYPOTONY OF EYE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
IRITIS	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%
RETINOPATHY DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	0 (0.0%
CHOROIDAL DETACHMENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%
CHOROIDAL HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%
CORNEAL EDEMA	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
KERATITIS NEC	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
MACULAR EDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%
MACULOPATHY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%
RETINAL ARTERY EMBOLISM	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%
RETINAL TEAR (EXC DETACHMENT)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%
INVESTIGATIONS	6 (1.5%)	1 (0.3%)	3 (0.8%)	1 (0.3%)	1 (0.3%)	8 (2.0%)	5 (1.3%)
INTRAOCULAR PRESSURE INCREASED	6 (1.5%)	1 (0.3%)	3 (0.8%)	1 (0.3%)	1 (0.3%)	8 (2.0%)	5 (1.3%)
SURGICAL AND MEDICAL PROCEDURES	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%
POST-OPERATIVE COMPLICATIONS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
UNSPECIFIED COMPLICATION OF PROCEDURE NEC	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Table 7.1 Incidence of Adverse Events by System Organ Class All Studies by Treatment Safety Population

			Hemorrha	ge Clearance	s Studies			Oth	Other Indications_		
	Cont	rol			Vitrase						
System Organ Class / Preferred Term	ww	Saline	7.5 IU	37.5 IU	55 IU	75 IU	Total Vitrase	Vitrase 50-500 IU	Saline Control	Other Active [1]	
NUMBER OF PATIENTS	18	417	327	130	377	609	1443	84	21	70	
NUMBER OF PATIENTS WITH AT LEAST ONE ADVERSE EVENT	18 (100%)	347 (83%)	221 (68%)	60 (46%)	331 (88%)	458 (75%)	1070 (74%)	75 (89%)	19 (90%)	51 (73%)	
EYE DISORDERS IRITIS	17 (94%) 4 (22%)	334 (80%) 151 (36%)	212 (65%) 124 (38%)	53 (41%) 3 (2%)	323 (86%) 223 (59%)	455 (75%) 274 (45%)	1043 (72%) 624 (43%)	73 (87%) 11 (13%)	18 (86%) 1 (5%)	48 (69%) 5 (7%)	
OCULAR HYPEREMIA	4 (22%)	142 (34%)	113 (35%)	0 (0%)	204 (54%)	215 (35%)	532 (37%)	0 (0%)	0 (0%)	0 (0%)	
EYE PAIN	3 (17%)	86 (21%)	76 (23%)	3 (2%)	140 (37%)	168 (28%)	387 (27%)	15 (18%)	6 (29%)	2 (3%)	
EYE IRRITATION	10 (56%)	123 (29%)	91 (28%)	0 (0%)	132 (35%)	159 (26%)	382 (26%)	15 (18%)	4 (19%)	0 (0%)	
LACRIMATION INCREASED	4 (22%)	103 (25%)	66 (20%)	0 (0%)	124 (33%)	166 (27%)	356 (25%)	9 (11%)	3 (14%)	0 (0%)	
VITREOUS HEMORRHAGE	3 (17%)	99 (24%)	86 (26%)	0 (0%)	111 (29%)	104 (17%)	301 (21%)	0 (0%)	0 (0%)	0 (0%)	
ABNORMAL SENSATION IN EYE	2 (11%)	72 (17%)	62 (19%)	2 (2%)	101 (27%)	123 (20%)	288 (20%)	10 (12%)	5 (24%)	0 (0%)	
VISUAL ACUITY REDUCED	4 (22%)	76 (18%)	79 (24%)	0 (0%)	105 (28%)	102 (17%)	286 (20%)	15 (18%)	6 (29%)	7 (10%)	
VITREOUS FLOATERS	6 (33%)	70 (17%)	66 (20%)	1 (1%)	91 (24%)	105 (17%)	263 (18%)	6 (7%)	5 (24%)	2 (3%)	
PHOTOPHOBIA	6 (33%)	63 (15%)	60 (18%)	0 (0%)	87 (23%)	108 (18%)	255 (18%)	6 (7%)	3 (14%)	0 (0%)	
CONJUNCTIVAL EDEMA	1 (6%)	59 (14%)	48 (15%)	0 (0%)	96 (25%)	89 (15%)	233 (16%)	0 (0%)	0 (0%)	0 (0%)	
HYPOPYON	0 (0%)	0 (0%)	3 (1%)	42 (32%)	6 (2%)	80 (13%)	131 (9%)	2 (2%)	0 (0%)	1 (1%)	
RETINAL DETACHMENT	3 (17%)	35 (8%)	26 (8%)	5 (4%)	38 (10%)	51 (8%)	120 (8%)	0 (0%)	0 (0%)	0 (0%)	
PHOTOPSIA	0 (0%)	23 (6%)	24 (7%)	0 (0%)	45 (12%)	44 (7%)	113 (8%)	3 (4%)	2 (10%)	1 (1%) 5 (7%)	
CATARACT SUBCAPSULAR	2 (11%)	27 (6%)	34 (10%)	1 (1%)	29 (8%)	43 (7%)	107 (7%)	8 (10%)	4 (19%) 0 (0%)	5 (7%) 0 (0%)	
CATARACT NUCLEAR	5 (28%)	36 (9%)	29 (9%)	2 (2%)	37 (10%)	34 (6%)	102 (7%)	2 (2%)		4 (6%)	
EYE DISCHARGE	0 (0%)	31 (7%)	12 (4%)	1 (1%)	23 (6%)	48 (8%)	84 (6%)	10 (12%)	- :	- 1	
CATARACT CORTICAL	5 (28%)	27 (6%)	14 (4%)	1 (1%)	30 (8%)	31 (5%)	76 (5%)	3 (4%)		4 (6%) 0 (0%)	
CORNEAL EDEMA	1 (6%)	12 (3%)	18 (6%)	0 (0%)	22 (6%)	26 (4%)	66 (5%)	0 (0%)	0 (0%)	0 (0%)	
RUBEOSIS IRIDIS	1 (6%)	21 (5%)	17 (5%)	1 (1%)	21 (6%)	25 (4%)	64 (4%)	1 (1%)	0 (0%)	0 (0%)	
MACULAR EDEMA	1 (6%)	12 (3%)	22 (7%)	0 (0%)	16 (4%)	24 (4%)	62 (4%)	0 (0%)	0 (0%) 0 (0%)	0 (0%)	
IRIS ADHESIONS	2 (11%)	14 (3%)	10 (3%)	3 (2%)	13 (3%)	31 (5%)	57 (4%)	2 (2%)	0 (0%)	1 (1%)	
CORNEAL EROSION	1 (6%)	24 (6%)	10 (3%)	0 (0%)	25 (7%)	17 (3%)	52 (4%)	6 (7%)	0 (0%)	22 (31%)	
CORNEAL DISORDER NOS	0 (0%)	8 (2%)	6 (2%)	0 (0%)	18 (5%)	26 (4%)	50 (3%)	26 (31%)	0 (0%)	0 (0%)	
CONJUNCTIVAL HEMORRHAGE	0 (0%)	26 (6%)	12 (4%)	0 (0%)	17 (5%)	18 (3%)	47 (3%)	0 (0%) 0 (0%)	0 (0%)	0 (0%)	
НҮРНЕМА	0 (0%)	6 (1%)	9 (3%)	0 (0%)	14 (4%)	16 (3%)	39 (3%)	- • •	0 (0%)	0 (0%)	
CATARACT NEC	0 (0%)	17 (4%)	3 (1%)	0 (0%)	11 (3%)	21 (3%)	35 (2%)	- •	3 (14%)	2 (3%)	
VITREOUS HAEMORRHAGE	0 (0%)	6 (1%)	9 (3%)	6 (5%)	0 (0%)	18 (3%)	33 (2%) 31 (2%)	3 (4%) 9 (11%)	0 (0%)	8 (11%)	
CONJUNCTIVAL OEDEMA	0 (0%)	17 (4%)	0 (0%)	3 (2%)	0 (0%)	28 (5%)		0 (0%)	0 (0%)	0 (0%)	
RETINOPATHY DIABETIC	1 (6%)	11 (3%)	7 (2%)	1 (1%)	6 (2%)	14 (2%)	;:	0 (0%)	0 (0%)	0 (0%)	
BLINDNESS NEC	1 (6%)	6 (1%)	9 (3%)	0 (0%)	7 (2%)	9 (1%)	25 (2%) 24 (2%)	2 (2%)	0 (0%)	0 (0%)	
DRY EYE NEC	0 (0%)	7 (2%)	7 (2%)	0 (0%)	5 (1%)	12 (2%)	24 (28)	2 (28)	0 (0%)	5 (00)	

Note: One patient in study ACS201-HYA-002A received both 75 IU Vitrase and Saline. This patient is included in both groups here. Twelve patients in the "Probe Study" received two injections of 75 IU Vitrase. These patients are only counted once here.

Ocular Events include events reported for study eye and non-study eye.

^[1] Other Active treatments include SF6 (PVD-01-08961X) and ACS-101C (COR-01-08961X). Patients who received both Vitrase and another active study treatment are included in both groups.

Table 7.1 Incidence of Adverse Events by System Organ Class All Studies by Treatment Safety Population

		Hemorrha	ge Clearance	Studies	Other Indications					
	Con	trol			Vitrase					
							Total	Vitrase	Saline	Other
System Organ Class / Preferred Term	WW	Saline	7.5 IU	37.5 IU	55 IV	75 IU	Vitrase	50-500 IU	Control	Active [1]
	· · · · · · · · · · · · · · · · · · ·									
GLAUCOMA NOS	0 (0%)	6 (1%)	6 (2%)	0 (0%)	6 (2%)	12 (2%)	24 (2%)	0 (0%)	0 (0%)	0 (0%)
VISION BLURRED	0 (0%)	8 (2%)	11 (3%)	0 (0%)	7 (2%)	5 (1%)	23 (2%)	2 (2%)	2 (10%)	0 (0%)
UVEITIS NOS	1 (6%)	2 (<1%)	4 (1%)	3 (2%)	8 (2%)	7 (1%)	22 (2%)	0 (0%)	0 (0%)	0 (0%)
VITREOUS DETACHMENT	1 (6%)	3 (1%)	4 (1%)	0 (0%)	10 (3%)	7 (1%)	21 (1%)	1 (1%)	0 (0%)	3 (4%)
RED EYE	0 (0%)	14 (3%)	1 (<1%)	0 (0%)	0 (0%)	19 (3%)	20 (1%)	3 (4%)	3 (14%)	0 (0%)
KERATITIS NEC	0 (0%)	4 (1%)	4 (1%)	2 (2%)	4 (1%)	9 (1%)	19 (1%)	17 (20%)	0 (0%)	17 (24%)
MACULOPATHY	0 (0%)	5 (1%)	6 (2%)	0 (0%)	6 (2%)	6 (1%)	18 (1%)	0 (0%)	0 (0%)	0 (0%)
BLEPHARITIS	0 (0%)	2 (<1%)	5 (2%)	0 (0%)	3 (1%)	8 (1%)	16 (1%)	0 (0%)	0 (0%)	0 (0%)
EYELID OEDEMA	0 (0%)	1 (<1%)	0 (0%)	1 (1%)	0 (0%)	15 (2%)	16 (1%)	3 (4%)	0 (0%)	3 (4%)
OCULAR HYPERAEMIA	0 (0%)	10 (2%)	0 (0%)	1 (1%)	0 (0%)	15 (2%)	16 (1%)	22 (26%)	5 (24%)	0 (0%)
CATARACT NOS AGGRAVATED	1 (6%)	8 (2%)	6 (2%)	0 (0%).	5 (1%)	4 (1%)	15 (1%)	0 (0%)	0 (0%)	0 (0%)
INTRAOCULAR PRESSURE INCREASED	0 (0%)	3 (1%)	6 (2%)	0 (0%)	3 (1%)	6 (1%)	15 (1%)	0 (0%)	0 (0%)	0 (0%)
RETINAL HEMORRHAGE	0 (0%)	7 (2%)	6 (2%)	0 (0%)	6 (2%)	3 (<1%)	15 (1%)	0 (0%)	0 (0%)	0 (0%)
POSTERIOR CAPSULE OPACIFICATION	0 (0%)	3 (1%)	2 (1%)	0 (0%)	7 (2%)	5 (1%)	14 (1%)	0 (0%)	0 (0%)	0 (0%)
CORNEAL ABRASION	0 (0%)	2 (<1%)	4 (1%)	0 (0%)	5 (1%)	2 (<1%)	11 (1%)	6 (7%)	0 (0%)	7 (10%)
CORNEAL EPITHELIUM DEFECT	1 (6%)	2 (<1%)	3 (1%)	0 (0%)	5 (1%)	2 (<1%)	10 (1%)	2 (2%)	0 (0%)	0 (0%)
DIPLOPIA	0 (0%)	2 (<1%)	3 (1%)	0 (0%)	5 (1%)	2 (<1%)	10 (1%)	0 (0%)	0 (0%)	0 (0%)
HYPOTONY OF EYE	0 (0%)	2 (<1%)	2 (1%)	0 (0%)	2 (1%)	6 (1%)	10 (1%)	0 (0%)	0 (0%)	0 (0%)
RETINAL ISCHEMIA	0 (0%)	1 (<1%)	4 (1%)	0 (0%)	4 (1%)	2 (<1%)	10 (1%)	0 (0%)	0 (0%)	0 (0%)
CONJUNCTIVITIS NEC	0 (0%)	2 (<1%)	4 (1%)	0 (0%)	1 (<1%)	4 (1%)	9 (1%)	14 (17%)	0 (0%)	12 (17%)
IRIS DISORDER NOS	0 (0%)	0 (0%)	1 (<1%)	3 (2%)	0 (0%)	4 (1%)	8 (1%)	0 (0%)	0 (0%)	0 (0%)
RETINAL TEAR (EXC DETACHMENT)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	6 (2%)	2 (<1%)	8 (1%)	0 (0%)	0 (0%)	0 (0%)
EYE DEGENERATIVE DISORDER NOS	0 (0%)	0 (0%)	3 (1%)	0 (0%)	3 (1%)	1 (<1%)	7 (<1%)	0 (0%)	0 (0%)	0 (0%)
POST-OPERATIVE PAIN	1 (6%)	10 (2%)	0 (0%)	0 (0%)	2 (1%)	5 (1%)	7 (<1%)	0 (0%)	0 (0%)	0 (0%)
FOREIGN BODY RETAINED IN EYE	0 (0%)	1 (<1%)	4 (1%)	0 (0%)	2 (1%)	0 (0%)	6 (<1%)	0 (0%)	0 (0%)	0 (0%)
MYDRIASIS	0 (0%)	3 (1%)	2 (1%)	0 (0%)	0 (0%)	4 (1%)	6 (<1%)	0 (0%)	0 (0%)	0 (0%)
CORNEAL OEDEMA	0 (0%)	0 (0%)	0 (0%)	2 (2%)	0 (0%)	3 (<1%)	5 (<1%)	50 (60%)	3 (14%)	27 (39%)
OCULAR HYPERTENSION	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	3 (1%)	2 (<1%)	5 (<1%)	0 (0%)	0 (0%)	0 (0%)
PHOTOPHOBIA AGGRAVATED	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	3 (1%)	1 (<1%)	5 (<1%)	3 (4%)	3 (14%)	0 (0%)
RETINAL NEOVASCULARIZATION NOS	0 (0%)	0 (0%)	0 (ዕ%)	1 (1%)	1 (<1%)	3 (<1%)	5 (<1%)	0 (0%)	0 (0%)	0 (0%)
VITREOUS DISORDER NOS	0 (0%)	2 (<1%)	1 (<1%)	0 (0%)	2 (1%)	2 (<1%)	5 (<1%)	1 (1%)	0 (0%)	0 (0%) 0 (0%)
CONJUNCTIVITIS ALLERGIC	0 (0%)	0 (0%)	1 (<1%)	1 (1%)	1 (<1%)	1 (<1%)	4 (<1%)	0 (0%)	0 (0%)	
EYE ALLERGY	0 (0%)	0 (0%)	0 (0%)	0 (0%)	3 (1%)	1 (<1%)	4 (<1%)	0 (0%)	0 (0%)	0 (0%) 0 (0%)
EYELID PTOSIS	0 (0%)	1 (<1%)	3 (1%)	0 (0%)	0 (0%)	1 (<1%)	4 (<1%)	0 (0%)	0 (0%)	0 (0%)
HYPHAEMA	0 (0%)	0 (0%)	0 (0%)	2 (2%)	0 (0%)	2 (<1%)	4 (<1%)	0 (0%)	- ,	
KERATOCONJUNCTIVITIS	0 (0%)	1 (<1%)	1 (<1%)	1 (1%)	1 (<1%)	1 (<1%)	4 (<1%)	1 (1%) 0 (0%)	0 (0%)	0 (0%) 0 (0%)
MACULAR DEGENERATION	0 (0%)	1 (<1%)	2 (1%)	0 (0%)	2 (1%)	0 (0%)	4 (<1%)	- , : :	0 (0%)	0 (0%)
OPTIC ATROPHY	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	3 (1%)	0 (0%)	4 (<1%)	0 (0%)	0 (04)	0 (0%)

Note: One patient in study ACS201-HYA-002A received both 75 IU Vitrase and Saline. This patient is included in both groups here. Twelve patients in the "Probe Study" received two injections of 75 IU Vitrase. These patients are only counted once here.

Ocular Events include events reported for study eye and non-study eye.

^[1] Other Active treatments include SF6 (PVD-01-08961X) and ACS-101C (COR-01-08961X). Patients who received both Vitrase and another active study treatment are included in both groups.

s:\dat\acs\iss2002\sas\programs\t_ae_treat 06SEP2002 17:33

Table 7.1 Incidence of Adverse Events by System Organ Class All Studies by Treatment Safety Population

					Studies	Other Indications				
	Cont	rol		-	Vitrase					
					-		Total	Vitrase	Saline	Other
System Organ Class / Preferred Term	ww	Saline	7.5 IU	37.5 IU	55 IU 	75 IU	Vitrase	50-500 IU	Control	Active [1]
CORTICAL OPACITY	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	1 (<1%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)
IRIDOCYCLITIS	0 (0%)	0 (0%)	2 (1%)	0 (0%)	1 (<1%)	0 (0%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)
OPEN ANGLE GLAUCOMA NOS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	1 (<1%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)
PAINFUL RED EYES	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	1 (<1%)	2 (<1%)	3 (<1%)	1 (1%)	0 (0%)	0 (0%)
PSEUDOPHAKIA	0 (0%)	3 (1%)	0 (0%)	0 (0%)	3 (1%)	0 (0%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)
RETINAL ARTERY EMBOLISM	0 (0%)	0 (.0%)	2 (1%)	0 (0%)	0 (0%)	1 (<1%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)
RETINAL DISORDER NOS	0 (0%)	1 (<1%)	2 (1%)	0 (0%)	0 (0%)	1 (<1%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)
RETINAL MICROANEURYSMS	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	2 (1%)	0 (0%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)
RETINAL MICROANEURISMS RETINAL SCAR	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (1%)	1 (<1%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)
VISUAL DISTURBANCE NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	3 (<1%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)
APHAKIA	0 (0%)	2 (<1%)	1 (<1%)	0 (0%)	0 (0%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
BLINDNESS TRANSIENT	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
CATARACT UNILATERAL	0 (0%)	0 (0%)	0 (0%)	2 (2%)	0 (0%)	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
CHEMOSIS	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
CHEMOSIS CHOROIDAL DETACHMENT	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
CONJUNCTIVITIS (INFECTIVE) NEC	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
•	1 (6%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
CONJUNCTIVITIS VIRAL NOS CORNEAL OPACITY	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	2 (<1%)	3 (4%)	0 (0%)	2 (3%)
ERYTHEMA NEC	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	Q (0%)
EYE INFLAMMATION NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
HYALOSIS ASTEROID	0 (0%)	3 (1%)	2 (1%)	0 (0%)	0 (0%)	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
INTRAOCULAR PRESSURE DECREASED	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
KERATOPATHY BAND	- 1 1	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
KERATOPATHY NOS		0 (0%)	0 (0%)	1 (1%)	0 (0%)	1 (<1%)	2 (<1%)	4 (5%)	3 (14%)	2 (3%)
MACULAR OEDEMA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
MEIBOMIAN CYST	0 (0%)	0 (0%)	2 (1%)	0 (0%)	0 (0%)	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
OPTIC DISC HEMORRHAGE	0 (0%) 0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (1%)	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
PERIORBITAL HEMATOMA		0 (0%)	1 (<1%)	0 (0%)	0 (0%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
RETINAL DEGENERATION		0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
RETINAL DEPIGMENTATION	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
RETINAL VEIN THROMBOSIS	0 (0%) 0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
STRABISMUS NEC	T 1 T 1	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
VITREOUS OPACITIES	0 (0%)		0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
ANGLE CLOSURE GLAUCOMA	0 (0%)	0 (0%) 0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
ANISEIKONIA	0 (0%)			1 (1%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
ANTERIOR CHAMBER DEGENERATION	0 (0%)	0 (0%)	1 1 1	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
ARCUS SENILIS	0 (0%)	0 (0%)	- · ·-··	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
BLEPHAROCONJUNCTIVITIS	0 (0%)	0.(0%)	0 (0%)	0 (0.8)	7 (< 7.2)	0 (0.8)	1 (~10)	5 , 507	- , 007	- · · · - ·

Note: One patient in study ACS201-HYA-002A received both 75 IU Vitrase and Saline. This patient is included in both groups here. Twelve patients in the "Probe Study" received two injections of 75 IU Vitrase. These patients are only counted once here.

Ocular Events include events reported for study eye and non-study eye.

^[1] Other Active treatments include SF6 (PVD-01-08961X) and ACS-101C (COR-01-08961X). Patients who received both Vitrase and another active study treatment are included in both groups.

s:\dat\acs\iss2002\sas\programs\t_ae_treat 06SEP2002 17:33

Table 7.1 Incidence of Adverse Events by System Organ Class All Studies by Treatment Safety Population

			Other Indications							
	Cont	rol		ge Clearance	Vitrase					
System Organ Class / Preferred Term	ww	Saline	7.5 IU	37.5 IU	55 IU	75 IU	Total Vitrase	Vitrase 50-500 IU	Saline Control	Other Active (1)
BLINDNESS NIGHT BLOODSHOT EYE	0 (0%) 0 (0%)	0 (0%)	0 (0%) 0 (0%)	0 (0%)	0 (0%)	1 (<1%) 1 (<1%)	1 (<1%) 1 (<1%) 1 (<1%)	0 (0%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 0 (0%)	O (0%) O (0%) O (0%)
CCONJUNCTIVAL EDEMA CHALAZION CHORIORETINAL ATROPHY CHORIORETINAL DISORDER NOS CHOROIDAL HEMORRHAGE	0 (0%) 0 (0%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 1 (<1%) 1 (<1%) 0 (0%)	0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)	1 (<1%) 1 (<1%) 0 (0%) 0 (0%) 1 (<1%)	·1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%)	0 (0%) 0 (0%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 0 (0%) 0 (0%)	O (0%) O (0%) O (0%) O (0%)
COLOUR BLINDNESS NEC CONJUNCTIVAL CYST CORNEAL DEGENERATION CORNEAL SCAR	0 (0%) 0 (0%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 0 (0%) 0 (0%)	0 (0%) 1 (<1%) 0 (0%) 1 (<1%)	0 (0%) 0 (0%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 1 (<1%) 0 (0%)	1 (<1%) 0 (0%) 0 (0%) 0 (0%)	1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%)	0 (0%) 0 (0%) 1 (1%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 0 (0%) 0 (0%)
CORNEAL ULCER NEC CYCLITIS EYE HAEMORRHAGE NEC EYE INFECTION FUNGAL NOS	0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)	1 (<1%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%)	0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%)	0 (0%) 1 (<1%) 1 (<1%) 0 (0%) 0 (0%)	1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%)	1 (1%) 2 (2%) 0 (0%) 0 (0%)	O (0%) O (0%) O (0%) O (0%)	O (0%) O (0%) O (0%) O (0%)
EYE INFECTION STAPHYLOCOCCAL EYE INFECTION TOXOPLASMAL EYE INJURY NOS EYELID DISORDER NOS EYELID EDEMA	0 (0%) 0 (0%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 0 (0%) 0 (0%)	0 (0%) 1 (<1%) 0 (0%) 1 (<1%)	1 (<1%) 0 (0%) 1 (<1%) 0 (0%)	1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%)	0 (0%) 0 (0%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 0 (0%)
GLAUCOMA AGGRAVATED HERPES SIMPLEX OPHTHALMIC IRIS VASCULAR DISORDER NOS LACRIMAL DUCT OBSTRUCTION NOS	0 (0%) 0 (0%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 0 (0%) 0 (0%)	1 (<1%) 0 (0%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 1 (1%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%)	0 (0%) 1 (<1%) 0 (0%) 0 (0%) 1 (<1%)	1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%)	0 (0%) 0 (0%) 1 (1%) 0 (0%) 1 (1%)	0 (0%) 0 (0%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 0 (0%)
LENTICULAR OPACITIES OPTIC NEUROPATHY NOS PAPILLEDEMA PINGUECULA PORTE OPENATURE COMPLICATIONS NOS	0 (0%) 0 (0%) 0 (0%) 0 (0%)	2 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 1 (<1%) 1 (<1%) 0 (0%)	1 (1%) 0 (0%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%)	1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%)	0 (0%) 0 (0%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 0 (0%)
POST-OPERATIVE COMPLICATIONS NOS RETINAL ARTERY THROMBOSIS RETINAL VASCULITIS SCLERITIS NOS STYE	0 (0%) 0 (0%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 0 (0%) 0 (0%)	1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%)	0 (0%) 0 (0%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 0 (0%)	1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%)	0 (0%) 0 (0%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 0 (0%)
TIRED EYES TOPOGRAPHY CORNEAL ABNORMAL UVEITIS DIABETIC VISION ABNORMAL NEC VISUAL ACUITY REDUCED TRANSIENTLY	0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%)	0 (0%) 0 (0%) 1 (<1%) 1 (<1%) 0 (0%)	0 (0%) 0 (0%) 0 (0%) 0 (0%)	0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%)	1 (<1%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%)	1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%)	0 (0%) 0 (0%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 0 (0%)

Note: One patient in study ACS201-HYA-002A received both 75 IU Vitrase and Saline. This patient is included in both groups here. Twelve patients in the "Probe Study" received two injections of 75 IU Vitrase. These patients are only counted once here.

Ocular Events include events reported for study eye and non-study eye.

^[1] Other Active treatments include SF6 (PVD-01-08961X) and ACS-101C (COR-01-08961X). Patients who received both Vitrase and another active study treatment are included in both groups.

s:\dat\acs\iss2002\sas\programs\t_ae_treat 06SEP2002 17:33

Table 7.1 Incidence of Adverse Events by System Organ Class All Studies by Treatment Safety Population

			Other Indications							
	Cont	rol		ge Clearance	_Vitrase					
							Total	Vitrase	Saline	Other
System Organ Class / Preferred Term	WW	Saline	7.5 IU	37.5 IU	SS IU	75 IU	Vitrase	50-500 IU	Control	Active [1]
ACCOMMODATION DISORDER	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (2%)	1 (5%)	0 (0%)
CHORIORETINAL SCAR	1 (6%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
CONJUNCTIVAL HAEMORRHAGE	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	1 (5%)	0 (0%)
CONJUNCTIVITIS PAPILLARY	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	1 (1%)
CORECTOPIA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	1 (5%)	0 (0%)
CORNEAL DEPOSITS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	5 (6%)	0 (0%)	3 (4%)
CORNEAL DYSTROPHY	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	1 (1%)
CORNEAL EPITHELIUM DISORDER	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
CORNEAL GRAFT REJECTION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)
CORNEAL INFILTRATES	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	5 (6%)	0 (0%)	3 (4%)
CORNEAL LESION NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	1 (1%)
CORNEAL NEOVASCULARIZATION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (2%)	0 (0%)	0 (0%)
EXOPHTHALMOS ENDOCRINE	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
EYE HEMORRHAGE NEC	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
EYE INFECTION NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
IRIS NEVUS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
LENTICULAR PIGMENTATION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)
OPTIC NERVE INJURY NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
PUPILLARY REFLEX IMPAIRED	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	4 (5%)	0 (0%)	1 (1%)
RETINAL EXUDATES	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
RETINAL VASCULAR DISORDER NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
SUBEPITHELIAL OPACITIES	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (2%)	0 (0%)	3 (4%)
SOBBITINEDIAL OFACTIES	0 (0%)	0 (0.,	0 (00,	0 (00,	5 (55)		- , ,			
INVESTIGATIONS	6 (33%)	53 (13%)	57 (17%)	5 (4%)	59 (16%)	63 (10%)	184 (13%)	3 (4%)	1 (5%)	3 (4%)
INTRAOCULAR PRESSURE INCREASED	3 (17%)	43 (10%)	46 (14%)	3 (2%)	45 (12%)	46 (8%)	140 (10%)	1 (1%)	1 (5%)	1 (1%)
CORNEAL STAINING	0 (0%)	7 (2%)	8 (2%)	2 (2%)	9 (2%)	12 (2%)	31 (2%)	2 (2%)	0 (0%)	2 (3%)
BLOOD GLUCOSE INCREASED	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	1 (<1%)	3 (<1%)	4 (<1%)	0 (0%)	0 (0%)	0 (0%)
BLOOD CREATININE INCREASED	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	2 (<1%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)
BLOOD PRESSURE INCREASED	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	2 (1%)	1 (<1%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)
BLOOD CHOLESTEROL INCREASED	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
HEMATURIA PRESENT	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
INTRAOCULAR PRESSURE ABNORMAL	0 (0%)	0 (0%)	2 (1%)	0 (0%)	0 (0%)	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
BIOPSY NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
BLOOD GLUCOSE ABNORMAL	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
BLOOD GLUCOSE DECREASED	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0봉)
BLOOD GLUCOSE FLUCTUATION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
BLOOD PHOSPHATE DECREASED	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
BLOOD SODIUM DECREASED	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
DECOD SOUTON DECKEWSED	0 (0%)	U (U%)	0 (0%)	0 (0%)	0 (007	1 (710)	_ , ,	- , , , , , ,	- ,,	

Note: One patient in study ACS201-HYA-002A received both 75 IU Vitrase and Saline. This patient is included in both groups here. Twelve patients in the "Probe Study" received two injections of 75 IU Vitrase. These patients are only counted once here.

Ocular Events include events reported for study eye and non-study eye.

^[1] Other Active treatments include SF6 (PVD-01-08961X) and ACS-101C (COR-01-08961X). Patients who received both Vitrase and another active study treatment are included in both groups.

s:\dat\acs\iss2002\sas\programs\t_ae_treat 06SEP2002 17:33

Table 7.1 Incidence of Adverse Events by System Organ Class All Studies by Treatment Safety Population

	Hemorrhage Clearance Studies								Other Indications		
	Cont:	rol			Vitrase						
Sugram Owens Class / Duefedund Manua	1.77.1	G+1:	3 5 711	37 5 777		7F 111	Total	Vitrase 50-500 IU	Saline Control	Other Active [1]	
System Organ Class / Preferred Term	ww	Saline	7.5 IU	37.5 IU	55 IU	75 IU 	Vitrase	50-500 10		ACCIVE [I]	
BLOOD TRIGLYCERIDES INCREASED	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
BLOOD UREA INCREASED	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
CANDIDURIA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
COAGULATION FACTOR DECREASED	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
ELECTROCARDIOGRAM ABNORMAL NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
ENLARGED PROSTATE	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
LIVER FUNCTION TESTS NOS ABNORMAL	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	.0 (0%)	0 (0%)	
PROTEINURIA PRESENT	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
PROTHROMBIN TIME PROLONGED	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
RED BLOOD CELL SEDIMENTATION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
RATE INCREASED											
WEIGHT DECREASED	1 (6%)	2 (<1%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
CARDIAC ENZYMES INCREASED	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
HEMATOCRIT DECREASED	1 (6%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
HEMOGLOBIN DECREASED	1 (6%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
VISUAL ACUITY TESTS DISTANCE	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
SKIN & SUBCUTANEOUS TISSUE	2 (11%)	38 (9%)	27 (8%)	1 (1%)	50 (13%)	61 (10%)	139 (10%)	8 (10%)	2 (10%)	3 (4%)	
DISORDERS											
EYELID EDEMA	0 (0%)	15 (4%)	13 (4%)	0 (0%)	29 (8%)	25 (4%)	67 (5%)	0 (0%)	0 (0%)	0 (0%)	
ERYTHEMA NEC	0 (0%)	17 (4%)	8 (2%)	0 (0%)	21 (6%)	30 (5%)	59 (4%)	5 (6%)	2 (10%)	0 (0%)	
PRURITUS NOS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	2 (1%)	2 (<1%)	5 (<1%)	0 (0%)	0 (0%)	0 (0%)	
DERMATITIS NOS	0 (0%)	3 (1%)	0 (0%)	0 (0%)	3 (1%)	1 (<1%)	4 (<1%)	0 (0%)	0 (0%)	0 (0%)	
FOOT ULCER	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	3 (<1%)	4 (<1%)	1 (1%)	0 (0%)	1 (1%)	
SKIN ULCER NOS	0 (0%)	0 (0%)	2 (1%)	0 (0%)	0 (0%)	1 (<1%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)	
CONTUSION	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)	
CUTIS LAXA	0 (0%)	0 (0%)	2 (1%)	0 (0%)	0 (0%)	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)	
DERMATITIS ALLERGIC	1 (6%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	2 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)	
FACE EDEMA	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)	
OCULAR HYPEREMIA	0 (0%)	2 (<1%)	1 (<1%)	0 (0%)	0 (0%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)	
PERIORBITAL EDEMA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)	
PSORIASIS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)	
SKIN IRRITATION	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)	
SKIN LESION NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (1%)	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)	
ALOPECIA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
DIABETIC FOOT ULCER	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
DRY SKIN	1 (6%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
ECCHYMOSIS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	O (0%)	0 (0%)	0 (0%)	

Note: One patient in study ACS201-HYA-002A received both 75 IU Vitrase and Saline. This patient is included in both groups here. Twelve patients in the "Probe Study" received two injections of 75 IU Vitrase. These patients are only counted once here.

Ocular Events include events reported for study eye and non-study eye.

[1] Other Active treatments include SF6 (PVD-01-08961X) and ACS-101C (COR-01-08961X). Patients who received both Vitrase and another active study

treatment are included in both groups.

Table 7.1 Incidence of Adverse Events by System Organ Class All Studies by Treatment Safety Population

	Hemorrhage Clearance Studies						Other Indications			
	Cont	rol		3-	Vitrase					
System Organ Class / Preferred Term	ww	Saline	7.5 IU	37.5 IU		75 IŬ	Total Vitrase	Vitrase 50-500 IU	Saline Control	Other Active [1]
			0 (0%)	1 (1%)	0 (0%)	0 (0%)	1 (<1%)	2 (2%)	0 (0%)	2 (3%)
EYELID OEDEMA	0 (0%)	0 (0%) 1 (<1%)	0 (0%) 1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
LEG ULCER (EXC VARICOSE)	1 (6%) 0 (0%)	1 (<1%) 0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
PALMAR ERYTHEMA		0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
SKIN NECROSIS	0 (0%)		1	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
SKIN NODULE	0 (0%)	0 (0%)		0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
SKIN ULCER HEMORRHAGE	0 (0%)	0 (0%)		0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
STASIS ULCER	0 (0%)	0 (0%)	0 (0%)		0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
SWEATING INCREASED	0 (0%)	0 (0%)	1 (<1%)		1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
TELANGIECTASIA	0 (0%)	0 (0%)	0 (0%)		0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
INTERTRIGO	0 (0%)	1 (<1%)	0 (0%)	0 (0%)		0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
PRURIGO	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	. , .	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
URTICARIA NOS	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (007	0 (00)	• ,,	- , , ,
NERVOUS SYSTEM DISORDERS	1 (6%)	31 (7%)	30 (9%)	3 (2%)	40 (11%)	50 (8%)	123 (9%)	18 (21%)	4 (19%)	1 (1%)
HEADACHE NOS	0 (0%)	16 (4%)	13 (4%)	3 (2%)	20 (5%)	25 (4%)	61 (4%)	15 (18%)	3 (14%)	0 (0%)
CEREBROVASCULAR ACCIDENT NOS	1 (6%)	5 (1%)	4 (1%)	0 (0%)	5 (1%)	8 (1%)	17 (1%)	0 (0%)	0 (0%)	0 (0%)
DIZZINESS (EXC VERTIGO)	0 (0%)	2 (<1%)	1 (<1%)	0 (0%)	4 (1%)	6 (1%)	11 (1%)	1 (1%)	0 (0%)	0 (0%)
INSOMNIA NEC	0 (0%)	2 (<1%)	3 (1%)	0 (0%)	3 (1%)	4 (1%)	10 (1%)	0 (0%)	0 (0%)	0 (0%)
PUPILLARY DISORDER NOS	0 (0%)	0 (0%)	3 (1%)	0 (0%)	4 (1%)	3 (<1%)	10 (1%)	0 (0%)	0 (0%)	0 (0%)
SYNCOPE	0 (0%)	1 (<1%)	2 (1%)	0 (0%)	1 (<1%)	4 (1%)	7 (<1%)	0 (0%)	1 (5%)	0 (0%)
DEMENTIA NOS	0 (0%)	0 (0%)	2 (1%)	0 (0%)	1 (<1%)	0 (0%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)
HYPOESTHESIA	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	1 (<1%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)
BALANCE IMPAIRED NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
CONVULSIONS NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
FACIAL PALSY	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
MOVEMENT DISORDER NOS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
NEUROPATHY NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
TREMOR NEC	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (1%)	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
VISUAL FIELD DEFECT NOS	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
BURNING SENSATION NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	
DYSARTHRIA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
HEMIPARESIS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	
	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	
HEMORRHAGIC STROKE HYPOAESTHESIA	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	
LACUNAR INFARCTION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	
	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	
MIGRAINE NOS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	
OBSTRUCTIVE SLEEP APNEA SYNDROME	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
PARKINSON'S DISEASE NOS	0 (0%)	0 (03)	5 (00)	- (,	. ,					

^[1] Other Active treatments include SF6 (PVD-01-08961X) and ACS-101C (COR-01-08961X). Patients who received both Vitrase and another active study treatment are included in both groups.

s:\dat\acs\iss2002\sas\programs\t_ae_treat 06SEP2002 17:33

Table 7.1 Incidence of Adverse Events by System Organ Class All Studies by Treatment Safety Population

				ge Clearance	Studies	Other Indications				
	Cont	rol			Vitrase					- •
System Organ Class / Preferred Term	ww	Saline	7.5 IU	37.5 IU	55 IU	75 IU	Total Vitrase	Vitrase 50-500 IU	Saline Control	Other Active [1]
PUPILLARY REFLEX IMPAIRED	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
SPEECH DISORDER NEC	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
VISUAL PATHWAY DISORDER NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
VITH NERVE PARALYSIS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%) 0 (0%)
AMNESIA NEC	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
COMA NEC	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%) 0 (0%)
DEMENTIA OF THE ALZHEIMER'S TYPE	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (08)
NOS									2 (22)	0 (0%)
DEPRESSED LEVEL OF CONSCIOUSNESS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	- ,,
IIIRD NERVE PARALYSIS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (2%)	0 (0%)	
VOCAL CORD PARALYSIS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
INFECTIONS AND INFESTATIONS	2 (11%)	40 (10%)	29 (9%)	0 (0%)	40 (11%)	41 (7%)	110 (8%)	6 (7%)	3 (14%)	0 (0%)
NASOPHARYNGITIS	0 (0%)	3 (1%)	4 (1%)	0 (0%)	5 (1%)	7 (1%)	16 (1%)	0 (0%)	0 (0%)	0 (0%)
PNEUMONIA NOS	0 (0%)	5 (1%)	5 (2%)	0 (0%)	6 (2%)	4 (1%)	15 (1%)	0 (0%)	0 (0%)	0 (0%)
URINARY TRACT INFECTION NOS	1 (6%)	6 (1%)	3 (1%)	0 (0%)	3 (1%)	6 (1%)	12 (1%)	0 (0%)	0 (0%)	0 (0%)
INFLUENZA	1 (6%)	3 (1%)	4 (1%)	0 (0%)	4 (1%)	1 (<1%)	9 (1%)	2 (2%)	0 (0%)	0 (0%)
CELLULITIS	0 (0%)	4 (1%)	0 (0%)	0 (0%)	3 (1%)	5 (1%)	8 (1%)	0 (0%)	0 (0%)	0 (0%)
BRONCHITIS NOS	0 (0%)	2 (<1%)	1 (<1%)	0 (0%)	2 (1%)	4 (1%)	7 (<1%)	0 (0%)	0 (0%)	0 (0%)
LOCALISED INFECTION	0 (0%)	2 (<1%)	2 (1%)	0 (0%)	3 (1%)	2 (<1%)	7 (<1%)	0 (0%)	0 (0%)	0 (0%)
OSTEOMYELITIS NOS	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	4 (1%)	2 (<1%)	7 (<1%)	0 (0%)	0 (0%)	0 (0%)
SINUSITIS NOS	0 (0%)	2 (<1%)	3 (1%)	0 (0%)	1 (<1%)	3 (<1%)	7 (<1%)	0 (0%)	0 (0%)	0 (0%)
SEPSIS NOS	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	3 (1%)	1 (<1%)	5 (<1%)	0 (0%)	0 (0%)	0 (0%)
UPPER RESPIRATORY TRACT	1 (6%)	1 (<1%)	3 (1%)	0 (0%)	1 (<1%)	1 (<1%)	5 (<1%)	0 (0%)	0 (0%)	0 (0%)
INFECTION NOS	- ,,									
SKIN INFECTION NOS	0 (0%)	0 (0%)	3 (1%)	0 (0%)	0 (0%)	1 (<1%)	4 (<1%)	0 (0%)	0 (0%)	0 (0%)
HERPES ZOSTER	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (1%)	1 (<1%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)
PHARYNGITIS NOS	0 (0%)	2 (<1%)	2 (1%)	0 (0%)	1 (<1%)	0 (0%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)
BRONCHITIS ACUTE NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
FUNGAL INFECTION NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (1%)	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
ORAL CANDIDIASIS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
RESPIRATORY TRACT INFECTION NOS	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	2 (1%)	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
SKIN CANDIDA NOS	0 (0%)	0 (0%)	2 (1%)	0 (0%)	0 (0%)	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
STAPHYLOCOCCAL INFECTION NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (1%)	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
TOOTH INFECTION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
AMERICAN TRYPANOSOMIASIS	0 (0%)	0 (0%)	0 (0왕)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
ARTHROPOD BITE	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
BACTERIAL INFECTION NOS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
2.22.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2	- , ,	• , ,		•						

Note: One patient in study ACS201-HYA-002A received both 75 IU Vitrase and Saline. This patient is included in both groups here. Twelve patients in the "Probe Study" received two injections of 75 IU Vitrase. These patients are only counted once here.

Ocular Events include events reported for study eye and non-study eye.

[1] Other Active treatments include SF6 (PVD-01-08961X) and ACS-101C (COR-01-08961X). Patients who received both Vitrase and another active study treatment are included in both groups.

Table 7.1 Incidence of Adverse Events by System Organ Class All Studies by Treatment Safety Population

			Hemorrhage Clearance Studies					Other Indications			
	Cont	rol		J	Vitrase						
System Organ Class / Preferred Term	ww	Saline	7.5 IU	37.5 IU	55 IU	75 IÜ	Total Vitrase	Vitrase 50-500 IU	Saline Control	Other Active [1]	
BLADDER INFECTION NOS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
CANDIDAL INFECTION NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
CELLULITIS STAPHYLOCOCCAL	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
CYSTITIS NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
INJECTION SITE INFECTION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
LARYNGITIS NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
LOWER RESPIRATORY TRACT INFECTION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
LUNG INFECTION NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
NAIL TINEA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
OSTEOMYELITIS CHRONIC NOS	0 (0%)	0 (0%)	·1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
PHARYNGITIS STREPTOCOCCAL	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
PNEUMONIA HAEMOPHILUS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
PULMONARY TUBERCULOSIS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
ROUNDWORM INFECTION NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
SEPTIC ARTHRITIS NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
SEPTICEMIA STAPHYLOCOCCAL	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0왕)	0 (0%)	0 (0%)	
VAGINOSIS FUNGAL NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
WOUND INFECTION NEC	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
BLEPHARITIS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (5%)	0 (0%)	
BRONCHOPNEUMONIA NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	Q (0%)	0 (0%)	
CANDIDA NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
EAR INFECTION NOS	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
GASTROINTESTINAL INFECTION NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
HYPOPYON	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
INFECTED SKIN ULCER	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
KERATITIS HERPETIC	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (2%)	0 (0%)	0 (0%)	
KIDNEY INFECTION NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	
MYCOBACTERIAL INFECTION NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
PNEUMONIA MYCOPLASMAL	0 (0%)	1 (<1%)	0 (0%)	. 0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
PYELONEPHRITIS NOS	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
SKIN & SUBCUTANEOUS TISSUE	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
ABSCESS	0 (00)	# (120)		* , *-,	* ,						
SORE THROAT NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (2%)	1 (5%)	0 (0%)	
TONSILLITIS ACUTE NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (5%)	0 (0%)	
TUBERCULOSIS NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
UROSEPSIS	1 (6%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
CARDIAC DISORDERS	8 (44%)	26 (6%)	23 (7%)	0 (0%)	27 (7%)	43 (7%)	93 (6%)	1 (1%)	0 (0%)	0 (0%)	

Note: One patient in study ACS201-HYA-002A received both 75 IU Vitrase and Saline. This patient is included in both groups here. Twelve patients in the "Probe Study" received two injections of 75 IU Vitrase. These patients are only counted once here.

Ocular Events include events reported for study eye and non-study eye.

[1] Other Active treatments include SF6 (PVD-01-08961X) and ACS-101C (COR-01-08961X). Patients who received both Vitrase and another active study

treatment are included in both groups.

Table 7.1 Incidence of Adverse Events by System Organ Class All Studies by Treatment Safety Population

			Hemorrha	ge Clearance	Other Indications					
	Conti	rol		J	Vitrase_					
							Total	Vitrase	Saline	Other
System Organ Class / Preferred Term	ww	Saline	7.5 IU	37.5 IU	55 IU	75 IU	Vitrase	50~500 IU	Control	Active [1]
MYOCARDIAL INFARCTION	3 (17%)	5 (1%)	7 (2%)	0 (0%)	3 (1%)	12 (2%)	22 (2%)	0 (0%)	0 (0%)	0 (0%)
CARDIAC FAILURE CONGESTIVE	2 (11%)	6 (1%)	6 (2%)	0 (0%)	6 (2%)	7 (1%)	19 (1%)	0 (0%)	0 (0%)	0 (0%)
ANGINA UNSTABLE	0 (0%)	0 (0%)	2 (1%)	0 (0%)	3 (1%)	3 (<1%)	8 (1%)	0 (0%)	0 (0%)	0 (0%)
CARDIAC ARREST	0 (0%)	2 (<1%)	1 (<1%)	0 (0%)	5 (1%)	2 (<1%)	8 (1%)	0 (0%)	0 (0%)	0 (0%)
ATRIAL FIBRILLATION	1 (6%)	1 (<1%)	0 (0%)	0 (0%)	5 (1%)	2 (<1%)	7 (<1%)	0 (0%)	0 (0%)	0 (0%)
CARDIAC FAILURE NOS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	3 (<1%)	5 (<1%)	0 (0%)	0 (0%)	0 (0%)
EDEMA LOWER LIMB	0 (0%)	2 (<1%)	1 (<1%)	0 (0%)	2 (1%)	2 (<1%)	5 (<1%)	0 (0%)	0 (0%)	0 (0%)
PULMONARY EDEMA NOS	0 (0%)	4 (1%)	0 (0%)	0 (0%)	3 (1%)	2 (<1%)	5 (<1%)	0 1 0%}	0 (0%)	o ეዲ
ARRHYTHMIA NOS	0 (0%)	2 (<1%)	1 (<1%)	0 (0%)	2 (1%)	0 (0%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)
CARDIOMEGALY NOS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	2 (1%)	0 (0%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)
CARDIOVASCULAR DISORDER NOS	1 (6%)	3 (1%)	0 (0%)	0 (0%)	2 (1%)	1 (<1%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)
CORONARY ARTERY DISEASE NOS	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	1 (<1%)	1 (<1%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)
CORONARY ARTERY OCCLUSION	0 (0%)	2 (<1%)	2 (1%)	0 (0%)	1 (<1%)	0 (0%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)
ANGINA PECTORIS	1 (6%)	5 (1%)	0 (0%)	0 (0%)	2 (1%)	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
AORTIC VALVE STENOSIS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
ATRIOVENTRICULAR BLOCK NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
CARDIAC DISORDER NOS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
CARDIAC DISORDER NOS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
EDEMA PERIPHERAL	0 (0%)	1 (<1%)	2 (1%)	0 (0%)	0 (0%)	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
LEFT VENTRICULAR FAILURE	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	2 (1%)	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
MYOCARDIAL ISCHEMIA	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
PALPITATIONS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
AORTIC VALVE DISEASE NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
ATRIAL FLUTTER		0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
BRADYCARDIA NOS	1 (6%) 0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
CARDIAC FAILURE	,	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
CARDIO-RESPIRATORY ARREST	1 (6%)			0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
CARDIOGENIC SHOCK	0 (0%)			0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
CARDIOMYOPATHY NOS	0 (0%)	1 (<1%) 0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
DYSPNEA PAROXYSMAL NOCTURNAL	0 (0%)	0 (0%)	- ,	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
DYSPNOEA NOS	0 (0%)	- 1		0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
EDEMA UPPER LIMB	0 (0%)	0 (0%)	- •	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
ISCHEMIC CARDIOMYOPATHY	1 (6%)	0 (0%)		- • •	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
MYOCARDITIS NOS	0 (0%)	0 (0%)	- ,!		1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
VENTRICULAR EXTRASYSTOLES	0 (0%)	0 (0%)	0 (0%)	- ,,		0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
VENTRICULAR TACHYCARDIA	1 (6%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%) 0 (0%)		0 (0%)	0 (0%)	0 (0%)	0 (0%)
HYPERTROPHIC CARDIOMYOPATHY	0 (0%)	1 (<1%)	0 (0%)	0 (0%)			0 (0%)	1 (1%)	0 (0%)	0 (0%)
OEDEMA PERIPHERAL	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (04)	T (T.9)	0 (00)	0 . 0 . 7

^[1] Other Active treatments include SF6 (PVD-01-08961X) and ACS-101C (COR-01-08961X). Patients who received both Vitrase and another active study treatment are included in both groups.

s:\dat\acs\iss2002\sas\programs\t_ae_treat 06SEP2002 17:33

Table 7.1 Incidence of Adverse Events by System Organ Class All Studies by Treatment Safety Population

System Organ Class / Preferred Term		Hemorrhage Clearance Studies						Other Indications			
ORTHOPNEA ORTHOP		Cont	rol	nemorrad	ge erearance	Vitrase					0.1
ONTHOPMEA O	System Organ Class / Preferred Term			7.5 IU	37.5 IU	55 IU	75 IU	2			
STRINGER	ODEN OPEN OF THE O	0 (08)	2 (~1%)	n (n%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)			
VENTRICULAR HYPOKINESIA 0					0 (0%)	0 (0%)	0 (0%)	0 (0%)			
GASTROINTESTINAL DISORDERS 3 (17%) 26 (6%) 14 (4%) 1 (1%) 3 (3%) 12 (2%) 20 (2%) 2 (2%) 0 (0%) 0 (0%) 0 (0%) NAUSEA NAUSEA VOMITINS NOS 1 (6%) 16 (1%) 2 (1%) 0 (0%) 17 (2%) 3 (1%) 18 (1%) 10 (0%) 17 (2%) 3 (1%) 18 (1%) 0 (0%) 0 (=					0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
MAISSEA	GASTROINTESTINAL DISORDERS	3 (17%)	26 (6%)	14 (4%)	1 (1%)		55 ,		- ,	- , .	·
UNITING NOS 0 (0%) 6 (1%) 3 (1%) 0 (0%) 7 (2%) 3 (-1%) 13 (1%) 0 (0%) 0		1 (6%)	10 (2%)	5 (2%)	0 (0%)		,				
DIRRREA NOS O (0 %) 6 (1 %) 3 (1 %) O (0 %) 7 (2 %) 3 (1 %) O (0 %)		1 (6%)	6 (1%)	2 (1%)	0 (0%)					- ' :	
CASTROTINESTINAL HEMORRHAGE NOS 0 (0%) 6 (1%) 1 (-1%) 1 (-1%) 0 (0%) 3 (1%) 8 (1%) 1 (-1%) 0 (0%) 0 (0 (0%)	6 (1%)	3 (1%)				:			
ABDOMINAL PAIN NOS 0 (0%) 1 (-1%) 0 (0%) 3 (1%) 2 (-1%) 0 (0%) 3 (1%) 3 (-1%) 6 (-1%) 0 (0%)		0 (0%)	6 (1%)	1 (<1%)	- , ,					- ' :	
ABDOMINAL PAIN NOS 0 (0 %) 0 (0 %) 2 (1 %) 0 (0 %) 2 (1 %) 0 (0 %) 2 (1 %) 0 (0 %) 0		0 (0%)	1 (<1%)	1 (<1%)	0 (0%)			• •	- , ,	• • •	
DYSPEPSIA 1 (6%) 3 (1%) 2 (1%) 0 (0%) 2 (-1%) 0 (0%) 2 (1%) 0 (0%) 4 (-1%) 0 (0%) 0 (0%) 0 (0%) 2 (1%) 2 (-1%) 4 (-1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 3 (-1%) 0 (0%) 0 (0%) 0 (0%) 3 (-1%) 0 (0%)		0 (0%)	0 (0%)	2 (1%)							
BSOPHAGITIS NOS		1 (6%)	3 (1%)	2 (1%)	0 (0%)	- • :				* '	
GRITHIS NOS 0 (0%) 2 (-1%) 0 (0%) 0 (0%) 2 (-1%) 4 (-1%) 0 (0%) 0 (0%) 2 (-1%) 0 (0%)		0 (0%)	0 (0%)	0 (0%)	0 (0%)	- ,				- 1	- , ,
SORE THROAT NOS 0 (0\$) 2 (-1\$) 2 (1\$) 2 (1\$) 0 (0\$) 0 (0\$) 2 (-1\$) 1 (-1\$) 0 (0\$) 2 (1\$) 0 (0\$) 3 (-1\$) 0 (0\$) 3 (-1\$) 0 (0\$) 0		0 (0%)	2 (<1%)	0 (0%)	0 (0%)	:	- ,			- ,	
ABDOMINAL PAIN UPPER 0 (0\$) 2 (<1\$) 1 (<1\$) 0 (0\$) 2 (1\$) 0 (0\$) 3 (<1\$) 0 (0\$		0 (0%)	2 (<1%)	2 (1%)	0 (0%)				• ,,		
GASTRO-ESOPHAGEAL REFLUX DISEASE 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 1 (<1%) 3 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (<1%) 0 (0%)		0 (0%)	2 (<1%)	1 (<1%)	0 (0%)	- :					- ,
DIVERTICULUM INTESTINAL O (0\$) O (0		0 (-0%)	0 (0%)	1 (<1%)	0 (0%)				- , ,	- 1	
ESOPHAGEAL REFLUX 0 (0 *) 0		0 (0%)	0 (0%)	0 (0%)	0 (0%)						
GASTRIC ULCER 1		0 (0%)	0 (0%)	0 (0%)	0 (0%)			- , ,	- • :	- 1 1 1 1 1	
GASTROINTESTINAL UPSET 0 (0\$) 1 (<1\$) 0 (0\$		1 (6%)	1 (<1%)	0 (0%)	0 (0%)			- 1		- ' ' : :	
ABDOMINAL PAIN AGGRAVATED 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0		0 (0%)	1 (<1%)	0 (0%)	0 (0%)					• ,,	
ABDOMINAL TENDERNESS 0 (0\$) 0		0 (0%)	0 (0%)	0 (0%)	0 (0%)	- •	- ,		- ,	- ,	- ,
ASCITES 0 (0\$) 0 (0\$) 0 (0\$) 1 (<1\$) 0 (0\$) 1 (<1\$) 0 (0\$) 1 (<1\$) 0 (0\$) 1 (<1\$) 0 (0\$) 0 (0 (0%)	0 (0%)	0 (0%)	0 (0%)					• (,	
DUODENAL ULCER 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 1 (<1%) 0 (0		0 (0%)	0 (0%)	1 (<1%)	0 (0%)				- ,	• ,	
DUODENITIS 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%)		0 (0%)	1 (<1%)	0 (0%)	0 (0%)	- •		- '			
DYSPHAGIA O (0%) O (0 (0%)	1 (<1%)	0 (0%)	•	- 1 1 1 1	- ,	- •	- 1		
GASTRIC EROSIONS 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 0		0 (0%)	0 (0%)	0 (0%)	0 (0%)	- : . :		_ ,	- ,,	• • • • • •	
GASTRIC IRRITATION 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 0			0 (0%)	0 (0%)	0 (0%)		* 1 111		- ,		
GASTROENTERITIS NOS 0 (0%) 0 (0%) 0 (0%) 1 (1%) 0 (0%) 1 (1%) 0 (0%) 0		0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	• • •	•	- • • •		
GASTROINTESTINAL DISORDER NOS 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0		0 (0%)	0 (0%)	0 (0%)	1 (1%)				-	• • • • • • • • • • • • • • • • • • • •	
HEMATEMESIS 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0		0 (0%)	1 (<1%)	0 (0%)	0 (0%)			- : - :		* * * * * * * * * * * * * * * * * * * *	
HEMORRHOIDS 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%		0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)				,	
IMPAIRED GASTRIC EMPTYING		0 (0%)	0 (0%)	0 (0%)	0 (0%)		- 1			, , , , , ,	
INGULNAL HERNIA NOS 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0		- :	0 (0%)	1 (<1%)	0 (0%)			- ,			
PEPTIC ULCER			0 (0%)	0 (0%)	0 (0%)				- ,		
PEPTIC ULCER HEMORRHAGE 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) O(0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)			0 (0%)	0 (0%)	0 (0%)				- ' :		
$\begin{array}{cccccccccccccccccccccccccccccccccccc$			0 (0%)	0 (0%)	0 (0%)	0 (0%)		- ,		• 1	
	PERIODONTAL DISORDER NOS		0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	U (U4.	, 0 (0%)

Note: One patient in study ACS201-HYA-002A received both 75 IU Vitrase and Saline. This patient is included in both groups here. Twelve patients in the "Probe Study" received two injections of 75 IU Vitrase. These patients are only counted once here.

Ocular Events include events reported for study eye and non-study eye.

[1] Other Active treatments include SF6 (PVD-01-08961X) and ACS-101C (COR-01-08961X). Patients who received both Vitrase and another active study

treatment are included in both groups.

s:\dat\acs\iss2002\sas\programs\t_ae_treat 06SEP2002 17:33

Table 7.1 Incidence of Adverse Events by System Organ Class All Studies by Treatment Safety Population

			Hemorrha	ge Clearance	Studies		Other Indications			
	Cont	rol		3	Vitrase					
System Organ Class / Preferred Term	ww	Saline	7.5 IU	37.5 IU	55 IU	75 IU	Total Vitrase	Vitrase 50-500 IU	Saline Control	Other Active [1]
		0 (00)	o / os)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
PERITONEAL DISORDER NOS	0 (0%) 0 (0%)	0 (0%) 0 (0%)	0 (0%) 1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
PERITONEAL HEMORRHAGE		- , - ,		0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
PERITONITIS	0 (0%)	0 (0%) 0 (0%)	0 (0%) 0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
RECTAL BLEEDING	0 (0%)	- ,	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
RECTAL PROLAPSE	0 (0%)		- ,,	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
TOOTHACHE	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
ABDOMINAL DISTENSION	0 (0%)	1 (<1%)		- • :	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	1 (1%)
DIARRHOEA NOS	0 (0%)	0 (0%)	0 (0%)		0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
VOLVULUS OF BOWEL	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (00)	0 (00)	
METABOLISM AND NUTRITION DISORDERS	4 (22%)	21 (5%)	23 (7%)	0 (0%)	23 (6%)	28 (5%)	74 (5%)	1 (1%)	0 (0%)	1 (1%)
HYPERCHOLESTEROLEMIA	1 (6%)	5 (1%)	8 (2%)	0 (0%)	5 (1%)	5 (1%)	18 (1%)	0 (0%)	0 (0%)	0 (0%)
HYPOGLYCAEMIA NOS	0 (0%)	6 (1%)	0 (0%)	0 (0%)	2 (1%)	9 (1%)	11 (1%)	1 (1%)	0 (0%)	1 (1%)
HYPERGLYCEMIA NOS	0 (0%)	2 (<1%)	3 (1%)	0 (0%)	4 (1%)	1 (<1%)	8 (1%)	0 (0%)	0 (0%)	0 (0%)
DEHYDRATION	2 (11%)	2 (<1%)	1 (<1%)	0 (0%)	4 (1%)	2 (<1%)	7 (<1%)	0 (0%)	0 (0%)	0 (0%)
HYPERLIPIDEMIA NOS	0 (0%)	2 (<1%)	3 (1%)	0 (0%)	4 (1%)	0 (0%)	7 (<1%)	0 (0%)	0 (0%)	0 (0%)
APPETITE DECREASED NOS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	4 (1%)	6 (<1%)	0 (0%)	0 (0%)	0 (0%)
HYPERKALEMIA	1 (6%)	4 (1%)	2 (1%)	0 (0%)	2 (1%)	1 (<1%)	5 (<1%)	0 (0%)	0 (0%)	0 (0%)
DIABETIC NEUROPATHY NEC	0 (0%)	0 (0%)	2 (1%)	0 (0%)	0 (0%)	2 (<1%)	4 (<1%)	0 (0%)	0 (0%)	0 (0%)
DIABETIC COMA NOS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	2 (<1%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)
DIABETES MELLITUS AGGRAVATED	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
DIABETES MELLITUS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
INSULIN-DEPENDENT									- /	0 (00)
GOUT	1 (6%)	2 (<1%)	1 (<1%)	0 (0%)	0 (0%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
GOUT AGGRAVATED	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
HYPOCALCEMIA	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
HYPOKALEMIA	0 (0%)	3 (1%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
OBESITY	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
DIABETES MELLITUS NON	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
INSULIN-DEPENDENT										- / 001
DIABETIC AMYOTROPHY	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
DIABETIC COMPLICATION NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
DIABETIC EYE DISEASE NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
DIABETIC KETOACIDOSIS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
ELECTROLYTE IMBALANCE	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
GLUCOSE TOLERANCE IMPAIRED	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
HYPERLIPIDAEMIA NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
HYPERPHOSPHATEMIA	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)

Note: One patient in study ACS201-HYA-002A received both 75 IU Vitrase and Saline. This patient is included in both groups here. Twelve patients in the "Probe Study" received two injections of 75 IU Vitrase. These patients are only counted once here.

Ocular Events include events reported for study eye and non-study eye.
[1] Other Active treatments include SF6 (PVD-01-08961X) and ACS-101C (COR-01-08961X). Patients who received both Vitrase and another active study treatment are included in both groups.

s:\dat\acs\iss2002\sas\programs\t_ae_treat 06SEP2002 17:33

IMPLANT

Table 7.1 Incidence of Adverse Events by System Organ Class All Studies by Treatment Safety Population

Hemorrhage Clearance Studies Vitrase System Organ Class / Preferred Term WW Saline 7.5 IU 37.5 IU 55 IU 75 IU		Oth	er Indicati	ons
HYPERVOLEMIA 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (
HYPERVOLEMIA 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (Total	Vitrase	Saline	Other
HYPOGLYCAEMIC COMA O (0%) O (0%) O (0%) O (0%) D	Vitrase	50-500 IU	Control	Active [1]
HYPOGLYCAEMIC COMA O (0%) O (0%) O (0%) O (0%) D	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
HYPONATREMIA 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) HYPONATREMIA 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
HYPOVOLEMIA 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
INSULIN RESISTANCE	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
METABOLIC ACIDOSIS NOS 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) POLYPIPSIA 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) RETINOPATHY DIABETIC 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
POLYPIPSIA 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) RETINOPATHY DIABETIC 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
RETINOPATHY DIABETIC 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
REIINOPAIRI DIABETIC		0 (0%)	0 (0%)	0 (0%)
CALCIUM DEFICIENCY 1 (6%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)		0 (0%)	0 (0%)	0 (0%)
	0 (0%)		0 (0%)	0 (0%)
FLUID RETENTION 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)	0 (0%)	0 (0%) 0 (0%)	0 (0%)	0 (0%)
FOLATE DEFICIENCY 1 (6%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)	0 (0%)	- • •	0 (0%)	0 (0%)
HYPERURICEMIA 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
NONKETOTIC 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)	0 (0%)	0 (0%)	0 (04)	0 (0%)
HYPERGLYCEMIC-HYPEROSMOLAR COMA				
GENERAL DISORDERS AND 3 (17%) 31 (7%) 12 (4%) 5 (4%) 8 (2%) 48 (9%)	73 (5%)	8 (10%)	3 (14%)	1 (1%)
ADMINISTRATION SITE CONDITIONS				a / as)
PAIN NOS 0 (0%) 16 (4%) 1 (<1%) 1 (1%) 0 (0%) 28 (5%)	30 (2%)	2 (2%)	0 (0%)	0 (0%) 0 (0%)
CHEST PAIN NEC 1 (6%) 5 (1%) 6 (2%) 1 (1%) 2 (1%) 5 (1%)	14 (1%)	0 (0%)	0 (0%)	
FALL 0 (0%) 2 (<1%) 1 (<1%) 0 (0%) 0 (0%) 3 (<1%)	4 (<1%)	0 (0%)	0 (0%)	0 (0%)
FATIGUE 1 (6%) 0 (0%) 2 (1%) 0 (0%) 1 (<1%) 1 (<1%)	4 (<1%)	0 (0%)	0 (0%)	0 (0%)
PAIN IN FACE $0 (0\%) 0 (0\%) 0 (0\%) 0 (0\%) 4 (1\%)$	4 (<1%)	0 (0%)	0 (0%)	0 (0%)
SENSATION OF FOREIGN BODY NOS 0 (0%) 4 (1%) 0 (0%) 0 (0%) 4 (1%)	4 (<1%)	0 (0%)	0 (0%)	0 (0%)
WEAKNESS 1 (6%) 1 (<1%) 2 (1%) 0 (0%) 1 (<1%) 1 (<1%)	4 (<1%)	0 (0%)	0 (0%)	0 (0%)
EDEMA LOWER LIMB 1 (6%) 0 (0%) 0 (0%) 1 (<1%) 2 (<1%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)
PYREXIA 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 2 (<1%)	3 (<1%)	1 (1%)	1 (5%)	0 (0%)
DIFFICULTY IN WALKING 0 (0%) 0 (0%) 0 (0%) 2 (1%) 0 (0%)	2 (<1%)		0 (0%)	0 (0%)
EDEMA PERIPHERAL 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%)	2 (<1%)		0 (0%)	0 (0%)
APPLICATION SITE RIEEDING $0 (0\$) 0 (0\$) 0 (0\$) 1 (1\$) 0 (0\$) 0 (0\$)$	1 (<1%)		0 (0%)	0 (0%)
APPLICATION SITE ERYTHEMA 0 (0%) 0 (0%) 0 (0%) 1 (1%) 0 (0%) 0 (0%)	1 (<1%)		0 (0%)	0 (0%)
DEATH NOS 0 (0%) 2 (<1%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%)	1 (<1%)	0 (0%)	1 (5%)	0 (0%)
GROIN PAIN 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%)	1 (<1%)		0 (0%)	0 (0%)
HERNIA NOS 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%)	1 (<1%)		0 (0%)	0 (0%)
IMPATRED HEALING 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%)	1 (<1%)		0 (0%)	0 (0%)
LOWER EXTREMITY MASS 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%)	1 (<1%)		0 (0%)	0 (0%)
MASS NOS 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%)	1 (<1%)		0 (0%)	0 (0%)
MECHANICAL COMPLICATION OF 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)

Note: One patient in study ACS201-HYA-002A received both 75 IU Vitrase and Saline. This patient is included in both groups here Twelve patients in the "Probe Study" received two injections of 75 IU Vitrase. These patients are only counted once here.

Ocular Events include events reported for study eye and non-study eye. "Prope study" received two injections of 75 IU Vitrase. These patients are only counted once here.

Ocular Events include events reported for study eye and non-study eye.

[1] Other Active treatments include SF6 (PVD-01-08961X) and ACS-101C (COR-01-08961X). Patients who received both Vitrase and another active study

treatment are included in both groups.

s:\dat\acs\iss2002\sas\programs\t_ae_treat 06SEP2002 17:33

Table 7.1 Incidence of Adverse Events by System Organ Class All Studies by Treatment Safety Population

Hemorrhage Clearance Studies Other Indications Control Vitrase	her
	her
Total Vitrase Saline O	
System Organ Class / Preferred Term WW Saline 7.5 IU 37.5 IU 55 IU 75 IU Vitrase 50-500 IU Control Act	ive [1]
MULTI-ORGAN FAILURE 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0	(0%)
RIGORS 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0	(0%)
SENSATION OF PRESSURE NOS 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0	(0%)
SKIN INFECTION NOS 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 1 (<1%) 0 (0%) 0 (0%) 0	(0%)
HEMORRHAGE NOS 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0	(0%)
INJECTION SITE EXTRAVASATION 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0	(0%)
INJECTION SITE PAIN 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1	(1%)
INJECTION SITE REACTION NOS 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (2%) 1 (5%) 0	(0%)
MALAISE 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)	(0%)
MENTAL STATUS CHANGES 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)	(0%)
PERIPHERAL SWELLING 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0	(0%)
. SURGICAL AND MEDICAL PROCEDURES 2 (11%) 25 (6%) 15 (5%) 0 (0%) 27 (7%) 21 (3%) 63 (4%) 1 (1%) 0 (0%) 1	(1%)
POST-OPERATIVE COMPLICATIONS NOS 1 (6%) 10 (2%) 5 (2%) 0 (0%) 8 (2%) 6 (1%) 19 (1%) 0 (0%) 0 (0%)	(0%)
VITRECTOMY 0 (0%) 7 (2%) 2 (1%) 0 (0%) 4 (1%) 4 (1%) 10 (1%) 0 (0%) 0 (0%)	(0%)
UNSPECIFIED COMPLICATION OF 0 (0%) 2 (<1%) 2 (1%) 0 (0%) 4 (1%) 2 (<1%) 8 (1%) 0 (0%) 0 (0%)	(0%)
PROCEDURE NEC	
CORONARY ARTERY SURGERY 1 (6%) 0 (0%) 0 (0%) 0 (0%) 3 (<1%) 3 (<1%) 0 (0%) 0 (0%)	(0%)
FOOT AMPUTATION 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 2 (<1%) 0 (0%) 0 (0%) 0	(0%)
NAUSEA POST-OPERATIVE 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 2 (1%) 0 (0%) 2 (<1%) 0 (0%) 0 (0%)	(0%)
POST-OPERATIVE HEMORRHAGE 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (<1%) 0 (0%) 0 (0%) 0	(0%)
TOE AMPUTATION 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (1%) 0 (0%) 2 (<1%) 0 (0%) 0 (0%) 0	(0%)
TOOTH EXTRACTION NOS 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 2 (<1%) 0 (0%) 0 (0%) 0	(0%)
ARTERIAL BYPASS OPERATION (EXC 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0	(0%)
CORONARY ARTERY)	
ARTERIO-VENOUS FISTULA OPERATION 0 (0%) 1 (<1%) 1 (<1%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0	(0%)
BLOOD PRODUCT TRANSFUSION 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 1 (<1%) 0 (0%) 0	
CARDIAC PACEMAKER INSERTION 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%)	(0%)
CAROTID ENDARTERECTOMY 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0	(0%)
CHEMOTHERAPY NOS 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0	(0%)
EYE IRRITATION 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0	(0%)
FLUID REPLACEMENT PARENTERAL 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0	(0%)
FOOT OPERATION NOS 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 1 (<1%) 0 (0%) 0 (0%) 0	(0%)
HIP ARTHROPLASTY 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0	(0%)
INJECTION SITE OEDEMA 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0	(0%)
KNEE ARTHROPLASTY 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)	(0%)
LEG AMPUTATION 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 0	(0%)
LENS IMPLANT 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (<1%) 1 (<1%) 0 (0%) 0	(0%)

^{7 [1]} Other Active treatments include SF6 (PVD-01-08961X) and ACS-101C (COR-01-08961X). Patients who received both Vitrase and another active study treatment are included in both groups.

Table 7.1 Incidence of Adverse Events by System Organ Class All Studies by Treatment Safety Population

			Hemorrha	ge Clearance	Studies	Other Indications_				
	Cont	rol			Vitrase					
System Organ Class / Preferred Term	ww	Saline	7.5 IU	37.5 IU	ss ru	75 IU	Total Vitrase	Vitrase 50-500 IU	Saline Control	Other Active [1]
LIMB OPERATION NOS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
POST PROCEDURAL HEMORRHAGE	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
POST PROCEDURAL PAIN	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
POST-OPERATIVE PAIN	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
SCLERAL OPERATION NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
SHUNT OCCLUSION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
SKIN CYST EXCISION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
SUTURE LINE PAIN	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
VOMITING POST-OPERATIVE	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
APPLICATION SITE REACTION NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	D (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	1 (1%)
CARDIAC OPERATION NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
CRYOTHERAPY NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
DEVICE FAILURE NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
HOSPITALIZATION NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
METATARSAL EXCISION	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
WOUND DEBRIDEMENT	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
VASCULAR DISORDERS	0 (0%)	28 (7%)	15 (5%)	0 (0%)	24 (6%)	24 (4%)	63 (4%)	3 (4%)	0 (0%)	0 (0%)
HYPERTENSION NOS	0 (0%)	9 (2%)	6 (2%)	0 (0%)	13 (3%)	12 (2%)	31 (2%)	2 (2%)	0 (0%)	0 (0%)
HYPERTENSION AGGRAVATED	0 (0%)	6 (1%)	1 (<1%)	0 (0%)	6 (2%)	2 (<1%)	9 (1%)	0 (0%)	0 (0%)	0 (0%)
GANGRENE NOS	0 (0%)	3 (1%)	2 (1%)	0 (0%)	1 (<1%)	1 (<1%)	4 (<1%)	0 (0%)	0 (0%)	0 (0%)
HYPOTENSION NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	1 (<1%)	3 (<1%)	4 (<1%)	0 (0%)	0 (0%)	0 (0%)
TRANSIENT ISCHEMIC ATTACK	0 (0%)	4 (1%)	0 (0%)	0 (0%)	1 (<1%)	2 (<1%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)
PERIPHERAL VASCULAR DISEASE NOS	0 (0%)	4 (1%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
POSTURAL HYPOTENSION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (1%)	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
VENOUS THROMBOSIS DEEP LIMB	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
ARTERIAL ANEURYSM NOS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
ARTERIAL OCCLUSION NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
BLOOD PRESSURE FLUCTUATION	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
BLOOD PRESSURE INADEQUATELY	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
CONTROLLED								- />		0 (0%)
CAROTID ARTERY DISEASE NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
CAROTID ARTERY STENOSIS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
CEREBROVASCULAR ACCIDENT NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%) 0 (0%)
COLLAPSE	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	
HEMATOMA NOS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	
HOT FLUSHES NOS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%) 0 (0%)	0 (0%)	0 (0%) 0 (0%)
ISCHEMIC FOOT	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	০ (৩%)

Note: One patient in study ACS201-HYA-002A received both 75 IU Vitrase and Saline. This patient is included in both groups here. Twelve patients in the "Probe Study" received two injections of 75 IU Vitrase. These patients are only counted once here.

Ocular Events include events reported for study eye and non-study eye.

[1] Other Active treatments include SF6 (PVD-01-08961X) and ACS-101C (COR-01-08961X). Patients who received both Vitrase and another active study

treatment are included in both groups.

s:\dat\acs\iss2002\sas\programs\t ae treat 06SEP2002 17:33

NEONATAL)

Table 7.1 Incidence of Adverse Events by System Organ Class All Studies by Treatment Safety Population

			Hemorrha	ge Clearance	Studies		Other Indications			
	Cont	rol		5.	Vitrase					
System Organ Class / Preferred Term	ww	Saline	7.5 IU	37.5 IU		75 IU	Total Vitrase	Vitrase 50-500 IU	Saline Control	Other Active [1]
PERIPHERAL ISCHEMIA NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
POOR PERIPHERAL CIRCULATION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
PULMONARY EMBOLISM	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
PULMONARY HYPERTENSION NOS	0 (0%)	2 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
THROMBOEMBOLISM NOS	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
CEREBRAL INFARCTION	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
CEREBRAL ISCHEMIA	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
FLUSHING	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)
HYPERTENSIVE ENCEPHALOPATHY	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
LABILE HYPERTENSION	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
PERIPHERAL CIRCULATORY FAILURE	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
SUBARACHNOID HEMORRHAGE NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
RESPIRATORY, THORACIC AND	5 (28%)	12 (3%)	17 (5%)	0 (0%)	19 (5%)	15 (2%)	51 (4%)	7 (8%)	2 (10%)	0 (0%)
MEDIASTINAL DISORDERS	0 / 110)	3 (1%)	7 (2%)	0 (0%)	6 (2%)	4 (1%)	17 (1%)	0 (0%)	0 (0%)	0 (0%)
DYSPNEA NOS	2 (11%) 0 (0%)	3 (1%) 1 (<1%)	3 (1%)	0 (0%)	6 (2%)	3 (<1%)	12 (1%)	2 (2%)	0 (0%)	0 (0%)
COUGH		0 (0%)	0 (0%)	0 (0%)	3 (1%)	1 (<1%)	4 (<1%)	0 (0%)	0 (0%)	0 (0%)
CHRONIC OBSTRUCTIVE AIRWAYS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	3 (10)	1 (~10)	2 (120)	- ,,		
DISEASE	1 (6%)	2 (<1%)	2 (1%)	0 (0%)	0 (0%)	2 (<1%)	4 (<1%)	0 (0%)	0 (0%)	0 (0%)
PLEURAL EFFUSION	0 (0%)	3 (1%)	1 (<1%)	0 (0%)	0 (0%)	3 (<1%)	4 (<1%)	0 (0%)	0 (0%)	0 (0%)
RHINORRHEA	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	1 (<1%)	2 (<1%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)
EPISTAXIS LUNG INFILTRATION NOS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
SNEEZING	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
ASTHMA AGGRAVATED	2 (11%)	1 (<1%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
ASTHMA NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
ATELECTASIS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
DYSPNEA EXACERBATED	- 1	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
DYSPNEA EXERTIONAL		0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
DYSPNOEA NOS	0 (0%)	- , ,	- '	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
EMPHYSEMA	0 (0%)	0 (0%)		0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
HEMOPTYSIS	0 (0%)	0 (0%)		0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
HYPOXIA	0 (0%)	0 (0%)			0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
INTERSTITIAL LUNG DISEASE	0 (0%)	0 (0%)	1 (<1%) 1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
NASAL CONGESTION	0 (0%)	1 (<1%)	- •	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
PULMONARY FIBROSIS	0 (, 0%)	0 (0%)	0 (0%)		0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
RESPIRATORY FAILURE (EXC	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (08)	T (< T2)	T (< T.2)	5 (0%)	5 (00)	• , 00,

^[1] Other Active treatments include SF6 (PVD-01-08961X) and ACS-101C (COR-01-08961X). Patients who received both Vitrase and another active study treatment are included in both groups.

Table 7.1 Incidence of Adverse Events by System Organ Class All Studies by Treatment Safety Population

			Other Indications							
	Cont	rol		ge Clearance	Vitrase					
System Organ Class / Preferred Term	ww	Saline	7.5 IU	37.5 IU	SS IU	75 I U	Total Vitrase	Vitrase 50-500 IU	Saline Control	Other Active [1]
RHINITIS SEASONAL	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
SINUS PAIN	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
DYSPNEA PAROXYSMAL NOCTURNAL	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
NASOPHARYNGITIS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)
PNEUMONIA VIRAL NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
PULMONARY CONGESTION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)
RHINORRHOEA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)
SORE THROAT NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (2%)	2 (10%)	0 (0%)
RENAL AND URINARY DISORDERS	4 (22%)	19 (5%)	10 (3%)	1 (1%)	15 (4%)	19 (3%)	45 (3%)	1 (1%)	0 (0%)	0 (0%)
RENAL FAILURE NOS	1 (6%)	6 (1%)	4 (1%)	1 (1%)	6 (2%)	6 (1%)	17 (1%)	1 (1%)	0 (0%)	0 (0%)
RENAL IMPAIRMENT NOS	1 (6%)	2 (<1%)	2 (1%)	0 (0%)	5 (1%)	2 (<1%)	9 (1%)	0 (0%)	0 (0%)	0 (0%)
RENAL FAILURE ACUTE	3 (17%)	4 (1%)	2 (1%)	0 (0%)	2 (1%)	4 (1%)	8 (1%)	0 (0%)	0 (0%)	0 (0%)
RENAL FAILURE AGGRAVATED	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	2 (<1%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)
RENAL FAILURE CHRONIC	1 (6%)	3 (1%)	1 (<1%)	0 (0%)	1 (<1%)	1 (<1%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)
URINARY RETENTION	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	2 (<1%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)
CALCULUS RENAL NOS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
BLADDER PAIN	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
FLUID RETENTION	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
GLOMERULONEPHRITIS CHRONIC	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	O (0%)
GLOMERULONEPHRITIS MINIMAL LESION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
LOIN PAIN	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
POLYURIA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
RENAL ARTERY STENOSIS	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
RENAL FAILURE CHRONIC AGGRAVATED	1 (6%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
URINE DISCOLOURATION	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
BLADDER PROLAPSE	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
CALCULUS URINARY	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
DIABETIC NEPHROPATHY NOS	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
MICROALBUMINURIA	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
RENAL CYST NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
RENAL VASCULAR DISORDER NOS	0 (-0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
INJURY AND POISONING	0 (0%)	11 (3%)	9 (3%)	3 (2%)	9 (2%)	23 (4%)	44 (3%)	0 (0%)	0 (0%)	0 (0%)
LACERATION	0 (0%)	4 (1%)	0 (0%)	0 (0%)	1 (<1%)	5 (1%)	6 (<1%)	0 (0%)	0 (0%)	0 (0%)
FOOT FRACTURE	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	1 (<1%)	2 (<1%)	4 (<1%)	0 (0%)	0 (0%)	0 (0%)
HIP FRACTURE	0 (0%)	2 (<1%)	1 (<1%)	0 (0%)	0 (0%)	3 (<1%)	4 (<1%)	0 (0%)	0 (0%)	0 (0%)
CORNEAL EROSION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	3 (<1%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)

^[1] Other Active treatments include SF6 (PVD-01-08961X) and ACS-101C (COR-01-08961X). Patients who received both Vitrase and another active study treatment are included in both groups.

s:\dat\acs\iss2002\sas\programs\t_ae_treat 06SEP2002 17:33

Table 7.1 Incidence of Adverse Events by System Organ Class All Studies by Treatment Safety Population

			Hemorrha	ge Clearance	Studies		Other Indications			
	Cont	rol			Vitrase					
							Total	Vitrase	Saline	Other
System Organ Class / Preferred Term	ww 	Saline	7.5 IU	37.5 IU	55 IU	75 IU	Vitrase	50-500 IU	Control	Active [1]
DRUG TOXICITY NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	1 (<1%)	2 (<1%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)
ABRASION NOS	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
BURNS NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
FRACTURE NOS	0 (0%)	0 (0%)	2 (1%)	0 (0%)	0 (0%)	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
LEG FRACTURE	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)
ACCIDENT NOS	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
ACCIDENTAL OVERDOSE (THERAPEUTIC	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
AGENT)		, ,	, ,							
ANKLE FRACTURE	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
BACK INJURY NOS	0 (0%)	0 (0%)	.0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
BLISTER	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
CHEMICAL BURNS OF EYE	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (.0%)
CORNEAL ABRASION	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
FEMUR FRACTURE NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
FOREARM FRACTURE	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
HYPOTHERMIA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
INJURY NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
JOINT SPRAIN	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
LOCALISED INFECTION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
PHANTOM LIMB PAIN	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
RIB FRACTURE	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
SUNBURN	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
THERAPEUTIC AGENT TOXICITY	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
TIBIA FRACTURE	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
UPPER LIMB FRACTURE NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
WHIPLASH INJURY	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)
HEAD INJURY	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
MEDICATION ERROR	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
MUSCULOSKELETAL, CONNECTIVE TISSUE	0 (0%)	12 (3%)	11 (3%)	2 (2%)	10 (3%)	11 (2%)	34 (2%)	3 (4%)	1 (5%)	0 (0%)
AND BONE DISORDERS										
PAIN IN LIMB	0 (0%)	4 (1%)	5 (2%)	0 (0%)	3 (1%)	1 (<1%)	9 (1%)	2 (2%)	1 (5%)	0 (0%)
BACK PAIN	0 (0%)	1 (<1%)	2 (1%)	0 (0%)	2 (1%)	3 (<1%)	7 (<1%)	0 (0%)	0 (0%)	0 (0%)
ARTHRALGIA	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	1 (<1%)	2 (<1%)	4 (<1%)	0 (0%)	0 (0%)	0 (0%)
NECK PAIN	0 (0%)	1 (<1%)	1 (<1%)	1 (1%)	0 (0%)	2 (<1%)	4 (<1%)	0 (0%)	0 (0%)	0 (0%)
ARTHRITIS NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	2 (1%)	1 (<1%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)
MYALGIA	0 (0%)	2 (<1%)	0 (0%)	1 (1%)	0 (0%)	2 (<1%)	3 (<1%)	1 (1%)	0 (0%)	0 (0%)
TENDONITIS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	1 (<1%)	3 (<1%)	0 (0%)	0 (0%)	0 (0%)

^[1] Other Active treatments include SF6 (PVD-01-08961X) and ACS-101C (COR-01-08961X). Patients who received both Vitrase and another active study treatment are included in both groups.

s:\dat\acs\iss2002\sas\programs\t_ae_treat 06SEP2002 17:33

Table 7.1 Incidence of Adverse Events by System Organ Class All Studies by Treatment Safety Population

			Hemorrha	qe Clearanc	e Studies			Other Indications			
	Cont	rol			Vitrase					-	
System Organ Class / Preferred Term	ww	Saline	7.5 IU	37.5 IU	55 IU	75 IU	Total Vitrase	Vitrase 50-500 IU	Saline Control	Other Active [1]	
BACK PAIN AGGRAVATED	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
BUTTOCK PAIN	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
COSTAL PAIN	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
JAW DISORDER NOS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
MUSCLE CRAMPS	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
MUSCLE SPASMS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
OSTEOARTHRITIS NOS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
OSTEOPOROSIS NOS	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
ROTATOR CUFF SYNDROME	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
TENDONITIS EXACERBATED	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
BURSITIS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
JOINT STIFFNESS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
SCIATICA	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
PSYCHIATRIC DISORDERS	3 (17%)	7 (2%)	5 (2%)	0 (0%)	13 (3%)	10 (2%)	28 (2%)	0 (0%)	0 (0%)	0 (0%)	
DEPRESSION NEC	2 (11%)	1 (<1%)	2 (1%)	0 (0%)	4 (1%)	7 (1%)	13 (1%)	0 (0%)	0 (0%)	0 (0%)	
ANXIETY NEC	0 (0%)	1 (<1%)	2 (1%)	0 (0%)	5 (1%)	4 (1%)	11 (1%)	0 (0%)	0 (0%)	0 (0%)	
DELIRIUM	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (1%)	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)	
ALCOHOLIC WITHDRAWAL SYMPTOMS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
CONFUSION	0 (0%)	3 (1%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
DEPRESSION AGGRAVATED	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
DISORIENTATION	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
NEUROSIS NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
STRESS SYMPTOMS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
AGITATION	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
HALLUCINATION NOS	1 (6%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
SCHIZOPHRENIA NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
BLOOD AND LYMPHATIC SYSTEM	1 (6%)	10 (2%)	3 (1%)	0 (0%)	12 (3%)	11 (2%)	26 (2%)	0 (0%)	0 (0%)	0 (0%)	
DISORDERS						_ ,		0 / 00)		0 (00)	
ANEMIA NOS	1 (6%)	4 (1%)	2 (1%)	0 (0%)	12 (3%)	7 (1%)	21 (1%)	0 (0%)	0 (0%)	0 (0%) 0 (0%)	
ANAEMIA NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)		1 (<1%)	0 (0%)	• , ••,		
ANEMIA NOS AGGRAVATED	0 (0%)	3 (1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	o (0%)	0 (0%)	- ,,	
COAGULATION DISORDER NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%) 0 (0%)	
DISSEMINATED INTRAVASCULAR	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (08)	
COAGULATION	0 (00)	0 (05)	0 / 021	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
IRON DEFICIENCY ANEMIA	0 (0%)	0 (0%)	0 (0%)	. , ,			1 (<1%)	0 (0%)	0 (0%)	0 (0%)	
SECONDARY ANAEMIA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (< 14)	0 (08)	0 (08/	0 (0%)	

Note: One patient in study ACS201-HYA-002A received both 75 IU Vitrase and Saline. This patient is included in both groups here. Twelve patients in the "Probe Study" received two injections of 75 IU Vitrase. These patients are only counted once here.

Ocular Events include events reported for study eye and non-study eye.

[1] Other Active treatments include SF6 (PVD-01-08961X) and ACS-101C (COR-01-08961X). Patients who received both Vitrase and another active study

treatment are included in both groups.

s:\dat\acs\iss2002\sas\programs\t_ae_treat 06SEP2002 17:33

Table 7.1 Incidence of Adverse Events by System Organ Class All Studies by Treatment Safety Population

			Hemorrha	ge Clearance				0	Other Indications			
	Conti	rol			Vitrase							
System Organ Class / Preferred Term	ww	Saline	7.5 IU	37.5 IU	55 IU	75 IU	Total Vitrase	Vitrase 50-500 IU	Saline Control	Other Active [1]		
								- 4				
LEUCOCYTOSIS NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%		%) O (O%)		
NORMOCHROMIC NORMOCYTIC ANEMIA	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%		<pre>%) 0 (0%)</pre>		
SECONDARY ANEMIA	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%				
THROMBOCYTHEMIA	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%		%) 0 (O%)		
THROMBOCYTOPENIA	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%) 0 (0	%) O (O%)		
NEOPLASMS BENIGN AND MALIGNANT (INCLUDING CYSTS AND POLYPS)	0 (0%)	4 (1%)	5 (2%)	0 (0%)	3 (1%)	7 (1%)	15 (1%)	0 (0%	, - , -	\$) 0 (0%)		
BASAL CELL CARCINOMA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%		%) 0 (0%)		
BENIGN BREAST NEOPLASM NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%) 0 (0	%) 0 (0%)		
BENIGN NEOPLASM OF CHOROID	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%) 0 (0	%) 0 (0%)		
BENIGN SKIN NEOPLASM NOS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%) 0 (0	%) 0 (0%)		
BLADDER NEOPLASM NOS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%) 0 (0	%) 0 (0%)		
CHRONIC LEUKEMIA NOS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%) 0 (0	%) 0 (0%]		
COLON CANCER NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%) 0 (0	웅) 0 (0%)		
MALIGNANT MELANOMA OF SKIN STAGE	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 { 0%) 0 (0	% } 0 (0%)		
UNSPECIFIED												
METASTASES TO LUNG	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%) 0 (0	%) 0 (0%)		
MYELODYSPLASTIC SYNDROME NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%) 0 (0	%) 0 (0%)		
PROSTATE CANCER NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%) 0 (0	%) 0 (0%)		
RESPIRATORY TRACT NEOPLASM NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%) 0 (0	<pre>%) 0 (0%)</pre>		
SKIN CARCINOMA NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%) 0 (0	%) 0 { 0% }		
SKIN NEOPLASM NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%) 0 (0	%) 0 (0%)		
THYROID NEOPLASM NOS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%) 0 (0	%) 0 (0%)		
BREAST CANCER FEMALE NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%) 0 (0	%) 0 (0%)		
LIPOMA NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%	0 (-0	%) 0 (0%)		
NONHODGKIN'S LYMPHOMA NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%	0 (0	<pre>%) 0 (0%)</pre>		
RADIOACTIVE IODINE THERAPY	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%) 0 (0	<pre>%) 0 (0%)</pre>		
ENDOCRINE DISORDERS	0 (0%)	7 (2%)	2 (1%)	1 (1%)	2 (1%)	5 (1%)	10 (1%)	0 (0%) 0 (0	%) O (O%)		
DIABETES MELLITUS INADEQUATE	0 (0%)	5 (1%)	1 (<1%)	1 (1%)	1 (<1%)	4 (1%)	7 (<1%)	0 (0%) 0 (0	%) 0 (0% !		
CONTROL	0 (00,	3 (10)	- (/	- ,,	- (,	- , ,						
ADRENAL INSUFFICIENCY NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%) 0 (0	<pre>%) 0 (0%)</pre>		
GOITRE	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%	0 (0	%) O (O%)		
HYPOTHYROIDISM	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%	0 (0	왕) 0 (0%		
THYROTOXICOSIS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%) 0 (0	%) Q (0%)		
	, ,	_ ,,			- ,,		- /	0 / 05		e.) 0 (00.1		
IMMUNE SYSTEM DISORDERS	1 (6%)	2 (<1%)	3 (1%)	0 (0%)	1 (<1%)	2 (<1%)	6 (<1%)	0 (0%) 0 (0	<pre>%) 0 (0%)</pre>		

Other Active treatments include SF6 (PVD-01-08961X) and ACS-101C (COR-01-08961X). Patients who received both Vitrase and another active study treatment are included in both groups.

Table 7.1 Incidence of Adverse Events by System Organ Class All Studies by Treatment Safety Population

			Hemorrha	ge Clearance	Studies			Other Indications				
	Conti	rol			Vitrase				•		_	
System Organ Class / Preferred Term	ww	Saline	7.5 IU	37.5 IU	55 IU	75 IU	Total Vitrase	Vitrase 50-500 I	_	Saline Control	Other Active [1]	
DRUG HYPERSENSITIVITY	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)	2 (<1%)	2 (<1%)	0 (0)%)	0 (0%)	0 (0%)	
HYPERSENSITIVITY NOS	1 (6%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (0%)	2 (<1%)	o i o	18)	0 (0%)	0 (0%)	
KIDNEY TRANSPLANT REJECTION	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0	(\$(0 (0%)	0 (0%)	
MULTIPLE ALLERGIES	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0) %)	0 (0%)	0 (0%)	
GENERAL DISORDERS AND ADMINISTRATIVE SITE CONDITIONS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	2 (1%)	1 (<1%)	4 (<1%)	0 (0)*)	0 (0%)	.0 (0%)	
AXILLARY MASS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (()왕)	0 (0%)	0 (0%)	
EDEMA LOWER LIMB	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0) %)	0 (0%)		
LOWER EXTREMITY MASS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (() %)	0 (0%)	0 (0%)	
WEAKNESS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0) %)	0 (0%)	0 (0%)	
HEPATO-BILIARY DISORDERS	0 (0%)	3 (1%)	3 (1%)	0 (0%)	1 (<1%)	0 (0%)	4 (<1%)	0 (0)%)	0 (0%)		
CHOLECYSTITIS ACUTE NOS	0 (0%)	0 (0%)	2 (1%)	0 (0%)	0 (0%)	0 (0%)	2 (<1%)	0 (0)왕)	0 (0%)	0 (0%)	
CHOLELITHIASIS	0 (0%)	2 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0) 웅)	0 (0%)	0 (0%)	
HEPATITIS NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (()왕)	0 (0%)	0 (0%)	
HEPATOMEGALY	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (()왕)	0 (0%)	0 (0%)	
GALLBLADDER DISEASE NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (()왕)	0 (0%)	0 (0%)	
HEPATOSPLENOMEGALY NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0)%)	0 (0%)	0 (0%)	
HYPOPROTEINEMIA	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (() %)	0 (0%)	0 (0%)	
EAR AND LABYRINTH DISORDERS	0 (0%)	1 (<1%)	2 (1%)	0 (0%)	0 (0%)	1 (<1%)	3 (<1%)	0 (()%)	0 (0%)	0 (0%)	
EARACHE	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0)%)	0 (0%)	0 (0%)	
SUDDEN HEARING LOSS NOS	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0) %)	0 { 0%;	0 (0%)	
VERTIGO NEC	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0)왕)	0 (0%)	0 (0%)	
LABYRINTHITIS NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (() (%C	0 (0%)	0 (0%)	
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITION	0 (0%)	6 (1%)	0 (0%)	0 (0%)	1 (<1%)	2 (<1%)	3 (<1%)	0 (() }	0 (0%)	0 (0%)	
PYREXIA	0 (0%)	4 (1%)	0 (0%)	0 (0%)	0 (0%)	2 (<1%)	2 (<1%)	0 (() ક)	0 (0%)	0 (0%)	
THIRST	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	0 (0%)	1 (<1%)	0 (() % }	0 (0%)		
FISTULA NOS	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (()왕)	0 (0%)	0 (0%)	
PAIN IN FACE	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (() ક)	0 (0%)	0 (0%)	
REPRODUCTIVE SYSTEM AND BREAST DISORDERS	0 (0%)	2 (<1%)	0 (0%)	0 (0%)	0 (0%)	2 (<1%)	2 (<1%)	1 (3	1용)	0 (0%)		
BENIGN PROSTATIC HYPERPLASIA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 ((D%)	0 (0%)		
MENOPAUSE	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 ((0왕)	. 0 { 0%	0 (0%)	
PEROFFICE	0 (08)	0 (0%)	0 (00)	0 , 50/								

Note: One patient in study ACS201-HYA-002A received both 75 IU Vitrase and Saline. This patient is included in both groups here. Twelve patients in the "Probe Study" received two injections of 75 IU Vitrase. These patients are only counted once here. Ocular Events include events reported for study eye and non-study eye.

00

^[1] Other Active treatments include SF6 (PVD-01-08961X) and ACS-101C (COR-01-08961X). Patients who received both Vitrase and another active study treatment are included in both groups.

s:\dat\acs\iss2002\sas\programs\t_ae_treat 06SEP2002 17:33

Table 7.1 Incidence of Adverse Events by System Organ Class All Studies by Treatment Safety Population

			Hemorrhage	e Clearance				oth	Other Indications			
System Organ Class / Preferred Term	Contro	Saline	7.5 IU	37.5 IU	Vitrase 55 IU	75 IU	Total Vitrase	Vitrase 50-500 TU	Saline Control	Other Active [1]		
PROSTATIC DISORDER NOS PROSTATITIS VAGINAL HAEMORRHAGE	0 (0%) 0 (0%) 0 (0%)	1 (<1%) 1 (<1%) 0 (0%)	0 (0%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 1 (1%)	0 (0%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 0 (0%)						
CONGENITAL AND FAMILIAL/GENETIC DISORDERS CUTIS LAXA	0 (0%) 0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)		
REPRODUCTIVE AND BREAST DISORDERS PROSTATITIS	0 (0%)	0 (0%) 0 (0%)	0 (0%) 0 (0%)	0 (0%)	0 (0%) 0 (0%)	1 (<1%) 1 (<1%)	1 (<1%) 1 (<1%)	0 (0%) 0 (0%)	0 (0%) 0 (0%)	0 (0%) 0 (0%)		
PREGNANCY, PUERPERIUM AND PERINATAL CONDITIONS PREGNANCY NOS	0 (0%)	0 (0%)	0 (0%) 0 (0%)	0 (0%)	0 (0%) 0 (0%)	0 (0%)	0 (0%) 0 (0%)	0 (0%)	0 (0%)	1 (1%) 1 (1%)		

 ∞

Note: One patient in study ACS201-HYA-002A received both 75 IU Vitrase and Saline. This patient is included in both groups here. Twelve patients in the "Probe Study" received two injections of 75 IU Vitrase. These patients are only counted once here.

Ocular Events include events reported for study eye and non-study eye.

[1] Other Active treatments include SF6 (PVD-01-08961X) and ACS-101C (COR-01-08961X). Patients who received both Vitrase and another active study

treatment are included in both groups.

Table 7.2 Incidence of Adverse Events by System Organ Class All Studies by Study for Vitrase Groups Only Safety Population

System Organ Class / Preferred Term	Phase I [1]	V-01-VIT-08961X	ACS202-HYA-001US	ACS203-HYA-001MEX	VIT-02-08961X	VIT-03-08961X	Other Indications [2
NUMBER OF PATIENTS	68	31	153	225	602	364	84
NUMBER OF PATIENTS WITH AT LEAST ONE ADVERSE EVENT	1 (1.5%)	31 (100%)	93 (60.8%)	70 (31.1%)	593 (98.5%)	282 (77.5%)	75 (89.3%)
EYE DISORDERS	1 (1.5%)	31 (100%)	77 (50.3%)	69 (30.7%)	590 (98.0%)	275 (75.5%)	73 (86.9%)
IRITIS	0 (0.0%)	31 (100%)	3 (2.0%)	0 (0.0%)	438 (72.8%)	152 (41.8%)	11 (13.1%)
OCULAR HYPEREMIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	393 (65.3%)	139 (38.2%)	0 (0.0%)
EYE PAIN	0 (0.0%)	0 (0.0%)	9 (5.9%)	0 (0.0%)	286 (47.5%)	92 (25.3%)	15 (17.9%)
EYE IRRITATION	0 (0.0%)	15 (48.4%)	4 (2.6%)	0 (0.0%)	294 (48.8%)	69 (19.0%)	15 (17.9%)
LACRIMATION INCREASED	0 (0.0%)	26 (83.9%)	1 (0.7%)	0 (0.0%)	261 (43.4%)	68 (18.7%)	9 (10.7%)
VISUAL ACUITY REDUCED	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)	238 (39.5%)	47 (12.9%)	15 (17.9%)
VITREOUS HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	230 (38.2%)	71 (19.5%)	0 (0 0%)
ABNORMAL SENSATION IN EYE	0 (0.0%)	7 (22.6%)	2 (1.3%)	0 (0.0%)	227 (37.7%)	52 (14.3%)	10 (11.9%)
VITREOUS FLOATERS	0 (0.0%)	1 (3.2%)	5 (3.3%)	0 (0.0%)	207 (34.4%)	50 (13.7%)	6 (7.1%)
PHOTOPHORIA	0 (0.0%)	6 (19.4%)	1 (0.7%)	0 (0.0%)	197 (32.7%)	51 (14.0%)	6 (7.1%)
CONTINCTIVAL EDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	172 (28.6%)	61 (16.8%)	0 (0.0%)
HYPODYON	1 (1.5%)	0 (0.0%)	46 (30.1%)	56 (24.9%)	19 (3.2%)	9 (2.5%)	2 (2.4%)
RETINAL DETACHMENT	0 (0.0%)	2 (6.5%)	8 (5.2%)	1 (0.4%)	77 (12.8%)	32 (8.8%)	0 (0.0%)
PHOTOPSTA	0 (0.0%)	4 (12.9%)	3 (2.0%)	0 (0.0%)	87 (14.5%)	19 (5.2%)	3 (3.6%)
CATARACT SUBCARSIII.AR	0 (0.0%)	1 (3.2%)	2 (1.3%)	2 (0.9%)	86 (14.3%)	16 (4.4%)	8 (9.5%)
CATARACT NICLEAR	0 (0.0%)	3 (9.7%)	2 (1.3%)	0 (0.0%)	83 (13.8%)	14 (3.8%)	2 (2.4%)
EAL ULGCHARGE	0 (0.0%)	27 (87.1%)	2 (1.3%)	0 (0.0%)	45 (7.5%)	10 (2.7%)	10 (11.9%)
CATADACT CODTICAL	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	57 (9.5%)	18 (4.9%)	3 (3.6%)
CODMENT DISCRED NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	29 (4.8%)	21 (5.8%)	26 (31.0%)
CODMENT FORMS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	54 (9.0%)	12 (3.3%)	0 (0.0%)
DIRECTE TRIDE	0 (0.0%)	0 (0.0%)	2 (1.3%)	0 (0.0%)	52 (8.6%)	10 (2.7%)	1 (1.2%)
MACHIAD EDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	56 (9.3%)	6 (1.6%)	0 (0.0%)
MACULAR EDEMA	0 (0.0%)	0 (0.0%)	5 (3.3%)	2 (0.9%)	32 (5.3%)	18 (4.9%)	2 (2.4%)
IRIS ADHESIONS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	43 (7.1%)	9 (2.5%)	6 (7.1%)
CORNEAL EROSION	0 (0.0%)	3 (9.7%)	2 (1.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	50 (59.5%)
CORNEAL GEDEMA	0 (0.0%)	, ,		0 (0.0%)	42 (7.0%)	5 (1.4%)	0 (0.0%)
CONJUNCTIVAL HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	9 (10.7%)
CONJUNCTIVAL OEDEMA	0 (0.0%)	28 (90.3%)	3 (2.0%)	0 (0.0%)	37 (6.1%)	2 (0.5%)	0 (0.0%)
HYPHEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	22 (26.2%)
OCULAR HYPERAEMIA	0 (0.0%)	14 (45.2%)	1 (0.7%)		14 (2.3%)	13 (3.6%)	2 (26.2%)
CATARACT NEC	0 (0.0%)	6 (19.4%)	2 (1.3%)	0 (0.0%) 0 (0.0%)	15 (2.5%)	1 (0.3%)	17 (20.2%)
VISUAL ACUITY REDUCED VITREOUS HEMORRHAGE ABNORMAL SENSATION IN EYE VITREOUS FLOATERS PHOTOPHOBIA CONJUNCTIVAL EDEMA HYPOPYON RETINAL DETACHMENT PHOTOPSIA CATARACT SUBCAPSULAR CATARACT NUCLEAR EYE DISCHARGE CATARACT CORTICAL CORNEAL DISORDER NOS CORNEAL EDEMA RUBEOSIS IRIDIS MACULAR EDEMA IRIS ADHESIONS CORNEAL EROSION CORNEAL BEDEMA IRIS ADHESIONS CORNEAL EROSION CORNEAL ECDEMA CONJUNCTIVAL HEMORRHAGE CONJUNCTIVAL OEDEMA HYPHEMA OCULAR HYPERAEMIA CATARACT NEC KERATITIS NEC VITREOUS HAEMORRHAGE RETINOPATHY DIABETIC	0 (0.0%)	0 (0.0%)	3 (2.0%)		0 (0.0%)	0 (0.0%)	3 (3.6%)
VITREOUS HAEMORRHAGE	0 (0.0%)	12 (38.7%)	19 (12.4%)	2 (0.9%)		8 (2.2%)	0 (0.0%)
RETINOPATHY DIABETIC	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	19 (3.2%)	0 (0.0%)	2 (2.4%)
DRY BIE NEC	0 (0.05)	0 (0.0%)	1 (0.7%)	0 (0.0%)	23 (3.8%)		0 (0.0%)
BLINDNESS NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	21 (3.5%)	4 (1.1%)	
VISION BLURRED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	21 (3.5%)	2 (0.5%) 6 (1.6%)	2 (2.4%) 0 (0.0%)
GLAUCOMA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	18 (3.0%)	p (T.02)	0 (0.0%)

^[1] Includes ACS201-HYA-001A, ACS201-HYA-002A, Probe Study [2] Includes PVD-01-08961X, COR-01-08961X, COP-01-08961X

Table 7.2 Incidence of Adverse Events by System Organ Class All Studies by Study for Vitrase Groups Only Safety Population

stem Organ Class / Preferred Term	Phase I [1]	V-01-VIT-08961X	ACS202-HYA-001US	ACS203-HYA-001MEX	VIT-02-08961X	VIT-03-08961X	Other Indications [2
CONJUNCTIVITIS NEC	0 (0.0%)	1 (3.2%)	1 (0.7%)	0 (0.0%)	4 (0.7%)	3 (0.8%)	14 (16.7%)
RED EYE	0 (0.0%)	19 (61.3%)	1 (0.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (3.6%)
UVEITIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	8 (3.6%)	5 (0.8%)	9 (2.5%)	0 (0.0%)
VITREOUS DETACHMENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	21 (3.5%)	0 (0.0%)	1 (1.2%)
EYELID OEDEMA	0 (0.0%)	15 (48.4%)	1 (0.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (3.6%)
MACULOPATHY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	17 (2.8%)	1 (0.3%)	0 (0.0%)
CORNEAL ABRASION	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	10 (1.7%)	0 (0.0%)	6 (7.1%)
BLEPHARITIS	0 (0.0%)	0 (0.0%)	2 (1.3%)	0 (0.0%)	13 (2.2%)	1 (0.3%)	0 (0.0%)
CATARACT NOS AGGRAVATED	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	13 (2.2%)	1 (0.3%)	0 (0.0%)
	0 (0 00)	0 (0.0%)	0 (0.0%)	0 (0.0%)	12 (2.0%)	3 (0.8%)	0 (0.0%)
DETINAL UDMODDUACE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	14 (2.3%)	1 (0.3%)	0 (0.0%)
CELINAL DEMOKRAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	11 (1.8%)	3 (0.8%)	0 (0.0%)
INTRACCULAR PRESSURE INCREASED RETINAL HEMORRHAGE POSTERIOR CAPSULE OPACIFICATION CORNEAL EPITHELIUM DEFECT DIPLOPIA HYPOTONY OF EYE RETINAL ISCHEMIA IRIS DISORDER NOS PHOTOPHOBIA AGGRAVATED RETINAL TEAR (EXC DETACHMENT)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	9 (1.5%)	1 (0.3%)	2 (2.4%)
CORNEAL EPITACHION DEFECT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	10 (1.7%)	0 (0.0%)	0 (0.0%)
JIPLOPIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	9 (1.5%)	1 (0.3%)	0 (0.0%)
DESCRIPTION OF EIG	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	10 (1.7%)	0 (0.0%)	0 (0.0%)
RETINAL ISCHEMIA	0 (0.0%)	0 (0.0%)	3 (2.0%)	5 (2.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
IRIS DISORDER NOS	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	3 (0,5%)	1 (0.3%)	3 (3.6%)
HOTOPHOBIA AGGRAVATED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (1.0%)	2 (0.5%)	0 (0.0%)
ETINAL TEAR (EAC DETACHMENT)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (1.0%)	1 (0.3%)	0 (0.0%)
EYE DEGENERATIVE DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (1.0%)	1 (0.3%)	0 (0.0%)
POST-OPERATIVE PAIN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (1.0%)	0 (0.0%)	0 (0.0%)
FOREIGN BODY RETAINED IN EYE	0 (0.0%)	0 (0.0%)	2 (1.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (4.8%)
MACULAR OEDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (0.8%)	1 (0.3%)	0 (0.0%)
AYDRIASIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (0.8%)	0 (0.0%)	1 (1.2%)
VITREOUS DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (6.0%)
CORNEAL DEPOSITS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (6.0%)
CORNEAL INFILTRATES	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	3 (3.6%)
CORNEAL OPACITY	0 (0.0%)		1 (0.7%)	0 (0.0%)	3 (0.5%)	0 (0.0%)	1 (1.2%)
CERATOCONJUNCTIVITIS	0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%)	1 (0.4%)	2 (0.3%)	2 (0.5%)	0 (0.0%)
CULAR HYPERTENSION	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	4 (0.7%)	0 (0.0%)	0 (0.0%)
RETINAL NEOVASCULARIZATION NOS	0 (0.0%)		1 (0.7%)	0 (0.0%)	3 (0.5%)	0 (0.0%)	0 (0.0%)
ONJUNCTIVITIS ALLERGIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.5%)	1 (0.3%)	0 (0.0%)
SYE ALLERGY	0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (0.7%)	0 (0.0%)	0 (0.0%)
EYELID PTOSIS	0 (0.0%)	0 (0.0%)	1 (0.7%)	3 (1.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
HYPHAEMA	0 (0.0%) 0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.5%)	1 (0.3%)	0 (0.0%)
MACULAR DEGENERATION	U (U.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (0.7%)	0 (0.0%)	0 (0.0%)
OPTIC ATROPHY	0 (0.0%)		0 (0.0%)	0 (0.0%)	3 (0.5%)	0 (0.0%)	1 (1.2%)
PAINFUL RED EYES	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (4.8%)
EYE DEGENERATIVE DISORDER NOS POST-OPERATIVE PAIN FOREIGN BODY RETAINED IN EYE MACULAR OEDEMA MYDRIASIS VITREOUS DISORDER NOS CORNEAL DEPOSITS CORNEAL INFILTRATES CORNEAL OPACITY KERATOCONJUNCTIVITIS OCULAR HYPERTENSION RETINAL NEOVASCULARIZATION NOS CONJUNCTIVITIS ALLERGIC EYE ALLERGY EYE ALLERGY EYELD PTOSIS HYPHAEMA MACULAR DEGENERATION OPTIC ATROPHY PAINFUL RED EYES PUPPILLARY REFLEX IMPAIRED CORTICAL OPACITY EYE HAEMORRHAGE NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.5%)	0 (0.0%)	0 (0.0%)
CORTICAL OPACITY	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
		0 (0.0%)	1 (0.7%)	0 (0.0%)	3 (0.5%)	0 (0.0%)	0 (0.0%)
IRIDOCYCLITIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	1 (0.3%)	0 (0.0%)
OPEN ANGLE GLAUCOMA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.08)	2 (0.38)	1 (0.58)	0 (0.0%)

^[1] Includes ACS201-HYA-001A, ACS201-HYA-002A, Probe Study [2] Includes PVD-01-08961X, COR-01-08961X, COP-01-08961X

s:\dat\acs\iss2002\sas\programs\t_ae_study 06SEP2002 17:34

Table 7.2 Incidence of Adverse Events by System Organ Class All Studies by Study for Vitrase Groups Only Safety Population

stem Organ Class / Preferred Term	Phase I [1]	V-01-VIT-08961X	ACS202-HYA-001US	ACS203-HYA-001MEX	VIT-02-08961X	VIT-03-08961X	Other Indications [2
PSEUDOPHAKIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	1 (0.3%)	0 (0.0%)
RETINAL ARTERY EMBOLISM	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.5%)	0 (0.0%)	0 (0.0%)
RETINAL DISORDER NOS RETINAL MICROANEURYSMS RETINAL SCAR VISUAL DISTURBANCE NOS ACCOMMODATION DISORDER	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (1.3%) 0 (0.0%)	0 (0.0%)	3 (0.5%)	0 (0.0%)	0 (0.0%)
RETINAL MICROANEURYSMS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.5%)	0 (0.0%)	0 (0.0%)
RETINAL SCAR	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%)	1 (0.2%)	2 (0.5%)	0 (0.0%)
VISUAL DISTURBANCE NOS	0 (0.0%)	0 (0.0%)	2 (1.3%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
ACCOMMODATION DISORDER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
APHAKIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	1 (0.3%)	0 (0.0%)
ACCOMMODATION DISORDER APHAKIA BELINDNESS TRANSIENT CATARACT UNILATERAL CHEMOSIS CHOROIDAL DETACHMENT CONJUNCTIVITIS (INFECTIVE) NEC CONJUNCTIVITIS VIRAL NOS CORNEAL DEGENERATION CORNEAL NEOVASCULARIZATION CYCLITIS ERYTHEMA NEC EYE INFLAMMATION NOS HYALOSIS ASTEROID INTRAOCULAR PRESSURE DECREASED IRIS VASCULAR DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	1 (0.3%)	0 (0.0%)
CATARACT UNILATERAL	0 (0.0%)	0 (0.0%)	2 (1.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CHEMOSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	1 (0.3%)	0 (0.0%)
CHOROIDAL DETACHMENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	1 (0.3%)	0 (0.0%)
CONJUNCTIVITIS (INFECTIVE) NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	0 (0.0%)
CONJUNCTIVITIS VIRAL NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	0 (0.0%)
CORNEAL DEGENERATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	1 (1.2%)
CORNEAL NEOVASCIII.APIZATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
CVCITTIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	1 (1.2%)
EDVTUEMA NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
EVE INDEX NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
EIG INFOAMMATION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
TAMPACCIAN PRECCIME PROPERCED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
INTRACCULAR PRESSURE DECREASED	0 (0.0%)			0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
IRIS VASCULAR DISORDER NOS	0 (0.0%)	0 (0.0%)	1 (0.7%) 0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
KERATOPATHY BAND	0 (0.0%)		0 (0.0%)	0 (0.0%)	1 (0.2%)	1 (0.3%)	0 (0.0%)
KERATOPATHY NOS	0 (0.0%)	0 (0.0%)		0 (0.0%)	1 (0.2%)	0 (0.0%)	1 (1.2%)
LENTICULAR OPACITIES	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	0 (0.0%)
MEIBOMIAN CYST	0 (0.0%)	0 (0.0%)	0 (0.0%)		2 (0.3%)	0 (0.0%)	0 (0.0%)
OPTIC DISC HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	1 (0.3%)	0 (0.0%)
PERIORBITAL HEMATOMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		•	0 (0.0%)
RETINAL DEGENERATION	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
RETINAL DEPIGMENTATION	0 (0.0%)	0 (0.0%)	0 (0.03)	0 (0.0%)	2 (0.3%)	0 (0.0%)	
RETINAL VEIN THROMBOSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
STRABISMUS NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
SUBEPITHELIAL OPACITIES	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
VITREOUS OPACITIES	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
ANGLE CLOSURE GLAUCOMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
ANISEIKONIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
INTRACTULAR PRESSURE DECREASED IRIS VASCULAR DISORDER NOS KERATOPATHY BAND KERATOPATHY NOS LENTICULAR OPACITIES MEIBOMIAN CYST OPTIC DISC HEMORRHAGE PERIORBITAL HEMATOMA RETINAL DEGENERATION RETINAL DEPIGMENTATION RETINAL VEIN THROMBOSIS STRABISMUS NEC SUBEPITHELIAL OPACITIES VITREOUS OPACITIES ANGLE CLOSURE GLAUCOMA ANTERIOR CHAMBER DEGENERATION ARCUS SENILIS BLEPHAROCONJUNCTIVITIS BLEPHAROCONJUNCTIVITIS BLINDNESS NIGHT BLOODSHOT EYE CCONJUNCTIVAL EDEMA CHALAZION	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
ARCUS SENILIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
BLEPHAROCONJUNCTIVITIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
BLINDNESS NIGHT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
BLOODSHOT EYE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
CCONJUNCTIVAL EDEMA	0 (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
CHALAZTON	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)

⁸⁸⁰ [1] Includes ACS201-HYA-001A, ACS201-HYA-002A, Probe Study [2] Includes PVD-01-08961X, COR-01-08961X, COP-01-08961X

s:\dat\acs\iss2002\sas\programs\t_ae_study 06SEP2002 17:34

System Organ Class / Preferred Term	Phase I [1]	V-01-VIT-08961X	ACS202-HYA-001US	ACS203-HYA-001MEX	VIT-02-08961X	VIT-03-08961X	Other Indications [2]
CHORIORETINAL ATROPHY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
CHORIORETINAL DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
CHOROIDAL HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
COLOUR BLINDNESS NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
COLOUR BLINDNESS NEC CONJUNCTIVAL CYST CONJUNCTIVAL HAEMORRHAGE CONJUNCTIVITIS PAPILLARY CORECTOPIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
CONJUNCTIVAL HAEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
CONJUNCTIVITIS PAPILLARY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
CORECTOPIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
CORNEAL DYSTROPHY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
CORNEAL GRAFT REJECTION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
CORNEAL LESION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	I (1.2%)
CORNEAL SCAR	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
CONJUNCTIVITIS PAPILLARY CORRECTOPIA CORNEAL DYSTROPHY CORNEAL GRAFT REJECTION CORNEAL LESION NOS CORNEAL LESION NOS CORNEAL SCAR CORNEAL ULCER NEC EYE INFECTION FUNGAL NOS EYE INFECTION STAPHYLOCOCCAL EYE INFECTION TOXOPLASMAL EYE INJURY NOS EYELID DISORDER NOS EYELID EDEMA GLAUCOMA AGGRAVATED HERPES SIMPLEX OPHTHALMIC LACRIMAL DUCT OBSTRUCTION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
EYE INFECTION FUNGAL NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
EYE INFECTION STAPHYLOCOCCAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	· 0 (0.0%)	0 (0.0%)
EYE INFECTION TOXOPLASMAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
EYE INJURY NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
EYELID DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
EYELID EDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
GLAUCOMA AGGRAVATED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
HERPES SIMPLEX OPHTHALMIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
LACRIMAL DUCT OBSTRUCTION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
LENTICULAR PIGMENTATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
OPTIC NEUROPATHY NOS	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PAPILLEDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
DINCIPOUR A	0 1 0 08.1	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0 0%)
DOCT OPERATUR COMPLICATIONS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0 0%)
DETINAL ADDEDS MUDOMPOCIO	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
RETINAL MACONITATO	0 (0.0%)		0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
RETINAL VASCULITIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
POST-OPERATIVE COMPLICATIONS NOS RETINAL ARTERY THROMBOSIS RETINAL VASCULITIS SCLERITIS NOS STYE TIRED EYES TOPOGRAPHY CORNEAL ABNORMAL	0 (0.0%)	0 (0.0%)	O (D.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
SIIE	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
TIRED EYES	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
TOPOGRAPHY CORNEAL ABNORMAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
UVEITIS DIABETIC	0 (0.0%)	0 (0.0%)			1 (0.2%)	0 (0.0%)	0 (0.0%)
VISION ABNORMAL NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
UVEITIS DIABETIC VISION ABNORMAL NEC VISUAL ACUITY REDUCED TRANSIENTLY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.24)	0 (0.0%)	0 (0.04)
NVESTIGATIONS	0 (0.0%)	7 (22.6%)	8 (5.2%)	2 (0.9%)	139 (23.1%)	28 (7.7%)	3 (3.6%)
INTRAOCULAR PRESSURE INCREASED	0 (0.0%)	3 (9.7%)	6 (3.9%)	2 (0.9%)	107 (17.8%)	22 (6.0%)	1 (1.2%)
CORNEAL STAINING	0 (0.0%)	4 (12.9%)	2 (1.3%)	0 (0.0%)	20 (3.3%)	5 (1.4%)	2 (2.4%)
BLOOD GLUCOSE INCREASED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (0.7%) 3 (0.5%)	0 (0.0%)	0 (0.0%)
BLOOD CREATININE INCREASED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)
BLOOD PRESSURE INCREASED	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.9%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	2 (0.3%)	1 (0.3%)	0 (0.0%)

⁽¹⁾ Includes ACS201-HYA-001A, ACS201-HYA-002A, Probe Study (2) Includes PVD-01-08961X, COR-01-08961X, COP-01-08961X

Table 7.2 Incidence of Adverse Events by System Organ Class All Studies by Study for Vitrase Groups Only Safety Population

System Organ Class / Preferred Term	Phase I [1]	V-01-VIT-08961X	ACS202-HYA-001US	ACS203-HYA-001MEX	VIT-02-08961X	VIT-03-08961X	Other Indications [2]
BLOOD CHOLESTEROL INCREASED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
		0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
HEMATURIA PRESENT INTRAOCULAR PRESSURE ABNORMAL	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
DIODEV MOS	0 (0 0*)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
BLOOD GLUCOSE ABNORMAL BLOOD GLUCOSE DECREASED BLOOD GLUCOSE FLUCTUATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
BLOOD GLUCOSE DECREASED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
BLOOD GLUCOSE FLUCTUATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
BLOOD PHOSPHATE DECREASED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
BLOOD SODIUM DECREASED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
BLOOD TRIGLYCERIDES INCREASED		0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
RIOOD IREA INCREASED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
BLOOD UREA INCREASED CANDIDURIA COAGULATION FACTOR DECREASED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
CONCULATION FACTOR DECREASED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
COAGULATION FACTOR DECREASED ELECTROCARDIOGRAM ABNORMAL NOS ENLARGED PROSTATE LIVER FUNCTION TESTS NOS ABNORMAL	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
ENLARGED PROSTATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0 .0%)
LIVER PUNCTION TESTS NOS ARNORMAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
DROUBLIND A DRECENT	ስ (ስ ሲያ ነ	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%) 1 (0.2%)	0 (0.0%)	0 (0.0%)
PROTEINORIA FRESENI PROTHROMBIN TIME PROLONGED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
RED BLOOD CELL SEDIMENTATION RATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
INCREASED	0 (0.00)	0 (0111)					
WEIGHT DECREASED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
SKIN & SUBCUTANEOUS TISSUE DISORDERS	0 (0.0%)	10 (32.3%)	1 (0.7%)	0 (0.0%)	106 (17.6%)	22 (6.0%)	8 (9.5%)
EYELID EDEMA		0 (0.0%)	0 (0.0%)	0 (0.0%)	50 (8.3%)	17 (4.7%)	0 (0.0%)
EDVTUENA NEC	0 (0.0%)	10 (32.3%)	0 (0.0%)	0 (0.0%)	37 (6.1%)	12 (3.3%)	5 (6.0%)
פססי ווו.מים	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (0.7%)	0 (0.0%)	1 (1.2%)
DRIBITIE NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (0.7%) 4 (0.7%)	1 (0.3%)	0 (0.0%)
DEPMATITIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)			0 (0.0%)	0 (0.0%)
EVELID OFDEMA	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	0 (0.0%) 3 (0.5%)	0 (0.0%)	2 (2.4%)
SKIN HIGED WOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.5%)	0 (0.0%)	0 (0.0%)
CONTUSTON	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
CUTTE LAYA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
DEDMATTTIC ALLERGIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
FACE EDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
OCILAD HADEBENIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
DEPTOPRITAL EDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
EYELID EDEMA ERYTHEMA NEC FOOT ULCER PRURITUS NOS DERMATITIS NOS EYELID OEDEMA SKIN ULCER NOS CONTUSION CUTIS LAXA DERMATITIS ALLERGIC FACE EDEMA OCULAR HYPEREMIA PERIORBITAL EDEMA PSORIASIS SKIN IRRITATION SKIN LESION NOS ALOPECIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
CKIN IDDITATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
CKIN INCION NOC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
ALOPECIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
DIABETIC FOOT ULCER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
DRY SKIN	. 0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
DIABETIC FOOT ULCER DRY SKIN ECCHYMOSIS	0 (0.0%)			0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)

^[1] Includes ACS201-HYA-001A, ACS201-HYA-002A, Probe Study [2] Includes PVD-01-08961X, COR-01-08961X, COP-01-08961X

s:\dat\acs\iss2002\sas\programs\t_ae_study 06SEP2002 17:34

Other

ISTA Pharmaceuticals, Inc. Integrated Summary of Safety

							otner
System Organ Class / Preferred Term	Phase I [1]	V-01-VIT-08961X	ACS202-HYA-001US	ACS203-HYA-001MEX	VIT-02-08961X	VIT-03-08961X	Indications [2]
IPC INCED (FYC VARICOSE)	0 (0 0%)	0 (0.0%)	0 (0.0%)			0 (0.0%)	0 (0.0%)
DAIMAD POUTURMA	0 (0.04)	0 (0.0%)	0 (0 0%)	0 (0 0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
CYIN NECDOSIS	0 (0.04)	0 (0.0%) 0 (0.0%) 0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%)	1 (0.2%) 0 (0.0%) 1 (0.2%)	1 (0.3%)	0 (0.0%)
SKIN NECROSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
SKIN IN CED HEWODDHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
CTACIC HICEP	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
SWEATING INCREASED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
PALMAR ERYTHEMA SKIN NECROSIS SKIN NODULE SKIN ULCER HEMORRHAGE STASIS ULCER SWEATING INCREASED TELANGIECTASIA	0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
NERVOUS SYSTEM DISORDERS HEADACHE NOS CEREBROVASCULAR ACCIDENT NOS DIZZINESS (EXC VERTIGO) INSOMNIA NEC PUPILLARY DISORDER NOS SYNCOPE DEMENTIA NOS HYPOESTHESIA BALANCE IMPAIRED NOS CONVULSIONS NOS FACIAL PALSY IIRD NERVE PARALYSIS MOVEMENT DISORDER NOS NEUROPATHY NOS TREMOR NEC VISUAL FIELD DEFECT NOS BURNING SENSATION NOS DYSARTHRIA HEMIPARESIS HEMORRHAGIC STROKE HYPOAESTHESIA LACUNAR INFARCTION MIGRAINE NOS OBSTRUCTIVE SLEEP APNEA SYNDROME	0 (0.0%)	1 (3.2%)	6 (3.9%)	0 (0.0%)	94 (15.6%)	22 (6.0%)	18 (21.4%)
HEADACHE NOS	0 (0.0%)	1 (3.2%)	5 (3.3%)	0 (0.0%)	46 (7.6%)	9 (2.5%)	15 (17.9%)
CEREBROVASCULAR ACCIDENT NOS	0 (0.0%)	1 (3.2%) 1 (3.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	1 (0.7%)	0 (0.0%) 0 (0.0%) 0 (0.0%)	10 (1.7%)	6 (1.6%)	0 (0.0%)
DIZZINESS (EXC VERTIGO)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	10 (1.7%)	1 (0.3%)	1 (1.2%)
INSOMNIA NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	9 (1.5%)	1 (0.3%)	0 (0.0%)
PUPILLARY DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%)	7 (1.2%)	3 (0.8%)	0 (0.0%)
SYNCOPE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	7 (1.2%) 3 (0.5%)	0 (0.0%)	0 (0.0%)
DEMENTIA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	3 (0.5%)	0 (0.0%)	0 (0.0%)
HYPOESTHESIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.5%) 2 (0.3%)	0 (0.0%)	0 (0.0%)
BALANCE IMPAIRED NOS	0 (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
CONVILSIONS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
FACTAL PALSY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%) 2 (0.3%) 1 (0.2%) 0 (0.0%)	1 (0.3%)	0 (0.0%)
ITIRD NERVE PARALYSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
MOVEMENT DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%) 2 (0.3%)	0 (0.0%)	0 (0.0%)
NEUROPATHY NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
TREMOR NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
VISUAL FIELD DEFECT NOS	0 (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	0 (0.0%)	2 (0.3%) 1 (0.2%)	0 (0.0%)	0 (0.0%)
BURNING SENSATION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
DYSARTHRIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%) 1 (0.2%)	0 (0.0%)	0 (0.0%)
HEMIPARESIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
HEMORRHAGIC STROKE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0 0%)	0 (0.0%)
HYPOAESTHESIA	0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
LACUNAR INFARCTION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
MIGRAINE NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%)	1 (0.2%) 1 (0.2%)	0 (0.0%)	0 (0.0%)
OBSTRUCTIVE SLEEP APNEA SYNDROME	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
PARKINSON'S DISEASE NOS	0 (0.0%)	0 (0.03)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
PUPILLARY REFLEX IMPAIRED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		1 (0.3%)	0 (0.0%)
OBSTRUCTIVE SLEEP APNEA SYNDROME PARKINSON'S DISEASE NOS PUPILLARY REFLEX IMPAIRED SPEECH DISORDER NEC VISUAL PATHWAY DISORDER NOS	0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%)		1 (0.2%)	0 (0.0%)	
VISUAL PATHWAY DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
VITH NERVE PARALYSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
INFECTIONS AND INFESTATIONS NASOPHARYNGITIS PNEUMONIA NOS	0 (0.0%)	0 (0.0%) 0 (0.0%)	3 (2.0%) 0 (0.0%)	0 (0.0%)	93 (15.4%)	14 (3.8%)	6 (7.1%) 0 (0.0%)
NASOPHARYNGITIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	16 (2.7%)	0 (0.0%)	0 (0.0%)
PNEUMONIA NOS	0 (0.0%)	0 (0.0%)	2 (1.3%)	0 (0.0%)	12 (2.0%)	1 (0.3%)	0 (0.08)

^[1] Includes ACS201-HYA-001A, ACS201-HYA-002A, Probe Study
[2] Includes PVD-01-08961X, COR-01-08961X, COP-01-08961X

s:\dat\acs\iss2002\sas\programs\t_ae_study 06SEP2002 17:34

ystem Organ Class / Preferred Term	Phase I [1]		ACS202-HYA-001US	ACS203-HYA-001MEX	VIT-02-08961X	VIT-03-08961X	Other Indications [2
URINARY TRACT INFECTION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	12 (2.0%)	0 (0.0%)	0 (0.0%)
INFLUENZA	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	6 (1.0%)	2 (0.5%)	2 (2.4%)
CELLULITIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	7 (1.2%)	1 (0.3%)	0 (0.0%)
BRONCHITIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	7 (1.2%)	0 (0.0%)	0 (0.0%)
LOCALISED INFECTION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (1.0%)	1 (0.3%)	0 (0.0%)
OSTEOMYELITIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	7 (1.2%)	0 (0.0%)	0 (0.0%)
SINUSITIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (1.0%)	1 (0.3%)	0 (0.0%)
SEPSIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	3 (0.8%)	0 (0.0%)
UPPER RESPIRATORY TRACT INFECTION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (0.8%)	0 (0.0%)	0 (0.0%)
SKIN INFECTION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (0.7%)	0 (0.0%)	0 (0.0%)
HERPES ZOSTER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.5%)	0 (0.0%)	0 (0.0%)
PHARYNGITIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.5%)	0 (0.0%)	0 (0.0%)
BRONCHITIS ACUTE NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
FUNGAL INFECTION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
KERATITIS HERPETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
ORAL CANDIDIASIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	1 (0.3%)	0 (0.0%)
RESPIRATORY TRACT INFECTION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	1 (0.3%)	0 (0.0%)
SKIN CANDIDA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
SORE THROAT NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
STAPHYLOCOCCAL INFECTION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
TOOTH INFECTION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
AMERICAN TRYPANOSOMIASIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
ARTHROPOD BITE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
BACTERIAL INFECTION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
BLADDER INFECTION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
CANDIDAL INFECTION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	
CELLULITIS STAPHYLOCOCCAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
CYSTITIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	
INJECTION SITE INFECTION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
KIDNEY INFECTION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
LARYNGITIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	• ,
LOWER RESPIRATORY TRACT INFECTION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
LUNG INFECTION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
NAIL TINEA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
OSTEOMYELITIS CHRONIC NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
PHARYNGITIS STREPTOCOCCAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
PNEUMONIA HAEMOPHILUS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0 0%) 0 (0.0%)
PULMONARY TUBERCULOSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
ROUNDWORM INFECTION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
SEPTIC ARTHRITIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
SEPTICEMIA STAPHYLOCOCCAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
VAGINOSIS FUNGAL NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
WOUND INFECTION NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)

^[1] Includes ACS201-HYA-001A, ACS201-HYA-002A, Probe Study [2] Includes PVD-01-08961X, COR-01-08961X, COP-01-08961X

System Organ Class / Preferred Term	Phase I [1]	V-01-VIT-08961X	ACS202-HYA-001US	ACS203-HYA-001MEX	VIT-02-08961X	VIT-03-08961X	Other Indications [2]
CARDIAC DISORDERS	0 (0.0%)	2 (6.5%)	8 (5.2%)	0 (0.0%)	68 (11.3%)	15 (4.1%)	1 (1.2%)
CARDIAC DISORDERS MYOCARDIAL INFARCTION CARDIAC FAILURE CONGESTIVE	0 (0.0%)	2 (6.5%)	3 (2.0%)	0 (0.0%)	14 (2.3%)	3 (0.8%)	0 (0.0%)
CARDIAC FAILURE CONGESTIVE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%)	16 (2.7%)	3 (0.8%)	0 (0.0%)
ANGINA UNSTABLE	0 (0.0%)	0 (0.0%)			8 (1.3%)	0 (0.0%)	0 (0.0%)
CARDIAC FAILURE CONGESTIVE ANGINA UNSTABLE CARDIAC ARREST ATRIAL FIBRILLATION CARDIAC FAILURE NOS EDEMA LOWER LIMB PULMONARY EDEMA NOS ARRHYTHMIA NOS CARDIOWEGALY NOS CARDIOVASCULAR DISORDER NOS GORDANNA PERRON DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	7 (1.2%)	1 (0.3%)	0 (0.0%)
ATRIAL FIBRILLATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (0.8%)	2 (0.5%)	0 (0.0%)
CARDIAC FAILURE NOS	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	3 (0.5%)	1 (0.3%)	0 (0.0%)
EDEMA LOWER LIMB	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.5%)	2 (0.5%)	0 (0.0%)
PULMONARY EDEMA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.5%)	2 (0.5%)	0 (0.0%)
ARRHYTHMIA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	1 (0.3%)	0 (0.0%)
CARDIOMEGALY NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)-	3 (0.5%)	0 (0.0%)	0 (0.0%)
CARDIOVASCULAR DISORDER NOS	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
CORONARY ARTERY DISEASE NOS	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
CORONARY ARTERY OCCLUSION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (ዐ.ዐ%)	3 (0.5%)	0 (0.0%)	0 (0.0%)
ANGINA PECTORIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
AORTIC VALVE STENOSIS	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
ATRIOVENTRICULAR BLOCK NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	1 (0.3%)	0 (0.0%)
CARDIAC DISORDER NOS	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
CARDIAC MURMUR NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	1 (0.3%)	0 (0.0%)
EDEMA PERIPHERAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
LEFT VENTRICULAR FAILURE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	1 (0.3%)	0 (0.0%)
MYOCARDIAL ISCHEMIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
PALPITATIONS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
AORTIC VALVE DISEASE NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
CARDIOVASCULAR DISORDER NOS CORONARY ARTERY DISEASE NOS CORONARY ARTERY DISEASE NOS CORONARY ARTERY OCCLUSION ANGINA PECTORIS AORTIC VALVE STENOSIS ATRIOVENTRICULAR BLOCK NOS CARDIAC DISORDER NOS CARDIAC MURMUR NOS EDEMA PERIPHERAL LEFT VENTRICULAR FAILURE MYOCARDIAL ISCHEMIA PALPITATIONS AORTIC VALVE DISEASE NOS ATRIAL FLUTTER BRADYCARDIA NOS CARDIAC FAILURE CARDIO-RESPIRATORY ARREST CARDIOGENIC SHOCK CARDIOMYOPATHY NOS DYSPNEA PAROXYSMAL NOCTURNAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
BRADYCARDIA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
CARDIAC FAILURE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
CARDIO-RESPIRATORY ARREST	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
CARDIOGENIC SHOCK	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
CARDIOMYOPATHY NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
DYSPNEA PAROXYSMAI, NOCTURNAI.	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
DYSPNOED NOS	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
FDEMA HODER TIMB	0 (0 0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0 0%)	0 (0.0%)
ISCHEMIC CARDIOMYOPATHY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
MYOCARDITE MOS	0 (0 0%)	0 (0.0%)	0 (0.0%)		1 (0.2%)	0 (0.0%)	0 (0.0%)
OFDEMA DEDIBUEDAT.	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
VENTOTOTITAD TYTDAGVGTOLDG	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
CARDIOMYOPATHY NOS DYSPNEA PAROXYSMAL NOCTURNAL DYSPNOEA NOS EDEMA UPPER LIMB ISCHEMIC CARDIOMYOPATHY MYOCARDITIS NOS OEDEMA PERIPHERAL VENTRICULAR EXTRASYSTOLES VENTRICULAR TACHYCARDIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
GASTROINTESTINAL DISORDERS	0 (0.0%)	1 (3.2%)	2 (1.3%)	0 (0.0%)	69 (11.5%)	10 (2.7%)	3 (3.6%)
NAUSEA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	28 (4.7%)	1 (0.3%)	2 (2.4%)
VOMITING NOS	0 (0.0%)	0 (0.0%)	1 (0.7%)		8 (1.3%)	5 (1.4%)	0 (0.0%)
DIARRHEA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	10 (1.7%)	3 (0.8%)	0 (0.0%)

^[1] Includes ACS201-HYA-001A, ACS201-HYA-002A, Probe Study

^[2] Includes PVD-01-08961X, COR-01-08961X, COP-01-08961X

Table 7.2 Incidence of Adverse Events by System Organ Class All Studies by Study for Vitrase Groups Only Safety Population

stem Organ Class / Preferred Term	Phase I [1]	V-01-VIT-08961X	ACS202-HYA-001US	ACS203-HYA-001MEX	VIT-02-08961X	VIT-03-08961X	Other Indications [2
CONSTIPATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	9 (1.5%)	3 (0.8%)	0 (0.0%)
CA CERO TAMES CERTAIN A LIEU CORDINA CO MACA	0 / 0 00)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (1.0%)	1 (0.3%)	0 (0.0%)
GASTROINIESTINAL HEMORRHAGE NOS ABDOMINAL PAIN NOS DYSPEPSIA ESOPHAGITIS NOS GASTRITIS NOS SORE THROAT NOS ABDOMINAL PAIN UPPER GASTRO-ESOPHAGEAL REFLUX DISEASE DIVERTICULUM INTESTINAL ESOPHAGEAL REFLUX GASTRIC ULCER GASTROINIESTINAL UPSET	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (1.0%)	0 (0.0%)	0 (0.0%)
DYSPEPSIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (0.7%)	0 (0.0%)	0 (0.0%)
ESOPHAGITIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.5%)	1 (0.3%)	0 (0.0%)
GASTRITIS NOS	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	2 (0.5%)	0 (0.0%)
SORE THROAT NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.5%)	1 (0.3%)	0 (0.0%)
ABDOMINAL PAIN UPPER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	1 (0.3%)	0 (0.0%)
GASTRO-ESOPHAGEAL REFLUX DISEASE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.5%)	0 (0.0%)	0 (0.0%)
DIVERTICULUM INTESTINAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	1 (0.3%)	0 (0.0%)
ESOPHAGEAL REFLUX	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
GASTRIC ULCER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
GASTROINTESTINAL UPSET	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
ABDOMINAL PAIN AGGRAVATED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
ABDOMINAL TENDERNESS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
ASCITES	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
DIARRHOEA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
DUODENAL ULCER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
DUODENITIS	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
DYSPHAGIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
GASTRIC EROSIONS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
GASTRIC IRRITATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
GASTROENTERITIS NOS	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
GASTROINTESTINAL DISORDER NOS	0 (0.0%)	O (D.O%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
HEMATEMESIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
HEMORRHOIDS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
IMPAIRED GASTRIC EMPTYING	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
INGUINAL HERNIA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
PEPTIC ULCER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
PEPTIC ULCER HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
PERIODONTAL DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
PERITONEAL DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
PERITONEAL HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%) 0 (0.0%)
PERITONITIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
RECTAL BLEEDING	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	
RECTAL PROLAPSE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%) 0 (0.0%)	0 (0.0%)
TOOTHACHE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
ENERAL DISORDERS AND ADMINISTRATION	0 (0.0%)	26 (83.9%)	6 (3.9%)	0 (0.0%)	41 (6.8%)	0 (0.0%)	8 (9.5%)
TTE CONDITIONS				- / 0 005	2 / 0 501	0 (0 08)	2 (2.4%)
PAIN NOS	0 (0.0%)	25 (80.6%)	2 (1.3%)	0 (0.0%)	3 (0.5%)	0 (0.0%) 0 (0.0%)	0 (0.0%)
CHEST PAIN NEC	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	13 (2.2%)	0 (0.0%)	0 (0.0%)
FALL	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (0.7%)	0 (0.08)	0 (0.08)

^[1] Includes ACS201-HYA-001A, ACS201-HYA-002A, Probe Study [2] Includes PVD-01-08961X, COR-01-08961X, COP-01-08961X

s:\dat\acs\iss2002\sas\programs\t_ae_study 06SEP2002 17:34

Table 7.2
Incidence of Adverse Events by System Organ Class
All Studies by Study for Vitrase Groups Only
Safety Population

ystem Organ Class / Preferred Term	Phase I [1]	V-01-VIT-08961X	ACS202-HYA-001US	ACS203-HYA-001MEX	VIT-02-08961X	VIT-03-08961X	Other Indications [2
FATIGUE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (0.7%)	0 (0.0%)	0 (0.0%)
PAIN IN FACE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (0.7%)	0 (0.0%)	0 (0.0%)
PYREXIA	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	1 (1.2%)
SENSATION OF FOREIGN BODY NOS		4 (12.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
WEAKNESS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (0.7%)	0 (0.0%)	0 (0.0%)
EDEMA LOWER LIMB	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.5%)	0 (0.0%)	0 (0.0%)
INJECTION SITE EXTRAVASATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (3.6%)
DIFFICULTY IN WALKING	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
EDEMA PERIPHERAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
INJECTION SITE REACTION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
APPLICATION SITE BLEEDING	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
APPLICATION SITE ERYTHEMA	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
DEATH NOS	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
GROIN PAIN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
HERNIA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
IMPAIRED HEALING	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
LOWER EXTREMITY MASS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
MASS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
		0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
MECHANICAL COMPLICATION OF IMPLANT MULTI-ORGAN FAILURE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
RIGORŜ	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
SENSATION OF PRESSURE NOS	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
SKIN INFECTION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
ETABOLISM AND NUTRITION DISORDERS		2 (6.5%)	2 (1.3%)	0 (0.0%)	61 (10.1%)	9 (2.5%)	1 (1.2%)
HYPERCHOLESTEROLEMIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	16 (2.7%)	2 (0.5%)	0 (0.0%)
HYPOGLYCAEMIA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	11 (1.8%)	0 (0.0%)	1 (1.2%)
HYPERGLYCEMIA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	8 (1.3%)	0 (0.0%)	0 (0.0%)
DEHYDRATION	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	6 (1.0%)	0 (0.0%)	0 (0.0%)
HYPERLIPIDEMIA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (0.8%)	2 (0.5%)	0 (0.0%)
APPETITE DECREASED NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (1.0%)	0 (0.0%)	0 (0.0%)
HYPERKALEMIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.5%)	2 (0.5%)	0 (0.0%)
DIABETIC NEUROPATHY NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	2 (0.5%)	0 (0.0%)
DIABETIC COMA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	1 (0.3%)	0 (0.0%)
DIABETES MELLITUS AGGRAVATED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
DIABETES MELLITUS INSULIN-DEPENDENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
GOUT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
GOUT AGGRAVATED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
HYPOCALCEMIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
HYPOKALEMIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
OBESITY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
DIABETES MELLITUS NON	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)

INSULIN-DEPENDENT

^[1] Includes ACS201-HYA-001A, ACS201-HYA-002A, Probe Study [2] Includes PVD-01-08961X, COR-01-08961X, COP-01-08961X

s:\dat\acs\iss2002\sas\programs\t_ae_study 06SEP2002 17:34

Other

ISTA Pharmaceuticals, Inc. Integrated Summary of Safety

System Organ Class / Preferred Term	Phase I [1]	V-01-VIT-08961X	ACS202-HYA-001US	ACS203-HYA-001MEX	VIT-02-08961X	VIT-03-08961X	Indications [2]
	 -						
DIABETIC AMYOTROPHY DIABETIC COMPLICATION NOS DIABETIC EYE DISEASE NOS DIABETIC KETOACIDOSIS ELECTROLYTE IMBALANCE GLUCOSE TOLERANCE IMPAIRED HYPERLIPIDAEMIA NOS HYPERPHOSPHATEMIA HYPERVOLEMIA HYPOGLYCAEMIC COMA HYPONATREMIA INSULIN RESISTANCE METABOLIC ACIDOSIS NOS POLYDIPSIA RETINOPATHY DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%) 1 (0.3%)	0 (0.0%) 0 (0.0%)
DIABETIC COMPLICATION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		0 (0.0%)
DIABETIC EVE DISEASE NOS	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
DIADETIC METOACIDOSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%) 1 (0.2%)	0 (0.0%)	0 (0.0%)
DIABBLE RELOACIDODIO	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
CHICOGE TOTEPANCE IMPAIRED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%) 0 (0.0%) 1 (0.2%) 0 (0.0%) 1 (0.2%) 0 (0.0%) 1 (0.2%)	0 (0.0%)	0 (0.0%)
GEOCOSE TOREMANCE IMPAIRED	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
HIPERDIFIDADMIA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
HIPERHOIPMIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
HIPERVOLEMIA COMA	0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
HIPOGLICAEMIC COMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
HYPONALREMIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
HYPOVOLEMIA	0 (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.28)	0 (0.0%)	
INSULIN RESISTANCE	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%)		1 (0.3%)	0 (0.0%)
METABOLIC ACIDOSIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
POLYDIPSIA	0 (0.00)	0 (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
RETINOPATHY DIABETIC	0 (0.0%)	0 (0.00)	- ,				
	0 (0 0%)	1 (3.2%)	1 (0.7%)	0 (0.0%)	50 (8.3%)	11 (3.0%)	3 (3.6%)
VASCULAR DISORDERS	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)	25 (4.2%)	5 (1.4%)	2 (2.4%)
HYPERTENSION NOS	0 (0 .0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	7 (1.2%)	2 (0.5%)	0 (0.0%)
HYPERTENSION AGGRAVATED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.5%) 4 (0.7%) 3 (0.5%) 2 (0.3%)	1 (0.3%)	0 (0.0%)
GANGRENE NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (0.7%)	0 (0.0%)	0 (0.0%)
HYPOTENSION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.5%)	0 (0.0%)	0 (0.0%)
TRANSIENT ISCHEMIC ATTACK	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
PERIPHERAL VASCULAR DISEASE NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	1 (0.3%)	0 (0.0%)
POSTURAL HYPOTENSION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%)	1 (0.2%) 1 (0.2%)	1 (0.3%)	0 (0.0%)
VENOUS THROMBOSIS DEEP LIMB	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
ARTERIAL ANEURYSM NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
ARTERIAL OCCLUSION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
BLOOD PRESSURE FLUCTUATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
BLOOD PRESSURE INADEQUATELY CONTROLLED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
CAROTID ARTERY DISEASE NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
CAROTID ARTERY STENOSIS	0 (0.0%)	0 (0.0%)		0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
CEREBROVASCULAR ACCIDENT NOS	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
COLLAPSE	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
FLUSHING	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
HEMATOMA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
HOT FLUSHES NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
ISCHEMIC FOOT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)
PERIPHERAL ISCHEMIA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
POOR PERIPHERAL CIRCULATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
PULMONARY EMBOLISM	0 (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
PULMONARY HYPERTENSION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%) 0 (0.0%)	0 (0.0%)	0 (0.0%)
BLOOD PRESSURE INADEQUATELY CONTROLLED CAROTID ARTERY DISEASE NOS CAROTID ARTERY STENOSIS CEREBROVASCULAR ACCIDENT NOS COLLAPSE FLUSHING HEMATOMA NOS HOT FLUSHES NOS ISCHEMIC FOOT PERIPHERAL ISCHEMIA NOS POOR PERIPHERAL CIRCULATION PULMONARY EMBOLISM PULMONARY HYPERTENSION NOS THROMBOEMBOLISM NOS	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

⁽¹⁾ Includes ACS201-HYA-001A, ACS201-HYA-002A, Probe Study (2) Includes PVD-01-08961X, COR-01-08961X, COP-01-08961X

Table 7.2 Incidence of Adverse Events by System Organ Class All Studies by Study for Vitrase Groups Only Safety Population

System Organ Class / Preferred Term	Phase I [1]	V-01-VIT-08961X	ACS202-HYA-001US	ACS203-HYA-001MEX	VIT-02-08961X	VIT-03-08961X	Other Indications [2]
			1 (0.7%)	0 (0.0%)	53 (8.8%)	7 (1.9%)	1 (1.2%)
SURGICAL AND MEDICAL PROCEDURES	0 (0.0%)	2 (6.5%)	0 (0.0%)	0 (0.0%)	15 (2.5%)	4 (1.1%)	0 (0.0%)
POST-OPERATIVE COMPLICATIONS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	7 (1.2%)	1 (0.3%)	0 (0,0%)
VITRECTOMY	0 (0.0%)	2 (6.5%)	0 (0.0%)	0 (0.0%)	8 (1.3%)	0 (0.0%)	0 (0.0%)
UNSPECIFIED COMPLICATION OF PROCEDURE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (1.50)	0 (0.00,	• (••••
NEC		0 / 0 081	0 (0.0%)	0 (0.0%)	3 (0.5%)	0 (0.0%)	0 (0.0%)
CORONARY ARTERY SURGERY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
FOOT AMPUTATION NAUSEA POST-OPERATIVE POST-OPERATIVE HEMORRHAGE TOE AMPUTATION TOOTH EXTRACTION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
NAUSEA POST-OPERATIVE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	1 (0.3%)	0 (0.0%)
POST-OPERATIVE HEMORRHAGE	0 (0.0%)	0 (0.0%)		0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
TOE AMPUTATION	0 (0.0%)	0 (0.0%)	0 (0.0%)		1 (0.2%)	1 (0.3%)	0 (0.0%)
TOOTH EXTRACTION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	1 (1.2%)
TOE AMPUTATION TOOTH EXTRACTION NOS APPLICATION SITE REACTION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
ARTERIAL BYPASS OPERATION (EXC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.26)	0 (0.08)	0 (0.00)
CORONARY ARTERY)				- 4>		0 (0.0%)	0 (0.0%)
ARTERIO-VENOUS FISTULA OPERATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
BLOOD PRODUCT TRANSFUSION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
CORONARY ARTERY) ARTERIO-VENOUS FISTULA OPERATION BLOOD PRODUCT TRANSFUSION CARDIAC PACEMAKER INSERTION CAROTID ENDARTERECTOMY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
CAROTID ENDARTERECTOMY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)		0 (0.0%)
CHEMOTHERAPY NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	- '
EVE TRRITATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
FIJITO PEDIACEMENT PARENTERAL.	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
FOOT OPPRATION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
UTD ADTUDODIACTY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
THIE COTTON CIME OF DEMA	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
THOSCITON SITE OFFICE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
INC. MADIENTON	0 (0.00)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
LEG AMPOIATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
LENS IMPLANT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
LIMB OPERATION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
POST PROCEDURAL HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
POST PROCEDURAL PAIN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
POST-OPERATIVE PAIN	0 (0.0%)	0 (0.0%)	0 (0.0%)	. 0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
SCLERAL OPERATION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
SHUNT OCCLUSION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
SKIN CYST EXCISION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
SUTURE LINE PAIN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
VOMITING POST-OPERATIVE	0 (0.0%)	0 (0.0%)	0 (0.0%)	•	1 (0.23)		
CAROTID ENDARTERECTOMY CHEMOTHERAPY NOS EYE IRRITATION FLUID REPLACEMENT PARENTERAL FOOT OPERATION NOS HIP ARTHROPLASTY INJECTION SITE OEDEMA KNEE ARTHROPLASTY LEG AMPUTATION LENS IMPLANT LIME OPERATION NOS POST PROCEDURAL HEMORRHAGE FOST PROCEDURAL PAIN POST-OPERATIVE PAIN SCLERAL OPERATION NOS SHUNT OCCLUSION SKIN CYST EXCISION SUTURE LINE PAIN VOMITING POST-OPERATIVE RESPIRATORY, THORACIC AND MEDIASTINAL	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	45 (7.5%)	5 (1.4%)	7 (8.3%)
DISORDERS					17 / 2 00.1	0 (0.0%)	0 (0.0%)
DYSPNEA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	17 (2.8%)	2 (0.5%)	2 (2.4%)
COUGH	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	10 (1.7%)	0 (0.0%)	0 (0.0%)
CHRONIC OBSTRUCTIVE AIRWAYS DISEASE	0 (0.0%).	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (0.7%)	•	0 (0.0%)
PLEURAL EFFUSION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (0.7%)	0 (0.0%)	0 (0.0%)

^[1] Includes ACS201-HYA-001A, ACS201-HYA-002A, Probe Study [2] Includes PVD-01-08961X, COR-01-08961X, COP-01-08961X

Other

Table 7.2 Incidence of Adverse Events by System Organ Class All Studies by Study for Vitrase Groups Only Safety Population

System Organ Class / Preferred Term	Phase I [1]	V-01-VIT-08961X	ACS202-HYA-001US	ACS203-HYA-001MEX	VIT-02-08961X	VIT-03-08961X	Other Indications [2]
					4 (0.7%)	0 (0.0%)	0 (0.0%)
RHINORRHEA EPISTAXIS LUNG INFILTRATION NOS SNEEZING SORE THROAT NOS ASTHMA AGGRAVATED ASTHMA NOS ATELECTASIS DYSPNEA EXACERBATED DYSPNEA EXERTIONAL DYSPNOEA NOS EMPHYSEMA HEMOPTYSIS HYPOXIA INTERSTITIAL LUNG DISEASE NASAL CONGESTION NASOPHARYNGITIS PULMONARY CONGESTION PULMONARY FIBROSIS RESPIRATORY FAILURE (EXC NEONATAL)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%)	3 (0.5%)	0 (0.0%)	0 (0.0%)
EPISTAXIS	0 (0.0%)	0 (0.0%)	0 (0.0%)		2 (0.3%)	0 (0.0%)	0 (0.0%)
LUNG INFILTRATION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
SNEEZING	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
SORE THROAT NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0 0%)	0 (0.0%)
ASTHMA AGGRAVATED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
ASTHMA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
ATELECTASIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
DYSPNEA EXACERBATED	0 (0.0%)	0 (0.0%)	0 (0.0%)		1 (0.2%)	0 (0.0%)	0 (0.0%)
DYSPNEA EXERTIONAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
DYSPNOEA NOS	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
EMPHYSEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
HEMOPTYSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
HYPOXIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
INTERSTITIAL LUNG DISEASE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)
NASAL CONGESTION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%) 0 (0.0%)	0 (0.0%)	1 (1.2%)
NASOPHARYNGITIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		0 (0.0%)	1 (1.2%)
PULMONARY CONGESTION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PULMONARY FIBROSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
RESPIRATORY FAILURE (EXC NEONATAL)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)		0 (0.0%)
RHINITIS SEASONAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	1 (1.2%)
RHINORRHOEA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
SINUS PAIN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
RENAL AND URINARY DISORDERS RENAL FAILURE NOS RENAL IMPAIRMENT NOS RENAL FAILURE ACUTE RENAL FAILURE AGGRAVATED RENAL FAILURE CHRONIC URINARY RETENTION CALCULUS RENAL NOS BLADDER PAIN FLUID RETENTION GLOMERULONEPHRITIS CHRONIC GLOMEPULONEPHRITIS MINIMAL LESION	0 (0.0%)	0 (0.0%)	1 (0.7%)		35 (5.8%)	9 (2.5%) 2 (0.5%)	1 (1.2%) 1 (1.2%)
RENAL FATLURE NOS	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	14 (2.3%)	0 (0.0%)	0 (0.0%)
RENAL IMPAIRMENT NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	9 (1.5%)	4 (1.1%)	0 (0.0%)
RENAL FATLURE ACUTE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (0.7%)		0 (0.0%)
PENAL FATLURE AGGRAVATED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.5%)	0 (0.0%)	0 (0.0%)
RENAL FAILURE CHRONIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	1 (0.3%)	0 (0.0%)
INTINARY PETENTION	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%)	. 0 (0.0%)	2 (0.3%)	1 (0.3%)	0 (0.0%)
CALCULIS RENAL NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
RIADDED DATM	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	
PLIITO PETENTION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
CIOMPDITONEPURITIS CHRONIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
CIOMPRIMONE PHRITIS MINIMAL LESION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
LOTH DATH	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
DOI VIDIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
DEMNI NEMEDA CLEMUCIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
REMAI MAILAI SIEMOSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
GLOMERULONEPHRITIS CHRONIC GLOMERULONEPHRITIS MINIMAL LESION LOIN PAIN POLYURIA RENAL ARTERY STENOSIS RENAL FAILURE CHRONIC AGGRAVATED URINE DISCOLOURATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
INJURY AND POISONING		4 (12.9%)	5 (3.3%)	0 (0.0%)	29 (4.8%)	6 (1.6%)	0 (0.0%)

^[1] Includes ACS201-HYA-001A, ACS201-HYA-002A, Probe Study [2] Includes PVD-01-08961X, COR-01-08961X, COP-01-08961X

s:\dat\acs\iss2002\sas\programs\t_ae_study 06SEP2002 17:34

Table 7.2 Incidence of Adverse Events by System Organ Class All Studies by Study for Vitrase Groups Only Safety Population

					***** 00 00061¥	17TT 03 00061Y	Other
ystem Organ Class / Preferred Term	Phase I [1]	V-01-VIT-08961X	ACS202-HYA-001US	ACS203-HYA-001MEX	VIT-02-08961X	V11-03-08961X	
LACERATION	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)	5 (0.8%)	0 (0.0%)	0 (0.0%)
FOOT FRACTURE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (0.7%)	0 (0.0%)	0 (0.0%)
HIP FRACTURE	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	2 (0.3%)	1 (0.3%)	0 (0.0%)
	0 (0.0%)	3 (9.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CORNEAL EROSION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.5%)	0 (0.0%)	0 (0.0%)
DRUG TOXICITY NOS	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
ABRASION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
BURNS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
FRACTURE NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	0 (0.0%)
LEG FRACTURE	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
ACCIDENT NOS ACCIDENTAL OVERDOSE (THERAPEUTIC	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	0 (0.0%)	0 (0.0%)	1 (0.707	5 (5:57.	, , ,		
GENT)	0 / 0 601	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
ANKLE FRACTURE	0 (0.0%)		0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
BACK INJURY NOS	0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
BLISTER	0 (0.0%)		0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
CHEMICAL BURNS OF EYE	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CORNEAL ABRASION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
FEMUR FRACTURE NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
FOREARM FRACTURE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
HYPOTHERMIA	0 (0.0%)	0 (0.0%)		0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
INJURY NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
JOINT SPRAIN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
LOCALISED INFECTION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
PHANTOM LIMB PAIN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
RIB FRACTURE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
SUNBURN	0 (0.0%)	0 (0.0%)	0 (0.0%)	•	1 (0.2%)	0 (0.0%)	0 (0.0%)
THERAPEUTIC AGENT TOXICITY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
TIBIA FRACTURE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
UPPER LIMB FRACTURE NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
WHIPLASH INJURY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0*)	0 (0.007
MUSCULOSKELETAL, CONNECTIVE TISSUE AND	0 (0.0%)	0 (0.0%)	2 (1.3%)	0 (0.0%)	27 (4.5%)	5 (1.4%)	3 (3.6%)
SONE DISORDERS				- /	0 / 1 5%)	0 (0.0%)	2 (2.4%)
PAIN IN LIMB	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	9 (1.5%) 5 (0.8%)	2 (0.5%)	0 (0.0%)
BACK PAIN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)
ARTHRALGIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (0.7%)	2 (0.5%)	1 (1.2%)
MYALGIA	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	0 (0.0%)	0 (0.5%)	0 (0.0%)
NECK PAIN	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	3 (0.5%)	0 (0.0%)	0 (0.0%)
ARTHRITIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.5%)		0 (0.0%)
TENDONITIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.5%)	0 (0.0%)	0 (0.0%)
BACK PAIN AGGRAVATED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
BUTTOCK PAIN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
COSTAL PAIN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.05)

^[1] Includes ACS201-HYA-001A, ACS201-HYA-002A, Probe Study [2] Includes PVD-01-08961X, COR-01-08961X, COP-01-08961X

s:\dat\acs\iss2002\sas\programs\t_ae_study 06SEP2002 17:34

Table 7.2 Incidence of Adverse Events by System Organ Class All Studies by Study for Vitrase Groups Only Safety Population

System Organ Class / Preferred Term	Phase I [1]	V-01-VIT-08961X	ACS202-HYA-001US	ACS203-HYA-001MEX	VIT-02-08961X	VIT-03-08961X	Other Indications [2]
						0 (0.0%)	0 (0.0%)
JAW DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%) 1 (0.2%)	0 (0.0%)	D (0.0%)
MUSCLE CRAMPS MUSCLE SPASMS OSTEOARTHRITIS NOS OSTEOPOROSIS NOS ROTATOR CUFF SYNDROME TENDONITIS EXACERBATED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
MUSCLE SPASMS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
OSTEOARTHRITIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
OSTEOPOROSIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
ROTATOR CUFF SYNDROME	0 (0.0%)	0 (0.0%)	• (• • • • •	,	1 (0.2%)	0 (0.0%)	0 (0.0%)
TENDONITIS EXACERBATED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.24)	0 (0.00)	0 (0.00)
PSYCHIATRIC DISORDERS DEPRESSION NEC ANXIETY NEC DELIRIUM ALCOHOLIC WITHDRAWAL SYMPTOMS CONFUSION	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	26 (4.3%)	1 (0.3%)	0 (0.0%)
DEPRESSION NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	13 (2.2%)	0 (0.0%)	0 (0.0%)
ANXIETY NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	11 (1.8%)	0 (0.0%)	0 (0.0%)
DELIRIUM	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
ALCOHOLIC WITHDRAWAL SYMPTOMS	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CONFUSION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
DEPRESSION AGGRAVATED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
DISORIENTATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
NEUROSIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
STRESS SYMPTOMS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
DIGOD NEW TUNDWANTS SUSPENS DISORDEDS	0 (0.0%)	0 (0,0%)	1 (0.7%)	0 (%0.0%)	24 (4.0%)	1 (0.3%)	0 (0.0%)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	20 (3.3%)	1 (0.3%)	0 (0.0%)
ANEMIA NOS	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
ANAEMIA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
ANEMIA NOS AGGRAVATED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
COAGULATION DISORDER NOS		0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
DISSEMINATED INTRAVASCULAR COAGULATION		0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
IRON DEFICIENCY ANEMIA SECONDARY ANAEMIA	0 (0.0%) 0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
NEOPLASMS BENIGN AND MALIGNANT	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)	11 (1.8%)	3 (0.8%)	0 (0.0%)
(INCLUDING CYSTS AND POLYPS)	0 (0.007	1 (3.23)					
BASAL CELL CARCINOMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
BENIGN BREAST NEOPLASM NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
BENIGN NEOPLASM OF CHOROID BENIGN SKIN NEOPLASM NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
BENIGN SKIN NEOPLASM NOS		0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	. 0 (0.0%)
BLADDER NEOPLASM NOS CHRONIC LEUKEMIA NOS COLON CANCER NOS MALIGNANT MELANOMA OF SKIN STAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0 0%)
CHRONIC LEUKEMIA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
COLON CANCER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
	0 (0.0%)	0 (0.00)	2 (== 3 - 7	•			
UNSPECIFIED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
METASTASES TO LUNG	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
MYELODYSPLASTIC SYNDROME NOS		1 (3.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PROSTATE CANCER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
RESPIRATORY TRACT NEOPLASM NOS	0 (0.0%)	0 (0.04)	0 (0.00)				

^[1] Includes ACS201-HYA-001A, ACS201-HYA-002A, Probe Study
[2] Includes PVD-01-08961X, COR-01-08961X, COP-01-08961X

s:\dat\acs\iss2002\sas\programs\t_ae_study 06SEP2002 17:34

Table 7.2 Incidence of Adverse Events by System Organ Class All Studies by Study for Vitrase Groups Only Safety Population

System Organ Class / Preferred Term			ACS202-HYA-001US	ACS203-HYA-001MEX	VIT-02-08961X	VIT-03-08961X	Other Indications [2]
SKIN CARCINOMA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
SKIN NEOPLASM NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
THYROID NEOPLASM NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
ENDOCRINE DISORDERS	0 (0.0%)	1 (3.2%)	1 (0.7%)	0 (0.0%)	7 (1.2%)	1 (0.3%)	0 (0.0%)
DIABETES MELLITUS INADEQUATE CONTROL	0 (0.0%)	1 (3.2%)	1 (0.7%)	0 (0.0%)	4 (0.7%)	1 (0.3%)	0 (0.0%)
ADRENAL INSUFFICIENCY NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
GOITRE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
HYPOTHYROIDISM	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
IMMUNE SYSTEM DISORDERS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (1.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%)
DRUG HYPERSENSITIVITY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
HYPERSENSITIVITY NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
KIDNEY TRANSPLANT REJECTION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
MULTIPLE ALLERGIES	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
GENERAL DISORDERS AND ADMINISTRATIVE SITE CONDITIONS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.5%)	1 (0.3%)	0 (0.0%)
AXILLARY MASS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
EDEMA LOWER LIMB	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
LOWER EXTREMITY MASS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
WEAKNESS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
HEPATO-BILIARY DISORDERS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.5%)	1 (0.3%)	0 (0.0%)
CHOLECYSTITIS ACUTE NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
CHOLECISTITIS ACUTE NOS CHOLELITHIASIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
HEPATITIS NOS HEPATOMEGALY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
EAR AND LABYRINTH DISORDERS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
EARACHE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
SUDDEN HEARING LOSS NOS VERTIGO NEC	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
GENERAL DISORDERS AND ADMINISTRATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.5%)	0 (0.0%)	0 (0.0%)
SITE CONDITION		2 / 2 261	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
PYREXIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
THIRST	0 (0.0%)	0 (0.0%)	0 (0.04)	- ,	- ,		
REPRODUCTIVE SYSTEM AND BREAST DISORDERS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	1 (1.2%)
BENIGN PROSTATIC HYPERPLASIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
MENOPAUSE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
VAGINAL HAEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)

^[1] Includes ACS201-HYA-001A, ACS201-HYA-002A, Probe Study [2] Includes PVD-01-08961X, COR-01-08961X, COP-01-08961X

s:\dat\acs\iss2002\sas\programs\t_ae_study 06SEP2002 17:34

Page 17 of 17

Table 7.2 Incidence of Adverse Events by System Organ Class All Studies by Study for Vitrase Groups Only Safety Population

System Organ Class / Preferred Term	Phase I [1]	V-01-VIT-08961X	ACS202-HYA-001US	ACS203-HYA-001MEX	VIT-02-08961X	VIT-03-08961X	Other Indications [2]
CONGENITAL AND FAMILIAL/GENETIC	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
DISORDERS CUTIS LAXA	0 (0.0%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
REPRODUCTIVE AND BREAST DISORDERS PROSTATITIS	0 (0.0%) 0 (0.0%)	1 (0.2%) 1 (0.2%)	0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%)			

^[1] Includes ACS201-HYA-001A, ACS201-HYA-002A, Probe Study [2] Includes PVD-01-08961X, COR-01-08961X, COP-01-08961X

Table 7.3
Incidence of Adverse Events by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

market Outer Class / Bus Court Mark	Cont		T E TH Witten	55 IU Vitrase	75 IU Vitrase
System Organ Class / Preferred Term		Saline	7.5 10 VICIASE		75 TO VICTASE
NUMBER OF PATIENTS	18	378	198	377	391
NUMBER OF PATIENTS WITH AT LEAST ONE ADVERSE EVENT	18 (100%)	317 (83.9%)	194 (98.0%)	331 (87.8%)	350 (89.5%)
EYE DISORDERS	17 (94.4%)	306 (81.0%)	193 (97.5%)	323 (85.7%)	349 (89.3%)
IRITIS	4 (22.2%)	128 (33.9%)	124 (62.6%)	223 (59.2%)	243 (62.1%)
OCULAR HYPEREMIA	4 (22.2%)	142 (37.6%)	113 (57.1%)	204 (54.1%)	215 (55.0%)
EYE IRRITATION	10 (55.6%)	112 (29.6%)	90 (45.5%)	132 (35.0%)	141 (36.1%)
EYE PAIN	3 (16.7%)	86 (22.8%)	74 (37.4%)	140 (37.1%)	164 (41.9%)
LACRIMATION INCREASED	4 (22.2%)	87 (23.0%)	65 (32.8%)	124 (32.9%)	140 (35.8%)
VITREOUS HEMORRHAGE	3 (16.7%)	99 (26.2%)	86 (43.4%)	111 (29.4%)	104 (26.6%)
VISUAL ACUITY REDUCED	4 (22.2%)	76 (20.1%)	79 (39.9%)	105 (27.9%)	101 (25.8%)
ABNORMAL SENSATION IN EYE	2 (11.1%)	68 (18.0%)	62 (31.3%)	101 (26.8%)	116 (29.7%)
VITREOUS FLOATERS	6 (33.3%)	70 (18.5%)	65 (32.8%)	91 (24.1%)	101 (25.8%)
PHOTOPHOBIA	6 (33.3%)	61 (16.1%)	59 (29.8%)	87 (23.1%)	102 (26.1%)
CONJUNCTIVAL EDEMA	1 (5.6%)	59 (15.6%)	48 (24.2%)	96 (25.5%)	89 (22.8%)
RETINAL DETACHMENT	3 (16.7%)	32 (8.5%)	24 (12.1%)	38 (10.1%)	47 (12.0%)
CATARACT NUCLEAR	5 (27.8%)	36 (9.5%)	29 (14.6%)	37 (9.8%)	31 (7.9%)
CATARACT SUBCAPSULAR	2 (11.1%)	27 (7.1%)	34 (17.2%)	29 (7.7%)	39 (10.0%)
PHOTOPSIA	0 (0.0%)	22 (5.8%)	23 (11.6%)	45 (11.9%)	38 (9.7%)
CATARACT CORTICAL	5 (27.8%)	27 (7.1%)	14 (7.1%)	30 (8.0%)	31 (7.9%)
RUBEOSIS IRIDIS	1 (5.6%)	21 (5.6%)	17 (8.6%)	21 (5.6%)	24 (6.1%)
CORNEAL EDEMA	1 (5.6%)	12 (3.2%)	18 (9.1%)	22 (5.8%)	26 (6.6%)
CORNEAL EROSION	1 (5.6%)	24 (6.3%)	10 (5.1%)	25 (6.6%)	17 (4.3%)
MACULAR EDEMA	1 (5.6%)	12 (3.2%)	22 (11.1%)	16 (4.2%)	24 (6.1%)
CONJUNCTIVAL HEMORRHAGE	0 (0.0%)	26 (6.9%)	12 (6.1%)	17 (4.5%)	18 (4.6%)
EYE DISCHARGE	0 (0.0%)	18 (4.8%)	11 (5.6%)	23 (6.1%)	21 (5.4%)
IRIS ADHESIONS	2 (11.1%)	14 (3.7%)	9 (4.5%)	13 (3.4%)	28 (7.2%)
CORNEAL DISORDER NOS	0 (0.0%)	8 (2.1%)	6 (3.0%)	18 (4.8%)	26 (6.6%)
НУРНЕМА	0 (0.0%)	6 (1.6%)	9 (4.5%)	14 (3.7%)	16 (4.1%)
CATARACT NEC	0 (0.0%)	12 (3.2%)	3 (1.5%)	11 (2.9%)	13 (3.3%)
RETINOPATHY DIABETIC	1 (5.6%)	11 (2.9%)	7 (3.5%)	6 (1.6%)	14 (3.6%)
BLINDNESS NEC	1 (5.6%)	6 (1.6%)	9 (4.5%)	7 (1.9%)	9 (2.3%)
VISION BLURRED	0 (0.0%)	8 (2.1%)	11 (5.6%)	7 (1.9%)	5 (1.3%)
DRY EYE NEC	0 (0.0%)	7 (1.9%)	7 (3.5%)	5 (1.3%)	11 (2.8%)
GLAUCOMA NOS	0 (0.0%)	6 (1.6%)	6 (3.0%)	6 (1.6%)	12 (3.1%)
HYPOPYON	0 (0.0%)	0 (0.0%)	1 (0.5%)	6 (1.6%)	21 (5.4%)
VITREOUS DETACHMENT	1 (5.6%)	3 (0.8%)	4 (2.0%)	10 (2.7%)	7 (1.8%)
CATARACT NOS AGGRAVATED	1 (5.6%)	8 (2.1%)	5 (2.5%)	5 (1.3%)	4 (1.0%)
MACULOPATHY	0 (0.0%)	5 (1.3%)	6 (3.0%)	6 (1.6%)	6 (1.5%)
RETINAL HEMORRHAGE	0 (0.0%)	7 (1.9%)	6 (3.0%)	6 (1.6%)	3 (0.8%)
KERATITIS NEC	0 (0.0%)	4 (1.1%)	4 (2.0%)	4 (1.1%)	8 (2.0%)
INTRAOCULAR PRESSURE INCREASED	0 (0.0%)	3 (0.8%)	6 (3.0%)	3 (0.8%)	6 (1.5%)
POST-OPERATIVE PAIN	1 (5.6%)	10 (2.6%)	0 (0.0%)	2 (0.5%)	5 (1.3%)
POST-OPERATIVE PAIN POSTERIOR CAPSULE OPACIFICATION	0 (0.0%)	3 (0.8%)	2 (1.0%)	7 (1.9%)	5 (1.3%)
	1 (5.6%)	2 (0.5%)	2 (1.0%)	8 (2.1%)	4 (1.0%)
UVEITIS NOS	T (2.64)	4 (0.5%)	2 (1.0%)	0 (2.18)	4 (I.O.)

Table 7.3

Incidence of Adverse Events by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Contr	ol			
System Organ Class / Preferred Term	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
				·	
	- 4			3 (0.8%)	7 (1.8%)
BLEPHARITIS	0 (0.0%)	2 (0.5%)	4 (2.0%)	5 (1.3%)	2 (0.5%)
CORNEAL EPITHELIUM DEFECT	1 (5.6%)	2 (0.5%)	3 (1.5%)		2 (0.5%)
CORNEAL ABRASION	0 (0.0%)	2 (0.5%)	3 (1.5%)	5 (1.3%)	2 (0.5%)
DIPLOPIA	0 (0.0%)	2 (0.5%)	3 (1.5%)	5 (1.3%)	6 (1.5%)
HYPOTONY OF EYE	0 (0.0%)	2 (0.5%)	2 (1.0%)	2 (0.5%)	2 (0.5%)
RETINAL ISCHEMIA	0 (0.0%)	1 (0.3%)	4 (2.0%)	4 (1.1%)	3 (0.8%)
CONJUNCTIVITIS NEC	0 (0.0%)	2 (0.5%)	3 (1.5%)	1 (0.3%)	4 (1.0%)
MYDRIASIS	0 (0.0%)	3 (0.8%)	2 (1.0%)	0 (0.0%)	- ,
RETINAL TEAR (EXC DETACHMENT)	0 (0.0%)	1 (0.3%)	0 (0.0%)	6 (1.6%)	2 (0.5%) 1 (0.3%)
EYE DEGENERATIVE DISORDER NOS	0 (0.0%)	0 (0.0%)	3 (1.5%)	3 (0.8%)	
FOREIGN BODY RETAINED IN EYE	0 (0.0%)	1 (0.3%)	4 (2.0%)	2 (0.5%)	0 (0.0%)
VITREOUS DISORDER NOS	0 (0.0%)	2 (0.5%)	1 (0.5%)	2 (0.5%)	2 (0.5%)
PSEUDOPHAKIA	0 (0.0%)	3 (0.8%)	0 (0.0%)	3 (0.8%)	0 (0.0%)
EYELID PTOSIS	0 (0.0%)	1 (0.3%)	3 (1.5%)	0 (0.0%)	1 (0.3%)
INTRAOCULAR PRESSURE DECREASED	0 (0.0%)	3 (0.8%)	2 (1.0%)	0 (0.0%)	0 (0.0%)
MACULAR DEGENERATION	0 (0.0%)	1 (0.3%)	2 (1.0%)	2 (0.5%)	0 (0.0%)
OCULAR HYPERTENSION	0 (0.0%)	1 (0.3%)	0 (0.0%)	3 (0.8%)	1 (0.3%)
OPTIC ATROPHY	0 (0.0%)	1 (0.3%)	1 (0.5%)	3 (0.8%)	0 (0.0%)
PAINFUL RED EYES	0 (0.0%)	2 (0.5%)	0 (0.0%)	1 (0.3%)	2 (0.5%)
PHOTOPHOBIA AGGRAVATED	0 (0.0%)	1 (0.3%)	0 (0.0%)	3 (0.8%)	1 (0.3%)
APHAKIA	0 (0.0%)	2 (0.5%)	1 (0.5%)	0 (0.0%)	1 (0.3%)
EYE ALLERGY	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.8%)	1 (0.3%)
KERATOCONJUNCTIVITIS	0 (0.0%)	1 (0.3%)	1 (0.5%)	1 (0.3%)	1 (0.3%)
RETINAL DISORDER NOS	0 (0.0%)	1 (0.3%)	2 (1.0%)	0 (0.0%)	1 (0.3%)
RETINAL MICROANEURYSMS	0 (0.0%)	1 (0.3%)	1 (0.5%)	2 (0.5%)	0 (0.0%)
RETINAL NEOVASCULARIZATION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	3 (0.8%)
CHEMOSIS	0 (0.0%)	1 (0.3%)	1 (0.5%)	0 (0.0%)	1 (0.3%)
CONJUNCTIVITIS ALLERGIC	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	1 (0.3%)
CONJUNCTIVITIS VIRAL NOS	1 (5.6%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
CORTICAL OPACITY	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	1 (0.3%)
IRIDOCYCLITIS	0 (0.0%)	0 (0.0%)	2 (1.0%)	1 (0.3%)	0 (0.0%)
LENTICULAR OPACITIES	0 (0.0%)	2 (0.5%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
OPEN ANGLE GLAUCOMA NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	1 (0.3%)
RETINAL ARTERY EMBOLISM	0 (0.0%)	0 (0.0%)	2 (1.0%)	0 (0.0%)	1 (0.3%)
RETINAL SCAR	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	1 (0.3%)
BLINDNESS TRANSIENT	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	0 (0.0%)
CHOROIDAL DETACHMENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
CONJUNCTIVITIS (INFECTIVE) NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
CORNEAL OPACITY	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	0 (0.0%)
ERYTHEMA NEC	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	0 (0.0%)
EYE INFLAMMATION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
HYALOSIS ASTEROID	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.3%)
KERATOPATHY BAND	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.3%)
KERATOPATHY NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	0 (0.0%)
MEIBOMIAN CYST	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
OPTIC DISC HEMORRHAGE	0 (0.0%)	0 (0.0%)	2 (1.0%)	0 (0.0%)	Q (0.0%)

Table 7.3
Incidence of Adverse Events by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Contr	ol			
stem Organ Class / Preferred Term		Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitra
PERIORBITAL HEMATOMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	0 (0.0
RETINAL DEPIGMENTATION	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	0 (0.0
RETINAL VEIN THROMBOSIS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.3
STRABISMUS NEC	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.3
VISUAL ACUITY REDUCED TRANSIENTLY	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3
VITREOUS OPACITIES	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.3
ANGLE CLOSURE GLAUCOMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0
NISEIKONIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.
RCUS SENILIS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.
BLEPHAROCONJUNCTIVITIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.
LINDNESS NIGHT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
LOODSHOT EYE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
CONJUNCTIVAL EDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
HALAZION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
HORIORETINAL ATROPHY	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.
HORIORETINAL DISORDER NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.
HORIORETINAL SCAR	1 (5.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.
HOROIDAL HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
OLOUR BLINDNESS NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
ONJUNCTIVAL CYST	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.
ORNEAL DEGENERATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.
ORNEAL EPITHELIUM DISORDER	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.
ORNEAL SCAR	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.
ORNEAL ULCER NEC	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.
YCLITIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0,0%)	1 (0.
XOPHTHALMOS ENDOCRINE	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.
YE HEMORRHAGE NEC	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0
YE INFECTION FUNGAL NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.
YE INFECTION NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0
YE INFECTION STAPHYLOCOCCAL	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0
YE INFECTION TOXOPLASMAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0
	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.
YE INJURY NOS		0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
YELID DISORDER NOS	0 (0.0%) 0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0
YELID EDEMA	•	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0
LAUCOMA AGGRAVATED	0 (0.0%)			0 (0.0%)	1 (0
ERPES SIMPLEX OPHTHALMIC	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%)	0 (0.
RIS NEVUS	0 (0.0%)	1 (0.3%)		·	0 (0.
ACRIMAL DUCT OBSTRUCTION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	•
CULAR HYPERAEMIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%)	1 (0.
OPTIC NERVE INJURY NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)		,
PAPILLEDEMA	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.
PINGUECULA	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.
POST-OPERATIVE COMPLICATIONS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
RETINAL DEGENERATION	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.
RETINAL EXUDATES	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.
RETINAL VASCULAR DISORDER NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.

Table 7.3
Incidence of Adverse Events by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

RETINAL VASCULITIS O (0.0\$)		Control					
SCIERTITS NOS O (0.0%) O (0.0%) 1 (0.5%) O (0.0%) O	Class / Preferred Term	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase	
SCLERTIS NOS STYE 0 (0.0\$) 0 (0.0\$) 1 (0.5\$) 0 (0.0\$) 0 (0.0\$) 1 (0.5\$) 0 (0.0\$) 1 (0.0\$) 0 (0.0\$) 1	SCHLITIS	0 (0 0%)	0 (0 0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	
STYE						0 (0.0%)	
TODGGRAPHY CONDEAL ABNORMAL	305					0 (0.0%)	
VISION ABNORMAL NEC	CODMENT ADMODMAT	- • •			•	0 (0.0%)	
VISION ABNORMAL NEC						0 (0.0%)	
VISUAL DISTURBANCE NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.0				·		0 (0.0%)	
INVESTIGATIONS INTRACCULAR PRESSURE INCREASED 3 (16.7%) 42 (11.1%) 42 (21.2%) 45 (11.9%) 42 (CORNEAL STAINING 0 (0.0%) 7 (1.9%) 8 (4.0%) 9 (2.4%) 8 (EVANDED STAINING (0.0%) 7 (1.9%) 8 (4.0%) 9 (2.4%) 8 (EVANDED STAINING (0.0%) 7 (1.9%) 8 (4.0%) 9 (2.4%) 8 (EVANDED STAINING (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 3 (0.0%) 1 (0.3%) 3 (0.0%) 1 (0.3%) 3 (0.0%) 1 (0.3%) 1 (0.3%) 3 (0.0%) 1 (0.3%					•	1 (0.3%)	
INTRACCULAR PRESSURE INCREASED 3 (16.7%) 42 (11.1%) 42 (21.2%) 45 (11.9%) 42 (CORNEAL STAINING 0 (0.0%) 7 (1.9%) 8 (4.0%) 9 (2.4%) 8 (8.0%) 9 (2.4%) 8 (9.0%) 1 (0.3%) 3 (1.0%) 3 (1.0%) 3	TORDANCE NOS	0 (0.00)				, ,	
CORNEAL STAINING CORNEASED CORNEAL STAINING CORNEASED CORN	NS				· · · · · · · · · · · · · · · · · · ·	55 (14.1%)	
BLOOD GLUCOSE INCREASED 0 (0.0%) 1 (0.3%) 3 (0.0%) 1 (0.3%) 3 (0.0%) 3 (0.	R PRESSURE INCREASED	3 (16.7%)				42 (10.7%)	
BLOOD PRESSURE INCREASED BLOOD PRESSURE INCREASED COUNTY OF COUN	AINING	0 (0.0%)	7 (1.9%)	8 (4.0%)		8 (2.0%)	
BLOOD CREATININE INCREASED 0 (0.0\$) 1 (0.3\$) 1 (0.3\$) 0 (0.0\$) 2 (WEIGHT DECREASED 1 (5.6\$) 2 (0.5\$) 0 (0.0\$) 1 (0.3\$) 0 (BLOOD CHOLESTEROL INCREASED 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 1 (0.3\$) 0 (I (0.3\$) 0 (0.0\$) 1 (0.3\$) 0 (I (0.0\$) 0 (0.0\$) 1 (0.0\$) 0 (0.0\$) 1 (0.0\$) 1 (I WEMATURIA PRESENT 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 1 (0.3\$) 1 (I WITACCULAR PRESSURE ABNORMAL 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 1 (0.0\$) 1 (I WITACCULAR PRESSURE ABNORMAL 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 1 (0.3\$) 1 (BLOOD GLUCOSE ABNORMAL 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 1 (0.3\$) 0 (BLOOD GLUCOSE DECREASED 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 1 (0.5\$) 0 (0.0\$) 1 (BLOOD GLUCOSE FILUTUATION 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 1 (0.5\$) 0 (BLOOD SODIUM DECREASED 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 1 (BLOOD SODIUM DECREASED 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 1 (CANDIDURIA 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 1 (0.0\$) 1 (CANDIDURIA 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 1 (0.3\$) 0 (CANDIDURIA 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 1 (0.3\$) 0 (CANDIACENZYMES INCREASED 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 1 (CANDIACENZYMES INCREASED 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (CANDIDURIA CARDIAC ENZYMES INCREASED 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (CANDIDURIA (0.0\$) 0 (0.0\$)	OSE INCREASED	0 (0.0%)	1 (0.3%)			3 (0.8%)	
WEIGHT DECREASED 1 (5.6\$) 2 (0.5\$) 0 (0.0\$) 1 (0.3\$) 0 (0.0\$) 1 (0.3\$) 0 (0.0\$) 0 (0.0\$) 2 (0.0\$) 0 (0.0\$) 0 (0.0\$) 2 (0.0\$) 0 (0.0\$) 1 (0.3\$) 0 (0.0\$) 2 (0.0\$) 1 (0.3\$) 0 (0.0\$) 1 (0.3\$) 1 (0.3\$) 1 (0.3\$) 1 (0.0\$	SURE INCREASED	0 (0.0%)	2 (0.5%)	0 (0.0%)		1 (0.3%)	
BLOOD CHOLESTEROL INCREASED 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (BLOOD UREA INCREASED 0 (0.0%) 1 (0.3%) 0 (0.0%) 0 (0.0%) 1 (HEMATURIA PRESENT 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 1 (HEMATURIA PRESENTE ABNORMAL 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (BIOPSY NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 1 (BLOOD GLUCOSE ABNORMAL 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.5%) 0 (0.0%) 1 (0.3%) 0 (BLOOD GLUCOSE DECREASED 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.5%) 0 (0.0%) 1 (0.5%) 0 (BLOOD SULUCOSE FLUCTUATION 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.	TININE INCREASED	0 (0.0%)	1 (0.3%)	1 (0.5%)	0 (0.0%)	2 (0.5%)	
BLOOD UREA INCREASED O (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 1 (0.0%)	REASED	1 (5.6%)	2 (0.5%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	
HEMATURIA PRESENT 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 1 (0.3%) 1 (1.0%) 1 (0.3%) 1 (1.0%) 1	ESTEROL INCREASED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	
INTRAOCULAR PRESSURE ABNORMAL O (0.0%)	INCREASED	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
INTRAOCULAR PRESSURE ABNORMAL 0 (0.0%) 0 (0.0%) 2 (1.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.0%) 1 (0.0%) 0 (0.0%) 1 (0.0%) 0 (0.0%) 1 (0.0%) 0 (0.0%) 1 (0.0%) 0 (0.0%) 1 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.0%) 0 (0.0%) 1 (0.0%) 0 (0.0%) 1 (0.	PRESENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	
BIOPSY NOS BLOOD GLUCOSE ABNORMAL BLOOD GLUCOSE DECREASED O (0.0%) O (0.		0 (0.0%)	0 (0.0%)	2 (1.0%)	0 (0.0%)	0 (0.0%)	
BLOOD GLUCOSE ABNORMAL BLOOD GLUCOSE DECREASED O (0.0%) O (0.0%) O (0.0%) D (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
BLOOD GLUCOSE DECREASED 0 (0.0%) 0 (0.0%) 1 (0.5%) 0 (0.0%) 0 (0.0%) BLOOD GLUCOSE FLUCTUATION 0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	
BLOOD GLUCOSE FLUCTUATION 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (BLOOD PHOSPHATE DECREASED 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (BLOOD SODIUM DECREASED 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (BLOOD TRIGLYCERIDES INCREASED 0 (0.0%) 0 (0.0%) 1 (0.5%) 0 (0.0%) 1 (CANDIDURIA 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.5%) 0 (0.0%) 0 (CARDIAC ENZYMES INCREASED 0 (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 0 (COAGULATION FACTOR DECREASED 0 (0.0%) 1 (0.3%) 0 (0.0%) 0 (0.0%) 1 (0.0%) 1 (0.0%) 1 (0.0%) 1 (0.0%) 0 (0.0		0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	
BLOOD PHOSPHATE DECREASED 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (BLOOD SODIUM DECREASED 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (BLOOD TRIGLYCERIDES INCREASED 0 (0.0%) 0 (0.0%) 1 (0.5%) 0 (0.0%) 0 (CANDIDURIA CARDIAC ENZYMES INCREASED 0 (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.0%) 0 (COAGULATION FACTOR DECREASED 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.0%) 1 (ENLARGED PROSTATE 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.5%) 0 (0.0%) 0 (0.0%) 0 (HEMATOCRIT DECREASED 1 (5.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (HEMOGLOBIN DECREASED 1 (5.6%) 0 (0.0				0 (0.0%)	0 (0.0%)	1 (0.3%)	
BLOOD SODIUM DECREASED 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.0%) 1 (0.0%) 0 (0.0%) 1 (0.0%) 0 (0.0			0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
BLOOD TRIGLYCERIDES INCREASED 0 (0.0%) 0 (0.0%) 1 (0.5%) 0 (0.0%)					0 (0.0%)	1 (0.3%)	
CANDIDURIA O (0.0%) O (0.0%) O (0.0%) 1 (0.3%) O (0.3%) O (0.0%) CARDIAC ENZYMES INCREASED O (0.0%) 1 (0.3%) O (0.0%) O (0.			· · · · · · · · · · · · · · · · · · ·		0 (0.0%)	0 (0.0%)	
CARDIAC ENZYMES INCREASED 0 (0.0%) 1 (0.3%) 0 (0.0%) 0 (0.0%) 0 (COAGULATION FACTOR DECREASED 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.0	— -				1 (0.3%)	0 (0.0%)	
COAGULATION FACTOR DECREASED 0 (0.0%) 0 (· · · · · ·		0 (0.0%)	
ENLARGED PROSTATE 0 (0.0%) 0 (0.0%) 1 (0.5%) 0 (0.0%) 0 (HEMATOCRIT DECREASED 1 (5.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (HEMOGLOBIN DECREASED 1 (5.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (LIVER FUNCTION TESTS NOS ABNORMAL 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (PROTEINURIA PRESENT 0 (0.0%) 0 (0.0%) 1 (0.5%) 0 (0.0%) 0 (PROTHROMBIN TIME PROLONGED				, ,		1 (0.3%)	
HEMATOCRIT DECREASED 1 (5.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (HEMOGLOBIN DECREASED 1 (5.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (LIVER FUNCTION TESTS NOS ABNORMAL 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (PROTEINURIA PRESENT 0 (0.0%) 0 (0.0%) 1 (0.5%) 0 (0.0%) 0 (PROTHROMBIN TIME PROLONGED				· · · · · · · · · · · · · · · · · · ·		0 (0.0%)	
HEMOGLOBIN DECREASED 1 (5.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (LIVER FUNCTION TESTS NOS ABNORMAL 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (PROTEINURIA PRESENT 0 (0.0%) 0 (0.0%) 1 (0.5%) 0 (0.0%) 0 (PROTHROMBIN TIME PROLONGED						0 (0.0%)	
LIVER FUNCTION TESTS NOS ABNORMAL 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (PROTEINURIA PRESENT 0 (0.0%) 0 (0.0%) 1 (0.5%) 0 (0.0%) 0 (PROTHROMBIN TIME PROLONGED 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (The state of the s			0 (0.0%)	
PROTEINURIA PRESENT 0 (0.0%) 0 (0.0%) 1 (0.5%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 0 (0.0%) 1 (0.0%) 0						0 (0.0%)	
PROTHROMBIN TIME PROLONGED 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (·	0 (0.0%)	
PROTINGHELM TIME TROBURGED		· · ·				0 (0.0%)	
KED BEOOD CEDE DEDINERATION WATER INCREMEDED	··· -					1 (0.3%)	
	CEDS SESIMENTATION RATE INCREASES	0 (0.007			·		
SKIN & SONCOTARDOOD TIDDON DIDORDHAD					· · · · · · · · · · · · · · · · · · ·	51 (13.0%)	
HIBBID BEING			· · · · · · · · · · · · · · · · · · ·		• • •	25 (6.4%)	
INTIMENT AND			•	· · · · · ·		20 (5.1%)	
BERENTITE ROD					•	1 (0.3%)	
INDICATION NOD	OS			•		2 (0.5%)	
1001 OHGHK				· ·		3 (0.8%)	
OCCUPAC INTERCEPTATION	EREMIA	· · ·		•		1 (0.3%)	
CONTROLOR					•	1 (0.3%)	
DERMATITIS ALLERGIC 1 (5.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (ALLERGIC	1 (5.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	

Table 7.3
Incidence of Adverse Events by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Contr	ol			
System Organ Class / Preferred Term	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
•					
DRY SKIN	1 (5.6%)	1 (0.3%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
FACE EDEMA	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
LEG ULCER (EXC VARICOSE)	1 (5.6%)	1 (0.3%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
SKIN IRRITATION	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
SKIN ULCER NOS	0 (0.0%)	0 (0.0%)	2 (1.0%)	0 (0.0%)	1 (0.3%)
CUTIS LAXA	0 (0.0%)	0 (0.0%)	2 (1.0%)	0 (0.0%)	0 (0.0%)
PERIORBITAL EDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
PSORIASIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)
SKIN LESION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	0 (0.0%)
URTICARIA NOS	0 (0.0%)	2 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
ALOPECIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
DIABETIC FOOT ULCER	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
ECCHYMOSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
INTERTRIGO	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PALMAR ERYTHEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
PRURIGO	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
SKIN NECROSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
SKIN NODULE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
SKIN ULCER HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
STASIS ULCER	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
SWEATING INCREASED	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
TELANGIECTASIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
INFECTIONS AND INFESTATIONS	2 (11.1%)	39 (10.3%)	28 (14.1%)	40 (10.6%)	39 (10.0%)
NASOPHARYNGITIS	0 (0.0%)	3 (0.8%)	4 (2.0%)	5 (1.3%)	7 (1.8%)
URINARY TRACT INFECTION NOS	1 (5.6%)	6 (1.6%)	3 (1.5%)	3 (0.8%)	6 (1.5%)
PNEUMONIA NOS	0 (0.0%)	5 (1.3%)	4 (2.0%)	6 (1.6%)	3 (0.8%)
CELLULITIS	0 (0.0%)	4 (1.1%)	0 (0.0%)	3 (0.8%)	5 (1.3%)
INFLUENZA	1 (5.6%)	3 (0.8%)	4 (2.0%)	4 (1.1%)	0 (0.0%)
BRONCHITIS NOS	0 (0.0%)	2 (0.5%)	1 (0.5%)	2 (0.5%)	4 (1.0%)
LOCALISED INFECTION	0 (0.0%)	2 (0.5%)	2 (1.0%)	3 (0.8%)	2 (0.5%)
SINUSITIS NOS	0 (0.0%)	2 (0.5%)	3 (1.5%)	1 (0.3%)	3 (0.8%)
OSTEOMYELITIS NOS	0 (0.0%)	1 (0.3%)	1 (0.5%)	4 (1.1%)	2 (0.5%)
UPPER RESPIRATORY TRACT INFECTION NOS	1 (5.6%)	1 (0.3%)	3 (1.5%)	1 (0.3%)	1 (0.3%)
SEPSIS NOS	0 (0.0%)	1 (0.3%)	1 (0.5%)	3 (0.8%)	1 (0.3%)
PHARYNGITIS NOS	0 (0.0%)	2 (0.5%)	2 (1.0%)	1 (0.3%)	0 (0.0%)
RESPIRATORY TRACT INFECTION NOS	0 (0.0%)	2 (0.5%)	0 (0.0%)	2 (0.5%)	0 (0.0%)
SKIN INFECTION NOS	0 (0.0%)	0 (0.0%)	3 (1.5%)	0 (0.0%)	1 (0.3%)
HERPES ZÖSTER	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	1 (0.3%)
BRONCHITIS ACUTE NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)
CANDIDAL INFECTION NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
EAR INFECTION NOS	0 (0.0%)	2 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
FUNGAL INFECTION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	0 (0.0%)
INFECTED SKIN ULCER	0 (0.0%)	2 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
ORAL CANDIDIASIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
SKIN CANDIDA NOS	0 (0.0%)	0 (0.0%)	2 (1.0%)	0 (0.0%)	0 (0.0%)

Table 7.3
Incidence of Adverse Events by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Contr	Control				
System Organ Class / Preferred Term	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase	
	_ ,		0 (0 00)	0 / 0 5%	0 (0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	
STAPHYLOCOCCAL INFECTION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	0 (0.0%)	
TOOTH INFECTION	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	
VAGINOSIS FUNGAL NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	
WOUND INFECTION NEC	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	
AMERICAN TRYPANOSOMIASIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
ARTHROPOD BITE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
BACTERIAL INFECTION NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	
BLADDER INFECTION NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	
BRONCHOPNEUMONIA NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
CANDIDA NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
CELLULITIS STAPHYLOCOCCAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	
CYSTITIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
GASTROINTESTINAL INFECTION NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
HYPOPYON	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
INJECTION SITE INFECTION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
KERATITIS HERPETIC	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
LARYNGITIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	
LOWER RESPIRATORY TRACT INFECTION	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	
LUNG INFECTION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	
MYCOBACTERIAL INFECTION NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
NAIL TINEA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
OSTEOMYELITIS CHRONIC NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	
	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	
PHARYNGITIS STREPTOCOCCAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	
PNEUMONIA HAEMOPHILUS			0 (0.0%)	0 (0.0%)	0 (0.0%)	
PNEUMONIA MYCOPLASMAL	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
PULMONARY TUBERCULOSIS	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	
PYELONEPHRITIS NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)			
ROUNDWORM INFECTION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
SEPTIC ARTHRITIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
SEPTICEMIA STAPHYLOCOCCAL	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	
SKIN & SUBCUTANEOUS TISSUE ABSCESS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
TUBERCULOSIS NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
UROSEPSIS	1 (5.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
NERVOUS SYSTEM DISORDERS	1 (5.6%)	30 (7.9%)	28 (14.1%)	40 (10.6%)	48 (12.3%)	
HEADACHE NOS	0 (0.0%)	16 (4.2%)	12 (6.1%)	20 (5.3%)	23 (5.9%)	
CEREBROVASCULAR ACCIDENT NOS	1 (5.6%)	4 (1.1%)	3 (1.5%)	5 (1.3%)	8 (2.0%)	
DIZZINESS (EXC VERTIGO)	0 (0.0%)	2 (0.5%)	1 (0.5%)	4 (1.1%)	6 (1.5%)	
INSOMNIA NEC	0 (0.0%)	2 (0.5%)	3 (1.5%)	3 (0.8%)	4 (1.0%)	
PUPILLARY DISORDER NOS	0 (0.0%)	0 (0.0%)	3 (1.5%)	4 (1.1%)	3 (0.8%)	
SYNCOPE	0 (0.0%)	1 (0.3%)	2 (1.0%)	1 (0.3%)	4 (1.0%)	
DEMENTIA NOS	0 (0.0%)	0 (0.0%)	2 (1.0%)	1 (0.3%)	0 (0.0%)	
HYPOESTHESIA	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	1 (0.3%)	
VISUAL FIELD DEFECT NOS	0 (0.0%)	1 (0.3%)	1 (0.5%)	0 (0.0%)	1 (0.3%)	
BALANCE IMPAIRED NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	
	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	
CONVULSIONS NOS	0 (0.08)	0 (0.08)	0 (0.0%)	0 (0.0%)	2 (0.5%)	

Table 7.3

Incidence of Adverse Events by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Contro	Control			
System Organ Class / Preferred Term	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
FACIAL PALSY	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
HEMORRHAGIC STROKE	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
MOVEMENT DISORDER NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	0 (0.0%)
NEUROPATHY NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
TREMOR NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	0 (0.0%)
AMNESIA NEC	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
BURNING SENSATION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
COMA NEC	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
DEMENTIA OF THE ALZHEIMER'S TYPE NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
DEPRESSED LEVEL OF CONSCIOUSNESS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
DYSARTHRIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
HEMIPARESIS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
HYPOAESTHESIA	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
IIIRD NERVE PARALYSIS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
LACUNAR INFARCTION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
MIGRAINE NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
OBSTRUCTIVE SLEEP APNEA SYNDROME	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
PARKINSON'S DISEASE NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
PUPILLARY REFLEX IMPAIRED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
SPEECH DISORDER NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
VISUAL PATHWAY DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
VITH NERVE PARALYSIS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
VOCAL CORD PARALYSIS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CARDIAC DISORDERS	8 (44.4%)	24 (6.3%)	20 (10.1%)	27 (7.2%)	36 (9.2%)
CARDIAC FAILURE CONGESTIVE	2 (11.1%)	5 (1.3%)	6 (3.0%)	6 (1.6%)	7 (1.8%)
MYOCARDIAL INFARCTION	3 (16.7%)	5 (1.3%)	5 (2.5%)	3 (0.8%)	9 (2.3%)
CARDIAC ARREST	0 (0.0%)	2 (0.5%)	1 (0.5%)	5 (1.3%)	2 (0.5%)
ATRIAL FIBRILLATION	1 (5.6%)	1 (0.3%)	0 (0.0%)	5 (1.3%)	2 (0.5%)
PULMONARY EDEMA NOS	0 (0.0%)	4 (1.1%)	0 (0.0%)	3 (0.8%)	2 (0.5%)
ANGINA PECTORIS	1 (5.6%)	5 (1.3%)	0 (0.0%)	2 (0.5%)	0 (0.0%)
ANGINA UNSTABLE	0 (0.0%)	0 (0.0%)	2 (1.0%)	3 (0.8%)	3 (0.8%)
EDEMA LOWER LIMB	0 (0.0%)	2 (0.5%)	1 (0.5%)	2 (0.5%)	2 (0.5%)
CARDIOVASCULAR DISORDER NOS	1 (5.6%)	3 (0.8%)	0 (0.0%)	2 (0.5%)	0 (0.0%)
ARRHYTHMIA NOS	0 (0.0%)	2 (0.5%)	1 (0.5%)	2 (0.5%)	0 (0.0%)
CORONARY ARTERY OCCLUSION	0 (0.0%)	2 (0.5%)	2 (1.0%)	1 (0.3%)	0 (0.0%)
CARDIAC FAILURE NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	2 (0.5%)
CARDIOMEGALY NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	2 (0.5%)	0 (0.0%)
CORONARY ARTERY DISEASE NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
EDEMA PERIPHERAL	0 (0.0%)	1 (0.3%)	2 (1.0%)	0 (0.0%)	0 (0.0%)
LEFT VENTRICULAR FAILURE	0 (0.0%)	1 (0.3%)	0 (0.0%)	2 (0.5%)	0 (0.0%)
MYOCARDIAL ISCHEMIA	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
ATRIOVENTRICULAR BLOCK NOS	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%)	2 (0.5%) 0 (0.0%)
BRADYCARDIA NOS	1 (5.6%)	0 (0.0%)		1 (0.3%) 1 (0.3%)	0 (0.0%)
CARDIAC MURMUR NOS	0 (0.0%)	0 (0.0%)	1 (0.5%) 0 (0.0%)	0 (0.0%)	1 (0.3%)
CARDIO-RESPIRATORY ARREST	1 (5.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.36)

Table 7.3
Incidence of Adverse Events by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Contr	Control			
System Organ Class / Preferred Term	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
CARDIOMYOPATHY NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
ISCHEMIC CARDIOMYOPATHY	1 (5.6%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
ORTHOPNEA	0 (0.0%)	2 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PALPITATIONS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
VENTRICULAR TACHYCARDIA	1 (5.6%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
AORTIC VALVE DISEASE NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
AORTIC VALVE DISEASE NOS AORTIC VALVE STENOSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
ATRIAL FLUTTER	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
CARDIAC DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
CARDIAC FAILURE	•		0 (0.0%)	1 (0.3%)	0 (0.0%)
CARDIOGENIC SHOCK	0 (0.0%)	0 (0.0%)	, , ,	0 (0.0%)	1 (0.3%)
DYSPNEA PAROXYSMAL NOCTURNAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	•	0 (0.0%)
EDEMA UPPER LIMB	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
HYPERTROPHIC CARDIOMYOPATHY	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
MYOCARDITIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
VENTRICULAR EXTRASYSTOLES	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
VENTRICULAR HYPOKINESIA	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
GASTROINTESTINAL DISORDERS	3 (16.7%)	26 (6.9%)	14 (7.1%)	35 (9.3%)	30 (7.7%)
NAUSEA	1 (5.6%)	10 (2.6%)	5 (2.5%)	13 (3.4%)	11 (2.8%)
VOMITING NOS	1 (5.6%)	6 (1.6%)	2 (1.0%)	7 (1.9%)	4 (1.0%)
DIARRHEA NOS	0 (0.0%)	6 (1.6%)	3 (1.5%)	7 (1.9%)	3 (0.8%)
CONSTIPATION	0 (0.0%)	6 (1.6%)	1 (0.5%)	3 (0.8%)	8 (2.0%)
DYSPEPSIA	1 (5.6%)	3 (0.8%)	2 (1.0%)	2 (0.5%)	0 (0.0%)
GASTROINTESTINAL HEMORRHAGE NOS	0 (0.0%)	1 (0.3%)	1 (0.5%)	3 (0.8%)	3 (0.8%)
ABDOMINAL PAIN NOS	0 (0.0%)	0 (0.0%)	2 (1.0%)	2 (0.5%)	2 (0.5%)
SORE THROAT NOS	0 (0.0%)	2 (0.5%)	2 (1.0%)	0 (0.0%)	2 (0.5%)
ABDOMINAL PAIN UPPER	0 (0.0%)	2 (0.5%)	1 (0.5%)	2 (0.5%)	0 (0.0%)
GASTRITIS NOS	0 (0.0%)	2 (0.5%)	0 (0.0%)	2 (0.5%)	1 (0.3%)
ESOPHAGITIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	2 (0.5%)
GASTRIC ULCER	1 (5.6%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
GASTRO-ESOPHAGEAL REFLUX DISEASE	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	1 (0.3%)
GASTROINTESTINAL UPSET	0 (0.0%)	1 (0.3%)	0 (0.0%)	2 (0.5%)	0 (0.0%)
DIVERTICULUM INTESTINAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	0 (0.0%)
DUODENAL ULCER	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
ESOPHAGEAL REFLUX	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	0 (0.0%)
GASTROINTESTINAL DISORDER NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
ABDOMINAL DISTENSION	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
ABDOMINAL PAIN AGGRAVATED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
ABDOMINAL TENDERNESS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
ASCITES	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
DUODENITIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
DYSPHAGIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
GASTRIC EROSIONS		0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
GASTRIC IRRITATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
HEMATEMESIS	0 (0.0%)	0 (0.0%)	0 (0.08)	1 (0.36)	0 (0.0%)

Table 7.3
Incidence of Adverse Events by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

System Organ Class / Preferred Term		Control			
	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
WENODOWO TO C	0 (0 0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
HEMORRHOIDS	0 (0.0%)		1 (0.5%)	0 (0.0%)	0 (0.0%)
IMPAIRED GASTRIC EMPTYING	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
INGUINAL HERNIA NOS	0 (0.0%)	0 (0.0%)		1 (0.3%)	0 (0.0%)
PEPTIC ULCER	0 (0.0%)	0 (0.0%)	0 (0.0%)		1 (0.3%)
PEPTIC ULCER HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%)	1 (0.3%)
PERIODONTAL DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)		• •
PERITONEAL DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
PERITONEAL HEMORRHAGE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
PERITONITIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
RECTAL BLEEDING	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
RECTAL PROLAPSE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
TOOTHACHE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
VOLVULUS OF BOWEL	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
METABOLISM AND NUTRITION DISORDERS	4 (22.2%)	20 (5.3%)	22 (11.1%)	23 (6.1%)	25 (6.4%)
HYPERCHOLESTEROLEMIA	1 (5.6%)	5 (1.3%)	8 (4.0%)	5 (1.3%)	5 (1.3%)
HYPOGLYCAEMIA NOS	0 (0.0%)	5 (1.3%)	0 (0.0%)	2 (0.5%)	9 (2.3%)
DEHYDRATION	2 (11.1%)	2 (0.5%)	0 (0.0%)	4 (1.1%)	2 (0.5%)
HYPERGLYCEMIA NOS	0 (0.0%)	2 (0.5%)	3 (1.5%)	4 (1.1%)	1 (0.3%)
HYPERKALEMIA	1 (5.6%)	4 (1.1%)	2 (1.0%)	2 (0.5%)	1 (0.3%)
HYPERLIPIDEMIA NOS	0 (0.0%)	2 (0.5%)	3 (1.5%)	4 (1.1%)	0 (0.0%)
APPETITE DECREASED NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	4 (1.0%)
GOUT	1 (5.6%)	2 (0.5%)	1 (0.5%)	0 (0.0%)	1 (0.3%)
HYPOKALEMIA	0 (0.0%)	3 (0.8%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
DIABETIC NEUROPATHY NEC	0 (0.0%)	0 (0.0%)	2 (1.0%)	0 (0.0%)	2 (0.5%)
DIABETIC COMA NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	2 (0.5%)
GOUT AGGRAVATED	0 (0.0%)	1 (0.3%)	1 (0.5%)	0 (0.0%)	1 (0.3%)
DIABETES MELLITUS AGGRAVATED	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	0 (0.0%)
	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	0 (0.0%)
DIABETES MELLITUS INSULIN-DEPENDENT	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
DIABETIC COMPLICATION NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.3%)
HYPOCALCEMIA	- ,		0 (0.0%)	1 (0.3%)	1 (0.3%)
OBESITY	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)
CALCIUM DEFICIENCY	1 (5.6%)	0 (0.0%)	0 (0.0%)	•	1 (0.3%)
DIABETES MELLITUS NON INSULIN-DEPENDENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	- ,,
DIABETIC AMYOTROPHY	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
DIABETIC KETOACIDOSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
ELECTROLYTE IMBALANCE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
FLUID RETENTION	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
FOLATE DEFICIENCY	1 (5.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
GLUCOSE TOLERANCE IMPAIRED	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
HYPERPHOSPHATEMIA	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
HYPERURICEMIA	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
HYPERVOLEMIA	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
HYPOGLYCAEMIC COMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
HYPONATREMIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
HYPOVOLEMIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)

Table 7.3
Incidence of Adverse Events by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Control				
System Organ Class / Preferred Term	ww		7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
INSULIN RESISTANCE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
METABOLIC ACIDOSIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
NONKETOTIC HYPERGLYCEMIC-HYPEROSMOLAR COMA	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
POLYDIPSIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
VASCULAR DISORDERS	0 (0.0%)	27 (7.1%)	14 (7.1%)	24 (6.4%)	23 (5.9%)
HYPERTENSION NOS	0 (0.0%)	9 (2.4%)	6 (3.0%)	13 (3.4%)	11 (2.8%)
HYPERTENSION AGGRAVATED	0 (0.0%)	6 (1.6%)	1 (0.5%)	6 (1.6%)	2 (0.5%)
TRANSIENT ISCHEMIC ATTACK	0 (0.0%)	4 (1.1%)	0 (0.0%)	1 (0.3%)	2 (0.5%)
GANGRENE NOS	0 (0.0%)	2 (0.5%)	2 (1.0%)	1 (0.3%)	1 (0.3%)
PERIPHERAL VASCULAR DISEASE NOS	0 (0.0%)	4 (1.1%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
HYPOTENSION NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	3 (0.8%)
PULMONARY HYPERTENSION NOS	0 (0.0%)	2 (0.5%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
ARTERIAL OCCLUSION NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
CAROTID ARTERY STENOSIS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
POSTURAL HYPOTENSION	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	0 (0.0%)
VENOUS THROMBOSIS DEEP LIMB	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)
ARTERIAL ANEURYSM NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
BLOOD PRESSURE FLUCTUATION	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
BLOOD PRESSURE INADEQUATELY CONTROLLED	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
CAROTID ARTERY DISEASE NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
CEREBRAL INFARCTION	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CEREBRAL ISCHEMIA	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CEREBROVASCULAR ACCIDENT NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
COLLAPSE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
HEMATOMA NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
HOT FLUSHES NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
HYPERTENSIVE ENCEPHALOPATHY	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
ISCHEMIC FOOT	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
LABILE HYPERTENSION	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PERIPHERAL CIRCULATORY FAILURE	0 (0.0%)	1 (0.3%)	0 (0.0%) 0 (0.0%)	0 (0.0%)	0 (0.0%)
PERIPHERAL ISCHEMIA NOS	0 (0.0%)	0 (0.0%)		0 (0.0%)	1 (0.3%)
POOR PERIPHERAL CIRCULATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
PULMONARY EMBOLISM	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
SUBARACHNOID HEMORRHAGE NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
THROMBOEMBOLISM NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
SURGICAL AND MEDICAL PROCEDURES	2 (11.1%)	23 (6.1%)	15 (7.6%)	27 (7.2%)	18 (4.6%)
POST-OPERATIVE COMPLICATIONS NOS	1 (5.6%)	10 (2.6%)	5 (2.5%)	8 (2.1%)	6 (1.5%)
VITRECTOMY	0 (0.0%)	6 (1.6%)	2 (1.0%)	4 (1.1%)	2 (0.5%)
UNSPECIFIED COMPLICATION OF PROCEDURE NEC	0 (0.0%)	2 (0.5%)	2 (1.0%)	4 (1.1%)	2 (0.5%)
CORONARY ARTERY SURGERY	1 (5.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.8%)
NAUSEA POST-OPERATIVE	0 (0.0%)	1 (0.3%)	0 (0.0%)	2 (0.5%)	0 (0.0%)
ARTERIO-VENOUS FISTULA OPERATION	0 (0.0%)	1 (0.3%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
FOOT AMPUTATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
POST-OPERATIVE HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	0 (0.0%)

Table 7.3
Incidence of Adverse Events by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Contr	ol			
System Organ Class / Preferred Term	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
TOE AMPUTATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	0 (0.0%)
TOOTH EXTRACTION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
ARTERIAL BYPASS OPERATION (EXC CORONARY ARTERY)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
BLOOD PRODUCT TRANSFUSION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
CARDIAC OPERATION NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CARDIAC PACEMAKER INSERTION	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
CAROTID ENDARTERECTOMY	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
CHEMOTHERAPY NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
DEVICE FAILURE NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYE IRRITATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
FLUID REPLACEMENT PARENTERAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
FOOT OPERATION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
HIP ARTHROPLASTY	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
HOSPITALIZATION NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
KNEE ARTHROPLASTY	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
LEG AMPUTATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
LENS IMPLANT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
LIMB OPERATION NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
METATARSAL EXCISION	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
POST PROCEDURAL HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
POST PROCEDURAL PAIN	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
POST-OPERATIVE PAIN	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
SCLERAL OPERATION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
SHUNT OCCLUSION	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
SKIN CYST EXCISION	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
SUTURE LINE PAIN	० (०.०%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
VOMITING POST-OPERATIVE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
WOUND DEBRIDEMENT	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	5 (27.8%)	12 (3.2%)	16 (8.1%)	19 (5.0%)	15 (3.8%)
DYSPNEA NOS	2 (11.1%)	3 (0.8%)	7 (3.5%)	6 (1.6%)	4 (1.0%)
COUGH	0 (0.0%)	1 (0.3%)	3 (1.5%)	6 (1.6%)	3 (0.8%)
PLEURAL EFFUSION	1 (5.6%)	2 (0.5%)	2 (1.0%)	0 (0.0%)	2 (0.5%)
RHINORRHEA	0 (0.0%)	3 (0.8%)	1 (0.5%)	0 (0.0%)	3 (0.8%)
ASTHMA NOS	2 (11.1%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
CHRONIC OBSTRUCTIVE AIRWAYS DISEASE	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.8%)	1 (0.3%)
EPISTAXIS	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	2 (0.5%)
DYSPNEA EXERTIONAL	0 (0.0%)	1 (0.3%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
LUNG INFILTRATION NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	0 (0.0%)
NASAL CONGESTION	0 (0.0%)	1 (0.3%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
SNEEZING	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.3%)
ASTHMA AGGRAVATED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
ATELECTASIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
DYSPNEA EXACERBATED	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
DYSPNEA PAROXYSMAL NOCTURNAL	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EMPHYSEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)

s:\dat\acs\iss2002\sas\programs\t_ae_dose 06SEP2002 17:34

Table 7.3
Incidence of Adverse Events by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Control				
System Organ Class / Preferred Term	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
	- />	- /		0 (0 08)	0 (0 0%)
HEMOPTYSIS	0 (0.0%)	0 (0.0%)	1 (0.5%) 0 (0.0%)	0 (0.0%) 1 (0.3%)	0 (0.0%) 0 (0.0%)
HYPOXIA	0 (0.0%)	0 (0.0%)	•	0 (0.0%)	0 (0.0%)
INTERSTITIAL LUNG DISEASE	0 (0.0%)	0 (0.0%) 1 (0.3%)	1 (0.5%) 0 (0.0%)	0 (0.0%)	0 (0.0%)
PNEUMONIA VIRAL NOS	0 (0.0%) 0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
PULMONARY FIBROSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
RESPIRATORY FAILURE (EXC NEONATAL)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
RHINITIS SEASONAL	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
SINUS PAIN	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.00)	0 (0.007
RENAL AND URINARY DISORDERS	4 (22.2%)	18 (4.8%)	10 (5.1%)	15 (4.0%)	19 (4.9%)
RENAL FAILURE NOS	1 (5.6%)	6 (1.6%)	4 (2.0%)	6 (1.6%)	6 (1.5%)
RENAL FAILURE ACUTE	3 (16.7%)	4 (1.1%)	2 (1.0%)	2 (0.5%)	4 (1.0%)
RENAL IMPAIRMENT NOS	1 (5.6%)	2 (0.5%)	2 (1.0%)	5 (1.3%)	2 (0.5%)
RENAL FAILURE CHRONIC	1 (5.6%)	3 (0.8%)	1 (0.5%)	1 (0.3%)	1 (0.3%)
RENAL FAILURE AGGRAVATED	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	2 (0.5%)
URINARY RETENTION	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	2 (0.5%)
CALCULUS RENAL NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.3%)
DIABETIC NEPHROPATHY NOS	0 (0.0%)	2 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
FLUID RETENTION	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
RENAL ARTERY STENOSIS	0 (0.0%)	1 (0.3%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
RENAL FAILURE CHRONIC AGGRAVATED	1 (5.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
BLADDER PAIN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
BLADDER PROLAPSE	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
GLOMERULONEPHRITIS CHRONIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
GLOMERULONEPHRITIS MINIMAL LESION	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
LOIN PAIN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
MICROALBUMINURIA	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
POLYURIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
RENAL CYST NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
RENAL VASCULAR DISORDER NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%)
URINE DISCOLOURATION	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	3 (16.7%)	13 (3.4%)	12 (6.1%)	8 (2.1%)	21 (5.4%)
CHEST PAIN NEC	1 (5.6%)	5 (1.3%)	6 (3.0%)	2 (0.5%)	5 (1.3%)
FALL	0 (0.0%)	2 (0.5%)	1 (0.5%)	0 (0.0%)	3 (0.8%)
WEAKNESS	1 (5.6%)	1 (0.3%)	2 (1.0%)	1 (0.3%)	1 (0.3%)
FATIGUE	1 (5.6%)	0 (0.0%)	2 (1.0%)	1 (0.3%)	1 (0.3%)
EDEMA LOWER LIMB	1 (5.6%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	2 (0.5%)
PAIN IN FACE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (1.0%)
PAIN NOS	0 (0.0%)	1 (0.3%)	1 (0.5%)	0 (0.0%)	2 (0.5%)
DIFFICULTY IN WALKING	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	0 (0.0%)
EDEMA PERIPHERAL	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	0 (0.0%)
MULTI-ORGAN FAILURE	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
PYREXIA.	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.3%)
DEATH NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
GROIN PAIN	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)

¹⁰

Table 7.3
Incidence of Adverse Events by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Control					
System Organ Class / Preferred Term	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase	
HEMORRHAGE NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
HERNIA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
IMPAIRED HEALING	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	
LOWER EXTREMITY MASS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
MALAISE	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
MASS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	
MECHANICAL COMPLICATION OF IMPLANT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
MENTAL STATUS CHANGES	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
PERIPHERAL SWELLING	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
SKIN INFECTION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
INJURY AND POISONING	0 (0.0%)	10 (2.6%)	7 (3.5%)	9 (2.4%)	19 (4.9%)	
LACERATION	0 (0.0%)	4 (1.1%)	0 (0.0%)	1 (0.3%)	4 (1.0%)	
FOOT FRACTURE	0 (0.0%)	1 (0.3%)	1 (0.5%)	1 (0.3%)	2 (0.5%)	
DRUG TOXICITY NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	2 (0.5%)	
HIP FRACTURE	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	3 (0.8%)	
ANKLE FRACTURE	0 (0.0%)	1 (0.3%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	
BURNS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	
FEMUR FRACTURE NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	
FRACTURE NOS	0 (0.0%)	0 (0.0%)	2 (1.0%)	0 (0.0%)	0 (0.0%)	
JOINT SPRAIN	0 (0.0%)	1 (0.3%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	
LEG FRACTURE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	
ABRASION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
BACK INJURY NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	
BLISTER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
CHEMICAL BURNS OF EYE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	
FOREARM FRACTURE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	
HEAD INJURY	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
HYPOTHERMIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
INJURY NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
LOCALISED INFECTION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
MEDICATION ERROR	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
PHANTOM LIMB PAIN	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	
RIB FRACTURE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
SUNBURN	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	
THERAPEUTIC AGENT TOXICITY	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	
TIBIA FRACTURE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
UPPER LIMB FRACTURE NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	
WHIPLASH INJURY	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	
MUSCULOSKELETAL, CONNECTIVE TISSUE AND BONE DISORDERS	0 (0.0%)	12 (3.2%)	11 (5.6%)	10 (2.7%)	11 (2.8%)	
PAIN IN LIMB	0 (0.0%)	4 (1.1%)	5 (2.5%)	3 (0.8%)	1 (0.3%)	
BACK PAIN	0 (0.0%)	1 (0.3%)	2 (1.0%)	2 (0.5%)	3 (0.8%)	
ARTHRALGIA	0 (0.0%)	1 (0.3%)	1 (0.5%)	1 (0.3%)	2 (0.5%)	
ARTHRITIS NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	2 (0.5%)	1 (0.3%)	
MYALGIA	0 (0.0%)	2 (0.5%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	

s:\dat\acs\iss2002\sas\programs\t_ae_dose 06SEP2002 17:34

Table 7.3
Incidence of Adverse Events by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Contr	ol			
System Organ Class / Preferred Term	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
NECK PAIN	0 (0.0%)	1 (0.3%)	1 (0.5%)	0 (0.0%)	2 (0.5%)
TENDONITIS	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	1 (0.3%)
MUSCLE CRAMPS	0 (0.0%)	1 (0.3%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
OSTEOPOROSIS NOS	0 (0.0%)	1 (0.3%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
BACK PAIN AGGRAVATED	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
BURSITIS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
BUTTOCK PAIN	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
COSTAL PAIN	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
JAW DISORDER NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
JOINT STIFFNESS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
MUSCLE SPASMS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
OSTEOARTHRITIS NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
ROTATOR CUFF SYNDROME	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
SCIATICA	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
TENDONITIS EXACERBATED	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
IDMOONITE BARCERDATED	0 (0.01)	0 (0.00)			
PSYCHIATRIC DISORDERS	3 (16.7%)	7 (1.9%)	4 (2.0%)	13 (3.4%)	10 (2.6%)
DEPRESSION NEC	2 (11.1%)	1 (0.3%)	2 (1.0%)	4 (1.1%)	7 (1.8%)
ANXIETY NEC	0 (0.0%)	1 (0.3%)	2 (1.0%)	5 (1.3%)	4 (1.0%)
CONFUSION	0 (0.0%)	3 (0.8%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
DELIRIUM	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	0 (0.0%)
DISORIENTATION	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
HALLUCINATION NOS	1 (5.6%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
AGITATION	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
DEPRESSION AGGRAVATED	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
NEUROSIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
SCHIZOPHRENIA NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
STRESS SYMPTOMS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	1 (5.6%)	10 (2.6%)	3 (1.5%)	12 (3.2%)	10 (2.6%)
ANEMIA NOS	1 (5.6%)	4 (1.1%)	2 (1.0%)	12 (3.2%)	7 (1.8%)
ANEMIA NOS AGGRAVATED	0 (0.0%)	3 (0.8%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
COAGULATION DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
DISSEMINATED INTRAVASCULAR COAGULATION	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
IRON DEFICIENCY ANEMIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
LEUCOCYTOSIS NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
NORMOCHROMIC NORMOCYTIC ANEMIA	0 (0.0%)		0 (0.0%)	0 (0.0%)	1 (0.3%)
SECONDARY ANAEMIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%)
SECONDARY ANEMIA	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
THROMBOCYTHEMIA	0 (0.0%)	1 (0.3%)			0 (0.0%)
THROMBOCYTOPENIA	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
NEOPLASMS BENIGN AND MALIGNANT (INCLUDING CYSTS AND POLYPS)	0 (0.0%)	3 (0.8%)	5 (2.5%)	3 (0.8%)	6 (1.5%)
BASAL CELL CARCINOMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
BENIGN BREAST NEOPLASM NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
BENIGN NEOPLASM OF CHOROID	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)

s:\dat\acs\iss2002\sas\programs\t_ae_dose 06SEP2002 17:34

Table 7.3
Incidence of Adverse Events by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Control				
System Organ Class / Preferred Term	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
BENIGN SKIN NEOPLASM NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
BLADDER NEOPLASM NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
CHRONIC LEUKEMIA NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
COLON CANCER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
LIPOMA NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
MALIGNANT MELANOMA OF SKIN STAGE UNSPECIFIED	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
METASTASES TO LUNG	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
MYELODYSPLASTIC SYNDROME NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
NONHODGKIN'S LYMPHOMA NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
RADIOACTIVE IODINE THERAPY	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
RESPIRATORY TRACT NEOPLASM NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
SKIN CARCINOMA NOS	0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%) 1 (0.3%)	1 (0.3%) 0 (0.0%)
SKIN NEOPLASM NOS	0 (0.0%)		- • • • • •	0 (0.0%)	0 (0.0%)
THYROID NEOPLASM NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
ENDOCRINE DISORDERS	0 (0.0%)	7 (1.9%)	2 (1.0%)	2 (0.5%)	4 (1.0%)
DIABETES MELLITUS INADEQUATE CONTROL	0 (0.0%)	5 (1.3%)	1 (0.5%)	1 (0.3%)	3 (0.8%)
HYPOTHYROIDISM	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
ADRENAL INSUFFICIENCY NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
GOITRE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
THYROTOXICOSIS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITION	0 (0.0%)	6 (1.6%)	0 (0.0%)	1 (0.3%)	2 (0.5%)
PYREXIA	0 (0.0%)	4 (1.1%)	0 (0.0%)	0 (0.0%)	2 (0.5%)
FISTULA NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PAIN IN FACE	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
THIRST	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
TMMUNE SYSTEM DISORDERS	1 (5.6%)	2 (0.5%)	13 (1.5%)	1 (0.3%)	2 (0.5%)
DRUG HYPERSENSITIVITY	0 (0.0%)	2 (0.5%)	0 (0.0%)	0 (0.0%)	2 (0.5%)
HYPERSENSITIVITY NOS	1 (5.6%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	0 (0.0%)
KIDNEY TRANSPLANT REJECTION	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
MULTIPLE ALLERGIES	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
HEPATO-BILIARY DISORDERS	0 (0.0%)	3 (0.8%)	3 (1.5%)	1 (0.3%)	0 (0.0%)
CHOLELITHIASIS	0 (0.0%)	2 (0.5%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
CHOLECYSTITIS ACUTE NOS	0 (0,0%)	0 (0.0%)	2 (1.0%)	0 (0.0%)	0 (0.0%)
GALLBLADDER DISEASE NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
HEPATITIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
HEPATOMEGALY	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
HEPATOSPLENOMEGALY NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
HYPOPROTEINEMIA	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
GENERAL DISORDERS AND ADMINISTRATIVE SITE CONDITIONS	0 (0.0%)	0 (0.0%)	1 (0.5%)	2 (0.5%)	1 (0.3%)
AXILLARY MASS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
EDEMA LOWER LIMB	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)

s:\dat\acs\iss2002\sas\programs\t_ae_dose 06SEP2002 17:34

Table 7.3
Incidence of Adverse Events by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Contro	ol			
System Organ Class / Preferred Term	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase

LOWER EXTREMITY MASS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
WEAKNESS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
REPRODUCTIVE SYSTEM AND BREAST DISORDERS	0 (0.0%)	2 (0.5%)	0 (0.0%)	0 (0.0%)	2 (0.5%)
BENIGN PROSTATIC HYPERPLASIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
MENOPAUSE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
PROSTATIC DISORDER NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PROSTATITIS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EAR AND LABYRINTH DISORDERS	0 (0.0%)	1 (0.3%)	2 (1.0%)	0 (0.0%)	0 (0.0%)
EARACHE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
LABYRINTHITIS NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
SUDDEN HEARING LOSS NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
REPRODUCTIVE AND BREAST DISORDERS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
PROSTATITIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)

Table 7.4
Incidence of Adverse Events by System Organ Class
PVD Study (PVD-01-08961X) by Treatment
Safety Population

System Organ Class / Preferred Term	Vitrase 75 IU	SF6	Vitrase 75 IU + SF6	Saline
NUMBER OF PATIENTS	15	15	14	16
NUMBER OF PATIENTS WITH AT LEAST ONE ADVERSE EVENT	11 (73%)	8 (53%)	10 (71%)	14 (88%)
EYE DISORDERS VISUAL ACUITY REDUCED VITREOUS FLOATERS CATARACT SUBCAPSULAR MACULAR OEDEMA VITREOUS HAEMORRHAGE EYE PAIN PHOTOPHOBIA AGGRAVATED PHOTOPSIA PUPILLARY REFLEX IMPAIRED VITREOUS DETACHMENT ABNORMAL SENSATION IN EYE CATARACT CORTICAL LACRIMATION INCREASED CATARACT NUCLEAR IRITIS EYE IRRITATION HYPOPYON	6 (40%) 4 (27%) 2 (13%) 2 (13%) 2 (13%) 3 (20%) 2 (13%) 3 (20%) 1 (7%)	2 (13%) 1 (7%) 0 (0%) 1 (7%) 0 (0%) 0 (0%) 1 (7%) 0 (0%) 3 (20%) 0 (0%) 1 (7%) 0 (0%)	4 (29%) 0 (0%) 3 (21%) 2 (14%) 1 (7%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)	6 (38%) 5 (31%) 4 (25%) 3 (19%) 3 (19%) 3 (19%) 2 (13%) 0 (0%) 2 (13%) 0 (0%) 2 (13%)
IRIS VASCULAR DISORDER NOS RUBEOSIS IRIDIS VITREOUS DISORDER NOS	1 (7%) 1 (7%) 1 (7%)	0 (0%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 0 (0%)
NERVOUS SYSTEM DISORDERS IIIRD NERVE PARALYSIS SYNCOPE	1 (7%) 1 (7%) 0 (0%)	0 (0%) 0 (0%)	1 (7%) 1 (7%) 0 (0%)	1 (6%) 0 (0%) 1 (6%)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS DEATH NOS INJECTION SITE PAIN	0 (0%) 0 (0%) 0 (0%)	1 (7%) 0 (0%) 1 (7%)	0 (0%) 0 (0%)	1 (6%) 1 (6%) 0 (0%)
INFECTIONS AND INFESTATIONS BLEPHARITIS KIDNEY INFECTION NOS	1 (7%) O (0%) 1 (7%)	0 (0%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 0 (0%)	1 (6%) 1 (6%) 0 (0%)
SKIN & SUBCUTANEOUS TISSUE DISORDERS ERYTHEMA NEC FOOT ULCER	0 (0%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 0 (0%)	1 (7%) 0 (0%) 1 (7%)	1 (6%) 1 (6%) 0 (0%)
GASTROINTESTINAL DISORDERS DIARRHOEA NOS	0 (0%) 0 (0%)	0 (0%) 0 (0%)	1 (7%) 1 (7%)	0 (0%) 0 (0%)

NOTE: Ocular Events include events reported for study eye and non-study eye.

s:\dat\acs\iss2002\sas\programs\t_ae_treat_PVD 12SEP2002 14:32

Table 7.4
Incidence of Adverse Events by System Organ Class
PVD Study (PVD-01-08961X) by Treatment
Safety Population

			Vitrase 75 IU	
System Organ Class / Preferred Term	Vitrase 75 IU	SF6	+ SF6	Saline
INVESTIGATIONS	0 (0%)	1 (7%)	0 (0%)	0 (0%)
INTRAOCULAR PRESSURE INCREASED	0 (0%)	1 (7%)	0 (0%)	0 (0%)
METABOLISM AND NUTRITION DISORDERS	0 (0%)	0 (0%)	1 (7%)	0 (0%)
HYPOGLYCAEMIA NOS	0 (0%)	0 (0%)	1 (7%)	0 (0%)
RENAL AND URINARY DISORDERS	1 (7%)	0 (0%)	0 (0%)	0 (0%)
RENAL FAILURE NOS	1 (7%)	0 (0%)	0 (0%)	0 (0%)

Table 8
Incidence of Related Adverse Events by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

NUMBER OF PATIENTS 18 378 198 377 391 NUMBER OF PATIENTS WITH AT LEAST ONE RELATED ADVERSE EVENT 11 (61.1%) 244 (64.6%) 168 (84.8%) 290 (76.9%) 326 (83.4%) EVE DISCORDERS 1 (5.6%) 106 (29.0%) 100 (50.5%) 202 (53.6%) 231 (59.1%) CULLAR HYPERENIA 1 (5.6%) 106 (29.0%) 100 (50.5%) 202 (53.6%) 231 (59.1%) EVE PAIN 1 (5.6%) 11 (29.0%) 100 (50.5%) 202 (53.6%) 231 (59.1%) EVE PAIN 1 (5.6%) 11 (29.0%) 100 (50.5%) 202 (53.6%) 231 (59.1%) EVE PAIN 1 (5.6%) 57 (15.1%) 48 (24.2%) 113 (30.0%) 128 (12.7%) EVE FRITATION 1 (5.6%) 57 (15.1%) 48 (24.2%) 113 (30.0%) 128 (12.7%) LACRIMATION INCREASED 1 (5.6%) 56 (14.8%) 45 (22.7%) 94 (24.9%) 103 (26.3%) LACRIMATION INCREASED 1 (5.6%) 56 (14.8%) 45 (22.7%) 94 (24.9%) 103 (26.3%) HONOTHORITA BERNARTION IN EYE 1 (5.6%) 50 (13.2%) 43 (21.7%) 76 (20.7%) 92 (22.5%) HONOTHORITA BERNARTON IN EYE 1 (5.6%) 50 (13.2%) 43 (21.7%) 76 (20.7%) 65 (14.8%) VITTEGUS HERMOREIKAGE 1 (5.6%) 49 (13.0%) 30 (15.2%) 74 (19.6%) 77 (13.7%) VITTEGUS HERMOREIKAGE 1 (5.6%) 25 (6.6%) 26 (16.8%) 26 (16.2%) 37 (9.8%) FRETINAL DETACHMENT 1 (5.6%) 11 (2.9%) 20 (10.1%) 20 (5.5%) 18 (4.9%) RETINAL DETACHMENT 1 (5.6%) 16 (4.2%) 12 (6.1%) 12 (6.1%) 12 (5.6%) 12 (5.6%) CATABRACT CONTINCTUAL 1 (5.6%) 16 (4.2%) 12 (6.1%) 12 (6.1%) 12 (5.6%) 12 (5.6%) CATABRACT CONTINCTUAL BERNAR 1 (5.6%) 16 (4.2%) 12 (6.1%) 12 (6.1%) 12 (5.6%) 12 (5.6%) RETINAL DETACHMENT 1 (5.6%) 16 (4.2%) 12 (6.1%) 12 (6.1%) 12 (5.6%) 12 (5.6%) CATABRACT CONTINCTUAL BERNAR 1 (5.6%) 16 (4.2%) 16 (3.0%) 16 (4.2%) 16 (3.0%) 16 (4.6%) RETINAL DETACHMENT 1 (5.6%) 16 (4.2%) 16 (3.0%) 16 (4.2%) 16 (3.0%) 16 (4.6%) RETINAL DETACHMENT 1 (5.6%) 16 (4.2%) 16 (3.0%) 16 (4.2%) 16 (3.0%) 16 (4.6%) RETINAL DETACHMENT 1 (5.6%) 16 (4.2%) 12 (6.1%) 12 (6.1%) 12 (5.6%) 12 (5.6%) CATABRACT CONTINCTUAL 1 (5.6%) 16 (4.2%) 16 (3.0%) 16 (4.2%) 16 (3.0%) 16 (4.6%) RETINAL DETACHMENT 1 (5.6%) 16 (4.2%) 16 (3.0%) 16 (4.2%) 16 (3.0%) 16 (4.6%) RETINAL DETACHMENT 1 (5.6%) 16 (4.2%) 16 (3.0%) 16 (4.2%) 16 (3.0%) 16 (4.6%) RETINAL DETACHMENT 1 (5.6%) 16 (4.2		Cont	rol			
NUMBER OF PATIENTS WITH AT LEAST ONE RELATED ADVERSE EVENT 11 (61.1*) 244 (64.6*) 168 (84.8*) 29 (76.9*) 326 (83.4*) EYE DISORDERS 11 (61.1*) 243 (64.3*) 168 (84.8*) 288 (76.4*) 326 (83.4*) IRITIS 1 (5.6*) 106 (28.0*) 100 (50.5*) 202 (53.6*) 231 (59.1*) IRITIS 1 (5.6*) 113 (29.9*) 85 (42.9*) 118 (41.9*) 128 (41.9*) IRITIS 1 (5.6*) 113 (29.9*) 85 (42.9*) 118 (41.9*) 128 (41.9*) IRITIS 1 (5.6*) 13 (29.9*) 85 (42.9*) 118 (41.9*) 128 (41.9*) 128 (42.9*) IRITIS 1 (5.6*) 13 (29.9*) 85 (42.9*) 113 (30.0*) 128 (42.7*) IRITIS 1 (5.6*) 13 (29.9*) 85 (42.9*) 13 (30.0*) 128 (42.7*) IRITIS 1 (5.6*) 13 (29.9*) 85 (42.9*) 13 (30.0*) 128 (42.7*) IRITIS 2 (42.9*) 13 (30.0*) 128 (42.9*) IRITIS 2 (42.9*) 13 (42.9*) 13 (42.9*) 13 (42.9*) 13 (42.9*) IRITIS 2 (42.9*) 13 (42.9*) 13 (42.9*) 13 (42.9*) 13 (42.9*) IRITIS 2 (42.9*) 13 (42.9*) 13 (42.9*) 13 (42.9*) 13 (42.9*) 13 (42.9*) IRITIS 2 (42.9*) 13 (4	System Organ Class / Preferred Term	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
EVE DISORDERS 11 (61.1%) 243 (64.3%) 168 (84.8%) 288 (76.4%) 326 (83.4%) IRITIS 1 (5.6%) 110 (28.0%) 100 (50.5%) 202 (33.6%) 231 (59.1%) CCULAR HYPEREMIA 1 (5.6%) 113 (29.9%) 85 (42.9%) 1158 (41.9%) 138 (46.8%) EVE PAIN 1 (5.6%) 113 (29.9%) 85 (42.9%) 1158 (41.9%) 128 (46.8%) EVE PAIN 1 (5.6%) 57 (15.1%) 48 (24.2%) 113 (30.0%) 128 (32.7%) LACKIMATION INCREASED 1 (5.6%) 56 (14.8%) 45 (22.7%) 94 (24.9%) 103 (26.3%) LACKIMATION INCREASED 1 (5.6%) 56 (14.8%) 45 (22.7%) 94 (24.9%) 103 (26.3%) RANDORHAL EXEMBATION IN EVE 1 (5.6%) 56 (14.8%) 45 (22.7%) 94 (24.9%) 103 (26.3%) RANDORHAL EXEMBATION IN EVE 1 (5.6%) 56 (14.8%) 45 (22.7%) 94 (24.9%) 103 (26.3%) ROUNDINGTIVAL EDEMA 1 (5.6%) 49 (21.1%) 41 (20.7%) 63 (26.7%) 92 (22.5%) ROUNDINGTIVAL EDEMA 1 (5.6%) 49 (21.1%) 41 (20.7%) 63 (26.7%) 92 (22.5%) ROUNDINGTIVAL EDEMA 1 (5.6%) 49 (21.1%) 41 (20.7%) 63 (26.7%) 95 (21.7%) VITEROUS PLOATERS 3 (16.7%) 42 (11.1%) 41 (20.7%) 63 (26.7%) 77 (19.7%) VITEROUS PLOATERS 3 (16.7%) 42 (11.1%) 40 (20.2%) 98 (15.4%) 77 (19.7%) VITEROUS PROGRERAGE 1 (5.6%) 49 (21.1%) 40 (20.2%) 98 (15.4%) 77 (19.7%) VITEROUS PROGRERAGE 1 (5.6%) 49 (21.1%) 40 (20.2%) 98 (15.4%) 77 (19.7%) VITEROUS PROGRERAGE 1 (5.6%) 40 (21.1%) 40 (20.2%) 98 (15.4%) 77 (19.7%) VITEROUS PROGRERAGE 1 (5.6%) 40 (2.9%) 10 (2.6%) 10 (2.8%) 10 (2.6%)	NUMBER OF PATIENTS	18	378	198	377	391
INITIS	NUMBER OF PATIENTS WITH AT LEAST ONE RELATED ADVERSE EVENT	11 (61.1%)	244 (64.6%)	168 (84.8%)	290 (76.9%)	326 (83.4%)
COLULAR HYPEREMIA	EYE DISORDERS		243 (64.3%)			
EVE IRITATION	IRITIS	1 (5.6%)	106 (28.0%)	100 (50.5%)	202 (53.6%)	231 (59.1%)
EVE IRRITATION 5 (27.8\$) 79 (20.9\$) 61 (30.8\$) 96 (25.5\$) 103 (26.3\$) ANDORMAL SENSATION IN EYE 1 (5.6\$) 50 (13.2\$) 43 (21.7\$) 78 (20.7\$) 92 (23.5\$) ANDORMAL SENSATION IN EYE 1 (5.6\$) 50 (13.2\$) 43 (21.7\$) 78 (20.7\$) 92 (23.5\$) PHOTOPIODIA 3 (16.7\$) 42 (11.1\$) 41 (2.7\$) 63 (16.7\$) 85 (21.7\$) CONJUNCTIVAL EDEMA 1 (5.6\$) 49 (13.0\$) 30 (15.2\$) 74 (19.6\$) 77 (19.7\$) VITREOUS FLOATERS 3 (16.7\$) 42 (11.1\$) 43 (21.1\$) 40 (2.2\$) 88 (15.4\$) 74 (18.9\$) VISUAL ACUITY REDUCED 2 (11.1\$) 43 (11.4\$) 47 (23.7\$) 66 (17.5\$) 58 (14.8\$) VITREOUS HEMORRINGE 1 (5.6\$) 52 (6.6\$) 32 (16.2\$) 37 (9.8\$) 29 (7.4\$) PHOTOPSIA 0 (0.0\$) 14 (3.7\$) 18 (9.1\$) 25 (6.6\$) 28 (7.2\$) PHOTOPSIA 0 (0.0\$) 14 (3.7\$) 18 (9.1\$) 25 (6.6\$) 28 (7.2\$) RETINAL DETACHMENT 1 (5.6\$) 10 (2.6\$) 11 (2.9\$) 20 (1.1\$) 20 (5.3\$) 18 (4.6\$) RETINAL DETACHMENT 1 (5.6\$) 10 (2.6\$) 12 (6.1\$) 18 (4.8\$) 22 (5.6\$) CATARACAT NUCLEAR 1 (5.6\$) 16 (4.2\$) 12 (6.1\$) 18 (4.8\$) 22 (5.6\$) CATARACAT CORTICAL 1 (5.6\$) 16 (4.2\$) 12 (6.1\$) 18 (4.3\$) 20 (5.4\$) 10 (2.6\$) 18 (4.8\$) CONNEAL EROSION 0 (0.0\$) 16 (4.2\$) 6 (3.0\$) 14 (3.7\$) 11 (2.9\$) CONNEAL EROSION 0 (0.0\$) 13 (3.8\$) 4 (2.0\$) 14 (3.7\$) 12 (5.8\$) IRIS ADHESIONS 0 (0.0\$) 13 (3.8\$) 4 (2.0\$) 14 (3.7\$) 12 (5.8\$) IRIS ADHESIONS 0 (0.0\$) 1 (4.3\$) 3 (1.5\$) 1 (2.2\$) 18 (4.6\$) CONJUNCTIVAL HEMORRHAGE 0 (0.0\$) 1 (0.0\$) 1 (0.3\$) 1 (0.5\$) 5 (1.3\$) 1 (2.3\$) 1 (2.3\$) HYPHOTOPIAL EDIDMA 0 (0.0\$) 1 (0.0\$) 1 (0.3\$) 1 (0.5\$) 5 (1.3\$) 1 (2.3\$) 1 (2.3\$) HYPHOTOPIAL EDIDMA 0 (0.0\$) 1 (0.0\$) 1 (0.3\$) 1 (0.5\$) 5 (1.3\$) 1 (2.3\$) 1 (2.3\$) IRIS ADHESIONS 1 (5.6\$) 1 (0.0\$) 1 (0.	OCULAR HYPEREMIA	1 (5.6%)	113 (29.9%)		158 (41.9%)	
LACRIMATION INCREASED ARNORMAL SINNATION IN EYB 1 (5.6%) 56 (14.8%) 45 (22.7%) 94 (24.9%) 103 (26.3%) PHOTOPHOBIA 1 (5.6%) 42 (11.1%) 41 (20.7%) 63 (16.7%) 85 (21.7%) PHOTOPHOBIA 1 (5.6%) 49 (13.0%) 30 (15.2%) 74 (19.6%) 77 (19.7%) VITREOUS FLOATERS 3 (16.7%) 42 (11.1%) 40 (20.2%) 58 (15.4%) 77 (19.7%) VITREOUS FLOATERS 3 (16.7%) 42 (11.1%) 40 (20.2%) 58 (15.4%) 77 (19.7%) VITREOUS FLOATERS 4 (11.1%) 40 (20.2%) 58 (15.4%) 77 (19.7%) VITREOUS HEMORRHAGE 1 (5.6%) 25 (6.6%) 32 (16.2%) 37 (9.8%) 29 (7.4%) VITREOUS HEMORRHAGE 1 (5.6%) 25 (6.6%) 32 (16.2%) 37 (9.8%) 29 (7.4%) VITREOUS HEMORRHAGE 1 (5.6%) 10 (2.6%) 12 (6.1%) 18 (4.6%) CATARACT SUECASSULAR 1 (5.6%) 10 (2.6%) 12 (6.1%) 18 (4.8%) CATARACT CORTICAL 1 (5.6%) 16 (4.2%) 12 (6.1%) 18 (4.8%) 18 (4.6%) CATARACT CORTICAL 1 (5.6%) 16 (4.2%) 12 (6.1%) 12 (6.1%) 18 (4.6%) CATARACT CORTICAL 1 (5.6%) 16 (4.2%) 13 (1.5%) 19 (5.9%) 19 (4.9%) CORNEAL BROSION 0 (0.0%) 16 (4.2%) 3 (1.5%) 19 (5.0%) 19 (4.9%) CORNEAL BROSION 0 (0.0%) 13 (3.4%) 3 (1.5%) 19 (5.0%) 19 (4.9%) CORNEAL BROSION 0 (0.0%) 13 (3.4%) 3 (1.5%) 19 (5.0%) 19 (4.9%) CORNEAL BROSION 0 (0.0%) 13 (3.8%) 4 (2.0%) 14 (3.7%) 11 (2.8%) CONNEAL BROSION 0 (0.0%) 13 (3.8%) 4 (2.0%) 14 (3.7%) 11 (2.8%) CONNEAL BEORGA 0 (0.0%) 13 (3.8%) 4 (2.0%) 14 (3.7%) 18 (4.6%) CONNEAL BEORGA 0 (0.0%) 13 (3.8%) 3 (1.5%) 12 (3.2%) 14 (3.6%) EVE DISCHARGE 0 (0.0%) 14 (3.7%) 6 (3.0%) 6 (1.6%) 8 (2.0%) EVE DISCHARGE 0 (0.0%) 14 (3.7%) 6 (3.0%) 6 (1.6%) 8 (2.0%) EVE DISCHARGE 0 (0.0%) 17 (3.0%) 10 (3.0%) 6 (1.6%) 8 (2.0%) EVE DISCHARGE 0 (0.0%) 10 (3.0%) 10 (3.0%) 6 (1.6%) 8 (2.1%) EVE DISCHARGE 0 (0.0%) 14 (3.7%) 6 (3.0%) 6 (1.6%) 8 (2.0%) EVE DISCHARGE 0 (0.0%) 10 (3.0%) 10 (3.0%) 6 (1.6%) 8 (2.0%) EVE DISCHARGE 0 (0.0%) 10 (3.0%) 10 (3.0%) 10 (3.0%) 6 (1.6%) 8 (2.0%) EVE DISCHARGE 0 (0.0%) 10 (3.0%) 10 (3.0%) 6 (1.6%) 8 (2.1%) EVE DISCHARGE 0 (0.0%) 10 (3.0%) 10 (3.0%) 10 (3.0%) 10 (3.0%) 10 (3.0%) EVE DISCHARGE 0 (0.0%) 10 (3.0%) 10 (3.0%) 10 (3.0%) 10 (3.0%) 10 (3.0%) 10 (3.0%) EVE DISCHARGE 0 (0.0%) 10 (3.0%) 10 (3.0%) 10 (3.0%)	EYE PAIN	1 (5.6%)	57 (15.1%)			
ARNORMAL SENSATION IN EYE 1 (5.6\$) 50 (13.2\$) 43 (21.7\$) 78 (20.7\$) 92 (23.5\$) PHOTOPHOBIA 3 (16.7\$) 42 (11.1\$) 41 (20.7\$) 63 (16.7\$) 85 (21.7\$) CONJUNCTIVAL REDIMA 1 (5.6\$) 49 (13.0\$) 30 (15.2\$) 74 (19.6\$) 77 (19.7\$) VITEROUS FLOATERS 3 (16.7\$) 42 (11.1\$) 40 (20.2\$) 58 (15.4\$) 74 (19.6\$) 77 (19.7\$) VITEROUS FLOATERS 3 (16.7\$) 42 (11.1\$) 43 (11.4\$) 47 (23.7\$) 66 (17.5\$) 58 (15.4\$) 74 (18.9\$) VITEROUS EMPORTHAGE 1 (5.6\$) 25 (6.6\$) 32 (16.2\$) 37 (9.8\$) 29 (7.4\$) PHOTOPSIA 0 (0.0\$) 14 (3.7\$) 18 (9.1\$) 25 (6.6\$) 32 (16.2\$) 37 (9.8\$) 29 (7.4\$) PHOTOPSIA 0 (0.0\$) 14 (3.7\$) 18 (9.1\$) 25 (6.6\$) 22 (5.6\$) PHOTOPSIA 0 (0.0\$) 14 (3.7\$) 18 (9.1\$) 25 (6.6\$) 22 (5.6\$) PHOTOPSIA RETHNAL DETACHMENT 1 (5.6\$) 10 (2.6\$) 12 (6.1\$) 18 (4.8\$) 22 (5.6\$) RETHNAL DETACHMENT 1 (5.6\$) 10 (2.6\$) 12 (6.1\$) 18 (4.8\$) 22 (5.6\$) CATARACT NUCLEAR 1 (5.6\$) 16 (4.2\$) 12 (6.1\$) 18 (4.8\$) 22 (5.6\$) CATARACT CONTICLL CATARACT CONTICLL CATARACT SUBCAPSIUM 1 (5.6\$) 16 (4.2\$) 12 (6.1\$) 18 (4.8\$) 19 (2.6\$) CONNEAL REOSION 1 (5.6\$) 16 (4.2\$) 3 (1.5\$) 19 (5.0\$) 19 (4.9\$) CONNEAL DISORDER NOS 2 (11.1\$) 3 (0.8\$) 4 (2.0\$) 14 (3.7\$) 11 (2.8\$) CONNEAL DISORDER NOS 2 (11.1\$) 3 (0.8\$) 4 (2.0\$) 14 (3.7\$) 12 (3.2\$) 14 (3.6\$) IRIS ADHESIONS 2 (11.1\$) 3 (0.8\$) 4 (2.0\$) 16 (4.2\$) 6 (3.0\$) 10 (2.7\$) 14 (3.6\$) IRIS ADHESIONS 2 (11.1\$) 3 (0.8\$) 4 (2.0\$) 18 (2.1\$) 17 (5.4\$) IRIS ADHESIONS 2 (11.1\$) 3 (0.8\$) 1 (0.5\$) 5 (1.3\$) 8 (2.1\$) 17 (5.4\$) IRIS ADHESIONS 2 (11.1\$) 3 (0.8\$) 1 (0.5\$) 1 (0.		5 (27.8%)	79 (20.9%)			103 (26.3%)
PHOTOPHOBIA CONJUNCTIVAL EDEMA 1 (5.6%) 42 (11.1%) 41 (20.7%) 63 (16.7%) 85 (21.7%) VITEROUS FLOATERS 3 (16.7%) 42 (11.1%) 40 (20.2%) 58 (15.4%) 74 (19.6%) VITEROUS FLOATERS 3 (16.7%) 42 (11.1%) 40 (20.2%) 58 (15.4%) 74 (19.7%) VITURAL ACUITY REDUCED 2 (11.1%) 43 (11.4%) 47 (23.7%) 66 (17.5%) 58 (15.4%) 74 (19.7%) VITURAL ACUITY REDUCED 1 (5.6%) 25 (6.6%) 32 (16.2%) 37 (9.8%) 29 (7.4%) VITUROUS HEMORRHAGE 1 (5.6%) 25 (6.6%) 32 (16.2%) 37 (9.8%) 29 (7.4%) CATARACT SUBCARSULLAR 0 (0.0.0%) 11 (2.9%) 20 (10.1%) 20 (5.3%) 18 (4.6%) RETINAL DETACHMENT 1 (5.6%) 10 (2.6%) 12 (6.1%) 20 (5.3%) 18 (4.6%) RETINAL DETACHMENT 1 (5.6%) 10 (4.2%) 12 (6.1%) 20 (5.3%) 18 (4.6%) CATARACT NUCLEAR 1 (5.6%) 16 (4.2%) 12 (6.1%) 18 (4.8%) 10 (2.6%) CATARACT CORTICAL 1 (5.6%) 16 (4.2%) 12 (6.1%) 18 (4.8%) 19 (4.6%) CATARACT CORTICAL 1 (5.6%) 16 (4.2%) 12 (6.1%) 18 (4.8%) 19 (4.6%) CORNEAL EROSION 0 (0.0%) 3 (0.8%) 4 (2.0%) 14 (3.7%) 11 (2.8%) CORNEAL DISORDER NOS 0 (0.0%) 3 (0.8%) 4 (2.0%) 14 (3.7%) 11 (3.6%) IRIS ADHESIONS 2 (11.1%) 3 (0.8%) 4 (2.0%) 10 (2.7%) 18 (4.6%) RUBEOSIS IRIDIS 2 (11.1%) 3 (0.8%) 4 (2.0%) 10 (2.7%) 18 (4.6%) RUBEOSIS IRIDIS 1 (5.6%) 5 (1.3%) 8 (4.0%) 8 (2.1%) 17 (4.3%) RUBEOSIS IRIDIS 1 (5.6%) 5 (1.3%) 8 (4.0%) 8 (2.1%) 17 (4.3%) RUBEOSIS IRIDIS 1 (5.6%) 5 (1.3%) 8 (4.0%) 8 (2.1%) 17 (4.3%) RUBEOSIS IRIDIS 1 (5.6%) 5 (1.3%) 8 (4.0%) 8 (2.1%) 17 (4.3%) RUBEOSIS IRIDIS 1 (5.6%) 5 (1.3%) 8 (4.0%) 8 (2.1%) 17 (4.3%) RUBEOSIS IRIDIS 1 (5.6%) 10 (0.0%) 1 (0.0%) 1 (0.5%) 6 (1.6%) 21 (5.4%) RUFUTIS NOS 1 (5.6%) 10 (0.0%) 1 (0.0%) 1 (0.5%) 6 (1.6%) 21 (5.4%) RUFUTIS NOS 1 (5.6%) 10 (0.0%) 1 (0.0%) 1 (0.5%) 6 (1.6%) 3 (0.8%) RUFUTIS NOS 1 (5.6%) 10 (0.0%) 1 (0.0%) 1 (0.5%) 3 (0.8%) 1 (0.5%) 3 (0.8%) 1 (0.5%) 1 (0.5%) 3 (0.8%) 1 (0.5%) 1	LACRIMATION INCREASED	1 (5.6%)	56 (14.8%)	45 (22.7%)	94 (24.9%)	103 (26.3%)
COLUNIOTIVAL EDEMA	ABNORMAL SENSATION IN EYE	1 (5.6%)	50 (13.2%)	43 (21.7%)	78 (20.7%)	92 (23.5%)
VITEGUIS FLOATERS 3 (16.7%) 42 (11.1%) 40 (20.2%) 58 (15.4%) 74 (18.9%) VISUAL ACUITY REDUCED 2 (11.1%) 43 (11.4%) 47 (23.7%) 66 (17.5%) 58 (14.9%) VITEGUIS HEMORRHAGE 1 (5.6%) 25 (6.6%) 32 (16.2%) 37 (9.8%) 29 (7.4%) FOOTOPISTA 0 (0.0%) 14 (3.7%) 66 (17.5%) 26 (6.6%) 28 (7.2%) CATARACT SUBCAPSULAR 0 (0.0%) 11 (2.9%) 20 (10.1%) 20 (5.3%) 18 (4.6%) CATARACT SUBCAPSULAR 1 (5.6%) 10 (2.6%) 12 (6.1%) 20 (5.3%) 18 (4.6%) CATARACT NUCLEAR 1 (5.6%) 16 (4.2%) 3 (1.5%) 22 (5.8%) 10 (2.6%) CATARACT NUCLEAR 1 (5.6%) 16 (4.2%) 3 (1.5%) 22 (5.8%) 10 (2.6%) CATARACT NUCLEAR 1 (5.6%) 16 (4.2%) 3 (1.5%) 19 (5.0%) 19 (4.9%) CATARACT NUCLEAR 1 (5.6%) 16 (4.2%) 3 (1.5%) 19 (5.0%) 19 (4.9%) CATARACT NUCLEAR 1 (5.6%) 16 (4.2%) 3 (1.5%) 19 (5.0%) 19 (4.9%) CATARACT NUCLEAR 1 (5.6%) 16 (4.2%) 3 (1.5%) 19 (5.0%) 19 (4.9%) CATARACT NUCLEAR 1 (5.6%) 16 (4.2%) 3 (1.5%) 19 (5.0%) 19 (4.9%) CATARACT NUCLEAR 1 (5.6%) 16 (4.2%) 3 (1.5%) 19 (5.0%) 19 (4.9%) CATARACT NUCLEAR 1 (5.6%) 1 (5.6%) 1 (6.4.2%) 3 (1.5%) 19 (5.0%) 19 (4.9%) CATARACT NUCLEAR 1 (5.6%) 1 (6.4.2%) 3 (1.5%) 19 (5.0%) 19 (4.9%) CATARACT NUCLEAR 1 (5.6%) 1 (6.4.2%) 3 (1.5%) 19 (5.0%) 19 (4.9%) CATARACT NUCLEAR 1 (5.6%) 1 (6.4.2%) 3 (1.5%) 19 (5.0%) 19 (4.9%) CATARACT NUCLEAR 1 (5.6%) 1 (6.4.2%) 3 (1.5%) 19 (5.0%) 19 (4.9%) CATARACT NUCLEAR 1 (5.6%) 1 (6.4.2%) 3 (1.5%) 19 (5.0%) 19 (4.9%) CATARACT NUCLEAR 1 (5.6%) 1 (6.4.2%)	PHOTOPHOBIA	3 (16.7%)	42 (11.1%)	41 (20.7%)	63 (16.7%)	85 (21.7%)
VISUAL ACUITY REDUCED 2 (11.1%) 43 (11.4%) 47 (23.7%) 66 (17.5%) 58 (14.8%) VITROUS HEMORRHAGE 1 (5.6%) 25 (6.6%) 32 (16.2%) 37 (9.8%) 29 (7.4%) PHOTOPSIA 0 (0.0%) 14 (3.7%) 18 (9.1%) 25 (6.6%) 28 (7.2%) CATARACT SUBCAPSULAR 0 (0.0%) 11 (2.9%) 20 (10.1%) 20 (5.3%) 18 (4.6%) RETINAL DETACHMENT 1 (5.6%) 10 (2.6%) 12 (6.1%) 18 (4.8%) 22 (5.6%) CATARACT CORTICAL 1 (5.6%) 16 (4.2%) 12 (6.1%) 18 (4.8%) 22 (5.6%) CATARACT CORTICAL 1 (5.6%) 16 (4.2%) 3 (1.5%) 19 (4.9%) CORNEAL EROSION 0 (0.0%) 3 (0.8%) 4 (2.0%) 14 (3.7%) 11 (2.8%) CORNEAL EROSION 0 (0.0%) 3 (0.8%) 3 (1.5%) 12 (6.1%) 12 (6.1%) 18 (4.8%) 12 (6.1%) 19 (4.9%) EYE DISCHARGE 0 (0.0%) 3 (0.8%) 4 (2.0%) 14 (3.7%) 11 (2.8%) EYE DISCHARGE 0 (0.0%) 3 (0.8%) 3 (1.5%) 12 (3.2%) 14 (3.7%) 11 (2.8%) CONNINCTIVAL HEMORRHAGE 0 (0.0%) 14 (3.7%) 6 (3.0%) 6 (1.6%) 8 (2.0%) CONNINCTIVAL HEMORRHAGE 0 (0.0%) 14 (3.7%) 6 (3.0%) 6 (1.6%) 8 (2.0%) CONNINCTIVAL HEMORRHAGE 0 (0.0%) 14 (3.7%) 6 (3.0%) 6 (1.6%) 8 (2.0%) CONNINCTIVAL HEMORRHAGE 0 (0.0%) 3 (0.8%) 3 (1.5%) 6 (1.6%) 8 (2.1%) RUBBOSIS IRIDIS 1 (5.6%) 5 (1.3%) 8 (4.0%) 6 (1.6%) 9 (2.3%) HYPPHEMA 0 (0.0%) 3 (0.8%) 3 (1.5%) 6 (1.6%) 9 (2.3%) HYPPHYON 0 (0.0%) 3 (0.8%) 3 (1.5%) 6 (1.6%) 9 (2.3%) HYPPHYON 0 (0.0%) 3 (0.8%) 3 (1.5%) 6 (1.6%) 9 (2.3%) HYPPHYON 0 (0.0%) 3 (0.8%) 3 (1.5%) 5 (1.3%) 6 (1.6%) 3 (0.8%) WITTEOUS DETACHMENT 0 (0.0%) 1 (0.0%) 3 (0.8%) 3 (1.5%) 5 (1.3%) 6 (1.6%) 3 (0.8%) WITTEOUS DETACHMENT 0 (0.0%) 1 (0.0%) 1 (0.3%) 1 (0.5%) 3 (0.8%) 1 (0.5%) 3 (0.8%) HYPHYON NACULAR EDBMA 0 (0.0%) 2 (0.5%) 1 (0.5%) 3 (0.8%) 1 (0.5%) 3 (0.8%) 1 (0.5%) 1 (0.3%) HYPHEMA 0 (0.0%) 2 (0.5%) 1 (0.5%) 3 (0.8%) 1 (0.5%) 3 (0.8%) 1 (0.5%) 3 (0.8%) HYPHEMA 0 (0.0%) 2 (0.5%) 1 (0.5%) 3 (0.8%) 1 (0.5%) 3 (0.8%) 1 (0.5%) 3 (0.8%) HYPHEMA 0 (0.0%) 2 (0.5%) 1 (0.5%) 3 (0.8%) 1 (0.5%) 3 (0.8%) 1 (0.5%) 3 (0.8%) HYPHEMA 0 (0.0%) 2 (0.5%) 1 (0.0%) 2 (0.5%) 3 (0.8%) 1 (0.5%) 3 (0.8%) 1 (0.5%) 3 (0.8%) HYPHEMA 0 (0.0%) 2 (0.0%) 1 (0.0%) 1 (0.0%) 1 (0.0%) 1 (0.0%) 1 (0.0%) 1 (0.5%) 1 (0.5%) 1 (0.5%) 1 (0.5%) 1	CONJUNCTIVAL EDEMA	1 (5.6%)	49 (13.0%)	30 (15.2%)	74 (19.6%)	77 (19.7%)
VITEOUS HEMORRIAGE 1 (5.6%) 22 (6.6%) 32 (16.2%) 37 (9.8%) 29 (7.4%) PHOTOPSIA 0 (0.0%) 14 (3.7%) 18 (9.1%) 25 (6.6%) 28 (7.2%) CATARACT SUBCAPSULAR 0 (0.0%) 11 (2.9%) 20 (10.1%) 20 (5.3%) 18 (4.6%) RETINAL DETACHMENT 1 (5.6%) 16 (4.2%) 12 (6.1%) 12 (6.1%) 22 (5.6%) 10 (2.6%) 12 (6.1%) 22 (5.6%) 12 (6.1%) 22 (5.6%) 12 (6.1%) 22 (5.6%) 12 (6.1%) 22 (6	VITREOUS FLOATERS	3 (16.7%)	42 (11.1%)	40 (20.2%)	58 (15.4%)	74 (18.9%)
PHOTOPSIA CATARACT SUBCAPSULAR 0 (0.0%) 14 (3.7%) 18 (9.1%) 25 (6.6%) 28 (7.2%) CATARACT SUBCAPSULAR 0 (0.0%) 11 (2.9%) 20 (10.1%) 20 (5.3%) 18 (4.6%) RETINAL DETACHMENT 1 (5.6%) 10 (2.6%) 12 (6.1%) 18 (4.8%) 22 (5.6%) CATARACT NUCLEAR 1 (5.6%) 16 (4.2%) 3 (1.5%) 19 (5.0%) 10 (2.6%) CATARACT CORTICAL 1 (5.6%) 16 (4.2%) 3 (1.5%) 19 (5.0%) 10 (2.6%) CATARACT CORTICAL 1 (5.6%) 16 (4.2%) 3 (1.5%) 19 (5.0%) 10 (2.6%) CONNEAL EROSION 0 (0.0%) 16 (4.2%) 6 (3.0%) 14 (3.7%) 11 (2.8%) CONNEAL DISORDER NOS 0 (0.0%) 13 (3.4%) 3 (1.5%) 12 (3.2%) 14 (3.7%) 11 (2.8%) EYE DISCHARGE 1 (1.1%) 3 (0.8%) 4 (2.0%) 10 (2.7%) 18 (4.6%) EYE DISCHARGE 0 (0.0%) 13 (3.4%) 3 (1.5%) 12 (3.2%) 14 (3.7%) 21 (5.4%) EYE DISCHARGE 0 (0.0%) 14 (3.7%) 6 (3.0%) 6 (1.6%) 8 (2.0%) CONNUNCTIVAL HEMORRHAGE 0 (0.0%) 14 (3.7%) 6 (3.0%) 6 (1.6%) 8 (2.0%) CONNUNCTIVAL HEMORRHAGE 0 (0.0%) 14 (3.7%) 6 (3.0%) 6 (1.6%) 8 (2.0%) CONNEAL EDBMA 0 (0.0%) 14 (3.7%) 6 (3.0%) 6 (1.6%) 8 (2.0%) RUBBOSIS IRIDIS 1 (5.6%) 5 (1.3%) 8 (4.0%) 6 (1.6%) 9 (2.3%) HYPOPTON 0 (0.0%) 3 (0.8%) 3 (1.5%) 5 (1.3%) 8 (2.1%) 17 (4.3%) HYPHEMA 0 (0.0%) 3 (0.8%) 3 (1.5%) 5 (1.3%) 8 (2.0%) VITIEOUS DETACHMENT 0 (0.0%) 1 (0.3%) 1 (0.5%) 6 (1.6%) 3 (0.8%) VITIEOUS DETACHMENT 0 (0.0%) 1 (0.3%) 1 (0.5%) 5 (1.3%) 8 (2.0%) VITIEOUS DETACHMENT 0 (0.0%) 1 (0.3%) 1 (0.5%) 5 (1.3%) 8 (2.0%) CATARACT NOS AGGRAVATED 0 (0.0%) 1 (0.3%) 1 (0.5%) 3 (0.8%) 1 (0.5%) 3 (0.8%) 1 (0.5%) 1 (0.5%) 3 (0.8%) 1 (0.5%) 1 (0	VISUAL ACUITY REDUCED	2 (11.1%)	43 (11.4%)	47 (23.7%)	66 (17.5%)	58 (14.8%)
CATARACT SUBCAPSULAR RETINIAL DETACHMENT 1 (5.6%) 10 (2.6%) 12 (6.1%) 18 (4.8%) 22 (5.6%) 10 (2.6%) 12 (6.1%) 18 (4.8%) 22 (5.6%) 10 (2.6%) 12 (6.1%) 18 (4.8%) 22 (5.6%) 10 (2.6%) 12 (6.1%) 18 (4.8%) 22 (5.6%) 10 (2.6%) 12 (6.1%) 18 (4.8%) 22 (5.6%) 10 (2.6%) 16 (4.2%) 12 (6.1%) 18 (4.8%) 22 (5.8%) 10 (2.6%) 16 (4.2%) 12 (6.1%) 18 (4.8%) 22 (5.8%) 10 (2.6%) 16 (4.2%) 12 (6.1%) 19 (5.0%) 19 (4.9%) 10 (2.6%) 16 (4.2%) 16 (4.2%) 16 (3.0%) 14 (3.7%) 11 (2.8%) 10 (2.6%) 16 (4.2%) 16 (3.0%) 14 (3.7%) 11 (2.8%) 10 (2.6%) 10 (2.6%) 14 (3.7%) 11 (2.8%) 10 (2.6%) 10 (2.6%) 14 (3.7%) 11 (2.8%) 10 (2.6%) 10 (2.6%) 10 (2.6%) 10 (2.6%) 10 (2.6%) 10 (2.6%) 10 (2.6%) 11 (3.6%) 11 (3.6%) 13 (3.4%) 3 (1.5%) 12 (3.2%) 14 (3.7%) 12 (3.2%) 14 (3.7%) 12 (3.2%) 14 (3.7%) 12 (3.2%) 14 (3.6%) 11 (3.6%) 13 (3.4%) 3 (1.5%) 12 (3.2%) 14 (3.6%) 11 (3.6%) 11 (3.6%) 12 (3.2%) 14 (3.6%) 11 (3.6%) 12 (3.2%) 14 (3.6%) 12 (3.2%) 14 (3.6%) 12 (3.2%) 14 (3.6%) 12 (3.2%) 14 (3.6%) 12 (3.	VITREOUS HEMORRHAGE	1 (5.6%)	25 (6.6%)	32 (16.2%)	37 (9.8%)	29 (7.4%)
RETINAL DETACHMENT CATARACT NUCLEAR 1 (5.6%) 10 (2.6%) 12 (6.1%) 18 (4.8%) 22 (5.6%) CATARACT NUCLEAR 1 (5.6%) 16 (4.2%) 12 (6.1%) 22 (5.8%) 10 (2.6%) CATARACT CORTICAL 1 (5.6%) 16 (4.2%) 3 (1.5%) 19 (5.0%) 10 (2.6%) CORNEAL EROSION 0 (0.0%) 16 (4.2%) 6 (3.0%) 14 (3.7%) 11 (2.8%) CORNEAL DISCORDER NOS 0 (0.0%) 3 (0.8%) 4 (2.0%) 14 (3.7%) 11 (2.8%) EYE DISCHARGE 0 (0.0%) 13 (3.4%) 3 (1.5%) 12 (3.2%) 14 (3.7%) EYE DISCHARGE 1 (1.1%) 3 (0.8%) 4 (2.0%) 10 (2.7%) 18 (4.6%) EYE DISCHARGE 0 (0.0%) 13 (3.4%) 3 (1.5%) 12 (3.2%) 14 (3.6%) EYE DISCHARGE 0 (0.0%) 14 (3.7%) 6 (3.0%) 6 (1.6%) 18 (4.6%) CONJUNCTIVAL HEMORRHAGE 0 (0.0%) 14 (3.7%) 6 (3.0%) 6 (1.6%) 18 (4.6%) CONDUNCTIVAL HEMORRHAGE 0 (0.0%) 4 (1.1%) 4 (2.0%) 10 (2.7%) 18 (4.6%) CORNEAL EDEMA 0 (0.0%) 4 (1.1%) 4 (2.0%) 8 (2.1%) 17 (4.3%) HYPOPYON 0 (0.0%) 0 (0.0%) 1 (0.5%) 6 (1.6%) 9 (2.3%) HYPOPYON 0 (0.0%) 0 (0.0%) 1 (0.5%) 5 (1.3%) 6 (1.6%) 21 (5.4%) HYPHENA 0 (0.0%) 3 (0.8%) 3 (1.5%) 5 (1.3%) 6 (1.6%) 21 (5.4%) MACULAR EDEMA 0 (0.0%) 3 (0.8%) 3 (1.5%) 5 (1.3%) 4 (1.0%) MACULAR EDEMA 0 (0.0%) 3 (0.8%) 3 (1.5%) 5 (1.3%) 6 (1.6%) 21 (5.4%) MACULAR EDEMA 0 (0.0%) 1 (0.3%) 1 (0.5%) 5 (1.3%) 4 (1.0%) MACULOPATHY 0 (0.0%) 1 (0.3%) 1 (0.5%) 5 (1.6%) 3 (0.8%) 4 (1.0%) MACULOPATHY 0 (0.0%) 2 (0.5%) 1 (0.5%) 6 (1.6%) 3 (0.8%) MACULOPATHY 0 (0.0%) 2 (0.5%) 1 (0.5%) 2 (0.5%) 4 (1.0%) MACULOPATHY 0 (0.0%) 2 (0.5%) 1 (0.5%) 2 (0.5%) 4 (1.0%) MACULOPATHY 0 (0.0%) 2 (0.5%) 1 (0.5%) 2 (0.5%) 3 (0.8%) 1 (0.5%) DATA ETE NEC 0 (0.0%) 2 (0.5%) 1 (0.5%) 2 (0.5%) 3 (0.8%) 1 (0.5%) DATA ETE NEC 0 (0.0%) 2 (0.5%) 1 (0.5%) 2 (0.5%) 3 (0.8%) 1 (0.5%) DATA ETE NEC 0 (0.0%) 2 (0.5%) 1 (0.5%) 2 (0.5%) 3 (0.8%) 1 (0.5%) DATA ETE NEC 0 (0.0%) 2 (0.5%) 1 (0.5%) 3 (0.8%) 1 (0.5%) 2 (0.5%) 3 (0.8%) DATA ETE NEC 0 (0.0%) 2 (0.5%) 1 (0.5%) 3 (0.8%) 1 (0.5%) 2 (0.5%) 3 (0.8%) 1 (0.5%) DATA ETE NEC 0 (0.0%) 2 (0.5%) 1 (0.5%) 3 (0.8%) 1 (0.5%) 2 (0.5%) 3 (0.8%) 1 (0.5%) 2 (0.5%) 3 (0.8%) 1 (0.5%) 3 (0.8%) 1 (0.5%) 3 (0.8%) 1 (0.5%) 3 (0.8%) 1 (0.5%) 3 (0.8%) 1 (0.5%) 3 (0.8%) 1 (0.5%) 3 (0.8%) 1 (0	PHOTOPSIA	0 (0.0%)	14 (3.7%)	18 (9.1%)	25 (6.6%)	28 (7.2%)
CATARACT NUCLEAR 1 (5.6*) 16 (4.2*) 12 (6.1*) 22 (5.8*) 10 (2.6*) CATARACT CORTICAL 1 (5.6*) 16 (4.2*) 3 (1.5*) 19 (5.0*) 19 (4.9*) CORNEAL EROSION 0 (0.0*) 16 (4.2*) 6 (3.0*) 14 (3.7*) 11 (2.8*) CORNEAL DISORDER NOS 0 (0.0*) 3 (0.8*) 4 (2.0*) 14 (3.7*) 21 (5.4*) EYE DISCHARGE 0 (0.0*) 13 (3.4*) 3 (1.5*) 12 (3.2*) 14 (3.6*) IRIS ADHESIONS 2 (11.1*) 3 (0.8*) 4 (2.0*) 10 (2.7*) 18 (4.6*) CONNUNCTIVAL HEMORRHAGE 0 (0.0*) 14 (3.7*) 6 (3.0*) 6 (1.6*) 18 (4.6*) CONNUNCTIVAL HEMORRHAGE 0 (0.0*) 14 (3.7*) 6 (3.0*) 6 (1.6*) 8 (2.0*) RUBEOSIS IRIDIS 1 (5.6*) 5 (1.3*) 8 (4.0*) 6 (1.6*) 9 (2.3*) HYPOPVON 0 (0.0*) 1 (0.0*) 1 (0.5*) 6 (1.6*) 9 (2.3*) HYPOPVON 0 (0.0*) 3 (0.8*) 3 (1.5*) 5 (1.3*) 6 (1.5*) MACULAR EDEMA 0 (0.0*) 3 (0.8*) 3 (1.5*) 5 (1.3*) 6 (1.5*) UVEITIS NOS 1 (5.6*) 1 (0.3*) 1 (0.5*) 5 (1.3*) 6 (1.6*) 21 (5.4*) MACULOPATHY MACULOPATHY MACULOPATHY MACULOPATHY MACULOPATHY 0 (0.0*) 1 (0.3*) 1 (0.5*) 3 (0.8*) 4 (1.0*) KERATITIS NEC 0 (0.0*) 1 (0.0*) 2 (0.5*) 1 (0.5*) 3 (0.8*) 1 (0.5*) CATARACT NEC CATARA	CATARACT SUBCAPSULAR	0 (0.0%)	11 (2.9%)	20 (10.1%)	20 (5.3%)	18 (4.6%)
CATARACT CORTICAL CORNEAL EROSION O (0.0%) 16 (4.2%) 3 (1.5%) 19 (5.0%) 19 (4.9%) CORNEAL EROSION O (0.0%) 16 (4.2%) 6 (3.0%) 14 (3.7%) 11 (2.8%) CORNEAL DISORDER NOS O (0.0%) 3 (0.8%) 4 (2.0%) 14 (3.7%) 21 (5.4%) EYE DISCHARGE EYE DISCHARGE O (0.0%) 3 (0.8%) 3 (1.5%) 12 (3.2%) 14 (3.7%) 21 (5.4%) EYE DISCHARGE CONJUNCTIVAL HEMORRHAGE O (0.0%) 14 (3.7%) 6 (3.0%) 6 (1.6%) 8 (2.0%) CONJUNCTIVAL HEMORRHAGE O (0.0%) 14 (3.7%) 6 (3.0%) 6 (1.6%) 8 (2.0%) CONJUNCTIVAL HEMORRHAGE O (0.0%) 14 (3.7%) 6 (3.0%) 6 (1.6%) 9 (2.3%) HYPOPYON O (0.0%) 1 (5.5%) 5 (1.3%) 8 (4.0%) 6 (1.6%) 9 (2.3%) HYPOPYON O (0.0%) 3 (0.8%) 3 (1.5%) 5 (1.3%) 6 (1.6%) 9 (2.3%) HYPOPYON O (0.0%) 3 (0.8%) 3 (1.5%) 5 (1.3%) 6 (1.6%) 9 (2.3%) MACULAR EDEMA O (0.0%) 3 (0.8%) 3 (1.5%) 5 (1.3%) 6 (1.6%) 9 (2.0%) VITREOUS DETACHMENT O (0.0%) 1 (0.3%) 1 (0.5%) 5 (1.3%) 8 (2.0%) VITREOUS DETACHMENT O (0.0%) 1 (0.3%) 1 (0.5%) 5 (1.3%) 9 (0.8%) AUCULOPATHY O (0.0%) 1 (0.3%) 3 (0.8%) 3 (1.5%) 3 (0.8%) 4 (1.0%) DRY EYE NEC CATARACT NEC CATARACT NEC O (0.0%) 1 (0.3%) 3 (0.8%) 3 (0.8%) 4 (1.0%) DRY EYE NEC DIPLOPIA DIPLOPIA O (0.0%) 0 (0.0%) 1 (0.5%) 1 (0.5%) 2 (0.5%) 3 (0.8%) 1 (0.5%) 5 (1.3%) POSTERIOR CAPSULE OPACIFICATION O (0.0%) 0 (0.0%) 1 (0.5%) 1 (0.5%) 3 (0.8%) 1 (0.5%) 5 (1.3%) POSTERIOR CAPSULE OPACIFICATION O (0.0%) 0 (0.0%) 1 (0.5%) 1 (0.5%) 2 (0.5%) 2 (0.5%) 1 (0.5%) 2 (0.5%) 2 (0.5%) BLINDNESS NEC HYPOTOMY OF EYE O (0.0%) 1 (0.0%) 1 (0.5%) 1 (0.5%) 1 (0.5%) 2 (0.5%) 2 (0.5%) 4 (1.0%) POSTERIOR CAPSULE OPACIFICATION O (0.0%) 1 (0.0%) 1 (0.5%) 1 (0.5%) 1 (0.5%) 2 (0.5%) 2 (0.5%) 1 (0.5%) 2 (0.5%) 2 (0.5%) 4 (1.0%) POSTERIOR CAPSULE OPACIFICATION O (0.0%) 0 (0.0%) 1 (0.5%) 1 (0.5%) 1 (0.5%) 2 (0.5%) 2 (0.5%) 1 (0.5%) 2 (0.5%) 2 (0.5%) 1 (0.5%) 2 (0.5%) 2 (0.5%) 1 (0.5%) 2 (0.5%) 2 (0.5%) 2 (0.5%) 2 (0.5%) 2 (0.5%) 2 (0.5%) 2 (0.5%) 2 (0.5%) 2 (0.5%) 2 (0.5%) 2 (0.5%) 2 (0.5%)	RETINAL DETACHMENT	1 (5.6%)	10 (2.6%)	12 (6.1%)	18 (4.8%)	22 (5.6%)
CORNEAL EROSION CORNEAL DISORDER NOS O (0.0%) 3 (0.0%) 4 (2.0%) 14 (3.7%) 11 (2.8%) CORNEAL DISORDER NOS O (0.0%) 3 (0.0%) 3 (0.0%) 14 (3.7%) 21 (5.4%) EYE DISCHARGE O (0.0%) 13 (3.4%) 3 (1.5%) 12 (3.2%) 14 (3.6%) IRIS ADHESIONS 2 (11.1%) 3 (0.0%) 4 (2.0%) 10 (2.7%) 18 (4.6%) CONJUNCTIVAL HEMORRHAGE O (0.0%) 14 (3.7%) 6 (3.0%) 6 (1.6%) 18 (4.6%) CORNEAL EDEMA O (0.0%) 14 (1.1%) 4 (2.0%) 8 (2.1%) 17 (4.3%) RUBEOSIS IRIDIS 1 (5.6%) 5 (1.3%) 8 (4.0%) 6 (1.6%) 9 (2.3%) HYPOPYON O (0.0%) 0 (0.0%) 1 (0.5%) 6 (1.6%) 9 (2.3%) HYPOPYON O (0.0%) 3 (0.0%) 3 (0.8%) 3 (1.5%) 5 (1.3%) 6 (1.6%) HYPHEMA O (0.0%) 3 (0.8%) 3 (1.5%) 5 (1.3%) 6 (1.6%) UVEITIS NOS UVEITIS NOS 1 (5.6%) 1 (0.3%) 1 (0.5%) 5 (1.3%) 6 (1.6%) 3 (0.8%) VITREOUS DETACHMENT O (0.0%) 1 (0.3%) 1 (0.5%) 5 (1.6%) 3 (0.8%) KERATITIS NEC O (0.0%) 1 (0.3%) 1 (0.5%) 6 (1.6%) 3 (0.8%) KERATITIS NEC CATARACT NOS AGGRAVATED O (0.0%) 2 (0.5%) 1 (0.5%) 2 (0.5%) 3 (0.8%) DIPLOPIA GLAUCOMA NOS POPTERIOR CAPSULE OPACIFICATION O (0.0%) 2 (0.5%) 1 (0.5%) 2 (0.5%) 3 (0.8%) DIPLOPIA GLAUCOMA NOS POSTERIOR CAPSULE OPACIFICATION O (0.0%) 1 (0.5%) 1 (0.5%) 3 (0.8%) 1 (0.5%) 2 (0.5%) DIPLOPIA HYPOTONY OF EYE HYPOTON	CATARACT NUCLEAR	1 (5.6%)	16 (4.2%)	12 (6.1%)	22 (5.8%)	10 (2.6%)
CORNEAL DISORDER NOS O (0.0%) 3 (0.8%) 4 (2.0%) 14 (3.7%) 21 (5.4%) EYE DISCHARGE O (0.0%) 13 (3.4%) 3 (1.5%) 12 (3.2%) 14 (3.6%) 17 (3.6%) 17 (3.6%) 18 (4.6%) 10 (2.7%) 10 (2.7%) 1	CATARACT CORTICAL	1 (5.6%)	16 (4.2%)	3 (1.5%)	19 (5.0%)	19 (4.9%)
EYE DISCHARGE O (0.0\$) 13 (3.4\$) 3 (1.5\$) 12 (3.2\$) 14 (3.6\$) IRIS ADHESIONS CONJUNCTIVAL HEMORRHAGE O (0.0\$) 14 (3.7\$) 6 (3.0\$) 6 (1.6\$) 8 (2.0\$) CORNEAL EDEMA O (0.0\$) 4 (1.1\$) 4 (2.0\$) 8 (2.1\$) 17 (4.3\$) RUBEOSIS IRIDIS RUBEOSIS IRIDIS 1 (5.6\$) 5 (1.3\$) 8 (4.0\$) 6 (1.6\$) 9 (2.3\$) HYPOPYON O (0.0\$) 0 (0.0\$) 1 (0.5\$) 6 (1.6\$) 9 (2.3\$) HYPOPYON O (0.0\$) 3 (0.8\$) 3 (1.5\$) 5 (1.3\$) 6 (1.6\$) 9 (5.4\$) HYPHEMA O (0.0\$) 3 (0.8\$) 3 (1.5\$) 5 (1.3\$) 6 (1.6\$) 9 (5.4\$) HYPHEMA O (0.0\$) 3 (0.8\$) 3 (1.5\$) 5 (1.3\$) 6 (1.6\$) 9 (5.4\$) HYPHEMA O (0.0\$) 3 (0.8\$) 3 (1.5\$) 5 (1.3\$) 6 (1.6\$) 9 (5.4\$) HYPHEMA O (0.0\$) 3 (0.8\$) 3 (1.5\$) 5 (1.3\$) 6 (1.6\$) 9 (5.5\$) HYPHEMA O (0.0\$) 1 (0.3\$) 1 (0.5\$) 5 (1.3\$) 6 (1.6\$) 9 (1.0\$) HYPHEMA O (0.0\$) 2 (0.5\$) 1 (0.5\$) 5 (1.3\$) 6 (1.6\$) 9 (1.0\$) HYPHEMA O (0.0\$) 1 (0.3\$) 1 (0.5\$) 5 (1.3\$) 4 (1.0\$) HYPHEMA O (0.0\$) 1 (0.3\$) 1 (0.5\$) 5 (1.3\$) 6 (1.6\$) 9 (1.0\$) HYPHEMA O (0.0\$) 1 (0.3\$) 1 (0.5\$) 5 (1.3\$) 6 (1.6\$) 9 (1.0\$) HYPHEMA O (0.0\$) 1 (0.3\$) 1 (0.5\$) 5 (1.3\$) 6 (1.6\$) 9 (0.8\$) HYPHEMA O (0.0\$) 1 (0.3\$) 1 (0.5\$) 5 (1.3\$) 6 (1.6\$) 9 (0.8\$) HYPHEMA O (0.0\$) 1 (0.3\$) 1 (0.5\$) 5 (1.3\$) 6 (1.6\$) 9 (0.8\$) HYPHEMA O (0.0\$) 1 (0.3\$) 1 (0.5\$) 5 (1.3\$) 6 (1.6\$) 9 (0.8\$) HYPHEMA O (0.0\$) 1 (0.5\$) 1 (0.5\$) 3 (0.8\$) 1 (0.5\$) 1 (0.5\$) 1 (0.5\$) 1 (0.8\$) HYPHEMA O (0.0\$) 1 (0.0\$) 1 (0.5\$) 1	CORNEAL EROSION	0 (0.0%)	16 (4.2%)	6 (3.0%)	14 (3.7%)	11 (2.8%)
IRIS ADHESIONS 2 (11.1%) 3 (0.8%) 4 (2.0%) 10 (2.7%) 18 (4.6%) CONJUNCTIVAL HEMORRHAGE 0 (0.0%) 14 (3.7%) 6 (3.0%) 6 (1.6%) 8 (2.0%) CORNERL EDEMA 0 (0.0%) 4 (1.1%) 4 (2.0%) 8 (2.1%) 17 (4.3%) RUBEOSIS IRIDIS 1 (5.6%) 5 (1.3%) 8 (4.0%) 6 (1.6%) 9 (2.3%) HYPOPYON 0 (0.0%) 0 (0.0%) 1 (0.5%) 6 (1.6%) 21 (5.4%) HYPHEMA 0 (0.0%) 3 (0.8%) 3 (1.5%) 5 (1.3%) 6 (1.6%) 21 (5.4%) MACULAR EDEMA 0 (0.0%) 3 (0.8%) 3 (1.5%) 5 (1.3%) 8 (4.0%) 6 (1.6%) 21 (5.4%) MACULAR EDEMA 0 (0.0%) 3 (0.8%) 3 (1.5%) 5 (1.3%) 8 (2.0%) UVEITIS NOS 1 (5.6%) 1 (0.3%) 1 (0.5%) 5 (1.3%) 4 (1.0%) MACULOPATHY 0 (0.0%) 1 (0.3%) 1 (0.5%) 5 (1.3%) 4 (1.0%) MACULOPATHY 0 (0.0%) 1 (0.3%) 1 (0.5%) 5 (1.3%) 4 (1.0%) KERATITIS NEC 0 (0.0%) 1 (0.3%) 3 (1.5%) 3 (0.8%) 4 (1.0%) KERATITIS NEC 0 (0.0%) 1 (0.3%) 3 (1.5%) 2 (0.5%) 3 (0.8%) CATARACT NOS AGGRAVATED 1 (5.6%) 3 (0.8%) 0 (0.0%) 2 (0.5%) 1 (0.5%) 3 (0.8%) CATARACT NOS AGGRAVATED 1 (5.6%) 3 (0.8%) 0 (0.0%) 3 (0.8%) 1 (0.5%) 3 (0.8%) DRY EYE NEC DIPLOPIA 0 (0.0%) 2 (0.5%) 1 (0.5%) 3 (0.8%) 1 (0.3%) GLAUCOMA NOS 0 (0.0%) 2 (0.5%) 1 (0.5%) 3 (0.8%) 1 (0.3%) GLAUCOMA NOS 0 (0.0%) 2 (0.5%) 1 (0.5%) 3 (0.8%) GLAUCOMA NOS 0 (0.0%) 2 (0.5%) 1 (0.5%) 3 (0.8%) COSTERIOR CAPSULE OPACIFICATION 0 (0.0%) 2 (0.5%) 0 (0.0%) 1 (0.5%) 3 (0.8%) BLINDNESS NEC 0 (0.0%) 1 (0.3%) 1 (0.5%) 3 (0.8%) 2 (0.5%) BLINDNESS NEC 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.5%) 1 (0.3%) 4 (1.0%) MYDRIASIS 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.5%) 1 (0.5%) 4 (1.0%) MYDRIASIS	CORNEAL DISORDER NOS	0 (0.0%)	3 (0.8%)	4 (2.0%)	14 (3.7%)	21 (5.4%)
CONJUNCTIVAL HEMORRHAGE O (0.0%) 14 (3.7%) 6 (3.0%) 6 (1.6%) 8 (2.0%) CORNEAL EDEMA O (0.0%) 4 (1.1%) 4 (2.0%) 8 (2.1%) 17 (4.3%) HIGHORY CONNEAL EDEMA RUBEOSIS IRIDIS 1 (5.6%) 5 (1.3%) 8 (4.0%) 6 (1.6%) 9 (2.3%) HYPOPYON O (0.0%) 0 (0.0%) 1 (0.5%) 6 (1.6%) 21 (5.4%) HYPOPYON O (0.0%) 3 (0.8%) 3 (1.5%) 5 (1.3%) 6 (1.6%) 21 (5.4%) HYPHEMA MACULAR EDEMA O (0.0%) 3 (0.8%) 3 (1.5%) 5 (1.3%) 6 (1.5%) WITTEOUS DETACHMENT O (0.0%) 1 (0.3%) 1 (0.5%) 5 (1.3%) 4 (1.0%) WITTEOUS DETACHMENT MACULOPATHY MERATITIS NEC O (0.0%) 1 (0.3%) 3 (0.5%) 3 (0.8%) 4 (1.0%) WITTEOUS DETACHMENT MERATITIS NEC O (0.0%) 1 (0.3%) 3 (0.5%) 3 (0.8%) 4 (1.0%) CATARACT NEC CATARACT NEC O (0.0%) 1 (0.3%) 3 (0.5%) 3 (0.8%) 4 (1.0%) CATARACT NOS AGGRAVATED DRY EVE NEC O (0.0%) 2 (0.5%) 1 (0.5%) 3 (0.8%) 1 (0.3%) 1 (0.5%) 3 (0.8%) 1 (0.3%) 1 (0.5%) 1 (0.5%) 1 (0.5%) 1 (0.5%) 1 (0.3%) 1 (0.5%) 1 (0.3%) 1 (0.5%) 1 (0.5%) 1 (0.3%) 1 (0.5%) 1 (0.	EYE DISCHARGE	0 (0.0%)	13 (3.4%)	3 (1.5%)	12 (3.2%)	14 (3.6%)
CORNEAL EDEMA CORNEAL EDEMA RUBEOSIS IRIDIS 1 (5.6%) 5 (1.3%) 8 (4.0%) 6 (1.6%) 9 (2.3%) RUBEOSIS IRIDIS 1 (5.6%) 5 (1.3%) 8 (4.0%) 6 (1.6%) 9 (2.3%) HYPOPYON 0 (0.0%) 0 (0.0%) 1 (0.5%) 6 (1.6%) 9 (2.3%) HYPHEMA 0 (0.0%) 3 (0.8%) 3 (1.5%) 5 (1.3%) 6 (1.5%) MACULAR EDEMA 0 (0.0%) 3 (0.8%) 3 (1.5%) 5 (1.3%) 6 (1.5%) MACULAR EDEMA 0 (0.0%) 3 (0.8%) 3 (1.5%) 5 (1.3%) 6 (1.5%) MACULAR EDEMA 0 (0.0%) 1 (0.3%) 1 (0.5%) 5 (1.3%) 6 (1.6%) VITREOUS DETACHMENT 0 (0.0%) 1 (0.3%) 1 (0.5%) 5 (1.3%) 4 (1.0%) VITREOUS DETACHMENT 0 (0.0%) 1 (0.3%) 1 (0.5%) 6 (1.6%) 3 (0.8%) MACULOPATHY KERATITIS NEC 0 (0.0%) 2 (0.5%) 1 (0.5%) 3 (0.8%) CATARACT NEC CATARACT NOS AGGRAVATED 1 (5.6%) 3 (0.8%) 3 (1.5%) 2 (0.5%) 4 (1.0%) CATARACT NOS AGGRAVATED 1 (5.6%) 3 (0.8%) 0 (0.0%) 2 (0.5%) 1 (0.5%) 3 (0.8%) DIPLOPIA 0 (0.0%) 2 (0.5%) 1 (0.5%) 3 (0.8%) 1 (0.3%) GLAUCOMA NOS POSTERIOR CAPSULE OPACIFICATION 0 (0.0%) 2 (0.5%) 0 (0.0%) 2 (0.5%) 1 (0.5%) 3 (0.8%) VISION BLURRED 0 (0.0%) 1 (0.5%) 3 (0.8%) 2 (0.5%) VISION BLURRED 0 (0.0%) 0 (0.0%) 1 (0.5%) 3 (0.8%) 2 (0.5%) BLINDNESS NEC 0 (0.0%) 1 (0.3%) 1 (0.5%) 1 (0.3%) 4 (1.0%) MYDRIASIS	IRIS ADHESIONS	2 (11.1%)	3 (0.8%)	4 (2.0%)	10 (2.7%)	18 (4.6%)
RUBEOSIS IRIDIS 1 (5.6%) 5 (1.3%) 8 (4.0%) 6 (1.6%) 9 (2.3%) HYPOPYON 0 (0.0%) 0 (0.0%) 1 (0.5%) 6 (1.6%) 21 (5.4%) HYPHEMA 0 (0.0%) 3 (0.8%) 3 (1.5%) 5 (1.3%) 6 (1.6%) 21 (5.4%) MACULAR EDEMA 0 (0.0%) 3 (0.8%) 3 (1.5%) 5 (1.3%) 6 (1.5%) 10 (0.8%) UVEITIS NOS UVEITIS NOS 1 (5.6%) 1 (0.3%) 1 (0.5%) 5 (1.3%) 4 (1.0%) VITREOUS DETACHMENT 0 (0.0%) 1 (0.3%) 1 (0.5%) 6 (1.6%) 3 (0.8%) VITREOUS DETACHMENT 0 (0.0%) 1 (0.3%) 1 (0.5%) 6 (1.6%) 3 (0.8%) VITREOUS DETACHMENT MACULOPATHY 0 (0.0%) 2 (0.5%) 3 (0.8%) 4 (1.0%) KERATITIS NEC CATARACT NEC 0 (0.0%) 2 (0.5%) 3 (0.8%) 4 (1.0%) DRY EYE NEC CATARACT NOS AGGRAVATED 1 (5.6%) 3 (0.8%) 0 (0.0%) 2 (0.5%) 3 (0.8%) DRY EYE NEC 0 (0.0%) 2 (0.5%) 1 (0.5%) 3 (0.8%) 1 (0.3%) DRY EYE NEC 0 (0.0%) 2 (0.5%) 1 (0.5%) 3 (0.8%) 1 (0.3%) DRY EYE NEC 0 (0.0%) 2 (0.5%) 1 (0.5%) 3 (0.8%) 1 (0.3%) DRY EYE NEC 0 (0.0%) 2 (0.5%) 1 (0.5%) 3 (0.8%) 1 (0.3%) DRY EYE NEC 0 (0.0%) 2 (0.5%) 1 (0.5%) 3 (0.8%) 1 (0.3%) DRY EYE NEC 0 (0.0%) 2 (0.5%) 1 (0.5%) 3 (0.8%) 1 (0.3%) DRY EYE NEC 0 (0.0%) 2 (0.5%) 1 (0.5%) 3 (0.8%) 1 (0.3%) DRY EYE NEC 0 (0.0%) 2 (0.5%) 1 (0.5%) 3 (0.8%) 1 (0.3%) DRY EYE NEC 0 (0.0%) 2 (0.5%) 1 (0.5%) 3 (0.8%) 1 (0.3%) DRY EYE NEC 0 (0.0%) 2 (0.5%) 1 (0.5%) 3 (0.8%) 1 (0.3%) DRY EYE NEC 0 (0.0%) 2 (0.5%) 1 (0.5%) 3 (0.8%) 1 (0.3%) 1 (0.5%)	CONJUNCTIVAL HEMORRHAGE	0 (0.0%)	14 (3.7%)	6 (3.0%)	6 (1.6%)	8 (2.0%)
HYPOPYON HYPHEMA O(0.0%) O(0.0%) 1(0.5%) 6(1.6%) 21(5.4%) HYPHEMA O(0.0%) 3(0.8%) 3(1.5%) 5(1.3%) 6(1.5%) MACULAR EDEMA UVEITIS NOS UVEITIS NOS 1(5.6%) 1(0.3%) 1(0.5%) 5(1.3%) 4(1.0%) VITREOUS DETACHMENT O(0.0%) 1(0.3%) 1(0.5%) 5(1.3%) 4(1.0%) MACULOPATHY O(0.0%) 1(0.3%) 1(0.5%) 6(1.6%) 3(0.8%) MACULOPATHY O(0.0%) 1(0.3%) 1(0.5%) 6(1.6%) 3(0.8%) MACULOPATHY O(0.0%) 1(0.3%) 3(1.5%) 2(0.5%) 3(0.8%) 4(1.0%) KERATITIS NEC CATARACT NEC O(0.0%) 1(0.3%) 3(1.5%) 2(0.5%) 3(0.8%) 4(1.0%) CATARACT NOS AGGRAVATED O(0.0%) 1(5.6%) 3(0.8%) 0(0.0%) 2(0.5%) 3(0.8%) 1(0.3%) DRY EYE NEC DIPLOPIA GLAUCOMA NOS O(0.0%) 2(0.5%) 1(0.5%) 3(0.8%) 1(0.5%) 3(0.8%) POSTERIOR CAPSULE OPACIFICATION O(0.0%) 2(0.5%) 0(0.0%) 1(0.5%) 2(0.5%) 2(0.5%) VISION BLURRED O(0.0%) 1(0.5%) 1(0.5%) 3(0.8%) 2(0.5%) VISION BLURRED HYPOTONY OF EYE MYDRIASIS O(0.0%) 1(0.3%) 0(0.0%) 1(0.5%) 1(0.3%) 4(1.0%) MYDRIASIS	CORNEAL EDEMA	0 (0.0%)	4 (1.1%)	4 (2.0%)	8 (2.1%)	17 (4.3%)
HYPHEMA MACULAR EDEMA O (0.0%) 3 (0.8%) 3 (1.5%) 5 (1.3%) 6 (1.5%) MACULAR EDEMA O (0.0%)	RUBEOSIS IRIDIS	1 (5.6%)	5 (1.3%)	8 (4.0%)		9 (2.3왕)
MACULAR EDEMA O (0.0%) 3 (0.8%) 3 (1.5%) 3 (0.8%) 8 (2.0%) UVEITIS NOS 1 (5.6%) 1 (0.3%) 1 (0.5%) 5 (1.3%) 4 (1.0%) VITREOUS DETACHMENT O (0.0%) 1 (0.3%) 1 (0.5%) 6 (1.6%) 3 (0.8%) MACULOPATHY KERATITIS NEC O (0.0%) 1 (0.3%) 3 (1.5%) 2 (0.5%) 3 (0.8%) CATARACT NEC O (0.0%) 2 (0.5%) 0 (0.0%) 2 (0.5%) 3 (0.8%) CATARACT NOS AGGRAVATED DIPLOPIA DIPLOPIA GLAUCOMA NOS GLAUCOMA NOS POSTERIOR CAPSULE OPACIFICATION O (0.0%) 2 (0.5%) 0 (0.0%) 2 (0.5%) 0 (0.0%) 2 (0.5%) VISION BLURRED BLURRED HYPOTONY OF EYE MYDRIASIS O (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.5%) 3 (0.8%) 2 (0.5%) MYDRIASIS O (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.5%) 3 (0.8%) 2 (0.5%) MYDRIASIS	HYPOPYON	0 (0.0%)	0 (0.0%)	1 (0.5%)	6 (1.6%)	21 (5.4%)
UVEITIS NOS 1 (5.6%) 1 (0.3%) 1 (0.5%) 5 (1.3%) 4 (1.0%) VITREOUS DETACHMENT 0 (0.0%) 1 (0.3%) 1 (0.5%) 6 (1.6%) 3 (0.8%) MACULOPATHY 0 (0.0%) 2 (0.5%) 1 (0.5%) 3 (0.8%) 4 (1.0%) KERATITIS NEC CATARACT NEC 0 (0.0%) 1 (0.3%) CATARACT NEC CATARACT NOS AGGRAVATED 1 (5.6%) 3 (0.8%) 0 (0.0%) 2 (0.5%) 0 (0.0%) 2 (0.5%) 0 (0.0	HYPHEMA	0 (0.0%)	3 (0.8%)	3 (1.5%)	5 (1.3%)	6 (1.5%)
VITREOUS DETACHMENT 0 (0.0%) 1 (0.3%) 1 (0.5%) 6 (1.6%) 3 (0.8%) MACULOPATHY 0 (0.0%) 2 (0.5%) 1 (0.5%) 3 (0.8%) 4 (1.0%) KERATITIS NEC 0 (0.0%) 1 (0.3%) 3 (1.5%) 2 (0.5%) 3 (0.8%) CATARACT NEC 0 (0.0%) 2 (0.5%) 0 (0.0%) 2 (0.5%) 4 (1.0%) CATARACT NOS AGGRAVATED 1 (5.6%) 3 (0.8%) 0 (0.0%) 3 (0.8%) 1 (0.5%) 3 (0.8%) 1 (0.3%) DRY EYE NEC 0 (0.0%) 2 (0.5%) 1 (0.5%) 2 (0.5%) 3 (0.8%) 1 (0.3%) DIPLOPIA 0 (0.0%) 2 (0.5%) 1 (0.5%) 3 (0.8%) 1 (0.3%) GLAUCOMA NOS 0 (0.0%) 2 (0.5%) 1 (0.5%) 3 (0.8%) 1 (0.3%) POSTERIOR CAPSULE OPACIFICATION 0 (0.0%) 2 (0.5%) 0 (0.0%) 2 (0.5%) 0 (0.0%) 2 (0.5%) VISION BLURRED 0 (0.0%) 0 (0.0%) 1 (0.3%) 2 (0.5%) 2 (0.5%) 2 (0.5%) BLINDNESS NEC 0 (0.0%) 1 (0.3%) 1 (0.3%) 2 (0.5%) 4 (1.0	MACULAR EDEMA	0 (0.0%)	3 (0.8%)	3 (1.5%)	3 (0.8%)	8 (2.0%)
MACULOPATHY 0 (0.0%) 2 (0.5%) 1 (0.5%) 3 (0.8%) 4 (1.0%) KERATITIS NEC 0 (0.0%) 1 (0.3%) 3 (1.5%) 2 (0.5%) 3 (0.8%) CATARACT NEC 0 (0.0%) 2 (0.5%) 0 (0.0%) 2 (0.5%) 4 (1.0%) CATARACT NOS AGGRAVATED 1 (5.6%) 3 (0.8%) 0 (0.0%) 2 (0.5%) 3 (0.8%) 1 (0.3%) DAY EYE NEC 0 (0.0%) 2 (0.5%) 1 (0.5%) 2 (0.5%) 3 (0.8%) 1 (0.3%) DIPLOPIA 0 (0.0%) 2 (0.5%) 1 (0.5%) 2 (0.5%) 3 (0.8%) 1 (0.3%) GLAUCOMA NOS 0 (0.0%) 2 (0.5%) 1 (0.5%) 3 (0.8%) 1 (0.3%) POSTERIOR CAPSULE OPACIFICATION 0 (0.0%) 2 (0.5%) 0 (0.0%) 2 (0.5%) 2 (0.5%) 2 (0.5%) VISION BLURRED 0 (0.0%) 0 (0.0%) 1 (0.3%) 1 (0.3%) 2 (0.5%) BLINDNESS NEC 0 (0.0%) 1 (0.3%) 1 (0.3%) 2 (0.5%) HYPOTONY OF EYE 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) </td <td>UVEITIS NOS</td> <td>1 (5.6%)</td> <td>1 (0.3%)</td> <td>1 (0.5%)</td> <td>5 (1.3%)</td> <td>4 (1.0%)</td>	UVEITIS NOS	1 (5.6%)	1 (0.3%)	1 (0.5%)	5 (1.3%)	4 (1.0%)
KERATITIS NEC 0 (0.0%) 1 (0.3%) 3 (1.5%) 2 (0.5%) 3 (0.8%) CATARACT NEC 0 (0.0%) 2 (0.5%) 0 (0.0%) 2 (0.5%) 4 (1.0%) CATARACT NOS AGGRAVATED 1 (5.6%) 3 (0.8%) 0 (0.0%) 3 (0.8%) 1 (0.5%) 3 (0.8%) 1 (0.3%) DIPLOPIA 0 (0.0%) 2 (0.5%) 1 (0.5%) 2 (0.5%) 3 (0.8%) 1 (0.3%) GLAUCOMA NOS 0 (0.0%) 2 (0.5%) 1 (0.5%) 3 (0.8%) 1 (0.3%) POSTERIOR CAPSULE OPACIFICATION 0 (0.0%) 2 (0.5%) 0 (0.0%) 2 (0.5%) 2 (0.5%) 2 (0.5%) VISION BLURRED 0 (0.0%) 0 (0.0%) 1 (0.5%) 3 (0.8%) 2 (0.5%) BLINDNESS NEC 0 (0.0%) 1 (0.3%) 1 (0.5%) 1 (0.3%) 2 (0.5%) HYPOTONY OF EYE 0 (0.0%) 0 (0.0%) 1 (0.0%) 1 (0.3%) 4 (1.0%) MYDRIASIS 0 (0.0%) 1 (0.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 4 (1.0%)	VITREOUS DETACHMENT	0 (0.0%)	1 (0.3%)	1 (0.5%)	6 (1.6%)	3 (0.8%)
CATARACT NEC CATARACT NOS AGGRAVATED 1 (5.6%) 3 (0.8%) 0 (0.0%) 3 (0.8%) 1 (0.3%) DRY EYE NEC 0 (0.0%) 2 (0.5%) 1 (0.5%) 2 (0.5%) 3 (0.8%) DIPLOPIA GLAUCOMA NOS POSTERIOR CAPSULE OPACIFICATION 0 (0.0%) 2 (0.5%) 0 (0.0%) 2 (0.5%) 1 (0.5%) 2 (0.5%) 2 (0.5%) BLINDNESS NEC 0 (0.0%) 0 (0.0%) 1 (0.5%) 3 (0.8%) 2 (0.5%) BLINDNESS NEC 0 (0.0%) 1 (0.5%) 3 (0.8%) 2 (0.5%) HYPOTONY OF EYE 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.5%) 3 (0.8%) 2 (0.5%) MYDRIASIS	MACULOPATHY	0 (0.0%)	2 (0.5%)	1 (0.5%)	3 (0.8%)	4 (1.0%)
CATARACT NOS AGGRAVATED 1 (5.6%) 3 (0.8%) 0 (0.0%) 3 (0.8%) 1 (0.3%) DRY EYE NEC 0 (0.0%) 2 (0.5%) 1 (0.5%) 2 (0.5%) 3 (0.8%) DIPLOPIA 0 (0.0%) 2 (0.5%) 1 (0.5%) 3 (0.8%) 1 (0.3%) GLAUCOMA NOS 0 (0.0%) 0 (0.0%) 1 (0.5%) 0 (0.0%) 5 (1.3%) POSTERIOR CAPSULE OPACIFICATION 0 (0.0%) 2 (0.5%) 0 (0.0%) 2 (0.5%) 2 (0.5%) 2 (0.5%) 2 (0.5%) VISION BLURRED 0 (0.0%) 0 (0.0%) 1 (0.5%) 3 (0.8%) 2 (0.5%) BLINDNESS NEC 0 (0.0%) 1 (0.3%) 1 (0.3%) 2 (0.5%) HYPOTONY OF EYE 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 4 (1.0%) MYDRIASIS 0 (0.0%) 1 (0.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 4 (1.0%)	KERATITIS NEC	0 (0.0%)	1 (0.3%)	3 (1.5%)	2 (0.5%)	3 (0.8%)
DRY EYE NEC 0 (0.0%) 2 (0.5%) 1 (0.5%) 2 (0.5%) 3 (0.8%) DIPLOPIA 0 (0.0%) 2 (0.5%) 1 (0.5%) 3 (0.8%) 1 (0.3%) GLAUCOMA NOS 0 (0.0%) 0 (0.0%) 1 (0.5%) 0 (0.0%) 5 (1.3%) POSTERIOR CAPSULE OPACIFICATION 0 (0.0%) 2 (0.5%) 0 (0.0%) 2 (0.5%) 2 (0.5%) VISION BLURRED 0 (0.0%) 0 (0.0%) 1 (0.5%) 3 (0.8%) 2 (0.5%) BLINDNESS NEC 0 (0.0%) 1 (0.3%) 1 (0.5%) 1 (0.3%) 2 (0.5%) HYPOTONY OF EYE 0 (0.0%) 0 (0.0%) 1 (0.0%) 1 (0.3%) 4 (1.0%) MYDRIASIS	CATARACT NEC	0 (0.0%)	2 (0.5%)	0 (0.0%)	2 (0.5%)	4 (1.0%)
DIPLOPIA 0 (0.0%) 2 (0.5%) 1 (0.5%) 3 (0.8%) 1 (0.3%) GLAUCOMA NOS 0 (0.0%) 0 (0.0%) 1 (0.5%) 0 (0.0%) 5 (1.3%) POSTERIOR CAPSULE OPACIFICATION 0 (0.0%) 2 (0.5%) 0 (0.0%) 2 (0.5%) VISION BLURRED 0 (0.0%) 0 (0.0%) 1 (0.5%) 3 (0.8%) 2 (0.5%) BLINDNESS NEC 0 (0.0%) 1 (0.3%) 1 (0.5%) 1 (0.3%) 2 (0.5%) HYPOTONY OF EYE 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 4 (1.0%) MYDRIASIS	CATARACT NOS AGGRAVATED	1 (5.6%)	3 (0.8%)	0 (0.0%)	3 (0.8%)	1 (0.3%)
GLAUCOMA NOS 0 (0.0%) 0 (0.0%) 1 (0.5%) 0 (0.0%) 5 (1.3%) POSTERIOR CAPSULE OPACIFICATION 0 (0.0%) 2 (0.5%) 2 (0.5%) 2 (0.5%) VISION BLURRED 0 (0.0%) 0 (0.0%) 1 (0.5%) 3 (0.8%) 2 (0.5%) BLINDNESS NEC 0 (0.0%) 1 (0.3%) 1 (0.5%) 1 (0.3%) 2 (0.5%) HYPOTONY OF EYE 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 4 (1.0%) MYDRIASIS 0 (0.0%) 1 (0.3%) 0 (0.0%) 0 (0.0%) 4 (1.0%)	DRY EYE NEC	0 (0.0%)	2 (0.5%)	1 (0.5%)	2 (0.5%)	3 (0.8%)
GLAUCOMA NOS 0 (0.0%) 0 (0.0%) 1 (0.5%) 0 (0.0%) 5 (1.3%) POSTERIOR CAPSULE OPACIFICATION 0 (0.0%) 2 (0.5%) 0 (0.0%) 2 (0.5%) 2 (0.5%) VISION BLURRED 0 (0.0%) 0 (0.0%) 1 (0.5%) 3 (0.8%) 2 (0.5%) BLINDNESS NEC 0 (0.0%) 1 (0.3%) 1 (0.5%) 1 (0.3%) 2 (0.5%) HYPOTONY OF EYE 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 4 (1.0%) MYDRIASIS	DIPLOPIA	0 (0.0%)	2 (0.5%)	1 (0.5%)	3 (0.8%)	1 (0.3%)
POSTERIOR CAPSULE OPACIFICATION 0 (0.0%) 2 (0.5%) 0 (0.0%) 2 (0.5%) 2 (0.5%) 2 (0.5%) VISION BLURRED 0 (0.0%) 0 (0.0%) 1 (0.5%) 3 (0.8%) 2 (0.5%) BLINDNESS NEC 0 (0.0%) 1 (0.3%) 1 (0.5%) 1 (0.3%) 2 (0.5%) HYPOTONY OF EYE 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 4 (1.0%) MYDRIASIS 0 (0.0%) 1 (0.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 4 (1.0%)	GLAUCOMA NOS					5 (1.3%)
VISION BLURRED 0 (0.0%) 0 (0.0%) 1 (0.5%) 3 (0.8%) 2 (0.5%) BLINDNESS NEC 0 (0.0%) 1 (0.3%) 1 (0.5%) 1 (0.3%) 2 (0.5%) HYPOTONY OF EYE 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 4 (1.0%) MYDRIASIS 0 (0.0%) 1 (0.3%) 0 (0.0%) 0 (0.0%) 4 (1.0%)	POSTERIOR CAPSULE OPACIFICATION	· · ·			2 (0.5%)	2 (0.5%)
BLINDNESS NEC 0 (0.0%) 1 (0.3%) 1 (0.5%) 1 (0.3%) 2 (0.5%) HYPOTONY OF EYE 0 (0.0%) 0 (0.0%) 1 (0.3%) 4 (1.0%) MYDRIASIS 0 (0.0%) 1 (0.3%) 0 (0.0%) 0 (0.0%) 4 (1.0%)			· · · · · · · · · · · · · · · · · · ·			2 (0.5%)
HYPOTONY OF EYE 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 4 (1.0%) MYDRIASIS 0 (0.0%) 1 (0.3%) 0 (0.0%) 0 (0.0%) 4 (1.0%)		· · ·				2 (0.5%)
MYDRIASIS 0 (0.0%) 1 (0.3%) 0 (0.0%) 4 (1.0%)		·				4 (1.0%)
	PHOTOPHOBIA AGGRAVATED	0 (0.0%)	1 (0.3%)	0 (0.0%)	3 (0.8%)	1 (0.3%)

s:\dat\acs\iss2002\sas\programs\t_rae_dose 06SEP2002 17:34

Table 8
Incidence of Related Adverse Events by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Control				
System Organ Class / Preferred Term	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
CONJUNCTIVITIS NEC	0 (0.0%)	0 (0.0%)	2 (1.0%)	0 (0.0%)	2 (0.5%)
CORNEAL EPITHELIUM DEFECT	1 (5.6%)	0 (0.0%)	2 (1.0%)	1 (0.3%)	0 (0.0%)
FOREIGN BODY RETAINED IN EYE	0 (0.0%)	1 (0.3%)	2 (1.0%)	1 (0.3%)	0 (0.0%)
INTRAOCULAR PRESSURE INCREASED	0 (0.0%)	0 (0.0%)	2 (1.0%)	1 (0.3%)	1 (0.3%)
RETINAL TEAR (EXC DETACHMENT)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (1.1%)	0 (0.0%)
RETINOPATHY DIABETIC	0 (0.0%)	2 (0.5%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
VITREOUS DISORDER NOS	0 (0.0%)	1 (0.3%)	1 (0.5%)	0 (0.0%)	2 (0.5%)
CORNEAL ABRASION	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	1 (0.3%)
CORTICAL OPACITY	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	1 (0.3%)
INTRAOCULAR PRESSURE DECREASED	0 (0.0%)	1 (0.3%)	2 (1.0%)	0 (0.0%)	0 (0.0%)
IRIDOCYCLITIS	0 (0.0%)	0 (0.0%)	2 (1.0%)	1 (0.3%)	0 (0.0%)
RETINAL HEMORRHAGE	0 (0.0%)	1 (0.3%)	1 (0.5%)	1 (0.3%)	0 (0.0%)
BLEPHARITIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	0 (0.0%)
CHOROIDAL DETACHMENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
CONJUNCTIVITIS (INFECTIVE) NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
EYE DEGENERATIVE DISORDER NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	0 (0.0%)
MACULAR DEGENERATION	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	0 (0.0%)
OCULAR HYPERTENSION	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
PSEUDOPHAKIA	0 (0.0%)	~1 (0.3%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
RETINAL DISORDER NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
STRABISMUS NEC	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.3%)
VITREOUS OPACITIES	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.3%)
	- •	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
APHAKIA BLINDNESS NIGHT	0 (0.0%) 0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	- • •	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
BLINDNESS TRANSIENT	0 (0.0%)		· · · · · · · · · · · · · · · · · · ·	0 (0.0%)	1 (0.3%)
BLOODSHOT EYE	0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
CCONJUNCTIVAL EDEMA	0 (0.0%)		0 (0.0%) 1 (0.5%)	0 (0.0%)	0 (0.0%)
CHORIORETINAL ATROPHY	0 (0.0%)	0 (0.0%)		0 (0.0%)	
CHORIORETINAL DISORDER NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	- •	0 (0.0%)
COLOUR BLINDNESS NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
CONJUNCTIVITIS VIRAL NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
CORNEAL OPACITY	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
CYCLITIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
ERYTHEMA NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
EYE ALLERGY	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
EYE INFECTION TOXOPLASMAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
EYE INFLAMMATION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
EYELID DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
EYELID EDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
EYELID PTOSIS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
KERATOCONJUNCTIVITIS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
KERATOPATHY NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
LENTICULAR OPACITIES	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
MEIBOMIAN CYST	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
OCULAR HYPERAEMIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
OPEN ANGLE GLAUCOMA NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)

Table 8
Incidence of Related Adverse Events by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

System Organ Class Preferred Torm		Contr	ro]			
PAINFULRED RYES 0 (0.04) 1 (0.34) 0 (0.08) 0 (0.08) 0 (0.08) PNINGUECULA 0 (0.04) 0 (0.08) 1 (0.54) 0 (0.08) 0 (0.08) POST-OPERATIVE PAINFUL (0.54) 0 (0.08) 1 (0.08) POST-OPERATIVE PAINFUL (0.54) 0 (0.08) 1 (0.08) POST-OPERATIVE PAINFUL (0.54) 0 (0.08) 1 (0.08) POST-OPERATIVE PAINFUL (0.54) 0 (0.08) 1 (0.08) POST-OPERATIVE PAINFUL (0.54) 0 (0.08) 1 (0.08) POST-OPERATIVE PAINFUL (0.54) 0 (0.08) 1 (0.08) POST-OPERATIVE PAINFUL (0.54) 0 (0.08) 1 (0.08) POST-OPERATIVE PAINFUL (0.54) 0 (0.08) POST-OPERATIVE PAINFUL (0.54) 0 (0.08) POST-OPERATIVE PAINFUL (0.54) POST-OPERATIVE PAINFUL (0.54) POST-OPERATIVE PAINFUL (0.54) POST-OPERATIVE PAINFUL (0.08) POST-OPERATIVE PAINF	System Organ Class / Preferred Term			7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
PAINFULRED RYES 0 (0.04) 1 (0.34) 0 (0.08) 0 (0.08) 0 (0.08) PNINGUECULA 0 (0.04) 0 (0.08) 1 (0.54) 0 (0.08) 0 (0.08) POST-OPERATIVE PAINFUL (0.54) 0 (0.08) 1 (0.08) POST-OPERATIVE PAINFUL (0.54) 0 (0.08) 1 (0.08) POST-OPERATIVE PAINFUL (0.54) 0 (0.08) 1 (0.08) POST-OPERATIVE PAINFUL (0.54) 0 (0.08) 1 (0.08) POST-OPERATIVE PAINFUL (0.54) 0 (0.08) 1 (0.08) POST-OPERATIVE PAINFUL (0.54) 0 (0.08) 1 (0.08) POST-OPERATIVE PAINFUL (0.54) 0 (0.08) 1 (0.08) POST-OPERATIVE PAINFUL (0.54) 0 (0.08) POST-OPERATIVE PAINFUL (0.54) 0 (0.08) POST-OPERATIVE PAINFUL (0.54) POST-OPERATIVE PAINFUL (0.54) POST-OPERATIVE PAINFUL (0.54) POST-OPERATIVE PAINFUL (0.08) POST-OPERATIVE PAINF	OPTIC ATPODHY	0 (0 0%)	0 (0 0%)	o (o o%)	1 (0 3%)	0 (0.0%)
PINGUECULA						
POST-OPERATIVE PAIN 0 (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.0%) 0 (0.0%) 1 (0.0%) 0 (0.0%) 1 (0.0%) 0 (0.0%) 1 (0.0%) 0 (0.0%) 1 (0.0%) 0 (0.0%) 1 (0.0%) 0 (0.0						·
RETINAL DEFIGMENTATION RETINAL ISCHEMIA 0 (0.0t) 0 (0.0t) 0 (0.0t) 0 (0.0t) 0 (0.0t) 1 (0.5t) 0 (0.0t) 1 (0.3t) RETINAL MICROARGERYSMS 0 (0.0t) 0 (0.0t) 0 (0.0t) 1 (0.5t) 0 (0.0t) 1 (0.5t) RETINAL MICROARGERYSMS 0 (0.0t) 0 (0.0t) 0 (0.0t) 0 (0.0t) 0 (0.0t) 1 (0.5t) 0 (0.0t) 1 (0.3t) RETINAL VEIN TREMBOSIS 0 (0.0t) 0 (0.0t) 0 (0.0t) 0 (0.0t) 0 (0.0t) 1 (0.3t) RETINAL VEIN TREMBOSIS 0 (0.0t) 0 (0.0t) 0 (0.0t) 0 (0.0t) 0 (0.0t) 1 (0.3t) RETINAL VEIN TREMBOSIS 0 (0.0t) 0 (0.0t) 0 (0.0t) 0 (0.0t) 1 (0.3t) 0 (0.0t) 1 (0.3t) RETINAL VEIN TREMBOSIS 0 (0.0t) 0 (0.0t) 0 (0.0t) 1 (0.5t) 0 (0.0t) 1 (0.3t) 0 (0.0t) UWRITED BIRETIC 0 (0.0t) 0 (0.0t) 0 (0.0t) 1 (0.5t) 0 (0.0t) 1 (0.3t) UWRITED BIRETIC 0 (0.0t) 0 (0.0t) 0 (0.0t) 1 (0.5t) 0 (0.0t) 1 (0.3t) INVESTIGATIONS 1NYESTIGATIONS 0 (0.0t) 24 (5.3t) 15 (6.8t) 15 (4.6t) 15 (4.6t) 16 (8.1t) 15 (4.6t) 16 (4.1t) CORNEAL STAINING 0 (0.0t) 24 (5.3t) 16 (8.1t) 15 (4.6t) 15 (4.1t) CORNEAL STAINING 0 (0.0t) 10 (0.0t) 20 (5.3t) 16 (8.1t) 15 (4.6t) 16 (8.1t) 16 (4.1t) 16 (8.1t) 16 (8.1t) 16 (4.1t) 16 (8.1t) 16 (8.1t) 16 (8.1t) 16 (4.1t) 16 (8.1t) 16 (8						
RETINAL ISCHEMIA RETINAL ISCHEMIA RETINAL SCAR RETINAL SC		- ,				0 (0.0%)
RETINAL MICROANBURYSMS RETINAL SCAR 0 (0.0\$)						1 (0.3%)
RETINAL SCAR RETINAL VEIN THROMBOSIS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) TOPOGRAPHY CORNRAL ABNORWAL 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) TOPOGRAPHY CORNRAL ABNORWAL 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) VISITIS DIABETIC 0 (0.0%) 0 (0.0%) 1 (0.5%) 0 (0.0%) 1 (0.3%) VISITIS DIABETIC 0 (0.0%) 0 (0.0%) 1 (0.5%) 0 (0.0%) 1 (0.5%) VISITIS DIABETIC 0 (0.0%) 0 (0.0%) 1 (0.0%) 0 (0.0%) 1 (0.5%) VISITIS DIABETIC 0 (0.0%) 0 (0.0%) 1 (0.0%) 0 (0.0%) 1 (0.5%) VISITIS DIABETIC 0 (0.0%) 0 (0.0%) 1 (0.0%) 0 (0.0%) 1 (0.5%) VISITIS DIABETIC 0 (0.0%) 24 (6.3%) 21 (10.6%) 24 (6.4%) 20 (5.1%) CORNRAL STAINING 0 (0.0%) 24 (5.3%) 16 (8.1%) 18 (4.6%) 16 (4.1%) CORNRAL STAINING 0 (0.0%) 4 (1.1%) 5 (2.5%) 6 (1.6%) 4 (1.0%) SKIN & SUBCUTANBOUS TISSUE DISORDERS 0 (0.0%) 1 (0.0%) 1 (0.0%) 1 (5.1%) 29 (7.7%) 25 (6.4%) RETIRBAL NIC 0 (0.0%) 1 (0.0%) 6 (1.6%) 6 (3.0%) 22 (5.8%) 19 (4.9%) RETIRBAL NIC 0 (0.0%) 1 (0						0 (0.0%)
RETINAL VEIN THROMBOSIS O (0.0%) 1 (0.3%) TOPOGRAPH CORNEAL ABNORMAL O (0.0%) O (0 (0.0%)	0 (0.0%)	1 (0.3%)
TOPOGRAPHY CORNEAL ANNORMAL UPON TO A COUNTY OF COUNTY O					0 (0.0%)	1 (0.3%)
UVEITIS DIABETIC VISUAL DISTURBANCE NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%)				0 (0.0%)	1 (0.3%)	0 (0.0%)
VISUAL DISTURBANCE NOS O (0.0%) O (0.0%) O (0.0%) D		- , ,		1 (0.5%)	0 (0.0%)	0 (0.0%)
NETRACCULAR PRESSURE INCREASED 0 (0.0\$) 20 (5.3\$) 16 (8.1\$) 18 (4.8\$) 16 (4.1\$)		•				
CORNEAL STAINING O (0.0\$) 4 (1.1\$) 5 (2.5\$) 6 (1.6\$) 4 (1.0\$) SKIN & SUBCUTANEOUS TISSUE DISORDERS EYELID EDEMA O (0.0\$) 15 (4.0\$) 10 (5.1\$) 29 (7.7\$) 25 (6.4\$) EYELID EDEMA O (0.0\$) 6 (1.6\$) 6 (3.0\$) 22 (5.8\$) 19 (4.9\$) ERYTHEMA NEC O (0.0\$) 9 (2.4\$) 3 (1.5\$) 14 (3.7\$) 12 (3.1\$) CUTIS LAYA O (0.0\$) 0 (0.0\$) 0 (0.0\$) 1 (0.5\$) 0 (0.0\$) 14 (3.7\$) 12 (3.1\$) CUTIS LAYA O (0.0\$) 0 (0.0\$) 0 (0.0\$) 1 (0.5\$) 0 (0.0\$) 1 (0.5\$) 0 (0.0\$) 1 (0.3\$) FACE EDEMA O (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 1 (0.0\$) 1 (0.3\$) FACE EDEMA O (0.0\$) 1 (0.3\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 1 (0.3\$) FERTOREITAL EDEMA O (0.0\$) 1 (0.3\$) 0 (0.0\$) 0 (0.0\$) 1 (0.3\$) FERTOREITAL EDEMA O (0.0\$) 0 (0.0\$) 0 (0.0\$) 1 (0.3\$) 0 (0.0\$) 0 (0.0\$) NERVOUS SYSTEM DISORDERS O (0.0\$) 4 (1.1\$) 4 (2.0\$) 7 (1.9\$) 14 (3.6\$) HEADACHE NOS DEPTILLARY DISORDER NOS O (0.0\$) 0 (0.0\$) 1 (0.5\$) 0 (0.0\$) 0 (0.0\$) VEUTIVILARY DISORDER NOS O (0.0\$) 0 (0.0\$) 1 (0.5\$) 2 (0.5\$) 1 (0.5\$) 2 (0.5\$) 3 (0.8\$) VISUAL FIELD DEFPCT NOS O (0.0\$) 0 (0.0\$) 1 (0.5\$) 2 (0.5\$) 1 (0.5\$) 2 (0.5\$) 1 (0.3\$) SYNCOPE SYNCOPE SURGICAL AND MEDICAL PROCEDURES O (0.0\$) 1 (0.3\$) 0 (0.0\$) 1 (0.3\$) 1 (0.3\$) EXERCITION OF PROCEDURES O (0.0\$) 1 (0.3\$) 1 (0.3\$) 3 (0.0\$) 1 (0.3\$) EXERCITION OF PROCEDURES O (0.0\$) 1 (0.3\$) 1 (0.3\$) 2 (1.0\$) 3 (0.0\$) 1 (0.3\$) FOST-OPERATIVE COMPLICATIONS NOS O (0.0\$) 0 (0.0\$) 0 (0.0\$) 1 (0.3\$) 1 (0.3\$) FOST-OPERATIVE HEMORRHAGE O (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 1 (0.3\$) FOST-OPERATIVE HEMORRHAGE O (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 1 (0.3\$) FOST-OPERATIVE HEMORRHAGE O (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 1 (0.3\$) FOST-OPERATIVE HEMORRHAGE O (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 1 (0.3\$) FOST-OPERATIVE HEMORRHAGE O (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 1 (0.3\$) FOST-OPERATIVE HEMORRHAGE O (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 1 (0.3\$) FOST-OPERATIVE HEMORRHAGE O (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 1 (0.3\$)	INVESTIGATIONS	0 (0.0%)	24 (6.3%)	21 (10.6%)	24 (6.4%)	20 (5.1%)
SKIN & SUBCUTANEOUS TISSUE DISORDERS EYELID EDEMA O (0.0\$) 15 (4.0\$) 10 (5.1\$) 29 (7.7\$) 25 (6.4\$) EYELID EDEMA O (0.0\$) 9 (2.4\$) 3 (1.5\$) 14 (3.7\$) 12 (3.1\$) CUTIS LAXA O (0.0\$) 0 (0.0\$) 9 (2.4\$) 3 (1.5\$) 14 (3.7\$) 12 (3.1\$) CUTIS LAXA O (0.0\$) 0 (0.0\$) 1 (0.5\$) 0 (0.0\$) 0 (0.0\$) ECCHYMOSIS O (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 1 (0.3\$) ECCHYMOSIS O (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 1 (0.3\$) ECCHYMOSIS O (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 1 (0.3\$) OCULAR HYPEREMIA O (0.0\$) 1 (0.0\$) 0 (0.0\$) 0 (0.0\$) 1 (0.3\$) OCULAR HYPEREMIA O (0.0\$) 1 (0.0\$) 0 (0.0\$) 0 (0.0\$) 1 (0.3\$) SWEATING INCREASED O (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) SWEATING INCREASED O (0.0\$) 0 (0.0\$) 1 (0.5\$) 0 (0.0\$) NERVOUS SYSTEM DISORDERS O (0.0\$) 4 4 (1.1\$) 4 (2.0\$) 7 (1.9\$) 14 (3.6\$) HEADACKE NOS O (0.0\$) 2 (0.5\$) 1 (0.5\$) 5 (1.3\$) 8 (2.0\$) VISUAL FIELD DEFECT NOS O (0.0\$) 1 (0.3\$) 1 (0.5\$) 2 (0.5\$) 3 (0.8\$) VISUAL FIELD DEFECT NOS O (0.0\$) 1 (0.3\$) 1 (0.3\$) 1 (0.5\$) 2 (0.5\$) 3 (0.8\$) IINSOMIA NEC O (0.0\$) 1 (0.3\$) 1 (0.3\$) 1 (0.3\$) 1 (0.3\$) SINCOPE SURGICAL AND MEDICAL PROCEDURES UNSPECIFIED COMPLICATION OF PROCEDURE O (0.0\$) 1 (0.3\$) 2 (1.0\$) 5 (1.3\$) 4 (1.0\$) SURGICAL AND MEDICAL PROCEDURES UNSPECIFIED COMPLICATION OF PROCEDURE NEC O (0.0\$) 1 (0.3\$) 2 (1.0\$) 2 (1.0\$) 3 (0.0\$) 0 (0.0\$) EVER INSTANTIANE O (0.0\$) 1 (0.3\$) 2 (1.0\$) 0 (0.0\$) 1 (0.3\$) 0 (0.0\$) EVER INSTANTIANE O (0.0\$) 1 (0.3\$) 2 (1.0\$) 0 (0.0\$) 1 (0.3\$) 0 (0.0\$) SURGICAL AND MEDICAL PROCEDURES UNSPECIFIED COMPLICATION OF PROCEDURE NEC O (0.0\$) 1 (0.3\$) 2 (1.0\$) 0 (0.0\$) 1 (0.3\$) 0 (0.0\$) EVER INSTANTIANE O (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 1 (0.3\$) 0 (0.0\$) 0 (0.0\$) EVER INSTANTIANE SURGICAL AND MEDICAL PROCEDURES O (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) EVER INSTANTIANE O (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$)	INTRAOCULAR PRESSURE INCREASED	0 (0.0%)	20 (5.3%)	16 (8.1%)	18 (4.8%)	16 (4.1%)
EVELID EDEMA ERYTHEMA NEC O (0.0%) 6 (1.6%) 6 (3.0%) 22 (5.8%) 19 (4.9%) CUTIS LAXA O (0.0%) 9 (2.4%) 3 (1.5%) 14 (3.7%) 12 (3.1%) CUTIS LAXA O (0.0%) 0 (0.0%) 1 (0.5%) 0 (0.0%) 1 (0.5%) 0 (0.0%) 1 (0.3%) ECCHYMOSIS O (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) ECCHYMOSIS O (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) CUTIS LAXA O (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) CUTIS LAXA O (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) CUTIS LAXA O (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) CUTIS LAXA O (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) CUTIS LAXA O (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) CUTIS LAXA O (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) CUTIS LAXA O (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) CUTIS LAXA O (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) CUTIS LAXA O (0.0%) 0 (CORNEAL STAINING		4 (1.1%)	5 (2.5%)	6 (1.6%)	4 (1.0%)
ERYTHEMA NBC CUTIS LAXA O (0.0\$) 9 (2.4\$) 3 (1.5\$) 14 (3.7\$) 12 (3.1\$) ECCHTMOSIS O (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) ECCHTMOSIS O (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 1 (0.3\$) FACE EDEMA O (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 1 (0.3\$) PERIORBITAL EDEMA O (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) EPRIORBITAL EDEMA O (0.0\$) 0 (0.0\$) 0 (0.0\$) 1 (0.3\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) ERRYCUSS SYSTEM DISORDERS O (0.0\$) 0 (0.0\$) 1 (0.5\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) ERRYCUSS SYSTEM DISORDERS O (0.0\$) 2 (0.5\$) 1 (0.5\$) 5 (1.3\$) 8 (2.0\$) FUTILLARY DISORDER NOS O (0.0\$) 0 (0.0\$) 1 (0.5\$) 5 (1.3\$) 8 (2.0\$) EVISIBLE FIELD DEFECT NOS O (0.0\$) 0 (0.0\$) 1 (0.5\$) 0 (0.0\$) 1 (0.3\$) INSONNIA NEC O (0.0\$) 0 (0.0\$) 1 (0.5\$) 0 (0.0\$) 1 (0.3\$) INSONNIA NEC O (0.0\$) 0 (0.0\$) 1 (0.3\$) 1 (0.5\$) 0 (0.0\$) 1 (0.3\$) EVISIBLE FIELD DEFECT NOS O (0.0\$) 0 (0.0\$) 1 (0.3\$) 1 (0.5\$) 0 (0.0\$) 1 (0.3\$) EVISIBLE FIELD DEFECT NOS O (0.0\$) 0 (0.0\$) 0 (0.0\$) 0 (0.0\$) 1 (0.3\$) 1 (0.3\$) EVISIBLE FIELD DEFECT NOS O (0.0\$) 0 (0.0\$) 1 (0.3\$) 1 (0.5\$) 0 (0.0\$) 1 (0.3\$) EVISIBLE FIELD DEFECT NOS O (0.0\$) 1 (0.3\$) 1 (0.5\$) 0 (0.0\$) 1 (0.3\$) EVISIBLE FIELD DEFECT NOS O (0.0\$) 1 (0.0\$) 0 (0.0\$) 1 (0.3\$) 1 (0.3\$) EVISIBLE FIELD DEFECT NOS O (0.0\$) 1 (0.0\$) 1 (0.3\$) 1 (0.3\$) 1 (0.3\$) EVISIBLE FIELD STANLEY OR	SKIN & SUBCUTANEOUS TISSUE DISORDERS	0 (0.0%)	15 (4.0%)	10 (5.1%)	29 (7.7%)	25 (6.4%)
CUTIS LAXA CUTIS LAXA CUTIS LAXA CUTIS LAXA CUCHYMOSIS CUCHYM	EYELID EDEMA	0 (0.0%)	6 (1.6%)	6 (3.0%)	22 (5.8%)	19 (4.9%)
ECCHYMOSIS FACE EDEMA O(0.0\$) O(0.0\$) O(0.0\$) O(0.0\$) O(0.0\$) FACE EDEMA O(0.0\$) PERIORBITAL EDEMA O(0.0\$) O(0	ERYTHEMA NEC	0 (0.0%)	9 (2.4%)	3 (1.5%)	14 (3.7%)	12 (3.1%)
FACE EDEMA OCULAR HYPEREMIA O(0.0%) O(CUTIS LAXA	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
OCULAR HYPEREMIA OCULAR HYPERIA HYPER	ECCHYMOSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
PERIORBITAL EDEMA SWEATING INCREASED 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) SWEATING INCREASED 0 (0.0%) 0 (0.0%) 1 (0.5%) 0 (0.0%) 0 (0.0%) NERVOUS SYSTEM DISORDERS 0 (0.0%) 4 (1.1%) 4 (2.0%) 7 (1.9%) 14 (3.6%) HEADACHE NOS 0 (0.0%) 2 (0.5%) 1 (0.5%) 5 (1.3%) 8 (2.0%) PUPILLARY DISORDER NOS 0 (0.0%) 0 (0.0%) 1 (0.5%) 2 (0.5%) 3 (0.8%) VISUAL FIELD DEFECT NOS 0 (0.0%) 0 (0.0%) 1 (0.3%) 1 (0.5%) 2 (0.5%) 3 (0.8%) VISUAL FIELD DEFECT NOS 0 (0.0%) 1 (0.3%) 1 (0.5%) 0 (0.0%) 1 (0.3%) INSOMNIA NEC 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 1 (0.3%) INTEM NERVE PARALYSIS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) PUPILLARY REPLEX IMPAIRED 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) SYNCOPE SURGICAL AND MEDICAL PROCEDURES 0 (0.0%) 1 (0.3%) 2 (1.0%) 3 (0.8%) 2 (0.5%) EYE IRRITATION 0 (0.0%) 1 (0.3%) 2 (1.0%) 3 (0.8%) 2 (0.5%) EYE IRRITATION 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) FOST-OPERATIVE COMPLICATION NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) GASTROINTESTINAL DISORDERS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) GASTROINTESTINAL DISORDERS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%)	FACE EDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
NERVOUS SYSTEM DISORDERS 0 (0.0%) 0 (0.0%) 1 (0.5%) 0 (0.0%) 0 (0	OCULAR HYPEREMIA	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
NERVOUS SYSTEM DISORDERS 0 (0.0%) 4 (1.1%) 4 (2.0%) 7 (1.9%) 14 (3.6%) HEADACHE NOS 0 (0.0%) 2 (0.5%) 1 (0.5%) 5 (1.3%) 8 (2.0%) PUPILLARY DISORDER NOS 0 (0.0%) 0 (0.0%) 1 (0.5%) 2 (0.5%) 3 (0.8%) VISUAL FIELD DEFFECT NOS 0 (0.0%) 1 (0.3%) 1 (0.5%) 0 (0.0%) 1 (0.3%) IINGONNIA NEC 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 1 (0.3%) IIIRD NERVE PARALYSIS 0 (0.0%) 1 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) PUPILLARY REFLEX IMPAIRED 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) SYNCOPE SURGICAL AND MEDICAL PROCEDURES 0 (0.0%) 1 (0.3%) 4 (2.0%) 5 (1.3%) 4 (1.0%) UNSPECIFIED COMPLICATION OF PROCEDURE NEC 0 (0.0%) 1 (0.3%) 2 (1.0%) 3 (0.8%) 2 (0.5%) EYE IRRITATION 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) POST-OPERATIVE COMPLICATIONS NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) SCLERAL OPERATIVE HEMORRHAGE 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) GASTROINTESTINAL DISORDERS 0 (0.0%) 2 (0.5%) 2 (1.0%) 0 (0.0%) 1 (0.3%)	PERIORBITAL EDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
HEADACHE NOS PUPILLARY DISORDER NOS O (0.0%) 2 (0.5%) 1 (0.5%) 5 (1.3%) 8 (2.0%) PUPILLARY DISORDER NOS O (0.0%) 0 (0.0%) 1 (0.5%) 2 (0.5%) 3 (0.8%) VISUAL FIELD DEFECT NOS O (0.0%) 1 (0.3%) 1 (0.5%) 0 (0.0%) 1 (0.3%) INSOMNIA NEC O (0.0%) 0 (0.0%) 1 (0.3%) 1 (0.3%) IIIRD NERVE PARALYSIS O (0.0%) 1 (0.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) PUPILLARY REFLEX IMPAIRED O (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) SYNCOPE SURGICAL AND MEDICAL PROCEDURES O (0.0%) 1 (0.3%) 2 (1.0%) 3 (0.8%) 2 (0.5%) VITRECTOMY O (0.0%) 1 (0.3%) 2 (1.0%) 3 (0.8%) 2 (0.5%) EYE IRRITATION D (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) POST-OPERATIVE COMPLICATIONS NOS O (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) POST-OPERATIVE HEMORRHAGE O (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) SCLERAL OPERATION NOS O (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) GASTROINTESTINAL DISORDERS O (0.0%) 2 (0.5%) 2 (1.0%) 2 (0.5%) 2 (0.5%)	SWEATING INCREASED	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
PUPILLARY DISORDER NOS 0 (0.0%) 0 (0.0%) 1 (0.5%) 2 (0.5%) 3 (0.8%) VISUAL FIELD DEFECT NOS 0 (0.0%) 1 (0.3%) 1 (0.5%) 0 (0.0%) 1 (0.3%) INSOMNIA NEC 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 1 (0.3%) ITIRD NERVE PARALYSIS 0 (0.0%) 1 (0.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) PUPILLARY REFLEX IMPAIRED 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) SYNCOPE SURGICAL AND MEDICAL PROCEDURES 0 (0.0%) 1 (0.3%) 4 (2.0%) 5 (1.3%) 4 (1.0%) UNSPECIFIED COMPLICATION OF PROCEDURE NEC 0 (0.0%) 1 (0.3%) 2 (1.0%) 3 (0.8%) 2 (0.5%) VITRECTOMY EYE IRRITATION 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) EYEI IRRITATION NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) POST-OPERATIVE COMPLICATIONS NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) POST-OPERATIVE HEMORRHAGE 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) SCLERAL OPERATION NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) SCLERAL OPERATION NOS 0 (0.0%) 2 (0.5%) 2 (1.0%) 2 (0.5%) 2 (0.5%)	NERVOUS SYSTEM DISORDERS	0 (0.0%)	4 (1.1%)	4 (2.0%)	7 (1.9%)	14 (3.6%)
VISUAL FIELD DEFECT NOS 0 (0.0%) 1 (0.3%) 1 (0.5%) 0 (0.0%) 1 (0.3%) INSOMNIA NEC 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 1 (0.3%) IIIRD NERVE PARALYSIS 0 (0.0%) 1 (0.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) PUPILLARY REFLEX IMPAIRED 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) SYNCOPE SURGICAL AND MEDICAL PROCEDURES 0 (0.0%) 1 (0.3%) 4 (2.0%) 5 (1.3%) 4 (1.0%) UNSPECIFIED COMPLICATION OF PROCEDURE NEC 0 (0.0%) 1 (0.3%) 2 (1.0%) 3 (0.8%) 2 (0.5%) EYE IRRITATION 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) EYE IRRITATION 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) POST-OPERATIVE COMPLICATIONS NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) POST-OPERATIVE HEMORRHAGE 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) SCLERAL OPERATION NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) GASTROINTESTINAL DISORDERS 0 (0.0%) 2 (0.5%) 2 (1.0%) 2 (0.5%) 2 (0.5%)	HEADACHE NOS	0 (0.0%)	2 (0.5%)	1 (0.5%)	5 (1.3%)	8 (2.0%)
INSOMNIA NEC IITRD NERVE PARALYSIS O (0.0%) O (0.0%) O (0.0%) O (0.0%) I (0.3%) I (0.3%) I (0.3%) O (0.0%) PUPILLARY REFLEX IMPAIRED O (0.0%) SURGICAL AND MEDICAL PROCEDURES O (0.0%) UNSPECIFIED COMPLICATION OF PROCEDURE NEC O (0.0%) UNSPECIFIED COMPLICATION OF PROCEDURE NEC O (0.0%) POST-OPERATIVE COMPLICATIONS NOS O (0.0%) O (0.	PUPILLARY DISORDER NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	2 (0.5%)	3 (0.8%)
IIIRD NERVE PARALYSIS 0 (0.0%) 1 (0.3%) 0 (0.0%	VISUAL FIELD DEFECT NOS	0 (0.0%)	1 (0.3%)	1 (0.5%)	0 (0.0%)	1 (0.3%)
PUPILLARY REFLEX IMPAIRED 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) SYNCOPE 0 (0.0%) 0 (0.0%) 1 (0.5%) 0 (0.0%) <td>INSOMNIA NEC</td> <td>0 (0.0%)</td> <td>0 (0.0%)</td> <td>0 (0.0%)</td> <td>1 (0.3%)</td> <td>1 (0.3%)</td>	INSOMNIA NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
SYNCOPE SURGICAL AND MEDICAL PROCEDURES O (0.0%) O (0.0%) 1 (0.5%) O (0.0%) 1 (0.5%) O (0.0%) 5 (1.3%) 4 (1.0%) UNSPECIFIED COMPLICATION OF PROCEDURE NEC O (0.0%) O (IIIRD NERVE PARALYSIS		1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
SURGICAL AND MEDICAL PROCEDURES 0 (0.0%) 1 (0.3%) 4 (2.0%) 5 (1.3%) 4 (1.0%) UNSPECIFIED COMPLICATION OF PROCEDURE NEC 0 (0.0%) 1 (0.3%) 2 (1.0%) 3 (0.8%) 2 (0.5%) VITRECTOMY 0 (0.0%) 0 (0.0%) 2 (1.0%) 0 (0.0%) 0 (0.0%) EYE IRRITATION 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) POST-OPERATIVE COMPLICATIONS NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) POST-OPERATIVE HEMORRHAGE 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) SCLERAL OPERATION NOS 0 (0.0%) 0 (0.0%	PUPILLARY REFLEX IMPAIRED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
UNSPECIFIED COMPLICATION OF PROCEDURE NEC 0 (0.0%) 1 (0.3%) 2 (1.0%) 3 (0.8%) 2 (0.5%) VITRECTOMY 0 (0.0%) 0 (0.0%) 2 (1.0%) 0 (0.0%) 0 (0.0%) EYE IRRITATION 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) POST-OPERATIVE COMPLICATIONS NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) POST-OPERATIVE HEMORRHAGE 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) SCLERAL OPERATION NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) CASTROINTESTINAL DISORDERS 0 (0.0%) 2 (0.5%) 2 (0.5%) 2 (0.5%)	SYNCOPE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
VITRECTOMY 0 (0.0%) 0 (0.0%) 2 (1.0%) 0 (0.0%) 0 (0.0%) EYE IRRITATION 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) POST-OPERATIVE COMPLICATIONS NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) POST-OPERATIVE HEMORRHAGE 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) SCLERAL OPERATION NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (0.5%) 2 (0.5%) 2 (0.5%) 2 (0.5%) 2 (0.5%) 2 (0.5%)	SURGICAL AND MEDICAL PROCEDURES	0 (0.0%)	1 (0.3%)	4 (2.0%)	5 (1.3%)	4 (1.0%)
EYE IRRITATION 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) POST-OPERATIVE COMPLICATIONS NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) POST-OPERATIVE HEMORRHAGE 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 2 (0.5%) </td <td>UNSPECIFIED COMPLICATION OF PROCEDURE NEC</td> <td>0 (0.0%)</td> <td>1 (0.3%)</td> <td>2 (1.0%)</td> <td>3 (0.8%)</td> <td>2 (0.5%)</td>	UNSPECIFIED COMPLICATION OF PROCEDURE NEC	0 (0.0%)	1 (0.3%)	2 (1.0%)	3 (0.8%)	2 (0.5%)
POST-OPERATIVE COMPLICATIONS NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) POST-OPERATIVE HEMORRHAGE 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 0 (0.0%) <td>VITRECTOMY</td> <td>0 (0.0%)</td> <td>0 (0.0%)</td> <td>2 (1.0%)</td> <td>0 (0.0%)</td> <td>0 (0.0%)</td>	VITRECTOMY	0 (0.0%)	0 (0.0%)	2 (1.0%)	0 (0.0%)	0 (0.0%)
POST-OPERATIVE HEMORRHAGE 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) SCLERAL OPERATION NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) GASTROINTESTINAL DISORDERS 0 (0.0%) 2 (0.5%) 2 (0.5%) 2 (0.5%) 2 (0.5%)	EYE IRRITATION	0 (0.0%)				- ,,
SCLERAL OPERATION NOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) GASTROINTESTINAL DISORDERS 0 (0.0%) 2 (0.5%) 2 (0.5%) 2 (0.5%) 2 (0.5%) 2 (0.5%)	POST-OPERATIVE COMPLICATIONS NOS	0 (0.0%)				
GASTROINTESTINAL DISORDERS 0 (0.0%) 2 (0.5%) 2 (0.5%) 2 (0.5%)	POST-OPERATIVE HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
	SCLERAL OPERATION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
NAUSEA 0 (0.0%) 1 (0.3%) 1 (0.5%) 0 (0.0%) 1 (0.3%)	GASTROINTESTINAL DISORDERS					
	NAUSEA	0 (0.0%)	1 (0.3%)	1 (0.5%)	0 (0.0%)	1 (0.3%)

Table 8
Incidence of Related Adverse Events by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Contr	ol			
System Organ Class / Preferred Term	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
VOMITING NOS	0 (0.0%)	1 (0.3%)	1 (0.5%)	1 (0.3%)	0 (0.0%)
CONSTIPATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
DIARRHEA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
CARDIAC DISORDERS ANGINA PECTORIS CARDIAC FAILURE CONGESTIVE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
INFECTIONS AND INFESTATIONS HYPOPYON PNEUMONIA NOS	0 (0.0%)	1 (0.3%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
INJURY AND POISONING DRUG TOXICITY NOS HEAD INJURY	0 (0.0%)	2 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PSYCHIATRIC DISORDERS ANXIETY NEC DEPRESSION NEC	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.3%)
	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
VASCULAR DISORDERS HYPERTENSION NOS PERIPHERAL ISCHEMIA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)
	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
BLOOD AND LYMPHATIC SYSTEM DISORDERS ANEMIA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITION THIRST	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS PAIN IN FACE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
METABOLISM AND NUTRITION DISORDERS HYPERCHOLESTEROLEMIA	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
RENAL AND URINARY DISORDERS RENAL FAILURE CHRONIC	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Table 9
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

		Control								
System Organ Class / Preferred Term	W	w 	Sa	line	7.5 IU V	Vitrase	55 IU	Vitrase	75 IU	Vitrase
NUMBER OF PATIENTS		18	;	378	1:	98		377		391
NUMBER OF PATIENTS WITH AT LEAST ONE ADVERSE EVENT	17 (94.4%)	298	(78.8%)	193 (97.5%)	323	(85.7%)	349	(89.3%)
EYE DISORDERS		94.4%)	-	(78.6%)		97.0%)		(85.4%)		(89.3%)
IRITIS		22.2%)		(33.3%)		62.1%)		(58.9%)		(62.1%)
OCULAR HYPEREMIA	-	22.2%)		(37.0%)		57.1%)		(53.6%)		(55.0%)
EYE IRRITATION		55.6%)		(29.4%)		45.5%)		(35.0%)		(35.5%)
EYE PAIN		11.1%)		(22.2%)		36.4%)		(36.9%)		(41.2%)
LACRIMATION INCREASED	4 (22.2%)	87	(23.0%)	65 (32.8%)	124	(32.9%)		(35.5%)
VISUAL ACUITY REDUCED	4 (22.2%)	74	(19.6%)	77 (:	38.9%)	101	(26.8%)		(25.1%)
ABNORMAL SENSATION IN EYE	2 (11.1%)	68	(18.0%)	62 (31.3%)	101	(26.8%)		(29.2%)
VITREOUS FLOATERS	6 (33.3%)	67	(17.7%)	63 (31.8%)		(23.3%)	100	(25.6%)
VITREOUS HEMORRHAGE	2 (11.1%)	66	(17.5%)		35.4%)		(24.1%)	90	(23.0%)
PHOTOPHOBIA	6 (33.3%)	60	(15.9%)	59 (:	29.8%)	86	(22.8%)		(26.1%)
CONJUNCTIVAL EDEMA	1 (5.6%)	59	(15.6%)	48 (24.2%)		(25.5%)	89	(22.8%)
CATARACT NUCLEAR	5 (27.8%)	34	(9.0%)	27 (13.6%)	37	(9.8%)	29	(7.4%)
RETINAL DETACHMENT	3 (16.7%)	26	(6.9%)	22 (11.1%)	35	(9.3%)	45	(11.5%
CATARACT SUBCAPSULAR	2 (11.1%)	26	(6.9%)	33 (16.7%)	29	(7.7%)	38	(9.7%
PHOTOPSIA	0 (0.0%)	22	(5.8%)	22 (11.1%)	45	(11.9%)	38	(9.7%
CATARACT CORTICAL	5 (27.8%)	27	(7.1%)	14 (7.1%)	30	(8.0%)	31	(7.9%
CORNEAL EROSION	1 (5.6%)	24	(6.3%)	10 (5.1%)	25	(6.6%)	17	(4.3%
CORNEAL EDEMA	1 (5.6%)	12	(3.2%)	17 (8.6%)	20	(5.3%)	24	(6.1%
RUBEOSIS IRIDIS	1 (5.6%)	19	(5.0%)	16 (8.1%)	17	(4.5%)	19	(4.9%
EYE DISCHARGE	0 (0.0%)	18	(4.8%)	10 (5.1%)	23	(6.1%)	20	(5.1%
CONJUNCTIVAL HEMORRHAGE	0 (0.0%)	25	(6.6%)	11 (5.6%)	14	(3.7%)	18	(4.6%
IRIS ADHESIONS	2 (11.1%)	13	(3.4%)	9 (4.5%)	13	(3.4%)	27	(6.9%
MACULAR EDEMA	1 (5.6%)	11	(2.9%)	16 (8.1%)	11	(2.9%)	19	(4.9%
CORNEAL DISORDER NOS	0 (0.0%)	8	(2.1%)	6 (3.0%)	17	(4.5%)	25	(6.4%
НҮРНЕМА	0 (0.0%)	6	(1.6%)	8 (4.0%)	12	(3.2%)	15	(3.8%
CATARACT NEC	0 (0.0%)	10	(2.6%)	1 (0.5%)	10	(2.7%)	9	(2.3%
BLINDNESS NEC	1 (5.6%)	4	(1.1%)	9 (4.5%)	6	(1.6%)	9	(2.3%
HYPOPYON	0 (0.0%)	0	(0.0%)	1 (0.5%)	6	(1.6%)	21	(5.4%
DRY EYE NEC		0.0%)	6	(1.6%)	7 (3.5%)	5	(1.3%)	9	(2.3%
GLAUCOMA NOS	0 ((0.0%)	5	(1.3%)	5 (2.5%)	3	(0.8%)	12	(3.1%
VISION BLURRED		0.0%)	5	(1.3%)	10 (5.1%)	5	(1.3%)	4	(1.0%
CATARACT NOS AGGRAVATED	1 (5.6%)	8	(2.1%)	4 (2.0%)	5	(1.3%)	3	(0.8%
KERATITIS NEC		0.0%)		(1.1%)	4 (2.0%)		(1.1%)	8	(2.0%
VITREOUS DETACHMENT		5.6%)	2	(0.5%)	3 (1.5%)	9	(2.4%)	5	(1.3%
MACULOPATHY		(0.0%)		(1.3%)	4 (2.0%)	5	(1.3%)	5	(1.3%
INTRAOCULAR PRESSURE INCREASED		(0.0%)		(0.8%)		3.0%)		(0.8%)	6	(1.5%
UVEITIS NOS		(5.6%)		(0.5%)		1.0%)		(1.9%)		(1.0%
POST-OPERATIVE PAIN		5.6%)		(1.9%)		0.0%)		(0.5%)	5	(1.3%
POSTERIOR CAPSULE OPACIFICATION		0.0%)		(0.8%)	1 ((1.6%)		(1.3%
RETINOPATHY DIABETIC		0.0%)		(1.1%)		0.5%)		(0.8%)		(1.5%
BLEPHARITIS		0.0%)		(0.3%)		1.5%)		(0.8%)		(1.3%

Table 9
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Contr	ol			
stem Organ Class / Preferred Term		Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitras
HYPOTONY OF EYE	0 (0.0%)	2 (0.5%)	2 (1.0%)	2 (0.5%)	6 (1.5
RETINAL HEMORRHAGE	0 (0.0%)	5 (1.3%)	2 (1.0%)	5 (1.3%)	0 (0.0
CORNEAL EPITHELIUM DEFECT	1 (5.6%)	1 (0.3%)	3 (1.5%)	4 (1.1%)	2 (0.5
DIPLOPIA	0 (0.0%)	2 (0.5%)	3 (1.5%)	4 (1.1%)	2 (0.5
RETINAL ISCHEMIA	0 (0.0%)	1 (0.3%)	3 (1.5%)	4 (1.1%)	2 (0.5
CONJUNCTIVITIS NEC	0 (0.0%)	2 (0.5%)	3 (1.5%)	1 (0.3%)	2 (0.5
CORNEAL ABRASION	0 (0.0%)	1 (0.3%)	2 (1.0%)	3 (0.8%)	2 (0.5
MYDRIASIS	0 (0.0%)	3 (0.8%)	1 (0.5%)	0 (0.0%)	4 (1.0
RETINAL TEAR (EXC DETACHMENT)	0 (0.0%)	1 (0.3%)	0 (0.0%)	5 (1.3%)	2 (0.5
FOREIGN BODY RETAINED IN EYE	0 (0.0%)	1 (0.3%)	4 (2.0%)	2 (0.5%)	0 (0.0
EYE DEGENERATIVE DISORDER NOS	0 (0.0%)	0 (0.0%)	3 (1.5%)	2 (0.5%)	1 (0.3
PSEUDOPHAKIA	0 (0.0%)	3 (0.8%)	0 (0.0%)	3 (0.8%)	0 (0.0
EYELID PTOSIS	0 (0.0%)	1 (0.3%)	3 (1.5%)	0 (0.0%)	1 (0.3
INTRAOCULAR PRESSURE DECREASED	0 (0.0%)	3 (0.8%)	2 (1.0%)	0 (0.0%)	0 (0.0
OPTIC ATROPHY	0 (0.0%)	1 (0.3%)	1 (0.5%)	3 (0.8%)	0 (0.0
PHOTOPHOBIA AGGRAVATED	0 (0.0%)	1 (0.3%)	0 (0.0%)	3 (0.8%)	1 (0.3
VITREOUS DISORDER NOS	0 (0.0%)	2 (0.5%)	1 (0.5%)	0 (0.0%)	2 (0.5
APHAKIA	0 (0.0%)	2 (0.5%)	1 (0.5%)	0 (0.0%)	1 (0.3
EYE ALLERGY	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.8%)	1 (0.3
KERATOCONJUNCTIVITIS	0 (0.0%)	1 (0.3%)	1 (0.5%)	1 (0.3%)	1 (0.
OCULAR HYPERTENSION ,	0 (0.0%)	1 (0.3%)	0 (0.0%)	2 (0.5%)	1 (0.3
PAINFUL RED EYES	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	2 (0.
CHEMOSIS	0 (0.0%)	1 (0.3%)	1 (0.5%)	0 (0.0%)	1 (0.
CORTICAL OPACITY	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	1 (0.
IRIDOCYCLITIS	0 (0.0%)	0 (0.0%)	2 (1.0%)	1 (0.3%)	0 (0.
LENTICULAR OPACITIES	0 (0.0%)	2 (0.5%)	0 (0.0%)	0 (0.0%)	1 (0.
MACULAR DEGENERATION	0 (0.0%)	0 (0.0%)	2 (1.0%)	1 (0.3%)	0 (0.
OPEN ANGLE GLAUCOMA NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	1 (0.3
RETINAL DISORDER NOS	0 (0.0%)	1 (0.3%)	1 (0.5%)	0 (0.0%)	1 (0.
RETINAL MICROANEURYSMS	0 (0.0%)	1 (0.3%)	1 (0.5%)	1 (0.3%)	0 (0.
RETINAL SCAR	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	1 (0.
BLINDNESS TRANSIENT	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	0 (0.
CHOROIDAL DETACHMENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.
CONJUNCTIVITIS (INFECTIVE) NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.
CONJUNCTIVITIS ALLERGIC	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.
CONJUNCTIVITIS VIRAL NOS	1 (5.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
CORNEAL OPACITY	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	0 (0.
KERATOPATHY BAND	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.
KERATOPATHY NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	0 (0.0
MEIBOMIAN CYST	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.
PERIORBITAL HEMATOMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	0 (0.0
RETINAL ARTERY EMBOLISM	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.
RETINAL DEPIGMENTATION	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	0 (0.
STRABISMUS NEC	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.3
VISUAL ACUITY REDUCED TRANSIENTLY	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3
VITREOUS OPACITIES	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.3

s:\dat\acs\iss2002\sas\programs\t_ocae_dose 06SEP2002 17:34

Table 9
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Contro	ol			
System Organ Class / Preferred Term		Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
ANGLE CLOSURE GLAUCOMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
ANISEIKONIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
ARCUS SENILIS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
BLEPHAROCONJUNCTIVITIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
BLINDNESS NIGHT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
BLOODSHOT EYE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
CCONJUNCTIVAL EDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
CHALAZION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
CHORIORETINAL ATROPHY	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
CHORIORETINAL DISORDER NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
CHOROIDAL HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
COLOUR BLINDNESS NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
CORNEAL DEGENERATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
CORNEAL SCAR	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
CORNEAL ULCER NEC	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
CYCLITIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
ERYTHEMA NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
EXOPHTHALMOS ENDOCRINE	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYE HEMORRHAGE NEC	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYE INFECTION FUNGAL NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
EYE INFECTION NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYE INFECTION STAPHYLOCOCCAL	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
EYE INFECTION TOXOPLASMAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
EYE INFLAMMATION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
EYELID DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
EYELID EDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
HERPES SIMPLEX OPHTHALMIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
IRIS NEVUS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
LACRIMAL DUCT OBSTRUCTION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
OCULAR HYPERAEMIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
OPTIC DISC HEMORRHAGE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
OPTIC NERVE INJURY NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PAPILLEDEMA	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
PINGUECULA	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
POST-OPERATIVE COMPLICATIONS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
RETINAL DEGENERATION	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
RETINAL EXUDATES	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
RETINAL VASCULITIS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%) 1 (0.3%)
RETINAL VEIN THROMBOSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%)
SCLERITIS NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)		0 (0.0%)
TOPOGRAPHY CORNEAL ABNORMAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
UVEITIS DIABETIC	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%) 0 (0.0%)	0 (0.0%)
VISION ABNORMAL NEC	0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%)	1 (0.5%) 0 (0.0%)	0 (0.0%)	1 (0.3%)
VISUAL DISTURBANCE NOS	0 (0.0%)	0 (0.04)	0 (0.08)	0 (0.0%)	I (0.3%)
INVESTIGATIONS	3 (16.7%)	44 (11.6%)	48 (24.2%)	50 (13.3%)	46 (11.8%)

s:\dat\acs\iss2002\sas\programs\t_ocae_dose 06SEP2002 17:34

Table 9
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Conti	rol			
System Organ Class / Preferred Term	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
INTRAOCULAR PRESSURE INCREASED	3 (16.7%)	39 (10.3%)	40 (20.2%)		
CORNEAL STAINING	0 (0.0%)	6 (1.6%)	8 (4.0%)	9 (2.4%)	8 (2.0%)
INTRAOCULAR PRESSURE ABNORMAL	0 (0.0%)	0 (0.0%)	2 (1.0%)	0 (0.0%)	0 (0.0%)
SKIN & SUBCUTANEOUS TISSUE DISORDERS	0 (0.0%)	26 (6.9%)	19 (9.6%)		38 (9.7%) 25 (6.4%)
EYELID EDEMA	0 (0.0%)	15 (4.0%)	12 (6.1%)	29 (7.7%) 21 (5.6%)	20 (5.1%)
ERYTHEMA NEC	0 (0.0%)	15 (4.0%) 2 (0.5%)	8 (4.0%) 1 (0.5%)	0 (0.0%)	1 (0.3%)
OCULAR HYPEREMIA	0 (0.0%)	0 (0.0%)	2 (1.0%)	0 (0.0%)	0 (0.0%)
CUTIS LAXA	0 (0.0%) 0 (0.0%)	0 (0.0%)			1 (0.3%)
PERIORBITAL EDEMA DERMATITIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%) 0 (0.0%)	1 (0.3%)
ECCHYMOSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
PRURITUS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
SURGICAL AND MEDICAL PROCEDURES	1 (5.6%)	14 (3.7%)	7 (3.5%)	13 (3.4%)	8 (2.0%)
POST-OPERATIVE COMPLICATIONS NOS	1 (5.6%)	8 (2.1%)	4 (2.0%)	5 (1.3%)	4 (1.0%)
UNSPECIFIED COMPLICATION OF PROCEDURE NEC	0 (0.0%)	2 (0.5%)	2 (1.0%)	4 (1.1%)	2 (0.5%)
VITRECTOMY	0 (0.0%)	4 (1.1%)	2 (1.0%)	1 (0.3%)	1 (0.3%)
EYE IRRITATION	0 (0.0%)	0 (0.0%)	2 (1.0%) 0 (0.0%)	1 (0.3%) 1 (0.3%)	0 (0.0%)
LENS IMPLANT	0 (0.0%)	0 (0.0%)		0 (0.0%)	1 (0.3%)
POST-OPERATIVE HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%)	1 (0.3%)	0 (0.0%)
SCLERAL OPERATION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
SUTURE LINE PAIN	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
NERVOUS SYSTEM DISORDERS	0 (0.0%)	1 (0.3%)	5 (2.5%)	4 (1.1%)	7 (1.8%)
PUPILLARY DISORDER NOS	0 (0.0%)	0 (0.0%)	3 (1.5%)	4 (1.1%)	3 (0.8%)
VISUAL FIELD DEFECT NOS	0 (0.0%)	1 (0.3%)	1 (0.5%)	0 (0.0%)	1 (0.3%)
FACIAL PALSY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
HEADACHE NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
PUPILLARY REFLEX IMPAIRED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
VITH NERVE PARALYSIS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
IMMUNE SYSTEM DISORDERS	0 (0.0%)	0 (0.0%)	2 (1.0%)	1 (0.3%)	·
HYPERSENSITIVITY NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	0 (0.0%)
MULTIPLE ALLERGIES	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
INJURY AND POISONING	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	
CHEMICAL BURNS OF EYE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
HEAD INJURY	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
·	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	
BENIGN NEOPLASM OF CHOROID	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
RADIOACTIVE IODINE THERAPY	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
MECHANICAL COMPLICATION OF IMPLANT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)

s:\dat\acs\iss2002\sas\programs\t_ocae_dose 06SEP2002 17:34

Page 5 of 5

Table 9
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Contro	ol			
System Organ Class / Preferred Term	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
INFECTIONS AND INFESTATIONS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
HYPOPYON	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
VASCULAR DISORDERS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
PERIPHERAL ISCHEMIA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)

Table 9.a

Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

System Organ Class / Preferred Term	Sa	lline		Vitrase U Vitrase
NUMBER OF PATIENTS		378		768
NUMBER OF PATIENTS WITH AT LEAST ONE ADVERSE EVENT	298	(78.8%)	672	(87.5%)
EYE DISORDERS	297	(78.6%)	671	(87.4%)
IRITIS	126	(33.3%) (37.0%)	465	(60.5%)
OCULAR HYPEREMIA	140	(37.0%)	417	(54.3%)
EYE PAIN	84	(22.2%)	300	(39.1%)
EYE IRRITATION	111	(22.2%) (29.4%)	271	(35.3%)
LACRIMATION INCREASED	87	(23.0%) (18.0%)	263	(34.2%)
ABNORMAL SENSATION IN EYE	68	(18.0%)	215	(28.0%)
VISUAL ACUITY REDUCED	74	(19.6%)	199	(25.9%)
VITREOUS FLOATERS	67	(19.6%) (17.7%)	188	(24.5%)
PHOTOPHOBIA	60	115 421	(88	174 521
VITREOUS HEMORRHAGE	66	(17.5%) (15.6%)	181	(23.6%)
CONJUNCTIVAL EDEMA	59	(15.6%)	185	(24.1%)
RETINAL DETACHMENT	26	(6.9%)	80	(10.4%)
PHOTOPSIA	22	(6.9%) (5.8%)	83	(10.8%)
CATARACT NUCLEAR	34	(9.0%)	66	(8.6%)
CATARACT SUBCAPSULAR	26	(9.0%) (6.9%)	67	(8.7%)
CATARACT CORTICAL	27	(7.1%)	61	(7.9%)
CORNEAL EROSION	24	(6.3%)	42	(5.5%)
EYE DISCHARGE	18	(4.8%)	43	(5.6%)
CONJUNCTIVAL HEMORRHAGE	25	(6.6%)	32	(4.2%)
CORNEAL EDEMA	12	(3.2%)	44	(5.7%)
RUBEOSIS IRIDIS	19	(5.0%)	36	(4.7%)
IRIS ADHESIONS	13	(3.4%)	40	(5,2%)
CORNEAL DISORDER NOS	8	(2.1%)	42	(5.5%)
MACULAR EDEMA	11	(2.1%) (2.9%)	30	(3.9%)
НУРНЕМА		(1.6%)	27	(3.5%)
CATARACT NEC	1.0	(1.6%) (2.6%)	19	(2.5%)
HYPOPYON	0	(0.0%)	27	(3.5%)
DRY EYE NEC	6	(0.0%) (1.6%)	14	(1.8%)
GLAUCOMA NOS	5	/ 1 381	15	(20%)
BLINDNESS NEC	4	(1.1%)	15	(2.0%)
CATARACT NOS AGGRAVATED		(2.1%)		(1.0%)
KERATITIS NEC	4	(1.1%)	12	(1.6%)
VITREOUS DETACHMENT		(0.5%)		(1.8%)
MACULOPATHY		(1.3%)		(1.3%)
POST-OPERATIVE PAIN	7	(1.9%)	7	(0.9%)
POSTERIOR CAPSULE OPACIFICATION				(1.4%)
VISION BLURRED	5	(0.8%) (1.3%)	9	(1.2%)
RETINOPATHY DIABETIC	4	(1.1%)	9	
UVEITIS NOS	2	(1.1%) (0.5%)	11	(1.4%)
INTRAOCULAR PRESSURE INCREASED				(1.2%)
HYPOTONY OF EYE	2	(0.8%) (0.5%)	8	(1.0%)
	_	,	-	. =

Table 9.a
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

vstem Organ Class / Preferred Term	Saline	55 IU Vitras & 75 IU Vitra
RETINAL HEMORRHAGE		5 (0.7%)
BLEPHARITIS	2 (1.3%)	9 (0.7%)
DIPLOPIA	1 (0.3%) 2 (0.5%)	8 (1.0%) 6 (0.8%)
DIPLOPIA RETINAL TEAR (EXC DETACHMENT)	2 (0.5%)	5 (0.84)
	1 (0.3%)	7 (0.9%) 6 (0.8%)
CORNEAL EPITHELIUM DEFECT		
MYDRIASIS	3 (0.8%)	4 (0.5%) 6 (0.8%)
RETINAL ISCHEMIA		
CORNEAL ABRASION	1 (0.3%)	
PSEUDOPHAKIA	3 (0.8%)	
CONJUNCTIVITIS NEC	2 (0.5%)	
PHOTOPHOBIA AGGRAVATED		4 (0.5%)
EYE ALLERGY	0 (0.0%)	
OCULAR HYPERTENSION	1 (0.3%)	3 (0.4%)
OPTIC ATROPHY	1 (0.3%)	3 (0.4%)
PAINFUL RED EYES	1 (0.3%) 2 (0.5%)	3 (0.4%)
VITREOUS DISORDER NOS		
APHAKIA	2 (0.5%)	1 (0.1%)
EYE DEGENERATIVE DISORDER NOS	0 (0.0%)	3 (0.4%)
FOREIGN BODY RETAINED IN EYE	1 (0.3%)	2 (0.3%)
INTRAOCULAR PRESSURE DECREASED	3 (0.8%)	0 (0.0%)
KERATOCONJUNCTIVITIS	1 (0.3%)	2 (0.3%)
LENTICULAR OPACITIES	2 (0.5%)	1 (0.1%)
RETINAL SCAR	0 (0.0%)	3 (0.4%)
CHEMOSIS		1 (0.1%)
CHOROIDAL DETACHMENT	0 (0.0%)	
CONJUNCTIVITIS (INFECTIVE) NEC		2 (0.3%)
CORTICAL OPACITY	0 (0.0%)	2 (0.3%)
EYELID PTOSIS	1 (0.3%)	1 (0.1%)
MEIBOMIAN CYST	0 (0.0%)	2 (0.3%)
OPEN ANGLE GLAUCOMA NOS		
PERIORBITAL HEMATOMA	0 (0.0%) 0 (0.0%)	2 (0.3%)
RETINAL DISORDER NOS		
RETINAL MICROANEURYSMS	1 (0.3%) 1 (0.3%)	1 (0.1%)
VISUAL ACUITY REDUCED TRANSIENTLY	1 (0.3%)	
ANGLE CLOSURE GLAUCOMA	0 (0.0%)	
ANISEIKONIA	0 (0.0%)	1 (0.1%)
	0 (0.0%)	
BLEPHAROCONJUNCTIVITIS		
BLINDNESS NIGHT	0 (0.0%)	
BLINDNESS TRANSIENT	0 (0.0%)	
BLOODSHOT EYE	0 (0.0%)	
CCONJUNCTIVAL EDEMA	0 (0.0%)	
CHALAZION	0 (0.0%)	1 (0.1%)
CHOROIDAL HEMORRHAGE	0 (0.0%)	1 (0.1%)
COLOUR BLINDNESS NEC		
CONJUNCTIVITIS ALLERGIC	0 (0.0%) 0 (0.0%) 0 (0.0%)	1 (0.1%)
CONJUNCTIVITIS VIRAL NOS	0 (0.0%)	1 (0.1%)

Table 9.a

Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

ystem Organ Class / Preferred Term	Saline	55 IU Vitras & 75 IU Vitra
CORNEAL DEGENERATION	0 (0.0%)	1 (0.1%)
CORNEAL OPACITY	0 (0.0%)	1 (0.1%) 1 (0.1%) 1 (0.1%) 1 (0.1%) 0 (0.0%) 0 (0.0%) 1 (0.1%) 0 (0.0%) 1 (0.1%)
CYCLITIS	0 (0.0%)	1 (0.1%)
ERYTHEMA NEC	0 (0.0%)	1 (0.1%)
EXOPHTHALMOS ENDOCRINE	1 (0.3%)	0 (0.0%)
EYE HEMORRHAGE NEC	1 (0.3%)	0 (0.0%)
EYE INFECTION FUNGAL NOS	0 (0.0%)	1 (0.1%)
EYE INFECTION NOS	1 (0.3%)	0 (0.0%
EYE INFECTION TOXOPLASMAL	0 (0.0%)	1 (0.1%)
EYE INFLAMMATION NOS	0 (0.0%)	1 (0.1%
EYELID DISORDER NOS	0 (0.0%)	1 (0.1%
EYELID EDEMA	0 (0.0%)	1 (0.1%
HERPES SIMPLEX OPHTHALMIC	0 (0.0%)	1 (0.1%
IRIDOCYCLITIS	0 (0.0%)	1 (0.1%
IRIS NEVUS	1 (0.3%)	0 (0.0%
KERATOPATHY BAND	0 (0.0%)	1 (0.1%
KERATOPATHY NOS	0 (0.0%)	1 (0.1%
LACRIMAL DUCT OBSTRUCTION NOS	0 (0.00)	1 (0 1%
MACULAR DEGENERATION	0 (0.0%)	1 (0.1%
OCULAR HYPERAEMIA	0 (0.0%)	1 (0.18
OPTIC NERVE INJURY NOS	1 (0.0%)	0 (0 . 1 %
POST-OPERATIVE COMPLICATIONS NOS	1 (0.3%)	1 / 0.0%
	0 (0.0%)	1 (0.1%
RETINAL ARTERY EMBOLISM	0 (0.0%)	1 (0.16
RETINAL DEPIGMENTATION	0 (0.0%)	1 (0.1%
RETINAL EXUDATES	1 (0.3%)	0 (0.0%
RETINAL VEIN THROMBOSIS	0 (0.0%)	1 (0.1%
STRABISMUS NEC	0 (0.0%)	1 (0.1%
TOPOGRAPHY CORNEAL ABNORMAL	0 (0.0%)	1 (0.1%
VISUAL DISTURBANCE NOS	0 (0.0%)	1 (0.1%
VITREOUS OPACITIES	0 (0.0%)	1 (0.1% 1 (0.1%
VESTIGATIONS	44 (11.6%)	96 (12.5% 82 (10.7%
INTRAOCULAR PRESSURE INCREASED	39 (10.3%)	82 (10.7%
CORNEAL STAINING	6 (1.6%)	17 (2.2%
IN & SUBCUTANEOUS TISSUE DISORDERS	26 (6.9%)	77 (10.0% 54 (7.0% 41 (5.3% 1 (0.1% 2 (0.3% 1 (0.1%
EYELID EDEMA	15 (4.0%)	54 { 7.0%
ERYTHEMA NEC	15 (4.0%)	41 (5.3%
OCULAR HYPEREMIA	2 (0.5%)	1 (0.1%
PERIORBITAL EDEMA	0 (0.0%)	2 (0.3%
DERMATITIS NOS	0 (0.0%)	1 (0.1%
ECCHYMOSIS	0 (0.0%)	1 (0.1%
PRURITUS NOS	0 (0.0%)	1 (0.1%
JRGICAL AND MEDICAL PROCEDURES	14 (3.7%)	21 (2.7%
POST-OPERATIVE COMPLICATIONS NOS	8 (2.1%)	9 (1.2%

Table 9.a

Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

System Organ Class / Preferred Term	Saline	55 IU Vitrase & 75 IU Vitrase
UNSPECIFIED COMPLICATION OF PROCEDURE NEC		6 (0.8%)
VITRECTOMY	4 (1.1%)	2 (0.3%)
EYE IRRITATION		1 (0.1%)
LENS IMPLANT	0 (0.0%)	1 (0.1%)
POST-OPERATIVE HEMORRHAGE	0 (0.0%)	1 (0.1%)
SCLERAL OPERATION NOS	0 (0.0%)	1 (0.1%) 1 (0.1%)
SUTURE LINE PAIN	0 (0.0%)	1 (0.1%)
NERVOUS SYSTEM DISORDERS	1 (0.3%)	11 (1.4%)
PUPILLARY DISORDER NOS	0 (0.0%)	7 (0.9%) 1 (0.1%)
VISUAL FIELD DEFECT NOS	1 (0.3%)	1 (0.1%)
FACIAL PALSY	0 (0.0%)	1 (0.1%)
HEADACHE NOS	0 (0.0%)	1 (0.1%)
PUPILLARY REFLEX IMPAIRED	0 (0.0%)	1 (0.1%)
INJURY AND POISONING		1 (0.1%)
CHEMICAL BURNS OF EYE		1 (0.1%)
HEAD INJURY	1 (0.3%)	0 (0.0%)
NEOPLASMS BENIGN AND MALIGNANT (INCLUDING CYSTS AND POLYPS)		
BENIGN NEOPLASM OF CHOROID		1 (0.1%)
RADIOACTIVE IODINE THERAPY	1 (0.3%)	0 (0.0%)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	0 (0.0%)	1 (0.1%)
MECHANICAL COMPLICATION OF IMPLANT	0 (0.0%)	1 (0.1%)
IMMUNE SYSTEM DISORDERS	0 (0.0%)	1 (0.1%) 1 (0.1%)
HYPERSENSITIVITY NOS	0 (0.0%)	1 (0.1%)
INFECTIONS AND INFESTATIONS	1 (0.3%)	0 (0.0%) 0 (0.0%)
HYPOPYON	1 (0.3%)	0 (0.0%)
VASCULAR DISORDERS		1 (0.1%)
PERIPHERAL ISCHEMIA NOS	0 (0.0%)	1 (0.1%)

Table 10
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Control					
System Organ Class / Preferred Term	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase	
NUMBER OF PATIENTS	18	378	198	377	391	
NUMBER OF PATIENTS WITH AT LEAST ONE RELATED ADVERSE EVENT	11 (61.1%)	244 (64.6%)	168 (84.8%)	290 (76.9%)	326 (83.4%)	
NONDER OF ATTACKED WITH ME BERGE ONE REMITED PERSONS EVENT	11 (01:10)	211 (01100)	200 (01.00)	(10150)		
EYE DISORDERS	11 (61.1%)	243 (64.3%)	168 (84.8%)	288 (76.4%)	326 (83.4%)	
IRITIS	1 (5.6%)	106 (28.0%)	100 (50.5%)	202 (53.6%)	231 (59.1%)	
OCULAR HYPEREMIA	1 (5.6%)	113 (29.9%)	85 (42.9%)	158 (41.9%)	183 (46.8%)	
EYE PAIN	1 (5.6%)	57 (15.1%)	48 (24.2%)	113 (30.0%)	128 (32.7%)	
EYE IRRITATION	5 (27.8%)	79 (20.9%)	61 (30.8%)	96 (25.5%)	103 (26.3%)	
LACRIMATION INCREASED	1 (5.6%)	56 (14.8%)	45 (22.7%)	94 (24.9%)	103 (26.3%)	
ABNORMAL SENSATION IN EYE	1 (5.6%)	50 (13.2%)	43 (21.7%)	78 (20.7%)	92 (23.5%)	
PHOTOPHOBIA	3 (16.7%)	42 (11.1%)	41 (20.7%)	63 (16.7%)	85 (21.7%)	
CONJUNCTIVAL EDEMA	1 (5.6%)	49 (13.0%)	30 (15.2%)	74 (19.6%)	77 (19.7%)	
VITREOUS FLOATERS	3 (16.7%)	42 (11.1%)	40 (20.2%)	58 (15.4%)	74 (18.9%)	
VISUAL ACUITY REDUCED	2 (11.1%)	43 (11.4%)	47 (23.7%)	66 (17.5%)	58 (14.8%)	
VITREOUS HEMORRHAGE	1 (5.6%)	25 (6.6%)	32 (16.2%)	37 (9.8%)	29 (7.4%)	
PHOTOPSIA	0 (0.0%)	14 (3.7%)	18 (9.1%)	25 (6.6%)	28 (7.2%)	
CATARACT SUBCAPSULAR	0 (0.0%)	11 (2.9%)	20 (10.1%)	20 (5.3%)	17 (4.3%)	
RETINAL DETACHMENT	1 (5.6%)	10 (2.6%)	12 (6.1%)	18 (4.8%)	22 (5.6%)	
CATARACT NUCLEAR	1 (5.6%)	16 (4.2%)	12 (6.1%)	22 (5.8%)	10 (2.6%)	
CATARACT CORTICAL	1 (5.6%)	16 (4.2%)	3 (1.5%)	19 (5.0%)	19 (4.9%)	
CORNEAL EROSION	0 (0.0%)	16 (4.2%)	6 (3.0%)	14 (3.7%)	11 (2.8%)	
CORNEAL DISORDER NOS	0 (0.0%)	3 (0.8%)	4 (2.0%)	14 (3.7%)	21 (5.4%)	
EYE DISCHARGE	0 (0.0%)	13 (3.4%)	3 (1.5%)	12 (3.2%)	14 (3.6%)	
IRIS ADHESIONS	2 (11.1%)	3 (0.8%)	4 (2.0%)	10 (2.7%)	18 (4.6%)	
CONJUNCTIVAL HEMORRHAGE	0 (0.0%)	14 (3.7%)	6 (3.0%)	6 (1.6%)	8 (2.0%)	
CORNEAL EDEMA	0 (0.0%)	4 (1.1%)	4 (2.0%)	8 (2.1%)	17 (4.3%)	
RUBEOSIS IRIDIS	1 (5.6%)	5 (1.3%)	8 (4.0%)	6 (1.6%)	9 (2.3%)	
HYPOPYON	0 (0.0%)	0 (0.0%)	1 (0.5%)	6 (1.6%)	21 (5.4%)	
HYPHEMA	0 (0.0%)	3 (0.8%)	3 (1.5%)	5 (1.3%)	6 (1.5%)	
MACULAR EDEMA	0 (0.0%)	3 (0.8%)	3 (1.5%)	3 (0.8%)	8 (2.0%)	
UVEITIS NOS	1 (5.6%)	1 (0.3%)	1 (0.5%)	5 (1.3%)	4 (1.0%)	
VITREOUS DETACHMENT	0 (0.0%)	1 (0.3%)	1 (0.5%)	6 (1.6%)	3 (0.8%)	
MACULOPATHY	0 (0.0%)	2 (0.5%)	1 (0.5%)	3 (0.8%)	4 (1.0%)	
KERATITIS NEC	0 (0.0%)	1 (0.3%)	3 (1.5%)	2 (0.5%)	3 (0,8%)	
CATARACT NEC	0 (0.0%)	2 (0.5%)	0 (0.0%)	2 (0.5%)	4 (1.0%)	
CATARACT NOS AGGRAVATED	1 (5.6%)	3 (0.8%)	0 (0.0%)	3 (0.8%)	1 (0.3%)	
DRY EYE NEC	0 (0.0%)	2 (0.5%)	1 (0.5%)	2 (0.5%)	3 (0.8%)	
DIPLOPIA	0 (0.0%)	2 (0.5%)	1 (0.5%)	3 (0.8%)	1 (0.3%)	
GLAUCOMA NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	5 (1.3%)	
POSTERIOR CAPSULE OPACIFICATION	0 (0.0%)	2 (0.5%)	0 (0.0%)	2 (0.5%)	2 (0.5%)	
VISION BLURRED	0 (0.0%)	0 (0.0%)	1 (0.5%)	3 (0.8%)	2 (0.5%)	
BLINDNESS NEC	0 (0.0%)	1 (0.3%)	1 (0.5%)	1 (0.3%)	2 (0.5%)	
HYPOTONY OF EYE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	4 (1.0%)	
MYDRIASIS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	4 (1.0%)	
PHOTOPHOBIA AGGRAVATED	0 (0.0%)	1 (0.3%)	0 (0.0%)	3 (0.8%)	1 (0.3%)	
FILOTOFILODIA AGGRAVATED	0 (0.0%)	1 (0.3%)	0 (0.0%)	3 (0.0%)	1 (0.3%)	

s:\dat\acs\iss2002\sas\programs\t_ocrae_dose 06SEP2002 17:34

Table 10
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Control				
ystem Organ Class / Preferred Term		Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitras
CONJUNCTIVITIS NEC	0 (0.0%)	0 (0.0%)	2 (1.0%)	0 (0.0%)	2 (0.5%
CORNEAL EPITHELIUM DEFECT	1 (5.6%)	0 (0.0%)	2 (1.0%)	1 (0.3%)	0 (0.0%
FOREIGN BODY RETAINED IN EYE	0 (0.0%)	1 (0.3%)	2 (1.0%)	1 (0.3%)	0 (0.0%
INTRAOCULAR PRESSURE INCREASED	0 (0.0%)	0 (0.0%)	2 (1.0%)	1 (0.3%)	1 (0.3%
RETINAL TEAR (EXC DETACHMENT)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (1.1%)	0 (0.0%
RETINOPATHY DIABETIC	0 (0.0%)	2 (0.5%)	0 (0.0%)	1 (0.3%)	1 (0.3%
VITREOUS DISORDER NOS	0 (0.0%)	1 (0.3%)	1 (0.5%)	0 (0.0%)	2 (0.5%
CORNEAL ABRASION	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	1 (0.3%
CORTICAL OPACITY	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	1 (0.3%
INTRAOCULAR PRESSURE DECREASED	0 (0.0%)	1 (0.3%)	2 (1.0%)	0 (0.0%)	0 (0.0%
,	0 (0.0%)		2 (1.0%)	1 (0.3%)	0 (0.0%
IRIDOCYCLITIS		0 (0.0%)	1 (0.5%)	1 (0.3%)	0 (0.0%
RETINAL HEMORRHAGE	0 (0.0%)	1 (0.3%)	0 (0.0%)	2 (0.5%)	0 (0.0%
BLEPHARITIS	0 (0.0%)	0 (0.0%)			1 (0.3%
CHOROIDAL DETACHMENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
CONJUNCTIVITIS (INFECTIVE) NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%
EYE DEGENERATIVE DISORDER NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	0 (.0.09
MACULAR DEGENERATION	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	0 (0.09
OCULAR HYPERTENSION	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.39
PSEUDOPHAKIA	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	0 (0.0
RETINAL DISORDER NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%
STRABISMUS NEC	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.3%
VITREOUS OPACITIES	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.3%
APHAKIA	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%
BLINDNESS NIGHT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.39
BLINDNESS TRANSIENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%
BLOODSHOT EYE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%
CCONJUNCTIVAL EDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%
CHORIORETINAL ATROPHY	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.09
CHORIORETINAL DISORDER NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.09
COLOUR BLINDNESS NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.35
CONJUNCTIVITIS VIRAL NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3
CORNEAL OPACITY	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0
CYCLITIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3
ERYTHEMA NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0
EYE ALLERGY	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0
EYE INFECTION TOXOPLASMAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3
EYE INFLAMMATION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3
EYELID DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3
EYELID EDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0
EYELID PTOSIS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0
KERATOCONJUNCTIVITIS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0
KERATOPATHY NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0
LENTICULAR OPACITIES	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3
MEIBOMIAN CYST	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0
	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%
OCULAR HYPERAEMIA	· · · · · · · · · · · · · · · · · · ·		•	0 (0.0%)	0 (0.0%
OPEN ANGLE GLAUCOMA NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.04

Table 10
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Conti	rol			
System Organ Class / Preferred Term	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
OPTIC ATROPHY	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
PAINFUL RED EYES	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0 0%)	0 (0.0%)
PINGUECULA	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
POST-OPERATIVE PAIN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
RETINAL DEPIGMENTATION	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
RETINAL ISCHEMIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
RETINAL MICROANEURYSMS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
RETINAL SCAR	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
RETINAL VEIN THROMBOSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
TOPOGRAPHY CORNEAL ABNORMAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
UVEITIS DIABETIC	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
VISUAL DISTURBANCE NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
VISUAL DISTURBANCE NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
INVESTIGATIONS	0 (0.0%)	24 (6.3%)	21 (10.6%)	24 (6.4%)	20 (5.1%)
INTRAOCULAR PRESSURE INCREASED	0 (0.0%)	20 (5.3%)	16 (8.1%)	18 (4.8%)	16 (4.1%)
CORNEAL STAINING	0 (0.0%)	4 (1.1%)	5 (2.5%)	6 (1.6%)	4 (1.0%)
SKIN & SUBCUTANEOUS TISSUE DISORDERS	0 (0.0%)	15 (4.0%)	9 (4.5%)	29 (7.7%)	24 (6.1%)
EYELID EDEMA	0 (0.0%)	6 (1.6%)	6 (3.0%)	22 (5.8%)	19 (4.9%)
ERYTHEMA NEC	0 (0.0%)	9 (2.4%)	3 (1.5%)	14 (3.7%)	12 (3.1%)
CUTIS LAXA	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
ECCHYMOSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
OCULAR HYPEREMIA	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0,0%)
PERIORBITAL EDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
SURGICAL AND MEDICAL PROCEDURES	0 (0.0%)	1 (0.3%)	4 (2.0%)	5 (1.3%)	4 (1.0%)
UNSPECIFIED COMPLICATION OF PROCEDURE NEC	0 (0.0%)	1 (0.3%)	2 (1.0%)	3 (0.8%)	2 (0.5%)
VITRECTOMY	0 (0.0%)	0 (0.0%)	2 (1.0%)	0 (0.0%)	0 (0.0%)
EYE IRRITATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
POST-OPERATIVE COMPLICATIONS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
POST-OPERATIVE COMPLICATIONS NOS POST-OPERATIVE HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
SCLERAL OPERATION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
SCLERAL OPERATION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
NERVOUS SYSTEM DISORDERS	0 (0.0%)	1 (0.3%)	2 (1.0%)	2 (0.5%)	6 (1.5%)
PUPILLARY DISORDER NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	2 (0.5%)	3 (0.8%)
VISUAL FIELD DEFECT NOS	0 (0.0%)	1 (0.3%)	1 (0.5%)	0 (0.0%)	1 (0.3%)
HEADACHE NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0 0%)	1 (0.3%)
PUPILLARY REFLEX IMPAIRED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
INFECTIONS AND INFESTATIONS	0 (0.0%)	1 (0,3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
HYPOPYON	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
INJURY AND POISONING	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
HEAD INJURY	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
TMOOKI	0 (0.0%)	± (0.5%)	J (0.0%)	J (0.0%)	5 (5.0%)
VASCULAR DISORDERS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)

Page 4 of 4

ISTA Pharmaceuticals, Inc. Integrated Summary of Safety

Table 10
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

System Organ Class / Preferred Term	Contro		7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
PERIPHERAL ISCHEMIA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)

Table 11 Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period of Onset Safety Population

Treatment: WW Control (n = 18)

System Organ Class / Preferred Term	Day0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
NUMBER OF PATIENTS WITH AT LEAST ONE ADVERSE EVENT	5 (27.8%)	2 (11.1%)	6 (33.3%)	11 (61.1%)	8 (44.4%)	9 (50.0%)	7 (38.9%)
EYE DISORDERS	5 (27.8%)	2 (11.1%)	6 (33.3%)	11 (61.1%)	8 (44.4%)	8 (44.4%)	7 (38.9%)
EYE IRRITATION	1 (5.6%)	1 (5.6%)	2 (11.1%)	0 (0.0%)	3 (16.7%)	5 (27.8%)	0 (0.0%)
PHOTOPHOBIA	3 (16.7%)	0 (0.0%)	1 (5.6%)	1 (5.6%)	1 (5.6%)	1 (5.6%)	0 (0.0%)
VITREOUS FLOATERS	1 (5.6%)	0 (0.0%)	2 (11.1%)	4 (22.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CATARACT CORTICAL	0 (0.0%)	0 (0.0%)	1 (5.6%)	1 (5.6%)	1 (5.6%)	1 (5.6%)	1 (5.6%)
CATARACT NUCLEAR	0 (0.0%)	1 (5.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	3 (16.7%)
LACRIMATION INCREASED	1 (5.6%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	1 (5.6%)	2 (11.1%)	0 (0.0%)
OCULAR HYPEREMIA	0 (0.0%)	0 (0.0%)	1 (5.6%)	1 (5.6%)	1 (5.6%)	1 (5.6%)	2 (11.1%)
IRITIS	0 (0.0%)	0 (0.0%)	1 (5.6%)	1 (5.6%)	1 (5.6%)	0 (0.0%)	0 (0.0%)
RETINAL DETACHMENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (16.7%)	0 (0.0%)
ABNORMAL SENSATION IN EYE	0 (0.0%)	0 (0.0%)	2 (11.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CATARACT SUBCAPSULAR	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)	0 (0.0%)	1 (5.6%
IRIS ADHESIONS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)	1 (5.6%)
VISUAL ACUITY REDUCED	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (11.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%
VITREOUS HEMORRHAGE	1 (5.6%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%
BLINDNESS NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%
CATARACT NOS AGGRAVATED	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
CONJUNCTIVAL EDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%
CONJUNCTIVITIS VIRAL NOS	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
CORNEAL EDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%
CORNEAL EPITHELIUM DEFECT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%
CORNEAL EROSION	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%
EYE PAIN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)	0 (0.0%
MACULAR EDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%
POST-OPERATIVE PAIN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%
RUBEOSIS IRIDIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%
UVEITIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%
VITREOUS DETACHMENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%
INVESTIGATIONS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	2 (11.1%
INTRAOCULAR PRESSURE INCREASED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	2 (11.1%
SURGICAL AND MEDICAL PROCEDURES	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%
POST-OPERATIVE COMPLICATIONS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%

Table 11

Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period of Onset
Safety Population

Treatment: Saline Control (n = 378)

System Organ Class / Preferred Term	Day0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
NUMBER OF PATIENTS WITH AT LEAST ONE ADVERSE EVENT	235 (62.2%)	63 (16.7%)	74 (19.6%)	62 (16.4%)	84 (22.2%)	115 (30.4%)	113 (29.9%
EYE DISORDERS	233 (61.6%)	63 (16.7%)	74 (19.6%)	58 (15.3%)	84 (22.2%)	106 (28.0%)	112 (29.6%
OCULAR HYPEREMIA	123 (32.5%)	6 (1.6%)	5 (1.3%)	0 (0.0%)	8 (2.1%)	9 (2.4%)	10 (2.6%
IRITIS	89 (23.5%)	17 (4.5%)	11 (2.9%)	3 (0.8%)	10 (2.6%)	17 (4.5%)	11 (2.9%
EYE DISORDERS OCULAR HYPEREMIA IRITIS EYE IRRITATION LACRIMATION INCREASED EYE PAIN VISUAL ACUITY REDUCED ABNORMAL SENSATION IN EYE VITREOUS FLOATERS	61 (16.1%)	9 (2.4%)	15 (4.0%)	9 (2.4%)	19 (5.0%)	14 (3.7%)	15 (4.0%
LACRIMATION INCREASED	39 (10.3%)	8 (2.1%)	14 (3.7%)	11 (2.9%)	10 (2.6%)	10 (2.6%)	10 (2.6%
EYE PAIN	52 (13.8%)	6 (1.6%)	5 (1.3%)	3 (0.8%)	11 (2.9%)	21 (5.6%)	13 (3.4%
VISUAL ACUITY REDUCED	9 (2.4%)	7 (1.9%)	11 (2.9%)	12 (3.2%)	20 (5.3%)	10 (2.6%)	18 (4.8%
ABNORMAL SENSATION IN EYE	44 (11.6%)	4 (1.1%)		7 (1.9%)	4 (1.1%)	10 (2.6%)	7 (1.9%
VITREOUS FLOATERS	9 (2.4%)	17 (4.5%)		11 (2.9%)	17 (4.5%)	14 (3.7%)	12 (3.2%
VITREOUS HEMORRHAGE	0 (0.0%)	1 (0.3%)		8 (2.1%)	14 (3.7%)	22 (5.8%)	26 (6.9%
РНОТОРНОВІА	18 (4.8%)	9 (2.4%)		10 (2.6%)	8 (2.1%)	11 (2.9%)	13 (3.4%
CONJUNCTIVAL EDEMA	48 (12.7%)	3 (0.8%)		2 (0.5%)	2 (0.5%)	3 (0.8%)	4 (1.1%
CATARACT NUCLEAR	1 (0.3%)	0 (0.0%)		3 (0.8%)	2 (0.5%)	6 (1.6%)	19 (5.0%
CATARACT CORTICAL	0 (0.0%)	1 (0.3%)		1 (0.3%)	1 (0.3%)	8 (2.1%)	13 (3.4%
CATARACT SUBCAPSULAR	0 (0.0%)	1 (0.3%)		2 (0.5%)	2 (0.5%)	3 (0.8%)	15 (4.09
CONJUNCTIVAL HEMORRHAGE	19 (5 0%)	1 (0.3%)		0 (0.0%)	1 (0.3%)	3 (0.8%)	2 (0.59
RETINAL DETACHMENT	0 (0 0%)	0 (0.0%)		3 (0.8%)	5 (1.3%)	5 (1.3%)	10 (2.6
CORNEAL EROSION	14 (3 7%)	5 (1.3%)		2 (0.5%)	0 (0.0%)	4 (1.1%)	2 (0.5
PHOTOPSIA	2 (0.70)	0 (0.0%)		4 (1.1%)	1 (0.3%)	3 (0.8%)	8 (2.1%
RUBEOSIS IRIDIS	0 (0 0%)	0 (0.0%)		1 (0.3%)	4 (1.1%)	2 (0.5%)	11 (2.9%
EYE DISCHARGE	12 (3 4%)	2 (0.5%)		0 (0.0%)	1 (0.3%)	1 (0.3%)	2 (0.5%
IRIS ADHESIONS	0 (0.0%)	1 (0.3%)		0 (0.0%)	1 (0.3%)	3 (0.8%)	7 (1.9%
CORNEAL EDEMA	1 (0.0%)	1 (0.3%)		0 (0.0%)	1 (0.3%)	5 (1.3%)	4 (1.19
MACULAR EDEMA	0 (0.34)	1 (0.3%)		0 (0.0%)	0 (0.0%)	3 (0.8%)	8 (2.1
CATARACT NEC	0 (0.0%)	0 (0.0%)		0 (0.0%)	1 (0.3%)	2 (0.5%)	5 (1.39
CATARACT NEC CATARACT NOS AGGRAVATED	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	4 (1.1%)	4 (1.15
CORNEAL DISORDER NOS	1 (0.0%)	2 (0.5%)		0 (0.0%)	0 (0.0%)	1 (0.3%)	3 (0.89
POST-OPERATIVE PAIN	1 (0.3%)	0 (0.0%)		0 (0.0%)	1 (0.3%)	3 (0.8%)	3 (0.8
DRY EYE NEC	0 (0.0%)	0 (0.0%)		0 (0.0%)	1 (0.3%)	0 (0.0%)	2 (0.5
HYPHEMA	2 (0.5%)	2 (0.5%)		0 (0.0%)	1 (0.3%)	2 (0.5%)	1 (0.3
MIPHEMA	0 (0.04)	0 (0.0%)		0 (0.0%)	2 (0.5%)	0 (0.0%)	3 (0.8
GLAUCOMA NOS	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	2 (0.5%)	4 (1.1
MACULOPATHY	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (1.1
RETINAL HEMORRHAGE	0 (0.0%)	0 (0.0%)			0 (0.0%)	2 (0.5%)	1 (0.3
VISION BLURRED	0 (0.0%)	0 (0.0%)		1 (0.3%)			
BLINDNESS NEC	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	2 (0.5%)	2 (0.59
EYE PAIN VISUAL ACUITY REDUCED ABNORMAL SENSATION IN EYE VITREOUS FLOATERS VITREOUS HEMORRHAGE PHOTOPHOBIA CONJUNCTIVAL EDEMA CATARACT NUCLEAR CATARACT SUBCAPSULAR CONJUNCTIVAL HEMORRHAGE RETINAL DETACHMENT CORNEAL EROSION PHOTOPSIA RUBEOSIS IRIDIS EYE DISCHARGE IRIS ADHESIONS CORNEAL EDEMA MACULAR EDEMA MACULAR EDEMA CATARACT NEC CATARACT NOS AGGRAVATED CORNEAL DISORDER NOS POST-OPERATIVE PAIN DRY EYE NEC HYPHEMA GLAUCOMA NOS MACULOPATHY RETINAL HEMORRHAGE VISION BLURRED BLINDNESS NEC KERATITIS NEC RETINOPATHY DIABETIC INTRAOCULAR PRESSURE INCREASED INTRAOCULAR PRESSURE INCREASED MYDRIASIS POSTERIOR CAPSULE OPACIFICATION PSEUDOPHAKIA	1 (0.3%)	1 (0.3%)		0 (0.0%)	1 (0.3%)	1 (0.3%)	
RETINOPATHY DIABETIC	0 (0.0%)	1 (0.3%)		0 (0.0%)	2 (0.5%)	0 (0.0%)	0 (0.0%
INTRAOCULAR PRESSURE DECREASED	1 (0.3%)	0 (0.0%)		0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%
INTRAOCULAR PRESSURE INCREASED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.8%)	0 (0.0%
MYDRIASIS	1 (0.3%)	0 (0.0%)		0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.39
POSTERIOR CAPSULE OPACIFICATION	0 (0.0%)	1 (0.3%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.59
PSEUDOPHAKIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	1 (0.3%

Events are included in the period in which they began.

s:\dat\acs\iss2002\sas\programs\t_ocae_onset 06SEP2002 17:34

Table 11

Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period of Onset
Safety Population

Treatment: Saline Control (n = 378)

System Organ Class / Preferred Term	Day0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
APHAKIA CONJUNCTIVITIS NEC DIPLOPIA HYPOTONY OF EYE LENTICULAR OPACITIES UVEITIS NOS VITREOUS DETACHMENT VITREOUS DISORDER NOS BLEPHARITIS CHEMOSIS CORNEAL ABRASION CORNEAL EPITHELIUM DEFECT EXOPHTHALMOS ENDOCRINE EYE HEMORRHAGE NEC EYE INFECTION NOS EYELID PTOSIS FOREIGN BODY RETAINED IN EYE IRIS NEVUS KERATOCONJUNCTIVITIS OCULAR HYPERTENSION OPTIC ATROPHY OPTIC ATROPHY OPTIC NERVE INJURY NOS PAINFUL RED EYES PHOTOPHOBIA AGGRAVATED RETINAL DISORDER NOS RETINAL EXUDATES RETINAL ISCHEMIA RETINAL TEAR (EXC DETACHMENT) VISUAL ACUITY REDUCED TRANSIENTLY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	0 (0.09
CONJUNCTIVITIS NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%
DIPLOPIA	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%
HYPOTONY OF EYE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%
LENTICULAR OPACITIES	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%
UVEITIS NOS	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%
VITREOUS DETACHMENT	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%
VITREOUS DISORDER NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%
BLEPHARITIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%
CHEMOSIS	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
CORNEAL ABRASION	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.09
CORNEAL EPITHELIUM DEFECT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.09
EXOPHTHALMOS ENDOCRINE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.09
EYE HEMORRHAGE NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3
EYE INFECTION NOS	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.09
EYELID PTOSIS	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.09
FOREIGN BODY RETAINED IN EYE	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.09
IRIS NEVUS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0
KERATOCONJUNCTIVITIS	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
OCULAR HYPERTENSION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3
OPTIC ATROPHY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3
OPTIC MIROPHI OPTIC NERVE INJURY NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0
PAINFUL RED EYES	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0
PHOTOPHOBIA AGGRAVATED	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
RETINAL DISORDER NOS	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
RETINAL EXUDATES	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3
RETINAL ISCHEMIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3
RETINAL ISCHEMIA RETINAL MICROANEURYSMS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3
RETINAL MICROANBORISMS RETINAL TEAR (EXC DETACHMENT)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0
VISUAL ACUITY REDUCED TRANSIENTLY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.09
NVESTIGATIONS	15 (4.0%)	4 (1.1%)	1 (0.3%)	5 (1.3%)	1 (0.3%)	12 (3.2%)	11 (2.9
INTRAOCULAR PRESSURE INCREASED	12 (3.2%)	3 (0.8%)	1 (0.3%)	4 (1.1%)	1 (0.3%)	11 (2.9%)	11 (2.9
CORNEAL STAINING	3 (0.8%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	0 (0.0
KIN & SUBCUTANEOUS TISSUE DISORDERS	14 (3.7%)	2 (0.5%)	3 (0.8%)	0 (0.0%)	2 (0.5%)	3 (0.8%)	3 (0.8
ERYTHEMA NEC	9 (2.4%)	1 (0.3%)	3 (0.8%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3
EYELID EDEMA	7 (1.9%)	2 (0.5%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	2 (0.5%)	3 (0.8
ERYTHEMA NEC EYELID EDEMA OCULAR HYPEREMIA	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0
SURGICAL AND MEDICAL PROCEDURES	3 (0.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	8 (2.1%)	2 (0.5
, POST-OPERATIVE COMPLICATIONS NOS	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (1.3%)	2 (0.5
VITRECTOMY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	3 (0.8%)	0 (0.0
UNSPECIFIED COMPLICATION OF PROCEDURE NEC	2 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%

Events are included in the period in which they began.

s:\dat\acs\iss2002\sas\programs\t_ocae_onset 06SEP2002 17:34

Table 11

Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period of Onset

Safety Population

Treatment: Saline Control (n = 378)

System Organ Class / Preferred Term	Day0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
INFECTIONS AND INFESTATIONS HYPOPYON	0 (0.0%) 0 (0.0%)	0 (0.0%)	1 (0.3%) 1 (0.3%)				
INJURY AND POISONING HEAD INJURY	0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%)	1 (0.3%) 1 (0.3%)	0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%)
NEOPLASMS BENIGN AND MALIGNANT (INCLUDING CYSTS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
AND POLYPS) RADIOACTIVE IODINE THERAPY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
NERVOUS SYSTEM DISORDERS VISUAL FIELD DEFECT NOS	1 (0.3%) 1 (0.3%)	0 (0.0%) 0 (0.0%)	· 0 (0.0%) 0 (0.0%)				

Table 11

Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period of Onset
Safety Population

Treatment: 7.5 IU Vitrase (n = 198)

System Organ Class / Preferred Term	Day0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
NUMBER OF PATIENTS WITH AT LEAST ONE ADVERSE EVENT	166 (83.8%)	55 (27.8%)	58 (29.3%)	67 (33.8%)	64 (32.3%)	102 (51.5%)	98 (49.5%)
EYE DISORDERS IRITIS OCULAR HYPEREMIA EYE IRRITATION VISUAL ACUITY REDUCED EYE PAIN VITREOUS HEMORRHAGE LACRIMATION INCREASED VITREOUS FLOATERS ABNORMAL SENSATION IN EYE PHOTOPHOBIA CONJUNCTIVAL EDEMA	165 (83.3%)	52 (26.3%)	55 (27.8%)	64 (32.3%)	62 (31.3%)	97 (49.0%)	98 (49.5%)
IRITIS	85 (42.9%)	11 (5.6%)	10 (5.1%)	7 (3.5%)	10 (5.1%)	21 (10.6%)	21 (10.6%)
OCULAR HYPEREMIA	99 (50.0%)	3 (1.5%)	4 (2.0%)	6 (3.0%)	4 (2.0%)	15 (7.6%)	17 (8.6%)
EYE IRRITATION	45 (22.7%)	9 (4.5%)	13 (6.6%)	14 (7.1%)	13 (6.6%)	15 (7.6%)	19 (9.6%)
VISUAL ACUITY REDUCED	23 (11.6%)	6 (3.0%)	10 (5.1%)	13 (6.6%)	13 (6.6%)	16 (8.1%)	16 (8.1%)
EYE PAIN	33 (16.7%)	7 (3.5%)	3 (1.5%)	6 (3.0%)	12 (6.1%)	20 (10.1%)	12 (6.1%)
VITREOUS HEMORRHAGE	1 (0.5%)	4 (2.0%)	6 (3.0%)	9 (4.5%)	14 (7.1%)	23 (11.6%)	25 (12.6%)
LACRIMATION INCREASED	26 (13.1%)	4 (2.0%)	13 (6.6%)	7 (3.5%)	9 (4.5%)	11 (5.6%)	14 (7.1%)
VITREOUS FLOATERS	17 (8.6%)	12 (6.1%)	14 (7.1%)	13 (6.6%)	10 (5.1%)	10 (5.1%)	10 (5.1%)
ABNORMAL SENSATION IN EYE	33 (16.7%)	2 (1.0%)	6 (3.0%)	5 (2.5%)	9 (4.5%)	11 (5.6%)	10 (5.1%)
PHOTOPHOBIA	14 (7.1%)	6 (3.0%)	11 (5.6%)	10 (5.1%)	9 (4.5%)	12 (6.1%)	17 (8.6%)
CONJUNCTIVAL EDEMA	30 (15.2%)	2 (1.0%)	3 (1.5%)	2 (1.0%)	2 (1.0%)	4 (2.0%)	11 (5.6%)
CATARACT SUBCAPSULAR	0 (0.0%)	1 (0.5%)	2 (1.0%)	3 (1.5%)	4 (2.0%)	10 (5.1%)	14 (7.1%)
CATARACT NUCLEAR	0 (0.0%)	1 (0.5%)	2 (1.0%)	6 (3.0%)	2 (1.0%)	6 (3.0%)	15 (7.6%)
PHOTOPSIA	3 (1.5%)	4 (2.0%)	1 (0.5%)	4 (2.0%)	5 (2.5%)	5 (2.5%)	6 (3.0%)
RETINAL DETACHMENT	0 (0.0%)	0 (0.0%)	2 (1.0%)	1 (0.5%)	4 (2.0%)	8 (4.0%)	8 (4.0%)
CORNEAL EDEMA	1 (0.5%)	0 (0.0%)	2 (1.0%)	1 (0.5%)	1 (0.5%)	6 (3.0%)	9 (4.5%)
MACULAR EDEMA	0 (0.0%)	0 (0.0%)	1 (0.5%)	2 (1.0%)	0 (0.0%)	3 (1.5%)	11 (5.6%)
RUBEOSIS IRIDIS	0 (0.0%)	0 (0.0%)	3 (1.5%)	3 (1.5%)	3 (1.5%)	2 (1.0%)	8 (4.0%)
CATARACT CORTICAL	1 (0.5%)	1 (0.5%)	2 (1.0%)	3 (1.5%)	2 (1.0%)	2 (1.0%)	5 (2.5%)
CONJUNCTIVAL HEMORRHAGE	6 (3.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.5%)	2 (1.0%)	2 (1.0%)
CORNEAL EROSION	5 (2.5%)	0 (0.0%)	1 (0.5%)	1 (0.5%)	1 (0.5%)	1 (0.5%)	2 (1.0%)
EYE DISCHARGE	4 (2.0%)	1 (0.5%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	3 (1.5%)
VISION BLURRED	1 (0.5%)	1 (0.5%)	1 (0.5%)	1 (0.5%)	0 (0.0%)	2 (1.0%)	4 (2.0%)
IRIS ADHESIONS	0 (0.0%)	1 (0.5%)	2 (1.0%)	1 (0.5%)	1 (0.5%)	1 (0.5%)	4 (2.0%)
BLINDNESS NEC	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	2 (1.0%)	5 (2.5%)
НУРНЕМА	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (2.0%)	4 (2.0%)
DRY EYE NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.5%)	5 (2.5%)
CORNEAL DISORDER NOS	4 (2.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.0%)
INTRAOCULAR PRESSURE INCREASED	1 (0.5%)	0 (0.0%)	0 (0.0%)	2 (1.0%)	0 (0.0%)	2 (1.0%)	2 (1.0%)
GLAUCOMA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	3 (1.5%)	2 (1.0%)
CATARACT NOS AGGRAVATED	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (1.5%)
FOREIGN BODY RETAINED IN EYE	1 (0.5%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	2 (1.0%)
KERATITIS NEC	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.5%)	1 (0.5%)
MACULOPATHY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	3 (1.5%)
					1 (0.5%)		1 (0.5%)
BLEPHARITIS CONTINUES NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.5%) 1 (0.5%)	1 (0.5%)
CONJUNCTIVITIS NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		1 (0.5%)
CORNEAL EPITHELIUM DEFECT	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)		1 (0.5%) 0 (0.0%)	
EYE DEGENERATIVE DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)			3 (1.5%)
EYELID PTOSIS	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.5%)	0 (0.0%)	1 (0.5%)	0 (0.0%)
RETINAL ISCHEMIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (1.5%)
VITREOUS DETACHMENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.0%)	0 (0.0%)	1 (0.5%)

s:\dat\acs\iss2002\sas\programs\t_ocae_onset 06SEP2002 17:34

Table 11

Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period of Onset
Safety Population

Treatment: 7.5 IU Vitrase (n = 198)

ystem Organ Class / Preferred Term	Day0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
CORNEAL ABRASION	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0
DIPLOPIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.0%)	0 (0.0
HYPOTONY OF EYE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	1 (0.5
INTRAOCULAR PRESSURE DECREASED	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0
IRIDOCYCLITIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.0
MACULAR DEGENERATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.5
RETINAL HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	1 (0.5
UVEITIS NOS	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5
APHAKIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0
ARCUS SENILIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5
BLINDNESS TRANSIENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0
CATARACT NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5
CHEMOSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0
CHORIORETINAL ATROPHY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0
CHORIORETINAL DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9
CONJUNCTIVITIS ALLERGIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0
CORNEAL OPACITY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0
CORNEAL SCAR	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
CORNEAL ULCER NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
CORTICAL OPACITY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.
EYE INFECTION STAPHYLOCOCCAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
HYPOPYON	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
KERATOPATHY BAND	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
KERATOPATHY NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.
MYDRIASIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.
OPEN ANGLE GLAUCOMA NOS	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.
OPTIC ATROPHY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
OPTIC DISC HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.
PAPILLEDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
PINGUECULA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
POSTERIOR CAPSULE OPACIFICATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.
RETINAL ARTERY EMBOLISM	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
RETINAL DEGENERATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
RETINAL DEPIGMENTATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
RETINAL DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.
RETINAL MICROANEURYSMS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
RETINAL VASCULITIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
RETINOPATHY DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
SCLERITIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.
STRABISMUS NEC	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.
UVEITIS DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.
VISION ABNORMAL NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
VITREOUS DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5
VITREOUS OPACITIES	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5

s:\dat\acs\iss2002\sas\programs\t_ocae_onset 06SEP2002 17:34

Table 11 Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period of Onset Safety Population

Treatment: 7.5 IU Vitrase (n = 198)

System Organ Class / Preferred Term	Day0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
THEORETANE	70 (5 78)	3 (1.5%)	3 (1.5%)	5 (2.5%)	3 (1.5%)	18 (9.1%)	16 (8.1%)
INVESTIGATIONS	10 (5.1%)						
INTRAOCULAR PRESSURE INCREASED	6 (3.0%)	2 (1.0%)	3 (1.5%)	5 (2.5%)	2 (1.0%)	16 (8.1%)	13 (6.6%)
CORNEAL STAINING	4 (2.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.5%)	2 (1.0%)
INTRAOCULAR PRESSURE ABNORMAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.5%)
SKIN & SUBCUTANEOUS TISSUE DISORDERS	8 (4.0%)	1 (0.5%)	1 (0.5%)	3 (1.5%)	4 (2.0%)	6 (3.0%)	2 (1.0%)
EYELID EDEMA	6 (3.0%)	0 (0.0%)	1 (0.5%)	2 (1.0%)	3 (1.5%)	4 (2.0%)	1 (0.5%)
ERYTHEMA NEC	1 (0.5%)	1 (0.5%)	0 (0.0%)	1 (0.5%)	2 (1.0%)	2 (1.0%)	1 (0.5%)
CUTIS LAXA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.5%)
OCULAR HYPEREMIA	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
OCOLAR HIFBRENIA	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.00)	0 (0.00)	0 (0.00)
SURGICAL AND MEDICAL PROCEDURES	2 (1.0%)	0 (0.0%)	1 (0.5%)	1 (0.5%)	0 (0.0%)	3 (1.5%)	1 (0.5%)
POST-OPERATIVE COMPLICATIONS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (1.5%)	1 (0.5%)
UNSPECIFIED COMPLICATION OF PROCEDURE NEC	2 (1.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
VITRECTOMY	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	0 (0.00,	. , ,	_ (0.00,	_ (,		- ,	
NERVOUS SYSTEM DISORDERS	1 (0.5%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	2 (1.0%)
PUPILLARY DISORDER NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.5%)
VISUAL FIELD DEFECT NOS	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
VITH NERVE PARALYSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
ATTU MEKAE LAKARISIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.00)	0 (0.04)	0 (0.00)	+ (0.50)

Table 11 Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period of Onset Safety Population

Treatment: 55 IU Vitrase (n = 377)

EVE DISCRIDERS 275 (72.94) 76 (20.24) 99 (26.34) 85 (22.54) 100 (26.54) 102 (27.14) 118 (3 IRITIS 198 (52.54) 21 (5.64) 15 (4.04) 6 (1.64) 10 (2.74) 14 (3.74) 16 (CULLAR HYBEREMIA 109 (28.54) 7 (1.94) 18 (2.14) 7 (1.94) 8 (2.14) 7 (1.94) 13 (3.44) 15 (EVE PAIN 109 (28.54) 7 (1.94) 11 (2.94) 8 (2.14) 7 (1.94) 13 (3.44) 15 (EVE PAIN 109 (28.54) 13 (3.44) 29 (7.74) 14 (3.74) 14 (3.74) 16 (4.54) 13 (3.44) 15 (EVE IRRITATION INCREASED 104 (28.54) 13 (3.44) 12 (7.74) 14 (3.74) 14 (3.74) 16 (4.54) 13 (3.44) 18 (1.44) 18 (System Organ Class / Preferred Term	Day0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
EXE DISCREES 275 (72.98) 76 (20.28) 95 (26.28) 85 (22.58) 100 (26.58) 102 (27.18) 118 (9 INITION 1970) 199 (15.58) 21 (5.68) 115 (1.68) 100 (2.78) 14 (3.78) 15 (1.60) 16 (1.68) 100 (2.78) 14 (3.78) 15 (1.60) 16 (1.68) 100 (2.78) 14 (3.78) 15 (1.60) 16 (1.68) 100 (2.78) 14 (3.78) 15 (1.60) 16 (1.68) 100 (2.78) 13 (3.48) 15 (1.60) 16 (1.68) 100 (2.78) 13 (3.48) 15 (1.60) 16 (99 (26.3%)	88 (23.3%)	104 (27.6%)	107 (28.4%)	122 (32.4%
INTITIS 198 (52.5*) 21 (5.6*) 15 (4.0*) 6 (1.6*) 10 (2.7*) 14 (3.7*) 16 (COULAR HYPEREMIA 199 (28.9*) 7 (1.9*) 8 (2.1*) 7 (1.9*) 8 (2.1*) 7 (1.9*) 13 (3.4*) 15 (EYE PAIN 109 (28.9*) 7 (1.9*) 11 (2.9*) 8 (2.1*) 12 (3.2*) 17 (4.5*) 13 (EYE RERITATION 76 (20.2*) 13 (3.4*) 27 (7.7*) 14 (3.7*) 18 (4.8*) 18 (4.8*) 18 (4.8*) 18 (LACKIMATION INCREASED 81 (21.5*) 6 (1.6*) 16 (4.2*) 20 (5.3*) 8 (2.1*) 10 (2.7*) 14	EYE DISORDERS	275 (72.9%)	76 (20.2%)	99 (26.3%)				118 (31.3%
COLLAR HYPERENTA	IRITIS	198 (52.5%)	21 (5.6%)	15 (4.0%)				16 (4.2%
EYE FAIN 109 (28,94) 7 (1,94) 21 (2,94) 8 (2,14) 12 (3,24) 17 (4,54) 13 (EYE IRRITATION 76 (20,24) 13 (3,44) 29 (7,74) 14 (3,74) 18 (4,84) 18 (OCULAR HYPEREMIA	182 (48.3%)	9 (2.4%)	7 (1.9%)				15 (4.0%
EYE IRRITATION 76 (20.2*) 13 (3.4*) 29 (7.7*) 14 (3.7*) 18 (4.8*) 18 (4.8*) 18 (4.8*) 18 (4.8*) 18 (4.8*) 18 (4.8*) 18 (4.8*) 18 (4.8*) 18 (4.8*) 18 (21.5*) 6 (1.6*) 5 (1.3*) 13 (3.4*) 10 (2.7*) 9 (2.4*) 11 (2.9*) 9 (2.4*) 17 (2.7*) 17 (2.7*) 18 (2.1*) 10 (2.7*) 19 (2.4*) 11 (2.9*) 19 (2.9*) 11	EYE PAIN	109 (28.9%)	7 (1.9%)					13 (3.4%
LACRIMATION INCREASED 81 (21.5*) 6 (1.5*) 16 (4.2*) 20 (5.3*) 8 (2.1*) 10 (2.7*) 14 (2.9*) 9 (ABNORMAL SENSATION IN SYE 70 (18.6*) 5 (1.3*) 13 (3.4*) 10 (2.7*) 9 (2.4*) 11 (2.9*) 9 (VISUAL ACUITY REDUCED 27 (7.2*) 8 (2.1*) 13 (3.4*) 13 (3.4*) 13 (3.4*) 27 (7.2*) 24 (6.4*) 17 (CONJUNCTIVAL EDEMA 85 (22.5*) 2 (0.5*) 2 (0.5*) 2 (0.5*) 5 (1.3*) 5 (VITREOUS HEMORRHAGE 1 (0.3*) 1 (0.3*) 7 (1.9*) 13 (3.4*) 13 (3.4*) 12 (0.5*) 2 (0.5*) 5 (1.3*) 5 (VITREOUS HEMORRHAGE 1 (1.1*) 13 (3.4*) 13 (3.4*) 13 (3.4*) 10 (2.7*) 10 (2.7*) 7 (1.9*) 18 (VITREOUS FLOATERS 23 (6.1*) 13 (3.4*) 21 (5.6*) 13 (3.4*) 10 (2.7*) 10 (2.7*) 7 (1.9*) 12 (3.2*) 13 (VITREOUS FLOATERS 7 (1.9*) 6 (1.6*) 13 (3.4*) 21 (5.6*) 13 (3.4*) 15 (4.0*) 12 (3.2*) 13 (CATARACT NUCLEBAR 7 (1.9*) 6 (1.6*) 13 (3.4*) 21 (5.6*) 13 (3.4*) 4 (1.1*) 6 (1.6*) 11 (2.9*) 11 (CATARACT SUCLEBAR 1 (0.0*) 1 (0.	EYE IRRITATION	76 (20.2%)	13 (3.4%)					18 (4.8%
ABROWAL SENSATION IN EYE 70 (18.6*) 5 (1.3\$) 13 (3.4\$) 10 (2.7\$) 9 (2.4\$) 11 (2.9\$) 9 (VISIGLA CAUTY REDUCED	LACRIMATION INCREASED	81 (21.5%)	6 (1.6%)			8 (2.1%)		14 (3.7%
VISUAL ACUITY REDUCED 27 (7.2*) 8 (2.1*) 13 (3.4*) 12 (3.4*) 27 (7.2*) 24 (6.4*) 17 (CONJUNCTIVAL EDEMA 85 (22.5*) 2 (0.5*) 2 (0.5*) 2 (0.5*) 2 (0.5*) 2 (0.5*) 5 (1.3*) 5 (1.3*) 5 (VITREOUS HEMORRHAGE 1 (0.3*) 1 (0.3*) 1 (0.3*) 7 (1.9*) 13 (3.4*) 12 (3.4*) 23 (6.1*) 25 (6.6*) 29 (PROTOPHORIA 42 (11.1*) 13 (3.4*) 13 (3.4*) 10 (2.7*) 10 (2.7*) 10 (2.7*) 7 (1.9*) 18 (1.7*) 11 (2.7*) 10 (2.7*) 10 (2.7*) 10 (2.7*) 10 (2.7*) 10 (2.7*) 10 (2.7*) 10 (2.7*) 10 (2.7*) 11 (2.7*)	ABNORMAL SENSATION IN EYE	70 (18.6%)	5 (1.3%)					9 (2.4%
CONUNINITIVAL EDEMA 85 (22,58) 2 (0.58) 2 (0.58) 2 (0.58) 2 (0.58) 2 (0.58) 5 (1.38) 5 (PHOTOPHOBIA 1 (0.38) 1 (0.38,48) 13 (3.48) 13 (3.48) 10 (2.78) 7 (1.98) 7 (1.98) 18 (PHOTOPHOBIA 1 (1.98) 6 (1.68) 13 (3.48) 10 (2.78) 10 (2.78) 7 (1.98) 18 (PHOTOPHOBIA 1 (1.98) 6 (1.68) 13 (3.48) 13 (3.48) 10 (2.78) 10 (2.78) 7 (1.98) 18 (PHOTOPHOBIA 1 (1.98) 6 (1.68) 13 (3.48) 18 (2.18) 4 (1.18) 6 (1.68) 11 (3.38)	VISUAL ACUITY REDUCED	27 (7.2%)	8 (2.1%)					17 (4.5%
VITEROUS HEMORRIAGE 1 (0.3\$) 1 (0.3\$) 7 (1.9\$) 13 (3.4\$) 23 (6.1\$) 25 (6.6\$) 29 (VITEROUS FLOATERS 23 (6.1\$) 13 (3.4\$) 13 (3.4\$) 15 (4.0\$) 12 (3.2\$) 18 (VITEROUS FLOATERS 23 (6.1\$) 13 (3.4\$) 12 (5.5\$) 13 (3.4\$) 15 (4.0\$) 12 (3.2\$) 13 (CATARACT NUCLEAR 2 (0.5\$) 1 (0.3\$) 7 (1.9\$) 14 (0.1\$) 6 (1.6\$) 13 (3.4\$) 8 (2.1\$) 4 (1.1\$) 6 (1.6\$) 11 (2.3\$) 11 (CATARACT SUCLEAR 2 (0.5\$) 1 (0.3\$) 7 (1.9\$) 1 (0.3\$) 9 (2.4\$) 5 (1.3\$) 15 (CATARACT SUCCLEAR 3 (0.8\$) 0 (0.0\$) 4 (1.1\$) 1 (0.3\$) 9 (2.4\$) 5 (1.3\$) 15 (CATARACT SUCLEARIAN 3 (0.8\$) 0 (0.0\$) 4 (1.1\$) 1 (0.3\$) 6 (1.6\$) 11 (2.9\$) 11 (CATARACT SUCLEARIAN 0 (0.0\$) 4 (1.1\$) 3 (0.8\$) 6 (1.6\$) 11 (2.9\$) 11 (CATARACT SUCLEARIAN 0 (0.0\$) 4 (1.1\$) 3 (0.8\$) 6 (1.6\$) 15 (1.3\$) 14 (CATARACT SUCLEARIAN 0 (0.0\$) 4 (1.1\$) 3 (0.8\$) 1 (0.3\$) 4 (1.1\$) 2 (0.5\$) 5 (1.3\$) 14 (CORNEAL EROSION 16 (4.2\$) 3 (0.8\$) 1 (0.3\$) 1 (0.3\$) 2 (0.5\$) 5 (1.3\$) 10 (0.0\$) 5 (EVE DISCHARGE 12 (3.2\$) 11 (0.3\$) 1 (0.3\$) 1 (0.3\$) 2 (0.5\$) 5 (1.3\$) 1 (0.3\$) 1 (0.3\$) 1 (0.3\$) 3 (0.8\$) 5 (1.3\$) 1 (0.3\$) 1 (0.3\$) 1 (0.3\$) 3 (0.8\$) 5 (1.3\$) 1 (0.3\$) 1 (0.3\$) 1 (0.3\$) 3 (0.8\$) 5 (1.3\$) 1 (0.3\$) 1 (0.3\$) 1 (0.3\$) 3 (0.8\$) 5 (1.3\$) 1 (0.3\$) 1	CONJUNCTIVAL EDEMA	85 (22.5%)	2 (0.5%)					5 (1.3%
PRITOPHOBICA VITREOUS FLOATERS 23 (6.11, 14) 13 (3.44) 13 (3.44) 10 (2.74) 10 (2.74) 7 (1.94) 12 (3.24) 13 (71.94) 12 (71.94) 13 (71.94) 13 (3.44) 13 (3.44) 15 (4.04) 12 (3.24) 13 (71.94) 13 (71.94) 14 (71.94) 15 (4.04) 12 (3.24) 13 (71.94) 14 (71.94) 14 (71.94) 15 (4.04) 12 (3.24) 13 (71.94) 14 (71.94) 14 (71.94) 15 (4.04) 12 (3.24) 13 (71.94) 14 (71.94) 14 (71.94) 15 (4.04) 12 (3.24) 13 (71.94) 14 (71.	VITREOUS HEMORRHAGE	1 (0.3%)	1 (0.3%)	7 (1.9%)				29 (7.7%
VITROUS FLOATERS	PHOTOPHOBIA	42 (11.1%)	13 (3.4%)	13 (3.4%)				18 (4.8%
PHOTOPSIA 7 (1.9%) 6 (1.6%) 13 (3.4%) 8 (2.1%) 4 (1.1%) 6 (1.6%) 11 (CATARACT NUCLEAR 2 (0.5%) 1 (0.3%) 7 (1.9%) 6 (1.6%) 11 (2.9%) 11 (0.2%) 7 (1.9%) 8 (0.0%) 4 (1.1%) 3 (0.8%) 6 (1.6%) 11 (2.9%) 11 (CATARACT CORTICAL 3 (0.0%) 4 (1.1%) 3 (0.8%) 6 (1.6%) 11 (2.9%) 11 (CATARACT SUBCAPSULAR 0 (0.0%) 4 (1.1%) 3 (0.8%) 5 (1.3%) 5 (1.3%) 12 (CORNEAL EROSION 16 (4.2%) 3 (0.8%) 1 (0.3%) 4 (1.1%) 2 (0.5%) 5 (1.3%) 12 (CORNEAL EROSION 16 (4.2%) 3 (0.8%) 1 (0.3%) 4 (1.1%) 2 (0.5%) 5 (1.3%) 12 (CORNEAL EDEMA 4 (1.1%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 3 (0.8%) 4 (1.1%) 1 (0.3%) 1 (0.3%) 3 (0.8%) 4 (1.1%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 3 (0.8%) 4 (1.1%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 2 (0.5%) 5 (1.3%) 7 (CORNEAL EDEMA 4 (1.1%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 2 (0.5%) 5 (1.3%) 7 (CORNEAL EDEMA 4 (1.1%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 2 (0.5%) 5 (1.3%) 7 (CORNEAL EDEMA 4 (1.1%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 2 (0.5%) 5 (1.3%) 7 (CORNEAL EDEMA 4 (1.1%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 2 (0.5%) 7 (CRUBEOSIS IRIDIS 1 (0.3%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 2 (0.5%) 7 (CONJUNCTIVAL HEMORRHAGE 9 (0.0%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 2 (0.5%) 7 (CONJUNCTIVAL HEMORRHAGE 9 (0.0%) 1 (0.3%	VITREOUS FLOATERS	23 (6.1%)	13 (3.4%)	21 (5.6%)	13 (3.4%)			13 (3.4%
RETINAL DETACHMENT 0 (0.0%) 3 (0.8%) (4 (1.1%) 3 (0.8%) 6 (1.6%) 5 (1.3%) 15 (CATARACT CORTICAL 3 (0.8%) 0 (0.0%) 4 (1.1%) 1 (0.3%) 6 (1.6%) 5 (1.3%) 14 (CATARACT CORTICAL 3 (0.8%) 0 (0.0%) 4 (1.1%) 1 (0.3%) 6 (1.6%) 5 (1.3%) 14 (CATARACT SURRACT S	PHOTOPSIA	7 (1.9%)	6 (1.6%)	13 (3.4%)	8 (2.1%)			11 (2.9%
RETINAL DETACHMENT O (0.0%) 3 (0.8%) 4 (1.1%) 3 (0.8%) 6 (1.6%) 11 (2.9%) 11 (CATARACT CORTICAL 3 (0.8%) 0 (0.0%) 4 (1.1%) 1 (0.3%) 6 (1.6%) 5 (1.3%) 14 (CATARACT SUBCAPSULAR O (0.0%) 4 (1.1%) 3 (0.8%) 5 (1.3%) 2 (0.5%) 5 (1.3%) 14 (CATARACT SUBCAPSULAR O (0.0%) 4 (1.1%) 3 (0.8%) 5 (1.3%) 2 (0.5%) 5 (1.3%) 12 (0.0%) 12	CATARACT NUCLEAR	2 (0.5%)	1 (0.3%)	7 (1.9%)	1 (0.3%)	9 (2.4%)	5 (1.3%)	15 (4.0%
CATARACT CORTICAL CATARACT SUBCAPSULAR 0 (0.0%) 4 (1.1%) 3 (0.8%) 5 (1.3%) 6 (1.6%) 5 (1.3%) 12 (CORNEAL EROSIUAR 0 (0.0%) 4 (1.1%) 3 (0.8%) 5 (1.3%) 2 (0.5%) 5 (1.3%) 12 (CORNEAL EROSIUAR 16 (4.2%) 3 (0.8%) 1 (0.3%) 4 (1.1%) 2 (0.5%) 5 (1.3%) 12 (CORNEAL EROSION 16 (4.2%) 3 (0.8%) 1 (0.3%) 4 (1.1%) 2 (0.5%) 5 (1.3%) 14 (1.1%) 1 (0.0%) 5 (EYE DISCHARGE 12 (3.2%) 1 (0.3%) 1 (0.3%) 3 (0.8%) 4 (1.1%) 1 (0.3%) 3 (0.8%) 4 (1.1%) 1 (0.0%) 5 (EYE DISCHARGE 12 (3.2%) 1 (0.3%) 1 (0.3%) 3 (0.8%) 4 (1.1%) 1 (0.3%) 1 (0.3%) 3 (0.8%) 4 (1.1%) 1 (0.0%) 1 (0.0%) 1 (0.0%) 1 (0.3%) 1 (0.3%) 2 (0.5%) 5 (1.3%) 7 (CORNEAL DISORDER NOS 12 (3.2%) 3 (0.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (0.5%) 5 (1.3%) 7 (CONDINCTIVAL HEMORRHAGE 12 (3.2%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 2 (0.5%) 7 (CONDINCTIVAL HEMORRHAGE 13 (1.1%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 5 (HYPHEMA 11 (0.3%) 1 (0.3%) 1 (0.0%) 1 (0.3%) 1 (0	RETINAL DETACHMENT	0 (0.0%)	3 (0.8%)	4 (1.1%)	3 (0.8%)	6 (1.6%)	11 (2.9%)	11 (2.9
CATARACT SUBCAPSULAR (0 (0.%) 4 (1.1%) 3 (0.8%) 5 (1.3%) 2 (0.5%) 5 (1.3%) 12 (CORNEAL EROSION 16 (4.2%) 3 (0.8%) 1 (0.3%) 4 (1.1%) 2 (0.5%) 0 (0.0%) 5 (EYE DISCHARGE 12 (3.2%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 3 (0.8%) 4 (1.1%) 1 (CORNEAL EDEMA 4 (1.1%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 3 (0.8%) 4 (1.1%) 1 (CORNEAL DISORDER NOS 12 (3.2%) 3 (0.8%) 0 (0.0%) 0 (0	CATARACT CORTICAL	3 (0.8%)	0 (0.0%)	4 (1.1%)	1 (0.3%)	6 (1.6%)	5 (1.3%)	14 (3.7
CORNEAL EROSION 16 (4.2%) 3 (0.8%) 1 (0.3%) 4 (1.1%) 2 (0.5%) 0 (0.0%) 5 (EYE DISCHARGE 12 (3.2%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 3 (0.8%) 4 (1.1%) 1 (CORNEAL EDEMA 4 (1.1%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 2 (0.5%) 5 (1.3%) 7 (CORNEAL DISORDER NOS 12 (3.2%) 3 (0.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (CONJUNCTIVAL HEMORRHAGE 12 (3.2%) 3 (0.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (0.5%) 7 (CONJUNCTIVAL HEMORRHAGE 13 (0.3%) 1 (0.3%) 1 (0.3%) 0 (0.0%) 0 (0.0%) 3 (0.5%) 7 (CONJUNCTIVAL HEMORRHAGE 14 (1.1%) 3 (0.8%) 1 (0.3%) 0 (0.0%) 0 (0.0%) 3 (0.8%) 0 (0.8%) 1 (0.3%)	CATARACT SUBCAPSULAR	0 (0.0%)	4 (1.1%)	3 (0.8%)	5 (1.3%)	2 (0.5%)	5 (1.3%)	12 (3.2
EYE DISCHARGE CORNEAL EDEMA 4 (1.1%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 3 (0.8%) 4 (1.1%) 1 (CORNEAL EDEMA 4 (1.1%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 2 (0.5%) 5 (1.3%) 7 (CORNEAL DISORDER NOS 12 (3.2%) 3 (0.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.5%) 5 (1.3%) 7 (RUBEOSIS IRIDIS 1 (0.3%) 0 (0.0%) 2 (0.5%) 4 (1.1%) 1 (0.3%) 2 (0.5%) 7 (CONJUNCTIVAL HEMORRHAGE 9 (2.4%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 3 (0.8%) 0 (0.0%) 3 (0.8%) 7 (IRIS ADHESIONS 4 (1.1%) 3 (0.8%) 1 (0.3%) 1 (0.3%) 0 (0.0%) 3 (0.8%) 5 (HYPHEMA 1 (0.3%) 0 (0.0%) 1 (0.3%) 1 (0.3%) 3 (0.8%) 6 (MACULAR EDEMA 1 (0.3%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 3 (0.8%) 6 (VITREOUS DETACHMENT 0 (0.0%) 1 (0.3%) 2 (0.5%) 1 (0.3%) 2 (0.5%) 0 (0.0%) 3 (0.8%) 6 (VITREOUS DETACHMENT 0 (0.0%) 1 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 3 (0.8%) 6 (UVEITIS NOS 6 (1.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 3 (0.8%) 6 (BLININDES NEC 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 1 (0.3%) 3 (0.8%) 3 (0.8%) 3 (0.8%) 3 (0.0%) 0 (0.0%) 1 (0.3%) 1 (0.3%) 3 (0.8%) 3 (0.8%) 3 (0.8%) 3 (0.8%) 3 (0.0%) 0 (0.0%) 1 (0.3%) 1 (0.3%) 3 (0.8%) 3 (0.8%) 3 (0.8%) 3 (0.8%) 3 (0.8%) 3 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 1 (0.3%) 3 (0.8%) 3 (0.0%) 3 (0	CORNEAL EROSION	16 (4.2%)	3 (0.8%)	1 (0.3%)	4 (1.1%)	2 (0.5%)	0 (0.0%)	5 (1.3
CORNEAL EDEMA 4 (1.1%) 1 (0.3%) 1 (0.3%) 2 (0.5%) 5 (1.3%) 7 (CORNEAL DISORDER NOS 12 (3.2%) 3 (0.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (RUBEOSIS IRIDIS 1 (0.3%) 0 (0.0%) 2 (0.5%) 4 (1.1%) 1 (0.3%) 2 (0.5%) 7 (CONJUNCTIVAL HEMORRHAGE 9 (2.4%) 1 (0.3%) 1 (0.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (0.8%) 0 (HYPHEMA 1 (0.3%) 0 (0.0%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 0 (0.0%) 3 (0.8%) 5 (HYPHEMA 1 (0.3%) 0 (0.0%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 3 (0.8%) 6 (MACULAR EDEMA 1 (0.3%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 3 (0.8%) 6 (CATARACT NEC UVEITIS NOS 6 (1.6%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 3 (0.8%) 5 (UVEITIS NEC CATARACT NOS AGGRAVATED 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 3 (0.0%) 1 (0.3%) 3 (0.0%) 1 (0.3%) 3 (0.0%) 1 (0.3%) 3 (0.0%) 1 (0.3%) 3 (0.0%) 1 (0.3%) 3 (0.0%) 1 (0.3%) 3 (0.0%) 1 (0.3%) 3 (0.0%) 1 (0.3%) 3 (0.0%) 1 (0.0%) 1 (0.3%) 3 (0.0%) 1 (0.0%) 1 (0.0%) 1 (0.0%) 1 (0.3%) 3 (0.0%) 1 (0.0%) 1 (0.3%) 3 (0.0%) 3 (0.0%) 1 (0.0%) 1 (0.3%) 3 (0.0%) 3 (0.0%) 1 (0.0%) 1 (0.3%) 3 (0.0%)	EYE DISCHARGE	12 (3,2%)	1 (0.3%)		1 (0.3%)	3 (0.8%)	4 (1.1%)	1 (0.3
CORNEAL DISORDER NOS 12 (3.2*) 3 (0.8*) 0 (0.0*) 0 (0.0*) 0 (0.0*) 0 (0.0*) 2 (RUBEOSIS IRIDIS 1 (0.3*) 0 (0.0*) 2 (0.5*) 4 (1.1*) 1 (0.3*) 2 (0.5*) 7 (RUBEOSIS IRIDIS 1 (0.3*) 0 (0.0*) 2 (0.5*) 4 (1.1*) 1 (0.3*) 2 (0.5*) 7 (RUBEOSIS IRIDIS 1 (0.3*) 1 (0.3*) 0 (0.0*) 0 (0.0*) 3 (0.8*) 0 (0.8*) 0 (0.0*) 1 (0.3*) 0 (0.0*) 0 (0.0*) 1 (0.3*) 0 (0.0*) 1 (0.3*) 0 (0.0*) 1 (0.3*) 1 (0.	CORNEAL EDEMA	4 (1.1%)	1 (0.3%)					7 (1.9
RUBEOSIS IRIDIS 1 (0.3\$) 0 (0.0\$) 2 (0.5\$) 4 (1.1\$) 1 (0.3\$) 2 (0.5\$) 7 (CONJUNCTIVAL HEMORRHAGE 9 (2.4\$) 1 (0.3\$) 1 (0.3\$) 0 (0.0\$) 0 (0.0\$) 3 (0.8\$) 0 (IRIS ADHESIONS 4 (1.1\$) 3 (0.8\$) 1 (0.3\$) 1 (0.3\$) 0 (0.0\$) 1 (0.3\$) 5 (HYPHEMA 1 (0.3\$) 0 (0.0\$) 1 (0.3\$) 3 (0.8\$) 6 (MACULAR EDEMA 1 (0.3\$) 0 (0.0\$) 1 (0.3\$) 3 (0.8\$) 6 (MACULAR EDEMA 1 (0.3\$) 0 (0.0\$) 1 (0.3\$) 3 (0.8\$) 6 (MACULAR EDEMA 1 (0.3\$) 0 (0.0\$) 1 (0.3\$) 2 (0.5\$) 0 (0.0\$) 3 (0.8\$) 6 (MACULAR EDEMA 0 (0.0\$) 1 (0.3\$) 2 (0.5\$) 0 (0.0\$) 1 (0.3\$) 3 (0.8\$) 6 (MACULAR EDEMA 1 (0.3\$) 0 (0.0\$) 1 (0.3\$) 2 (0.5\$) 0 (0.0\$) 3 (0.0\$) 0 (0.0\$) 1 (0.3\$) 3 (0.8\$) 6 (MACULAR EDEMA 1 (0.3\$) 0 (0.0\$) 1 (0.3\$) 2 (0.5\$) 0 (0.0\$) 3 (0.0\$) 0 (0.0\$) 1 (0.3\$) 3 (0.8\$) 6 (MACULAR EDEMA 1 (0.3\$) 0 (0.0\$) 1 (0.3\$) 2 (0.5\$) 1 (0.3\$) 3 (0.8\$) 6 (MACULAR EDEMA 1 (0.3\$) 0 (0.0\$) 1 (0.3\$) 1 (0.3\$) 3 (0.8\$) 6 (MACULAR EDEMA 1 (0.3\$) 0 (0.0\$) 1 (0.3\$) 1 (0.3\$) 3 (0.8\$) 6 (MACULAR EDEMA 1 (0.3\$) 0 (0.0\$) 1 (0.3\$) 1 (0.3\$) 3 (0.8\$) 6 (MACULAR EDEMA 1 (0.3\$) 0 (0.0\$) 1 (0.3\$) 1 (0.3\$) 3 (0.8\$) 6 (MACULAR EDEMA 1 (0.3\$) 0 (0.0\$) 1 (0.3\$) 2 (0.5\$) 0 (0.0\$) 3 (0.0\$)	CORNEAL DISORDER NOS	12 (3.2%)	3 (0.8%)					2 (0.5
CONJUNCTIVAL HEMORRHAGE 9 (2.4%) 1 (0.3%) 1 (0.3%) 0 (0.0%) 0 (0.0%) 3 (0.8%) 0 (IRIS ADHESIONS 4 (1.1%) 3 (0.8%) 1 (0.3%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 3 (0.8%) 6 (MACULAR EDEMA 1 (0.3%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 3 (0.8%) 6 (MACULAR EDEMA 1 (0.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 3 (0.8%) 6 (VITREOUS DETACHMENT 0 (0.0%) 1 (0.3%) 2 (0.5%) 1 (0.3%) 2 (0.5%) 0 (0.0%) 3 (0.8%) 6 (VITREOUS DETACHMENT 0 (0.0%) 1 (0.3%) 2 (0.5%) 1 (0.3%) 2 (0.5%) 0 (0.0%) 3 (0.8%) 5 (UVEITIS NOS 6 (1.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 3 (0.8%) 5 (UVEITIS NOS 6 (1.6%) 0 (0.0%) 0 (0.0%) 1 (0.0%) 0 (0.0	RUBEOSIS IRIDIS	1 (0.3%)	0 (0.0%)			1 (0.3%)	2 (0.5%)	7 (1.9
IRIS ADHESIONS	CONJUNCTIVAL HEMORRHAGE	9 (2.4%)	1 (0.3%)					0 (0.0
HYPHEMA 1 (0.3*) 0 (0.0*) 1 (0.3*) 0 (0.0*) 1 (0.3*) 3 (0.8*) 6 (MACULAR EDEMA 1 (0.3*) 0 (0.0*) 0 (0.0*) 0 (0.0*) 1 (0.3*) 3 (0.8*) 6 (YITREOUS DETACHMENT 0 (0.0*) 1 (0.3*) 2 (0.5*) 1 (0.3*) 2 (0.5*) 0 (0.0*) 3 (CATARACT NEC 0 (0.0*) 0 (0.0*) 0 (0.0*) 0 (0.0*) 1 (0.3*) 1 (0.3*) 5 (UVETTIS NOS 6 (1.6*) 0 (0.0*) 0 (0.0*) 0 (0.0*) 1 (0.3*) 1 (0.3*) 1 (0.3*) 5 (HYPOPYON 4 (1.1*) 2 (0.5*) 0 (0.0*)	IRIS ADHESTONS	4 (1.1%)	3 (0.8%)					5 (1.3
MACULAR EDEMA MACULAR EDEMA 1 (0.3*) 0 (0.0*) 0 (0.0*) 0 (0.0*) 1 (0.3*) 3 (0.8*) 6 (VITREOUS DETACHMENT 0 (0.0*) 1 (0.3*) 2 (0.5*) 1 (0.3*) 2 (0.5*) 0 (0.0*) 3 (CATARACT NEC 0 (0.0*) 0 (0.0*) 0 (0.0*) 0 (0.0*) 1 (0.3*) 2 (0.5*) 1 (0.3*) 1 (0.3*) 5 (UVEITIS NOS 6 (1.6*) 0 (0.0*) 0 (HYPHEMA	1 (0.3%)	0 (0.0%)		0 (0.0%)	1 (0.3%)	3 (0.8%)	6 (1.6
VITREOUS DETACHMENT O (0.0%) 1 (0.3%) 2 (0.5%) 1 (0.3%) 2 (0.5%) 0 (0.0%) 3 (CATARACT NEC UVEITIS NOS 6 (1.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 1 (0.3%) 5 (UVEITIS NOS 6 (1.6%) 0 (0.0	MACIII.AR EDEMA	1 (0.3%)	0 (0.0%)					6 (1.6
CATARACT NEC (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 1 (0.3%) 5 (UVEITIS NOS (6 (1.6%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 0 (0.0%) 0 (HYPOPYON (4 (1.1%) 2 (0.5%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) BLINDNESS NEC (CATARACT NOS AGGRAVATED (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 3 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 1 (0.3%) 3 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 1 (0.3%) 3 (0.0%) 0 (0.0	VITREOUS DETACHMENT	0 (0 0%)	1 (0.3%)					3 (0.8
UVEITIS NOS 6 (1.6%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 0 (0.0%) 0 (1.0%) 0 (CATABACT NEC	0 (0.0%)	0 (0 0%)					5 (1.3
HYPOPYON	INFITIS NOS	6 (1.6%)	0 (0.0%)					0 (0.0
BLINDNESS NEC 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 1 (0.3%) 3 (CATARACT NOS AGGRAVATED 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 1 (0.3%) 4 (DRY EYE NEC 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 1 (0.3%) 2 (MACULOPATHY 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (0.8%) 3 (POSTERIOR CAPSULE OPACIFICATION 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (0.8%) 2 (VISION BLURRED CCORNEAL EPITHELIUM DEFECT 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (0.8%) 2 (KERATITIS NEC 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 3 (0.8%) 1 (RETINAL HEMORRHAGE 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 2 (0.5%) 1 (RETINAL ISCHEMIA 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 2 (0.5%) 2 (RETINAL TEAR (EXC DETACHMENT) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 1 (0.3%) 2 (0.5%) 2 (0.5%) 2 (RETINAL TEAR (EXC DETACHMENT)	HADUDAUM	4 (7 1%)	2 (0.5%)					0 (0.0
CATARACT NOS AGGRAVATED 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 1 (0.3%) 4 (DRY EYE NEC 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 2 (MACULOPATHY 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (0.8%) 3 (POSTERIOR CAPSULE OPACIFICATION 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 5 (VISION BLURRED 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (0.8%) 2 (CORNEAL EPITHELIUM DEFECT 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 3 (0.8%) 1 (KERATITIS NEC 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 3 (0.8%) 1 (RETINAL HEMORRHAGE 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 2 (0.5%) 1 (RETINAL ISCHEMIA 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 2 (0.5%) 2 (RETINAL TEAR (EXC DETACHMENT) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 1 (0.3%) 2 (0.5%) 2 (RETINAL TEAR (EXC DETACHMENT)	RITUDIESS NEC	0 (0.0%)	0 (0 0%)					3 (0.8
DRY EYE NEC 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (0.5%) 0 (0.0%) 3 (0.8%) 3 (MACULOPATHY 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (0.8%) 3 (POSTERIOR CAPSULE OPACIFICATION 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 5 (VISION BLURRED 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (0.8%) 2 (CORNEAL EPITHELIUM DEFECT 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 3 (0.8%) 1 (KERATITIS NEC 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 3 (0.8%) 1 (RETINAL HEMORRHAGE 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 2 (0.5%) 2 (RETINAL ISCHEMIA 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 2 (0.5%) 2 (RETINAL TEAR (EXC DETACHMENT) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 1 (0.3%) 2 (0.5%) 2 (RETINAL TEAR (EXC DETACHMENT)	CATARACT NOS AGGRAVATED	0 (0.0%)	0 (0.01)					4 (1.1
MACULOPATHY 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (0.8%) 3 (POSTERIOR CAPSULE OPACIFICATION 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 5 (VISION BLURRED 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (0.8%) 2 (CORNEAL EPITHELIUM DEFECT 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 3 (0.8%) 1 (RETINAL HEMORRHAGE 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 2 (0.5%) 1 (RETINAL ISCHEMIA 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 2 (0.5%) 2 (RETINAL TEAR (EXC DETACHMENT) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 1 (0.3%) 2 (0.5%) 2 (RETINAL TEAR (EXC DETACHMENT)	DRY EVE NEC	0 (0.0%)	0 (0.007					2 (0.5
POSTERIOR CAPSULE OPACIFICATION O (0.0%) S (0.0	MACIT ODATHY	0 (0.0%)	0 (0.0%)					3 (0.8
VISION BLURRED 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (0.8%) 2 (CORNEAL EPITHELIUM DEFECT 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 3 (0.8%) 1 (KERATITIS NEC 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 1 (RETINAL HEMORRHAGE 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 2 (0.5%) 2 (RETINAL ISCHEMIA 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 2 (0.5%) 2 (RETINAL TEAR (EXC DETACHMENT) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 1 (0.3%) 2 (0.5%) 0 (DOCTEDIOD CARCILE ODACIETCATION	0 (0.0%)	0 (0.0%)	, ,				5 (1.3
CORNEAL EPITHELIUM DEFECT O (0.0%) O (0.0%) O (0.0%) D (0.0%)	VICTOR BLIDDED	0 (0.0%)	0 (0.0%)					2 (0.5
KERATITIS NEC 0 (0.0%)	CODMENT EDITEDITIEM DEFECT	0 (0.05)	0 (0.0%)					1 (0.3
RETINAL HEMORRHAGE 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 2 (0.5%) 2 (0.5%) 2 (0.5%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (0.5%) 2 (0.5%) 2 (0.5%) 2 (0.5%) 2 (0.5%) 0 (0.0%) 0	CORNERS SELICIBITON DELECT	0 (0.0%)	0 (0.0%)					1 (0.3
RETINAL ISCHEMIA 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (0.5%) 2 (RETINAL TEAR (EXC DETACHMENT) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 1 (0.3%) 2 (0.5%) 0 (0.0%) 0 (DEMINIT REWODDRIVE VEVVIII 19 NGC	0 (0.0%)	0 (0.0%)					2 (0.5
RETINAL ISCREMIA 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (0.5%) 2 (0.5%) 2 (0.5%) 0 (0.0%) 1 (0.3%) 1 (0.3%) 2 (0.5%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 1 (REILNAL DEMOKKHAGE	0 (0.0%)	0 (0.04)					2 (0.59
RELINAL DEAR (DAG DELACTMENT) U (U.U5) U (U.	RETINAL ISCHEMIA	0 (0.0%)	0 (0.0%)					0 (0.0%
	RETINAL TEAK (BAC DETACHMENT)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	3 (0.8%

Table 11

Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period of Onset

Safety Population
Treatment: 55 IU Vitrase (n = 377)

stem Organ Class / Preferred Term	_	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 18
CORNEAL ABRASION DIPLOPIA EYE ALLERGY GLAUCOMA NOS INTRAOCULAR PRESSURE INCREASED PHOTOPHOBIA AGGRAVATED RETINOPATHY DIABETIC EYE DEGENERATIVE DISORDER NOS FOREIGN BODY RETAINED IN EYE HYPOTONY OF EYE OCULAR HYPERTENSION OPTIC ATROPHY PERIORBITAL HEMATOMA POST-OPERATIVE PAIN PSEUDOPHAKIA RETINAL SCAR ANGLE CLOSURE GLAUCOMA ANISEIKONIA BLEPHAROCONJUNCTIVITIS BLINDNESS TRANSIENT CHOROIDAL DETACHMENT CONJUNCTIVITIS (INFECTIVE) NEC CONJUNCTIVITIS NEC CORNEAL DEGENERATION CORNEAL OPACITY ERYTHEMA NEC EYE INFECTION FUNGAL NOS EYELID EDEMA IRIDOCYCLITIS KERATOCONJUNCTIVITIS KERATOPATHY NOS LACRIMAL DUCT OBSTRUCTION NOS MACULAR DEGENERATION MEIBOMIAN CYST OPEN ANGLE GLAUCOMA NOS PAINFUL RED EYES RETINAL DEPIGMENTATION RETINAL MICROANEURYSMS TOPOGRAPHY CORNEAL ABNORMAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	1 (0.
DIPLOPIA	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.
EYE ALLERGY	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.
GLAUCOMA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	1 (0.
INTRAOCULAR PRESSURE INCREASED	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	2 (0.5%)	0 (0.
PHOTOPHOBIA AGGRAVATED	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.
RETINOPATHY DIABETIC	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	1 (0.
EYE DEGENERATIVE DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.
FOREIGN BODY RETAINED IN EYE	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.
HYPOTONY OF EYE	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.
OCILIAR HYPERTENSION	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0
OPTIC ATROPHY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.
PERIORRITAL HEMATOMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	0 (0.
POST-OPERATIVE DAIN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0
DCEIDODHAKIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0
DETINAL SCAP	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0
ANGLE CLOSURE CLAUCOMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0
ANTERTRONTA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0
DI PDUNDACANTINCTIVITTE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0
SUBPRANCONUNCTIVITS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0
SMODOLDY DEMYGRADAM	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0
CONTINUES (INDECEDED NO.	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0
CONTINUENCE AND CONTINUENCE OF CONTI	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0
CONJUNCTIVITIS NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0
CORNEAL DEGENERATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0
CORNEAL OPACITY	0 (0.04)		0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0
CORTICAL OPACITY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0
ERYTHEMA NEC	1 (0.3%)	0 (0.0%)					0 (0
EYE INFECTION FUNGAL NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0
EYELID EDEMA	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0
IRIDOCYCLITIS	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)			0 (0
KERATOCONJUNCTIVITIS	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
KERATOPATHY NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%)	1 (0 1 (0
LACRIMAL DUCT OBSTRUCTION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		0 (0.0%)	
MACULAR DEGENERATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0
MEIBOMIAN CYST	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0
OPEN ANGLE GLAUCOMA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0
PAINFUL RED EYES	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0
RETINAL DEPIGMENTATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0
RETINAL MICROANEURYSMS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0
TOPOGRAPHY CORNEAL ABNORMAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0
VESTIGATIONS	10 (2.7%)	3 (0.8%)	3 (0.8%)	3 (0.8%)	5 (1.3%)	16 (4.2%)	16 (4
INTRAOCULAR PRESSURE INCREASED	4 (1.1%)	1 (0.3%)	3 (0.8%)	2 (0.5%)	5 (1.3%)	16 (4.2%)	15 (4
CORNEAL STAINING	6 (1.6%)	2 (0.5%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.

Table 11
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period of Onset Safety Population

Treatment: 55 IU Vitrase (n = 377)

System Organ Class / Preferred Term	Day0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
SKIN & SUBCUTANEOUS TISSUE DISORDERS	26 (6.9%)	2 (0.5%)	3 (0.8%)	2 (0.5%)	1 (0.3%)	7 (1.9%)	3 (0.8%)
EYELID EDEMA	22 (5.8%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	4 (1.1%)	2 (0.5%)
ERYTHEMA NEC	11 (2.9%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	7 (1.9%)	2 (0.5%)
PERIORBITAL EDEMA	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PRURITUS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
SURGICAL AND MEDICAL PROCEDURES	5 (1.3%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	0 (0.0%)	4 (1.1%)	2 (0.5%)
POST-OPERATIVE COMPLICATIONS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	3 (0.8%)	1 (0.3%)
UNSPECIFIED COMPLICATION OF PROCEDURE NEC	3 (0.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
EYE IRRITATION	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
POST-OPERATIVE HEMORRHAGE	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
SUTURE LINE PAIN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
VITRECTOMY	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
NERVOUS SYSTEM DISORDERS	2 (0.5%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
PUPILLARY DISORDER NOS	2 (0.5%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
IMMUNE SYSTEM DISORDERS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
HYPERSENSITIVITY NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
INJURY AND POISONING	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)
CHEMICAL BURNS OF EYE	0 (0.0%)	0 (0.0%)		0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)

Table 11 Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class

Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period of Onset

Safety Population
Treatment: 75 IU Vitrase (n = 391)

Day0-Day 1 Day 2-Day 7 Day 8-Day 30 Day 31-Day 60 Day 61-Day 90 Day 90-Day 180 > Day 180 System Organ Class / Preferred Term 77 (19.7%) 102 (26.1%) 92 (23.5%) 106 (27.1%) 129 (33.0%) 131 (33.5%) NUMBER OF PATIENTS WITH AT LEAST ONE ADVERSE EVENT 314 (80.3%) EYE DISORDERS 314 (80.3%) 75 (19.2%) 98 (25.1%) 92 (23.5%) 104 (26.6%) 127 (32.5%) 129 (33.0%) 7 (1.8%) 9 (2,3%) 17 (4.3%) 14 (3.6%) 231 (59.1%) 24 (6.1%) 13 (3.3%) IRITIS 12 (3.1%) 8 (2.0%) 11 (2.8%) 198 (50.6%) 6 (1.5%) 9 (2.3%) 7 (1.8%) OCULAR HYPEREMIA 20 (5.1%) EYE PAIN 111 (28.4%) 15 (3.8%) 10 (2.6%) 8 (2.0%) 8 (2.0%) 23 (5.9%) 76 (19.4%) 22 (5.6%) 14 (3.6%) 15 (3.8%) 14 (3.6%) 15 (3.8%) LACRIMATION INCREASED 10 (2.6%) 69 (17.6%) 20 (5.1%) 24 (6.1%) 20 (5.1%) 17 (4.3%) 17 (4.3%) 21 (5.4%) EYE IRRITATION 76 (19.4%) 10 (2.6%) 15 (3.8%) 10 (2.6%) ABNORMAL SENSATION IN EYE 14 (3.6%) 13 (3.3%) 9 (2.3%) 52 (13.3%) 16 (4.1%) 13 (3.3%) 10 (2.6%) 11 (2.8%) 11 (2.8%) 15 (3.8%) PHOTOPHOBIA 27 (6.9%) 18 (4.6%) 17 (4.3%) 21 (5.4%) 19 (4.9%) 28 (7.2%) 13 (3.3%) VITREOUS FLOATERS 24 (6.1%) 18 (4.6%) 23 (5.9%) VISUAL ACUITY REDUCED 31 (7.9%) 12 (3.1%) 11 (2.8%) 13 (3.3%) 3 (0.8%) 81 (20.7%) 2 (0.5%) 1 (0.3%) 1 (0.3%) 3 (0.8%) 5 (1.3%) CONJUNCTIVAL EDEMA 10 (2.6%) 32 (8.2%) 40 (10.2%) 6 (1.5%) 8 (2.0%) VITREOUS HEMORRHAGE 0 (0.0%) 2 (0.5%) 9 (2.3%) 19 (4.9%) 16 (4.1%) 5 (1.3%) RETINAL DETACHMENT 0 (0.0%) 0 (0.0%) 2 (0.5%) 5 (1.3%) 4 (1.0%) 1 (0.3%) 1 (0.3%) 6 (1.5%) 4 (1.0%) 17 (4.3%) CATARACT SUBCAPSULAR 3 (0.8%) 3 (0.8%) 11 (2.8%) PHOTOPSIA 8 (2.0%) 3 (0.8%) 9 (2.3%) 6 (1.5%) 2 (0.5%) 5 (1.3%) 4 (1.0%) 10 (2.6%) 7 (1.8%) CATARACT CORTICAL 2 (0.5%) 1 (0.3%) CATARACT NUCLEAR 1 (0.3%) 1 (0.3%) 3 (0.8%) 2 (0.5%) 5 (1.3%) 7 (1.8%) 10 (2.6%) 6 (1.5%) 1 (0.3%) 4 (1.0%) 3 (0.8%) 3 (0.8%) 3 (0.8%) IRIS ADHESIONS 0 (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 5 (1.3%) 4 (1.0%) CORNEAL DISORDER NOS 17 (4.3%) CORNEAL EDEMA 19 (4.9%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (0.5%) 1 (0.3%) 7 (1.8%) 18 (4.6%) 2 (0.5%) 1 (0.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) HYPOPYON 2 (0.5%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 13 (3.3%) 2 (0.5%) 1 (0.3%) EYE DISCHARGE 3 (0.8%) 4 (1.0%) 9 (2.3%) 0 (0.0%) 3 (0.8%) 2 (0.5%) MACULAR EDEMA 0 (0.0%) 2 (0.5%) 4 (1.0%) 0 (0.0%) 0 (0.0%) 2 (0.5%) 3 (0.8%) 9 (2.3%) RUBEOSIS IRIDIS 3 (0.8%) 1 (0.3%) CONJUNCTIVAL HEMORRHAGE 11 (2.8%) 0 (0.0%) 1 (0.3%) 2 (0.5%) 0 (0.0%) 2 (0.5%) 0 (0.0%) 3 (0.8%) 2 (0.5%) 2 (0.5%) CORNEAL EROSION 11 (2.8%) 1 (0.3%) 5 (1.3%) 2 (0.5%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 1 (0.3%) 6 (1.5%) HYPHEMA 1 (0.3%) 2 (0.5%) 0 (0.0%) 0 (0.0%) 3 (0.8%) 3 (0.8%) 3 (0.8%) GLAUCOMA NOS 0 (0.0%) 1 (0.3%) 0 (0.0%) 3 (0.8%) 0 (0.0%) 6 (1.5%) BLINDNESS NEC 0 (0.0%) CATARACT NEC 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 5 (1.3%) 4 (1.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 6 (1.5%) DRY EYE NEC 0 (0.0%) 0 (0.0%) 1 (0.3%) 1 (0.3%) 0 (0.0%) 2 (0.5%) 4 (1.0%) KERATITIS NEC 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 0 (0.0%) 4 (1.0%) 2 (0.5%) HYPOTONY OF EYE 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 4 (1.0%) INTRAOCULAR PRESSURE INCREASED 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 4 (1.0%) 1 (0.3%) RETINOPATHY DIABETIC 1 (0.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (0.5%) 3 (0.8%) BLEPHARITIS 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 0 (0.0%) 3 (0.8%) 1 (0.3%) MACULOPATHY 1 (0.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 2 (0.5%) 1 (0.3%) POST-OPERATIVE PAIN POSTERIOR CAPSULE OPACIFICATION 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 4 (1.0%) VITREOUS DETACHMENT 0 (0.0%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 0 (0.0%) 1 (0.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) MYDRIASIS 2 (0.5%) 1 (0.3%) 0 (0.0%) 1 (0.3%) UVEITIS NOS 4 (1.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)

Events are included in the period in which they began.

00

s:\dat\acs\iss2002\sas\programs\t_ocae_onset 06SEP2002 17:34

Table 11

Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period of Onset

Safety Population
Treatment: 75 IU Vitrase (n = 391)

stem Organ Class / Preferred Term	Day0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 18
VISION BLURRED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	3 (0 .
CATARACT NOS AGGRAVATED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	2 (0.
CONJUNCTIVITIS NEC	2 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.
CORNEAL ABRASION	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.
CORNEAL EPITHELIUM DEFECT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0
DIPLOPIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	0 (0
PAINFUL RED EYES	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	0 (0
RETINAL ISCHEMIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0
RETINAL TEAR (EXC DETACHMENT)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0
VITREOUS DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0
APHAKIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0
BLINDNESS NIGHT	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0
BLOODSHOT EYE	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0
CCONJUNCTIVAL EDEMA	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0
CHALAZION	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0
CHEMOSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0
CHOROIDAL DETACHMENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0
CHOROIDAL HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0
OLOUR BLINDNESS NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0
ONJUNCTIVITIS (INFECTIVE) NEC	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0
ONJUNCTIVITIS ALLERGIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 ((
ONTINCTIVITIS VIRAL NOS	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 ((
ORTICAL OPACITY	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 ((
YCLITIS	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0
EYE ALLERGY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0
TYE DEGENERATIVE DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0
TYE INTECTION TOXOPLASMAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0
EYE TNELAMMATTON NOS	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0
EYELID DISORDER NOS	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0
CYELID PIOSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0
HERDES SIMPLEX OPHTHALMIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	ō (c
CERATOCONJUNCTIVITIS	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 ((
CERATOPATHY BAND	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 ((
ENTICHTAR OPACITIES	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 ((
ETROMIAN CYST	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0
CITAR HYPERAEMIA	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0
OCIDAR HYPERTENSION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0
DEN ANGLE GLAHCOMA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0
PHOTOPHOBIA AGGRAVATED	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	Ö (C
POST-OPERATIVE COMPLICATIONS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0
RETINAL ARTERY EMBOLISM	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0
RETINAL DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0
RETINAL ISCHEMIA RETINAL TEAR (EXC DETACHMENT) VITREOUS DISORDER NOS APHAKIA BLINDNESS NIGHT BLOODSHOT EYE CCONJUNCTIVAL EDEMA CHALAZION CHEMOSIS CHOROIDAL DETACHMENT CHOROIDAL HEMORRHAGE COLOUR BLINDNESS NEC CONJUNCTIVITIS (INFECTIVE) NEC CONJUNCTIVITIS ALLERGIC CONJUNCTIVITIS VIRAL NOS CORTICAL OPACITY CYCLITIS EYE ALLERGY EYE DEGENERATIVE DISORDER NOS EYE INFECTION TOXOPLASMAL EYE INFLAMMATION NOS EYELID DISORDER NOS EYELID DISORDER NOS EYELID PTOSIS HERPES SIMPLEX OPHTHALMIC KERATOCONJUNCTIVITIS KERATOPATHY BAND LENTICULAR OPACITIES MEIBOMIAN CYST OCULAR HYPERAEMIA OCULAR HYPERAEMIA OCULAR HYPERTENSION OPEN ANGLE GLAUCOMA NOS PHOTOPHOBIA AGGRAVATED POST-OPERATIVE COMPLICATIONS NOS RETINAL ARTERY EMBOLISM RETINAL DISORDER NOS RETINAL VEIN THROMBOSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0
RETINAL VEIN THROMBOSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0
ADIIIID . SIN IIIIONDODID	5 (0.00)	0 (0.00/	0 (0.007	- ,/	,	= (,	- , -

Table 11

Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period of Onset

Safety Population
Treatment: 75 IU Vitrase (n = 391)

System Organ Class / Preferred Term	Day0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
			- (0 (0 08)	0 / 0 00)	1 (0.3%)
STRABISMUS NEC	0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%) 1 (0.3%)	0 (0.3%)
VISUAL ACUITY REDUCED TRANSIENTLY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
VISUAL DISTURBANCE NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
STRABISMUS NEC VISUAL ACUITY REDUCED TRANSIENTLY VISUAL DISTURBANCE NOS VITREOUS OPACITIES		0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
INVESTIGATIONS INTRAOCULAR PRESSURE INCREASED	15 (3.8%)	4 (1.0%)	6 (1.5%)	1 (0.3%)	2 (0.5%)	19 (4.9%)	13 (3.3%)
INTRAOCULAR PRESSURE INCREASED	12 (3.1%)	2 (0.5%)	4 (1.0%)	1 (0.3%)	2 (0.5%)	18 (4.6%)	12 (3.1%)
CORNEAL STAINING	4 (1.0%)	2 (0.5%)	2 (0.5%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
SKIN & SUBCUTANEOUS TISSUE DISORDERS	25 (6.4%)	1 (0.3%)	2 (0.5%)	2 (0.5%)	3 (0.8%)	4 (1.0%)	3 (0.8%)
EYELID EDEMA	17 (4.3%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	3 (0.8%)	3 (0.8%)	2 (0.5%)
ERYTHEMA NEC	12 (3.1%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	2 (0.5%)	3 (0.8%)	1 (0.3%)
DERMATITIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
ECCHYMOSIS	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
OCULAR HYPEREMIA	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PERIORBITAL EDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
SURGICAL AND MEDICAL PROCEDURES	2 (0.5%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	3 (0.8%)
POST-OPERATIVE COMPLICATIONS NOS	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	1 (0.3%)
UNSPECIFIED COMPLICATION OF PROCEDURE NEC	2 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
LENS IMPLANT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
SCLERAL OPERATION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
VITRECTOMY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
NERVOUS SYSTEM DISORDERS	2 (0.5%)	0 (0.0%)	2 (0.5%)	0 (0.0%)	3 (0.8%)	0 (0.0%)	0 (0.0%)
PUPILLARY DISORDER NOS	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	0 (0.0%)	0 (0.0%)
FACIAL PALSY	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
HEADACHE NOS	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PUPILLARY REFLEX IMPAIRED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)
VISUAL FIELD DEFECT NOS	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
MECHANICAL COMPLICATION OF IMPLANT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
NEOPLASMS BENIGN AND MALIGNANT (INCLUDING CYSTS AND POLYPS)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	·0 (0.0%)	1 (0.3%)
BENIGN NEOPLASM OF CHOROID	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
VASCULAR DISORDERS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%)	1 (0.3%)
PERIPHERAL ISCHEMIA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)

s:\dat\acs\iss2002\sas\programs\t_ocae_onset 06SEP2002 17:34

Page 1 of 10

ISTA Pharmaceuticals, Inc. Integrated Summary of Safety

Table 12

Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period of Onset Safety Population

Treatment: WW Control (n = 18)

System Organ Class / Preferred Term	Day0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
NUMBER OF PATIENTS WITH AT LEAST ONE RELATED ADVERSE EVENT	3 (16.7%)	2 (11.1%)	2 (11.1%)	6 (33.3%)	3 (16.7%)	3 (16.7%)	2 (11.1%)
EYE DISORDERS	3 (16.7%)	2 (11.1%)	2 (11.1%)	6 (33.3%)	3 (16.7%)	3 (16.7%)	2 (11.1%)
EYE IRRITATION	1 (5.6%)	1 (5.6%)	1 (5.6%)	0 (0.0%)	2 (11.1%)	1 (5.6%)	0 (0.0%)
PHOTOPHOBIA	2 (11.1%)	0 (0.0%)	1 (5.6%)	1 (5.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
VITREOUS FLOATERS	1 (5.6%)	0 (0.0%)	1 (5.6%)	2 (11.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
IRIS ADHESIONS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)	1 (5.6%)
ABNORMAL SENSATION IN EYE	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CATARACT CORTICAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)
CATARACT NOS AGGRAVATED	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CATARACT NUCLEAR	0 (0.0%)	1 (5.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CONJUNCTIVAL EDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)
CORNEAL EPITHELIUM DEFECT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)
LACRIMATION INCREASED	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)	1 (5.6%)	0 (0.0%)
OCULAR HYPEREMIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)	1 (5.6%)	1 (5.6%)
RETINAL DETACHMENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)
RUBEOSIS IRIDIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
UVEITIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
VISUAL ACUITY REDUCED	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
VITREOUS HEMORRHAGE	1 (5.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Table 12 Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period of Onset Safety Population Treatment: Saline Control (n = 378)

System Organ Class / Preferred Term	Day0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
NUMBER OF PATIENTS WITH AT LEAST ONE RELATED ADVERSE EVENT	202 (53.4%)	49 (13.0%)	53 (14.0%)	37 (9.8%)	39 (10.3%)	50 (13.2%)	49 (13.0%
EYE DISORDERS OCULAR HYPEREMIA IRITIS EYE IRRITATION EYE PAIN LACRIMATION INCREASED ABNORMAL SENSATION IN EYE CONJUNCTIVAL EDEMA VISUAL ACUITY REDUCED PHOTOPHOBIA VITREOUS FLOATERS VITREOUS HEMORRHAGE CATARACT CORTICAL CATARACT TUCLEAR CONJUNCTIVAL HEMORRHAGE PHOTOPSIA EYE DISCHARGE CATARACT SUBCAPSULAR RETINAL DETACHMENT RUBEOSIS IRIDIS CORNEAL EDEMA CATARACT NOS AGGRAVATED CORNEAL DEMA CATARACT NOS AGGRAVATED CORNEAL DEMA CATARACT NOS CORNEAL DEMA CATARACT NOS CORNEAL DEMA CATARACT NOS REGRAVATED CORNEAL DEMA CATARACT NOS CORNEAL DEMA CATARACT NOS HYPHEMA IRIS ADHESIONS MACULAR EDEMA CATARACT NEC DIPLOPIA DRY EYE NEC MACULOPATHY POSTERIOR CAPSULE OPACIFICATION RETINOPATHY DIABETIC APHAKIA BLINDNESS NEC FOREIGN BODY RETAINED IN EYE INTRAOCULAR PRESSURE DECREASED KERATITIS NEC KERATITIS NEC KERATITIS NEC KERATOCONJUNCTIVITIS MYDRIASIS PAINFUL RED EYES	200 (52.9%)	49 (13.0%)	53 (14.0%)	33 (8.7%)	39 (10.3%)	48 (12.7%)	48 (12.7%)
OCULAR HYPEREMIA	106 (28.0%)	6 (1.6%)	4 (1.1%)	0 (0.0%)	4 (1.1%)	1 (0.3%)	0 (0.0%
IRITIS	83 (22.0%)	15 (4.0%)	11 (2.9%)	2 (0.5%)	2 (0.5%)	5 (1.3%)	1 (0.3%
EYE IRRITATION	51 (13.5%)	8 (2.1%)	10 (2.6%)	7 (1.9%)	12 (3.2%)	3 (0.8%)	6 (1.6%
EYE PAIN	45 (11.9%)	4 (1.1%)	2 (0.5%)	1 (0.3%)	4 (1.1%)	1 (0.3%)	3 (0.8%
LACRIMATION INCREASED	32 (8.5%)	6 (1.6%)	10 (2.6%)	5 (1.3%)	5 (1.3%)	4 (1.1%)	2 (0.5%
ABNORMAL SENSATION IN EYE	37 (9.8%)	3 (0.8%)	4 (1.1%)	5 (1.3%)	2 (0.5%)	3 (0.8%)	2 (0.5%
CONJUNCTIVAL EDEMA	45 (11.9%)	3 (0.8%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%
VISUAL ACUITY REDUCED	7 (1.9%)	6 (1.6%)	8 (2.1%)	7 (1.9%)	7 (1.9%)	5 (1.3%)	8 (2.1%
PHOTOPHOBIA	15 (4.0%)	7 (1.9%)	8 (2.1%)	6 (1.6%)	3 (0.8%)	6 (1.6%)	4 (1.1%
VITREOUS FLOATERS	5 (1.3%)	14 (3.7%)	6 (1.6%)	8 (2.1%)	7 (1.9%)	7 (1.9%)	3 (0.8%
VITREOUS HEMORRHAGE	0 (0.0%)	1 (0.3%)	2 (0.5%)	5 (1.3%)	4 (1.1%)	11 (2.9%)	7 (1.9%
CATARACT CORTICAL	0 (0.0%)	1 (0.3%)	2 (0.5%)	0 (0.0%)	0 (0.0%)	6 (1.6%)	7 (1.9%
CATARACT NUCLEAR	1 (0.3%)		2 (0.5%)	2 (0.5%)	1 (0.3%)	1 (0.3%)	9 (2.4%
CORNEAL EROSION	11 (2.9%)			2 (0.5%)	0 (0.0%)	1 (0.3%)	0 (0.0%
CONJUNCTIVAL HEMORRHAGE	12 (3.2%)	1 (0.3%)		0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%
PHOTOPSIA	2 (0.5%)			3 (0.8%)	1 (0.3%)	2 (0.5%)	3 (0.8%
EYE DISCHARGE	11 (2.9%)			0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%
CATARACT SUBCAPSULAR	0 (0.0%)			1 (0.3%)	1 (0.3%)	1 (0.3%)	6 (1.6%
RETINAL DETACHMENT	0 (0.0%)	•		2 (0.5%)	2 (0.5%)	2 (0.5%)	2 (0.5%
RUBEOSIS IRIDIS	0 (0.0%)			0 (0.0%)	2 (0.5%)	1 (0.3%)	2 (0.5%
CORNEAL EDEMA	1 (0.3%)			0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%
CATARACT NOS AGGRAVATED	0 (0.0%)			0 (0.0%)	0 (0.0%)	2 (0.5%)	1 (0.3%
CORNEAL DISORDER NOS	1 (0.3%)			0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%
НУРНЕМА	0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%
IRIS ADHESIONS	0 (0.0%)			0 (0.0%)	0 (0.0%)	1 (0.3%)	2 (0.5%
MACULAR EDEMA	0 (0.0%)			0 (0.0%)	0 (0.0%)	2 (0.5%)	1 (0.3%
CATARACT NEC	0 (0.0%)			0 (0.0%)	1 (0.3%)	1 (0.3%)	0 (0.0%
DIPLOPIA	0 (0.0%)			0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%
DRY EYE NEC	2 (0.5%)	The state of the s		0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
MACULOPATHY	0 (0.0%)			0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%
POSTERIOR CAPSULE OPACIFICATION	0 (0.0%)			0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%
RETINOPATHY DIABETIC	0 (0.0%)			0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%
APHAKIA	0 (0.0%)			0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%
BLINDNESS NEC	0 (0.0%)			0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%
FOREIGN BODY RETAINED IN EYE	1 (0.3%)			0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
INTRAOCULAR PRESSURE DECREASED	1 (0.3%)			0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
INTRACCODAR PRESSURE DECREASED	1 (0.3%)			0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
KERATITIS NEC	1 (0.3%)			0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
KERATOCONJUNCTIVITIS MYDRIASIS	1 (0.3%)			· · · · · · · · · · · · · · · · · · ·	0 (0.0%)	0 (0.0%)	0 (0.0%
MYDRIASIS	1 (0.3%)			0 (0.0%)			0 (0.0%
PAINFUL RED EYES	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%

s:\dat\acs\iss2002\sas\programs\t_ocrae_onset 06SEP2002 17:34

Table 12 Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period of Onset Safety Population Treatment: Saline Control (n = 378)

System Organ Class / Preferred Term	Day0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
PHOTOPHOBIA AGGRAVATED	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PSEUDOPHAKIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
RETINAL DISORDER NOS	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
RETINAL HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
UVEITIS NOS	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)
VITREOUS DETACHMENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
VITREOUS DISORDER NOS	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
INVESTIGATIONS	12 (3.2%)	4 (1.1%)	1 (0.3%)	5 (1.3%)	0 (0.0%)	3 (0.8%)	2 (0.5%)
INTRAOCULAR PRESSURE INCREASED	10 (2.6%)	3 (0.8%)	1 (0.3%)	4 (1.1%)	0 (0.0%)	3 (0.8%)	^ 2 (0.5%)
CORNEAL STAINING	2 (0.5%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
SKIN & SUBCUTANEOUS TISSUE DISORDERS	12 (3.2%)	1 (0.3%)	2 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
ERYTHEMA NEC	7 (1.9%)	0 (0.0%)	2 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYELID EDEMA	5 (1.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
OCULAR HYPEREMIA	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
INFECTIONS AND INFESTATIONS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
HYPOPYON	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
INJURY AND POISONING	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
HEAD INJURY	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
NERVOUS SYSTEM DISORDERS	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
VISUAL FIELD DEFECT NOS	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
SURGICAL AND MEDICAL PROCEDURES	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
UNSPECIFIED COMPLICATION OF PROCEDURE NEC	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Table 12

Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period of Onset Safety Population

Treatment: 7.5 IU Vitrase (n = 198)

System Organ Class / Preferred Term	Day0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
NUMBER OF PATIENTS WITH AT LEAST ONE RELATED	147 (74.2%)		42 (21.2%)	48 (24.2%)	38 (19.2%)	44 (22.2%)	40 (20.2
EYE DISORDERS IRITIS OCULAR HYPEREMIA EYE IRRITATION EYE PAIN VISUAL ACUITY REDUCED LACRIMATION INCREASED ABNORMAL SENSATION IN EYE PHOTOPHOBIA VITREOUS FLOATERS VITREOUS HEMORRHAGE CONJUNCTIVAL EDEMA CATARACT SUBCAPSULAR PHOTOPSIA CATARACT NUCLEAR RETINAL DETACHMENT RUBEOSIS IRIDIS CONJUNCTIVAL HEMORRHAGE CORNEAL EROSION CORNEAL DISORDER NOS CORNEAL EDEMA IRIS ADHESIONS CATARACT CORTICAL EYE DISCHARGE HYPHEMA KERATITIS NEC MACULAR EDEMA CONJUNCTIVITIS NEC CORNEAL EPITHELIUM DEFECT FOREIGN BODY RETAINED IN EYE INTRAOCULAR PRESSURE DECREASED INTRAOCULAR PRESSURE INCREASED INTRAOCULAR PRESSURE INCREASED INTRAOCULAR PRESSURE INCREASED IRIDOCYCLITIS BLINDNESS NEC CHORIORETINAL ATROPHY CHORIORETINAL DISORDER NOS CORNEAL ABRASION CORNEAL ABRASION CORNEAL OPACITY JORTICAL OPACITY DIPLOPIA DRY EYE NEC	146 (73.7%)	38 (19.2%)	39 (19.7%)	46 (23.2%)	38 (19.2%)	42 (21.2%)	40 (20.2
IRITIS	80 (40.4%)	10 (5.1%)	8 (4.0%)	5 (2.5%)	6 (3.0%)	3 (1.5%)	6 (3.0
OCULAR HYPEREMIA	78 (39.4%)	2 (1.0%)	2 (1.0%)	3 (1.5%)	3 (1.5%)	2 (1.0%)	2 (1.0
EYE IRRITATION	40 (20.2%)	6 (3.0%)		8 (4.0%)	7 (3.5%)	4 (2.0%)	5 (2.5
EYE PAIN	29 (14.6%)	5 (2.5%)	3 (1.5%)	3 (1.5%)	5 (2.5%)	5 (2.5%)	4 (2.0
VISUAL ACUITY REDUCED	20 (10.1%)	4 (2.0%)		4 (2.0%)	9 (4.5%)	7 (3.5%)	6 (3.0
LACRIMATION INCREASED	23 (11.6%)	3 (1.5%)		7 (3.5%)	6 (3.0%)	4 (2.0%)	4 (2.0
ABNORMAL SENSATION IN EYE	27 (13.6%)	0 (0.0%)		4 (2.0%)	5 (2.5%)	5 (2.5%)	5 (2.5
PHOTOPHOBIA	11 (5.6%)	3 (1.5%)	9 (4.5%)	9 (4.5%)	6 (3.0%)	5 (2.5%)	4 (2.0
VITREOUS FLOATERS	12 (6.1%)	7 (3.5%)	7 (3.5%)	12 (6.1%)	4 (2.0%)	5 (2.5%)	2 (1.0
VITREOUS HEMORRHAGE	1 (0.5%)	1 (0.5%)	4 (2.0%)	7 (3.5%)	7 (3.5%)	10 (5.1%)	7 (3.5
CONJUNCTIVAL EDEMA	25 (12.6%)	1 (0.5%)	1 (0.5%)	1 (0.5%)	1 (0.5%)	1 (0.5%)	1 (0.5
CATARACT SUBCAPSULAR	0 (0.0%)	1 (0.5%)	2 (1.0%)	2 (1.0%)	0 (0.0%)	6 (3.0%)	9 (4.
PHOTOPSIA	3 (1.5%)	4 (2.0%)	1 (0.5%)	4 (2.0%)	4 (2.0%)	3 (1.5%)	3 (1.
CATARACT NUCLEAR	0 (0.0%)	1 (0.5%)	1 (0.5%)	3 (1.5%)	2 (1.0%)	2 (1.0%)	4 (2.
RETINAL DETACHMENT	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	2 (1.0%)	5 (2.5%)	4 (2.
RUBEOSIS IRIDIS	0 (0.0%)	0 (0.0%)	2 (1.0%)	2 (1.0%)	1 (0.5%)	0 (0.0%)	3 (1.
CONJUNCTIVAL HEMORRHAGE	5 (2.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.
CORNEAL EROSION	4 (2.0%)	0 (0.0%)	1 (0.5%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.
CORNEAL DISORDER NOS	3 (1.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
CORNEAL EDEMA	1 (0.5%)	0 (0.0%)	1 (0.5%)	1 (0.5%)	0 (0.0%)	1 (0.5%)	0 (0.
IRIS ADHESIONS	0 (0.0%)	1 (0.5%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.
CATARACT CORTICAL	0 (0.0%)	0 (0.0%)	1 (0.5%)	2 (1.0%)	0 (0.0%)	0 (0.0%)	1 (0.
EYE DISCHARGE	3 (1.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.
НҮРНЕМА	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.0%)	1 (0.
KERATITIS NEC	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.
MACULAR EDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	2 (1.
CONJUNCTIVITIS NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.
CORNEAL EPITHELIUM DEFECT	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
FOREIGN BODY RETAINED IN EYE	1 (0.5%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
INTRAOCULAR PRESSURE DECREASED	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.
INTRAOCULAR PRESSURE INCREASED	1 (0.5%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.
IRIDOCYCLITIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.
BLINDNESS NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
CHORIORETINAL ATROPHY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.
CHORIORETINAL DISORDER NOS	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0
CORNEAL ABRASION	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.
CORNEAL OPACITY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.
CORTICAL OPACITY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.
DIPLOPIA	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0
DRY EYE NEC	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5
DAI BIE NOC	0 (0.04)	0 (0.0%)	0 (0.06)	0 (0.0%)	0 (0.0%)	0 (0.0%)	± (U.

s:\dat\acs\iss2002\sas\programs\t_ocrae_onset 06SEP2002 17:34

Table 12 Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period of Onset Safety Population

Treatment: 7.5 IU Vitrase (n = 198)

System Organ Class / Preferred Term	Day0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
EYE DEGENERATIVE DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
EYELID PTOSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)
GLAUCOMA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)
HYPOPYON	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
MACULAR DEGENERATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
MACULOPATHY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
OPEN ANGLE GLAUCOMA NOS	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PINGUECULA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
RETINAL DEPIGMENTATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
RETINAL HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
RETINAL MICROANEURYSMS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
STRABISMUS NEC	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
UVEITIS DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
UVEITIS NOS	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
VISION BLURRED	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
VITREOUS DETACHMENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
VITREOUS DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
VITREOUS OPACITIES	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
INVESTIGATIONS	8 (4.0%)	3 (1.5%)	3 (1.5%)	3 (1.5%)	0 (0.0%)	4 (2.0%)	3 (1.5%)
INTRAOCULAR PRESSURE INCREASED	5 (2.5%)	2 (1.0%)	3 (1.5%)	3 (1.5%)	0 (0.0%)	4 (2.0%)	2 (1.0%)
CORNEAL STAINING	3 (1.5%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
SKIN & SUBCUTANEOUS TISSUE DISORDERS	6 (3.0%)	1 (0.5%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.5%)	1 (0.5%)
EYELID EDEMA	5 (2.5%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.5%)	0 (0.0%
ERYTHEMA NEC	1 (0.5%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%
CUTIS LAXA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%
SURGICAL AND MEDICAL PROCEDURES	2 (1.0%)	0 (0.0%)	1 (0.5%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%
UNSPECIFIED COMPLICATION OF PROCEDURE NEC	2 (1.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
VITRECTOMY	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
NERVOUS SYSTEM DISORDERS	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%
PUPILLARY DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%
VISUAL FIELD DEFECT NOS	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)



Table 12 Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period of Onset Safety Population

Treatment: 55 IU Vitrase (n = 377)

System Organ Class / Preferred Term	Day0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
NUMBER OF PATIENTS WITH AT LEAST ONE RELATED	259 (68.7%)		75 (19.9%)	60 (15.9%)	70 (18.6%)	53 (14.1%)	52 (13.8%
ADVERSE EVENT EYE DISORDERS IRITIS OCULAR HYPEREMIA EYE PAIN EYE PAIN EYE IRRITATION LACRIMATION INCREASED ABNORMAL SENSATION IN EYE CONJUNCTIVAL EDEMA VISUAL ACUITY REDUCED PHOTOPHOBIA VITREOUS FLOATERS VITREOUS HEMORRHAGE PHOTOPSIA CATARACT NUCLEAR CATARACT SUBCAPSULAR CATARACT CORTICAL RETINAL DETACHMENT CORNEAL DISORDER NOS CORNEAL EROSION EYE DISCHARGE IRIS ADHESIONS CORNEAL EDEMA CONJUNCTIVAL HEMORRHAGE HYPOPYON RUBEOSIS IRIDIS VITREOUS DETACHMENT HYPHEMA UVEITIS NOS CATARACT NOS AGGRAVATED MACULOPATHY PHOTOPHOBIA AGGRAVATED RETINAL TEAR (EXC DETACHMENT) VISION BLURRED BLEPHARITIS DIPLOPIA DRY EYE NEC KERATITIS NEC BLINDNESS NEC BLINDNESS TRANSIENT CATARACT NEC	256 (67.9%)	65 (17.2%)	75 (19.9%)	59 (15.6%)	68 (18.0%)	52 (13.8%)	52 (13.8%
IRITIS	184 (48.8%)	19 (5.0%)	13 (3.4%)	4 (1.1%)	6 (1.6%)	5 (1.3%)	4 (1.1%
OCULAR HYPEREMIA	150 (39.8%)	8 (2.1%)		4 (1.1%)	4 (1.1%)	2 (0.5%)	2 (0.5%
EYE PAIN	96 (25.5%)	6 (1.6%)		5 (1.3%)	9 (2.4%)	7 (1.9%)	3 (0.8%
EYE IRRITATION	64 (17.0%)	10 (2.7%)		9 (2.4%)	11 (2.9%)	4 (1.1%)	3 (0.8%
LACRIMATION INCREASED	66 (17.5%)	5 (1.3%)		17 (4.5%)	5 (1.3%)	4 (1.1%)	3 (0.8%
ABNORMAL SENSATION IN EYE	59 (15.6%)	4 (1.1%)	9 (2.4%)	8 (2.1%)	2 (0.5%)	4 (1.1%)	1 (0.3%
CONJUNCTIVAL EDEMA	69 (18.3%)	2 (0.5%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	2 (0.5%)	0 (0.0%
VISUAL ACUITY REDUCED	23 (6.1%)	5 (1.3%)	13 (3.4%)	8 (2.1%)	16 (4.2%)	12 (3.2%)	6 (1.6%
PHOTOPHOBIA	34 (9.0%)	12 (3.2%)	8 (2.1%)	6 (1.6%)	6 (1.6%)	4 (1.1%)	5 (1.3%
VITREOUS FLOATERS	18 (4.8%)	8 (2.1%)	12 (3.2%)	7 (1.9%)	13 (3.4%)	8 (2.1%)	4 (1.1%
VITREOUS HEMORRHAGE	1 (0.3%)	1 (0.3%)	4 (1.1%)	6 (1.6%)	13 (3.4%)	8 (2.1%)	10 (2.7%
PHOTOPSIA	6 (1.6%)	3 (0.8%)	8 (2.1%)	5 (1.3%)	3 (0.8%)	4 (1.1%)	3 (0.89
CATARACT NUCLEAR	2 (0.5%)	1 (0.3%)		1 (0.3%)	4 (1.1%)	4 (1.1%)	6 (1.69
CATARACT SUBCAPSULAR	0 (0.0%)	4 (1.1%)		4 (1.1%)	1 (0.3%)	2 (0.5%)	8 (2.1
CATARACT CORTICAL	3 (0.8%)	0 (0.0%)	3 (0.8%)	1 (0.3%)	2 (0.5%)	5 (1.3%)	7 (1.9
RETINAL DETACHMENT	0 (0.0%)	3 (0.8%)	4 (1.1%)	0 (0.0%)	4 (1.1%)	5 (1.3%)	5 (1.3
CORNEAL DISORDER NOS	11 (2.9%)	3 (0.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
CORNEAL EROSION	12 (3.2%)	3 (0.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
EYE DISCHARGE	10 (2.7%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0
IRIS ADHESIONS	4 (1.1%)	3 (0.8%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	2 (0.5
CORNEAL EDEMA	3 (0.8%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	2 (0.5%)	1 (0.3
CONJUNCTIVAL HEMORRHAGE	5 (1.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
HYPOPYON	4 (1.1%)	2 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
RUBEOSIS IRIDIS	1 (0.3%)	0 (0.0%)	1 (0.3%)	3 (0.8%)	1 (0.3%)	0 (0.0%)	1 (0.3
VITREOUS DETACHMENT	0 (0.0%)	1 (0.3%)	2 (0.5%)	0 (0.0%)	2 (0.5%)	0 (0.0%)	1 (0.3
HYPHEMA	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.8%)	1 (0.3
UVEITIS NOS	4 (1.1%)	0 (0.0%)		1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0
CATARACT NOS AGGRAVATED	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.8
MACULAR EDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	2 (0.5%)	0 (0.0
MACULOPATHY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	1 (0.3
PHOTOPHOBIA AGGRAVATED	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3
RETINAL TEAR (EXC DETACHMENT)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	0 (0.0
VISION BLURRED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	2 (0.5
BLEPHARITIS	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5
DIPLOPIA	0 (0.0%)	1 (0.3%)		0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0
DRY EYE NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3
KERATITIS NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3
BLINDNESS NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0,0
BLINDNESS TRANSIENT	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%
CATARACT NEC	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%

s:\dat\acs\iss2002\sas\programs\t_ocrae_onset 06SEP2002 17:34

Table 12 Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period of Onset Safety Population

Treatment: 55 IU Vitrase (n = 377)

System Organ Class / Preferred Term	-	-	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
CHOROIDAL DETACHMENT CONJUNCTIVITIS (INFECTIVE) NEC CORNEAL ABRASION CORNEAL EPITHELIUM DEFECT CORTICAL OPACITY ERYTHEMA NEC EYE ALLERGY EYE DEGENERATIVE DISORDER NOS EYELID EDEMA FOREIGN BODY RETAINED IN EYE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)
CONJUNCTIVITIS (INFECTIVE) NEC	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CORNEAL ABRASION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
CORNEAL EPITHELIUM DEFECT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
CORTICAL OPACITY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)
ERYTHEMA NEC	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYE ALLERGY	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYE DEGENERATIVE DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
EYELID EDEMA	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYELID EDEMA FOREIGN BODY RETAINED IN EYE	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
HYPOTONY OF EYE	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
INTRAOCULAR PRESSURE INCREASED	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
IRIDOCYCLITIS	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
KERATOPATHY NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
MACULAR DEGENERATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
MEIBOMIAN CYST	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
OCULAR HYPERTENSION	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
HYPOTONY OF EYE INTRAOCULAR PRESSURE INCREASED IRIDOCYCLITIS KERATOPATHY NOS MACULAR DEGENERATION MEIBOMIAN CYST OCULAR HYPERTENSION POSTERIOR CAPSULE OPACIFICATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
PSEUDOPHAKIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
RETINOPATHY DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
POSIERIOR CAPSULE OFACIFICATION PSEUDOPHAKIA RETINOPATHY DIABETIC TOPOGRAPHY CORNEAL ABNORMAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
SKIN & SUBCUTANEOUS TISSUE DISORDERS	22 (5.8%)	2 (0.5%)	3 (0.8%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	1 (0.3%
EYELID EDEMA	18 (4.8%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
ERYTHEMA NEC	10 (2.7%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	1 (0.3%)
ERYTHEMA NEC PERIORBITAL EDEMA	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
INVESTIGATIONS	9 (2.4%)	3 (0.8%)	2 (0.5%)	1 (0.3%)	3 (0.8%)	5 (1.3%)	3 (0.8%)
INTRAOCULAR PRESSURE INCREASED	4 (1.1%)	1 (0.3%)	2 (0.5%)	1 (0.3%)	3 (0.8%)	5 (1.3%)	3 (0.8%)
CORNEAL STAINING	5 (1.3%)	2 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
SURGICAL AND MEDICAL PROCEDURES	5 (1.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	3 (0.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
EYE IRRITATION	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
POST-OPERATIVE HEMORRHAGE	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
NERVOUS SYSTEM DISORDERS	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PUPILLARY DISORDER NOS	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Table 12 Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period of Onset Safety Population

Treatment: 75 IU Vitrase (n = 391)

System Organ Class / Preferred Term	Day0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
	302 (77.2%)	66 (16.9%)	75 (19.2%)	63 (16.1%)	56 (14.3%)	60 (15.3%)	49 (12.5%
ADVERSE EVENT EYE DISORDERS IRITIS OCULAR HYPEREMIA EYE PAIN EYE IRRITATION LACRIMATION INCREASED ABRORMAL SENSATION IN EYE PHOTOPHOBIA CONJUNCTIVAL EDEMA VITREOUS FLOATERS VISUAL ACUITY REDUCED VITREOUS HEMORRHAGE PHOTOPSIA RETINAL DETACHMENT CORNEAL DISORDER NOS HYPOPYON CATARACT CORTICAL IRIS ADHESIONS CATARACT SUBCAPSULAR CORNEAL EDEMA EYE DISCHARGE CORNEAL EROSION CATARACT NUCLEAR RUBEOSIS IRIDIS CONJUNCTIVAL HEMORRHAGE MACULAR EDEMA HYPHEMA GLAUCOMA NOS CATARACT NEC HYPOTONY OF EYE MACULOPATHY MYDRIASIS UVEITIS NOS DRY EYE NEC KERATITIS NEC VITREOUS DETACHMENT BLINDNESS NEC CONJUNCTIVITIS NEC POSTERIOR CAPSULE OPACIFICATION VISION BLURRED	302 (77.2%)	65 (16.6%)	73 (18.7%)	63 (16.1%)	55 (14.1%)	58 (14.8%)	48 (12.3%
IRITIS	223 (57.0%)	24 (6.1%)	12 (3.1%)	5 (1.3%)	3 (0.8%)	4 (1.0%)	5 (1.3%
OCULAR HYPEREMIA	174 (44.5%)	4 (1.0%)	5 (1.3%)	4 (1.0%)	2 (0.5%)	2 (0,.5%)	1 (0.39
EYE PAIN	101 (25.8%)	13 (3.3%)	7 (1.8%)	2 (0.5%)	4 (1.0%)	7 (1.8%)	3 (0.8
EYE IRRITATION	61 (15.6%)	17 (4.3%)	16 (4.1%)	12 (3.1%)	6 (1.5%)	7 (1.8%)	9 (2.3
LACRIMATION INCREASED	64 (16.4%)	8 (2.0%)	11 (2.8%)	8 (2.0%)	8 (2.0%)	5 (1.3%)	8 (2.0
ABNORMAL SENSATION IN EYE	71 (18.2%)	8 (2.0%)	8 (2.0%)	7 (1.8%)	3 (0.8%)	4 (1.0%)	2 (0.5
PHOTOPHOBIA	45 (11.5%)	9 (2.3%)	8 (2.0%)	11 (2.8%)	13 (3.3%)	5 (1.3%)	6 (1.5
CONJUNCTIVAL EDEMA	74 (18.9%)	2 (0.5%)	0 (0.0%)	1 (0.3%)	2 (0.5%)	0 (0.0%)	1 (0.3
VITREOUS FLOATERS	21 (5.4%)	11 (2.8%)	21 (5.4%)	14 (3.6%)	11 (2.8%)	11 (2.8%)	6 (1.5
VISUAL ACUITY REDUCED	27 (6.9%)	9 (2.3%)	9 (2.3%)	7 (1.8%)	10 (2.6%)	8 (2.0%)	5 (1.3
VITREOUS HEMORRHAGE	0 (0.0%)	1 (0.3%)	3 (0.8%)	3 (0.8%)	4 (1.0%)	12 (3.1%)	10 (2.6
PHOTOPSIA	8 (2.0%)	3 (0.8%)	7 (1.8%)	5 (1.3%)	1 (0.3%)	2 (0.5%)	4 (1.0
RETINAL DETACHMENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.8%)	5 (1.3%)	9 (2.3%)	7 (1.8
CORNEAL DISORDER NOS	17 (4.3%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	1 (0.3
HYPOPYON	18 (4.6%)	2 (0.5%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
CATARACT CORTICAL	0 (0.0%)	1 (0.3%)	1 (0.3%)	2 (0.5%)	3 (0.8%)	10 (2.6%)	3 (0.8
IRIS ADHESIONS	6 (1.5%)	1 (0.3%)	4 (1.0%)	3 (0.8%)	2 (0.5%)	2 (0.5%)	4 (1.0
CATARACT SUBCAPSULAR	2 (0.5%)	1 (0.3%)	0 (0.0%)	4 (1.0%)	3 (0.8%)	3 (0.8%)	4 (1.0
CORNEAL EDEMA	17 (4.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3
EYE DISCHARGE	9 (2.3%)	2 (0.5%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0)
CORNEAL EROSION	8 (2.0%)	1 (0.3%)	2 (0.5%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0
CORNEAD DROSION	8 (2.04)		2 (0.5%)	1 (0.3%)	2 (0.5%)	2 (0.5%)	1 (0.3
CATARACT NUCLEAR RUBEOSIS IRIDIS	1 (0.3%) 3 (0.8%)		0 (0.0%)	1 (0.3%)	2 (0.5%)	1 (0.3%)	2 (0.5
RUBEOSIS IRIDIS	3 (0.8%)	0 (0.0%)			0 (0.0%)		0 (0.0
CONJUNCTIVAL HEMORRHAGE	7 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		1 (0.3%)	
MACULAR EDEMA	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	4 (1.0
НҮРНЕМА	2 (0.5%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	1 (0.1
GLAUCOMA NOS	1 (0.3%)	2 (0.5%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	0 (0.
CATARACT NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	3 (0.1
HYPOTONY OF EYE	2 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.
MACULOPATHY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	3 (0.8%)	0 (0.1
MYDRIASIS	2 (0.5%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3
UVEITIS NOS	4 (1.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
DRY EYE NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.8
KERATITIS NEC	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3
VITREOUS DETACHMENT	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3
BLINDNESS NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3
CONJUNCTIVITIS NEC	2 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
POSTERIOR CAPSULE OPACIFICATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5
VISION BLURRED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5
VITREOUS DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5

 $\mathbf{\hat{C}}$ vents are included in the period in which they began.

s:\dat\acs\iss2002\sas\programs\t_ocrae_onset 06SEP2002 17:34

Table 12

Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period of Onset Safety Population

Treatment: 75 IU Vitrase (n = 391)

System Organ Class / Preferred Term	Day0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
BLINDNESS NIGHT	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
BLOODSHOT EYE	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CATARACT NOS AGGRAVATED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
CCONJUNCTIVAL EDEMA	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CHOROIDAL DETACHMENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
COLOUR BLINDNESS NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
CONJUNCTIVITIS (INFECTIVE) NEC	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CONJUNCTIVITIS VIRAL NOS	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CORNEAL ABRASION	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CORTICAL OPACITY	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CYCLITIS	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
DIPLOPIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
EYE INFECTION TOXOPLASMAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYE INFLAMMATION NOS	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYELID DISORDER NOS	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
INTRAOCULAR PRESSURE INCREASED	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
LENTICULAR OPACITIES	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
OCULAR HYPERAEMIA	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
OCULAR HYPERTENSION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
PHOTOPHOBIA AGGRAVATED	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
POST-OPERATIVE PAIN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)
RETINAL DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
RETINAL ISCHEMIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
RETINAL SCAR	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
RETINAL VEIN THROMBOSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
RETINOPATHY DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
STRABISMUS NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
VISUAL DISTURBANCE NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
VITREOUS OPACITIES	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
SKIN & SUBCUTANEOUS TISSUE DISORDERS	20 (5.1%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	2 (0.5%)	1 (0.3%)
EYELID EDEMA	15 (3.8%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	2 (0.5%)	1 (0.3%)
ERYTHEMA NEC	10 (2.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)
ECCHYMOSIS	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
INVESTIGATIONS	12 (3.1%)	3 (0.8%)	4 (1.0%)	0 (0.0%)	0 (0.0%)	5 (1.3%)	1 (0.3%)
INTRAOCULAR PRESSURE INCREASED	10 (2.6%)	2 (0.5%)	2 (0.5%)	0 (0.0%)	0 (0.0%)	5 (1.3%)	1 (0.3%)
CORNEAL STAINING	2 (0.5%)	1 (0.3%)	2 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
NERVOUS SYSTEM DISORDERS	2 (0.5%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	3 (0.8%)	0 (0.0%)	0 (0.0%)
PUPILLARY DISORDER NOS	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	0 (0.0%)	0 (0.0%)
_ HEADACHE NOS	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PUPILLARY REFLEX IMPAIRED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)
VISUAL FIELD DEFECT NOS	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

s:\dat\acs\iss2002\sas\programs\t_ocrae_onset 06SEP2002 17:34

Page 10 of 10

ISTA Pharmaceuticals, Inc.
Integrated Summary of Safety

Table 12

Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period of Onset Safety Population

Treatment: 75 IU Vitrase (n = 391)

System Organ Class / Preferred Term	Day0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
SURGICAL AND MEDICAL PROCEDURES	2 (0.5%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
UNSPECIFIED COMPLICATION OF PROCEDURE NEC	2 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
POST-OPERATIVE COMPLICATIONS NOS	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
SCLERAL OPERATION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
VASCULAR DISORDERS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
PERIPHERAL ISCHEMIA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)

Table 13 Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period During Which Event was Present Safety Population Treatment: WW Control (n = 18)

System Organ Class / Preferred Term	Day 0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
NUMBER OF PATIENTS WITH AT LEAST ONE ADVERSE EVENT	6 (33.3%)	7 (38.9%)	9 (50.0%)	14 (77.8%)	16 (88.9%)	13 (72.2%)	14 (77.8%)
EYE DISORDERS	6 (33.3%)	7 (38.9%)	9 (50.0%)	14 (77.8%)	16 (88.9%)	13 (72.2%)	13 (72.2%)
EYE IRRITATION	1 (5.6%)	1 (5.6%)	3 (16.7%)	3 (16.7%)	4 (22.2%)	9 (50.0%)	7 (38.9%)
PHOTOPHOBIA	3 (16.7%)	3 (16.7%)	4 (22.2%)	3 (16.7%)	2 (11.1%)	3 (16.7%)	1 (5.6%)
VITREOUS FLOATERS	1 (5.6%)	1 (5.6%)	3 (16.7%)	6 (33.3%)	6 (33.3%)	2 (11.1%)	1 (5.6%)
CATARACT CORTICAL	0 (0.0%)	0 (0.0%)	1 (5.6%)	2 (11.1%)	3 (16.7%)	3 (16.7%)	4 (22.2%)
CATARACT NUCLEAR	0 (0.0%)	1 (5.6%)	1 (5.6%)	1 (5.6%)	1 (5.6%)	2 (11.1%)	5 (27.8%)
IRITIS	1 (5.6%)	1 (5.6%)	2 (11.1%)	3 (16.7%)	3 (16.7%)	3 (16.7%)	2 (11.1%)
LACRIMATION INCREASED	1 (5.6%)	1 (5.6%)	1 (5.6%)	2 (11.1%)	3 (16.7%)	3 (16.7%)	2 (11.1%)
OCULAR HYPEREMIA	0 (0.0%)	0 (0.0%)	1 (5.6%)	2 (11.1%)	1 (5.6%)	2 (11.1%)	2 (11.1%)
VISUAL ACUITY REDUCED	2 (11.1%)	2 (11.1%)	2 (11.1%)	4 (22.2%)	4 (22.2%)	3 (16.7%)	2 (11.1%)
RETINAL DETACHMENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (16.7%)	0 (0.0%)
ABNORMAL SENSATION IN EYE	0 (0.0%)	0 (0.0%)	2 (11.1%)	2 (11.1%)	1 (5.6%)	1 (5.6%)	0 (0.0%)
CATARACT SUBCAPSULAR	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	1 (5.6%)	1 (5.6%)	1 (5.6%)
EYE PAIN	1 (5.6%)	1 (5.6%)	1 (5.6%)	1 (5.6%)	2 (11.1%)	0 (0.0%)	0 (0.0%)
IRIS ADHESIONS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	1 (5.6%)	2 (11.1%)
VITREOUS HEMORRHAGE	1 (5.6%)	1 (5.6%)	1 (5.6%)	1 (5.6%)	1 (5.6%)	0 (0.0%)	0 (0.0%)
BLINDNESS NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)
CATARACT NOS AGGRAVATED	0 (0.0%)	0 (0.0%)	1 (5.6%)	1 (5.6%)	1 (5.6%)	1 (5.6%)	0 (0.0%)
CONJUNCTIVAL EDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)
CONJUNCTIVITIS VIRAL NOS	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CORNEAL EDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)
CORNEAL EPITHELIUM DEFECT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)
CORNEAL EROSION	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	1 (5.6%)	0 (0.0%)	0 (0.0%)
MACULAR EDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	1 (5.6%)
POST-OPERATIVE PAIN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)
RUBEOSIS IRIDIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	1 (5.6%)	1 (5.6%)	0 (0.0%)
UVEITIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	1 (5.6%)	1 (5.6%)	0 (0.0%)
VITREOUS DETACHMENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)
INVESTIGATIONS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	3 (16.7%)
INTRAOCULAR PRESSURE INCREASED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	3 (16.7%)
SURGICAL AND MEDICAL PROCEDURES	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)
POST-OPERATIVE COMPLICATIONS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)

, (D)

Note: Events are included in all periods in which they are present.

The date of the nationals last visit is used for the resolved date of the event when the

Table 13

Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class

Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period During Which Event was Present Safety Population

Treatment: Saline Control (n = 378)

System Organ Class / Preferred Term	Day 0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
NUMBER OF PATIENTS WITH AT LEAST ONE ADVERSE EVENT	240 (63.5%)	248 (65.6%)	206 (54.5%)	162 (42.9%)	163 (43.1%)	181 (47.9%)	162 (42.9
NUMBER OF PATIENTS WITH AT LEAST ONE ADVERSE EVENT EYE DISORDERS OCULAR HYPEREMIA IRITIS EYE IRRITATION LACRIMATION INCREASED EYE PAIN VISUAL ACUITY REDUCED ABNORMAL SENSATION IN EYE VITREOUS HEMORRHAGE PHOTOPHOBIA CONJUNCTIVAL EDEMA CATARACT NUCLEAR CATARACT SUBCAPSULAR RETINAL DETACHMENT CONJUNCTIVAL HEMORRHAGE CORNEAL EROSION PHOTOPSIA RUBEOSIS IRIDIS EYE DISCHARGE CATARACT NOS AGGRAVATED CORNEAL EDEMA MACULAR EDEMA MACULAR EDEMA CATARACT NOS AGGRAVATED CORNEAL DISORDER NOS POST-OPERATIVE PAIN DRY EYE NEC HYPHEMA GLAUCOMA NOS MACULOPATHY RETINAL HEMORRHAGE VISION BLURRED BLINDNESS NEC KERATITIS NEC PSEUDOPHAKIA RETINOPATHY DIABETIC INTRAOCULAR PRESSURE DECREASED INTRAOCULAR PRESSURE INCREASED MYDRIASIS	237 (62.7%)	245 (64.8%)	204 (54.0%)	160 (42.3%)	162 (42.9%)	177 (46.8%)	161 (42.6
OCULAR HYPEREMIA	123 (32.5%)	127 (33.6%)	72 (19.0%)	22 (5.8%)	13 (3.4%)	20 (5.3%)	22 (5.8
IRITIS	89 (23.5%)	104 (27.5%)	72 (19.0%)	31 (8.2%)	23 (6.1%)	32 (8.5%)	22 (5.8
EYE IRRITATION	63 (16.7%)	67 (17.7%)	53 (14.0%)	38 (10.1%)	43 (11.4%)	50 (13.2%)	37 (9.8
LACRIMATION INCREASED	39 (10.3%)	45 (11.9%)	34 (9.0%)	31 (8.2%)	30 (7.9%)	32 (8.5%)	22 (5.8
EYE PAIN	52 (13.8%)	56 (14.8%)	31 (8.2%)	12 (3.2%)	18 (4.8%)	32 (8.5%)	24 (6.3
VISUAL ACUITY REDUCED	9 (2.4%)	16 (4.2%)	21 (5.6%)	25 (6.6%)	39 (10.3%)	38 (10.1%)	37 (9.8
ABNORMAL SENSATION IN EYE	45 (11.9%)	46 (12.2%)	28 (7.4%)	17 (4.5%)	14 (3.7%)	19 (5.0%)	18 (4.8
VITREOUS FLOATERS	9 (2.4%)	25 (6.6%)	30 (7.9%)	31 (8.2%)	38 (10.1%)	42 (11.1%)	33 (8.7
VITREOUS HEMORPHAGE	2 (0.5%)	3 (0.8%)	6 (1.6%)	14 (3.7%)	25 (6.6%)	39 (10.3%)	41 (10.8
PHOTOPHORIA	18 (4 8%)	26 (6.9%)	29 (7.7%)	30 (7.9%)	30 (7.9%)	34 (9.0%)	32 (8.5
CONTINCTIVAL FORMA	48 (12 7%)	51 (13.5%)	23 (6.1%)	9 (2.4%)	5 (1.3%)		8 (2.1
CATARACT MICTERS	1 (12.78)	1 (0.3%)	5 (1.3%)	8 (2.1%)	10 (2.6%)	16 (4.2%)	30 (7.
CATADACT CODTICAL	0 (0.5%)	1 (0.3%)	5 (1.3%)	6 (1.6%)	7 (1.9%)	15 (4.0%)	21 (5.
CATADACT CONTICAL	1 (0.0%)	2 (0.5%)	4 (1.1%)	6 (1.6%)	8 (2.1%)	10 (2.6%)	23 (6.
DETINAL DETACUMENT	1 (0.3%)	1 (0.3%)	3 (0.8%)	6 (1.6%)	10 (2.6%)	11 (2.9%)	15 (4.
CONTINUE DELACTIONI	10 (5 0%)	20 (5.3%)	15 (4.0%)	6 (1.6%)	1 (0.3%)	3 (0.8%)	2 (0.
CONJUNCTIVAL REMORRHAGE	19 (5.0%)	18 (4.8%)	10 (2.6%)	6 (1.6%)	3 (0.8%)	5 (1.3%)	5 (1.
CORNEAL EROSION	14 (3.75)	2 (0.5%)	6 (1.6%)	8 (2.1%)	7 (1.9%)	9 (2.4%)	13 (3.
PHOTOPSIA	2 (0.5%)	2 (0.58)	1 (0.3%)	2 (0.5%)	5 (1.3%)	5 (1.3%)	14 (3.
RUBEUSIS IRIDIS	0 (0.0%)	0 (0.0%)	5 (1.3%)	3 (0.8%)	2 (0.5%)	2 (0.5%)	3 (0.
EYE DISCHARGE	13 (3.4%)	14 (3.7%)		3 (0.8%) 5 (1.3%)		2 (0.5%) 7 (1.9%)	9 (2.
CATARACT NEC	4 (1.18)	4 (1.1%)	5 (1.3%)	5 (1.3%)	6 (1.6%)		
IRIS ADHESIONS	0 (0.0%)	1 (0.3%)	2 (0.5%)	1 (0.3%)	2 (0.5%)	5 (1.3%)	12 (3.
CORNEAL EDEMA	1 (0.3%)	2 (0.5%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	6 (1.6%)	6 (1.
MACULAR EDEMA	0 (0.0%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	4 (1.1%)	11 (2.
CATARACT NOS AGGRAVATED	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	1 (0.3%)		5 (1.
CORNEAL DISORDER NOS	1 (0.3%)	3 (0.8%)	4 (1.1%)	2 (0.5%)	1 (0.3%)	1 (0.3%)	3 (0.
POST-OPERATIVE PAIN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	3 (0.8%)	3 (0.
DRY EYE NEC	2 (0.5%)	2 (0.5%)	2 (0.5%)	2 (0.5%)	3 (0.8%)	1 (0.3%)	3 (0.
HYPHEMA	0 (0.0%)	2 (0.5%)	2 (0.5%)	1 (0.3%)	2 (0.5%)	3 (0.8%)	2 (0.
GLAUCOMA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	2 (0.5%)	4 (1.
MACULOPATHY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	5 (1.
RETINAL HEMORRHAGE	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	5 (1.
VISION BLURRED	0 (0.0%)	0 (0.0%)	1 (0.3%)	2 (0.5%)	2 (0.5%)	2 (0.5%)	2 (0.
BLINDNESS NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	3 (0.
KERATITIS NEC	1 (0.3%)	2 (0.5%)	2 (0.5%)	1 (0.3%)	2 (0.5%)	3 (0.8%)	1 (0.
PSEUDOPHAKIA	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	3 (0.8%)	3 (0.
RETINOPATHY DIABETIC	0 (0.0%)	1 (0.3%)	2 (0.5%)	1 (0.3%)	3 (0.8%)	3 (0.8%)	2 (0.
INTRAOCULAR PRESSURE DECREASED	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	2 (0.
INTRAOCULAR PRESSURE INCREASED	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)		0 (0.0
	- 1 - 7 - 7	1 (0.3%)		1 (0.3%)	1 (0.3%)	1 (0.3%)	2 (0.5

Note: Events are included in all periods in which they are present.

s:\dat\acs\iss2002\sas\programs\t_ocae_period 06SEP2002 17:35

Table 13 Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period During Which Event was Present Safety Population Treatment: Saline Control (n = 378)

System Organ Class / Preferred Term	Day 0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
POSTERIOR CAPSULE OPACIFICATION	0 (0.0%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	2 (0.5%)
APHAKIA CONJUNCTIVITIS NEC DIPLOPIA HYPOTONY OF EYE LENTICULAR OPACITIES HYPITIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	2 (0.5%)
CONJUNCTIVITIS NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
DIPLOPIA	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	2 (0.5%)	2 (0.5%)	2 (0.5%)
HYPOTONY OF EYE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	2 (0.5%)
LENTICULAR OPACITIES	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)
UVEITIS NOS	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)
VITREOUS DETACHMENT	0 (0.0%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	2 (0.5%)
VITREOUS DISORDER NOS	0 (0.0%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	2 (0.5%)
BLEPHARITIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)
CHEMOSIS	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CORNEAL ABRASION	1 (0.3%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CORNEAL EPITHELIUM DEFECT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
EXOPHTHALMOS ENDOCRINE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
EYE HEMORRHAGE NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
EYE INFECTION NOS	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYELID PTOSIS	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)
FOREIGN BODY RETAINED IN EYE	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)
IRIS NEVUS	0 (0 0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)
KERATOCONJUNCTIVITIS	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
OCULAR HYPERTENSION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
OPTIC ATROPHY	0 (0 0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
OPTIC NERVE INJURY NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
PAINFUL RED EYES	0 (0.00)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
PHOTOPHOBIA AGGRAVATED	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
RETINAL DISORDER NOS	0.50)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
RETINAL EXUDATES	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
RETINAL ISCHEMIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
RETINAL MICROANEURYSMS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
RETINAL TEAR (EXC DETACHMENT)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
LENTICULAR OPACITIES UVEITIS NOS VITREOUS DETACHMENT VITREOUS DISORDER NOS BLEPHARITIS CHEMOSIS CORNEAL ABRASION CORNEAL EPITHELIUM DEFECT EXOPHTHALMOS ENDOCRINE EYE HEMORRHAGE NEC EYE INFECTION NOS EYELID PTOSIS FOREIGN BODY RETAINED IN EYE IRIS NEVUS KERATOCONJUNCTIVITIS OCULAR HYPERTENSION OPTIC ATROPHY OPTIC NERVE INJURY NOS PAINFUL RED EYES PHOTOPHOBIA AGGRAVATED RETINAL DISORDER NOS RETINAL EXUDATES RETINAL MICROANEURYSMS RETINAL TEAR (EXC DETACHMENT) VISUAL ACUITY REDUCED TRANSIENTLY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
INTEGRICATIONS	15 (4 0%)	14 (3.7%)	10 (2.6%)	10 (2.6%)	8 (2.1%)	18 (4.8%)	17 (4.5%)
INTRAOCULAR PRESSURE INCREASED	12 (3.2%)	10 (2.6%)	9 (2.4%)	8 (2.1%)	7 (1.9%)	16 (4.2%)	17 (4.5%)
CORNEAL STAINING	3 (0.8%)	4 (1.1%)	1 (0.3%)	2 (0.5%)	1 (0.3%)	2 (0.5%)	0 (0.0%)
SKIN & SUBCUTANEOUS TISSUE DISORDERS	14 (3.7%)	16 (4.2%)	10 (2.6%)	5 (1.3%)	3 (0.8%)	5 (1.3%)	4 (1.1%)
ERYTHEMA NEC	9 (2.4%)		6 (1.6%)	5 (1.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)
EYELID EDEMA	7 (1.9%)			2 (0.5%)	2 (0.5%)	4 (1.1%)	4 (1.1%)
ERYTHEMA NEC EYELID EDEMA OCULAR HYPEREMIA			0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
SURGICAL AND MEDICAL PROCEDURES	3 (0.8%) 1 (0.3%)	1 (0.3%)		0 (0.0%)		8 (2.1%)	3 (0.8%)
POST-OPERATIVE COMPLICATIONS NOS	1 (0.3%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	5 (1.3%)	3 (0.8%)

Note: Events are included in all periods in which they are present.

s:\dat\acs\iss2002\sas\programs\t_ocae_period 06SEP2002 17:35

Table 13

Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class

Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period During Which Event was Present Safety Population

Treatment: Saline Control (n = 378)

System Organ Class / Preferred Term	Day 0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
VITRECTOMY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	3 (0.8%)	0 (0.0%)
UNSPECIFIED COMPLICATION OF PROCEDURE NEC	2 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
INFECTIONS AND INFESTATIONS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
HYPOPYON	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
INJURY AND POISONING	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
HEAD INJURY	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
NEOPLASMS BENIGN AND MALIGNANT (INCLUDING CYSTS AND POLYPS)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)
INTRAOCULAR MELANOMA NOS	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	0 (0.0%)
RADIOACTIVE IODINE THERAPY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
NERVOUS SYSTEM DISORDERS	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
VISUAL FIELD DEFECT NOS	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

9

Note: Events are included in all periods in which they are present.

Table 13

Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period During Which Event was Present
Safety Population

Treatment: 7.5 IU Vitrase (n = 198)

System Organ Class / Preferred Term	Day 0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
NUMBER OF PATIENTS WITH AT LEAST ONE ADVERSE EVENT	168 (84.8%)	174 (87.9%)	153 (77.3%)	141 (71.2%)	140 (70.7%)	151 (76.3%)	124 (62.6%)
NUMBER OF PATIENTS WITH AT LEAST ONE ADVERSE EVENT EYE DISORDERS IRITIS OCULAR HYPEREMIA EYE IRRITATION VISUAL ACUITY REDUCED EYE PAIN VITREOUS HEMORRHAGE LACRIMATION INCREASED VITREOUS FLOATERS ABNORMAL SENSATION IN EYE PHOTOPHOBIA CONJUNCTIVAL EDEMA CATARACT NUCLEAR PHOTOPSIA RETINAL DETACHMENT CORNEAL EDEMA MACULAR EDEMA RUBEOSIS IRIDIS CATARACT CORTICAL CONJUNCTIVAL HEMORRHAGE CORNEAL EROSION EYE DISCHARGE VISION BLURRED BLINDNESS NEC IRIS ADHESIONS HYPHEMA DRY EYE NEC CORNEAL DISORDER NOS GLAUCOMA NOS INTRAOCULAR PRESSURE INCREASED CATARACT NOS AGGRAVATED FOREIGN BODY RETAINED IN EYE KERATITIS NEC MACULOPATHY BLEPHARITIS CONJUNCTIVITIS NEC CORNEAL EPITHELIUM DEFECT DIPLOPIA EYE DEGENERATIVE DISORDER NOS EYELID PTOSIS	167 (84.3%)	173 (87.4%)	152 (76.8%)	138 (69.7%)	136 (68.7%)	148 (74.7%)	122 (61.6%)
IRITIS	85 (42.9%)	93 (47.0%)	67 (33.8%)	33 (16.7%)	27 (13.6%)	38 (19.2%)	32 (16.2%)
OCULAR HYPEREMIA	99 (50.0%)	97 (49.0%)	61 (30.8%)	20 (10.1%)	12 (6.1%)	20 (10.1%)	22 (11.1%)
EYE IRRITATION	46 (23.2%)	48 (24.2%)	44 (22.2%)	35 (17.7%)	36 (18.2%)	40 (20.2%)	36 (18.2%)
VISUAL ACUITY REDUCED	23 (11.6%)	29 (14.6%)	30 (15.2%)	34 (17.2%)	41 (20.7%)	49 (24.7%)	33 (16.7%)
EYE PAIN	33 (16.7%)	36 (18.2%)	26 (13.1%)	15 (7.6%)	20 (10.1%)	32 (16.2%)	21 (10.6%)
VITREOUS HEMORRHAGE	2 (1.0%)	5 (2.5%)	11 (5.6%)	19 (9.6%)	30 (15.2%)	48 (24.2%)	39 (19.7%)
LACRIMATION INCREASED	26 (13.1%)	27 (13.6%)	28 (14.1%)	25 (12.6%)	24 (12.1%)	26 (13.1%)	22 (11.1%)
VITREOUS FLOATERS	18 (9.1%)	29 (14.6%)	40 (20.2%)	47 (23.7%)	42 (21.2%)	35 (17.7%)	32 (16.2%)
ABNORMAL SENSATION IN EYE	33 (16.7%)	30 (15.2%)	21 (10.6%)	13 (6.6%)	17 (8.6%)	23 (11.6%)	23 (11.6%)
PHOTOPHOBIA	14 (7.1%)	18 (9.1%)	25 (12.6%)	28 (14.1%)	31 (15.7%)	36 (18.2%)	36 (18.2%)
CONJUNCTIVAL EDEMA	30 (15.2%)	30 (15.2%)	13 (6.6%)	4 (2.0%)	5 (2.5%)	7 (3.5%)	12 (6.1%)
CATARACT SUBCAPSULAR	0 (0.0%)	1 (0.5%)	3 (1.5%)	6 (3.0%)	9 (4.5%)	19 (9.6%)	28 (14.1%)
CATARACT NUCLEAR	0 (0.0%)	1 (0.5%)	3 (1.5%)	9 (4.5%)	11 (5.6%)	16 (8.1%)	23 (11.6%)
PHOTOPSIA	3 (1.5%)	7 (3.5%)	7 (3.5%)	7 (3.5%)	11 (5.6%)	14 (7.1%)	13 (6.6%)
RETINAL DETACHMENT	1 (0.5%)	1 (0.5%)	3 (1.5%)	3 (1.5%)	5 (2.5%)	12 (6.1%)	13 (6.6%
CORNEAL EDEMA	1 (0.5%)	1 (0.5%)	2 (1.0%)	3 (1.5%)	3 (1.5%)	9 (4.5%)	10 (5.1%
MACULAR EDEMA	0 (0 0%)	0 (0.0%)	1 (0.5%)	3 (1.5%)	3 (1.5%)	6 (3.0%)	16 (8.1%
RUBEOSIS IRIDIS	0 (0.0%)	0 (0.0%)	3 (1.5%)	6 (3.0%)	7 (3.5%)	9 (4.5%)	14 (7.1%
CATARACT CORTICAL	1 (0.5%)	2 (1.0%)		7 (3.5%)	7 (3.5%)	8 (4.0%)	9 (4.5%
CONJUNCTIVAL HEMORRHAGE	£ (3.3%)	6 (3.0%)		1 (0.5%)	1 (0.5%)	3 (1.5%)	2 (1.0%
CORNEAL EROSION	5 (2.5%)	5 (2.5%)		2 (1.0%)	2 (1.0%)	2 (1.0%)	3 (1.5%
EYE DISCHARGE	4 / 2 0%)	5 (2.5%)	3 (1.5%)	1 (0.5%)	1 (0.5%)	2 (1.0%)	4 (2.0%
VISION BLURRED	1 (0.5%)	2 (1.0%)	3 (1.5%)	3 (1.5%)	3 (1.5%)	2 (1.0%)	6 (3.0%
BLINDNESS NEC	1 (0.5%)	1 (0.5%)		2 (1.0%)	1 (0.5%)	3 (1.5%)	8 (4.0%
IRIS ADHESIONS	0 (0 0%)	1 (0.5%)		4 (2.0%)	3 (1.5%)	4 (2.0%)	7 (3.5%
HYPHEMA	1 (0.0%)	1 (0.5%)		1 (0.5%)	0 (0.0%)	4 (2.0%)	6 (3.0%
DRY EYE NEC	1 (0.5%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.5%)	1 (0.5%)	6 (3.0%
CORNEAL DISORDER NOS	4 (3.0%)	4 (2.0%)	1 (0.5%)	1 (0.5%)	1 (0.5%)	1 (0.5%)	3 (1.5%
CURNEAU DISORDER NOS	4 (2.0%)	0 (0.0%)		0 (0.0%)	1 (0.5%)	3 (1.5%)	3 (1.5%
GLAUCOMA NOS INTRAOCULAR PRESSURE INCREASED	1 (0.0%)	0 (0.0%)		2 (1.0%)	2 (1.0%)	4 (2.0%)	3 (1.5%
INTRACCULAR PRESSURE INCREASED	1 (0.5%)	1 (0.06)		1 (0.5%)	1 (0.5%)	1 (0.5%)	4 (2.0%
CATARACT NOS AGGRAVATED	1 (0.5%)	1 (0.5%)					
FOREIGN BODY RETAINED IN EYE	1 (0.5%)	2 (1.0%)	2 (1.0%)	1 (0.5%)	2 (1.0%)	1 (0.5%)	2 (1.0%
KERATITIS NEC	1 (0.5%)	1 (0.5%)	1 (0.5%)	1 (0.5%)	2 (1.0%)	2 (1.0%)	2 (1.0%
MACULOPATHY	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	1 (0.5%)	4 (2.0%
BLEPHARITIS	0 (0.0%)	0 (0.0%)		0 (0.0%)	1 (0.5%)	2 (1.0%)	2 (1.0%
CONJUNCTIVITIS NEC	0 (0.0%)	0 (0.0%)		0 (0.0%)	1 (0.5%)	2 (1.0%)	2 (1.0%
CORNEAL EPITHELIUM DEFECT	0 (0.0%)	0 (0.0%)		1 (0.5%)	1 (0.5%)	1 (0.5%)	1 (0.5%
DIPLOPIA	1 (0.5%)	1 (0.5%)		1 (0.5%)	1 (0.5%)	3 (1.5%)	2 (1.0%
EYE DEGENERATIVE DISORDER NOS	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (1.5%)
EYELID PTOSIS	0 (0.0%)	0 (0.0%)	1 (0.5%)	2 (1.0%)	2 (1.0%)	2 (1.0%)	1 (0.5%)

Note: Events are included in all periods in which they are present.

s:\dat\acs\iss2002\sas\programs\t_ocae period 06SEP2002 17:35

Table 13 Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period During Which Event was Present Safety Population

Treatment: 7.5 IU Vitrase (n = 198)

ystem Organ Class / Preferred Term	Day 0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
RETINAL ISCHEMIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (1.5
VITREOUS DETACHMENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.0%)	1 (0.5%)	2 (1.0
CORNEAL ABRASION	1 (0.5%)	1 (0.5%)		0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0
HYPOTONY OF EYE	0 (0.0%)	0 (0.0%)		1 (0.5%)	0 (0.0%)	0 (0.0%)	1 (0.5
INTRAOCULAR PRESSURE DECREASED	1 (0.5%)	1 (0.5%)		1 (0.5%)	1 (0.5%)	1 (0.5%)	0 (0.0
IRIDOCYCLITIS	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.0
MACULAR DEGENERATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	2 (1.0
RETINAL HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.5%)	0 (0.0%)	1 (0.
UVEITIS NOS	1 (0.5%)	1 (0.5%)	1 (0.5%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	1 (0.
APHAKIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.
ARCUS SENILIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
BLINDNESS TRANSIENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.
CATARACT NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
CHEMOSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.5%)	1 (0.
CHORIORETINAL ATROPHY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.
CHORIORETINAL DISORDER NOS	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
CONJUNCTIVITIS ALLERGIC	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.
CORNEAL OPACITY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.
CORNEAL SCAR	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
CORNEAL ULCER NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
CORTICAL OPACITY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.
EYE INFECTION STAPHYLOCOCCAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
HYPOPYON	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
KERATOCONJUNCTIVITIS	1 (0.5%)	1 (0.5%)		1 (0.5%)	1 (0.5%)	1 (0.5%)	1 (0.
KERATOPATHY BAND	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
KERATOPATHY NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.
MYDRIASIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.
OPEN ANGLE GLAUCOMA NOS	0 (0.0%)	1 (0.5%)	1 (0.5%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.
OPTIC ATROPHY	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
OPTIC DISC HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.
PAPILLEDEMA	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
PINGUECULA	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
POSTERIOR CAPSULE OPACIFICATION	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.
PSEUDOPHAKIA	1 (0.5%)	1 (0.5%)		1 (0.5%)	1 (0.5%)	1 (0.5%)	1 (0.
RETINAL ARTERY EMBOLISM	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
RETINAL DEGENERATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
RETINAL DEPIGMENTATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
RETINAL DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.
RETINAL MICROANEURYSMS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
RETINAL VASCULITIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
RETINOPATHY DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
SCLERITIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.
STRABISMUS NEC	0 (0.0%)	1 (0.5%)	1 (0.5%)	1 (0.5%)	1 (0.5%)	0 (0.0%)	0 (0.

Note: Events are included in all periods in which they are present.

s:\dat\acs\iss2002\sas\programs\t_ocae_period 06SEP2002 17:35

Table 13

Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class

Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period During Which Event was Present Safety Population

Treatment: 7.5 IU Vitrase (n = 198)

System Organ Class / Preferred Term	Day 0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
UVEITIS DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
VISION ABNORMAL NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
VITREOUS DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
VITREOUS OPACITIES	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
INVESTIGATIONS	10 (5.1%)	10 (5.1%)	9 (4.5%)	12 (6.1%)	10 (5.1%)	24 (12.1%)	24 (12.1%)
INTRAOCULAR PRESSURE INCREASED	6 (3.0%)	5 (2.5%)	6 (3.0%)	11 (5.6%)	8 (4.0%)	21 (10.6%)	20 (10.1%)
CORNEAL STAINING	4 (2.0%)	5 (2.5%)	3 (1.5%)	1 (0.5%)	2 (1.0%)	2 (1.0%)	3 (1.5%)
INTRAOCULAR PRESSURE ABNORMAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.5%)
SKIN & SUBCUTANEOUS TISSUE DISORDERS	8 (4.0%)	8 (4.0%)	7 (3.5%)	4 (2.0%)	7 (3.5%)	9 (4.5%)	7 (3.5%)
EYELID EDEMA	6 (3.0%)	5 (2.5%)	4 (2.0%)	3 (1.5%)	5 (2.5%)	6 (3.0%)	2 (1.0%)
ERYTHEMA NEC	1 (0.5%)	2 (1.0%)	2 (1.0%)	1 (0.5%)	3 (1.5%)	5 (2.5%)	4 (2.0%)
CUTIS LAXA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	2 (1.0%)
OCULAR HYPEREMIA	1 (0.5%)	1 (0.5%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
SURGICAL AND MEDICAL PROCEDURES	2 (1.0%)	0 (0.0%)	1 (0.5%)	1 (0.5%)	0 (0.0%)	3 (1.5%)	2 (1.0%)
POST-OPERATIVE COMPLICATIONS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (1.5%)	2 (1.0%)
VITRECTOMY	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
UNSPECIFIED COMPLICATION OF PROCEDURE NEC	2 (1.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
NERVOUS SYSTEM DISORDERS	1 (0.5%)	1 (0.5%)	1 (0.5%)	1 (0.5%)	1 (0.5%)	1 (0.5%)	3 (1.5%)
PUPILLARY DISORDER NOS	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.5%)	1 (0.5%)	1 (0.5%)	2 (1.0%)
VISUAL FIELD DEFECT NOS	1 (0.5%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
VITH NERVE PARALYSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
IMMUNE SYSTEM DISORDERS	2 (1.0%)	2 (1.0%)	2 (1.0%)	2 (1.0%)	2 (1.0%)	2 (1.0%)	2 (1.0%)
HYPERSENSITIVITY NOS	1 (0.5%)	1 (0.5%)	1 (0.5%)	1 (0.5%)	1 (0.5%)	1 (0.5%)	1 (0.5%)
MULTIPLE ALLERGIES	1 (0.5%)	1 (0.5%)	1 (0.5%)	1 (0.5%)	1 (0.5%)	1 (0.5%)	1 (0.5%)

167

Note: Events are included in all periods in which they are present.

The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing or 'Ongoing' is marked.

2 (0.5%)

2 (0.5%)

ISTA Pharmaceuticals, Inc. Integrated Summary of Safety

KERATITIS NEC

Table 13 Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period During Which Event was Present Safety Population Treatment: 55 IU Vitrase (n = 377)

Day 0-Day 1 Day 2-Day 7 Day 8-Day 30 Day 31-Day 60 Day 61-Day 90 Day 90-Day 180 > Day 180 System Organ Class / Preferred Term NUMBER OF PATIENTS WITH AT LEAST ONE ADVERSE EVENT 283 (75.1%) 289 (76.7%) 251 (66.6%) 215 (57.0%) 209 (55.4%) 208 (55,2%) 206 (54.6%) 169 (44.8%) EYE DISORDERS 281 (74.5%) 287 (76.1%) 251 (66.6%) 214 (56.8%) 207 (54.9%) IRITIS 208 (55.2%) 140 (37.1%) 59 (15.6%) 35 (9.3%) 32 (8.5%) 27 (7.2%) 198 (52.5%) 100 (26.5%) 39 (10.3%) 22 (5.8%) 25 (6.6%) 23 (6.1%) OCULAR HYPEREMIA 182 (48.3%) 187 (49.6%) EYE PAIN 110 (29.2%) 108 (28.6%) 65 (17.2%) 30 (8.0%) 25 (6.6%) 29 (7.7%) 26 (6.9%) 48 (12.7%) 47 (12.5%) 36 (9.5%) EYE IRRITATION 78 (20.7%) 84 (22.3%) 80 (21.2%) 59 (15.6%) 45 (11.9%) 36 (9.5%) 33 (8.8%) 85 (22.5%) 63 (16.7%) 48 (12.7%) LACRIMATION INCREASED 83 (22.0%) 52 (13.8%) 61 (16.2%) 48 (12.7%) 29 (7.7%) 38 (10.1%) VISUAL ACUITY REDUCED 36 (9.5%) 35 (9.3%) 71 (18.8%) 33 (8.8%) 23 (6.1%) ABNORMAL SENSATION IN EYE 74 (19.6%) 50 (13.3%) 33 (8.8%) 28 (7.4%) 85 (22.5%) 87 (23.1%) 37 (9.8%) 9 (2.4%) 9 (2.4%) 8 (2.1%) 9 (2.4%) CONJUNCTIVAL EDEMA 24 (6.4%) 43 (11.4%) 59 (15.6%) 52 (13.8%) VITREOUS HEMORRHAGE 5 (1.3%) 6 (1.6%) 12 (3.2%) 52 (13.8%) 55 (14.6%) 49 (13.0%) 41 (10.9%) VITREOUS FLOATERS 26 (6.9%) 37 (9.8%) 49 (13.0%) РНОТОРНОВІА 43 (11.4%) 53 (14.1%) 48 (12.7%) 43 (11.4%) 37 (9.8%) 34 (9.0%) 37 (9.8%) 21 (5.6%) 21 (5.6%) 22 (5.8%) PHOTOPSIA 8 (2.1%) 14 (3.7%) 24 (6.4%) 25 (6.6%) CATARACT NUCLEAR 3 (0.8%) 9 (2.4%) 10 (2.7%) 19 (5.0%) 20 (5.3%) 25 (6.6%) 2 (0.5%) 15 (4.0%) RETINAL DETACHMENT 1 (0.3%) 8 (2.1%) 7 (1.9%) 10 (2.7%) 18 (4.8%) 4 (1.1%) CATARACT CORTICAL 4 (1.1%) 4 (1.1%) 8 (2.1%) 9 (2.4%) 12 (3.2%) 16 (4.2%) 22 (5.8%) CATARACT SUBCAPSULAR 13 (3.4%) 13 (3.4%) 15 (4.0%) 24 (6.4%) 1 (0.3%) 5 (1.3%) 8 (2.1%) 7 (1.9%) 2 (0.5%) 6 (1.6%) CORNEAL EROSION 16 (4.2%) 18 (4.8%) 12 (3.2%) 11 (2.9%) 13 (3.4%) 14 (3.7%) 4 (1.1%) 3 (0.8%) 5 (1.3%) 8 (2.1%) 5 (1.3%) EYE DISCHARGE 10 (2.7%) 5 (1.3%) 3 (0.8%) 3 (0.8%) 4 (1.1%) 7 (1.9%) CORNEAL EDEMA 4 (1.1%) 0 (0.0%) 2 (0.5%) 12 (3.2%) 15 (4.0%) 7 (1.9%) 1 (0.3%) 0 (0.0%) CORNEAL DISORDER NOS 6 (1.6%) 12 (3.2%) 3 (0.8%) 7 (1.9%) 7 (1.9%) RUBEOSIS IRIDIS 2 (0.5%) 2 (0.5%) CONJUNCTIVAL HEMORRHAGE 9 (2.4%) 10 (2.7%) 10 (2.7%) 1 (0.3%) 1 (0.3%) 3 (0.8%) 0 (0.0%) IRIS ADHESIONS 4 (1.1%) 7 (1.9%) 4 (1.1%) 4 (1.1%) 3 (0.8%) 4 (1.1%) 6 (1.6%) HYPHEMA 1 (0.3%) 1 (0.3%) 2 (0.5%) 1 (0.3%) 1 (0.3%) 3 (0.8%) 8 (2.1%) MACULAR EDEMA 2 (0.5%) 2 (0.5%) 2 (0.5%) 3 (0.8%) 6 (1.6%) 11 (2.9%) 2 (0.5%) 3 (0.8%) CATARACT NEC 3 (0.8%) 3 (0.8%) 3 (0.8%) 4 (1.1%) 3 (0.8%) 8 (2.1%) 1 (0.3%) 7 (1.9%) VITREOUS DETACHMENT 2 (0.5%) 4 (1.1%) 5 (1.3%) 7 (1.9%) 6 (1.6%) CATARACT NOS AGGRAVATED 2 (0.5%) 2 (0.5%) 2 (0.5%) 2 (0.5%) 3 (0.8%) 4 (1.1%) 6 (1.6%) UVEITIS NOS 6 (1.6%) 3 (0.8%) 2 (0.5%) 1 (0.3%) 1 (0.3%) 0 (0.0%) 6 (1.6%) BLINDNESS NEC 1 (0.3%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 2 (0.5%) 2 (0.5%) 5 (1.3%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 3 (0.8%) 2 (0.5%) 3 (0.8%) 5 (1.3%) DRY EYE NEC 3 (0.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) HYPOPYON 4 (1.1%) 6 (1.6%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 5 (1.3%) POSTERIOR CAPSULE OPACIFICATION 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (0.8%) 5 (1.3%) MACULOPATHY 0 (0.0%) 2 (0.5%) 3 (0.8%) 1 (0.3%) 2 (0.5%) 1 (0.3%) RETINAL HEMORRHAGE 1 (0.3%) 1 (0.3%) 0 (0.0%) 2 (0.5%) 3 (0.8%) RETINAL TEAR (EXC DETACHMENT) 1 (0.3%) 1 (0.3%) 1 (0.3%) 2 (0.5%) VISION BLURRED 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (0.8%) 4 (1.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%) 3 (0.8%) 3 (0.8%) CORNEAL EPITHELIUM DEFECT 0 (0.0%) 1 (0.3%) 2 (0.5%) 3 (0.8%) DIPLOPIA 1 (0.3%) 2 (0.5%) 2 (0.5%) 1 (0.3%)

Note: Events are included in all periods in which they are present.

0 (0.0%)

0 (0.0%)

1 (0.3%)

1 (0.3%)

0 (0.0%)

The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing or 'Ongoing' is marked.

s:\dat\acs\iss2002\sas\programs\t ocae period 06SEP2002 17:35

Table 13

Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period During Which Event was Present
Safety Population

Treatment: 55 IU Vitrase (n = 377)

ystem Organ Class / Preferred Term	Day 0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
RETINAL ISCHEMIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	3 (0.8
BLEPHARITIS	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	3 (0.8
CORNEAL ABRASION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	3 (0.8
EYE ALLERGY	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3
GLAUCOMA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	2 (0.5
INTRAOCULAR PRESSURE INCREASED	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	2 (0.5%)	1 (0.39
OPTIC ATROPHY	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	3 (0.8
PHOTOPHOBIA AGGRAVATED	0 (0.0%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	1 (0.3
PSEUDOPHAKIA	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	2 (0.5%)	2 (0.5
RETINOPATHY DIABETIC	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	2 (0.5%)	2 (0.5
EYE DEGENERATIVE DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5
FOREIGN BODY RETAINED IN EYE	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	2 (0.5%)	2 (0.5%)	1 (0.39
HYPOTONY OF EYE	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3
OCULAR HYPERTENSION	1 (0.3%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3
PERIORBITAL HEMATOMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3
POST-OPERATIVE PAIN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3
RETINAL SCAR	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5
ANGLE CLOSURE GLAUCOMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0
ANISEIKONIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3
BLEPHAROCONJUNCTIVITIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3
BLINDNESS TRANSIENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3
CHOROIDAL DETACHMENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0
CONJUNCTIVITIS (INFECTIVE) NEC	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
CONJUNCTIVITIS NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0
CORNEAL DEGENERATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3
CORNEAL DEGENERATION CORNEAL OPACITY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3
CORTICAL OPACITY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	1 (0.3
ERYTHEMA NEC	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
		0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0
EYE INFECTION FUNGAL NOS	0 (0.0%)					0 (0.0%)	0 (0.0
EYELID EDEMA	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		0 (0.0
IRIDOCYCLITIS	1 (0.3%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
KERATOCONJUNCTIVITIS	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
KERATOPATHY NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3
LACRIMAL DUCT OBSTRUCTION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3
MACULAR DEGENERATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3
MEIBOMIAN CYST	0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3
OPEN ANGLE GLAUCOMA NOS	0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3
PAINFUL RED EYES	0 (0.0%)		0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0
RETINAL DEPIGMENTATION	0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3
RETINAL MICROANEURYSMS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3
TOPOGRAPHY CORNEAL ABNORMAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3
WESTIGATIONS	11 (2.9%)	12 (3.2%)	11 (2.9%)	10 (2.7%)	9 (2.4%)	22 (5.8%)	26 (6.9
· · · ·	,,	,,	,	· ·	- ,		•

Note: Events are included in all periods in which they are present.

The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing or 'Ongoing' is marked.

s:\dat\acs\iss2002\sas\programs\t_ocae_period 06SEP2002 17:35

Page 10 of 13

ISTA Pharmaceuticals, Inc.
Integrated Summary of Safety

Table 13
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period During Which Event was Present
Safety Population

Treatment: 55 IU Vitrase (n = 377)

System Organ Class / Preferred Term	Day 0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
INTRAOCULAR PRESSURE INCREASED	5 (1.3%)	5 (1.3%)	7 (1.9%)	7 (1.9%)	8 (2.1%)	21 (5.6%)	25 (6.6%)
CORNEAL STAINING	6 (1.6%)	7 (1.9%)	4 (1.1%)	4 (1.1%)	1 (0.3%)	1 (0.3%)	1 (0.3%)
SKIN & SUBCUTANEOUS TISSUE DISORDERS	26 (6.9%)	28 (7.4%)	15 (4.0%)	5 (1.3%)	3 (0.8%)	9 (2.4%)	8 (2.1%)
EYELID EDEMA	22 (5.8%)	23 (6.1%)	8 (2.1%)	2 (0.5%)	2 (0.5%)	6 (1.6%)	7 (1.9%)
ERYTHEMA NEC	11 (2.9%)	12 (3.2%)	6 (1.6%)	2 (0.5%)	1 (0.3%)	7 (1.9%)	6 (1.6%)
PERIORBITAL EDEMA	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PRURITUS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
SURGICAL AND MEDICAL PROCEDURES	5 (1.3%)	2 (0.5%)	1 (0.3%)	2 (0.5%)	1 (0.3%)	5 (1.3%)	3 (0.8%)
POST-OPERATIVE COMPLICATIONS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	4 (1.1%)	2 (0.5%)
UNSPECIFIED COMPLICATION OF PROCEDURE NEC	3 (0.8%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
EYE IRRITATION	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
POST-OPERATIVE HEMORRHAGE	1 (0.3%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
SUTURE LINE PAIN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
VITRECTOMY	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
NERVOUS SYSTEM DISORDERS	2 (0.5%)	2 (0.5%)	1 (0.3%)	2 (0.5%)	1 (0.3%)	2 (0.5%)	2 (0.5%)
PUPILLARY DISORDER NOS	2 (0.5%)	2 (0.5%)	1 (0.3%)	2 (0.5%)	1 (0.3%)	2 (0.5%)	2 (0.5%)
IMMUNE SYSTEM DISORDERS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
HYPERSENSITIVITY NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
INJURY AND POISONING	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	0 (0.0%)
CHEMICAL BURNS OF EYE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	0 (0.0%)

170

Note: Events are included in all periods in which they are present.

The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing or 'Ongoing' is marked.

Table 13

Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period During Which Event was Present
Safety Population

Treatment: 75 IU Vitrase (n = 391)

System Organ Class / Preferred Term	Day 0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
NUMBER OF PATIENTS WITH AT LEAST ONE ADVERSE EVENT	319 (81.6%)	329 (84.1%)	265 (67.8%)	212 (54.2%)	224 (57.3%)	219 (56.0%)	201 (51.49
EYE DISORDERS IRITIS OCULAR HYPEREMIA EYE PAIN LACRIMATION INCREASED EYE IRRITATION ABNORMAL SENSATION IN EYE PHOTOPHOBIA VITREOUS FLOATERS VISUAL ACUITY REDUCED VITREOUS HEMORRHAGE CONJUNCTIVAL EDEMA RETINAL DETACHMENT CATARACT SUBCAPSULAR PHOTOPSIA	319 (81.6%)	328 (83.9%)	263 (67.3%)	209 (53.5%)	220 (56.3%)	218 (55.8%)	199 (50.99
IRITIS	232 (59.3%)	235 (60.1%)	147 (37.6%)	55 (14.1%)	30 (7.7%)	30 (7.7%)	28 (7.29
OCULAR HYPEREMIA	199 (50.9%)	200 (51.2%)	97 (24.8%)	36 (9.2%)	21 (5.4%)	21 (5.4%)	26 (6.69
EYE PAIN	114 (29.2%)	116 (29.7%)	66 (16.9%)	38 (9.7%)	31 (7.9%)	43 (11.0%)	33 (8.49
LACRIMATION INCREASED	78 (19.9%)	81 (20.7%)	62 (15.9%)	51 (13.0%)	48 (12.3%)	48 (12.3%)	36 (9.2
EYE IRRITATION	71 (18.2%)	85 (21.7%)	67 (17.1%)	59 (15.1%)	56 (14.3%)	53 (13.6%)	43 (11.0
ABNORMAL SENSATION IN EYE	76 (19.4%)	80 (20.5%)	59 (15.1%)	38 (9.7%)	28 (7.2%)	36 (9.2%)	31 (7.9
PHOTOPHOBIA	53 (13.6%)	63 (16.1%)	49 (12.5%)	35 (9.0%)	42 (10.7%)	39 (10.0%)	33 (8.4
VITREOUS FLOATERS	30 (7.7%)	43 (11.0%)	56 (14.3%)	54 (13.8%)	51 (13.0%)	55 (14.1%)	46 (11.8
VISUAL ACUITY REDUCED	34 (8.7%)	42 (10.7%)	40 (10.2%)	41 (10.5%)	52 (13.3%)	57 (14.6%)	46 (11.8
VITREOUS HEMORRHAGE	5 (1.3%)	7 (1.8%)	12 (3.1%)	19 (4.9%)	26 (6.6%)	55 (14.1%)	62 (15.9
CONJUNCTIVAL EDEMA	81 (20.7%)	83 (21.2%)	32 (8.2%)	6 (1.5%)		6 (1.5%)	11 (2.8
RETINAL DETACHMENT	1 (0.3%)	1 (0.3%)	3 (0.8%)	8 (2.0%)	15 (3.8%)	28 (7.2%)	26 (6.6
CATARACT SUBCAPSULAR	4 (1 0%)	5 (1.3%)	6 (1.5%)	11 (2.8%)	15 (3.8%)	19 (4.9%)	29 (7.4
PHOTOPSIA	8 (2.0%)	8 (2.0%)	12 (3.1%)	14 (3.6%)	15 (3.8%)	16 (4.1%)	21 (5.4
CATARACT CORTICAL	3 (0.8%)	4 (1.0%)	6 (1.5%)	11 (2.8%)	15 (3.8%)	23 (5.9%)	25 (6.4
CATARACT NUCLEAR	1 (0.3%)	2 (0.5%)	5 (1.3%)	6 (1.5%)	11 (2.8%)	16 (4.1%)	23 (5.9
			9 (2.3%)	11 (2.8%)	11 (2.8%)		16 (4.1
CORNEAL DISORDER NOS	10 (1.5%)	18 (4.6%)	8 (2.0%)	4 (1.0%)	3 (0.8%)	12 (3.1%) 6 (1.5%)	
CORNEAL EDEMA	20 (4.0%)	20 (5.1%)	3 (0.8%)	1 (0.3%)		0 (1.5%)	8 (2.0
HYPOPYON	10 (3.1%)	20 (5.1%)	4 (1.0%)	1 (0.3%)	1 (0.3%)	3 (0.8%)	9 (2.3
EYE DISCHARGE	10 (2.00/	15 (3.8%)	9 (2.3%)	4 (1.0%)		1 (0.3%)	0 (0.0
MACULAR EDEMA	13 (3.36)	0 (0.0%)			4 (1.0%)	2 (0.5%)	3 (0.8
RUBEOSIS IRIDIS	0 (0.05)	4 (1.0%)	3 (0.8%)	5 (1.3%)	8 (2.0%)	11 (2.8%)	15 (3.8
CONJUNCTIVAL HEMORRHAGE	4 (1.06)	4 (1.0%)	4 (1.0%)	5 (1.3%)	7 (1.8%)	5 (1.3%)	11 (2.8
CORNEAL EROSION	11 (2.8%)	10 (2.6%)	6 (1.5%)	2 (0.5%)	1 (0.3%)	4 (1.0%)	2 (0.5
HYPHEMA	11 (2.8%)	12 (3.1%)	10 (2.6%)	3 (0.8%)	6 (1.5%)	6 (1.5%)	5 (1.3
GLAUCOMA NOS	2 (0.5%)	3 (0.8%)	2 (0.5%)	1 (0.3%)	2 (0.5%)	8 (2.0%)	9 (2.3
BLINDNESS NEC	1 (0.3%)	3 (0.8%)	3 (0.8%)	1 (0.3%)	4 (1.0%)	7 (1.8%)	6 (1.9
IRIS ADHESIONS CORNEAL DISORDER NOS CORNEAL EDEMA HYPOPYON EYE DISCHARGE MACULAR EDEMA RUBEOSIS IRIDIS CONJUNCTIVAL HEMORRHAGE CORNEAL EROSION HYPHEMA GLAUCOMA NOS BLINDNESS NEC CATARACT NEC	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	3 (0.8%)	3 (0.8%)	9 (2.3
CATARACT NEC	0 (0.0%) 1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (1.3%)	6 (1.5
DRY EYE NEC	1 (0.3%)	1 (0.3%)	2 (0.5%)	2 (0.5%)	2 (0.5%)	2 (0.5%)	8 (2.0
KERATITIS NEC	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	3 (0.8%)	6 (1.5
HYPOTONY OF EYE	2 (0.5%)	2 (0.5%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	4 (1.0
INTRAOCULAR PRESSURE INCREASED	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	4 (1.0
CORNEAL EROSION HYPHEMA GLAUCOMA NOS BLINDNESS NEC CATARACT NEC DRY EYE NEC KERATITIS NEC HYPOTONY OF EYE INTRAOCULAR PRESSURE INCREASED RETINOPATHY DIABETIC BLEPHARITIS CATARACT NOS AGGRAVATED MACULOPATHY POST-OPERATIVE PAIN POSTERIOR CAPSULE OPACIFICATION VITREOUS DETACHMENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	5 (1.3%)	3 (0.8
BLEPHARITIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	2 (0.5%)	4 (1.0
CATARACT NOS AGGRAVATED	2 (0.5%)	2 (0.5%)	2 (0.5%)	2 (0.5%)	2 (0.5%)	3 (0.8%)	4 (1.0
MACULOPATHY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	4 (1.0%)	4 (1.0
POST-OPERATIVE PAIN	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	2 (0.5%)	1 (0.3
POSTERIOR CAPSULE OPACIFICATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	4 (1.0
VITREOUS DETACHMENT	0 (0.0%)	1 (0.3%)	2 (0.5%)	3 (0.8%)	4 (1.0%)	3 (0.8%)	4 (1.0

Note: Events are included in all periods in which they are present.

Table 13

Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period During Which Event was Present
Safety Population

Treatment: 75 IU Vitrase (n = 391)

System Organ Class / Preferred Term	Day 0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
			· • • • • • • • • • • • • • • • • • • •		· · · · · · · · · · · · · · · · · · ·		
MYDRIASIS	2 (0.5%)	3 (0.8%)	3 (0.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
UVEITIS NOS	4 (1.0%)	4 (1.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
VISION BLURRED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	4 (1.0%)
CONJUNCTIVITIS NEC	2 (0.5%)	2 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CORNEAL ABRASION	1 (0.3%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
CORNEAL EPITHELIUM DEFECT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
DIPLOPIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	2 (0.5%)
PAINFUL RED EYES	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	1 (0.3%)
RETINAL ISCHEMIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	2 (0.5%)
RETINAL TEAR (EXC DETACHMENT)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)
VITREOUS DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)
APHAKIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
BLINDNESS NIGHT	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)
BLOODSHOT EYE	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CCONJUNCTIVAL EDEMA	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CHALAZION	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
CHEMOSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
CHOROIDAL DETACHMENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)
CHOROIDAL HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)
COLOUR BLINDNESS NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
CONJUNCTIVITIS (INFECTIVE) NEC	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CONJUNCTIVITIS ALLERGIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
CONJUNCTIVITIS VIRAL NOS	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CORTICAL OPACITY	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)
CYCLITIS	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYE ALLERGY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
EYE DEGENERATIVE DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
EYE INFECTION TOXOPLASMAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	0 (0.0%)
EYE INFLAMMATION NOS	1 (0.3%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYELID DISORDER NOS	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYELID PTOSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
HERPES SIMPLEX OPHTHALMIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)
KERATOCONJUNCTIVITIS	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
KERATOPATHY BAND	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	0 (0.0%)
LENTICULAR OPACITIES	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
MEIBOMIAN CYST	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
OCULAR HYPERAEMIA	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
OCULAR HYPERTENSION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
OPEN ANGLE GLAUCOMA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
PHOTOPHOBIA AGGRAVATED	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
POST-OPERATIVE COMPLICATIONS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
RETINAL ARTERY EMBOLISM	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
RETINAL DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)

Note: Events are included in all periods in which they are present.

Table 13

Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period During Which Event was Present
Safety Population

Treatment: 75 IU Vitrase (n = 391)

System Organ Class / Preferred Term	Day 0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
RETINAL SCAR	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	0 (0.0%)
RETINAL VEIN THROMBOSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
STRABISMUS NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
VISUAL ACUITY REDUCED TRANSIENTLY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
VISUAL DISTURBANCE NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
RETINAL SCAR RETINAL VEIN THROMBOSIS STRABISMUS NEC VISUAL ACUITY REDUCED TRANSIENTLY VISUAL DISTURBANCE NOS VITREOUS OPACITIES	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
INVESTIGATIONS INTRAOCULAR PRESSURE INCREASED	16 (4.1%)	15 (3.8%)	13 (3.3%)	9 (2.3%)	8 (2.0%)	22 (5.6%)	24 (6.1%)
INTRAOCULAR PRESSURE INCREASED	13 (3.3%)	10 (2.6%)	8 (2.0%)	7 (1.8%)	7 (1.8%)	21 (5.4%)	24 (6.1%)
CODNEST CENTRIC	ላ / ገ ለዔነ	6 (1.5%)	5 (1.3%)	2 (0.5%)	1 (0.3%)	1 (0.3%)	1 (0.3%)
SKIN & SUBCUTANEOUS TISSUE DISORDERS EYELID EDEMA ERYTHEMA NEC DERMATITIS NOS ECCHYMOSIS OCULAR HYPEREMIA PERIORBITAL EDEMA NERVOUS SYSTEM DISORDERS	25 (6.4%)	25 (6.4%)	12 (3.1%)	5 (1.3%)	5 (1.3%)	6 (1.5%)	6 (1.5%)
EYELID EDEMA	17 (4.3%)	16 (4.1%)	5 (1.3%)	2 (0.5%)	4 (1.0%)	5 (1.3%)	5 (1.3%)
ERYTHEMA NEC	12 (3.1%)	13 (3.3%)	7 (1.8%)	3 (0.8%)	3 (0.8%)	3 (0.8%)	3 (0.8%)
DERMATITIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	(\$0.0)	0 (0.0%)	1 (0.3%)
ECCHYMOSIS	1 (0.3%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
OCULAR HYPEREMIA	1 (0.3%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PERIORBITAL EDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
NERVOUS SYSTEM DISORDERS	2 (0.5%)		2 (0.5%)	1 (0.3%)	4 (1.0%)	3 (0.8%)	3 (0.8%)
PUPILLARY DISORDER NOS	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	2 (0.5%)	2 (0.5%)
FACIAL PALSY	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)
HEADACHE NOS	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PUPILLARY REFLEX IMPAIRED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)
VISUAL FIELD DEFECT NOS	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
SURGICAL AND MEDICAL PROCEDURES	2 (0.5%)		1 (0.3%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	3 (0.8%)
POST-OPERATIVE COMPLICATIONS NOS	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	1 (0.3%)
LENS IMPLANT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
SCLERAL OPERATION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
SCLERAL OPERATION NOS UNSPECIFIED COMPLICATION OF PROCEDURE NEC VITRECTOMY	2 (0.5%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
VITRECTOMY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
MECHANICAL COMPLICATION OF IMPLANT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
NEOPLASMS BENIGN AND MALIGNANT (INCLUDING CYSTS AND POLYPS)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
BENIGN NEOPLASM OF CHOROID	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
VASCULAR DISORDERS	0 (0.0%)			0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
PERIPHERAL ISCHEMIA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)

Note: Events are included in all periods in which they are present.

s:\dat\acs\iss2002\sas\programs\t_ocae_period 06SEP2002 17:35

Page 1 of 10

ISTA Pharmaceuticals, Inc. Integrated Summary of Safety

Table 14

Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period During Which Event was Present
Safety Population

Treatment: WW Control (n = 18)

System Organ Class / Preferred Term	Day 0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
NUMBER OF PATIENTS WITH AT LEAST ONE RELATED ADVERSE EVENT	3 (16.7%)	4 (22.2%)	5 (27.8%)	7 (38.9%)	9 (50.0%)	10 (55.6%)	7 (38.9%)
EYE DISORDERS	3 (16.7%)	4 (22.2%)	5 (27.8%)	7 (38.9%)	9 (50.0%)	10 (55.6%)	7 (38.9%)
EYE IRRITATION	1 (5.6%)	1 (5.6%)	2 (11.1%)	2 (11.1%)	3 (16.7%)	4 (22.2%)	3 (16.7%)
PHOTOPHOBIA	2 (11.1%)	2 (11.1%)	3 (16.7%)	3 (16.7%)	1 (5.6%)	1 (5.6%)	0 (0.0%)
VITREOUS FLOATERS	1 (5.6%)	1 (5.6%)	2 (11.1%)	3 (16.7%)	3 (16.7%)	2 (11.1%)	1 (5.6%)
IRIS ADHESIONS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	1 (5.6%)	2 (11.1%)
VISUAL ACUITY REDUCED	1 (5.6%)	1 (5.6%)	1 (5.6%)	2 (11.1%)	2 (11.1%)	2 (11.1%)	1 (5.6%)
ABNORMAL SENSATION IN EYE	0 (0.0%)	0 (0.0%)	1 (5.6%)	1 (5.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CATARACT CORTICAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)
CATARACT NOS AGGRAVATED	0 (0.0%)	0 (0.0%)	1 (5.6%)	1 (5.6%)	1 (5.6%)	1 (5.6%)	0 (0.0%)
CATARACT NUCLEAR	0 (0.0%)	1 (5.6%)	1 (5.6%)	1 (5.6%)	1 (5.6%)	1 (5.6%)	1 (5.6%)
CONJUNCTIVAL EDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)
CORNEAL EPITHELIUM DEFECT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)
EYE PAIN	1 (5.6%)	1 (5.6%)	1 (5.6%)	1 (5.6%)	1 (5.6%)	0 (0.0%)	0 (0.0%)
IRITIS	1 (5.6%)	1 (5.6%)	1 (5.6%)	1 (5.6%)	1 (5.6%)	1 (5.6%)	1 (5.6%)
LACRIMATION INCREASED	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	1 (5.6%)	1 (5.6%)	1 (5.6%)
OCULAR HYPEREMIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)	I (5.6%)	1 (5.6%)
RETINAL DETACHMENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)
RUBEOSIS IRIDIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	1 (5.6%)	1 (5.6%)	0 (0.0%)
UVEITIS NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	1 (5.6%)	1 (5.6%)	0 (0.0%)
VITREOUS HEMORRHAGE	1 (5.6%)	1 (5.6%)	1 (5.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

174

Note: Events are included in all periods in which they are present.

The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing or 'Ongoing' is marked.

Table 14

Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period During Which Event was Present
Safety Population

Treatment: Saline Control (n = 378)

System Organ Class / Preferred Term	Day 0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
NUMBER OF PATIENTS WITH AT LEAST ONE RELATED ADVERSE EVENT EYE DISORDERS OCULAR HYPEREMIA IRITIS EYE IRRITATION EYE PAIN LACRIMATION INCREASED ABNORMAL SENSATION IN EYE CONJUNCTIVAL EDEMA VISUAL ACUITY REDUCED PHOTOPHOBIA VITREOUS FLOATERS VITREOUS HEMORRHAGE CATARACT CORTICAL CATARACT NUCLEAR CORNEAL EROSION CONJUNCTIVAL HEMORRHAGE PHOTOPSIA EYE DISCHARGE CATARACT SUBCAPSULAR RETINAL DETACHMENT RUBEOSIS IRIDIS CORNEAL EDEMA CATARACT NOS AGGRAVATED CORNEAL DISORDER NOS HYPHEMA IRIS ADHESIONS MACULAR EDEMA DIPLOPIA DRY EYE NEC MACULOPATHY POSTERIOR CAPSULE OPACIFICATION RETINOPATHY DIABETIC APHAKIA BLINDMESS NEC FOREIGN BODY RETAINED IN EYE INTRAOCULAR PRESSURE DECREASED KERATICIS NEC KERATOCONJUNCTIVITIS MYDRIASIS	203 (53.7%)	209 (55.3%)	165 (43.7%)	122 (32.3%)	104 (27.5%)	105 (27.8%)	92 (24.3%)
EYE DISORDERS	201 (53.2%)	207 (54.8%)	163 (43.1%)	119 (31.5%)	103 (27.2%)	105 (27.8%)	91 (24.1%)
OCULAR HYPEREMIA	106 (28.0%)	110 (29.1%)	66 (17.5%)	19 (5.0%)	7 (1.9%)	7 (1.9%)	4 (1.1%)
IRITIS	83 (22.0%)	96 (25.4%)	67 (17.7%)	27 (7.1%)	14 (3.7%)	12 (3.2%)	6 (1.6%)
EYE IRRITATION	53 (14.0%)	56 (14.8%)	42 (11.1%)	30 (7.9%)	32 (8.5%)	29 (7.7%)	20 (5.3%)
EYE PAIN	45 (11.9%)	48 (12.7%)	22 (5.8%)	8 (2.1%)	8 (2.1%)	7 (1.9%)	5 (1.3%)
LACRIMATION INCREASED	32 (8.5%)	36 (9.5%)	27 (7.1%)	19 (5.0%)	14 (3.7%)	15 (4.0%)	9 (2.4%)
ABNORMAL SENSATION IN EYE	37 (9.8%)	37 (9.8%)	20 (5.3%)	11 (2.9%)	9 (2.4%)	8 (2.1%)	8 (2.1%)
CONJUNCTIVAL EDEMA	45 (11.9%)	48 (12.7%)	21 (5.6%)	7 (1.9%)	3 (0.8%)	1 (0.3%)	1 (0.3%)
VISUAL ACUITY REDUCED	7 (1.9%)	13 (3.4%)	17 (4.5%)	17 (4.5%)	20 (5.3%)	20 (5.3%)	20 (5.3%)
PHOTOPHOBIA	15 (4.0%)	22 (5.8%)	24 (6.3%)	23 (6.1%)	18 (4.8%)	19 (5.0%)	14 (3.7%)
VITREOUS FLOATERS '	5 (1.3%)	19 (5.0%)	23 (6.1%)	22 (5.8%)	22 (5.8%)	23 (6.1%)	16 (4.2%)
VITREOUS HEMORRHAGE	0 (0.0%)	1 (0.3%)	3 (0.8%)	8 (2.1%)	10 (2.6%)	16 (4.2%)	15 (4.0%)
CATARACT CORTICAL	0 (0.0%)	1 (0.3%)	3 (0.8%)	3 (0.8%)	3 (0.8%)	9 (2.4%)	12 (3.2%)
CATARACT NUCLEAR	1 (0.3%)	1 (0.3%)	3 (0.8%)	5 (1.3%)	6 (1.6%)	7 (1.9%)	15 (4.0%)
CORNEAL EROSION	11 (2.9%)	14 (3.7%)	7 (1.9%)	5 (1.3%)	2 (0.5%)	2 (0.5%)	0 (0.0%)
CONJUNCTIVAL HEMORRHAGE	12 (3.2%)	13 (3.4%)	10 (2.6%)	4 (1.1%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
PHOTOPSIA	2 (0.5%)	2 (0.5%)	5 (1.3%)	7 (1.9%)	6 (1.6%)	8 (2.1%)	7 (1.9%)
EYE DISCHARGE	11 (2.9%)	11 (2.9%)	3 (0.8%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	0 (0.0%)
CATARACT SUBCAPSULAR	0 (0.0%)	1 (0.3%)	2 (0.5%)	3 (0.8%)	4 (1.1%)	5 (1.3%)	10 (2.6%)
RETINAL DETACHMENT	0 (0.0%)	0 (0.0%)	2 (0.5%)	4 (1.1%)	5 (1.3%)	5 (1.3%)	4 (1.1%)
RUBEOSIS IRIDIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	2 (0.5%)	4 (1.1%)
CORNEAL EDEMA	1 (0.3%)	2 (0.5%)	1 (0.3%)	1 (0.3%)	. 0 (0.0%)	1 (0.3%)	1 (0.3%)
CATARACT NEC	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	2 (0.5%)	3 (0.8%)	2 (0.5%)
CATARACT NOS AGGRAVATED	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	3 (0.8%)	2 (0.5%)
CORNEAL DISORDER NOS	1 (0.3%)	1 (0.3%)	2 (0.5%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	0 (0.0%)
НУРНЕМА	0 (0.0%)	2 (0.5%)	2 (0.5%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	0 (0.0%)
IRIS ADHESIONS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	3 (0.8%)
MACULAR EDEMA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	3 (0.8%)
DIPLOPIA	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	2 (0.5%)	2 (0.5%)	2 (0.5%)
DRY EYE NEC	2 (0.5%)	2 (0.5%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)
MACULOPATHY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)
POSTERIOR CAPSULE OPACIFICATION	0 (0.0%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	1 (0.3%)
RETINOPATHY DIABETIC	0 (0.0%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	1 (0.3%)
APHAKIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
BLINDNESS NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
FOREIGN BODY RETAINED IN EYE	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)
INTRAOCULAR PRESSURE DECREASED	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
KERATITIS NEC	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	0 (0.0%)
KERATOCONJUNCTIVITIS	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
MYDRIASIS	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Note: Events are included in all periods in which they are present.

s:\dat\acs\iss2002\sas\programs\t_ocrae_period 06SEP2002 17:35

Table 14
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period During Which Event was Present Safety Population
Treatment: Saline Control (n = 378)

System Organ Class / Preferred Term	Day 0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
PAINFUL RED EYES	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
PHOTOPHOBIA AGGRAVATED	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PSEUDOPHAKIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
RETINAL DISORDER NOS	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
RETINAL HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
UVEITIS NOS	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)
VITREOUS DETACHMENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
VITREOUS DISORDER NOS	0 (0.0%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)
INVESTIGATIONS	12 (3.2%)	12 (3.2%)	9 (2.4%)	9 (2.4%)	6 (1.6%)	7 (1.9%)	5 (1.3%)
INTRAOCULAR PRESSURE INCREASED	10 (2.6%)	9 (2.4%)	8 (2.1%)	7 (1.9%)	5 (1.3%)	6 (1.6%)	5 (1.3%)
CORNEAL STAINING	2 (0.5%)	3 (0.8%)	1 (0.3%)	2 (0.5%)	1 (0.3%)	1 (0.3%)	0 (0.0%)
SKIN & SUBCUTANEOUS TISSUE DISORDERS	12 (3.2%)	13 (3.4%)	7 (1.9%)	2 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
ERYTHEMA NEC	7 (1.9%)	7 (1.9%)	3 (0.8%)	2 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYELID EDEMA	5 (1.3%)	6 (1.6%)	4 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
OCULAR HYPEREMIA	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
INFECTIONS AND INFESTATIONS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
HYPOPYON	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
INJURY AND POISONING	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
HEAD INJURY	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
NERVOUS SYSTEM DISORDERS	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
VISUAL FIELD DEFECT NOS	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
SURGICAL AND MEDICAL PROCEDURES	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
UNSPECIFIED COMPLICATION OF PROCEDURE NEC	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

176

Note: Events are included in all periods in which they are present.

The date of the patient is last visit is used for the resolved date of the events.

Table 14

Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class

Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period During Which Event was Present

Safety Population

Treatment: 7.5 IU Vitrase (n = 198)

System Organ Class / Preferred Term	Day 0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
	3.m /m. 00.	150 (75.8%)	125 (63.1%)	107 (54.0%)	103 (52.0%)	98 (49.5%)	77 (38.9%)
EYE DISORDERS	146 (73.7%)	149 (75.3%)	125 (63.1%)	105 (53.0%)	100 (50.5%)	96 (48.5%)	74 (37.4%)
IRITIS	80 (40.4%)	88 (44.4%)	62 (31.3%)	29 (14.6%)	20 (10.1%)	16 (8.1%)	13 (6.6%)
OCULAR HYPEREMIA	78 (39.4%)	76 (38.4%)	44 (22.2%)	12 (6.1%)	7 (3.5%)	7 (3.5%)	6 (3.0%)
EYE IRRITATION	40 (20.2%)	40 (20.2%)	31 (15.7%)	22 (11.1%)	22 (11.1%)	19 (9.6%)	15 (7.6%)
EYE PAIN	29 (14.6%)	31 (15.7%)	23 (11.6%)	12 (6.1%)	10 (5.1%)	12 (6.1%)	6 (3.0%)
VISUAL ACUITY REDUCED	20 (10.1%)	24 (12.1%)	22 (11.1%)	19 (9.6%)	23 (11.6%)	24 (12.1%)	11 (5.6%)
LACRIMATION INCREASED	23 (11.6%)	23 (11.6%)	21 (10.6%)	19 (9.6%)	20 (10.1%)	18 (9.1%)	10 (5.1%)
ABNORMAL SENSATION IN EYE	23 (11.6%) 27 (13.6%)	23 (11.6%)	13 (6.6%)	10 (5.1%)	12 (6.1%)	14 (7.1%)	16 (8.1%)
PHOTOPHOBIA	11 (5.6%)	13 (6.6%)	19 (9.6%)	23 (11.6%)	23 (11.6%)	21 (10.6%)	17 (8.6%
VITREOUS FLOATERS	12 (6.1%)	18 (9.1%)	24 (12.1%)	31 (15.7%)	28 (14.1%)	22 (11.1%)	16 (8.1%
VITREOUS HEMORRHAGE	1 (0.5%)	2 (1.0%)	6 (3.0%)	13 (6.6%)	18 (9.1%)	24 (12.1%)	10 (5.1%)
CONJUNCTIVAL EDEMA	25 (12.6%)	25 (12.6%)	9 (4.5%)	2 (1.0%)	2 (1.0%)	2 (1.0%)	2 (1.0%
CATARACT SUBCAPSULAR	0 (0.0%)		3 (1.5%)	5 (2.5%)	5 (2.5%)	11 (5.6%)	17 (8.6%)
PHOTOPSIA	3 (1.5%)		7 (3.5%)	7 (3.5%)	10 (5.1%)	11 (5.6%)	9 (4.5%
CATARACT NUCLEAR	0 (0.0%)		2 (1.0%)	5 (2.5%)	7 (3.5%)	8 (4.0%)	10 (5.1%
RETINAL DETACHMENT	1 (0.5%)		2 (1.0%)	1 (0.5%)	3 (1.5%)		7 (3.5%
RUBEOSIS IRIDIS	0 (0.0%)		2 (1.0%)	4 (2.0%)	5 (2.5%)	5 (2.5%)	6 (3.0%)
CONJUNCTIVAL HEMORRHAGE	5 (2.5%)		2 (1.0%)	0 (0.0%)	1 (0.5%)	1 (0.5%)	0 (0.0%
					1 (0.5%)	0 (0.0%)	0 (0.0%
CORNEAL EROSION	4 (2.0%)		2 (1.0%)	2 (1.0%)			
CORNEAL DISORDER NOS	3 (1.5%)		1 (0.5%)	1 (0.5%)	1 (0.5%)	1 (0.5%)	2 (1.0%
CORNEAL EDEMA	1 (0.5%)		1 (0.5%)	2 (1.0%)	1 (0.5%)	2 (1.0%)	0 (0.0%
IRIS ADHESIONS	0 (0.0%)		2 (1.0%)	2 (1.0%)	2 (1.0%)	2 (1.0%)	3 (1.5%
CATARACT CORTICAL	0 (0.0%)		1 (0.5%)	3 (1.5%)	2 (1.0%)	2 (1.0%)	3 (1.5%
EYE DISCHARGE	3 (1.5%)		1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
HYPHEMA	1 (0.5%)		1 (0.5%)	1 (0.5%)	0 (0.0%)	2 (1.0%)	2 (1.0%
KERATITIS NEC	1 (0.5%)		1 (0.5%)	1 (0.5%)	1 (0.5%)	1 (0.5%)	1 (0.5%
MACULAR EDEMA	0 (0.0%)		0 (0.0%)	1 (0.5%)	1 (0.5%)	1 (0.5%)	3 (1.5%
CONJUNCTIVITIS NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.5%)	1 (0.5%
CORNEAL EPITHELIUM DEFECT	0 (0.0%)			1 (0.5%)	1 (0.5%)	0 (0.0%)	1 (0.5%
FOREIGN BODY RETAINED IN EYE	1 (0.5%)		2 (1.0%)	1 (0.5%)	1 (0.5%)	0 (0.0%)	1 (0.5%)
INTRAOCULAR PRESSURE DECREASED	1 (0.5%)		1 (0.5%)	1 (0.5%)	1 (0.5%)	1 (0.5%)	0 (0.0%
IRIDOCYCLITIS	0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.0%
BLINDNESS NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
CHORIORETINAL ATROPHY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)
CHORIORETINAL DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
CORNEAL ABRASION	1 (0.5%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
. CORNEAL OPACITY	0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%
- CORTICAL OPACITY	0 (0.0%)			0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.5%
DIPLOPIA	0 (0.0%)			0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%
DRY EYE NEC	0 (0.0%)			0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%

Note: Events are included in all periods in which they are present.

s:\dat\acs\iss2002\sas\programs\t_ocrae_period 06SEP2002 17:35

Table 14

Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period During Which Event was Present
Safety Population

Treatment: 7.5 IU Vitrase (n = 198)

System Organ Class / Preferred Term	Day 0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
EYE DEGENERATIVE DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
EYELID PTOSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)
GLAUCOMA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)
HYPOPYON	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
INTRAOCULAR PRESSURE INCREASED	1 (0.5%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.5%)	1 (0.5%)	1 (0.5%)
MACULAR DEGENERATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
MACULOPATHY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
OPEN ANGLE GLAUCOMA NOS	0 (0.0%)	1 (0.5%)	1 (0.5%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PINGUECULA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
RETINAL DEPIGMENTATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
RETINAL HEMORRHAGE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
RETINAL MICROANEURYSMS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
STRABISMUS NEC	0 (0.0%)	1 (0.5%)	1 (0.5%)	1 (0.5%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
UVEITIS DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
UVEITIS NOS	1 (0.5%)	1 (0.5%)	1 (0.5%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
VISION BLURRED	1 (0.5%)	1 (0.5%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
VITREOUS DETACHMENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.5%)	1 (0.5%)
VITREOUS DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
VITREOUS OPACITIES	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0 5%)
INVESTIGATIONS	8 (4.0%)	8 (4.0%)	7 (3.5%)	8 (4.0%)	4 (2.0%)	6 (3.0%)	6 (3.0%)
INTRAOCULAR PRESSURE INCREASED	5 (2.5%)	4 (2.0%)	5 (2.5%)	8 (4.0%)	4 (2.0%)	6 (3.0%)	5 (2.5%)
CORNEAL STAINING	3 (1.5%)	4 (2.0%)	2 (1.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
SKIN & SUBCUTANEOUS TISSUE DISORDERS	6 (3.0%)	6 (3.0%)	4 (2.0%)	1 (0.5%)	0 (0.0%)	1 (0.5%)	1 (0.5%)
EYELID EDEMA	5 (2.5%)	4 (2.0%)	2 (1.0%)	1 (0.5%)	0 (0.0%)	1 (0.5%)	0 (0.0%)
ERYTHEMA NEC	1 (0.5%)	2 (1.0%)	2 (1.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)
CUTIS LAXA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
NERVOUS SYSTEM DISORDERS	1 (0.5%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.5%)
PUPILLARY DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.5%)
VISUAL FIELD DEFECT NOS	1 (0.5%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
SURGICAL AND MEDICAL PROCEDURES	2 (1.0%)	0 (0.0%)	1 (0.5%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
VITRECTOMY	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
UNSPECIFIED COMPLICATION OF PROCEDURE NEC	2 (1.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

170

Note: Events are included in all periods in which they are present.

The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing or 'Ongoing' is marked.

Table 14

Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period During Which Event was Present
Safety Population
Treatment: 55 IU Vitrase (n = 377)

System Organ Class / Preferred Term	Day 0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
NUMBER OF PATIENTS WITH AT LEAST ONE RELATED ADVERSE EVENT	261 (69.2%)	268 (71.1%)	223 (59.2%)	178 (47.2%)	164 (43.5%)	154 (40.8%)	109 (28.9%
ADVERSE EVENT EYE DISORDERS IRITIS OCULAR HYPEREMIA EYE PAIN EYE IRRITATION LACRIMATION INCREASED ABNORMAL SENSATION IN EYE CONJUNCTIVAL EDEMA VISUAL ACUITY REDUCED PHOTOPHOBIA VITREOUS FLOATERS VITREOUS HEMORRHAGE PHOTOPSIA	258 (68.4%)	265 (70.3%)	222 (58.9%)	178 (47.2%)	162 (43.0%)	150 (39.8%)	109 (28.9%
IRITIS	184 (48.8%)	194 (51.5%)	131 (34.7%)	56 (14.9%)	30 (8.0%)	22 (5.8%)	13 (3.4%
OCULAR HYPEREMIA	150 (39.8%)	155 (41.1%)	82 (21.8%)	31 (8.2%)	14 (3.7%)	9 (2.4%)	2 (0.5%
EYE PAIN	96 (25.5%)	94 (24.9%)	54 (14.3%)	22 (5.8%)	17 (4.5%)	16 (4.2%)	12 (3.2%
EYE IRRITATION	65 (17.2%)	69 (18.3%)	57 (15.1%)	39 (10.3%)	34 (9.0%)	26 (6.9%)	12 (3.2%
LACRIMATION INCREASED	67 (17.8%)	68 (18.0%)	47 (12.5%)	36 (9.5%)	36 (9.5%)	25 (6.6%)	16 (4.2%
ABNORMAL SENSATION IN EYE	60 (15.9%)	63 (16.7%)	41 (10.9%)	26 (6.9%)	16 (4.2%)	17 (4.5%)	6 (1.6%
CONJUNCTIVAL EDEMA	69 (18.3%)	71 (18.8%)	30 (8.0%)	6 (1.6%)	6 (1.6%)	4 (1.1%)	3 (0.8%
VISUAL ACUITY REDUCED	24 (6 4%)	29 (7.7%)	31 (8.2%)	32 (8.5%)	35 (9.3%)	37 (9.8%)	22 (5.8%
PHOTOPHOBIA	35 (9 3%)	45 (11.9%)	39 (10.3%)	34 (9.0%)	27 (7.2%)	23 (6.1%)	20 (5.3%
VITREOUS FLOATERS	19 (5.5%)	25 (6.6%)	30 (8.0%)	32 (8.5%)	37 (9.8%)	32 (8.5%)	22 (5.8%
VITREOUS HEMORRHAGE	7 (0.3%)	2 (0.5%)	5 (1.3%)	10 (2.7%)	20 (5.3%)	24 (6.4%)	19 (5.0%
PHOTOPSIA	6 (1.6%)	9 (2.4%)	16 (4.2%)	15 (4.0%)	13 (3.4%)	14 (3.7%)	12 (3.2%
CATARACT NUCLEAR	2 (0.5%)	3 (0.8%)	7 (1.9%)	8 (2.1%)	12 (3.2%)	13 (3.4%)	14 (3.7%
CATARACT NOCHEAR CATARACT SUBCAPSULAR	1 (0.3%)		7 (1.9%)	11 (2.9%)	10 (2.7%)	10 (2.7%)	16 (4.2%
CATARACI SOBCAPSULAR CATARACT CORTICAL	4 (1.1%)		7 (1.9%)	8 (2.1%)	7 (1.9%)	12 (3.2%)	13 (3.4%
			7 (1.9%)	3 (0.8%)	6 (1.6%)	10 (2.7%)	6 (1.6%
RETINAL DETACHMENT	0 (0.0%)			1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%
CORNEAL DISORDER NOS	11 (2.9%)		6 (1.6%)				0 (0.0%
CORNEAL EROSION	12 (3.2%)		9 (2.4%)	6 (1.6%)	1 (0.3%)	0 (0.0%)	
EYE DISCHARGE	10 (2.7%)		1 (0.3%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%
IRIS ADHESIONS	4 (1.1%)		3 (0.8%)	3 (0.8%)	2 (0.5%)	3 (0.8%)	2 (0.5%
CORNEAL EDEMA	3 (0.8%)	4 (1.1%)	3 (0.8%)	2 (0.5%)	2 (0.5%)	3 (0.8%)	2 (0.5%
CONJUNCTIVAL HEMORRHAGE	5 (1.3%)		6 (1.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
HYPOPYON	4 (1.1%)		3 (0.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
RUBEOSIS IRIDIS	1 (0.3%)		1 (0.3%)	4 (1.1%)	5 (1.3%)	3 (0.8%)	3 (0.8%
VITREOUS DETACHMENT	0 (0.0%)		3 (0.8%)	3 (0.8%)	5 (1.3%)	4 (1.1%)	4 (1.1%
HYPHEMA	1 (0.3%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	3 (0.8%)	3 (0.8%
UVEITIS NOS	4 (1.1%)	4 (1.1%)	2 (0.5%)	2 (0.5%)	1 (0.3%)	1 (0.3%)	0 (0.0%
RETINAL TEAR (EXC DETACHMENT)	1 (0.3%)	1 (0.3%)	1 (0.3%)	2 (0.5%)	2 (0.5%)	2 (0.5%)	0 (0.0%
CATARACT NOS AGGRAVATED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.8%
DIPLOPIA	1 (0.3%)		2 (0.5%)	1 (0.3%)	1 (0.3%)	2 (0.5%)	2 (0.5%
DRY EYE NEC	1 (0.3%)		1 (0.3%)	2 (0.5%)	2 (0.5%)	2 (0.5%)	3 (0.8%
MACULAR EDEMA	0 (0.0%)		0 (0.0%)	0 (0.0%)	1 (0.3%)	3 (0.8%)	3 (0.8%
MACULOPATHY	0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	3 (0.8%
PHOTOPHOBIA AGGRAVATED	0 (0.0%)		1 (0.3%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	1 (0.3%
VICTON BIJIDDED	0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	3 (0.8%
BLEPHARITIS	0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%
CATARACT NEC	1 (0.3%)		1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	2 (0.5%
•	0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	2 (0.5%
KERATITIS NEC POSTERIOR CAPSULE OPACIFICATION	1 (0.3%)			0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%
POSTERIOR CAPSULE OPACIFICATION	± (∪.3%)	⊥ (∪.3%)	T (0.72)	0 (0.04)	0 (0.08)	0 (0.03)	⊥ (∪.3₹

Note: Events are included in all periods in which they are present.

s:\dat\acs\iss2002\sas\programs\t_ocrae_period 06SEP2002 17:35

Table 14

Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period During Which Event was Present
Safety Population

Treatment: 55 IU Vitrase (n = 377)

System Organ Class / Preferred Term	Day 0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
BLINDNESS NEC BLINDNESS TRANSIENT CHOROIDAL DETACHMENT CONJUNCTIVITIS (INFECTIVE) NEC CORNEAL ABRASION CORNEAL EPITHELIUM DEFECT CORTICAL OPACITY ERYTHEMA NEC EYE ALLERGY EYE DEGENERATIVE DISORDER NOS EYELID EDEMA FOREIGN BODY RETAINED IN EYE HYPOTONY OF EYE INTRACCULAR PRESSURE INCREASED IRIDOCYCLITIS KERATOPATHY NOS MACULAR DEGENERATION MEIBOMIAN CYST OCULAR HYPERTENSION OPTIC ATROPHY PSEUDOPHAKIA RETINAL HEMORRHAGE RETINOPATHY DIABETIC TOPOGRAPHY CORNEAL ABNORMAL	0 (0.0%)	0 (0.0%)	0 (.0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%
BLINDNESS TRANSIENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%
CHOROIDAL DETACHMENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%
CONJUNCTIVITIS (INFECTIVE) NEC	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
CORNEAL ABRASION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%
CORNEAL EPITHELIUM DEFECT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%
CORTICAL OPACITY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	1 (0.3%
ERYTHEMA NEC	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
EYE ALLERGY	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
EYE DEGENERATIVE DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%
EYELID EDEMA	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
FOREIGN BODY RETAINED IN EYE	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%
HYPOTONY OF EYE	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	0 (0.0%
INTRAOCULAR PRESSURE INCREASED	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%
IRIDOCYCLITIS	1 (0.3%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
KERATOPATHY NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%
MACULAR DEGENERATION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%
MEIBOMIAN CYST	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%
OCULAR HYPERTENSION	1 (0.3%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
OPTIC ATROPHY	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%
PSEUDOPHAKIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%
RETINAL HEMORRHAGE	I (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%
RETINOPATHY DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%
TOPOGRAPHY CORNEAL ABNORMAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%
SKIN & SUBCUTANEOUS TISSUE DISORDERS EYELID EDEMA ERYTHEMA NEC PERIORBITAL EDEMA	22 (5.8%)	24 (6.4%)	12 (3.2%)	4 (1.1%)	1 (0.3%)	2 (0.5%)	1 (0.3%
EYELID EDEMA	18 (4.8%)	19 (5.0%)	6 (1.6%)	2 (0.5%)	0 (0.0%)	1 (0.3%)	1 (0.3%
ERYTHEMA NEC	10 (2.7%)	11 (2.9%)		2 (0.5%)	1 (0.3%)	2 (0.5%)	1 (0.3%
PERIORBITAL EDEMA	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
INVESTIGATIONS INTRAOCULAR PRESSURE INCREASED CORNEAL STAINING	9 (2.4%)	10 (2.7%)		7 (1.9%)	4 (1.1%)	8 (2.1%)	4 (1.1%
INTRAOCULAR PRESSURE INCREASED	4 (1.1%)	4 (1.1%)		4 (1.1%)	4 (1.1%)	8 (2.1%)	4 (1.1%
		, ,	4 (1.1%)	3 (0.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%
SURGICAL AND MEDICAL PROCEDURES UNSPECIFIED COMPLICATION OF PROCEDURE NEC EYE IRRITATION POST-OPERATIVE HEMORRHAGE	5 (1.3%)	2 (0.5%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
UNSPECIFIED COMPLICATION OF PROCEDURE NEC	3 (0.8%)	1 (0.3%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
EYE IRRITATION	1 (0.3%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
		1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
NERVOUS SYSTEM DISORDERS PUPILLARY DISORDER NOS	1 (0.3%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%
PUPILLARY DISORDER NOS	1 (0.3%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%
	, ,	,		•			

Note: Events are included in all periods in which they are present.

s:\dat\acs\iss2002\sas\programs\t_ocrae period 06SEP2002 17:35

Table 14

Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period During Which Event was Present
Safety Population

Treatment: 75 IU Vitrase (n = 391)

System Organ Class / Preferred Term	Day 0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
NUMBER OF PATIENTS WITH AT LEAST ONE RELATED ADVERSE EVENT	304 (77.7%)	312 (79.8%)	240 (61.4%)	173 (44.2%)	158 (40.4%)	147 (37.6%)	126 (32.2%)
EYE DISORDERS IRITIS OCULAR HYPEREMIA EYE PAIN LACRIMATION INCREASED EYE IRRITATION ABNORMAL SENSATION IN EYE PHOTOPHOBIA CONJUNCTIVAL EDEMA VITREOUS PLOATERS VISUAL ACUITY REDUCED VITREOUS HEMORRHAGE PHOTOPSIA CORNEAL DISORDER NOS RETINAL DETACHMENT HYPOPYON CATARACT CORTICAL CORNEAL EDEMA IRIS ADHESIONS CATARACT SUBCAPSULAR EYE DISCHARGE CORNEAL EROSION CATARACT NUCLEAR RUBEOSIS IRIDIS CONJUNCTIVAL HEMORRHAGE MACULAR EDEMA HYPHEMA GLAUCOMA NOS CATARACT NEC HYPOTONY OF EYE MACULOPATHY MYDRIASIS UVEITIS NOS DRY EYE NEC KERATITIS NEC VITREOUS DETACHMENT BLINDNESS NEC CONJUNCTIVITIS NEC POSTERIOR CAPSULE OPACIFICATION VISION BLURRED	304 (77.7%)	311 (79.5%)	239 (61.1%)	171 (43.7%)	156 (39.9%)	145 (37.1%)	123 (31.5%)
IRITIS	224 (57.3%)	228 (58.3%)	141 (36.1%)	50 (12.8%)	22 (5.6%)	11 (2.8%)	12 (3.1%)
OCULAR HYPEREMIA	175 (44.8%)	176 (45.0%)	85 (21.7%)	29 (7.4%)	11 (2.8%)	8 (2.0%)	8 (2.0%)
EYE PAIN	103 (26.3%)	103 (26.3%)	59 (15.1%)	29 (7.4%)	20 (5.1%)	22 (5.6%)	13 (3.3%)
LACRIMATION INCREASED	65 (16.6%)	67 (17.1%)	49 (12.5%)	33 (8.4%)	30 (7.7%)	27 (6.9%)	20 (5.1%)
EYE IRRITATION	62 (15.9%)	73 (18.7%)	56 (14.3%)	43 (11.0%)	34 (8.7%)	26 (6.6%)	20 (5.1%)
ABNORMAL SENSATION IN EYE	71 (18.2%)	71 (18.2%)	47 (12.0%)	28 (7.2%)	16 (4.1%)	18 (4.6%)	13 (3.3%)
PHOTOPHOBIA	46 (11.8%)	53 (13.6%)	39 (10.0%)	29 (7.4%)	36 (9.2%)	30 (7.7%)	19 (4.9%)
CONJUNCTIVAL EDEMA	74 (18.9%)	76 (19.4%)	29 (7.4%)	5 (1.3%)	2 (0.5%)	2 (0.5%)	3 (0.8%
VITREOUS FLOATERS	22 (5 6%)	33 (8.4%)	47 (12.0%)	45 (11.5%)	39 (10.0%)	35 (9.0%)	21 (5.4%)
VISUAL ACUITY REDUCED	29 (7.4%)	34 (8.7%)	31 (7.9%)	28 (7.2%)	29 (7.4%)	30 (7.7%)	15 (3.8%)
VITREOUS HEMORRHAGE	0 (0 08)	1 (0.3%)	4 (1.0%)	7 (1.8%)	10 (2.6%)	20 (5.1%)	16 (4.1%)
PHOTOPSIA	0 (0.0%)	8 (2.0%)	10 (2.6%)	12 (3.1%)	12 (3.1%)	12 (3.1%)	11 (2.8%)
CORNEAL DISORDER NOS	10 (4.6%)	18 (4.6%)	8 (2.0%)	4 (1.0%)	3 (0.8%)	2 (0.5%)	3 (0.8%
CORNEAL DISORDER NOS	16 (4.0%)	0 (0.0%)	0 (0,0%)	3 (0.8%)	7 (1.8%)	13 (3.3%)	16 (4.1%
RETINAL DETACHMENT	0 (0.0%)	0 (0.0%)	4 (1,0%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	0 (0.0%)
HYPOPYON	18 (4.6%)	20 (5.1%)					15 (3.8%)
CATARACT CORTICAL	0 (0.0%)	1 (0.3%)	2 (0.5%)	4 (1.0%)	7 (1.8%)	16 (4.1%)	
CORNEAL EDEMA	18 (4.6%)	18 (4.6%)	3 (0.8%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	2 (0.5%
IRIS ADHESIONS	6 (1.5%)	7 (1.8%)	9 (2.3%)	11 (2.8%)	10 (2.6%)	10 (2.6%)	8 (2.0%
CATARACT SUBCAPSULAR	2 (0.5%)	3 (0.8%)	3 (0.8%)	6 (1.5%)	9 (2.3%)	11 (2.8%)	12 (3.1%
EYE DISCHARGE	9 (2.3%)	11 (2.8%)	8 (2.0%)	3 (0.8%)	2 (0.5%)	1 (0.3%)	2 (0.5%
CORNEAL EROSION	8 (2.0%)	9 (2.3%)	7 (1.8%)	2 (0.5%)	3 (0.8%)	2 (0.5%)	0 (0.0%
CATARACT NUCLEAR	1 (0.3%)	2 (0.5%)	4 (1.0%)	4 (1.0%)	6 (1.5%)	7 (1.8%)	8 (2.0%
RUBEOSIS IRIDIS	3 (0.8%)	3 (0.8%)	3 (0.8%)	4 (1.0%)	5 (1.3%)	4 (1.0%)	4 (1.0%)
CONJUNCTIVAL HEMORRHAGE	7 (1.8%)	6 (1.5%)	3 (0.8%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%
MACULAR EDEMA	0 (0.0%)	0 (0.0%)	1 (0.3%)	2 (0.5%)	3 (0.8%)	4 (1.0%)	8 (2.0%
НҮРНЕМА	2 (0.5%)	3 (0.8%)	2 (0.5%)	0 (0.0%)	1 (0.3%)	2 (0.5%)	2 (0.5%
GLAUCOMA NOS	1 (0.3%)	3 (0.8%)	3 (0.8%)	1 (0.3%)	2 (0.5%)	3 (0.8%)	1 (0.3%
CATARACT NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	3 (0.8%
HYPOTONY OF EYE	2 (0.5%)	2 (0.5%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%
MACULOPATHY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	4 (1.0%)	3 (0.8%
MYDRIASIS	2 (0.5%)	3 (0.8%)	3 (0.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%
UVEITIS NOS	4 (1.0%)	4 (1.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
DRY EYE NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.8%
KERATITIS NEC	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)	1 (0.3%)	2 (0.5%
VITREOUS DETACHMENT	0 (0 0%)	1 (0.3%)		2 (0.5%)	2 (0.5%)	2 (0.5%)	3 (0.8%)
BLINDNESS NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	2 (0.5%
CONJUNCTIVITIS NEC	0 (0.0%)	2 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
DOCUMENTALIS NEC	2 (0.56)	0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)
POSTERIOR CAPSULE OPACIFICATION	0 (0.0%)	0 (0.0%)			0 (0.0%)	0 (0.0%)	
VISION BLURRED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)

Note: Events are included in all periods in which they are present.

s:\dat\acs\iss2002\sas\programs\t ocrae period 06SEP2002 17:35

Table 14

Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period During Which Event was Present
Safety Population

Treatment: 75 IU Vitrase (n = 391)

System Organ Class / Preferred Term	Day 0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
VITREOUS DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)
BLINDNESS NIGHT	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)
BLOODSHOT EYE	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CATARACT NOS AGGRAVATED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
CCONJUNCTIVAL EDEMA	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CHOROIDAL DETACHMENT	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)
COLOUR BLINDNESS NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
CONJUNCTIVITIS (INFECTIVE) NEC	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CONJUNCTIVITIS VIRAL NOS	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CORNEAL ABRASION	1 (0.3%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CORTICAL OPACITY	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)
CYCLITIS	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
DIPLOPIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
EYE INFECTION TOXOPLASMAL	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	0 (0.0%)
EYE INFLAMMATION NOS	1 (0.3%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYELID DISORDER NOS	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
INTRAOCULAR PRESSURE INCREASED	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
LENTICULAR OPACITIES	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
OCULAR HYPERAEMIA	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
OCULAR HYPERTENSION	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
PHOTOPHOBIA AGGRAVATED	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
POST-OPERATIVE PAIN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)
RETINAL DISORDER NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
RETINAL ISCHEMIA	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
RETINAL SCAR	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	0 (0.0%)
RETINAL VEIN THROMBOSIS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
RETINOPATHY DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
STRABISMUS NEC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
VISUAL DISTURBANCE NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
VITREOUS OPACITIES	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
SKIN & SUBCUTANEOUS TISSUE DISORDERS	20 (5.1%)	19 (4.9%)	10 (2.6%)	2 (0.5%)	1 (0.3%)	2 (0.5%)	2 (0.5%)
EYELID EDEMA	15 (3.8%)	14 (3.6%)	5 (1.3%)	1 (0.3%)	1 (0.3%)	2 (0.5%)	2 (0.5%)
ERYTHEMA NEC	10 (2.6%)	10 (2.6%)	5 (1.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)	1 (0.3%)
ECCHYMOSIS	1 (0.3%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
INVESTIGATIONS	12 (3.1%)	11 (2.8%)	8 (2.0%)	5 (1.3%)	3 (0.8%)	6 (1.5%)	4 (1.0%)
INTRAOCULAR PRESSURE INCREASED	10 (2.6%)	8 (2.0%)	5 (1.3%)	3 (0.8%)	2 (0.5%)	6 (1.5%)	4 (1.0%)
CORNEAL STAINING	2 (0.5%)	3 (0.8%)	3 (0.8%)	2 (0.5%)	1 (0.3%)	0 (0.0%)	0 (0.0%)
NERVOUS SYSTEM DISORDERS	2 (0.5%)	1 (0.3%)	1 (0.3%)	0 (0.0%)	3 (0.8%)	2 (0.5%)	2 (0.5%)
PUPILLARY DISORDER NOS	1 (0.3%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	2 (0.5%)	2 (0.5%)
HEADACHE NOS	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Note: Events are included in all periods in which they are present.

s:\dat\acs\iss2002\sas\programs\t_ocrae_period 06SEP2002 17:35

Page 10 of 10

ISTA Pharmaceuticals, Inc. Integrated Summary of Safety

Table 14

Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period During Which Event was Present
Safety Population

Treatment: 75 IU Vitrase (n = 391)

System Organ Class / Preferred Term	Day 0-Day 1	Day 2-Day 7	Day 8-Day 30	Day 31-Day 60	Day 61-Day 90	Day 90-Day 180	> Day 180
PUPILLARY REFLEX IMPAIRED	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)
VISUAL FIELD DEFECT NOS	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
SURGICAL AND MEDICAL PROCEDURES	2 (0.5%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
POST-OPERATIVE COMPLICATIONS NOS	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
SCLERAL OPERATION NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
UNSPECIFIED COMPLICATION OF PROCEDURE NEC	2 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
VASCULAR DISORDERS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
PERIPHERAL ISCHEMIA NOS	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)

Table 15
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Severity
Safety Population

	Conti	rol			
System Organ Class / Preferred Term Severity	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
NUMBER OF PATIENTS	18	378	198	377	391
NUMBER OF PATIENTS WITH AT LEAST ONE ADVERSE EVENT MILD	3 (16.7%)	110 (29.1%)	46 (23.2%)	70 (18.6%)	79 (20.2%)
MODERATE SEVERE	5 (27.8%) 9 (50.0%)	107 (28.3%) 81 (21.4%)	57 (28.8%) 90 (45.5%)	114 (30.2%) 139 (36.9%)	111 (28.4%) 159 (40.7%)
EYE DISORDERS MILD	3 (16.7%)	116 (30.7%)	48 (24.2%)	73 (19.4%)	80 (20.5%)
MODERATE SEVERE		103 (27.2%) 78 (20.6%)	60 (30.3%) 84 (42.4%)	113 (30.0%) 136 (36.1%)	115 (29.4%) 154 (39.4%)
		,			88 (22.5%)
IRITIS MILD MODERATE		96 (25.4%) 23 (6.1%)	83 (41.9%) 31 (15.7%)	95 (25.2%) 83 (22.0%)	102 (26.1%)
SEVERE	0 (0.0%)	7 (1.9%)	9 (4.5%)	44 (11.7%)	53 (13.6%)
OCULAR HYPEREMIA MILD MODERATE	4 (22.2%) 0 (0.0%)	99 (26.2%) 37 (9.8%)	72 (36.4%) 32 (16.2%)	126 (33.4%) 62 (16.4%)	144 (36.8%) 60 (15.3%)
SEVERE	0 (0.0%)	4 (1.1%)	9 (4.5%)	14 (3.7%)	11 (2.8%)
EYE IRRITATION MILD MODERATE	9 (50.0%) 0 (0.0%)	92 (24.3%) 16 (4.2%)	74 (37.4%) 12 (6.1%)	91 (24.1%) 29 (7.7%)	95 (24.3%) 31 (7.9%)
MODERATE SEVERE	1 (5.6%)	3 (0.8%)	4 (2.0%)	12 (3.2%)	13 (3.3%)
EYE PAIN MILD	1 (5.6%)	60 (15.9%)	54 (27.3%)	83 (22.0%)	95 (24.3%)
MODERATE SEVERE	1 (5.6%) 0 (0.0%)	20 (5.3%) 4 (1.1%)	13 (6.6%) 5 (2.5%)	42 (11.1%) 14 (3.7%)	48 (12.3%) 18 (4.6%)
LACRIMATION INCREASED MILD	1 (5.6%)	67 (17.7%)	41 (20.7%)	71 (18.8%)	78 (19.9%)
MODERATE SEVERE	3 (16.7%) 0 (0.0%)	14 (3.7%) 6 (1.6%)	16 (8.1%) 8 (4.0%)	39 (10.3%) 14 (3.7%)	41 (10.5%) 20 (5.1%)
VISUAL ACUITY REDUCED MILD	3 (16.7%)	49 (13.0%)	37 (18.7%)	58 (15.4%)	53 (13.6%)
MODERATE SEVERE		20 (5.3%) 5 (1.3%)	24 (12.1%) 16 (8.1%)	33 (8.8%) 10 (2.7%)	23 (5.9%) 22 (5.6%)
				•	,
ABNORMAL SENSATION IN EYE MILD MODERATE		55 (14.6%) 11 (2.9%)	38 (19.2%) 19 (9.6%)	67 (17.8%) 31 (8.2%)	79 (20.2%) 24 (6.1%)
SEVERE	0 (0.0%)	2 (0.5%)	5 (2.5%)	3 (0.8%)	11 (2.8%)
VITREOUS FLOATERS MILD MODERATE	1 (5.6%) 1 (5.6%)	37 (9.8%) 16 (4.2%)	28 (14.1%) 22 (11.1%)	52 (13.8%) 19 (5.0%)	56 (14.3%) 24 (6.1%)
SEVERE	4 (22.2%)	14 (3.7%)	13 (6.6%)	17 (4.5%)	20 (5.1%)
VITREOUS HEMORRHAGE MILD	1 (5.6%)	19 (5.0%)	16 (8.1%)	20 (5.3%)	24 (6.1%)

Table 15
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Severity
Safety Population

		Contr	ol			
System Organ Class / Preferred Term	Severity	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
VITREOUS HEMORRHAGE	MODERATE	0 (0.0%)	29 (7,7%)	28 (14.1%)	42 (11.1%)	30 (7.7%)
VITREOUS REMORRHAGE	SEVERE	1 (5.6%)	18 (4.8%)	26 (13.1%)	29 (7.7%)	36 (9.2%)
	SEVERE	1 (5.0%)	10 (4.0%/	20 (13.1%)	23 (7.78)	30 (3.24)
PHOTOPHOBIA	MILD	3 (16.7%)	35 (9.3%)	30 (15.2%)	33 (8.8%)	48 (12.3%)
	MODERATE	2 (11.1%)	15 (4.0%)	15 (7.6%)	38 (10.1%)	34 (8.7%)
	SEVERE	1 (5.6%)	10 (2.6%)	14 (7.1%)	15 (4.0%)	20 (5.1%)
			_			
CONJUNCTIVAL EDEMA	MILD	1 (5.6%)	49 (13.0%)	36 (18.2%)	70 (18.6%)	70 (17.9%)
	MODERATE	0 (0.0%)	9 (2.4%)	10 (5.1%)	21 (5.6%)	18 (4.6%)
	SEVERE	0 (0.0%)	1 (0.3%)	2 (1.0%)	5 (1.3%)	1 (0.3%)
CATARACT NUCLEAR	MILD	1 (5.6%)	10 (2.6%)	4 (2.0%)	12 (3.2%)	9 (2.3%)
CATARACI NOCHEAR	MODERATE	4 (22.2%)	16 (4.2%)	12 (6.1%)	16 (4.2%)	13 (3.3%)
	SEVERE	0 (0.0%)	8 (2.1%)	11 (5.6%)	9 (2.4%)	7 (1.8%)
	DHAHKB	0 (0.00)	0 (2.10)	11 (3,00,	, (2,110,	, (2.27,
RETINAL DETACHMENT	MILD	0 (0.0%)	6 (1.6%)	0 (0.0%)	8 (2.1%)	11 (2.8%)
	MODERATE	1 (5.6%)	8 (2.1%)	9 (4.5%)	10 (2.7%)	11 (2.8%)
	SEVERE	2 (11.1%)	12 (3.2%)	13 (6.6%)	17 (4.5%)	23 (5.9%)
		7 (5 69)	70 / 4 00)	00 (10 18)	16 / 4 2%)	24 / 6 1%)
CATARACT SUBCAPSULAR	MILD	1 (5.6%) 0 (0.0%)	18 (4.8%) 7 (1.9%)	20 (10.1%) 9 (4.5%)	16 (4.2%) 12 (3.2%)	24 (6.1%) 12 (3.1%)
	MODERATE SEVERE	1 (5.6%)	1 (0.3%)	4 (2.0%)	1 (0.3%)	2 (0.5%)
	SEVERE	1 (5.6%)	1 (0.34)	4 (2.00)	1 (0.3%)	2 (0.5%)
PHOTOPSIA	MILD	0 (0.0%)	12 (3.2%)	14 (7.1%)	31 (8.2%)	17 (4.3%)
	MODERATE	0 (0.0%)	6 (1.6%)	6 (3.0%)	12 (3.2%)	17 (4.3%)
	SEVERE	0 (0.0%)	4 (1.1%)	2 (1.0%)	2 (0.5%)	4 (1.0%)
CATARACT CORTICAL	MILD	5 (27.8%)	17 (4.5%)	8 (4.0%)	12 (3.2%)	19 (4.9%)
CAIAKACI COKIICAD	MODERATE	0 (0.0%)	8 (2.1%)	3 (1.5%)	13 (3.4%)	9 (2.3%)
	SEVERE	0 (0.0%)	2 (0.5%)	3 (1.5%)	5 (1.3%)	3 (0.8%)
			- ,,	- ,,	, ,	
CORNEAL EROSION	MILD	1 (5.6%)	19 (5.0%)	8 (4.0%)	19 (5.0%)	15 (3.8%)
	MODERATE	0 (0.0%)	5 (1.3%)	0 (0.0%)	5 (1.3%)	2 (0.5%)
	SEVERE	0 (0.0%)	0 (0.0%)	2 (1.0%)	1 (0.3%)	0 (0.0%)
CORNEAL EDEMA	MILD	1 (5.6%)	10 (2.6%)	7 (3.5%)	12 (3.2%)	16 (4.1%)
COMBAD DUBIN	MODERATE	0 (0.0%)	2 (0.5%)	8 (4.0%)	6 (1.6%)	6 (1.5%)
	SEVERE	0 (0.0%)	0 (0.0%)	2 (1.0%)	2 (0.5%)	2 (0.5%)
	~ · · · · · ·	3 , 0,	- ,,	_ ,,	- , - : /	= ,
RUBEOSIS IRIDIS	MILD	1 (5.6%)	6 (1.6%)	7 (3.5%)	8 (2.1%)	7 (1.8%)
	MODERATE	0 (0.0%)	9 (2.4%)	2 (1.0%)	6 (1.6%)	4 (1.0%)
}	SEVERE	0 (0.0%)	4 (1.1%)	7 (3.5%)	3 (0.8%)	8 (2.0%)

Table 15
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Severity Safety Population

		Control				
System Organ Class / Preferred Term	Severity	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
EYE DISCHARGE	MILD	0 (0.0%)	17 (4.5%)	8 (4.0%)	20 (5.3%)	17 (4.3%)
	MODERATE SEVERE	0 (0.0%) 0 (0.0%)	1 (0.3%) 0 (0.0%)	1 (0.5%) 1 (0.5%)	3 (0.8%) 0 (0.0%)	3 (0.8%) 0 (0.0%)
CONJUNCTIVAL HEMORRHAGE	MILD	0 (0.0%)	19 (5.0%)	8 (4.0%)	10 (2.7%)	14 (3.6%)
	MODERATE SEVERE	0 (0.0%) 0 (0.0%)	5 (1.3%) 1 (0.3%)	3 (1.5%) 0 (0.0%)	4 (1.1%) 0 (0.0%)	3 (0.8%) 1 (0.3%)
IRIS ADHESIONS	MILD	2 (11.1%)	8 (2.1%)	3 (1.5%)	7 (1.9%)	14 (3.6%)
	MODERATE SEVERE	0 (0.0%) 0 (0.0%)	5 (1.3%) 0 (0.0%)	4 (2.0%) 2 (1.0%)	5 (1.3%) 1 (0.3%)	7 (1.8%) 6 (1.5%)
MACULAR EDEMA	MILD	0 (0.0%)	5 (1.3%)	10 (5.1%)	5 (1.3%)	13 (3.3%)
	MODERATE SEVERE	1 (5.6%) 0 (0.0%)	6 (1.6%) 0 (0.0%)	5 (2.5%) 1 (0.5%)	5 (1.3%) 1 (0.3%)	5 (1.3%) 1 (0.3%)
CORNEAL DISORDER NOS	MILD	0 (0.0%)	8 (2.1%)	3 (1.5%)	11 (2.9%)	16 (4.1%
	MODERATE SEVERE	0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%)	1 (0.5%) 2 (1.0%)	4 (1.1%) 2 (0.5%)	7 (1.8%)
нурнема	MILD	0 (0.0%)	4 (1.1%)	5 (2.5%) 2 (1.0%)	7 (1.9%) 5 (1.3%)	6 (1.5% 3 (0.8%
	MODERATE SEVERE	0 (0.0%) 0 (0.0%)	0 (0.0%) 2 (0.5%)	1 (0.5%)	0 (0.0%)	6 (1.5%)
CATARACT NEC	MILD MODERATE	0 (0.0%) 0 (0.0%)	6 (1.6%) 3 (0.8%)	0 (0.0%) 0 (0.0%)	2 (0.5%) 5 (1.3%)	1 (0.3% 7 (1.8%
	SEVERE	0 (0.0%)	1 (0.3%)	1 (0.5%)	3 (0.8%)	1 (0.3%)
BLINDNESS NEC	MILD MODERATE	0 (0.0%) 1 (5.6%)	0 (0.0%) 0 (0.0%)	1 (0.5%) 0 (0.0%)	1 (0.3%) 1 (0.3%)	0 (0.0% 1 (0.3%
	SEVERE	0 (0.0%)	4 (1.1%)	8 (4.0%)	4 (1.1%)	8 (2.0%)
нуроруоп	MILD MODERATE	0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%)	2 (0.5%) 3 (0.8%)	10 (2.6% 5 (1.3%
	SEVERE	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	6 (1.5%)
DRY EYE NEC	MILD MODERATE	0 (0.0%) 0 (0.0%)	4 (1.1%) 2 (0.5%)	4 (2.0%) 3 (1.5%)	3 (0.8%) 2 (0.5%)	9 (2.3% 0 (0.0%
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
GLAUCOMA NOS	MILD MODERATE	0 (0.0%) 0 (0.0%)	2 (0.5%) 1 (0.3%)	1 (0.5%) 1 (0.5%)	0 (0.0%) 0 (0.0%)	2 (0.5%) 4 (1.0%)
	SEVERE	0 (0.0%)	2 (0.5%)	3 (1.5%)	3 (0.8%)	6 (1.5%

Table 15
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Severity Safety Population

			Contro	ol			
Sy	ystem Organ Class / Preferred Term	Severity	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
					• • • • • • • • • • • • • • • • • • • •		
	VISION BLURRED	MILD	0 (0.0%)	5 (1.3%)	8 (4.0%)	2 (0.5%)	2 (0.5%)
		MODERATE	0 (0.0%)	0 (0.0%)	2 (1.0%)	2 (0.5%)	1 (0.3%)
		SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
	CATARACT NOS AGGRAVATED	MILD	1 (5.6%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.3%)
		MODERATE	0 (0.0%)	4 (1.1%)	1 (0.5%)	2 (0.5%)	2 (0.5%)
		SEVERE	0 (0.0%)	4 (1.1%)	2 (1.0%)	3 (0.8%)	0 (0.0%)
	KERATITIS NEC	MILD	0 (0.0%)	3 (0.8%)	3 (1.5%)	3 (0.8%)	5 (1.3%)
		MODERATE	0 (0.0%)	1 (0.3%)	1 (0.5%)	1 (0.3%)	3 (0.8%)
		SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	VITREOUS DETACHMENT	MILD	1 (5.6%)	2 (0.5%)	2 (1.0%)	6 (1.6%)	3 (0.8%)
		MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.8%)	1 (0.3%)
		SEVERE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.3%)
	MACULOPATHY	MILD	0 (0.0%)	4 (1.1%)	2 (1.0%)	3 (0.8%)	2 (0.5%)
		MODERATE	0 (0.0%)	1 (0.3%)	1 (0.5%)	2 (0.5%)	2 (0.5%)
		SEVERE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.3%)
	INTRAOCULAR PRESSURE INCREASED	MILD	0 (0.0%)	1 (0.3%)	2 (1.0%)	2 (0.5%)	1 (0.3%)
		MODERATE	0 (0.0%)	1 (0.3%)	3 (1.5%)	0 (0.0%)	2 (0.5%)
		SEVERE	0 (0.0%)	1 (0.3%)	1 (0.5%)	1 (0.3%)	3 (0.8%)
	UVEITIS NOS	WILD	0 (0.0%)	1 (0.3%)	0 (0.0%)	5 (1.3%)	3 (0.8%)
		MODERATE	1 (5.6%)	1 (0.3%)	1 (0.5%)	1 (0.3%)	0 (0.0%)
		SEVERE	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	1 (0.3%)
	POST-OPERATIVE PAIN	MILĐ	0 (0.0%)	4 (1.1%)	0 (0.0%)	2 (0.5%)	3 (0.8%)
		MODERATE	1 (5.6%)	2 (0.5%)	0 (0.0%)	0 (0.0%)	2 (0.5%)
		SEVERE	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	POSTERIOR CAPSULE OPACIFICATION	MILD	0 (0.0%)	1 (0.3%)	1 (0.5%)	3 (0.8%)	4 (1.0%)
		MODERATE	0 (0.0%)	2 (0.5%)	0 (0.0%)	3 (0.8%)	1 (0.3%)
		SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0 0%)
	RETINOPATHY DIABETIC	MILD	0 (0.0%)	3 (0.8%)	1 (0.5%)	1 (0.3%)	1 (0.3%)
		MODERATE	0 (0.0%)	1 (0.3%)	0 (0.0%)	2 (0.5%)	4 (1.0%)
		SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	BLEPHARITIS	MILD	0 (0.0%)	1 (0.3%)	2 (1.0%)	2 (0.5%)	5 (1.3%)
يب		MODERATE	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	0 (0.0%)
-3		SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Table 15
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Severity
Safety Population

Outro Outro Class / Durbana d Tarr		Contr	ol				
System Organ Class / Preferred Term	Severity	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase	
HYPOTONY OF EYE	MILD	0 (0.0%)	1 (0.3%)	2 (1.0%)	1 (0.3%)	1 (0.3%)	
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	3 (0.8%)	
	SEVERE	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	
RETINAL HEMORRHAGE	MILD	0 (0.0%)	5 (1.3%)	2 (1.0%)	5 (1.3%)	0 (0.0%)	
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
CORNEAL EPITHELIUM DEFECT	MILD	1 (5.6%)	1 (0.3%)	1 (0.5%)	2 (0.5%)	1 (0.3%)	
	MODERATE	0 (0.0%)	0 (0.0%)	2 (1.0%)	1 (0.3%)	1 (0.3%)	
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	
DIPLOPIA	MILD	0 (0.0%)	2 (0.5%)	3 (1.5%)	4 (1.1%)	2 (0.5%)	
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
RETINAL ISCHEMIA	MILD	0 (0.0%)	1 (0.3%)	1 (0.5%)	1 (0.3%)	2 (0.5%)	
	MODERATE	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	0 (0.0%)	
	SEVERE	0 (0.0%)	0 (0.0%)	1 (0.5%)	2 (0.5%)	0 (0.0%)	
CONJUNCTIVITIS NEC	MILD	0 (0.0%)	2 (0.5%)	3 (1.5%)	0 (0.0%)	2 (0.5%)	
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
CORNEAL ABRASION	MILD	0 (0.0%)	1 (0.3%)	1 (0.5%)	1 (0.3%)	1 (0.3%)	
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	
	SEVERE	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	0 (0.0%)	
MYDRIASIS	MILD	0 (0.0%)	3 (0.8%)	1 (0.5%)	0 (0.0%)	3 (0.8%)	
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
RETINAL TEAR (EXC DETACHMENT)	MILD	0 (0.0%)	1 (0.3%)	0 (0.0%)	4 (1.1%)	0 (0.0%)	
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
FOREIGN BODY RETAINED IN EYE	MILD	0 (0.0%)	1 (0.3%)	2 (1.0%)	1 (0.3%)	0 (0.0%)	
	MODERATE	0 (0.0%)	0 (0.0%)	2 (1.0%)	0 (0.0%)	0 (0.0%)	
1	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	
EYE DEGENERATIVE DISORDER NOS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
)	SEVERE	0 (0.0%)	0 (0.0%)	3 (1.5%)	2 (0.5%)	1 (0.3%)	

Table 15
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Severity
Safety Population

		Contr	ol			
System Organ Class / Preferred Term	Severity	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
PSEUDOPHAKIA	MILD	0 (0.0%)	2 (0.5%)	0 (0.0%)	2 (0.5%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
	SEVERE	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%
EYELID PTOSIS	MILD	0 (0.0%)	0 (0.0%)	2 (1.0%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	1 (0.3%)	1 (0.5%)	0 (0.0%)	1 (0.3%
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
INTRAOCULAR PRESSURE DECREASED	MILD	0 (0.0%)	3 (0.8%)	1 (0.5%)	0 (0.0%)	0 (0.0%
	MODERATE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%
•	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
OPTIC ATROPHY	MILD	0 (0.0%)	1 (0.3%)	1 (0.5%)	3 (0.8%)	0 (0.0%
	MODERATE	0 (0 0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
PHOTOPHOBIA AGGRAVATED	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	MODERATE	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	1 (0.3%
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	0 (0.0%
VITREOUS DISORDER NOS	MILD	0 (0.0%)	1 (0.3%)	1 (0.5%)	0 (0.0%)	2 (0.5%
	MODERATE	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
APHAKIA	MILD	0 (0.0%)	2 (0.5%)	1 (0.5%)	0 (0.0%)	1 (0.3%
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
EYE ALLERGY	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.8%)	1 (0.3%
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
KERATOCONJUNCTIVITIS	MILD	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	MODERATE	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	0 (0.0%
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%
OCULAR HYPERTENSION	MILD	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	1 (0.3%
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
PAINFUL RED EYES	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	2 (0.5%
	MODERATE	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Table 15
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Severity
Safety Population

	Control					
stem Organ Class / Preferred Term	Severity	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
CHEMOSIS	MILD	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	MODERATE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CORTICAL OPACITY	MILD	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	1 (0.3%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
IRIDOCYCLITIS	MILD	0 (0.0%)	0 (0.0%)	2 (1.0%)	1 (0.3%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
LENTICULAR OPACITIES	MILD	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	SEVERE	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
MACULAR DEGENERATION	MILD	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
OPEN ANGLE GLAUCOMA NOS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	0 (0.0%)
RETINAL DISORDER NOS	MILD	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
RETINAL MICROANEURYSMS	MILD	0 (0.0%)	1 (0.3%)	1 (0.5%)	1 (0.3%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
RETINAL SCAR	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
BLINDNESS TRANSIENT	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
CHOROIDAL DETACHMENT	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)

Table 15
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Severity
Safety Population

	Control					
System Organ Class / Preferred Term	Severity -	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
CONJUNCTIVITIS (INFECTIVE) NEC	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
**************************************	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CONJUNCTIVITIS ALLERGIC	MILD	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.3%)
CONCULTATION INDUNCTO	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0,0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CONJUNCTIVITIS VIRAL NOS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
COMONCIIVIIID VIGHI NOD	MODERATE	1 (5.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CORNEAL OPACITY	MILD	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
CORNEAL OFACILI	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
KERATOPATHY BAND	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
RERAIOPAINI DAND	MODERATE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
KERATOPATHY NOS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
RERATOPATHI NOS	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
MEIBOMIAN CYST	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
MEIBOMIAN CISI	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PERIORBITAL HEMATOMA	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
PERIORBITAL NEWATOWA	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
RETINAL ARTERY EMBOLISM	MILD	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.3%)
RETINAL ARTERI EMBOLISM	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
RETINAL DEPIGMENTATION	MILD	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	0 (0.0%)
RETINAL DEFIGMENTATION	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
STRABISMUS NEC	MILD	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.3%)
• • • • • • • • • • • • • • • • • • •	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
□ nb	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Table 15
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Severity
Safety Population

ystem Organ Class / Preferred Term		Control				
	Severity	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
VISUAL ACUITY REDUCED TRANSIENTLY	MILD	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
VITREOUS OPACITIES	MILD	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.3%
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
ANGLE CLOSURE GLAUCOMA	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
ANISEIKONIA	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
ARCUS SENILIS	MILD	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
BLEPHAROCONJUNCTIVITIS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
BLINDNESS NIGHT	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.39
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.09
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
BLOODSHOT EYE	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.39
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.09
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.09
CCONJUNCTIVAL EDEMA	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.09
CHALAZION	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.09
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
CHORIORETINAL ATROPHY	MILD	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%

Table 15
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Severity
Safety Population

	Control					
ystem Organ Class / Preferred Term	Severity	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
CHORIORETINAL DISORDER NOS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CHOROIDAL HEMORRHAGE	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
COLOUR BLINDNESS NEC	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CORNEAL DEGENERATION	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CORNEAL SCAR	MILD	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
CORNEAL ULCER NEC	MILD	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CYCLITIS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
ERYTHEMA NEC	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
EXOPHTHALMOS ENDOCRINE	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	MODERATE	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
EYE HEMORRHAGE NEC	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	MODERATE	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYE INFECTION FUNGAL NOS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)

Table 15
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Severity
Safety Population

ystem Organ Class / Preferred Term		Control				
	Severity	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
EYE INFECTION NOS	MILD	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
EYE INFECTION STAPHYLOCOCCAL	MILD	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
EYE INFECTION TOXOPLASMAL	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
EYE INFLAMMATION NOS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
EYELID DISORDER NOS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
EYELID EDEMA	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
HERPES SIMPLEX OPHTHALMIC	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
IRIS NEVUS	MILD	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
LACRIMAL DUCT OBSTRUCTION NOS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.4
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.
OCULAR HYPERAEMIA	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.1
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.
OPTIC DISC HEMORRHAGE	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.
	MODERATE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0

Table 15
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Severity Safety Population

	Control					
System Organ Class / Preferred Term	Severity	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
OPTIC NERVE INJURY NOS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PAPILLEDEMA	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PINGUECULA	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
POST-OPERATIVE COMPLICATIONS NOS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
RETINAL DEGENERATION	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
RETINAL EXUDATES	MILD	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
RETINAL VASCULITIS	MILD	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
RETINAL VEIN THROMBOSIS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
SCLERITIS NOS	MILD	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
TOPOGRAPHY CORNEAL ABNORMAL	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
UVEITIS DIABETIC	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Table 15
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Severity
Safety Population

	Control						
System Organ Class / Preferred Term	Severity	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase	
VISION ABNORMAL NEC	MILD	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	
VIDION ADMONATE NEC	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
VISUAL DISTURBANCE NOS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
	MODERATE SEVERE	0 (0.0%) 0 (0.0%)					
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
INVESTIGATIONS	MILD	2 (11.1%)	22 (5.8%)	19 (9.6%)	23 (6.1%)	20 (5.1%)	
	MODERATE	1 (5.6%)	17 (4.5%)	20 (10.1%)	22 (5.8%)	15 (3.8%)	
	SEVERE	0 (0.0%)	5 (1.3%)	9 (4.5%)	5 (1.3%)	11 (2.8%)	
INTRAOCULAR PRESSURE INCREASED	MILD	2 (11.1%)	18 (4.8%)	13 (6.6%)	17 (4.5%)	16 (4.1%)	
4	MODERATE	1 (5.6%)	16 (4.2%)	18 (9.1%)	20 (5.3%)	13 (3.3%)	
	SEVERE	0 (0.0%)	5 (1.3%)	9 (4.5%)	5 (1.3%)	11 (2.8%)	
CORNEAL STAINING	MILD	0 (0.0%)	5 (1.3%)	6 (3.0%)	7 (1.9%)	6 (1.5%)	
	MODERATE	0 (0.0%)	1 (0.3%)	2 (1.0%)	2 (0.5%)	2 (0.5%)	
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
INTRAOCULAR PRESSURE ABNORMAL	MILD	0 (0.0%)	0 (0.0%)	2 (1.0%)	0 (0.0%)	0 (0.0%)	
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
SKIN & SUBCUTANEOUS TISSUE DISORDERS	MILD	0 (0.0%)	23 (6.1%)	13 (6.6%)	32 (8.5%)	31 (7.9%)	
	MODERATE	0 (0.0%)	3 (0.8%)	5 (2.5%)	6 (1.6%)	7 (1.8%)	
	SEVERE	O (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	0 (0.0%)	
EYELID EDEMA	MILD	0 (0.0%)	12 (3.2%)	10 (5.1%)	22 (5.8%)	19 (4.9%)	
	MODERATE	0 (0.0%)	3 (0.8%)	1 (0.5%)	6 (1.6%)	6 (1.5%)	
	SEVERE	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	0 (0.0%)	
ERYTHEMA NEC	MILD	0 (0.0%)	14 (3.7%)	5 (2.5%)	17 (4.5%)	18 (4.6%)	
	MODERATE	0 (0.0%)	1 (0.3%)	2 (1.0%)	3 (0.8%)	2 (0.5%)	
	SEVERE	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	0 (0.0%)	
OCULAR HYPEREMIA	MILD	0 (0.0%)	2 (0.5%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
	MODERATE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	
	SEVERË	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
CUTIS LAXA	MILD	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	
COIIS MAAA	MODERATE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	
స్	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	

Table 15
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Severity Safety Population

	Control					
System Organ Class / Preferred Term	Severity	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
PERIORBITAL EDEMA	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
PERIORBITAL EDEMA	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
DERMATITIS NOS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
ECCHYMOSIS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PRURITUS NOS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
SURGICAL AND MEDICAL PROCEDURES	MILD	0 (0.0%)	6 (1.6%)	2 (1.0%)	4 (1.1%)	3 (0.8%)
	MODERATE	1 (5.6%)	7 (1.9%)	1 (0.5%)	5 (1.3%)	4 (1.0%)
	SEVERE	0 (0.0%)	1 (0.3%)	4 (2.0%)	4 (1.1%)	1 (0.3%)
POST-OPERATIVE COMPLICATIONS NOS	MILD	0 (0.0%)	3 (0.8%)	2 (1.0%)	1 (0 3%)	2 (0.5%)
	MODERATE	1 (5.6%)	5 (1.3%)	1 (0.5%)	3 (0.8%)	2 (0.5%)
	SEVERE	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	0 (0.0%)
UNSPECIFIED COMPLICATION OF PROCEDURE NEC	MILD	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	1 (0.3%)	1 (0.5%)	1 (0.3%)	1 (0.3%)
	SEVERE	0 (0.0%)	0 (0.0%)	1 (0.5%)	3 (0.8%)	1 (0.3%)
VITRECTOMY	MILD	0 (0.0%)	2 (0.5%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
	MODERATE	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	SEVERE	0 (0.0%)	1 (0.3%)	2 (1.0%)	0 (0.0%)	0 (0.0%)
EYE IRRITATION	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
LENS IMPLANT	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
POST-OPERATIVE HEMORRHAGE	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
ມູ	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
₹	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Table 15
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Severity Safety Population

	Control					
System Organ Class / Preferred Term	Severity	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
agrant appropriation was		0 (0 0%)	0 (0 0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
SCLERAL OPERATION NOS	MILD MODERATE	0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
SUTURE LINE PAIN	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
NERVOUS SYSTEM DISORDERS	MILD	0 (0.0%)	1 (0.3%)	3 (1.5%)	3 (0.8%)	5 (1.3%)
	MODERATE	0 (0.0%)	0 (0.0%)	2 (1.0%)	1 (0.3%)	2 (0.5%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PUPILLARY DISORDER NOS	MILD	0 (0.0%)	0 (0.0%)	2 (1.0%)	3 (0.8%)	2 (0.5%)
	MODERATE	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	1 (0.3%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
VISUAL FIELD DEFECT NOS	MILD	0 (0.0%)	1 (0.3%)	1 (0.5%)	0 (0.0%)	1 (0.3%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
FACIAL PALSY	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
HEADACHE NOS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PUPILLARY REFLEX IMPAIRED	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
VITH NERVE PARALYSIS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
IMMUNE SYSTEM DISORDERS	MILD	0 (0.0%)	0 (0.0%)	2 (1.0%)	1 (0.3%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
HYPERSENSITIVITY NOS	MILD	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	0 (0.0%)
\mathbf{o}	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
c o	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Table 15
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Severity
Safety Population

	Control					
System Organ Class / Preferred Term	Severity	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
ACTUAL AND DESCRIPTION	MILD	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
MULTIPLE ALLERGIES	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
INJURY AND POISONING	MILD	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
CHEMICAL BURNS OF EYE	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
HEAD INJURY	MILD	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
NEOPLASMS BENIGN AND MALIGNANT (INCLUDING CYSTS AND POLYPS)	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	MODERATE	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
BENIGN NEOPLASM OF CHOROID	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
RADIOACTIVE IODINE THERAPY	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
MECHANICAL COMPLICATION OF IMPLANT	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
INFECTIONS AND INFESTATIONS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
→ HYPOPYON	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
5	SEVER E	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Page 17 of 17

ISTA Pharmaceuticals, Inc. Integrated Summary of Safety

Table 15
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Severity Safety Population

	Control					
System Organ Class / Preferred Term	Severity	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
				· · · · · · · · · · · · · · · · · · ·		
VASCULAR DISORDERS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PERIPHERAL ISCHEMIA NOS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Table 16
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Severity Safety Population

	Control					
System Organ Class / Preferred Term	Severity	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
NUMBER OF PATIENTS		18	378	198	377	391
NUMBER OF PATIENTS WITH AT LEAST ONE RELATED ADVERSE EVENT	MILD	4 (22.2%)	117 (31.0%)	59 (29.8%)	80 (21.2%)	93 (23.8%)
	MODERATE	3 (16.7%)	84 (22.2%)	48 (24.2%)	109 (28.9%)	117 (29.9%)
	SEVERE	4 (22.2%)	43 (11.4%)	61 (30.8%)	101 (26.8%)	116 (29.7%)
EYE DISORDERS	MILD	4 (22.2%)	118 (31.2%)	62 (31.3%)	80 (21.2%)	94 (24.0%)
	MODERATE	3 (16.7%)	84 (22.2%)	51 (25.8%)	109 (28.9%)	118 (30.2%)
	SEVERE	4 (22.2%)	41 (10.8%)	55 (27.8%)	99 (26.3%)	114 (29.2%)
IRITIS	MILD	1 (5.6%)	81 (21.4%)	70 (35.4%)	91 (24.1%)	84 (21.5%)
	MODERATE	0 (0.0%)	20 (5.3%)	24 (12.1%)	70 (18.6%)	98 (25.1%)
	SEVERE	0 (0.0%)	5 (1.3%)	6 (3.0%)	41 (10.9%)	49 (12.5%)
OCULAR HYPEREMIA	MILD	1 (5.6%)	79 (20.9%)	59 (29.8%)	100 (26.5%)	120 (30.7%)
	MODERATE	0 (0.0%)	30 (7.9%)	20 (10.1%)	50 (13.3%)	54 (13.8%)
	SEVERE	0 (0.0%)	4 (1.1%)	6 (3.0%)	8 (2.1%)	9 (2.3%)
EYE PAIN	MILD	1 (5.6%)	49 (13.0%)	38 (19.2%)	71 (18.8%)	79 (20.2%)
	MODERATE	0 (0.0%)	7 (1.9%)	7 (3.5%)	31 (8.2%)	34 (8.7%)
	SEVERE	0 (0.0%)	1 (0.3%)	3 (1.5%)	11 (2.9%)	15 (3.8%)
EYE IRRITATION	MILD	4 (22.2%)	64 (16.9%)	52 (26.3%)	69 (18.3%)	71 (18.2%)
	MODERATE	0 (0.0%)	12 (3.2%)	6 (3.0%)	19 (5.0%)	24 (6.1%)
	SEVERE	1 (5.6%)	3 (0.8%)	3 (1.5%)	8 (2.1%)	8 (2.0%)
LACRIMATION INCREASED	MILD	0 (0.0%)	42 (11.1%)	29 (14.6%)	54 (14.3%)	58 (14.8%)
	MODERATE	1 (5.6%)	12 (3.2%)	12 (6.1%)	29 (7.7%)	29 (7.4%)
	SEVERE	0 (0.0%)	2 (0.5%)	4 (2.0%)	11 (2.9%)	16 (4.1%)
ABNORMAL SENSATION IN EYE	MILD	1 (5.6%)	40 (10.6%)	28 (14.1%)	54 (14.3%)	62 (15.9%)
	MODERATE	0 (0.0%)	9 (2.4%)	10 (5.1%)	21 (5.6%)	21 (5.4%)
	SEVERE	0 (0.0%)	1 (0.3%)	5 (2.5%)	3 (0.8%)	9 (2.3%)
РНОТОРНОВІА	MILD	0 (0.0%)	25 (6.6%)	24 (12.1%)	28 (7.4%)	43 (11.0%)
	MODERATE	2 (11.1%)	10 (2.6%)	6 (3.0%)	25 (6.6%)	27 (6.9%)
	SEVERE	1 (5.6%)	7 (1.9%)	11 (5.6%)	10 (2.7%)	15 (3.8%)
CONJUNCTIVAL EDEMA	MILD	1 (5.6%)	42 (11.1%)	27 (13.6%)	55 (14.6%)	59 (15.1%)
	MODERATE	0 (0.0%)	6 (1.6%)	3 (1.5%)	15 (4.0%)	17 (4.3%)
	SEVERE	0 (0.0%)	1 (0.3%)	0 (0.0%)	4 (1.1%)	1 (0.3%)
VITREOUS FLOATERS	MILD	1 (5.6%)	25 (6.6%)	18 (9.1%)	33 (8.8%)	44 (11.3%)

Table 16
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Severity Safety Population

		Contr			55 TTT TT: 000	25 TH 11/2-
stem Organ Class / Preferred Term	Severity	WW	Saline	7.5 IU Vitrase	55 10 Vitrase	75 IU Vitr
VITREOUS FLOATERS	MODERATE	1 (5.6%)	9 (2.4%)	14 (7.1%)	13 (3.4%)	17 (4.
	SEVERE	1 (5.6%)	8 (2.1%)	8 (4.0%)	12 (3.2%)	13 (3.
VISUAL ACUITY REDUCED	MILD	2 (11.1%)	30 (7.9%)	30 (15.2%)	40 (10.6%)	32 (8.
	MODERATE	0 (0.0%)	11 (2.9%)	9 (4.5%)	18 (4.8%)	16 (4
	SEVERE	0 (0.0%)	2 (0.5%)	8 (4.0%)	8 (2.1%)	10 (2
VITREOUS HEMORRHAGE	MILD	1 (5.6%)	5 (1.3%)	9 (4.5%)	7 (1.9%)	10 (2
	MODERATE	0 (0.0%)	12 (3.2%)	11 (5.6%)	14 (3.7%)	10 (2
	SEVERE	0 (0.0%)	8 (2.1%)	12 (6.1%)	16 (4.2%)	9 (2
PHOTOPSIA	MILD	0 (0.0%)	7 (1.9%)	14 (7.1%)	17 (4.5%)	12 (3
	MODERATE	0 (0.0%)	4 (1.1%)	2 (1.0%)	6 (1.6%)	12 (3
	SEVERE	0 (0.0%)	3 (0.8%)	2 (1.0%)	2 (0.5%)	4 (1
CATARACT SUBCAPSULAR	MILD	0 (0.0%)	6 (1.6%)	13 (6.6%)	12 (3.2%)	13 (3
	MODERATE	0 (0.0%)	5 (1.3%)	4 (2.0%)	7 (1.9%)	3 (0
	SEVERE	0 (0.0%)	0 (0.0%)	3 (1.5%)	1 (0.3%)	1 (0
RETINAL DETACHMENT	MILD	0 (0.0%)	1 (0.3%)	0 (0.0%)	3 (0.8%)	5 (1
	MODERATE	0 (0.0%)	4 (1.1%)	4 (2.0%)	5 (1.3%)	3 (0
	SEVERE	1 (5.6%)	5 (1.3%)	8 (4.0%)	10 (2.7%)	14 (3
CATARACT NUCLEAR	MILD	0 (0.0%)	5 (1.3%)	2 (1.0%)	11 (2.9%)	4 (1
	MODERATE	1 (5.6%)	10 (2.6%)	6 (3.0%)	7 (1.9%)	6 (1 0 (0
	SEVERE	0 (0.0%)	1 (0.3%)	4 (2.0%)	4 (1.1%)	0 (0
CATARACT CORTICAL	MILD	1 (5.6%)	12 (3.2%)	1 (0.5%)	12 (3.2%)	12 (3
	MODERATE	0 (0.0%)	3 (0.8%)	2 (1.0%)	6 (1.6%)	4 (1
	SEVERE	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	3 (0
CORNEAL EROSION	MILD	0 (0.0%)	13 (3.4%)	5 (2.5%)	11 (2.9%)	10 (2
	MODERATE	0 (0.0%)	3 (0.8%)	0 (0.0%)	3 (0.8%)	1 (0
	SEVERE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0
CORNEAL DISORDER NOS	MILD	0 (0.0%)	3 (0.8%)	2 (1.0%)	9 (2.4%)	13 (3
	MODERATE	0 (0.0%)	0 (0.0%)	1 (0.5%)	3 (0.8%)	7 (1
	SEVERE	0 (0.0%)	0 (0.0%)	1 (0.5%)	2 (0.5%)	1 (0
EYE DISCHARGE	MILD	0 (0.0%)	13 (3.4%)	3 (1.5%)	9 (2.4%)	11 (2
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.8%)	3 (0
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0

Table 16
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Severity Safety Population

		Contr				
System Organ Class / Preferred Term	Severity	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
IRIS ADHESIONS	MILD	2 (11.1%)	1 (0.3%)	1 (0.5%)	6 (1.6%)	9 (2.3%)
	MODERATE	0 (0.0%)	2 (0.5%)	3 (1.5%)	4 (1.1%)	5 (1.3%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (1.0%)
CONJUNCTIVAL HEMORRHAGE	MILD	0 (0.0%)	12 (3.2%)	6 (3.0%)	4 (1.1%)	6 (1.5%)
	MODERATE	0 (0.0%)	2 (0.5%)	0 (0.0%)	2 (0.5%)	1 (0.3%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
CORNEAL EDEMA	MILD	0 (0.0%)	3 (0.8%)	3 (1.5%)	5 (1.3%)	13 (3.3%)
	MODERATE	0 (0.0%)	1 (0.3%)	1 (0.5%)	2 (0.5%)	4 (1.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
RUBEOSIS IRIDIS	MILD	1 (5.6%)	1 (0.3%)	6 (3.0%)	3 (0.8%)	4 (1.0%)
	MODERATE	0 (0.0%)	3 (0.8%)	1 (0.5%)	2 (0.5%)	2 (0.5%)
	SEVERE	0 (0.0%)	1 (0.3%)	1 (0.5%)	1 (0.3%)	3 (0.8%)
HYPOPYON	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	10 (2.6%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.8%)	5 (1.3%)
	SEVERE	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	6 (1.5%)
НҮРНЕМА	MILD	0 (0.0%)	2 (0.5%)	2 (1.0%)	3 (0.8%)	2 (0.5%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	1 (0.3%)
	SEVERE	0 (0.0%)	1 (0.3%)	1 (0.5%)	0 (0.0%)	3 (0.8%)
MACULAR EDEMA	MILD	0 (0.0%)	1 (0.3%)	2 (1.0%)	2 (0.5%)	5 (1.3%)
	MODERATE	0 (0.0%)	2 (0.5%)	1 (0.5%)	1 (0.3%)	2 (0.5%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
UVEITIS NOS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (1.1%)	3 (0.8%)
	MODERATE	1 (5.6%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.3%)
VITREOUS DETACHMENT	MILD	0 (0.0%)	1 (0.3%)	1 (0.5%)	3 (0.8%)	2 (0.5%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.8%)	1 (0.3%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
MACULOPATHY	MILD	0 (0.0%)	2 (0.5%)	1 (0.5%)	2 (0.5%)	1 (0.3%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	2 (0.5%)
. •	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
KERATITIS NEC	MILD	0 (0.0%)	0 (0.0%)	3 (1.5%)	1 (0.3%)	1 (0.3%)
•••	MODERATE	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	2 (0.5%)
ير. مانيان	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Table 16
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Severity Safety Population

		Contro	ol			
System Organ Class / Preferred Term	Severity	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
CATARACT NEC	MILD	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
	MODERATE	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	4 (1.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
CATARACT NOS AGGRAVATED	MILD	1 (5.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	3 (0.8%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	0 (0.0%)
DRY EYE NEC	MILD	0 (0.0%)	2 (0.5%)	0 (0.0%)	1 (0.3%)	3 (0.8%)
	MODERATE	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
DIPLOPIA	MILD	0 (0.0%)	2 (0.5%)	1 (0.5%)	3 (0.8%)	1 (0.3%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
GLAUCOMA NOS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	SEVERE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	3 (0.8%)
POSTERIOR CAPSULE OPACIFICATION	MILD	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	2 (0.5%)
	MODERATE	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
VISION BLURRED	MILD	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	1 (0.3%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	1 (0.3%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
BLINDNESS NEC	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	1 (0.3%)	1 (0.5%)	1 (0.3%)	2 (0.5%)
HYPOTONY OF EYE	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
MYDRIASIS	MILD	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	3 (0.8%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PHOTOPHOBIA AGGRAVATED	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	0 (0.0%)

Table 16 Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Severity Safety Population

	_ ,	Control WW Saline			55 IU Vitrase	75 IU Vitra
stem Organ Class / Preferred Term	Severity		Sailne	7.5 IU Vitrase		75 10 VICIA
CONJUNCTIVITIS NEC	MILD	0 (0.0%)	0 (0.0%)	2 (1.0%)	0 (0.0%)	2 (0.5
CONCONCIA VALLO MAD	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
CORNEAL EPITHELIUM DEFECT	MILD	1 (5.6%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	0 (0.0
	MODERATE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
FOREIGN BODY RETAINED IN EYE	MILD	0 (0.0%)	1 (0.3%)	1 (0.5%)	0 (0.0%)	0 (0.
	MODERATE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.
INTRAOCULAR PRESSURE INCREASED	MILD	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.
	MODERATE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.
RETINAL TEAR (EXC DETACHMENT)	WILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.8%)	0 (0.
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.
RETINOPATHY DIABETIC	MILD	0 (0.0%)	2 (0.5%)	0 (0.0%)	1 (0.3%)	1 (0.
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.
VITREOUS DISORDER NOS	MILD	0 (0.0%)	1 (0.3%)	1 (0.5%)	0 (0.0%)	2 (0.
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.
CORNEAL ABRASION	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.
	SEVERE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.
CORTICAL OPACITY	MILD	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	1 (0.
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0 .
INTRAOCULAR PRESSURE DECREASED	MILD	0 (0.0%)	1 (0.3%)	1 (0.5%)	0 (0.0%)	0 (0
	MODERATE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.
IRIDOCYCLITIS	MILD	0 (0.0%)	0 (0.0%)	2 (1.0%)	1 (0.3%)	0 (0.
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.

Table 16
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Severity Safety Population

Severity	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitras
MILD MODERATE	0 (0.0%)	1 (0.3%)	1 (0.5%) 0 (0.0%)	1 (0.3%) 0 (0.0%)	0 (0.0%
SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
MILD MODERATE	0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%)	1 (0.3%) 1 (0.3%)	0 (0.0% 0 (0.0%
SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
MILD MODERATE	0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0% 1 (0.3%
SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%
MILD MODERATE	0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%)	1 (0.3%) 0 (0.0%)	1 (0.3% 0 (0.0%
SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
MILD MODERATE	0 (0.0%) 0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%
SEVERE	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	0 (0.0%
MILD MODERATE	0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%) 1 (0.5%)	1 (0.3%) 0 (0.0%)	0 (0.0% 0 (0.0%
SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
MILD MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%) 0 (0.0%)	1 (0.3%
SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
MILD MODERATE	0 (0.0%) 0 (0.0%)	1 (0.3%) 0 (0.0%)	0 (0.0%) 0 (0.0%)	1 (0.3%) 0 (0.0%)	0 (0.0% 0 (0.0% 0 (0.0%
MODERATE	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0% 1 (0.3% 0 (0.0%
MILD	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.3%
MODERATE SEVERE	0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0% 0 (0.0%
MILD	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.3% 0 (0.0%
SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	MILD MODERATE SEVERE	MILD 0 (0.0%) MODERATE 0 (0.0%) MILD 0 (0.0%) MILD 0 (0.0%) MODERATE 0 (0.0%) MILD 0 (0.0%) MODERATE 0 (0.0%) MODERATE 0 (0.0%) MILD 0 (0.0%) MODERATE 0 (0.0%) MILD 0 (0.0%) MILD 0 (0.0%) MODERATE 0 (0.0%) MILD 0 (0.0%) MODERATE 0 (0.0%) MILD 0 (0.0%) MODERATE 0 (0.0%) MODERATE 0 (0.0%) MODERATE 0 (0.0%) MILD 0 (0.0%) MODERATE 0 (0.0%)	MILD	MILD	MILD

Table 16
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Severity Safety Population

		Control				
System Organ Class / Preferred Term	Severity	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
APHAKIA	MILD	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
APRAKIA	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
BLINDNESS NIGHT	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
BLINDNESS TRANSIENT	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
BLOODSHOT EYE	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CCONJUNCTIVAL EDEMA	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CHORIORETINAL ATROPHY	MILD	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CHORIORETINAL DISORDER NOS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
COLOUR BLINDNESS NEC	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CONJUNCTIVITIS VIRAL NOS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CORNEAL OPACITY	MILD	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CYCLITIS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
I	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Table 16
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Severity Safety Population

			Contr	01			
System Organ	Class / Preferred Term	Severity	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
ERYTHEMA N		MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
BRITING M		MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYE ALLERGY		MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
		MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYE INFECT	ON TOXOPLASMAL	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
		MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYE INFLAMM	MATION NOS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
		MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYELID DISC	ORDER NOS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
		MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYELID EDEM	AN	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
		MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYELID PTOS	SIS	MILD	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
		MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
KERATOCONJ	NCTIVITIS	MILD	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
KERATOPATHY	NOS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
		MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
LENTICULAR	OPACITIES	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
		SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
MEIBOMIAN	CYST	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
نب		MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
X		SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Table 16 Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Severity Safety Population

		Contr	ol			
ystem Organ Class / Preferred Term	Severity	ww 	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitras
OCULAR HYPERAEMIA	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
open angle glaucoma nos	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	SEVERE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%
OPTIC ATROPHY	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
PAINFUL RED EYES	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	MODERATE	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
PINGUECULA	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	MODERATE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
OST-OPERATIVE PAIN	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
ETINAL DEPIGMENTATION	MILD	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
RETINAL ISCHEMIA	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
RETINAL MICROANEURYSMS	MILD	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
RETINAL SCAR	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
RETINAL VEIN THROMBOSIS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%

Table 16
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Severity Safety Population

		Contr					
System Organ Class / Preferred Term	Severity	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase	
TOPOGRAPHY CORNEAL ABNORMAL	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
UVEITIS DIABETIC	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	MODERATE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
VISUAL DISTURBANCE NOS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
INVESTIGATIONS	MILD	0 (0.0%)	10 (2.6%)	8 (4.0%)	9 (2.4%)	9 (2.3%)	
	MODERATE	0 (0.0%)	12 (3.2%)	9 (4.5%)	12 (3.2%)	6 (1.5%)	
	SEVERE	0 (0.0%)	2 (0.5%)	4 (2.0%)	3 (0.8%)	5 (1.3%)	
INTRAOCULAR PRESSURE INCREASED	MILD	0 (0.0%)	7 (1.9%)	4 (2.0%)	5 (1.3%)	6 (1.5%)	
	MODERATE	0 (0.0%)	11 (2.9%)	8 (4.0%)	10 (2.7%)	5 (1.3%)	
	SEVERE	0 (0.0%)	2 (0.5%)	4 (2.0%)	3 (0.8%)	5 (1.3%)	
CORNEAL STAINING	MILD	0 (0.0%)	3 (0.8%)	4 (2.0%)	4 (1.1%)	3 (0.8%)	
	MODERATE	0 (0.0%)	1 (0.3%)	1 (0.5%)	2 (0.5%)	1 (0.3%)	
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
SKIN & SUBCUTANEOUS TISSUE DISORDERS	MILD	0 (0.0%)	15 (4.0%)	6 (3.0%)	23 (6.1%)	20 (5.1%)	
	MODERATE	0 (0.0%)	0 (0.0%)	3 (1.5%)	6 (1.6%)	4 (1.0%)	
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
EYELID EDEMA	MILD	0 (0.0%)	6 (1.6%)	5 (2.5%)	16 (4.2%)	15 (3.8%)	
	MODERATE	0 (0.0%)	0 (0.0%)	1 (0.5%)	6 (1.6%)	4 (1.0%)	
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
ERYTHEMA NEC	MILD	0 (0.0%)	9 (2.4%)	2 (1.0%)	11 (2.9%)	11 (2.8%)	
	MODERATE	0 (0.0%)	0 (0.0%)	1 (0.5%)	3 (0.8%)	1 (0.3%)	
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
CUTIS LAXA	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	MODERATE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
ECCHYMOSIS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	

Table 16
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Severity Safety Population

		Contr	ol			
System Organ Class / Preferred Term	Severity	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
OCULAR HYPEREMIA	MILD	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		- /		0 (0 00)	2 (2 20)	0 (0 00)
PERIORBITAL EDEMA	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
SURGICAL AND MEDICAL PROCEDURES	MILD	0 (0.0%)	1 (0.3%)	0 (0.0%)	2 (0.5%)	2 (0.5%)
	MODERATE	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	1 (0.3%)
	SEVERE	0 (0.0%)	0 (0.0%)	3 (1.5%)	2 (0.5%)	1 (0.3%)
UNSPECIFIED COMPLICATION OF PROCEDURE NEC	MILD	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
ONSPECTITED COMPLICATION OF PROCEDURE NEC	MODERATE	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	1 (0.3%)
	SEVERE	0 (0.0%)	0 (0.0%)	1 (0.5%)	2 (0.5%)	1 (0.3%)
	SEVERE	0 (0.0%)	0 (0.00)	1 (0.50)	2 (0.50,	± (0.30)
VITRECTOMY	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	2 (1.0%)	0 (0.0%)	0 (0.0%)
EYE IRRITATION	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
BIB TRRITATION	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DUVIKU	0 (0.01)	0 (0.00)	0 (0.00,	0 (0.007	0 (0.007
POST-OPERATIVE COMPLICATIONS NOS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
POST-OPERATIVE HEMORRHAGE	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
1001-OFERATIVE HENORMIAGE	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DUVUKU	0 (0.00)	0 (0.00,	0 (0.007	0 (0.007	0 (0.00)
SCLERAL OPERATION NOS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
NERVOUS SYSTEM DISORDERS	MILD	0 (0.0%)	1 (0.3%)	1 (0.5%)	2 (0.5%)	4 (1.0%)
	MODERATE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	2 (0.5%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		- , 5.557	- ,,	. ,/	- (/	- ,,
PUPILLARY DISORDER NOS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	2 (0.5%)
→ ¹	MODERATE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.3%)
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
materials.						

. Table 16
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Severity Safety Population

		Contr	ol				
System Organ Class / Preferred Term	Severity -	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase	
VISUAL FIELD DEFECT NOS	MILD	0 (0.0%)	1 (0.3%)	1 (0.5%)	0 (0.0%)	1 (0.3%)	
VISOAD FIEDD DEFECT NOS	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
HEADACHE NOS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
READACHE NOS	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
PUPILLARY REFLEX IMPAIRED	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
POPIDDARI REFEEX IMPAIRED	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
INFECTIONS AND INFESTATIONS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
INFECTIONS AND INFESTATIONS	MODERATE	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
НАБОБАОИ	WILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	MODERATE	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
INJURY AND POISONING	MILD	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
HEAD INJURY	MILD	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
VASCULAR DISORDERS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
PERIPHERAL ISCHEMIA NOS	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
	SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	

\$0 \$0

Table 17
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Sex Safety Population

		Cont	rol							
	W			line	7.5 IU	Vitrase	55 IU '	Vitrase		/itrase
System Organ Class / Preferred Term	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
NUMBER OF PATIENTS	13	5	183	195	100	98	193	184	215	175
NUMBER OF PATIENTS WITH AT LEAST ONE ADVERSE EVENT	12 (92%)	5 (100%)	151 (83%)	147 (75%)	100 (100%)	93 (95%)	163 (84%)	160 (87%)	192 (89%)	156 (89%
EYE DISORDERS	12 (92%)	5 (100%)	151 (83%)	146 (75%)	99 (99%)	93 (95%)	162 (84%)	160 (87%)	192 (89%)	156 (89%)
IRITIS	2 (15%)	2 (40%)	64 (35%)	62 (32%)	66 (66%)	57 (58%)	115 (60%)	107 (58%)	141 (66%)	102 (58%
OCULAR HYPEREMIA	2 (15%)	2 (40%)	69 (38%)	71 (36%)	65 (65%)	48 (49%)	96 (50%)	106 (58%)	120 (56%)	95 (54%
EYE IRRITATION	8 (62%)	2 (40%)	51 (28%)	60 (31%)	42 (42%)	48 (49%)	60 (31%)	72 (39%)	74 (34%)	65 (37%
EYE PAIN	1 (8%)	1 (20%)	44 (24%)	40 (21%)	36 (36%)	36 (37%)	62 (32%)	77 (42%)	84 (39%)	77 (44%
LACRIMATION INCREASED	2 (15%)	2 (40%)	44 (24%)	43 (22%)	37 (37%)	28 (29%)	55 (28%)	69 (38%)	80 (37%)	59 (34%
VISUAL ACUITY REDUCED	3 (23%)	1 (20%)	38 (21%)	36 (18%)	36 (36%)	41 (42%)	55 (28%)	46 (25%)	59 (27%)	39 (22%
ABNORMAL SENSATION IN EYE	2 (15%)	0 (0%)	36 (20%)	32 (16%)	31 (31%)	31 (32%)	44 (23%)	57 (31%)	63 (29%)	51 (29%
VITREOUS FLOATERS	4 (31%)	2 (40%)	37 (20%)	30 (15%)	31 (31%)	32 (33%)	39 (20%)	49 (27%)	56 (26%)	44 (25%
VITREOUS HEMORRHAGE	2 (15%)	0 (0%)	36 (20%)	30 (15%)	30 (30%)	40 (41%)	47 (24%)	44 (24%)	47 (22%)	43 (25%
PHOTOPHOBIA	4 (31%)	2 (40%)	36 (20%)	24 (12%)	28 (28%)	31 (32%)	39 (20%)	47 (26%)	58 (27%)	44 (25%
	1 (8%)	0 (0%)	33 (18%)	26 (13%)	24 (24%)	24 (24%)	45 (23%)	51 (28%)	55 (26%)	34 (19%
CONJUNCTIVAL EDEMA	- • - •	2 (40%)	21 (11%)	13 (7%)	15 (15%)	12 (12%)	22 (11%)	15 (8%)	17 (8%)	12 (7%
CATARACT NUCLEAR		0 (0%)	15 (8%)	11 (6%)	16 (16%)	6 (6%)	17 (9%)	18 (10%)	30 (14%)	15 (9%
RETINAL DETACHMENT	3 (23%)		10 (5%)	16 (8%)	16 (16%)	17 (17%)	15 (8%)	14 (8%)	17 (8%)	20 (11%
CATARACT SUBCAPSULAR	1 (8%)	1 (20%)	,	10 (5%)	6 (6%)	16 (16%)	19 (10%)	26 (14%)	23 (11%)	15 (9%
PHOTOPSIA	0 (0%)	0 (0%)	12 (7%)	· ·	9 (9%)	5 (5%)	15 (8%)	15 (8%)	18 (8%)	13 (7%
CATARACT CORTICAL	3 (23%)	2 (40%)	12 (7%)	,	* 1 - 1	5 (5%)	12 (6%)	13 (7%)	9 (4%)	8 (5%
CORNEAL EROSION	0 (0%)	1 (20%)	8 (4%)	16 (8%)		" :	12 (6%)	8 (4%)	16 (7%)	8 (5%
CORNEAL EDEMA	1 (8%)	0 (0%)	7 (4%)	5 (3%)	13 (13%)	1 1	6 (3%)	11 (6%)	13 (6%)	6 (3%
RUBEOSIS IRIDIS	0 (0%)	1 (20%)	11 (6%)	8 (4%)	8 (8%)		11 (6%)	12 (7%)	10 (5%)	10 (6%
EYE DISCHARGE	0 (0%)	0 (0%)	10 (5%)	8 (4%)	7 (7%)			8 (4%)	7 (3%)	11 (6%
CONJUNCTIVAL HEMORRHAGE	0 (0%)	0 (0%)	13 (7%)	12 (6%)	7 (7%)	4 (4%)		5 (3%)	16 (7%)	11 (6%
IRIS ADHESIONS	2 (15%)	0 (0%)	6 (3%)	7 (4%)	5 (5%)	4 (4%)	8 (4%)		12 (6%)	7 (4%
MACULAR EDEMA	0 (0%)	1 (20%)	6 (3%)	5 (3%)	6 (6%)	10 (10%)	8 (4%)			9 (5%
CORNEAL DISORDER NOS	0 (0%)	0 (0%)	1 (1%)	7 (4%)	4 (4%)	2 (2%)	8 (4%)	9 (5%)		- ,
HYPHEMA	0 (0%)	0 (0%)	2 (1%)	4 (2%)	4 (4%)	4 (4%)	4 (2%)	8 (4%)	7 (3%)	
CATARACT NEC	0 (0%)	0 (0%)	6 (3%)	4 (2%)	0 (0%)	1 (1%)	3 (2%)	7 (4%)	6 (3%)	3 (2% 4 (2%
BLINDNESS NEC	1 (8%)	0 (0%)	3 (2%)	1 (1%)	8 (8%)	1 (1%)	3 (2%)	3 (2%)	5 (2%)	- •
HYPOPYON	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	2 (1%)	4 (2%)	13 (6%)	8 (5%
DRY EYE NEC	0 (0%)	0 (0%)	2 (1%)	4 (2%)	3 (3%)	4 (4%)	3 (2%)	2 (1%)	3 (1%)	6 (3%
GLAUCOMA NOS	0 (0%)	0 (0%)	4 (2%)	1 (1%)	1 (1%)	4 (4%)	2 (1%)	1 (1%)	9 (4%)	3 (2%
VISION BLURRED	0 (0%)	0 (0%)	1 (1%)	4 (2%)	5 (5%)	5 (5%)	3 (2%)	2 (1%)	2 (1%)	2 (1%
CATARACT NOS AGGRAVATED	1 (8%)	0 (0%)	2 (1%)	6 (3%)	2 (2%)	2 (2%)	1 (1%)	4 (2%)	1 (0%)	2 (1%
KERATITIS NEC	0 (0%)	0 (0%)	0 (0%)	4 (2%)	1 (1%)	3 (3%)	1 (1%)	3 (2%)	4 (2%)	4 (2%
VITREOUS DETACHMENT	1 (8%)	0 (0%)	1 (1%)	1 (1%)	1 (1%)	2 (2%)	6 (3%)	3 (2%)	2 (1%)	3 (2%
MACULOPATHY	0 (0%)	0 (0%)	2 (1%)	3 (2%)	1 (1%)	3 (3%)	3 (2%)	2 (1%)	2 (1%)	3 (2%
INTRAOCULAR PRESSURE INCREASED	0 (0%)	0 (0%)	2 (1%)	1 (1%)	4 (4%)	2 (2%)	2 (1%)	1 (1%)	2 (1%)	4 (2%
UVEITIS NOS	1 (8%)	0 (0%)	2 (1%)	0 (0%)	1 (1%)	1 (1%)	3 (2%)	4 (2%)	0 (0%)	4 (2%
POST-OPERATIVE PAIN	1 (8%)	0 (0%)	2 (1%)	5 (3%)	0 (0%)	0 (0%)	2 (1%)	0 (0%)	3 (1%)	2 (1%
POST-OPERATIVE PAIN POSTERIOR CAPSULE OPACIFICATION	0 (0%)	0 (0%)	2 (1%)	1 (1%)	1 (1%)	0 (0%)	2 (1%)	4 (2%)	4 (2%)	1 (1%

Table 17

Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Sex Safety Population

•		Contr	rol							_
	W	<u> </u>	Sal	ine	7.5 IU 1		55 IU V		75 IU V	
System Organ Class / Preferred Term	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
RETINOPATHY DIABETIC	O (O%)	0 (0%)	2 (1%)	2 (1%)	1 (1%)	0 (0%)	1 (1%)	2 (1%)	3 (1%)	3 (2%
BLEPHARITIS	0 (0%)	0 (0%)	0 (0%)	1 (1%)	1 (1%)	2 (2%)	3 (2%)	0 (0%)	0 (0%)	5 (3%
HYPOTONY OF EYE	0 (0%)	0 (0%)	1 (1%)	1 (1%)	1 (1%)	1 (1%)	1 (1%)	1 (1%)	5 (2%)	1 (1%
RETINAL HEMORRHAGE	0 (0%)	0 (0%)	2 (1%)	3 (2%)	1 (1%)	1 (1%)	1 (1%)	4 (2%)	0 (0%)	0 (0%
CORNEAL EPITHELIUM DEFECT	1 (8%)	0 (0%)	1 (1%)	0 (0%)	1 (1%)	2 (2%)	4 (2%)	0 (0%)	0 (0%)	2 (1%
DIPLOPIA	0 (0%)	0 (0%)	2 (1%)	0 (0%)	1 (1%)	2 (2%)	0 (0%)	4 (2%)	1 (0%)	1 (1%
RETINAL ISCHEMIA	0 (0%)	0 (0%)	1 (1%)	0 (0%)	1 (1%)	2 (2%)	2 (1%)	2 (1%)	1 (0%)	1 (1%
CORNEAL ABRASION	0 (0%)	0 (0%)	0 (0%)	1 (1%)	1 (1%)	1 (1%)	1 (1%)	2 (1%)	1 (0%)	1 (1%
MYDRIASIS	0 (0%)	0 (0%)	1 (1%)	2 (1%)	1 (1%)	0 (0%)	0 (0%)	D (0%)	3 (1%)	1 (1%
RETINAL TEAR (EXC DETACHMENT)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	5 (3%)	0 (0%)	2 (1%)	0 (0%
CONJUNCTIVITIS NEC	0 (0%)	0 (0%)	0 (0%)	2 (1%)	1 (1%)	2 (2%)	1 (1%)	0 (0%)	0 (0%)	1 (1%
FOREIGN BODY RETAINED IN EYE	0 (0%)	0 (0%)	1 (1%)	0 (0%)	1 (1%)	3 (3%)	1 (1%)	1 (1%)	0 (0%)	0 (0%
EYE DEGENERATIVE DISORDER NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	3 (3%)	0 (0%)	1 (1%)	1 (1%)	1 (0%)	0 (0%
PSEUDOPHAKIA	0 (0%)	0 (0%)	1 (1%)	2 (1%)	0 (0%)	0 (0%)	1 (1%)	2 (1%)	0 (0%)	0 (0%
EYELID PTOSIS	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	3 (3%)	0 (0%)	0 (0%)	1 (0%)	0 (0%
INTRAOCULAR PRESSURE DECREASED	0 (0%)	0 (0%)	1 (1%)	2 (1%)	2 (2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%
OPTIC ATROPHY	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	3 (2%)	0 (0%)	0 (0%
PHOTOPHOBIA AGGRAVATED	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	2 (1%)	0 (0%)	1 (1%
VITREOUS DISORDER NOS	0 (0%)	0 (0%)	1 (1%)	1 (1%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	1 (1%
APHAKIA	0 (0%)	0 (0%)	2 (1%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%
EYE ALLERGY	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	2 (1%)	1 (0%)	0 (0%
KERATOCONJUNCTIVITIS	0 (0%)	0 (0%)	0 (0%)	1 (1%)	1 (1%)	0 (0%)	0 (0%)	1 (1%)	1 (0%)	0 (0%
OCULAR HYPERTENSION	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	1 (1%)	1 (0%)	0 (0%
PAINFUL RED EYES	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	2 (1%)	0 (0%
CHEMOSIS	0 (0%)	0 (0%)	0 (0%)	1 (1%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%
CORTICAL OPACITY	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	1 (1%
IRIDOCYCLITIS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (2%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%
LENTICULAR OPACITIES	0 (0%)	0 (0%)	1 (1%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%
MACULAR DEGENERATION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	1 (1%)	1 (1%)	0 (0%)	0 (0%)	0 (0%
OPEN ANGLE GLAUCOMA NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	1 (1%)	1 (0%)	0 (0%
RETINAL DISORDER NOS	0 (0%)	0 (0%)	0 (0%)	1 (1%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%
RETINAL MICROANEURYSMS	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	1 (1%)	0 (0%)	0 (0%
RETINAL SCAR	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	1 (1%)	1 (0%)	0 (0%
BLINDNESS TRANSIENT	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	1 (1%)	0 (0%)	0 (0%)	0 (0%
CHOROIDAL DETACHMENT	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	Ò (0%)	1 (1%)	0 (0%)	0 (0%)	1 (1%
CONJUNCTIVITIS (INFECTIVE) NEC	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	Q (O%)	1 (0%)	0 (0%
CONJUNCTIVITIS ALLERGIC	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	1 (1%
CONJUNCTIVITIS VIRAL NOS	0 (0%)	1 (20%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%
CORNEAL OPACITY	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	1 (1%)	0 (0%)	0 (0%)	0 (0%
KERATOPATHY BAND	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%
KERATOPATHY NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%
MEIBOMIAN CYST	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	1 (0%)	0 (0%
PERIORBITAL HEMATOMA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (1%)	0 (0%)	0 (0%
	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%
RETINAL ARTERY EMBOLISM	0 (05)	0 (0%)	0 (05)	0 (05)	1 (1%)	0 (0%)	0 (00)	0 (0%)	0 (0%)	0 (0%

Table 17

Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Sex Safety Population

		Cont:							9F TT 17	: n
	W		Sal			Vitrase	55 IU V:	itrase Female	75 IU V Male	rase Female
System Organ Class / Preferred Term	Male	Female	Male	Female	Male	Female	rale	remate	11016	
STRABISMUS NEC	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%
VISUAL ACUITY REDUCED TRANSIENTLY	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%
VITREOUS OPACITIES	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%
ANGLE CLOSURE GLAUCOMA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%
ANISEIKONIA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%
ARCUS SENILIS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%
BLEPHAROCONJUNCTIVITIS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%
BLINDNESS NIGHT	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%
BLOODSHOT EYE	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%
CCONJUNCTIVAL EDEMA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%
CHALAZION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%
CHORIORETINAL ATROPHY	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%
CHORIORETINAL DISORDER NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%
CHOROIDAL HEMORRHAGE	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%
COLOUR BLINDNESS NEC	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%
CORNEAL DEGENERATION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%
CORNEAL SCAR	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%
CORNEAL ULCER NEC	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%
	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	O (0%)	0 (0%)	1 (1%
CYCLITIS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%
ERYTHEMA NEC	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%
EXOPHTHALMOS ENDOCRINE	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	90) 0
EYE HEMORRHAGE NEC		0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%
EYE INFECTION FUNGAL NOS	- , ,	+ · · · ·	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%
EYE INFECTION NOS	- ,	* * * * * * * * * * * * * * * * * * * *	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%
EYE INFECTION STAPHYLOCOCCAL	0 (0%)	• • • • •	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%
EYE INFECTION TOXOPLASMAL	0 (0%)	• , ,	• ,	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%
EYE INFLAMMATION NOS	0 (0%)	0 (0%)	• (,	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%
EYELID DISORDER NOS	0 (0%)	0 (0%)	0 (0%)		0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 { 0%
EYELID EDEMA	0 (0%)	0 (0%)	0 (0%)	- 1		0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (09
HERPES SIMPLEX OPHTHALMIC	0 (0%)	0 (0%)	0 (0%)			0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%
IRIS NEVUS	0 (0%)	0 (0%)	0 (0%)	1 (1%)	- 1 1 111	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%
LACRIMAL DUCT OBSTRUCTION NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)		0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%
OCULAR HYPERAEMIA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	- 1 - 11		0 (0%)	0 (0%)	0 (0%)	0 (0%
OPTIC DISC HEMORRHAGE	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)		0 (0%)	0 (0%)	0 (0%)	0 (0%
OPTIC NERVE INJURY NOS	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%
PAPILLEDEMA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)		0 (0%)	0 (0%)	0 (0%
PINGUECULA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	- •	0 (0%)	0 (0%)	1 (1%
POST-OPERATIVE COMPLICATIONS NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)			0 (0%)	0 (0%
RETINAL DEGENERATION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%
RETINAL EXUDATES	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)		0 (0%)	0 (0%
RETINAL VASCULITIS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)		1 (0%)	0 (0
RETINAL VEIN THROMBOSIS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)		0 (0%)	0 (01
SCLERITIS NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	· · · · · · · · · · · · · · · · · · ·	0 (0%)	0 (0%
TOPOGRAPHY CORNEAL ABNORMAL	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%
UVEITIS DIABETIC	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	U (U-8)	0 (08

Table 17
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Sex Safety Population

		Cont						• .		• .
	W		Sal			Vitrase	55 IU V		75 IU V	
System Organ Class / Preferred Term	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
VISION ABNORMAL NEC	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%
VISUAL DISTURBANCE NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%
INVESTIGATIONS	3 (23%)	0 (0%)	22 (12%)	22 (11%)	25 (25%)	23 (23%)	30 (16%)	20 (11%)	24 (11%)	22 (13%
INTRAOCULAR PRESSURE INCREASED	3 (23%)	0 (0%)	20 (11%)	19 (10%)	23 (23%)	17 (17%)	27 (14%)	15 (8%)	22 (10%)	18 (10
CORNEAL STAINING	0 (0%)	0 (0%)	3 (2%)	3 (2%)	2 (2%)	6 (6%)	3 (2%)	6 (3%)	3 (1%)	5 (3 9
INTRAOCULAR PRESSURE ABNORMAL	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%
SKIN & SUBCUTANEOUS TISSUE DISORDERS	0 (0%)	0 (0%)	12 (7%)	14 (7%)	10 (10%)	9 (9%)	17 (9%)	22 (12%)	24 (11%)	14 (89
EYELID EDEMA	0 (0%)	0 (0%)	7 (4%)	8 (4%)	8 (8%)	4 (4%)	12 (6%)	17 (9%)	17 (8%)	8 (5
ERYTHEMA NEC	0 (0%)	0 (0%)	7 (4%)	8 (4%)	4 (4%)	4 (4%)	8 (4%)	13 (7%)	14 (7%)	6 (3
OCULAR HYPEREMIA	0 (0%)	0 (0%)	1 (1%)	1 (1%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	1 (1
CUTIS LAXA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0
PERIORBITAL EDEMA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	1 (0%)	0 (0
DERMATITIS NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1
ECCHYMOSIS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0
PRURITUS NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (09
SURGICAL AND MEDICAL PROCEDURES	1 (8%)	0 (0%)	8 (4%)	6 (3%)	5 (5%)	2 (2%)	8 (4%)	5 (3%)	4 (2%)	4 (25
POST-OPERATIVE COMPLICATIONS NOS	1 (8%)	0 (0%)	4 (2%)	4 (2%)	3 (3%)	1 (1%)	2 (1%)	3 (2%)	2 (1%)	2 (1
UNSPECIFIED COMPLICATION OF	0 (0%)	0 (0%)	0 (0%)	2 (1%)	2 (2%)	0 (0%)	2 (1%)	2 (1%)	1 (0%)	1 (1
PROCEDURE NEC	. , ,									
VITRECTOMY	0 (0%)	0 (0%)	4 (2%)	0 (0%)	1 (1%)	1 (1%)	1 (1%)	0 (0%)	1 (0%)	0 (0
EYE IRRITATION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0
LENS IMPLANT	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0
POST-OPERATIVE HEMORRHAGE	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0
SCLERAL OPERATION NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1
SUTURE LINE PAIN	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0
			- (0 (0%)	4 / 483	1 / 19.1	1 (1%)	3 (2%)	6 (3%)	1 (19
NERVOUS SYSTEM DISORDERS	0 (0%)	0 (0%)	1 (1%)	0 (0%)	4 (4%)	1 (1%)	- ,,	3 (2%)	3 (1%)	0 (0
PUPILLARY DISORDER NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	3 (3%)	0 (0%)	- · -·•	- , ,	1 (0%)	0 (0
VISUAL FIELD DEFECT NOS	0 (0%)	0 (0%)	1 (1%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	-		0 (0
FACIAL PALSY	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)		- , ,	1 (1
HEADACHE NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	- , -
PUPILLARY REFLEX IMPAIRED	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	
VITH NERVE PARALYSIS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0
IMMUNE SYSTEM DISORDERS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (2%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (05
HYPERSENSITIVITY NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	
MULTIPLE ALLERGIES	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0
INJURY AND POISONING	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (04
CHEMICAL BURNS OF EYE	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	
HEAD INJURY	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0

Page 5 of 5

Table 17
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Sex Safety Population

		Contr	ol							
	W	TW .	Sal	ine	7.5 IU V	/itrase	55 IU V:	itrase	75 IU V	trase
System Organ Class / Preferred Term	Male	Female	Male	Female	Male	Pemale	Male	Female	Male	Female
NEOPLASMS BENIGN AND MALIGNANT	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)
(INCLUDING CYSTS AND POLYPS) BENIGN NEOPLASM OF CHOROID	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)
RADIOACTIVE IODINE THERAPY	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
GENERAL DISORDERS AND	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)
ADMINISTRATION SITE CONDITIONS MECHANICAL COMPLICATION OF IMPLANT	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)
INFECTIONS AND INFESTATIONS	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
HYPOPYON	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
VASCULAR DISORDERS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)
PERIPHERAL ISCHEMIA NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)

Table 18

Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Sex Safety Population

		Cont	rol						95 TV 1	
	WW		Sal	ine	7.5 IU '		55 IU V		75 IU \ Male	Female
System Organ Class / Preferred Term	Male	Female	Male	Female	Male 	Female	Male	Female	mare	remare
NUMBER OF PATIENTS	13	5	183	195	100	98	193	184	215	175
NUMBER OF PATIENTS WITH AT LEAST ONE RELATED ADVERSE EVENT	10 (77%)	1 (20%)	116 (63%)	128 (66%)	85 (85%)	83 (85%)	145 (75%)	145 (79%)	182 (85%)	143 (82%)
EYE DISORDERS IRITIS OCULAR HYPEREMIA EYE PAIN EYE PAIN EYE IRRITATION LACRIMATION INCREASED ABNORMAL SENSATION IN EYE PHOTOPHOBLA CONJUNCTIVAL EDEMA VITREOUS FLOATERS VISUAL ACULTY REDUCED VITREOUS HEMORRHAGE PHOTOPSIA CATARACT SUBCAPSULAR RETINAL DETACHMENT CATARACT NUCLEAR CATARACT CORTICAL CORNEAL EROSION CORNEAL EROSION CORNEAL BERORDER NOS EYE DISCHARGE IRIS ADHESIONS CONJUNCTIVAL HEMORRHAGE CORNEAL EDEMA RUBEOSIS IRIDIS HYPOPYON HYPHEMA	10 (77%) 1 (8%) 1 (8%) 5 (38%) 1 (8%) 1 (8%) 3 (23%) 1 (8%) 3 (23%) 1 (8%) 0 (0%) 0 (0%) 1 (8%) 1 (8%) 1 (8%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)	1 (20%) 0 (0%)	116 (63%) 50 (27%) 52 (28%) 29 (16%) 37 (20%) 28 (14%) 26 (14%) 26 (14%) 26 (14%) 26 (14%) 18 (10%) 15 (8%) 10 (5%) 4 (2%) 7 (4%) 5 (3%) 0 (0%) 7 (4%) 2 (1%) 5 (3%) 0 (0%) 0 (0%) 0 (0%)	127 (65%) 56 (29%) 61 (31%) 28 (14%) 28 (14%) 28 (12%) 16 (8%) 23 (12%) 20 (10%) 25 (13%) 10 (5%) 4 (2%) 7 (4%) 3 (2%) 6 (3%) 8 (4%) 11 (6%) 3 (2%) 6 (3%) 11 (1%) 9 (5%) 2 (1%) 2 (1%) 2 (1%) 3 (2%)	85 (85%) 53 (53%) 50 (50%) 23 (23%) 30 (30%) 26 (26%) 21 (21%) 20 (20%) 15 (15%) 21 (21%) 17 (17%) 3 (3%) 9 (9%) 6 (6%) 2 (2%) 2 (2%) 2 (2%) 2 (2%) 3 (3%) 4 (4%) 2 (2%) 4 (1%) 2 (2%)	83 (85%) 47 (48%) 35 (36%) 25 (26%) 31 (32%) 19 (19%) 22 (22%) 21 (21%) 15 (15%) 26 (27%) 15 (15%) 11 (11%) 3 (3%) 6 (6%) 1 (1%) 2 (2%) 2 (2%) 2 (2%) 4 (4%) 0 (0%) 1 (1%)	143 (74%) 102 (53%) 76 (39%) 53 (27%) 48 (25%) 34 (18%) 28 (15%) 39 (20%) 26 (13%) 26 (13%) 38 (20%) 17 (9%) 12 (6%) 8 (4%) 7 (4%) 7 (4%) 7 (4%) 8 (4%) 7 (4%) 3 (2%) 2 (1%) 3 (2%)	145 (79%) 100 (54%) 82 (45%) 60 (33%) 48 (26%) 51 (28%) 44 (24%) 35 (19%) 35 (19%) 32 (17%) 28 (15%) 20 (11%) 11 (7%) 11 (6%) 7 (4%) 4 (2%) 4 (2%) 4 (2%) 1 (1%) 3 (2%) 4 (2%) 4 (2%) 4 (2%) 5 (2%) 6 (3%) 1 (1%) 7 (4%) 7 (4%) 7 (4%) 7 (4%) 7 (4%) 9 (2%) 9 (2%) 1 (1%) 1 (2%) 1 (2%) 1 (1%) 1 (2%) 1 (1%)	182 (85%) 134 (62%) 104 (48%) 68 (32%) 51 (24%) 55 (26%) 52 (24%) 48 (22%) 48 (22%) 39 (18%) 36 (17%) 16 (7%) 18 (8%) 9 (4%) 13 (6%) 7 (3%) 13 (6%) 7 (3%) 8 (4%) 3 (1%) 11 (5%) 6 (3%) 13 (6%) 3 (1%) 14 (5%) 6 (3%) 13 (6%) 3 (1%) 14 (2%)	143 (82%) 97 (55%) 79 (45%) 60 (34%) 52 (30%) 48 (22%) 38 (22%) 38 (22%) 29 (17%) 35 (20%) 22 (13%) 13 (7%) 10 (6%) 7 (4%) 9 (5%) 8 (5%) 7 (4%) 10 (6%) 7 (4%) 10 (6%) 6 (3%) 8 (5%) 7 (4%) 10 (6%) 5 (3%) 8 (5%) 7 (4%) 10 (6%) 5 (3%) 8 (5%) 7 (4%) 10 (6%) 5 (3%) 8 (5%) 7 (4%) 10 (6%) 5 (3%) 8 (5%) 7 (4%) 10 (6%) 5 (3%) 8 (5%) 7 (4%) 10 (6%) 10 (
MACULAR EDEMA WACULAR EDEMA UVEITIS NOS VITREOUS DETACHMENT MACULOPATHY KERATITIS NEC CATARACT NEC CATARACT NOS AGGRAVATED DRY EYE NEC DIPLOPIA GLAUCOMA NOS POSTERIOR CAPSULE OPACIFICATION VISION BLURRED BLINDNESS NEC HYPOTONY OF EYE	0 (0%) 0 (0%) 1 (8%) 0 (0%) 0 (0%) 0 (0%) 1 (8%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)	0 (0%) 1 (1%) 0 (0%) 1 (1%) 0 (0%) 2 (1%) 0 (0%) 1 (1%) 2 (1%) 0 (0%) 2 (1%) 0 (0%) 1 (1%) 0 (0%)	3 (2%) 0 (0%) 1 (1%) 1 (1%) 0 (0%) 3 (2%) 1 (1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)	1 (1%) 1 (1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (1%) 0 (0%) 0 (0%) 1 (1%) 1 (1%) 0 (0%)	2 (2%) 0 (0%) 1 (1%) 1 (1%) 3 (3%) 0 (0%) 0 (0%) 1 (1%) 1 (1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)	2 (1%) 1 (1%) 5 (2%) 1 (1%) 1 (1%) 0 (0%) 2 (1%) 0 (0%) 1 (1%) 2 (1%) 0 (0%)	1 (1%) 4 (2%) 1 (1%) 0 (0%) 1 (1%) 3 (2%) 0 (0%) 3 (2%) 0 (0%) 1 (1%) 1 (1%) 1 (1%) 1 (1%)	4 (2%) 0 (0%) 0 (0%) 2 (1%) 0 (0%) 3 (1%) 0 (0%) 1 (0%) 1 (0%) 1 (0%) 3 (1%) 1 (0%) 0 (0%) 3 (1%)	4 (2% 4 (2% 3 (2% 2 (1% 3 (2% 1 (1% 2 (1% 1 (1% 2 (1% 1 (1%

s:\dat\acs\iss2002\sas\programs\t_ocrae_sex 06SEP2002 17:36

Table 18
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Sex
Safety Population

		Conti								• .
		rw	Sal		7.5 IU V		55 IU V		75 IU V	
tem Organ Class / Preferred Term	Male	Female	Male	Female	Male	Female	Male	Female	Male	Femal
MYDRIASIS	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	3 (1%)	1 (
PHOTOPHOBIA AGGRAVATED	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	2 (1%)	0 (0%)	1 (
CORNEAL EPITHELIUM DEFECT	1 (8%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (2%)	1 (1%)	0 (0%)	0 (0%)	0 (
FOREIGN BODY RETAINED IN EYE	0 (0%)	0 (0%)	1 (1%)	0 (0%)	1 (1%)	1 (1%)	0 (0%)	1 (1%)	0 (ወ%)	0 (
NTRAOCULAR PRESSURE INCREASED	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (2%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	1 (
RETINAL TEAR (EXC DETACHMENT)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	4 (2%)	0 (0%)	0 (0%)	0 {
RETINOPATHY DIABETIC	0 (0%)	0 (0%)	0 (0%)	2 (1%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	1 (0%)	0 (
TITREOUS DISORDER NOS	0 (0%)	0 (0%)	1 (1%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	1 (
CONJUNCTIVITIS NEC	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	1 (
	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	1 (1%)	0 (0%)	1 (0%)	0 (
CORNEAL ABRASION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	1 (
CORTICAL OPACITY	- 1 - 11	0 (0%)	0 (0%)	1 (1%)	2 (2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (
INTRAOCULAR PRESSURE DECREASED	- ,,	- ,	0 (0%)	0 (0%)	2 (2%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (
RIDOCYCLITIS	0 (0%)		0 (0%)	1 (1%)	0 (0%)	1 (1%)	0 (0%)	1 (1%)	0 (0%)	0 -(
RETINAL HEMORRHAGE	0 (0%)	0 (0%)	:	0 (0%)	0 (0%)	0 (0%)	2 (1%)	0 (0%)	0 (0%)	0 (
BLEPHARITIS	0 (0%)	0 (0%)	0 (0%)		0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	1 (
HOROIDAL DETACHMENT	0 (0%)	0 (0%)	0 (0%)				1 (1%)	0 (0%)	1 (0%)	o (
ONJUNCTIVITIS (INFECTIVE) NEC	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)		- •	1 (1%)	0 (0%)	0 (
YE DEGENERATIVE DISORDER NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)		- ,,	0 (0%)	0 (
ACULAR DEGENERATION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	1 (1%)		1 (0%)	0 (
CULAR HYPERTENSION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)		
SEUDOPHAKIA	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (
ETINAL DISORDER NOS	0 (0%)	0 (0%)	0 (0%)	1 (1%)	.0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (
TRABISMUS NEC	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (
ITREOUS OPACITIES	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (
PHAKIA	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (
LINDNESS NIGHT	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (
LINDNESS TRANSIENT	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (
BLOODSHOT EYE	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (
CONJUNCTIVAL EDEMA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (
	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (
CHORIORETINAL ATROPHY	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 {
HORIORETINAL DISORDER NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (
OLOUR BLINDNESS NEC	- , ,		0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (
ONJUNCTIVITIS VIRAL NOS	0 (0%)		0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (
ORNEAL OPACITY	0 (0%)	0 (0%)		0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (
YCLITIS	0 (0%)	0 (0%)	- •		0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (
RYTHEMA NEC	0 (0%)	0 (0%)	0 (0%)	• ,,	* 1 * 11	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (
YE ALLERGY	0 (0%)	0 (0%)	0 (0%)	0 (0%)	• • •	,	0 (0%)	0 (0%)	1 (0%)	o (
YE INFECTION TOXOPLASMAL	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)		0 (0%)	0 (0%)	1 (0%)	0 (
YE INFLAMMATION NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)		0 (0%)	0 (0%)	1 (
YELID DISORDER NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	* *		0 (0%)	0 (
SYELID EDEMA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	• (,		0 (
EYELID PTOSIS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	• (/	0 (
KERATOCONJUNCTIVITIS	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
KERATOPATHY NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (
LENTICULAR OPACITIES	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	O (0%)	1 (

s:\dat\acs\iss2002\sas\programs\t_ocrae_sex 06SEP2002 17:36

Table 18
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Sex
Safety Population

		_Cont	rol							
	ww		Sal	ine	7.5 IU		55 IU V		75 IU V	
System Organ Class / Preferred Term	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
MEIBOMIAN CYST	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)
OCULAR HYPERAEMIA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)
OPEN ANGLE GLAUCOMA NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
OPTIC ATROPHY	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)
PAINFUL RED EYES	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
PINGUECULA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
POST-OPERATIVE PAIN	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)
RETINAL DEPIGMENTATION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
RETINAL ISCHEMIA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)
RETINAL MICROANEURYSMS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
RETINAL SCAR	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)
RETINAL VEIN THROMBOSIS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)
TOPOGRAPHY CORNEAL ABNORMAL	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)
UVEITIS DIABETIC	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
VISUAL DISTURBANCE NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)
INVESTIGATIONS	0 (0%)	0 (0%)	11 (6%)	13 (7%)	9 (9%)	12 (12%)	17 (9%)	7 (4%)	11 (5%)	9 (5%)
INTRAOCULAR PRESSURE INCREASED	0 (0%)	0 (0%)	10 (5%)	10 (5%)	8 (8%)	8 (8%)	14 (7%)	4 (2%)	9 (4%)	7 (4%)
CORNEAL STAINING	0 (0%)	0 (0%)	1 (1%)	3 (2%)	1 (1%)	4 (4%)	3 (2%)	3 (2%)	2 (1%)	2 (1%)
SKIN & SUBCUTANEOUS TISSUE DISORDERS	0 (0%)	0 (0%)	5 (3%)	10 (5%)	5 (5%)	4 (4%)	14 (7%)	15 (8%)	18 (8%)	6 (3%)
EYELID EDEMA	0 (0%)	0 (0%)	2 (1%)	4 (2%)	4 (4%)	2 (2%)	9 (5%)	13 (7%)	13 (6%)	6 (3%)
ERYTHEMA NEC	0 (0%)	0 (0%)	3 (2%)	6 (3%)	2 (2%)	1 (1%)	7 (4%)	7 (4%)	10 (5%)	2 (1%)
CUTIS LAXA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
ECCHYMOSIS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)
OCULAR HYPEREMIA	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
PERIORBITAL EDEMA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)
SURGICAL AND MEDICAL PROCEDURES	0 (0%)	0 (0%)	0 (0%)	1 (1%)	3 (3%)	1 (1%)	4 (2%)	1 (1%)	1 (0%)	3 (2%)
UNSPECIFIED COMPLICATION OF	0 (0%)	0 (0%)	0 (0%)	1 (1%)	2 (2%)	0 (0%)	2 (1%)	1 (1%)	1 (0%)	1 (1%)
PROCEDURE NEC VITRECTOMY	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
EYE IRRITATION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	० (०%)
POST-OPERATIVE COMPLICATIONS NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)
POST-OPERATIVE COMPLICATIONS NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)
SCLERAL OPERATION NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)
NERVOUS SYSTEM DISORDERS	0 (0%)	0 (0%)	1 (1%)	0 (0%)	2 (2%)	0 (0%)	0 (0%)	2 (1%)	5 (2%)	1 (1%)
PUPILLARY DISORDER NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	2 (1%)	3 (1%)	0 (0%)
VISUAL FIELD DEFECT NOS	0 (0%)	0 (0%)	1 (1%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)
HEADACHE NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)
PUPILLARY REFLEX IMPAIRED	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)
INFECTIONS AND INFESTATIONS	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
HYPOPYON	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

s:\dat\acs\iss2002\sas\programs\t_ocrae_sex 06SEP2002 17:36

Page 4 of 4

Table 18
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Sex
Safety Population

		Contr	ol							_
	WW		Sali	.ne	7.5 IU V	/itrase	55 IU V:	itrase	75 IU V	itrase
System Organ Class / Preferred Term	Male	Female								
INJURY AND POISONING HEAD INJURY	0 (0%) 0 (0%)	0 (0%) 0 (0%)	0 (0%) 0 (0%)	1 (1%) 1 (1%)	0 (0%)	O (0%) O (0%)	0 (0%) 0 (0%)	0 (0%) 0 (0%)	0 (0%) 0 (0%)	0 (0%)
VASCULAR DISORDERS PERIPHERAL ISCHEMIA NOS	0 (0%) 0 (0%)	1 (0%) 1 (0%)	0 (0%) 0 (0%)							

Table 19
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Age
Safety Population

		Cont	rol							
	ww	W	Sa	line	7.5 IU	Vitrase	55 IU \		75 IU V	
	< 60	>= 60	< 60	>= 60	< 60	>= 60	< 60	>= 60	< 60	>= 60
System Organ Class / Preferred Term	years	years	years	years	years	years	years	years	years	years
NUMBER OF PATIENTS	3	15	151	224	95	103	164	212	151	240
NUMBER OF PATIENTS WITH AT LEAST ONE ADVERSE EVENT	3 (100%)	14 (93%)	119 (79%)	177 (79%)	93 (98%)	100 (97%)	141 (86%)	181 (85%)	140 (93%)	209 (87%
EYE DISORDERS	3 (100%)	14 (93%)	119 (79%)	176 (79%)	93 (98%)	99 (96%)	140 (85%)	181 (85%)	140 (93%)	209 (87%
IRITIS	1 (33%)	3 (20%)	45 (30%)	81 (36%)	56 (59%)	67 (65%)	99 (60%)	123 (58%)	104 (69%)	139 (58%
OCULAR HYPEREMIA	0 (0%)	4 (27%)	58 (38%)	82 (37%)	59 (62%)	54 (52%)	80 (49%)	121 (57%)	92 (61%)	123 (51%
EYE IRRITATION	2 (67%)	8 (53%)	48 (32%)	61 (27%)	47 (49%)	43 (42%)	62 (38%)	69 (33%)	67 (44%)	72 (30%
EYE PAIN	0 (0%)	2 (13%)	33 (22%)	51 (23%)	36 (38%)	36 (35%)	62 (38%)	77 (36%)	66 (44%)	95 (409
LACRIMATION INCREASED	0 (0%)	4 (27%)	40 (26%)	47 (21%)	35 (37%)	30 (29%)	58 (35%)	66 (31%)	57 (38%)	82 (349
VISUAL ACUITY REDUCED	0 (0%)	4 (27%)	26 (17%)	48 (21%)	33 (35%)	44 (43%)	44 (27%)	57 (27%)	43 (28%)	55 (235
ABNORMAL SENSATION IN EYE	0 (0%)	2 (13%)	25 (17%)	43 (19%)	27 (28%)	35 (34%)	43 (26%)	58 (27%)	48 (32%)	66 (289
VITREOUS FLOATERS	1 (33%)	5 (33%)	24 (16%)	43 (19%)	27 (28%)	36 (35%)	37 (23%)	50 (24%)	44 (29%)	56 (23
	0 (0%)	2 (13%)	30 (20%)	36 (16%)	32 (34%)	38 (37%)	41 (25%)	50 (24%)	40 (26%)	50 (21
VITREOUS HEMORRHAGE	1 (33%)	5 (33%)	33 (22%)	27 (12%)	31 (33%)	28 (27%)	39 (24%)	47 (22%)	51 (34%)	51 (21
PHOTOPHOBIA	0 (0%)	1 (7%)	32 (21%)	27 (12%)	20 (21%)	28 (27%)	41 (25%)	55 (26%)	41 (27%)	48 (20
CONJUNCTIVAL EDEMA		3 (20%)	13 (9%)	21 (9%)	14 (15%)	13 (13%)	13 (8%)	24 (11%)	12 (8%)	17 (7
CATARACT NUCLEAR	2 (67%)	2 (13%)	16 (11%)	10 (4%)	14 (15%)	8 (8%)	22 (13%)	13 (6%)	25 (17%)	20 (8
RETINAL DETACHMENT	1 (33%)		15 (10%)	11 (5%)	15 (16%)	18 (17%)	11 (7%)	18 (8%)	16 (11%)	22 (9
CATARACT SUBCAPSULAR	1 (33%)		14 (9%)	8 (4%)	14 (15%)	8 (8%)	21 (13%)	24 (11%)	15 (10%)	23 (10
PHOTOPSIA	0 (0%)	0 (0%)	12 (8%)	15 (7%)	4 (4%)	10 (10%)	12 (7%)	18 (8%)	13 (9%)	18 (8
CATARACT CORTICAL	0 (0%)	5 (33%)	•	14 (6%)	5 (5%)	5 (5%)	9 (5%)	16 (8%)	8 (5%)	9 (4
CORNEAL EROSION	1 (33%)	0 (0%)		11 (5%)	10 (11%)	7 (7%)	8 (5%)	12 (6%)	7 (5%)	17 (7
CORNEAL EDEMA	0 (0%)	1 (7%)	- 1 - 1	9 (4%)	11 (12%)	5 (5%)	9 (5%)	8 (4%)	12 (8%)	7 (3
RUBEOSIS IRIDIS	0 (0%)	1 (7%)	10 (7%)	- 1	4 (4%)	6 (6%)	8 (5%)	15 (7%)	8 (5%)	12 (5
EYE DISCHARGE	0 (0%)	0 (0%)	8 (5%)	10 (4%)	4 (4%)	7 (7%)	4 (2%)	10 (5%)	12 (8%)	6 (3
CONJUNCTIVAL HEMORRHAGE	0 (0%)	0 (0%)	8 (5%)	17 (8%)		2 (2%)	6 (4%)	7 (3%)	15 (10%)	12 (5
IRIS ADHESIONS	0 (0%)	2 (13%)	7 (5%)	6 (3%)			6 (4%)	5 (2%)	13 (9%)	6 (3
MACULAR EDEMA	0 (0%)	1 (7%)	3 (2%)	8 (4%)	5 (5%)	;	6 (4%)	11 (5%)	13 (9%)	12 (5
CORNEAL DISORDER NOS	0 (0%)	0 (0%)	0 (0%)	8 (4%)	2 (2%)		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	8 (4%)	8 (5%)	7 (3
HYPHEMA	0 (0%)	0 (0%)	3 (2%)	3 (1%)	2 (2%)	6 (6%)	- : ".:	7 (3%)	5 (3%)	4 (2
CATARACT NEC	0 (0%)	0 (0%)	6 (4%)	4 (2%)	1 (1%)	0 (0%)	T 1 T 1	2 (1%)	4 (3%)	5 (2
BLINDNESS NEC	0 (0%)	1 (7%)	1 (1%)	3 (1%)	7 (7%)	2 (2%)	* 1 = ::	- •	10 (7%)	11 (5
HYPOPYON	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	4 (2%)	- ,	3 (2%)	6 (3
DRY EYE NEC	0 (0%)	0 (0%)	3 (2%)	3 (1%)	3 (3%)		2 (1%)	2 (= - ;	7 (5%)	5 (2
GLAUCOMA NOS	0 (0%)	0 (0%)	3 (2%)	2 (1%)	1 (1%)		2 (1%)	1 (0%)		4 (2
VISION BLURRED	0 (0%)	0 (0%)	3 (2%)	2 (1%)	5 (5%)		1 (1%)	4 (2%)	• ,,	0 (0
CATARACT NOS AGGRAVATED	0 (0%)	1 (7%)	2 (1%)	6 (3%)	0 (0%)	4 (4%)	1 (1%)	4 (2%)	3 (2%)	3 (1
KERATITIS NEC	0 (0%)	0 (0%)	0 (0%)	4 (2%)	2 (2%)		2 (1%)	2 (1%)	5 (3%)	3 (1
VITREOUS DETACHMENT	0 (0%)	1 (7%)	1 (1%)	1 (0%)	1 (1%)	2 (2%)	9 (5%)	0 (0%)	2 (1%)	- : -
	0 (0%)	0 (0%)	1 (1%)	4 (2%)	3 (3%)	1 (1%)	0 (0%)	5 (2%)	1 (1%)	4 (2
MACULOPATHY	0 (0%)	0 (0%)	_ (10)	= , + , ,					_	

Note: One patient in study VIT-02-08961X (Saline) and three patients in study VIT-03-08961X (two Saline and one 55 IU) had calculated ages resolving to zero due to incorrect birth dates recorded. These values are not included in the age calculation. In addition, patients with a missing DOB were not included in the age calculation.

s:\dat\acs\iss2002\sas\programs\t_ocae_age 06SEP2002 17:36

Table 19
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Age
Safety Population

		Cont								
		TW	Sa1		7.5 IU \		55 IU V		75 IU V	
	< 60	>= 60	< 60	>= 60	< 60	>= 60	< 60	>= 60	< 60	>= 60
System Organ Class / Preferred Term	years	years	years	years	years	years	years	years 	years	years
INTRAOCULAR PRESSURE INCREASED	0 (0%)	0 (0%)	1 (1%)	2 (1%)	2 (2%)	4 (4%)	1 (1%)	2 (1%)	2 (1%)	4 (2%)
UVEITIS NOS	0 (0%)	1 (7%)	1 (1%)	1 (0%)	0 (0%)	2 (2%)	5 (3%)	2 (1%)	2 (1%)	2 (1%)
POST-OPERATIVE PAIN	1 (33%)	0 (0%)	1 (1%)	6 (3%)	0 (0%)	0 (0%)	0 (0%)	2 (1%)	3 (2%)	2 (1%)
POSTERIOR CAPSULE OPACIFICATION	0 (0%)	0 (0%)	1 (1%)	2 (1%)	0 (0%)	1 (1%)	3 (2%)	3 (1%)	3 (2%)	2 (1%)
RETINOPATHY DIABETIC	0 (0%)	0 (0%)	1 (1%)	3 (1%)	1 (1%)	0 (0%)	3 (2%)	0 (0%)	5 (3%)	1 (0%)
BLEPHARITIS	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	3 (3%)	0 (0%)	3 (1%)	2 (1%)	3 (1%)
HYPOTONY OF EYE	0 (0%)	0 (0%)	0 (0%)	2 (1%)	1 (1%)	1 (1%)	0 (0%)	2 (1%)	3 (2%)	3 (1%)
RETINAL HEMORRHAGE	0 (0%)	0 (0%)	1 (1%)	4 (2%)	2 (2%)	0 (0%)	2 (1%)	3 (1%)	0 (0%)	0 (0%)
CORNEAL EPITHELIUM DEFECT	0 (0%)	1 (7%)	1 (1%)	0 (0%)	1 (1%)	2 (2%)	3 (2%)	1 (0%)	1 (1%)	1 (0%)
DIPLOPIA	0 (0%)	0 (0%)	0 (0%)	2 (1%)	0 (0%)	3 (3%)	2 (1%)	2 (1%)	2 (1%)	0 (0%)
RETINAL ISCHEMIA	0 (0%)	0 (0%)	1 (1%)	0 (0%)	2 (2%)	1 (1%)	3 (2%)	1 (0%)	1 (1%)	1 (0%)
CONJUNCTIVITIS NEC	0 (0%)	0 (0%)	1 (1%)	1 (0%)	0 (0%)	3 (3%)	1 (1%)	0 (0%)	0 (0%)	2 (1%)
CORNEAL ABRASION	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	2 (2%)	1 (1%)	2 (1%)	1 (1%)	1 (0%) 3 (1%)
MYDRIASIS	0 (0%)	0 (0%)	1 (1%)	2 (1%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	1 (1%)	3 (1%) 2 (1%)
RETINAL TEAR (EXC DETACHMENT)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)	2 (1%)	3 (1%)	0 (0%)	
FOREIGN BODY RETAINED IN EYE	0 (0%)	0 (0%)	1 (1%)	0 (0%)	1 (1%)	3 (3%)	1 (1%)	1 (0%)	0 (0%) 0 (0%)	0 (0%)
EYE DEGENERATIVE DISORDER NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	3 (3%)	0 (0%)	2 (1%)	0 (0%) 2 (1%)	0 (0%) 0 (0%)	0 (0%)
PSEUDOPHAKIA	0 (0%)	0 (0%)	0 (0%)	3 (1%)	0 (0%)	0 (0%)	1 (1%) 0 (0%)	0 (0%)	1 (1%)	0 (0%)
EYELID PTOSIS	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	3 (3%)	• , • - ,	0 (0%)	0 (0%)	0 (0%)
INTRAOCULAR PRESSURE DECREASED	0 (0%)	0 (0%)	2 (1%)	1 (0%)	0 (0%)	2 (2%)		2 (1%)	0 (0%)	0 (0%)
OPTIC ATROPHY	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	1 (1%) 0 (0%)	1 (1%) 2 (1%)	1 (0%)	1 (1%)	0 (0%)
PHOTOPHOBIA AGGRAVATED	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	0 (0%) 1 (1%)	0 (0%)	0 (0%)	1 (1%)	1 (0%)
VITREOUS DISORDER NOS	0 (0%)	0 (0%)	1 (1%)	1 (0%)	0 (0%) 1 (1%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)
APHAKIA	0 (0%)	0 (0%)	1 (1%)	1 (0%) 0 (0%)	- ,,	0 (0%)	1 (1%)	2 (1%)	1 (1%)	0 (0%)
EYE ALLERGY	.0 (0%)	0 (0%)	0 (0%)		- 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	0 (0%)	0 (0%)	1 (0%)	0 (0%)	1 (0%)
KERATOCONJUNCTIVITIS	0 (0%)	0 (0%)	0 (0%)	1 (0%) 0 (0%)	1 (1%) 0 (0%)	0 (0%)	1 (1%)	1 (0%)	0 (0%)	1 (0%)
OCULAR HYPERTENSION	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	2 (1%)	0 (0%)
PAINFUL RED EYES	0 (0%)	0 (0%) 0 (0%)	1 (1%) 0 (0%)	1 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)
CHEMOSIS	0 (0%)		0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	1 (0%)
CORTICAL OPACITY	0 (0%)	0 (0%)		0 (0%)	1 (1%)	1 (1%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)
IRIDOCYCLITIS	0 (0%)	0 (0%) 0 (0%)	0 (0%) 2 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)
LENTICULAR OPACITIES	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (2%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)
MACULAR DEGENERATION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	1 (0%)
OPEN ANGLE GLAUCOMA NOS	. , ,	0 (0%)	1 (1%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)
RETINAL DISORDER NOS	0 (0%)	0 (0%)	1 (1%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)
RETINAL MICROANEURYSMS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (1%)	1 (1%)	0 (0%)
RETINAL SCAR	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)
BLINDNESS TRANSIENT CHOROIDAL DETACHMENT	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	1 (0%)
CONJUNCTIVITIS (INFECTIVE) NEC	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	1 (0%)
CONJUNCTIVITIS (INFECTIVE) NEC	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)
COMPONCITATIO WIMPERGIC	0 1 001	0 / 401	0 (20)	- \ /	,					

Note: One patient in study VIT-02-08961X (Saline) and three patients in study VIT-03-08961X (two Saline and one 55 IU) had calculated ages resolving to zero due to incorrect birth dates recorded. These values are not included in the age calculation. In addition, patients with a missing DOB were not included in the age calculation.

s:\dat\acs\iss2002\sas\programs\t_ocae_age 06SEP2002 17:36

Table 19 Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Age Safety Population

		Cont	rol							
	W			ine	7.5 IU V	Vitrase	55 IV V:	itrase	75 IU V	itrase
	< 60	>= 60	< 60	>= 60	< 60	>= 60		>= 60	< 60	>= 60
System Organ Class / Preferred Term	years	years	years	years	years	years	years	years	years	years
CONJUNCTIVITIS VIRAL NOS	0 (0%)	1 (7%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)
CORNEAL OPACITY	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)
KERATOPATHY BAND	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)
KERATOPATHY NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)
MEIBOMIAN CYST	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	1 (0%)
PERIORBITAL HEMATOMA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (1%)	0 (0%)	0 (0%)
RETINAL ARTERY EMBOLISM	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)
RETINAL DEPIGMENTATION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)
STRABISMUS NEC	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)
VISUAL ACUITY REDUCED TRANSIENTLY	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)
VITREOUS OPACITIES	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)
ANGLE CLOSURE GLAUCOMA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	० (०%)	0 (0%)
ANISEIKONIA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)
ARCUS SENILIS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
BLEPHAROCONJUNCTIVITIS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)
BLINDNESS NIGHT	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)
BLOODSHOT EYE	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)
CCONJUNCTIVAL EDEMA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)
CHALAZION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)
CHORIORETINAL ATROPHY	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
CHORIORETINAL DISORDER NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
CHOROIDAL HEMORRHAGE	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)
COLOUR BLINDNESS NEC	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)
CORNEAL DEGENERATION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)
	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
CORNEAL SCAR	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
CORNEAL ULCER NEC	- ,		0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)
CYCLITIS	0 (0%)	- • •	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)
ERYTHEMA NEC	0 (0%)	- ,,	* * * * * * * * * * * * * * * * * * * *	1 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
EXOPHTHALMOS ENDOCRINE	0 (0%)	0 (0%)		1 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
EYE HEMORRHAGE NEC	0 (0%)	0 (0%)	0 (0%)		* * * * * * * * * * * * * * * * * * * *	0 (0%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)
EYE INFECTION FUNGAL NOS	0 (0%)	0 (0%)	0 (0%)			0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
EYE INFECTION NOS	0 (0%)	0 (0%)	1 (1%)			0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
EYE INFECTION STAPHYLOCOCCAL	0 (0%)	0 (0%)	0 (0%)	0 (0%)		0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)
EYE INFECTION TOXOPLASMAL	0 (0%)	0 (0%)	0 (0%)	0 (0%)		0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)
EYE INFLAMMATION NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	- • •	0 (0%)	0 (0%)	0 (0%)	1 (0%)
EYELID DISORDER NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)		1 (0%)	0 (0%)	0 (0%)
EYELID EDEMA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	• ,	0 (0%)	1 (1%)	0 (0%)
HERPES SIMPLEX OPHTHALMIC	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)		0 (0%)	0 (0%)	0 (0%)
IRIS NEVUS	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)
LACRIMAL DUCT OBSTRUCTION NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	_ ,	1 (1%)	0 (0%)
OCULAR HYPERAEMIA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	T / T2)	0 (08)

Note: One patient in study VIT-02-08961X (Saline) and three patients in study VIT-03-08961X (two Saline and one 55 IU) had calculated ages resolving to zero due to incorrect birth dates recorded. These values are not included in the age calculation. In addition, patients with a missing DOB were not included in the age calculation.

s:\dat\acs\iss2002\sas\programs\t_ocae_age 06SEP2002 17:36

Table 19
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Age
Safety Population

System Organ Class / Preferred Term Column			Cont	rol							
OPTIC DISC HEMORRHAGE OF 10 O		WW			ine	7.5 IU	Vitrase	55 IU V	itrase	75 IU V	itrase
OPTIC DISC HEMORRHAGE O (04)		< 60	>= 60	< 60	>= 60	< 60	>= 60	< 60	>= 60	< 60	> ≠ 60
PAPTILEDEMA O (04) 0	System Organ Class / Preferred Term	years	years	years	years	years	years	years	years	years	years
PAPTILEDEMA O (04) 0			·								
PAPILLEDEMA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	OPTIC DISC HEMORRHAGE	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
PENDURCULLA 0 (04) 0 (04) 0 (04) 0 (04) 0 (04) 0 (04) 0 (04) 0 (04) 0 (04) 0 (04) 0 (04) 0 (04) 0 (04) 1 (04) 8 POST-OPERATIVE COMPLICATIONS NOS 0 (04) 0 (OPTIC NERVE INJURY NOS	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	- \/	
CONTROL COMPLICATIONS NOS	PAPILLEDEMA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)		•		
RETINAL DEGINERATION 0 (0%) 0	PINGUECULA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	- • •		. ,	
RETINAL EXIDATES 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	POST-OPERATIVE COMPLICATIONS NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)				- ,	- , ,
RETINAL VASCULITIS O	RETINAL DEGENERATION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	,	- • •			
RETINAL VEIN THROMBOSIS 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (0%) 0 (0%	RETINAL EXUDATES	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)			- ,		
SCLERTIS NOS 0 (0\$) 0 (RETINAL VASCULITIS	0 (0%)	0 (0%)				- • - •	- , ,		- •	
TOPOGRAPHY CORNEAL ABNORMAL O (0%) O	RETINAL VEIN THROMBOSIS	0 (0%)	0 (0%)				7 1 771	- • •			- ,
UNEITIS DIRBETIC 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	SCLERITIS NOS	0 (0%)	0 (0%)	- ,,				,			• • • • • • • • • • • • • • • • • • • •
VISION ABNORMAL NEC 0 (0%) 0	TOPOGRAPHY CORNEAL ABNORMAL	0 (0%)	0 (0%)						- ,		- • •
VISUAL DISTURBANCE NOS 0 (0\$)	UVEITIS DIABETIC	0 (0%)	- (,							- ,,	
INVESTIGATIONS 0 (0%) 3 (20%) 17 (11%) 27 (12%) 24 (25%) 24 (23%) 18 (11%) 32 (15%) 24 (16%) 22 (9%) 1NTRACCULAR PRESSURE INCREASED 0 (0%) 3 (20%) 15 (10%) 24 (11%) 20 (21%) 20 (19%) 15 (9%) 27 (13%) 22 (15%) 18 (8%) CORNEAL STAINING 0 (0%) 0 (0	VISION ABNORMAL NEC	0 (0%)	- •				- • •	- • •		- '	
INTRAOCULAR PRESSURE INCREASED 0 (0%) 3 (20%) 15 (10%) 24 (11%) 20 (21%) 20 (19%) 15 (9%) 27 (13%) 22 (15%) 18 (8%) CORNEAL STAINING 0 (0%) 0 (0%) 0 (0%) 2 (1%) 4 (2%) 4 (4%) 4 (4%) 4 (4%) 3 (2%) 6 (3%) 4 (3%) 4 (2%) 18 (VISUAL DISTURBANCE NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)
INTRAOCULAR PRESSURE INCREASED O(0\$) 3 (0\$) 3 (20\$) 15 (10\$) 24 (11\$) 20 (21\$) 20 (19\$) 15 (9\$) 27 (13\$) 22 (15\$) 18 (8\$) 10 CORNEAL STAINING O(0\$) 0 (0\$) 0 (0\$) 0 (0\$) 0 (0\$) 0 (0\$) 0 (0\$) 1 (1\$) 1 (1\$) 1 (1\$) 0 (0\$) 0	INVESTIGATIONS	0 (0%)	3 (20%)	17 (11%)	27 (12%)	24 (25%)	24 (23%)	18 (11%)	32 (15%)	24 (16%)	
CORNEAL STAINING O(0\$) O		0 (0%)	3 (20%)	15 (10%)	24 (11%)	20 (21%)	20 (19%)	15 (9%)	27 (13%)	22 (15%)	18 (8%)
INTRAOCULAR PRESSURE ABNORMAL 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (1%) 1 (1%) 1 (1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) SKIN & SUBCUTANEOUS TISSUE DISORDERS 0 (0%) 0 (0%) 0 (0%) 9 (6%) 17 (8%) 13 (14%) 6 (6%) 17 (10%) 22 (10%) 16 (11%) 22 (9%) EYELID EDEMA 0 (0%) 0 (0%) 0 (0%) 6 (4%) 9 (4%) 8 (8%) 4 (4%) 14 (9%) 15 (7%) 10 (7%) 15 (6%) EYYTHEMA NEC 0 (0%) 0 (0%) 0 (0%) 1 (1%) 1 (1%) 1 (1%) 1 (1%) 15 (7%) 10 (7%) 15 (6%) EYTHEMA NEC 0 (0%) 0 (0%) 0 (0%) 1 (1		0 (0%)		2 (1%)	4 (2%)	4 (4%)	4 (4%)	3 (2%)			
EYELID EDEMA O (0 %) O (0 %		0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
EYELID EDEMA	SKIN & SUBCUTANTOUS TISSUE DISORDERS	በ (በ%)	በ (በ%)	9 (6%)	17 (8%)	13 (14%)	6 (6%)	17 (10%)	22 (10%)	16 (11%)	22 (9%)
ERYTHEMA NEC O (0\$) O (0\$) O (0\$) 3 (2\$) 12 (5\$) 8 (8\$) O (0\$) 8 (5\$) 13 (6\$) 9 (6\$) 11 (5\$) OCULAR HYPEREMIA O (0\$) O (0\$) O (0\$) D (- ,,		6 (4%)	9 (4%)	8 (8%)	4 (4%)	14 (9%)	15 (7%)	10 (7%)	15 (6%)
OCULAR HYPEREMIA O(0%) O(0%) O(0%) D(0%)		• •		3 (2%)	12 (5%)	8 (8%)	0 (0%)	8 (5%)	13 (6%)	9 (6%)	
CUTIS LAXA O (0%) O (0					1 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	
PERIORBITAL EDEMA O (0%) O (- ,		0 (0%)	0 (0%)	1 (1%)	1 (1%)	0 (0%)	0 (0%)	- ,,	
DERMATITIS NOS 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (0%) ECCHYMOSIS PRURITUS NOS 0 (0%) 0			•	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	- ,		
ECCHYMOSIS PRURITUS NOS 0 (0%) 0 (0%		0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	•		
PRURITUS NOS 0 (0%) 0		0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)				
SURGICAL AND MEDICAL PROCEDURES 1 (33%) 0 (0%) 2 (1%) 12 (5%) 5 (3%) 2 (2%) 1 (1%) 4 (2%) 2 (1%) 2 (1%) 1 (0%) 1 (1%) 1 (0%) 1 (1%) 1 (0%) 1 (1%) 1 (0%) 1 (1%) 1 (0%) 1 (1%) 1 (0%) 1 (1%) 1 (0%) 1 (1%) 1 (0%) 1 (1%) 1 (0%) 1 (1%) 1 (0%) 1 (0%) 1 (1%) 1 (0%) 1 (1%) 1 (0%) 1 (1%) 1 (0%) 1 (1%) 1 (0%) 1 (1%) 1 (0%) 1 (1%) 1 (0%) 1 (1%) 1 (0%) 1 (1%) 1 (0%) 1 (1%) 1 (0%) 1 (1%) 1 (0%) 1 (1%) 1 (0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)
POST-OPERATIVE COMPLICATIONS NOS 1 (33%) 0 (0%) 2 (1%) 6 (3%) 2 (2%) 2 (2%) 1 (1%) 4 (2%) 2 (1%) 2 (1%) 1 (0%) UNSPECIFIED COMPLICATION OF 0 (0%) 0 (0%) 0 (0%) 2 (1%) 1 (1%) 1 (1%) 3 (2%) 1 (0%) 1 (1%) 1 (0%) PROCEDURE NEC VITRECTOMY 0 (0%) 0 (0%) 0 (0%) 4 (2%) 2 (2%) 0 (0%) 1 (1%) 0 (0%) 0 (0%) 1 (0%) EYE IRRITATION 0 (0%) 0 (0	SUDGICAL AND MEDICAL PROCEDURES	1 (33%)	0 (0%)	2 (1%)	12 (5%)	5 (5%)	2 (2%)	7 (4%)	6 (3%)		
UNSPECIFIED COMPLICATION OF 0 (0%) 0 (0%) 0 (0%) 2 (1%) 1 (1%) 3 (2%) 1 (0%) 1 (1%) 1 (0%) PROCEDURE NEC VITRECTOMY 0 (0%) 0 (0%) 0 (0%) 4 (2%) 2 (2%) 0 (0%) 1 (1%) 0 (0%) 0 (0%) 1 (0%) EYE IRRITATION 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) LENS IMPLANT 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) POST-OPERATIVE HEMORRHAGE 0 (0%) 0	* * *			2 (1%)	6 (3%)	2 (2%)	2 (2%)	1 (1%)	4 (2%)		- ,
PROCEDURE NEC VITRECTOMY 0 (0%) 0 (0%) 0 (0%) 4 (2%) 2 (2%) 0 (0%) 1 (1%) 0 (0%) 0 (0%) 1 (0%) EYE IRRITATION 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (1%) 0 (0%) 0 (0%) 0 (0%) LENS IMPLANT 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) POST-OPERATIVE HEMORRHAGE 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)				0 (0%)	2 (1%)	1 (1%)	1 (1%)	3 (2%)	1 (0%)	1 (1%)	1 (0%)
VITRECTOMY 0 (0%) 0 (0%) 0 (0%) 4 (2%) 2 (2%) 0 (0%) 1 (1%) 0 (0%) 0 (0%) 1 (0%) EYE IRRITATION 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (1%) 0 (0%) 0 (0%) 0 (0%) LENS IMPLANT 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (1%) POST-OPERATIVE HEMORRHAGE 0 (0%)		0 (007									
EYE IRRITATION 0 (0%) 0		0 (0%)	0 (0%)	0 (0%)	4 (2%)	2 (2%)	0 (0%)			,	
LENS IMPLANT 0 (0%) 0 (0 (0%)	0 (0%)	0 (0%)	0 (0%)			- ,	
POST-OPERATIVE HEMORRHAGE 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (0%) 0 (0%) 1 (0%)				0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	- ,	• • • • • •	- , ,
$\frac{1}{2}$		- •		0 (0%)	0 (0%)	0 (0%)	0 (0%)				
SUISRAU UPBRATION NOS	SCLERAL OPERATION NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	- ,,			
SUTURE LINE PAIN 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)		0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)

Note: One patient in study VIT-02-08961X (Saline) and three patients in study VIT-03-08961X (two Saline and one 55 IU) had calculated ages resolving to zero due to incorrect birth dates recorded. These values are not included in the age calculation. In addition, patients with a missing DOB were not included in the age calculation.

s:\dat\acs\iss2002\sas\programs\t_ocae_age 06SEP2002 17:36

Table 19
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Age
Safety Population

	Control										
	W	W	Sal	ine	7.5 IU V	7.5 IU Vitrase		55 IU Vitrase		75 IU Vitrase	
	< 60	>= 60	< 60	>= 60		>= 60	< 60	>= 60	< 60	>= 60	
System Organ Class / Preferred Term	years	years	years	years	years	years	years	years	years	years	
NERVOUS SYSTEM DISORDERS	C (0%)	0 (0%)	0 (0%)	1 (0%)	4 (4%)	1 (1%)	1 (1%)	3 (1%)	5 (3%)	2 (1%)	
PUPILLARY DISORDER NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (2%)	1 (1%)	1 (1%)	3 (1%)	3 (2%)	0 (0%)	
VISUAL FIELD DEFECT NOS	0 (0%)	0 (0%)	0 (0%)	1 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	
FACIAL PALSY	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	
HEADACHE NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	
PUPILLARY REFLEX IMPAIRED	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	
VITH NERVE PARALYSIS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
IMMUNE SYSTEM DISORDERS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	1 (1%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)	
HYPERSENSITIVITY NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)	
MULTIPLE ALLERGIES	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
INJURY AND POISONING	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)	
CHEMICAL BURNS OF EYE	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)	
HEAD INJURY	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
NEOPLASMS BENIGN AND MALIGNANT (INCLUDING CYSTS AND POLYPS)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	
BENIGN NEOPLASM OF CHOROID	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	
RADIOACTIVE IODINE THERAPY	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	
MECHANICAL COMPLICATION OF IMPLANT	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	
INFECTIONS AND INFESTATIONS	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
HYPOPYON	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
VASCULAR DISORDERS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	
PERIPHERAL ISCHEMIA NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	

22

Note: One patient in study VIT-02-08961X (Saline) and three patients in study VIT-03-08961X (two Saline and one 55 IU) had calculated ages resolving to zero due to incorrect birth dates recorded. These values are not included in the age calculation. In addition, patients with a missing DOB were not included in the age calculation.

Table 20
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Age
Safety Population

			trol								
		W		line	7.5 IU			Vitrase	75 IU Vitrase		
	< 60	>= 60	< 60	>= 60	< 60	>= 60	< 60	>= 60	< 60	>= 60 years	
System Organ Class / Preferred Term	years	years	years	years	years	years	years	years	years	years	
NUMBER OF PATIENTS	3	15	151	224	95	103	164	212	151	240	
NUMBER OF PATIENTS WITH AT LEAST ONE RELATED ADVERSE EVENT	0 (0%)	11 (73%)	107 (71%)	135 (60%)	83 (87%)	85 (83%)	125 (76%)	164 (77%)	132 (87%)	194 (81	
EYE DISORDERS	0 (0%)	11 (73%)	107 (71%)	134 (60%)	83 (87%)	85 (83%)	124 (76%)	163 (77%)	132 (87%)	194 (81	
IRITIS	0 (0%)	1 (7%)	40 (26%)	66 (29%)	43 (45%)	57 (55%)	88 (54%)	114 (54%)	100 (66%)	131 (5	
OCULAR HYPEREMIA	0 (0%)	1 (7%)	49 (32%)	64 (29%)	46 (48%)	39 (38%)	62 (38%)	95 (45%)	76 (50%)	107 (45	
EYE PAIN	0 (0%)	1 (7%)	24 (16%)	33 (15%)	23 (24%)	25 (24%)	47 (29%)	66 (31%)	51 (34%)	77 (32	
EYE IRRITATION	0 (0%)	5 (33%)	38 (25%)	39 (17%)	32 (34%)	29 (28%)	44 (27%)	52 (25%)	48 (32%)	55 (23	
LACRIMATION INCREASED	0 (0%)	1 (7%)	25 (17%)	31 (14%)	22 (23%)	23 (22%)	43 (26%)	51 (24%)	42 (28%)	61 (29	
ABNORMAL SENSATION IN EYE	0 (0%)	1 (7%)	22 (15%)	28 (13%)	17 (18%)	26 (25%)	33 (20%)	45 (21%)	36 (24%)	56 (23	
PHOTOPHOBIA	0 (0%)	3 (20%)	24 (16%)	18 (8%)	19 (20%)	22 (21%)	28 (17%)	35 (17%)	42 (28%)	43 (18	
CONJUNCTIVAL EDEMA	0 (0%)	1 (7%)	30 (20%)	19 (8%)	10 (11%)	20 (19%)	32 (20%)	42 (20%)	36 (24%)	41 (1	
VISUAL ACUITY REDUCED	0 (0%)	2 (13%)	16 (11%)	27 (12%)	19 (20%)	28 (27%)	29 (18%)	37 (17%)	26 (17%)	32 (1	
VITREOUS FLOATERS	0 (0%)	3 (20%)	17 (11%)	25 (11%)	17 (18%)	23 (22%)	23 (14%)	34 (16%)	30 (20%)	44 (18	
VITREOUS FEMORRHAGE	0 (0%)	1 (7%)	15 (10%)	10 (4%)	17 (18%)	15 (15%)	16 (10%)	21 (10%)	11 (7%)	18 (8	
	0 (0%)	0 (0%)	9 (6%)	5 (2%)	11 (12%)	7 (7%)	11 (7%)	14 (7%)	11 (7%)	17 (1	
PHOTOPSIA	0 (0%)	0 (0%)	8 (5%)	3 (1%)	8 (8%)	12 (12%)	7 (4%)	13 (6%)	7 (5%)	10 (
CATARACT SUBCAPSULAR		1 (7%)	6 (4%)	4 (2%)	7 (7%)	5 (5%)	11 (7%)	7 (3%)	12 (8%)	10 (4	
RETINAL DETACHMENT			5 (3%)	11 (5%)	6 (6%)	6 (6%)	7 (4%)	15 (7%)	5 (3%)	5 ()	
CATARACT NUCLEAR	0 (0%)	1 (7%)	- ,,	7 (3%)	1 (1%)	2 (2%)	5 (3%)	14 (7%)	10 (7%)	9 (
CATARACT CORTICAL	0 (0%)	1 (7%)	9 (6%)		3 (3%)	3 (3%)	4 (2%)	10 (5%)	4 (3%)	7 (
CORNEAL EROSION	0 (0%)	0 (0%)	8 (5%)	- , ,	,	3 (3%)	4 (2%)	10 (5%)	11 (7%)	10 (
CORNEAL DISORDER NOS	0 (0%)	0 (0%)	0 (0%)	3 (1%)	1 (1%)	2 (2%)	4 (2%)	8 (4%)	4 (3%)	10 (
EYE DISCHARGE	0 (0%)	0 (0%)	7 (5%)	6 (3%)	1 (1%)		5 (3%)	5 (2%)	10 (7%)	8 (3	
IRIS ADHESIONS	0 (0%)	2 (13%)	0 (0%)	3 (1%)	3 (3%)	1 (1%)		3 (1%)	5 (3%)	3 (
CONJUNCTIVAL HEMORRHAGE	0 (0%)	0 (0%)	6 (4%)	8 (4%)	3 (3%)	3 (3%)			6 (4%)	11 (
CORNEAL EDEMA	0 (0%)	0 (0%)	0 (0%)	4 (2%)	1 (1%)	3 (3%)	0 (0%)		5 (3%)	4 {	
RUBEOSIS IRIDIS	0 (0%)	1 (7%)	1 (1%)	4 (2%)	6 (6%)	2 (2%)	3 (2%)		- ,	- '	
HYPOPYON	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	4 (2%)	2 (1%)	10 (7%)		
НҮРНЕМА	0 (0%)	0 (0%)	2 (1%)	1 (0%)	1 (1%)	2 (2%)	0 (0%)	5 (2%)	3 (2%)	3 (
MACULAR EDEMA	0 (0%)	0 (0%)	0 (0%)	3 (1%)	1 (1%)	2 (2%)	1 (1%)	2 (1%)	5 (3%)	3 (
UVEITIS NOS	0 (0%)	1 (7%)	0 (0%)	1 (0%)	0 (0%)	1 (1%)	3 (2%)	2 (1%)	2 (1%)	2 (
VITREOUS DETACHMENT	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	1 (1%)	6 (4%)	0 (0%)	2 (1%)	1 (
MACULOPATHY	0 (0%)	0 (0%)	0 (0%)	2 (1%)	1 (1%)	0 (0%)	0 (0%)	3 (1%)	1 (1%)	3 (
KERATITIS NEC	0 (0%)	0 (0%)	0 (0%)	1 (0%)	1 (1%)	2 (2%)	1 (1%)	1 (0%)	2 (1%)	1 (
CATARACT NEC	0 (0%)	0 (0%)	2 (1%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	1 (0%)	3 (2%)	1 (
	0 (0%)	1 (7%)	1 (1%)	2 (1%)	0 (0%)	0 (0%)	1 (1%)	2 (1%)	1 (1%)	0 (
CATARACT NOS AGGRAVATED	•	0 (0%)	0 (0%)	2 (1%)	1 (1%)	0 (0%)	1 (1%)	1 (0%)	1 (1%)	2 (
DRY EYE NEC	0 (0%)		0 (0%)	2 (1%)	0 (0%)	1 (1%)	2 (1%)	1 (0%)	1 (1%)	0 ((
DIPLOPIA	0 (0%)	0 (0%)	0 (08)	2 (±5)	0 (0%)	1 (10/	2 . 20,	= :/		•	

Note: One patient in study VIT-02-08961X (Saline) and three patients in study VIT-03-08961X (two Saline and one 55 IU) had calculated ages resolving to zero due to incorrect birth dates recorded. These values are not included in the age calculation. In addition, patients with a missing DOB were not included in the age calculation.

s:\dat\acs\iss2002\sas\programs\t_ocrae_age 06SEP2002 17:36

Table 20
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Age
Safety Population

	Control										
	WW		Sal	ine	7.5 IU V	itrase	55 IU V:	itrase	75 IU V	itrase	
	< 60	>= 60	< 60	>= 60	< 60	>= 60		>= 60	< 60	>= 60	
System Organ Class / Preferred Term	years	years	years	years	years	years	years	years	years	years	
***************************************		- 									
GLAUCOMA NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	2 (1%)	3 (1%)	
POSTERIOR CAPSULE OPACIFICATION	0 (0%)	0 (0%)	1 (1%)	1 (0%)	0 (0%)	0 (0%)	1 (1%)	1 (0%)	1 (1%)	1 (0%)	
VISION BLURRED	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	3 (1%)	0 (0%)	2 (1%)	
BLINDNESS NEC	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	1 (1%)	0 (0%)	1 (0%)	2 (1%)	0 (0%)	
HYPOTONY OF EYE	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	3 (2%)	1 (0%)	
MYDRIASIS	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	3 (1%)	
PHOTOPHOBIA AGGRAVATED	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)	2 (1%)	1 (0%)	1 (1%)	0 (0%)	
CONJUNCTIVITIS NEC	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (2%)	0 (0%)	0 (0%)	0 (0%)	2 (1%)	
CORNEAL EPITHELIUM DEFECT	0 (0%)	1 (7%)	0 (0%)	0 (0%)	0 (0%)	2 (2%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)	
FOREIGN BODY RETAINED IN EYE	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	2 (2%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)	
INTRAOCULAR PRESSURE INCREASED	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	1 (1%)	1 (1%)	0 (0%)	0 (0%)	1 (0%)	
RETINAL TEAR (EXC DETACHMENT)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (1%)	2 (1%)	0 (0%)	0 (0%)	
RETINOPATHY DIABETIC	0 (0%)	0 (0%)	1 (1%)	1 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	1 (0%)	
VITREOUS DISORDER NOS	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	1 (1%)	1 (0%)	
CORNEAL ABRASION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	1 (0%)	0 (0%)	1 (0%)	
CORTICAL OPACITY	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	1 (0%)	
INTRAOCULAR PRESSURE DECREASED	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	2 (2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
IRIDOCYCLITIS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	1 (1%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	
RETINAL HEMORRHAGE	0 (0%)	0 (0%)	0 (0%)	1 (0%)	1 (1%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	
BLEPHARITIS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (1%)	0 (0%)	0 (0%)	
CHOROIDAL DETACHMENT	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	1 (0%)	
CONJUNCTIVITIS (INFECTIVE) NEC	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	1 (0%)	
EYE DEGENERATIVE DISORDER NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	
MACULAR DEGENERATION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)	
OCULAR HYPERTENSION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	1 (0%)	
PSEUDOPHAKIA	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)	
RETINAL DISORDER NOS	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	
STRABISMUS NEC	0 (0%)	·0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	
VITREOUS OPACITIES	0 (0%)	0 (0%)	0 (0%)	0 '(0%)	0 (0%)	I (1%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	
APHAKIA	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
BLINDNESS NIGHT	0 (0%)	0 (0%)	0 (0%)	O (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%) 0 (0%)	
BLINDNESS TRANSIENT	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)		
BLOODSHOT EYE	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)		
CCONJUNCTIVAL EDEMA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	
CHORIORETINAL ATROPHY	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
CHORIORETINAL DISORDER NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%) 1 (0%)	
COLOUR BLINDNESS NEC	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	_ (,	
CONJUNCTIVITIS VIRAL NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	,	
CORNEAL OPACITY	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%) 1 (1%)	0 (0%) 0 (0%)	
O CYCLITIS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	T (T&)	0 (0%)	

CYCLITIS

0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)

Note: One patient in study VIT-02-08961X (Saline) and three patients in study VIT-03-08961X (two Saline and one 55 IU) had calculated ages resolving to zero due to incorrect birth dates recorded. These values are not included in the age calculation. In addition, patients with a missing DOB were not included in the age calculation.

Table 20
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Age
Safety Population

				Conti	col									
		WW	7			Sali	ne	7.5	J IU	Vitrase	55 IU	Vitrase	75 IU V	
	< 6	0	>= 6	50	< 60	-	>= 60	< 60	3	>= 60	< 60	>= 60	< 60	>= 60
System Organ Class / Preferred Term	year	s	year	s	years	3 	years	years	s 	years	years	years	years	years
ERYTHEMA NEC	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%) 1 (0%)	0 (0%)	0 (0%)
EYE ALLERGY	0 (0%)	o (0%)	o i	0%)	0 (0%)	o (0%)	0 (0%)	0 (0%	1 (0%)	0 (0%)	0 (0%)
EYE INFECTION TOXOPLASMAL	o (0%)	ō (0%)	ō i	0%)	0 (0%)	o (0%)	0 (0%)	0 (0%	0 (0%)	1 (1%)	0 (0%)
EYE INFLAMMATION NOS	0 (0%)	o (0%)	o i	0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%	0 (0%)	1 (1%)	0 (0%)
EYELID DISORDER NOS	o i	0%)	ō (0%)	οì	0%)	0 (0%)	o (0%)	0 (0%)	0 (0%	0 (0%)	0 (0%)	1 (0%)
EYELID EDEMA	0 (0%)	0 (0%)	o (0%)	0 (0%)	o (0%)	0 (0%)	0 (0%	1 (0%)	0 (0%)	0 (0%)
EYELID PTOSIS ·	ŏ (0%)	ō (0%)	ŏ (0%)	0 (0%)	o (0%)	1 (1%)	0 (0%	0 (0%)	0 (0%)	0 (0%)
KERATOCONJUNCTIVITIS	5 0	0%)	ō (0%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)	0 (0%	0 (0%)	0 (0%)	0 (0%)
KERATOPATHY NOS	0 0	0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%	1 (0%)	0 (0%)	0 (0%
LENTICULAR OPACITIES	οi	0%)	o (0%)	o i	0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%) 0 (0%)	0 (0%)	1 (0%)
MEIBOMIAN CYST	0 (0%)	ō (0%)	o (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%) 1 (0%)	0 (0%)	0 (0%)
OCULAR HYPERAEMIA	j 0	0%)	0 (0%)	o i	0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%) 0 (0%)	1 (1%)	0 (0%)
OPEN ANGLE GLAUCOMA NOS	οί	0%)	ō (0%)	o (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%) 0 (0%)	0 (0%)	0 (0%)
OPTIC ATROPHY	ō i	0%)	o (0%)	o i	0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%) 0 (0%)	0 (0%)	0 (0%)
PAINFUL RED EYES	o i	0%)	o (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%) 0 (0%)	0 (0%)	0 (0%)
PINGUECULA	0 (0%)	0 (0%)	ō i	0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%) 0 (0%)	0 (0%)	0 (0%)
POST-OPERATIVE PAIN	0 (0%)	ō (0%)	o (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%) 0 (0%)	0 (0%)	1 (0%)
RETINAL DEPIGMENTATION	οì	0%)	ō (0%)	o (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%) 0 (0%)	0 (0%)	0 (0%)
RETINAL ISCHEMIA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%) 0 (0%)	1 (1%)	0 (0%)
RETINAL MICROANEURYSMS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%) 0 (0%)	Q (0%)	0 (0%
RETINAL SCAR	ō (0%)	o i	0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%) 0 (0%)	1 (1%)	0 (0%)
RETINAL VEIN THROMBOSIS	ō ì	0%)	0 (0%)	o (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%) 0 (0%)	0 (0%)	1 (0%
TOPOGRAPHY CORNEAL ABNORMAL	ō (0%)	0 (0%)	0 (0왕)	0 (0%)	0 (0%)	0 (0%)	0 (0%		0 (0%)	0 (0%
UVEITIS DIABETIC	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%		0 (0%)	0 (0%)
VISUAL DISTURBANCE NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%) 0 (0%)	1 (1%)	0 (0%)
INVESTIGATIONS	0 (0%)	0 (0왕)	8 (5%)	16 (7%)	10 (11%)	11 (11%)	5 (3%		11 (7%)	9 (4%
INTRAOCULAR PRESSURE INCREASED	0 (0%)	0 (0%)	7 (5%)	13 (6%)	7 (7%)	9 (9%)	3 (2%		8 (5%)	8 (3%)
CORNEAL STAINING	0 (0%)	0 (0%)	1 (18)	3 (1%)	3 (3%)	2 (2%)	2 (1%) 4 (2%)	3 (2%)	1 (0%)
SKIN & SUBCUTANEOUS TISSUE DISORDERS	0 (0%)	0 (0%)	4 (3%)	11 (5%)	6 (6%)	3 (3%)	13 (8%		9 (6%)	15 (6%)
EYELID EDEMA	0 (0%)	0 (0%)	1 (1%)	5 (2%)	4 (4%)	2 (2%)	11 (7%	•	6 (4%)	13 (5%
ERYTHEMA NEC	0 (0%)	0 (0왕)	2 (1%)	7 (3%)	3 (3%)	0 (0%)	4 (2%		5 (3%)	7 (3%
CUTIS LAXA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0왕)	1 (1%)	0 (0%		0 (0%)	0 (0%
ECCHYMOSIS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0왕)	0 (0%)	0 (0%	•	0 (0%)	1 (0%
OCULAR HYPEREMIA	0 (0%)	0 (0왕)	1 (1%)	0 (0%)	o (0왕)	0 (0%)	0 (0%		0 (0%)	0 (0%
PERIORBITAL EDEMA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0왕)	0 (0%)	1 (1%) 0 (0%)	0 (0%)	0 (0%
SURGICAL AND MEDICAL PROCEDURES	0 (0왕)	0 (0%)	0 (0%}	1 (0%)	3 (3%)	1 (1%)	5 (3%) 0 (0%)	2 (1%)	2 (1%

Note: One patient in study VIT-02-08961X (Saline) and three patients in study VIT-03-08961X (two Saline and one 55 IU) had calculated ages resolving to zero due to incorrect birth dates recorded. These values are not included in the age calculation. In addition, patients with a missing DOB were not included in the age calculation.

229

Table 20
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Age Safety Population

		Cont	rol							
	W	<u> </u>	Sal	ine	7.5 IU	Vitrase	55 IU V	itrase	75 IU V	itrase
System Organ Class / Preferred Term	< 60 years	>= 60 years	< 60 years	>= 60 years	< 60 years	>= 60 years	< 60 years	>= 60 years	< 60 years	>= 60 years
UNSPECIFIED COMPLICATION OF	o (0%)	0 (0%)	0 (0%)	1 (0%)	1 (1%)	1 (1%)	3 (2%)	0 (0%)	1 (1%)	1 (0%)
PROCEDURE NEC		0 (10)	• (• • • • • • • • • • • • • • • • • •	_ (- ,,		- ,,			
VITRECTOMY	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
EYE IRRITATION	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)
POST-OPERATIVE COMPLICATIONS NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)
POST-OPERATIVE HEMORRHAGE	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)
SCLERAL OPERATION NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)
NERVOUS SYSTEM DISORDERS	0 (0%)	0 (0%)	0 (0%)	1 (0%)	2 (2%)	0 (0%)	0 (0%)	2 (1%)	4 (3%)	2 (1%)
PUPILLARY DISORDER NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	2 (1%)	3 (2%)	0 (0%)
VISUAL FIELD DEFECT NOS	0 (0%)	0 (0%)	0 (0%)	1 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)
HEADACHE NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)
PUPILLARY REFLEX IMPAIRED	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)
INFECTIONS AND INFESTATIONS	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
HYPOPYON	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
INJURY AND POISONING	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
HEAD INJURY	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
VASCULAR DISORDERS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)
PERIPHERAL ISCHEMIA NOS	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)

230

Note: One patient in study VIT-02-08961X (Saline) and three patients in study VIT-03-08961X (two Saline and one 55 IU) had calculated ages resolving to zero due to incorrect birth dates recorded. These values are not included in the age calculation. In addition, patients with a missing DOB were not included in the age calculation.

Table 21
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Race
Safety Population

		Con	trol						
System Organ Class / Preferred Term	Race	<u>ww</u>	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase			
NUMBER OF PATIENTS	CAUCASIAN	7	255	97	250	265			
	HISPANIC	5	65	74	73	70			
	OTHER	6	58	27	54	56			
NUMBER OF PATIENTS WITH AT LEAST ONE ADVERSE EVENT	CAUCASIAN	6 (85.7%)	195 (76.5%)	95 (97.9%)	201 (80.4%)	225 (84.9%)			
	HISPANIC	5 (100%)	59 (90.8%)	73 (98.6%)	72 (98.6%)	70 (100%)			
	OTHER	6 (100%)	44 (75.9%)	25 (92.6%)	50 (92.6%)	54 (96.4%)			
EYE DISORDERS	CAUCASIAN	6 (85.7%)	194 (76.1%)	95 (97.9%)	201 (80.4%)	225 (84.9%)			
	HISPANIC	5 (100%)	59 (90.8%)	73 (98.6%)	72 (98.6%)	70 (100%)			
	OTHER	6 (100%)	44 (75.9%)	24 (88.9%)	49 (90.7%)	54 (96.4%)			
IRITIS	CAUCASIAN	1 (14.3%)	68 (26.7%)	60 (61.9%)	131 (52.4%)	145 (54.7%)			
	HISPANIC	0 (0.0%)	33 (50.8%)	48 (64.9%)	60 (82.2%)	61 (87.1%)			
	OTHER	3 (50.0%)	25 (43.1%)	15 (55.6%)	31 (57.4%)	37 (66.1%)			
OCULAR HYPEREMIA	CAUCASIAN	0 (0.0%)	84 (32.9%)	62 (63.9%)	127 (50.8%)	130 (49.1%)			
	HISPANIC	3 (60.0%)	37 (56.9%)	38 (51.4%)	50 (68.5%)	57 (81.4%)			
	OTHER	1 (16.7%)	19 (32.8%)	13 (48.1%)	25 (46.3%)	28 (50.0%)			
EYE IRRITATION	CAUCASIAN	4 (57.1%)	71 (27.8%)	46 (47.4%)	70 (28.0%)	89 (33.6%)			
	HISPANIC	4 (80.0%)	24 (36.9%)	32 (43.2%)	44 (60.3%)	28 (40.0%)			
	OTHER	2 (33.3%)	16 (27.6%)	12 (44.4%)	18 (33.3%)	22 (39.3%)			
EYE PAIN	CAUCASIAN	0 (0.0%)	49 (19.2%)	34 (35.1%)	72 (28.8%)	97 (36.6%)			
	HISPANIC	0 (0.0%)	21 (32.3%)	30 (40.5%)	45 (61.6%)	36 (51.4%)			
	OTHER	2 (33.3%)	14 (24.1%)	8 (29.6%)	22 (40.7%)	28 (50.0%)			
LACRIMATION INCREASED	CAUCASIAN	0 (0.0%)	48 (18.8%)	30 (30.9%)	72 (28.8%)	82 (30.9%)			
	HISPANIC	3 (60.0%)	26 (40.0%)	27 (36.5%)	31 (42.5%)	32 (45.7%)			
	OTHER	1 (16.7%)	13 (22.4%)	8 (29.6%)	21 (38.9%)	25 (44.6%)			
VISUAL ACUITY REDUCED	CAUCASIAN	1 (14.3%)	50 (19.6%)	44 (45.4%)	62 (24.8%)	63 (23.8%)			
	HISPANIC	2 (40.0%)	11 (16.9%)	26 (35.1%)	25 (34.2%)	20 (28.6%)			
	OTHER	1 (16.7%)	13 (22.4%)	7 (25.9%)	14 (25.9%)	15 (26.8%)			
ABNORMAL SENSATION IN EYE	CAUCASIAN	1 (14.3%)	40 (15.7%)	31 (32.0%)	59 (23.6%)	69 (26.0%)			
	HISPANIC	1 (20.0%)	16 (24.6%)	23 (31.1%)	28 (38.4%)	24 (34.3%)			
	OTHER	0 (0.0%)	12 (20.7%)	8 (29.6%)	14 (25.9%)	21 (37.5%)			
VITREOUS FLOATERS	CAUCASIAN	3 (42.9%)	46 (18.0%)	36 (37.1%)	54 (21.6%)	66 (24.9%)			
O TIMBOOD TESTIFICATION	HISPANIC	1 (20.0%)	8 (12.3%)	16 (21.6%)	24 (32.9%)	18 (25.7%)			
ين	OTHER	2 (33.3%)	13 (22.4%)	11 (40.7%)	10 (18.5%)	16 (28.6%)			

s:\dat\acs\iss2002\sas\programs\t_ocae_race 06SEP2002 17:36

Table 21
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Race Safety Population

		Cont	rol				
System Organ Class / Preferred Term	Race	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase	
W77777000 W70077000	a.v.a.a.v.v	2 (24 25)	45 (33 68)	70 (40 75)	CA (25 C%)	59 (22.3%)	
VITREOUS HEMORRHAGE	CAUCASIAN HISPANIC	1 (14.3%) 0 (0.0%)	45 (17.6%) 11 (16.9%)	39 (40.2%) 18 (24.3%)	64 (25.6%) 18 (24.7%)	14 (20.0%)	
	OTHER	1 (16.7%)	10 (17.2%)	13 (48.1%)	9 (16.7%)	17 (30.4%)	
PHOTOPHOBIA	CAUCASIAN	3 (42.9%)	37 (14.5%)	31 (32.0%)	48 (19.2%)	64 (24.2%)	
	HISPANIC	0 (0.0%)	9 (13.8%)	20 (27.0%)	23 (31.5%)	19 (27.1%)	
	OTHER	3 (50.0%)	14 (24.1%)	8 (29.6%)	15 (27.8%)	19 (33.9%)	
CONJUNCTIVAL EDEMA	CAUCASIAN	0 (0.0%)	40 (15.7%)	29 (29.9%)	56 (22.4%)	54 (20.4%)	
	HISPANIC	1 (20.0%)	13 (20.0%)	16 (21.6%)	29 (39.7%)	25 (35.7%)	
	OTHER	0 (0.0%)	6 (10.3%)	3 (11.1%)	11 (20.4%)	10 (17.9%)	
CATARACT NUCLEAR	CAUCASIAN	1 (14.3%)	21 (8.2%)	13 (13.4%)	21 (8.4%)	17 (6.4%)	
	HISPANIC	3 (60.0%)	7 (10.8%)	11 (14.9%)	11 (15.1%)	5 (7.1%)	
	OTHER	1 (16.7%)	6 (10.3%)	3 (11.1%)	5 (9.3%)	7 (12.5%)	
RETINAL DETACHMENT	CAUCASIAN	0 (0.0%)	16 (6.3%)	16 (16.5%)	20 (8.0%)	27 (10.2%)	
	HISPANIC	1 (20.0%)	4 (6.2%)	5 (6.8%)	8 (11.0%)	6 (8.6%)	
	OTHER	2 (33.3%)	6 (10.3%)	1 (3.7%)	7 (13.0%)	12 (21.4%)	
CATARACT SUBCAPSULAR	CAUCASIAN	0 (0.0%)	15 (5.9%)	20 (20.6%)	19 (7.6%)	23 (8.7%)	
	HISPANIC	1 (20.0%)	9 (13.8%)	11 (14.9%)	5 (6.8%)	9 (12.9%)	
	OTHER	1 (16.7%)	2 (3.4%)	2 (7.4%)	5 (9.3%)	6 (10.7%)	
PHOTOPSIA	CAUCASIAN	0 (0.0%)	12 (4.7%)	10 (10.3%)	22 (8.8%)	23 (8.7%)	
	HISPANIC	0 (0.0%)	4 (6.2%)	10 (13.5%)	16 (21.9%)	9 (12.9%)	
	OTHER	0 (0.0%)	6 (10.3%)	2 (7.4%)	7 (13.0%)	6 (10.7%)	
CATARACT CORTICAL	CAUCASIAN	1 (14.3%)	20 (7.8%)	9 (9.3%)	21 (8.4%)	23 (8.7%)	
	HISPANIC	2 (40.0%)	3 (4.6%)	3 (4.1%)	8 (11.0%)	6 (8.6%)	
	OTHER	2 (33.3%)	4 (6.9%)	2 (7.4%)	1 (1.9%)	2 (3.6%)	
CORNEAL EROSION	CAUCASIAN	0 (0.0%)	17 (6.7%)	6 (6.2%)	17 (6.8%)	15 (5.7%)	
	HISPANIC	0 (0.0%)	5 (7.7%)	3 (4.1%)	6 (8.2%)	2 (2.9%)	
	OTHER	1 (16.7%)	2 (3.4%)	1 (3.7%)	2 (3.7%)	0 (0.0%)	
CORNEAL EDEMA	CAUCASIAN	0 (0.0%)	7 (2.7%)	7 (7.2%)	10 (4.0%)	14 (5.3%)	
	HISPANIC	0 (0.0%)	4 (6.2%)	9 (12.2%)	8 (11.0%)	6 (8.6%)	
	OTHER	1 (16.7%)	1 (1.7%)	1 (3.7%)	2 (3.7%)	4 (7.1%)	
RUBEOSIS IRIDIS	CAUCASIAN	0 (0.0%)	14 (5.5%)	9 (9.3%)	11 (4.4%)	6 (2.3%)	
ů	HISPANIC	1 (20.0%)	3 (4.6%)	6 (8.1%)	6 (8.2%)	6 (8.6%)	
~ ຕ	OTHER	0 (0.0%)	2 (3.4%)	1 (3.7%)	0 (0.0%)	7 (12.5%)	

s:\dat\acs\iss2002\sas\programs\t_ocae_race 06SEP2002 17:36

Table 21
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Race Safety Population

		Cont				
System Organ Class / Preferred Term	Race	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
EYE DISCHARGE	CAUCASIAN	0 (0.0%)	9 (3.5%)	4 (4.1%)	13 (5.2%)	10 (3.8%)
Did Dictinical	HISPANIC	0 (0.0%)	8 (12.3%)	6 (8.1%)	9 (12.3%)	7 (10.0%)
	OTHER	0 (0.0%)	1 (1.7%)	0 (0.0%)	1 (1.9%)	3 (5.4%)
CONJUNCTIVAL HEMORRHAGE	CAUCASIAN	0 (0.0%)	16 (6.3%)	4 (4.1%)	6 (2.4%)	9 (3.4%)
	HISPANIC	0 (0.0%)	6 (9.2%)	7 (9.5%)	8 (11.0%)	7 (10.0%)
	OTHER	0 (0.0%)	3 (5.2%)	0 (0.0%)	0 (0.0%)	2 (3.6%)
IRIS ADHESIONS	CAUCASIAN \	0 (0.0%)	7 (2.7%)	4 (4.1%)	9 (3.6%)	14 (5.3%)
	HISPANIC	0 (0.0%)	3 (4.6%)	5 (6.8%)	3 (4.1%)	7 (10.0%)
	OTHER	2 (33.3%)	3 (5.2%)	0 (0.0%)	1 (1.9%)	6 (10.7%)
MACULAR EDEMA	CAUCASIAN	0 (0.0%)	6 (2.4%)	11 (11.3%)	8 (3.2%)	10 (3.8%)
	HISPANIC	1 (20.0%)	5 (7.7%)	5 (6.8%)	3 (4.1%)	7 (10.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (3.6%)
CORNEAL DISORDER NOS	CAUCASIAN	0 (0.0%)	6 (2.4%)	2 (2.1%)	14 (5.6%)	15 (5.7%)
	HISPANIC	0 (0.0%)	1 (1.5%)	2 (2.7%)	3 (4.1%)	5 (7.1%)
	OTHER	0 (0.0%)	1 (1.7%)	2 (7.4%)	0 (0.0%)	5 (8.9%)
НҰРНЕМА	CAUCASIAN	0 (0.0%)	3 (1.2%)	6 (6.2%)	6 (2.4%)	8 (3.0%)
	HISPANIC	0 (0.0%)	2 (3.1%)	1 (1.4%)	5 (6.8%)	3 (4.3%)
	OTHER	0 (0.0%)	1 (1.7%)	1 (3.7%)	1 (1.9%)	4 (7.1%)
CATARACT NEC	CAUCASIAN	0 (0.0%)	8 (3.1%)	0 (0.0%)	4 (1.6%)	6 (2.3%)
	HISPANIC	0 (0.0%)	1 (1.5%)	1 (1.4%)	2 (2.7%)	1 (1.4%)
	OTHER	0 (0.0%)	1 (1.7%)	0 (0.0%)	4 (7.4%)	2 (3.6%)
BLINDNESS NEC	CAUCASIAN	0 (0.0%)	2 (0.8%)	3 (3.1%)	3 (1.2%)	5 (1.9%)
	HISPANIC	0 (0.0%)	2 (3.1%)	5 (6.8%)	2 (2.7%)	0 (0.0%)
	OTHER	1 (16.7%)	0 (0.0%)	1 (3.7%)	1 (1.9%)	4 (7.1%)
HYPOPYON	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.8%)	10 (3.8%)
	HISPANIC	0 (0.0%)	0 (0.0%)	1 (1.4%)	3 (4.1%)	9 (12.9%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	2 (3.6%)
DRY EYE NEC	CAUCASIAN	0 (0.0%)	3 (1.2%)	2 (2.1%)	4 (1.6%)	6 (2.3%)
	HISPANIC	0 (0.0%)	3 (4.6%)	3 (4.1%)	1 (1.4%)	3 (4.3%)
	OTHER	0 (0.0%)	0 (0.0%)	2 (7.4%)	0 (0.0%)	0 (0.0%)
GLAUCOMA NOS	CAUCASIAN	0 (0.0%)	1 (0.4%)	4 (4.1%)	0 (0.0%)	9 (3.4%)
<i>∾</i>	HISPANIC	0 (0.0%)	3 (4.6%)	1 (1.4%)	1 (1.4%)	1 (1.4%)
ω	OTHER	0 (0.0%)	1 (1.7%)	0 (0.0%)	2 (3.7%)	2 (3.6%)

s:\dat\acs\iss2002\sas\programs\t_ocae_race 06SEP2002 17:36

Table 21
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Race
Safety Population

		Cont	rol			oo 75 III Wirkago				
System Organ Class / Preferred Term	Race	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase				
VISION BLURRED	CAUCASIAN	0 (0.0%)	3 (1.2%)	4 (4.1%)	4 (1.6%)	3 (1.1%)				
	HISPANIC	0 (0.0%)	2 (3.1%)	5 (6.8%)	0 (0.0%)	1 (1.4%)				
	OTHER	0 (0.0%)	0 (0.0%)	1 (3.7%)	1 (1.9%)	0 (0.0%)				
CATARACT NOS AGGRAVATED	CAUCASIAN	0 (0.0%)	6 (2.4%)	3 (3.1%)	4 (1.6%)	1 (0.4%)				
	HISPANIC	0 (0.0%)	1 (1.5%)	0 (0.0%)	1 (1.4%)	2 (2.9%)				
	OTHER	1 (16.7%)	1 (1.7%)	1 (3.7%)	0 (0.0%)	0 (0.0%)				
KERATITIS NEC	CAUCASIAN	0 (0.0%)	3 (1.2%)	1 (1.0%)	2 (0.8%)	8 (3.0%)				
1001111110 1100	HISPANIC	0 (0.0%)	0 (0.0%)	3 (4.1%)	2 (2.7%)	0 (0.0%)				
	OTHER	0 (0.0%)	1 (1.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)				
VITREOUS DETACHMENT	CAUCASIAN	0 (0.0%)	1 (0.4%)	2 (2.1%)	4 (1.6%)	2 (0.8%)				
VIIIDOOD DELIICIMEENI	HISPANIC	1 (20.0%)	1 (1.5%)	0 (0.0%)	5 (6.8%)	1 (1.4%)				
	OTHER	0 (0.0%)	0 (0.0%)	1 (3.7%)	0 (0.0%)	2 (3.6%)				
MACULOPATHY	CAUCASIAN	0 (0.0%)	2 (0.8%)	2 (2.1%)	3 (1.2%)	4 (1.5%)				
144444444	HISPANIC	0 (0.0%)	2 (3.1%)	2 (2.7%)	1 (1.4%)	0 (0.0%)				
	OTHER	0 (0.0%)	1 (1.7%)	0 (0.0%)	1 (1.9%)	1 (1.8%)				
INTRAOCULAR PRESSURE INCREASED	CAUCASIAN	0 (0.0%)	3 (1.2%)	5 (5.2%)	1 (0.4%)	5 (1.9%)				
INTROCOLAR TRADOONS INCREMEDS	HISPANIC	0 (0.0%)	0 (0.0%)	1 (1.4%)	2 (2.7%)	1 (1.4%)				
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)				
UVEITIS NOS	CAUCASIAN	0 (0.0%)	2 (0.8%)	2 (2.1%)	5 (2.0%)	4 (1.5%)				
0.01110 1.00	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)				
	OTHER	1 (16.7%)	0 (0.0%)	0 (0.0%)	2 (3.7%)	0 (0.0%)				
POST-OPERATIVE PAIN	CAUCASIAN	0 (0.0%)	6 (2.4%)	0 (0.0%)	2 (0.8%)	3 (1.1%)				
LODI OLDINATIVO CLIEN	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.9%)				
	OTHER	1 (16.7%)	1 (1.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)				
POSTERIOR CAPSULE OPACIFICATION	CAUCASIAN	0 (0.0%)	2 (0.8%)	1 (1.0%)	5 (2.0%)	4 (1.5%)				
TODIARION CALDODD GLACIFICATION	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)				
	OTHER	0 (0.0%)	1 (1.7%)	0 (0.0%)	0 (0.0%)	1 (1.8%)				
RETINOPATHY DIABETIC	CAUCASIAN	0 (0.0%)	3 (1.2%)	1 (1.0%)	2 (0.8%)	3 (1.1%)				
	HISPANIC	0 (0.0%)	1 (1.5%)	0 (0.0%)	1 (1.4%)	0 (0.0%)				
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (5.4%)				
blepharitis	CAUCASIAN	0 (0.0%)	1 (0.4%)	2 (2.1%)	2 (0.8%)	3 (1.1%)				
•	HISPANIC	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	1 (1.4%)				
ມ ຣ	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	1 (1.8%)				

s:\dat\acs\iss2002\sas\programs\t_ocae_race 06SEP2002 17:36

Table 21
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Race
Safety Population

		Cont				_
stem Organ Class / Preferred Term	Race	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitra
HYPOTONY OF EYE	CAUCASIAN	0 (0.0%)	2 (0.8%)	2 (2.1%)	1 (0.4%)	3 (1.1%
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.9%
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	1 (1.8%
RETINAL HEMORRHAGE	CAUCASIAN	0 (0.0%)	2 (0.8%)	1 (1.0%)	3 (1.2%)	0 (0.0%
	HISPANIC	0 (0.0%)	2 (3.1%)	1 (1.4%)	2 (2.7%)	0 (0.0%
	OTHER	0 (0.0%)	1 (1.7%)	0 (0.0%)	0 (0.0%)	0 (0.09
CORNEAL EPITHELIUM DEFECT	CAUCASIAN	0 (0.0%)	0 (0.0%)	1 (1.0%)	2 (0.8%)	1 (0.4%
	HISPANIC	0 (0.0%)	1 (1.5%)	1 (1.4%)	1 (1.4%)	0 (0.0%
	OTHER	1 (16.7%)	0 (0.0%)	1 (3.7%)	1 (1.9%)	1 (1.8%
DIPLOPIA	CAUCASIAN	0 (0.0%)	2 (0.8%)	1 (1.0%)	1 (0.4%)	1 (0.4%
	HISPANIC	0 (0.0%)	0 (0.0%)	1 (1.4%)	2 (2.7%)	0 (0.0%
	OTHER	0 (0.0%)	0 (0.0%)	1 (3.7%)	1 (1.9%)	1 (1.8%
RETINAL ISCHEMIA	CAUCASIAN	0 (0.0%)	0 (0.0%)	2 (2.1%)	0 (0.0%)	1 (0.4
	HISPANIC	0 (0.0%)	1 (1.5%)	1 (1.4%)	3 (4.1%)	1 (1.4
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	0 (0.0
NJUNCTIVITIS NEC	CAUCASIAN	0 (0.0%)	1 (0.4%)	1 (1.0%)	1 (0.4%)	1 (0.4
	HISPANIC	0 (0.0%)	0 (0.0%)	2 (2.7%)	0 (0.0%)	1 (1.4
	OTHER	0 (0.0%)	1 (1.7%)	0 (0.0%)	0 (0.0%)	0 (0.0
CORNEAL ABRASION	CAUCASIAN	0 (0.0%)	1 (0.4%)	1 (1.0%)	3 (1.2%)	2 (0.8
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
	OTHER	0 (0.0%)	0 (0.0%)	1 (3.7%)	0 (0.0%)	0 (0.0
MYDRIASIS	CAUCASIAN	0 (0.0%)	2 (0.8%)	0 (0.0%)	0 (0.0%)	4 (1.5
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
	OTHER	0 (0.0%)	1 (1.7%)	1 (3.7%)	0 (0.0%)	0 (0.0
RETINAL TEAR (EXC DETACHMENT)	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (1.6%)	2 (0.8
	HISPANIC	0 (0.0%)	1 (1.5%)	0 (0.0%)	1 (1.4%)	0 (0.0
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
FOREIGN BODY RETAINED IN EYE	CAUCASIAN	0 (0.0%)	1 (0.4%)	- \/	0 (0.0%)	0 (0.0
	HISPANIC	0 (0.0%)	0 (0.0%)	1 (1.4%)	1 (1.4%)	0 (0.0
	OTHER	0 (0.0%)	0 (0.0%)	2 (7.4%)	1 (1.9%)	0 (0.0
EYE DEGENERATIVE DISORDER NOS	CAUCASIAN	0 (0.0%)	0 (0.0%)	1 (1.0%)	0 (0.0%)	1 (0.4
	HISPANIC	0 (0.0%)	0 (0.0%)	2 (2.7%)	1 (1.4%)	0 (0.0
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	0 (0.0

s:\dat\acs\iss2002\sas\programs\t_ocae_race 06SEP2002 17:36

Table 21
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Race
Safety Population

		Cont				
System Organ Class / Preferred Term	Race	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
PSEUDOPHAKIA	CAUCASIAN	0 (0.0%)	3 (1.2%)	0 (0.0%)	2 (0.8%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYELID PTOSIS	CAUCASIAN	0 (0.0%)	1 (0.4%)	1 (1.0%)	0 (0.0%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	1 (3.7%)	0 (0.0%)	1 (1.8%)
INTRAOCULAR PRESSURE DECREASED	CAUCASIAN	0 (0.0%)	2 (0.8%)	2 (2.1%)	0 (0.0%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	1 (1.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
OPTIC ATROPHY	CAUCASIAN	0 (0.0%)	1 (0.4%)	0 (0.0%)	1 (0.4%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	1 (1.4%)	2 (2.7%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PHOTOPHOBIA AGGRAVATED	CAUCASIAN	0 (0.0%)	1 (0.4%)	0 (0.0%)	2 (0.8%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	0 (0.0%)
VITREOUS DISORDER NOS	CAUCASIAN	0 (0.0%)	1 (0.4%)	1 (1.0%)	0 (0.0%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)
	OTHER	0 (0.0%)	1 (1.7%)	0 (0.0%)	0 (0.0%)	1 (1.8%)
APHAKIA	CAUCASIAN	0 (0.0%)	1 (0.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	1 (1.7%)	0 (0.0%)	0 (0.0%)	1 (1.8%)
EYE ALLERGY	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (1.2%)	1 (0.4%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
KERATOCONJUNCTIVITIS	CAUCASIAN	0 (0.0%)	1 (0.4%)	1 (1.0%)	1 (0.4%)	1 (0.4%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
OCULAR HYPERTENSION	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	HISPANIC	0 (0.0%)	1 (1.5%)	0 (0.0%)	1 (1.4%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	0 (0.0%)
PAINFUL RED EYES	CAUCASIAN	0 (0.0%)	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
57	V 11111	- (/	5 (5.56)	- (/	- ,,	- '

Table 21
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Race
Safety Population

		Cont	rol			
System Organ Class / Preferred Term	Race	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
GYENOGY G	CAUCASIAN	0 (0.0%)	1 (0.4%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
CHEMOSIS	HISPANIC	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CORTICAL OPACITY	CAUCASIAN	0 (0.0%)	0 (0.0%)	1 (1.0%)	1 (0.4%)	1 (0.4%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
IRIDOCYCLITIS	CAUCASIAN	0 (0.0%)	0 (0.0%)	1 (1.0%)	0 (0.0%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	1 (1.4%)	1 (1.4%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
LENTICULAR OPACITIES	CAUCASIAN	0 (0.0%)	1 (0.4%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	1 (1.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
MACULAR DEGENERATION	CAUCASIAN	0 (0.0%)	0 (0.0%)	2 (2.1%)	1 (0.4%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
OPEN ANGLE GLAUCOMA NOS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)
	OTHER	0 (0.0%)	0 (0.0%)	1 (3.7%)	0 (0.0%)	0 (0.0%)
RETINAL DISORDER NOS	CAUCASIAN	0 (0.0%)	1 (0.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.8%)
RETINAL MICROANEURYSMS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	HISPANIC	0 (0.0%)	1 (1.5%)	1 (1.4%)	1 (1.4%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
RETINAL SCAR	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.8%)	1 (0.4%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
BLINDNESS TRANSIENT	CAUCASIAN	0 (0.0%)	0 (0.0%)	1 (1.0%)	1 (0.4%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CHOROIDAL DETACHMENT	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
<i>)</i>	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

s:\dat\acs\iss2002\sas\programs\t_ocae_race 06SEP2002 17:36

Table 21
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Race
Safety Population

stem Organ Class / Preferred Term		Control				
	Race	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
CONJUNCTIVITIS (INFECTIVE) NEC	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CONJUNCTIVITIS ALLERGIC	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	HISPANIC	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CONJUNCTIVITIS VIRAL NOS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	1 (16.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CORNEAL OPACITY	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	0 (0.0%)
KERATOPATHY BAND	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	HISPANIC	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
KERATOPATHY NOS	CAUCASIAN	0 (0.0%)	0 (0.0%)	1 (1.0%)	1 (0.4%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
MEIBOMIAN CYST	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PERIORBITAL HEMATOMA	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
RETINAL ARTERY EMBOLISM	CAUCASIAN	0 (0.0%)	0 (0.0%)	1 (1.0%)	0 (0.0%)	1 (0.4%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
RETINAL DEPIGMENTATION	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
STRABISMUS NEC	CAUCASIAN	0 (0.0%)	0 (0.0%)	1 (1.0%)	0 (0.0%)	1 (0.4%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

s:\dat\acs\iss2002\sas\programs\t_ocae_race 06SEP2002 17:36

Table 21
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Race
Safety Population

	Control			_		
stem Organ Class / Preferred Term	Race	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
VISUAL ACUITY REDUCED TRANSIENTLY	CAUCASIAN	0 (0.0%)	1 (0.4%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
VITREOUS OPACITIES	CAUCASIAN	0 (0.0%)	0 (0.0%)	1 (1.0%)	0 (0.0%)	1 (0.4%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
ANGLE CLOSURE GLAUCOMA	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
ANISEIKONIA	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
ARCUS SENILIS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
BLEPHAROCONJUNCTIVITIS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
BLINDNESS NIGHT	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
BLOODSHOT EYE	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CCONJUNCTIVAL EDEMA	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.8%)
CHALAZION	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
1	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CHORIORETINAL ATROPHY	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
•	HISPANIC	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

s:\dat\acs\iss2002\sas\programs\t_ocae_race 06SEP2002 17:36

Table 21
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Race
Safety Population

	Control			_		
stem Organ Class / Preferred Term	Race		Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
CHORIORETINAL DISORDER NOS	CAUCASIAN	0 (0.0%)	0 (0.0%)	1 (1.0%)	0 (0.0%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CHOROIDAL HEMORRHAGE	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
COLOUR BLINDNESS NEC	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CORNEAL DEGENERATION	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CORNEAL SCAR	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
ORNEAL ULCER NEC	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CYCLITIS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
ERYTHEMA NEC	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0,0%)	0 (0.0%)
EXOPHTHALMOS ENDOCRINE	CAUCASIAN	0 (0.0%)	1 (0.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYE HEMORRHAGE NEC	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	HISPANIC	0 (0.0%)	1 (1.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYE INFECTION FUNGAL NOS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

s:\dat\acs\iss2002\sas\programs\t_ocae_race 06SEP2002 17:36

Table 21
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Race
Safety Population

	Control					
System Organ Class / Preferred Term	Race	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
EYE INFECTION NOS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	HISPANIC	0 (0.0%)	1 (1.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYE INFECTION STAPHYLOCOCCAL	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYE INFECTION TOXOPLASMAL	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
and inidelion long. Distrib	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYE INFLAMMATION NOS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
EIE INFERMATION NOS	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYELID DISORDER NOS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYELID EDEMA	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
HERPES SIMPLEX OPHTHALMIC	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
MANUEL CHILINITY	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
IRIS NEVUS	CAUCASIAN	0 (0.0%)	1 (0.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
INIS NEVUS	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	V111211				•	, , , , , , ,
LACRIMAL DUCT OBSTRUCTION NOS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
OCULAR HYPERAEMIA	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
OPTIC DISC HEMORRHAGE	CAUCASIAN	0 (0.0%)	0 (0.0%)	1 (1.0%)	0 (0.0%)	0 (0.0%)
\$	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
handa	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Table 21
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Race
Safety Population

	Control						
System Organ Class / Preferred Term	Race	<u>ww</u>	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase	
ODDIC NODE THAT WO	CAUCASIAN	0 (0.0%)	1 (0.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
OPTIC NERVE INJURY NOS	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
PAPILLEDEMA	CAUCASIAN	0 (0.0%)	0 (0.0%)	1 (1.0%)	0 (0.0%)	0 (0.0%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
PINGUECULA	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	1 (3.7%)	0 (0.0%)	0 (0.0%)	
POST-OPERATIVE COMPLICATIONS NOS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
RETINAL DEGENERATION	CAUCASIAN	0 (0.0%)	0 (0.0%)	1 (1.0%)	0 (0.0%)	0 (0.0%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
RETINAL EXUDATES	CAUCASIAN	0 (0.0%)	1 (0.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
RETINAL VASCULITIS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
RETINAL VEIN THROMBOSIS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.8%)	
SCLERITIS NOS	CAUCASIAN	0 (0.0%)	0 (0.0%)	1 (1.0%)	0 (0.0%)	0 (0.0%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
TOPOGRAPHY CORNEAL ABNORMAL	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	0 (0.0%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%) 0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	U (U.U%)	
No uveitis diabetic	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
444	HISPANIC	0 (0.0%)	0 (0.0%)	1 (1.4%) 0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%)	
N2	OTHER	0 (0.0%)	0 (0.0%)	0 (0.08)	0 (0.08)	0 (0.0%)	

s:\dat\acs\iss2002\sas\programs\t_ocae_race 06SEP2002 17:36

Table 21
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Race Safety Population

	Control						
System Organ Class / Preferred Term	Race	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase	
VISION ABNORMAL NEC	CAUCASIAN	0 (0.0%)	0 (0.0%)	1 (1.0%)	0 (0.0%)	0 (0.0%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
VISUAL DISTURBANCE NOS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.8%)	
INVESTIGATIONS	CAUCASIAN	1 (14.3%)	25 (9.8%)	31 (32.0%)	32 (12.8%)	29 (10.9%)	
···	HISPANIC	0 (0.0%)	10 (15.4%)	13 (17.6%)	8 (11.0%)	7 (10.0%)	
	OTHER	2 (33.3%)	9 (15.5%)	4 (14.8%)	10 (18.5%)	10 (17.9%)	
INTRAOCULAR PRESSURE INCREASED	CAUCASIAN	1 (14.3%)	22 (8.6%)	26 (26.8%)	24 (9.6%)	24 (9.1%)	
	HISPANIC	0 (0.0%)	8 (12.3%)	10 (13.5%)	8 (11.0%)	6 (8.6%)	
	OTHER	2 (33.3%)	9 (15.5%)	4 (14.8%)	10 (18.5%)	10 (17.9%)	
CORNEAL STAINING	CAUCASIAN	0 (0.0%)	4 (1.6%)	4 (4.1%)	8 (3.2%)	5 (1.9%)	
	HISPANIC	0 (0.0%)	2 (3.1%)	4 (5.4%)	1 (1.4%)	1 (1.4%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (3.6%)	
INTRAOCULAR PRESSURE ABNORMAL	CAUCASIAN	0 (0.0%)	0 (0.0%)	1 (1.0%)	0 (0.0%)	0 (0.0%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	1 (3.7%)	0 (0.0%)	0 (0.0%)	
SKIN & SUBCUTANEOUS TISSUE DISORDERS	CAUCASIAN	0 (0.0%)	15 (5.9%)	12 (12.4%)	20 (8.0%)	20 (7.5%)	
	HISPANIC	0 (0.0%)	8 (12.3%)	7 (9.5%)	11 (15.1%)	13 (18.6%)	
	OTHER	0 (0.0%)	3 (5.2%)	0 (0.0%)	8 (14.8%)	5 (8.9%)	
EYELID EDEMA	CAUCASIAN	0 (0.0%)	7 (2.7%)	6 (6.2%)	14 (5.6%)	14 (5.3%)	
	HISPANIC	0 (0.0%)	5 (7.7%)	6 (8.1%)	9 (12.3%)	9 (12.9%)	
	OTHER	0 (0.0%)	3 (5.2%)	0 (0.0%)	6 (11.1%)	2 (3.6%)	
ERYTHEMA NEC	CAUCASIAN	0 (0.0%)	11 (4.3%)	4 (4.1%)	13 (5.2%)	13 (4.9%)	
	HISPANIC	0 (0.0%)	4 (6.2%)	4 (5.4%)	5 (6.8%)	4 (5.7%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (5.6%)	3 (5.4%)	
OCULAR HYPEREMIA	CAUCASIAN	0 (0.0%)	2 (0.8%)	1 (1.0%)	0 (0.0%)	1 (0.4%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
CUTIS LAXA	CAUCASIAN	0 (0.0%)	0 (0.0%)	2 (2.1%)	0 (0.0%)	0 (0.0%)	
N	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
4	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	

s:\dat\acs\iss2002\sas\programs\t_ocae_race 06SEP2002 17:36

Table 21
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Race
Safety Population

	Control					
System Organ Class / Preferred Term	Race	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
DEDITORITMAL EDEMA	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PERIORBITAL EDEMA	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	0 (0.0%)
DERMATITIS NOS	CAUCASIAN	0 (0.0%)	0 (0,0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
DERMITTE NOS	HISPANIC	0 (0.0%)	0 (0,0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
ECCHYMOSIS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.8%)
PRURITUS NOS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
SURGICAL AND MEDICAL PROCEDURES	CAUCASIAN	0 (0.0%)	9 (3.5%)	4 (4.1%)	8 (3.2%)	6 (2.3%)
	HISPANIC	0 (0.0%)	5 (7.7%)	2 (2.7%)	2 (2.7%)	1 (1.4%)
	OTHER	1 (16.7%)	0 (0.0%)	1 (3.7%)	3 (5.6%)	1 (1.8%)
POST-OPERATIVE COMPLICATIONS NOS	CAUCASIAN	0 (0.0%)	7 (2.7%)	3 (3.1%)	3 (1.2%)	3 (1.1%)
	HISPANIC	0 (0.0%)	1 (1.5%)	0 (0.0%)	1 (1.4%)	1 (1.4%)
	OTHER	1 (16.7%)	0 (0.0%)	1 (3.7%)	1 (1.9%)	0 (0.0%)
UNSPECIFIED COMPLICATION OF PROCEDURE NEC	CAUCASIAN	0 (0.0%)	2 (0.8%)	2 (2.1%)	3 (1.2%)	1 (0.4%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	1 (1.8%)
VITRECTOMY	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	HISPANIC	0 (0.0%)	4 (6.2%)	2 (2.7%)	1 (1.4%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYE IRRITATION	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
LENS IMPLANT	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
O POST-OPERATIVE HEMORRHAGE	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
4	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	0 (0.0%)

s:\dat\acs\iss2002\sas\programs\t_ocae_race 06SEP2002 17:36

Table 21
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Race
Safety Population

	Control						
System Organ Class / Preferred Term	Race	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase	
SCLERAL OPERATION NOS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
SUTURE LINE PAIN	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	0 (0.0%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
NERVOUS SYSTEM DISORDERS	CAUCASIAN	0 (0.0%)	0 (0.0%)	2 (2.1%)	2 (0.8%)	3 (1.1%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	1 (1.4%)	1 (1.4%)	2 (2.9%)	
	OTHER	0 (0.0%)	1 (1.7%)	2 (7.4%)	1 (1.9%)	2 (3.6%)	
PUPILLARY DISORDER NOS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.8%)	1 (0.4%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	1 (1.4%)	1 (1.4%)	1 (1.4%)	
	OTHER	0 (0.0%)	0 (0.0%)	2 (7.4%)	1 (1.9%)	1 (1.8%)	
VISUAL FIELD DEFECT NOS	CAUCASIAN	0 (0.0%)	0 (0.0%)	1 (1.0%)	0 (0.0%)	1 (0.4%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	1 (1.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
FACIAL PALSY	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
HEADACHE NOS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.8%)	
PUPILLARY REFLEX IMPAIRED	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
VITH NERVE PARALYSIS	CAUCASIAN	0 (0.0%)	0 (0.0%)	1 (1.0%)	0 (0.0%)	0 (0.0%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
IMMUNE SYSTEM DISORDERS	CAUCASIAN	0 (0.0%)	0 (0.0%)	2 (2.1%)	1 (0.4%)	0 (0.0%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
HYPERSENSITIVITY NOS	CAUCASIAN	0 (0.0%)	0 (0.0%)	1 (1.0%)	1 (0.4%)	0 (0.0%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	

s:\dat\acs\iss2002\sas\programs\t_ocae_race 06SEP2002 17:36

Table 21
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Race
Safety Population

	Control						
System Organ Class / Preferred Term	Race	<u> </u>	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase	
MULTIPLE ALLERGIES	CAUCASIAN	0 (0.0%)	0 (0.0%)	1 (1.0%)	0 (0.0%)	0 (0.0%)	
(10)11122 122210122	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
INJURY AND POISONING	CAUCASIAN	0 (0.0%)	1 (0.4%)	0 (0.0%)	1 (0.4%)	0 (0.0%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%) ·	0 (0.0%)	0 (0.0%)	
CHEMICAL BURNS OF EYE	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	0 (0.0%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
HEAD INJURY	CAUCASIAN	0 (0.0%)	1 (0.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
NEOPLASMS BENIGN AND MALIGNANT (INCLUDING CYSTS AND POLYPS)	CAUCASIAN	0 (0.0%)	1 (0.4%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
BENIGN NEOPLASM OF CHOROID	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
RADIOACTIVE IODINE THERAPY	CAUCASIAN	0 (0.0%)	1 (0.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
MECHANICAL COMPLICATION OF IMPLANT	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
INFECTIONS AND INFESTATIONS	CAUCASIAN	0 (0.0%)	1 (0.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
у нуроруом	CAUCASIAN	0 (0.0%)	1 (0.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	

s:\dat\acs\iss2002\sas\programs\t_ocae_race 06SEP2002 17:36

Page 17 of 17

Table 21
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Race
Safety Population

System Organ Class / Preferred Term	Race	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
VASCULAR DISORDERS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PERIPHERAL ISCHEMIA NOS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Table 22
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Race Safety Population

	Control						
System Organ Class / Preferred Term	Race	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase	
NUMBER OF PATIENTS	CAUCASIAN	7	255	97	250	265 70	
	HISPANIC	5	65 58	74 27	73 54	70 56	
	OTHER	6	58	21	54	36	
NUMBER OF PATIENTS WITH AT LEAST ONE RELATED ADVERSE EVENT	CAUCASIAN	5 (71.4%)	156 (61.2%)	82 (84.5%)	173 (69.2%)	205 (77.4%)	
	HISPANIC	4 (80.0%)	51 (78.5%)	66 (89.2%)	71 (97.3%)	70 (100%)	
	OTHER	2 (33.3%)	37 (63.8%)	20 (74.1%)	46 (85.2%)	51 (91.1%)	
EYE DISORDERS	CAUCASIAN	5 (71.4%)	155 (60.8%)	82 (84.5%)	173 (69.2%)	205 (77.4%)	
	HISPANIC	4 (80.0%)	51 (78.5%)	66 (89.2%)	71 (97.3%)	70 (100%)	
	OTHER	2 (33.3%)	37 (63.8%)	20 (74.1%)	44 (81.5%)	51 (91.1%)	
IRITIS	CAUCASIAN	0 (0.0%)	58 (22.7%)	47 (48.5%)	116 (46.4%)	135 (50.9%)	
	HISPANIC	0 (0.0%)	27 (41.5%)	41 (55.4%)	57 (78.1%)	61 (87.1%)	
	OTHER	1 (16.7%)	21 (36.2%)	12 (44.4%)	29 (53.7%)	35 (62.5%)	
OCULAR HYPEREMIA	CAUCASIAN	0 (0.0%)	68 (26.7%)	46 (47.4%)	102 (40.8%)	113 (42.6%)	
Occurred the broading of the second of the s	HISPANIC	1 (20.0%)	29 (44.6%)	28 (37.8%)	35 (47.9%)	47 (67.1%)	
	OTHER	0 (0.0%)	16 (27.6%)	11 (40.7%)	21 (38.9%)	23 (41.1%)	
EYE PAIN	CAUCASIAN	0 (0.0%)	35 (13.7%)	21 (21.6%)	60 (24.0%)	77 (29.1%)	
	HISPANIC	0 (0.0%)	11 (16.9%)	21 (28.4%)	35 (47.9%)	28 (40.0%)	
	OTHER	1 (16.7%)	11 (19.0%)	6 (22.2%)	18 (33.3%)	23 (41.1%)	
EYE IRRITATION	CAUCASIAN	4 (57.1%)	51 (20.0%)	30 (30.9%)	56 (22.4%)	67 (25.3%)	
	HISPANIC	1 (20.0%)	15 (23.1%)	24 (32.4%)	29 (39.7%)	20 (28.6%)	
	OTHER	0 (0.0%)	13 (22.4%)	7 (25.9%)	11 (20.4%)	16 (28.6%)	
LACRIMATION INCREASED	CAUCASIAN	0 (0.0%)	31 (12.2%)	23 (23.7%)	55 (22.0%)	61 (23.0%)	
	HISPANIC	1 (20.0%)	17 (26.2%)	15 (20.3%)	23 (31.5%)	24 (34.3%)	
	OTHER	0 (0.0%)	8 (13.8%)	7 (25.9%)	16 (29.6%)	18 (32.1%)	
ABNORMAL SENSATION IN EYE	CAUCASIAN	1 (14.3%)	28 (11.0%)	22 (22.7%)	48 (19.2%)	57 (21.5%)	
	HISPANIC	0 (0.0%)	13 (20.0%)	13 (17.6%)	19 (26.0%)	20 (28.6%)	
	OTHER	0 (0.0%)	9 (15.5%)	8 (29.6%)	11 (20.4%)	15 (26.8%)	
PHOTOPHOBIA	CAUCASIAN	3 (42.9%)	26 (10.2%)	20 (20.6%)	38 (15.2%)	53 (20.0%)	
	HISPANIC	0 (0.0%)	7 (10.8%)	14 (18.9%)	17 (23.3%)	16 (22.9%)	
N.D.	OTHER	0 (0.0%)	9 (15.5%)	7 (25.9%)	8 (14.8%)	16 (28.6%)	
CONJUNCTIVAL EDEMA	CAUCASIAN	0 (0.0%)	34 (13.3%)	17 (17.5%)	44 (17.6%)	46 (17.4%)	
	HISPANIC	1 (20.0%)	11 (16.9%)	10 (13.5%)	21 (28.8%)	22 (31.4%)	
	OTHER	0 (0.0%)	4 (6.9%)	3 (11.1%)	9 (16.7%)	9 (16.1%)	

s:\dat\acs\iss2002\sas\programs\t_ocrae_race 06SEP2002 17:36

Table 22
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Race Safety Population

	Control						
System Organ Class / Preferred Term	Race	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase	

VITREOUS FLOATERS	CAUCASIAN	3 (42.9%)	29 (11.4%)	21 (21.6%)	37 (14.8%)	52 (19.6%)	
	HISPANIC	0 (0.0%)	3 (4.6%)	11 (14.9%)	13 (17.8%)	12 (17.1%)	
	OTHER	0 (0.0%)	10 (17.2%)	8 (29.6%)	8 (14.8%)	10 (17.9%)	
VISUAL ACUITY REDUCED	CAUCASIAN	0 (0.0%)	27 (10.6%)	26 (26.8%)	40 (16.0%)	39 (14.7%)	
VISUAL ACUITE REDUCED	HISPANIC	1 (20.0%)	6 (9.2%)	16 (21.6%)	15 (20.5%)	11 (15.7%)	
	OTHER	1 (16.7%)	10 (17.2%)	5 (18.5%)	11 (20.4%)	8 (14.3%)	
	OTHER	1 (10.70)	10 (17.20)	3 (20.50)	22 (=0120)	• (21100)	
VITREOUS HEMORRHAGE	CAUCASIAN	0 (0.0%)	18 (7.1%)	19 (19.6%)	26 (10.4%)	20 (7.5%)	
	HISPANIC	0 (0.0%)	3 (4.6%)	9 (12.2%)	9 (12.3%)	5 (7.1%)	
	OTHER	1 (16.7%)	4 (6.9%)	4 (14.8%)	2 (3.7%)	4 (7.1%)	
PHOTOPSIA	CAUCASIAN	0 (0.0%)	8 (3.1%)	8 (8.2%)	13 (5.2%)	18 (6.8%)	
11101010111	HISPANIC	0 (0.0%)	4 (6.2%)	8 (10.8%)	8 (11.0%)	6 (8.6%)	
	OTHER	0 (0.0%)	2 (3.4%)	2 (7.4%)	4 (7.4%)	4 (7.1%)	
	annar ann	0 (0 0%)	6 (2.4%)	13 (13.4%)	14 (5.6%)	11 (4.2%)	
CATARACT SUBCAPSULAR	CAUCASIAN	0 (0.0%)	4 (6.2%)	6 (8.1%)	3 (4.1%)	3 (4.3%)	
	HISPANIC	0 (0.0%) 0 (0.0%)	1 (1.7%)	1 (3.7%)	3 (5.6%)	3 (5.4%)	
	OTHER	0 (0.0%)	1 (1.76)	1 (3./%)	3 (3.6%)	3 (3.40)	
RETINAL DETACHMENT	CAUCASIAN	0 (0.0%)	4 (1.6%)	9 (9.3%)	12 (4.8%)	12 (4.5%)	
	HISPANIC	1 (20.0%)	2 (3.1%)	3 (4.1%)	2 (2.7%)	1 (1.4%)	
•	OTHER	0 (0.0%)	4 (6.9%)	0 (0.0%)	4 (7.4%)	9 (16.1%)	
CATARACT NUCLEAR	CAUCASIAN	0 (0.0%)	9 (3.5%)	4 (4.1%)	14 (5.6%)	5 (1.9%)	
CILLIANICI INCUDITA	HISPANIC	1 (20.0%)	2 (3.1%)	7 (9.5%)	6 (8.2%)	3 (4.3%)	
	OTHER	0 (0.0%)	5 (8.6%)	1 (3.7%)	2 (3.7%)	2 (3.6%)	
CATARACT CORTICAL	CAUCASIAN	0 (0.0%)	10 (3.9%)	2 (2.1%)	14 (5.6%)	13 (4.9%)	
CATARACT CORTICAL	HISPANIC	1 (20.0%)	2 (3.1%)	1 (1.4%)	4 (5.5%)	4 (5.7%)	
	OTHER	0 (0.0%)	4 (6.9%)	0 (0.0%)	1 (1.9%)	2 (3.6%)	
	OTHER	0 (0.087	4 (0.50)	0 (0.00)	1 (1,50)	2 (3,00,	
CORNEAL EROSION	CAUCASIAN	0 (0.0%)	11 (4.3%)	4 (4.1%)	11 (4.4%)	10 (3.8%)	
	HISPANIC	0 (0.0%)	3 (4.6%)	1 (1.4%)	2 (2.7%)	1 (1.4%)	
	OTHER	0 (0.0%)	2 (3.4%)	1 (3.7%)	1 (1.9%)	0 (0.0%)	
CORNEAL DISORDER NOS	CAUCASIAN	0 (0.0%)	3 (1.2%)	1 (1.0%)	13 (5.2%)	12 (4.5%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	1 (1.4%)	1 (1.4%)	5 (7.1%)	
	OTHER	0 (0.0%)	0 (0.0%)	2 (7.4%)	0 (0.0%)	4 (7.1%)	
N EYE DISCHARGE	CAUCASIAN	0 (0.0%)	7 (2.7%)	1 (1.0%)	10 (4.0%)	9 (3.4%)	
LIE DIGUMAGE	HISPANIC	0 (0.0%)	5 (7.7%)	2 (2.7%)	2 (2.7%)	2 (2.9%)	
	OTHER	0 (0.0%)	1 (1.7%)	0 (0.0%)	0 (0.0%)	3 (5.4%)	
ω	OIRER	5 (0.0%)	+ (+. / 6/	0 (0.00)	0 (0.00)	3 (3.10)	

s:\dat\acs\iss2002\sas\programs\t_ocrae_race 06SEP2002 17:36

Table 22
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Race Safety Population

	Control			_		
stem Organ Class / Preferred Term	Race	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
IRIS ADHESIONS	CAUCASIAN	0 (0.0%)	1 (0.4%)	1 (1.0%)	8 (3.2%)	11 (4.2%)
	HISPANIC	0 (0.0%)	1 (1.5%)	3 (4.1%)	2 (2.7%)	4 (5.7%)
	OTHER	2 (33.3%)	1 (1.7%)	0 (0.0%)	0 (0.0%)	3 (5.4%)
CONJUNCTIVAL HEMORRHAGE	CAUCASIAN	0 (0.0%)	10 (3.9%)	3 (3.1%)	3 (1.2%)	4 (1.5%)
	HISPANIC	0 (0.0%)	2 (3.1%)	3 (4.1%)	3 (4.1%)	2 (2.9%)
	OTHER	0 (0.0%)	2 (3.4%)	0 (0.0%)	0 (0.0%)	2 (3.6%)
CORNEAL EDEMA	CAUCASIAN	0 (0.0%)	4 (1.6%)	2 (2.1%)	8 (3.2%)	10 (3.8%)
	HISPANIC	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	6 (8.6%)
	OTHER	0 (0.0%)	0 (0.0%)	1 (3.7%)	0 (0.0%)	1 (1.8%)
RUBEOSIS IRIDIS	CAUCASIAN	0 (0.0%)	4 (1.6%)	4 (4.1%)	4 (1.6%)	4 (1.5%)
	HISPANIC	1 (20.0%)	0 (0.0%)	4 (5.4%)	2 (2.7%)	3 (4.3%)
	OTHER	0 (0.0%)	1 (1.7%)	0 (0.0%)	0 (0.0%)	2 (3.6%)
HYPOPYON	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.8%)	10 (3.8%)
	HISPANIC	0 (0.0%)	0 (0.0%)	1 (1.4%)	3 (4.1%)	9 (12.9%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	2 (3.6%)
нурнема	CAUCASIAN	0 (0.0%)	2 (0.8%)	2 (2.1%)	5 (2.0%)	3 (1.1%)
	HISPANIC	0 (0.0%)	1 (1.5%)	1 (1.4%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (5.4%)
MACULAR EDEMA	CAUCASIAN	0 (0.0%)	1 (0.4%)	3 (3.1%)	2 (0.8%)	6 (2.3%)
	HISPANIC	0 (0.0%)	2 (3.1%)	0 (0.0%)	1 (1.4%)	2 (2.9%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
UVEITIS NOS	CAUCASIAN	0 (0.0%)	1 (0.4%)	1 (1.0%)	3 (1.2%)	4 (1.5%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	1 (16.7%)	0 (0.0%)	0 (0.0%)	2 (3.7%)	0 (0.0%)
VITREOUS DETACHMENT	CAUCASIAN	0 (0.0%)	1 (0.4%)	1 (1.0%)	2 (0.8%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (5.5%)	1 (1.4%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (3.6%)
MACULOPATHY	CAUCASIAN	0 (0.0%)	1 (0.4%)	1 (1.0%)	2 (0.8%)	3 (1.1%)
	HISPANIC	0 (0.0%)	1 (1.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	1 (1.8%)
KERATITIS NEC	CAUCASIAN	0 (0.0%)	1 (0.4%)	1 (1.0%)	1 (0.4%)	3 (1.1%)
	HISPANIC	0 (0.0%)	0 (0.0%)	2 (2.7%)	1 (1.4%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

s:\dat\acs\iss2002\sas\programs\t_ocrae_race 06SEP2002 17:36

Table 22
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Race Safety Population

	Control						
System Organ Class / Preferred Term	Race	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase	
CATARACT NEC	CAUCASIAN	0 (0.0%)	1 (0.4%)	0 (0.0%)	2 (0.8%)	2 (0.8%)	
0111.111.01 1110	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	1 (1.7%)	0 (0.0%)	0 (0.0%)	2 (3.6%)	
CATARACT NOS AGGRAVATED	CAUCASIAN	0 (0.0%)	2 (0.8%)	0 (0.0%)	3 (1.2%)	1 (0.4%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	1 (16.7%)	1 (1.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
DRY EYE NEC	CAUCASIAN	0 (0.0%)	1 (0.4%)	0 (0.0%)	1 (0.4%)	2 (0.8%)	
	HISPANIC	0 (0.0%)	1 (1.5%)	1 (1.4%)	1 (1.4%)	1 (1.4%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
DIPLOPIA	CAUCASIAN	0 (0.0%)	2 (0.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	1 (1.4%)	2 (2.7%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	1 (1.8%)	
GLAUCOMA NOS	CAUCASIAN	0 (0.0%)	0 (0.0%)	1 (1.0%)	0 (0.0%)	5 (1.9%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
POSTERIOR CAPSULE OPACIFICATION	CAUCASIAN	0 (0.0%)	1 (0.4%)	0 (0.0%)	2 (0.8%)	2 (0.8%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	1 (1.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
VISION BLURRED	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (1.2%)	2 (0.8%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
BLINDNESS NEC	CAUCASIAN	0 (0.0%)	1 (0.4%)	1 (1.0%)	1 (0.4%)	0 (0.0%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (3.6%)	
HYPOTONY OF EYE	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	2 (0.8%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.8%)	
MYDRIASIS	CAUCASIAN	0 (0.0%)	1 (0.4%)	0 (0.0%)	0 (0.0%)	4 (1.5%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
PHOTOPHOBIA AGGRAVATED	CAUCASIAN	0 (0.0%)	1 (0.4%)	0 (0.0%)	2 (0.8%)	0 (0.0%)	
ن الله الله الله الله الله الله الله الل	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)	
- Company	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	0 (0.0%)	

s:\dat\acs\iss2002\sas\programs\t_ocrae_race 06SEP2002 17:36

Table 22
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Race Safety Population

	Control					
System Organ Class / Preferred Term	Race	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
CONJUNCTIVITIS NEC	CAUCASIAN	0 (0.0%)	0 (0.0%)	1 (1.0%)	0 (0.0%)	1 (0.4%)
CONDUNCTIVITIS NEC	HISPANIC	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	1 (1.4%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CORNEAL EPITHELIUM DEFECT	CAUCASIAN	0 (0.0%)	0 (0.0%)	1 (1.0%)	1 (0.4%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	1 (16.7%)	0 (0.0%)	1 (3.7%)	0 (0.0%)	0 (0.0%)
FOREIGN BODY RETAINED IN EYE	CAUCASIAN	0 (0.0%)	1 (0.4%)	1 (1.0%)	0 (0.0%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	1 (1.4%)	1 (1.4%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
INTRAOCULAR PRESSURE INCREASED	CAUCASIAN	0 (0.0%)	0 (0.0%)	2 (2.1%)	0 (0.0%)	1 (0.4%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
RETINAL TEAR (EXC DETACHMENT)	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (1.2%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
RETINOPATHY DIABETIC	CAUCASIAN	0 (0.0%)	1 (0.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	HISPANIC	0 (0.0%)	1 (1.5%)	0 (0.0%)	1 (1.4%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.8%)
VITREOUS DISORDER NOS	CAUCASIAN	0 (0.0%)	1 (0.4%)	1 (1.0%)	0 (0.0%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.8%)
CORNEAL ABRASION	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	1 (3.7%)	0 (0.0%)	0 (0.0%)
CORTICAL OPACITY	CAUCASIAN	0 (0.0%)	0 (0.0%)	1 (1.0%)	1 (0.4%)	1 (0.4%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
INTRAOCULAR PRESSURE DECREASED	CAUCASIAN	0 (0.0%)	1 (0.4%)	2 (2.1%)	0 (0.0%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
1RIDOCYCLITIS	CAUCASIAN	0 (0.0%)	0 (0.0%)	1 (1.0%)	0 (0.0%)	0 (0.0%)
Y?	HISPANIC	0 (0.0%)	0 (0.0%)	1 (1.4%)	1 (1.4%)	0 (0.0%)
S	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

s:\dat\acs\iss2002\sas\programs\t_ocrae_race 06SEP2002 17:36

Table 22
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Race Safety Population

		Control		_		
stem Organ Class / Preferred Term	Race	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitras
RETINAL HEMORRHAGE	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	HISPANIC	0 (0.0%)	1 (1.5%)	1 (1.4%)	1 (1.4%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
BLEPHARITIS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.8%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CHOROIDAL DETACHMENT	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CONJUNCTIVITIS (INFECTIVE) NEC	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYE DEGENERATIVE DISORDER NOS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	1 (1.4%)	1 (1.4%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
ACULAR DEGENERATION	CAUCASIAN	0 (0.0%)	0 (0.0%)	1 (1.0%)	1 (0.4%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
OCULAR HYPERTENSION	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PSEUDOPHAKIA	CAUCASIAN	0 (0.0%)	1 (0.4%)	0 (0.0%)	1 (0.4%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
RETINAL DISORDER NOS	CAUCASIAN	0 (0.0%)	1 (0.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.8%)
STRABISMUS NEC	CAUCASIAN	0 (0.0%)	0 (0.0%)	1 (1.0%)	0 (0.0%)	1 (0.4%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
VITREOUS OPACITIES	CAUCASIAN	0 (0.0%)	0 (0.0%)	1 (1.0%)	0 (0.0%)	1 (0.4%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Table 22
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Race
Safety Population

	Control						
System Organ Class / Preferred Term	Race		Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase	
APHAKIA	CAUCASIAN	0 (0.0%)	1 (0.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
• • • • • • • • • • • • • • • • • • •	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
BLINDNESS NIGHT	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
BLINDNESS TRANSIENT	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	0 (0.0%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
BLOODSHOT EYE	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
CCONJUNCTIVAL EDEMA	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.8%)	
CHORIORETINAL ATROPHY	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
CHORIORETINAL DISORDER NOS	CAUCASIAN	0 (0.0%)	0 (0.0%)	1 (1.0%)	0 (0.0%)	0 (0.0%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
COLOUR BLINDNESS NEC	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
CONJUNCTIVITIS VIRAL NOS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
CORNEAL OPACITY	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)	
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
♥ CYCLITIS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
בי	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Σ							

s:\dat\acs\iss2002\sas\programs\t_ocrae_race 06SEP2002 17:36

Table 22
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Race
Safety Population

	Control		_			
stem Organ Class / Preferred Term	Race	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
ERYTHEMA NEC	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYE ALLERGY	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYE INFECTION TOXOPLASMAL	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYE INFLAMMATION NOS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYELID DISORDER NOS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYELID EDEMA	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYELID PTOSIS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
KERATOCONJUNCTIVITIS	CAUCASIAN	0 (0.0%)	1 (0.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
KERATOPATHY NOS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
LENTICULAR OPACITIES	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
MEIBOMIAN CYST	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

s:\dat\acs\iss2002\sas\programs\t_ocrae_race 06SEP2002 17:36

Table 22
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Race Safety Population

	Control							
System Organ Class / Preferred Term	Race	<u>ww</u>	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase		
OCULAR HYPERAEMIA	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)		
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
OPEN ANGLE GLAUCOMA NOS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
	OTHER	0 (0.0%)	0 (0.0%)	1 (3.7%)	0 (0.0%)	0 (0.0%)		
OPTIC ATROPHY	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)		
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
PAINFUL RED EYES	CAUCASIAN	0 (0.0%)	1 (0.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
PINGUECULA	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
	OTHER	0 (0.0%)	0 (0.0%)	1 (3.7%)	0 (0.0%)	0 (0.0%)		
POST-OPERATIVE PAIN	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)		
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
RETINAL DEPIGMENTATION	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
	HISPANIC	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)		
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
RETINAL ISCHEMIA	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)		
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
RETINAL MICROANEURYSMS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
	HISPANIC	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)		
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
RETINAL SCAR	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)		
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
RETINAL VEIN THROMBOSIS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
Ĭ	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.8%)		

s:\dat\acs\iss2002\sas\programs\t_ocrae_race 06SEP2002 17:36

Table 22
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Race Safety Population

	Control					
System Organ Class / Preferred Term	Race	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
TOPOGRAPHY CORNEAL ABNORMAL	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	0 (0.0%)
TOTOGRAFIE COMMENT TEMPORES	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
UVEITIS DIABETIC	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
VISUAL DISTURBANCE NOS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.8%)
INVESTIGATIONS	CAUCASIAN	0 (0.0%)	16 (6.3%)	13 (13.4%)	19 (7.6%)	14 (5.3%)
	HISPANIC	0 (0.0%)	3 (4.6%)	6 (8.1%)	3 (4.1%)	3 (4.3%)
	OTHER	0 (0.0%)	5 (8.6%)	2 (7.4%)	2 (3.7%)	3 (5.4%)
INTRAOCULAR PRESSURE INCREASED	CAUCASIAN	0 (0.0%)	13 (5.1%)	11 (11.3%)	13 (5.2%)	12 (4.5%)
	HISPANIC	0 (0.0%)	2 (3.1%)	3 (4.1%)	3 (4.1%)	2 (2.9%)
	OTHER	0 (0.0%)	5 (8.6%)	2 (7.4%)	2 (3.7%)	2 (3.6%)
CORNEAL STAINING	CAUCASIAN	0 (0.0%)	3 (1.2%)	2 (2.1%)	6 (2.4%)	2 (0.8%)
	HISPANIC	0 (0.0%)	1 (1.5%)	3 (4.1%)	0 (0.0%)	1 (1.4%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.8%)
SKIN & SUBCUTANEOUS TISSUE DISORDERS	CAUCASIAN	0 (0.0%)	9 (3.5%)	7 (7.2%)	16 (6.4%)	14 (5.3%)
	HISPANIC	0 (0.0%)	5 (7.7%)	2 (2.7%)	7 (9.6%)	6 (8.6%)
	OTHER	0 (0.0%)	1 (1.7%)	0 (0.0%)	6 (11.1%)	4 (7.1%)
EYELID EDEMA	CAUCASIAN	0 (0.0%)	2 (0.8%)	4 (4.1%)	12 (4.8%)	13 (4.9%)
	HISPANIC	0 (0.0%)	3 (4.6%)	2 (2.7%)	6 (8.2%)	5 (7.1%)
	OTHER	0 (0.0%)	1 (1.7%)	0 (0.0%)	4 (7.4%)	1 (1.8%)
ERYTHEMA NEC	CAUCASIAN	0 (0.0%)	7 (2.7%)	3 (3.1%)	11 (4.4%)	8 (3.0%)
	HISPANIC	0 (0.0%)	2 (3.1%)	0 (0.0%)	1 (1.4%)	2 (2.9%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (3.7%)	2 (3.6%)
CUTIS LAXA	CAUCASIAN	0 (0.0%)	0 (0.0%)	1 (1.0%)	0 (0.0%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
5 ECCHYMOSIS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
л	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
J.	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.8%)

s:\dat\acs\iss2002\sas\programs\t_ocrae_race 06SEP2002 17:36

Table 22
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Race Safety Population

	Control					
ystem Organ Class / Preferred Term	Race		Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
OCULAR HYPEREMIA	CAUCASIAN	0 (0.0%)	1 (0.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
**************************************	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PERIORBITAL EDEMA	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	0 (0.0%)
SURGICAL AND MEDICAL PROCEDURES	CAUCASIAN	0 (0.0%)	1 (0.4%)	2 (2.1%)	3 (1.2%)	3 (1.1%)
	HISPANIC	0 (0.0%)	0 (0.0%)	2 (2.7%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (3.7%)	1 (1.8%)
UNSPECIFIED COMPLICATION OF PROCEDURE NEC	CAUCASIAN	0 (0.0%)	1 (0.4%)	2 (2.1%)	2 (0.8%)	1 (0.4%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	1 (1.8%)
VITRECTOMY	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	2 (2.7%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYE IRRITATION	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
POST-OPERATIVE COMPLICATIONS NOS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
POST-OPERATIVE HEMORRHAGE	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.9%)	0 (0.0%)
SCLERAL OPERATION NOS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
NERVOUS SYSTEM DISORDERS	CAUCASIAN	0 (0.0%)	0 (0.0%)	1 (1.0%)	1 (0.4%)	3 (1.1%)
	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)
	OTHER	0 (0.0%)	1 (1.7%)	1 (3.7%)	1 (1.9%)	2 (3.6%)
PUPILLARY DISORDER NOS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
ა	HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)
$ar{\pi}$	OTHER	0 (0.0%)	0 (0.0%)	1 (3.7%)	1 (1.9%)	1 (1.8%)

Note: Percentages based on the total number of patients of the given race within each dose group.

CO

s:\dat\acs\iss2002\sas\programs\t_ocrae_race 06SEP2002 17:36

Table 22
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Race Safety Population

VISUAL FIELD DEFECT NOS CAUCASIAN 0 (0.0\$) 0 (0.0\$) 1 (1.0\$) 0 (0.0\$) 1 (0	System Organ Class / Preferred Term	Control					
HISPANIC O (0.0%) O (Race	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
HISPANIC O(0.0%) O(0.0%) O(0.0%) O(0.0%) O(0.0%) O(0.0%) O(0.0%) O(0.0% O(0.0%) O(0.0%	VICUAL PIPED DEPOCE NOC	CAHCACTAN	0 (0 0%)	0 (0 0%)	ን (1 ሰዓነ	0 (0 0%)	1 (0 4%)
Name	VISUAL FIELD DEFECT NOS		- •			· · · · · · · · · · · · · · · · · · ·	0 (0.0%)
HEADACHE NOS CAUCASIAN 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (1.0					· · · · · · · · · · · · · · · · · · ·		0 (0.0%)
HISPANIC O (0.0%) O (OTHER	0 (0.04)	7 / 2.16)	0 (0.00)	0 (0.01)	4 (4.54)
OTHER	HEADACHE NOS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PUPILLARY REFLEX IMPAIRED CAUCASIAN 0 (0.0%) 0		HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
HISPANIC 0 (0.0%) 0 (OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.8%)
HISPANIC O (0.0%) O (0.0	PUDITALARY REPLEX IMPAIRED	CAUCASTAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
OTHER 0 (0.0%) 0 (0.0	COLIDARIA NOI DOM TIMETADO					0 (0.0%)	0 (0.0%)
INFECTIONS AND INFESTATIONS CAUCASIAN 0 (0.0%) 1 (0.4%) 0 (0.0%)				•	·	0 (0.0%)	0 (0.0%)
HISPANIC 0 (0.0%) 0 (, ,	,			
HYPOPYON CAUCASIAN O (0.0%) O (0	INFECTIONS AND INFESTATIONS	CAUCASIAN	0 (0.0%)	1 (0.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
HYPOPYON CAUCASIAN 0 (0.0%) 1 (0.4%) 0 (0.0%) 0		HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	O (O.O%)
HISPANIC 0 (0.0%) 0 (OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
HISPANIC 0 (0.0%) 0 (НУРОРУОИ	CAUCASIAN	0 (0.0%)	1 (0.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
INJURY AND POISONING CAUCASIAN 0 (0.0%) 1 (0.4%) 0 (0.0%			0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
HISPANIC 0 (0.0%) 0 (OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
HISPANIC 0 (0.0%) 0 (INTIDY AND DOTSONING	CAUCASIAN	0 (0.0%)	1 (0.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
OTHER 0 (0.0%) 0 (0.0	INDURI MAD TOLOGISTIC		- •				0 (0.0%)
HISPANIC 0 (0.0%) 0 (0 (0.0%)
HISPANIC 0 (0.0%) 0 (ITEAD THITIDY	CALICACTAN	ለ (ስ ሴቄ\	1 / 0 4%)	0 / 0 0%)	0 (0 0%)	0 (0.0%)
OTHER 0 (0.0%) 0 (0.0	TAD INCORI						0 (0.0%)
VASCULAR DISORDERS CAUCASIAN 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)							0 (0.0%)
The desired by the second seco		OTABR	0 (0.0%)	0 (0.0%)	0 (0.00)	0 (0.00)	0 (0.007
HTSPANTC	VASCULAR DISORDERS	CAUCASIAN					0 (0.0%)
		HISPANIC	0 (0.0%)	0 (0.0%)			1 (1.4%)
OTHER 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.		OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PERIPHERAL ISCHEMIA NOS CAUCASIAN 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	PERIPHERAL ISCHEMIA NOS	CAUCASIAN	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		HISPANIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)
OTHER 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)		OTHER	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Table 23
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Diabetic Status
Safety Population

	Control						
System Organ Class / Preferred Term	Diabetic Status	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase	
NUMBER OF PATIENTS	NON-DIABETIC	2	86	25	104	80	
	DIABETIC: TYPE I	5	169	106	164	187	
	DIABETIC: TYPE II	11	123	67	109	124	
NUMBER OF PATIENTS WITH AT LEAST ONE ADVERSE EVENT	NON-DIABETIC	1 (50.0%)	63 (73.3%)	25 (100%)	84 (80.8%)	72 (90.0%)	
	DIABETIC: TYPE I	5 (100%)	132 (78.1%)	101 (95.3%)	135 (82.3%)	164 (87.7%)	
	DIABETIC: TYPE II	11 (100%)	103 (83.7%)	67 (100%)	104 (95.4%)	113 (91.1%)	
EYE DISORDERS	NON-DIABETIC	1 (50.0%)	63 (73.3%)	25 (100%)	84 (80.8%)	72 (90.0%)	
	DIABETIC: TYPE I	5 (100%)	132 (78.1%)	100 (94.3%)	135 (82.3%)	164 (87.7%)	
	DIABETIC: TYPE II	11 (100%)	102 (82.9%)	67 (100%)	103 (94.5%)	113 (91.1%)	
IRITIS	NON-DIABETIC	1 (50.0%)	29 (33.7%)	17 (68.0%)	54 (51.9%)	45 (56.3%)	
	DIABETIC: TYPE I	2 (40.0%)	48 (28.4%)	65 (61.3%)	90 (54.9%)	117 (62.6%)	
	DIABETIC: TYPE II	1 (9.1%)	49 (39.8%)	41 (61.2%)	78 (71.6%)	81 (65.3%)	
OCULAR HYPEREMIA	NON-DIABETIC	0 (0.0%)	33 (38.4%)	15 (60.0%)	50 (48.1%)	40 (50.0%)	
	DIABETIC: TYPE I	2 (40.0%)	56 (33.1%)	62 (58.5%)	88 (53.7%)	100 (53.5%)	
	DIABETIC: TYPE II	2 (18.2%)	51 (41.5%)	36 (53.7%)	64 (58.7%)	75 (60.5%)	
EYE IRRITATION	NON-DIABETIC	1 (50.0%)	23 (26.7%)	11 (44.0%)	25 (24.0%)	24 (30.0%)	
	DIABETIC: TYPE I	2 (40.0%)	43 (25.4%)	53 (50.0%)	54 (32.9%)	73 (39.0%)	
	DIABETIC: TYPE II	7 (63.6%)	45 (36.6%)	26 (38.8%)	53 (48.6%)	42 (33.9%)	
EYE PAIN	NON-DIABETIC	0 (0.0%)	16 (18.6%)	12 (48.0%)	34 (32.7%)	31 (38.8%)	
•	DIABETIC: TYPE I	2 (40.0%)	35 (20.7%)	37 (34.9%)	50 (30.5%)	76 (40.6%)	
	DIABETIC: TYPE II	0 (0.0%)	33 (26.8%)	23 (34.3%)	55 (50.5%)	54 (43.5%)	
LACRIMATION INCREASED	NON-DIABETIC	0 (0.0%)	13 (15.1%)	7 (28.0%)	27 (26.0%)	25 (31.3%)	
	DIABETIC: TYPE I	2 (40.0%)	40 (23.7%)	36 (34.0%)	47 (28.7%)	62 (33.2%)	
	DIABETIC: TYPE II	2 (18.2%)	34 (27.6%)	22 (32.8%)	50 (45.9%)	52 (41.9%)	
VISUAL ACUITY REDUCED	NON-DIABETIC	0 (0.0%)	13 (15.1%)	6 (24.0%)	23 (22.1%)	13 (16.3%)	
	DIABETIC: TYPE I	2 (40.0%)	37 (21.9%)	49 (46.2%)	43 (26.2%)	53 (28.3%)	
	DIABETIC: TYPE II	2 (18.2%)	24 (19.5%)	22 (32.8%)	35 (32.1%)	32 (25.8%)	
ABNORMAL SENSATION IN EYE	NON-DIABETIC	0 (0.0%)	12 (14.0%)	11 (44.0%)	23 (22.1%)	30 (37.5%)	
	DIABETIC: TYPE I	0 (0.0%)	27 (16.0%)	29 (27.4%)	44 (26.8%)	54 (28.9%)	
	DIABETIC: TYPE II	2 (18.2%)	29 (23.6%)	22 (32.8%)	34 (31.2%)	30 (24.2%)	
XITREOUS FLOATERS	NON-DIABETIC	0 (0.0%)	13 (15.1%)	7 (28.0%)	18 (17.3%)	18 (22.5%)	
	DIABETIC: TYPE I	2 (40.0%)	33 (19.5%)	37 (34.9%)	42 (25.6%)	58 (31.0%)	
6	DIABETIC: TYPE II	4 (36.4%)	21 (17.1%)	19 (28.4%)	28 (25.7%)	24 (19.4%)	

s:\dat\acs\iss2002\sas\programs\t_ocae_diab 06SEP2002 17:36

Table 23
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Diabetic Status
Safety Population

		Control				
System Organ Class / Preferred Term	Diabetic Status	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
VITREOUS HEMORRHAGE	NON-DIABETIC	1 (50.0%)	9 (10.5%)	7 (28.0%)	12 (11.5%)	9 (11.3%)
	DIABETIC: TYPE I	1 (20.0%)	36 (21.3%)	41 (38.7%)	51 (31.1%)	57 (30.5%)
	DIABETIC: TYPE II	0 (0.0%)	21 (17.1%)	22 (32.8%)	28 (25.7%)	24 (19.4%)
PHOTOPHOBIA	NON-DIABETIC	0 (0.0%)	8 (9.3%)	7 (28.0%)	14 (13.5%)	18 (22.5%)
PROTOPROBLA	DIABETIC: TYPE I	3 (60.0%)	30 (17.8%)	34 (32.1%)	40 (24.4%)	51 (27.3%)
	DIABETIC: TYPE II	3 (27.3%)	22 (17.9%)	18 (26.9%)	32 (29.4%)	33 (26.6%)
CONJUNCTIVAL EDEMA	NON-DIABETIC	0 (0.0%)	15 (17.4%)	6 (24.0%)	23 (22.1%)	18 (22.5%)
	DIABETIC: TYPE I	1 (20.0%)	26 (15.4%)	29 (27.4%)	44 (26.8%)	37 (19.8%)
	DIABETIC: TYPE II	0 (0.0%)	18 (14.6%)	13 (19.4%)	29 (26.6%)	34 (27.4%)
CATARACT NUCLEAR	NON-DIABETIC	0 (0.0%)	7 (8.1%)	6 (24.0%)	8 (7.7%)	11 (13.8%)
	DIABETIC: TYPE I	0 (0.0%)	14 (8.3%)	15 (14.2%)	13 (7.9%)	11 (5.9%)
	DIABETIC: TYPE II	5 (45.5%)	13 (10.6%)	6 (9.0%)	16 (14.7%)	7 (5.6%)
DOMINAL DOMACIONENTO	NON-DIABETIC	0 (0.0%)	5 (5.8%)	3 (12.0%)	11 (10.6%)	9 (11.3%)
RETINAL DETACHMENT	DIABETIC: TYPE I	1 (20.0%)	12 (7.1%)	13 (12.3%)	11 (6.7%)	23 (12.3%)
	DIABETIC: TYPE II	2 (18.2%)	9 (7.3%)	6 (9.0%)	13 (11.9%)	13 (10.5%)
	DIABETIC: TYPE II	2 (10.2%)	3 (/.3%)	6 (9.0%)	15 (11.5%)	13 (10.5%)
CATARACT SUBCAPSULAR	NON-DIABETIC	0 (0.0%)	5 (5.8%)	5 (20.0%)	9 (8.7%)	12 (15.0%)
	DIABETIC: TYPE I	0 (0.0%)	11 (6.5%)	19 (17.9%)	14 (8.5%)	16 (8.6%)
	DIABETIC: TYPE II	2 (18.2%)	10 (8.1%)	9 (13.4%)	6 (5.5%)	10 (8.1%)
PHOTOPSIA	NON-DIABETIC	0 (0.0%)	2 (2.3%)	1 (4.0%)	5 (4.8%)	4 (5.0%)
INOTOLDIA	DIABETIC: TYPE I	0 (0.0%)	12 (7.1%)	14 (13.2%)	14 (8.5%)	19 (10.2%)
	DIABETIC: TYPE II	0 (0.0%)	8 (6.5%)	7 (10.4%)	26 (23.9%)	15 (12.1%)
		a (50 08)	6 (7.0%)	1 (4.0%)	9 (8.7%)	8 (10.0%)
CATARACT CORTICAL	NON-DIABETIC	1 (50.0%)	12 (7.1%)	9 (8.5%)	8 (4.9%)	18 (9.6%)
	DIABETIC: TYPE I	3 (60.0%)	9 (7.1%)	4 (6.0%)	13 (11.9%)	5 (4.0%)
	DIABETIC: TYPE II	1 (9.1%)	9 (7.34)	4 (6.04)	13 (11.9%)	3 (4.0%)
CORNEAL EROSION	NON-DIABETIC	0 (0.0%)	5 (5.8%)	0 (0.0%)	5 (4.8%)	5 (6.3%)
	DIABETIC: TYPE I	0 (0.0%)	12 (7.1%)	7 (6.6%)	11 (6.7%)	9 (4.8%)
	DIABETIC: TYPE II	1 (9.1%)	7 (5.7%)	3 (4.5%)	9 (8.3%)	3 (2.4%)
CORNEAL EDEMA	NON-DIABETIC	0 (0.0%)	6 (7.0%)	1 (4.0%)	5 (4.8%)	7 (8.8%)
	DIABETIC: TYPE I	1 (20.0%)	5 (3.0%)	11 (10.4%)	9 (5.5%)	6 (3.2%)
	DIABETIC: TYPE II	0 (0.0%)	1 (0.8%)	5 (7.5%)	6 (5.5%)	11 (8.9%)
S. S. DVIDBOGYG TDYDYG	NOW DIADEMIA	0 (0 0%)	2 (2 5%)	2 (0 0%)	2 (1.9%)	3 (3.8%)
NUBEOSIS IRIDIS	NON-DIABETIC	0 (0.0%)	3 (3.5%)	2 (8.0%) 8 (7.5%)	9 (5.5%)	10 (5.3%)
୍ର	DIABETIC: TYPE I	0 (0.0%)	9 (5.3%) 7 (5.7%)	8 (7.5%) 6 (9.0%)	6 (5.5%)	6 (4.8%)
	DIABETIC: TYPE II	1 (9.1%)	/ (5./%)	6 (9.0%)	0 (3.3%)	0 (4.08)

s:\dat\acs\iss2002\sas\programs\t_ocae_diab 06SEP2002 17:36

Table 23 Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Diabetic Status Safety Population

			rol		CC TIT III	75 IU Vitras
stem Organ Class / Preferred Term	Diabetic Status	ww	Saline	7.5 IU Vitrase		75 10 VICE
EYE DISCHARGE	NON-DIABETIC	0 (0.0%)	7 (8.1%)	2 (8.0%)	4 (3.8%)	6 (7.5
	DIABETIC: TYPE I	0 (0.0%)	8 (4.7%)	3 (2.8%)	12 (7.3%)	7 (3.7
	DIABETIC: TYPE II	0 (0.0%)	3 (2.4%)	5 (7.5%)	7 (6.4%)	7 (5.6
CONJUNCTIVAL HEMORRHAGE	NON-DIABETIC	0 (0.0%)	5 (5.8%)	1 (4.0%)	2 (1.9%)	3 (3.8
	DIABETIC: TYPE I	0 (0.0%)	8 (4.7%)	6 (5.7%)	4 (2.4%)	6 (3.:
	DIABETIC: TYPE II	0 (0.0%)	12 (9.8%)	4 (6.0%)	8 (7.3%)	9 (7.
IRIS ADHESIONS	NON-DIABETIC	0 (0.0%)	3 (3.5%)	1 (4.0%)	5 (4.8%)	7 (8.
	DIABETIC: TYPE I	1 (20.0%)	8 (4.7%)	5 (4.7%)	6 (3.7%)	12 (6.
	DIABETIC: TYPE II	1 (9.1%)	2 (1.6%)	3 (4.5%)	2 (1.8%)	8 (6.
MACULAR EDEMA	NON-DIABETIC	0 (0.0%)	1 (1.2%)	1 (4.0%)	0 (0.0%)	0 (0.
	DIABETIC: TYPE I	0 (0.0%)	7 (4.1%)	11 (10.4%)	7 (4.3%)	11 (5.
	DIABETIC: TYPE II	1 (9.1%)	3 (2.4%)	4 (6.0%)	4 (3.7%)	8 (6.
CORNEAL DISORDER NOS	NON-DIABETIC	0 (0.0%)	3 (3.5%)	0 (0.0%)	4 (3.8%)	6 (7.
	DIABETIC: TYPE I	0 (0.0%)	4 (2.4%)	4 (3.8%)	8 (4.9%)	13 (7.
	DIABETIC: TYPE II	0 (0.0%)	1 (0.8%)	2 (3.0%)	5 (4.6%)	6 (4.
НҮРНЕМА	NON-DIABETIC	0 (0.0%)	1 (1.2%)	3 (12.0%)	4 (3.8%)	2 (2.
	DIABETIC: TYPE I	0 (0.0%)	2 (1.2%)	2 (1.9%)	3 (1.8%)	7 (3.
	DIABETIC: TYPE II	0 (0.0%)	3 (2.4%)	3 (4.5%)	5 (4.6%)	6 (4.
CATARACT NEC	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (5.8%)	3 (3.
	DIABETIC: TYPE I	0 (0.0%)	7 (4.1%)	0 (0.0%)	3 (1.8%)	3 (1.
	DIABETIC: TYPE II	0 (0.0%)	3 (2.4%)	1 (1.5%)	1 (0.9%)	3 (2.
BLINDNESS NEC	NON-DIABETIC	0 (0.0%)	1 (1.2%)	1 (4.0%)	1 (1.0%)	3 (3.
	DIABETIC: TYPE I	1 (20.0%)	0 (0.0%)	7 (6.6%)	3 (1.8%)	4 (2.
	DIABETIC: TYPE II	0 (0.0%)	3 (2.4%)	1 (1.5%)	2 (1.8%)	2 (1.
HYPOPYON	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.0%)	4 (5
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	1 (0.9%)	3 (1.8%)	5 (2
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.8%)	12 (9
DRY EYE NEC	NON-DIABETIC	0 (0.0%)	2 (2.3%)	0 (0.0%)	0 (0.0%)	3 (3,
	DIABETIC: TYPE I	0 (0.0%)	2 (1.2%)	2 (1.9%)	4 (2.4%)	4 (2.
	DIABETIC: TYPE II	0 (0.0%)	2 (1.6%)	5 (7.5%)	1 (0.9%)	2 (1.
GLAUCOMA NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.
	DIABETIC: TYPE I	0 (0.0%)	1 (0.6%)	4 (3.8%)	2 (1.2%)	8 (4 .
	DIABETIC: TYPE II	0 (0.0%)	4 (3.3%)	1 (1.5%)	1 (0.9%)	3 (2.
Note: Percentages based on the total number of p Type I Diabetes includes all insulin-depen	atients of the given diabetic dent diabetics.	status within	each dose group			

Table 23
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Diabetic Status
Safety Population

System Organ Class / Preferred Term	Diabetic Status	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
						
VISION BLURRED	NON-DIABETIC	0 (0.0%)	0 (0.0%)	2 (8.0%)	2 (1.9%)	1 (1.3%)
12201 22011122	DIABETIC: TYPE I	0 (0.0%)	4 (2.4%)	3 (2.8%)	2 (1.2%)	1 (0.5%)
	DIABETIC: TYPE II	0 (0.0%)	1 (0.8%)	5 (7.5%)	1 (0.9%)	2 (1.6%)
CATARACT NOS AGGRAVATED	NON-DIABETIC	0 (0.0%)	2 (2.3%)	1 (4.0%)	1 (1.0%)	0 (0.0%)
	DIABETIC: TYPE I	1 (20.0%)	3 (1.8%)	3 (2.8%)	3 (1.8%)	1 (0.5%)
	DIABETIC: TYPE II	0 (0.0%)	3 (2.4%)	0 (0.0%)	1 (0.9%)	2 (1.6%)
KERATITIS NEC	NON-DIABETIC	0 (0.0%)	2 (2.3%)	0 (0.0%)	1 (1.0%)	1 (1.3%)
RERAITILS NEC	DIABETIC: TYPE I	0 (0.0%)	1 (0.6%)	4 (3.8%)	1 (0.6%)	6 (3.2%)
	DIABETIC: TYPE II	0 (0.0%)	1 (0.8%)	0 (0.0%)	2 (1.8%)	1 (0.8%)
	DIABETIC: TIPE II	0 (0.0%)	1 (0.08)	0 (0.0%)	2 (1.00/	1 (0.00)
VITREOUS DETACHMENT	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.5%)
V11112400 D21110111111	DIABETIC: TYPE I	1 (20.0%)	2 (1.2%)	1 (0.9%)	3 (1.8%)	2 (1.1%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	2 (3.0%)	6 (5.5%)	1 (0.8%)
		. (0 (0 0%)	0 (0.0%)	1 (1.0%)	1 (1.3%)
MACULOPATHY	NON-DIABETIC	0 (0.0%)	0 (0.0%)	3 (2.8%)	2 (1.2%)	2 (1.1%)
	DIABETIC: TYPE I	0 (0.0%)	3 (1.8%)			
	DIABETIC: TYPE II	0 (0.0%)	2 (1.6%)	1 (1.5%)	2 (1.8%)	2 (1.6%)
INTRAOCULAR PRESSURE INCREASED	NON-DIABETIC	0 (0.0%)	0 (0.0%)	3 (12.0%)	1 (1.0%)	1 (1.3%)
	DIABETIC: TYPE I	0 (0.0%)	3 (1.8%)	3 (2.8%)	1 (0.6%)	5 (2.7%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)
		0 (0 00)	0 / 0 0%)	0 (0.0%)	0 (0.0%)	1 (1.3%)
UVEITIS NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	- ,		2 (1.1%)
	DIABETIC: TYPE I	1 (20.0%)	0 (0.0%)	2 (1.9%)	3 (1.8%)	
	DIABETIC: TYPE II	0 (0.0%)	2 (1.6%)	0 (0.0%)	4 (3.7%)	1 (0.8%)
POST-OPERATIVE PAIN	NON-DIABETIC	0 (0.0%)	2 (2.3%)	0 (0.0%)	1 (1.0%)	2 (2.5%)
1001 01 Maria 1 Maria	DIABETIC: TYPE I	0 (0.0%)	4 (2.4%)	0 (0.0%)	1 (0.6%)	1 (0.5%)
	DIABETIC: TYPE II	1 (9.1%)	1 (0.8%)	0 (0.0%)	0 (0.0%)	2 (1.6%)
			2 (2 00)	0 (0.0%)	0 (0.0%)	0 (0.0%)
POSTERIOR CAPSULE OPACIFICATION	NON-DIABETIC	0 (0.0%)	1 (1.2%)		3 (1.8%)	2 (1.1%)
	DIABETIC: TYPE I	0 (0.0%)	2 (1.2%)	1 (0.9%)	3 (2.8%)	3 (2,4%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (2.0%)	3 (2.4%)
RETINOPATHY DIABETIC	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	2 (1.2%)	1 (0.9%)	2 (1.2%)	6 (3.2%)
	DIABETIC: TYPE II	0 (0.0%)	2 (1.6%)	0 (0.0%)	1 (0.9%)	0 (0.0%)
DI HDUND TOTA	NON DIADERIC	0 (0 00)	0 (0.0%)	1 (4.0%)	2 (1.9%)	1 (1.3%)
D BLEPHARITIS	NON-DIABETIC	0 (0.0%)		0 (0.0%)	0 (0.0%)	3 (1.6%)
on a second seco	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)		1 (0.9%)	1 (0.8%)
₩/ P. w	DIABETIC: TYPE II	0 (0.0%)	1 (0.8%)	2 (3.0%)	1 (0.26)	1 (0.0%)

Note: Percentages based on the total number of patients of the given diabetic status within each dose group.

Type I Diabetes includes all insulin-dependent diabetics.

s:\dat\acs\iss2002\sas\programs\t_ocae_diab 06SEP2002 17:36

Table 23
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Diabetic Status
Safety Population

	Control							
System Organ Class / Preferred Term	Diabetic Status		Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase		
MILEOMONIA OF THE	NON BENDEWEG	0 (0 0%)	1 (1.2%)	0 (0.0%)	0 (0.0%)	1 (1.3%)		
HYPOTONY OF EYE	NON-DIABETIC DIABETIC: TYPE I	0 (0.0%) 0 (0.0%)	0 (0.0%)	1 (0.9%)	1 (0.6%)	2 (1.1%)		
	DIABETIC: TYPE II	0 (0.0%)	1 (0.8%)	1 (1.5%)	1 (0.9%)	3 (2.4%)		
RETINAL HEMORRHAGE	NON-DIABETIC	0 (0.0%)	1 (1.2%)	0 (0.0%)	1 (1.0%)	0 (0.0%)		
	DIABETIC: TYPE I	0 (0.0%)	2 (1.2%)	1 (0.9%)	2 (1.2%)	0 (0.0%)		
	DIABETIC: TYPE II	0 (0.0%)	2 (1.6%)	1 (1.5%)	2 (1.8%)	0 (0.0%)		
CORNEAL EPITHELIUM DEFECT	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
	DIABETIC: TYPE I	0 (0.0%)	1 (0.6%)	1 (0.9%)	2 (1.2%)	2 (1.1%)		
	DIABETIC: TYPE II	1 (9.1%)	0 (0.0%)	2 (3.0%)	2 (1.8%)	0 (0.0%)		
DIPLOPIA	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.9%)	0 (0.0%)		
	DIABETIC: TYPE I	0 (0.0%)	2 (1.2%)	3 (2.8%)	2 (1.2%)	2 (1.1%)		
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
RETINAL ISCHEMIA	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.3%)		
	DIABETIC: TYPE I	0 (0.0%)	1 (0.6%)	3 (2.8%)	2 (1.2%)	1 (0.5%)		
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.8%)	0 (0.0%)		
CONJUNCTIVITIS NEC	NON-DIABETIC	0 (0.0%)	2 (2.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	2 (1.9%)	1 (0.6%)	2 (1.1%)		
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	1 (1.5%)	0 (0.0%)	0 (0.0%)		
CORNEAL ABRASION	NON-DIABETIC	0 (0.0%)	1 (1.2%)	0 (0.0%)	2 (1.9%)	0 (0.0%)		
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	1 (0.9%)	1 (0.6%)	2 (1.1%)		
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	1 (1.5%)	0 (0.0%)	0 (0.0%)		
MYDRIASIS	NON-DIABETIC	0 (0.0%)	2 (2.3%)	0 (0.0%)	0 (0.0%)	1 (1.3%)		
	DIABETIC: TYPE I	0 (0.0%)	1 (0.6%)	1 (0.9%)	0 (0.0%)	2 (1.1%)		
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.8%)		
RETINAL TEAR (EXC DETACHMENT)	NON-DIABETIC	0 (0.0%)	1 (1.2%)	0 (0.0%)	2 (1.9%)	1 (1.3%)		
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.2%)	0 (0.0%)		
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	1 (0.8%)		
FOREIGN BODY RETAINED IN EYE	NON-DIABETIC	0 (0.0%)	0 (0.0%)	1 (4.0%)	1 (1.0%)	0 (0.0%)		
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	2 (1.9%)	0 (0.0%)	0 (0.0%)		
	DIABETIC: TYPE II	0 (0.0%)	1 (0.8%)	1 (1.5%)	1 (0.9%)	0 (0.0%)		
CONTRACTOR DISORDER NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.3%)		
n e e e e e e e e e e e e e e e e e e e	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	2 (1.9%)	1 (0.6%)	0 (0.0%)		
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	1 (1.5%)	1 (0.9%)	0 (0.0%)		

s:\dat\acs\iss2002\sas\programs\t_ocae_diab 06SEP2002 17:36

Table 23
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Diabetic Status
Safety Population

	Control					
System Organ Class / Preferred Term	Diabetic Status	WW -	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
PSEUDOPHAKIA	NON-DIABETIC	0 (0.0%)	1 (1.2%)	0 (0.0%)	2 (1.9%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	1 (0.6%)	0 (0.0%)	1 (0.6%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	1 (0.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYELID PTOSIS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	1 (0.6%)	2 (1.9%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	1 (1.5%)	0 (0.0%)	1 (0.8%)
INTRAOCULAR PRESSURE DECREASED	NON-DIABETIC	0 (0.0%)	1 (1.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	2 (1.2%)	2 (1.9%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
OPTIC ATROPHY	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	1 (0.9%)	1 (0.6%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	1 (0.8%)	0 (0.0%)	2 (1.8%)	0 (0.0%)
PHOTOPHOBIA AGGRAVATED	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	1 (0.6%)	0 (0.0%)	2 (1.2%)	1 (0.5%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)
VITREOUS DISORDER NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	2 (1.2%)	1 (0.9%)	0 (0.0%)	1 (0.5%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.8%)
APHAKIA	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	2 (1.2%)	1 (0.9%)	0 (0.0%)	1 (0.5%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYE ALLERGY	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.0%)	1 (1.3%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.2%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
KERATOCONJUNCTIVITIS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	1 (0.6%)	1 (0.9%)	0 (0.0%)	1 (0.5%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
OCULAR HYPERTENSION	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	1 (0.6%)	0 (0.0%)	1 (0.6%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	1 (0.8%)
PAINFUL RED EYES	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	० (०.०%)	1 (0.6%)	0 (0.0%)	1 (0.6%)	2 (1.1%)
<u>,</u>	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

s:\dat\acs\iss2002\sas\programs\t_ocae_diab 06SEP2002 17:36

Table 23
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Diabetic Status
Safety Population

	Control					
System Organ Class / Preferred Term	Diabetic Status	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
CHEMOSIS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.3%)
	DIABETIC: TYPE I	0 (0.0%)	1 (0.6%)	1 (0.9%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CORTICAL OPACITY	NON-DIABETIC	0 (0.0%)	0 (0.0%)	1 (4.0%)	0 (0.0%)	1 (1.3%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.6%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
IRIDOCYCLITIS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	2 (3.0%)	1 (0.9%)	0 (0.0%)
LENTICULAR OPACITIES	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	2 (1.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.8%)
MACULAR DEGENERATION	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.6%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	2 (3.0%)	0 (0.0%)	0 (0.0%)
OPEN ANGLE GLAUCOMA NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.6%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	1 (1.5%)	0 (0.0%)	1 (0.8%)
RETINAL DISORDER NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	1 (0.6%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	1 (1.5%)	0 (0.0%)	0 (0.0%)
RETINAL MICROANEURYSMS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	1 (0.8%)	1 (1.5%)	1 (0.9%)	0 (0.0%)
RETINAL SCAR	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.9%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.8%)
BLINDNESS TRANSIENT	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	1 (1.5%)	0 (0.0%)	0 (0.0%)
CHOROIDAL DETACHMENT	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.0%)	0 (0.0%)
n D	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
5)	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

s:\dat\acs\iss2002\sas\programs\t_ocae_diab 06SEP2002 17:36

Table 23
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Diabetic Status
Safety Population

System Organ Class / Preferred Term	Diabetic Status	Cont:	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
			_ /			0 / 0 083
CONJUNCTIVITIS (INFECTIVE) NEC	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.6%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.8%)
CONJUNCTIVITIS ALLERGIC	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.5%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CONJUNCTIVITIS VIRAL NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
•••••	DIABETIC: TYPE I	1 (20.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.8%)
CORNEAL OPACITY	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
COLUMN OFFICE A	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	1 (0.9%)	1 (0.6%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
KERATOPATHY BAND	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
IDIATOTATIL SIAS	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.5%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
KERATOPATHY NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	1 (0.9%)	1 (0.6%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
MEIBOMIAN CYST	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.0%)	1 (1.3%)
· · · · · · · · · · · · · · · · · · ·	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PERIORBITAL HEMATOMA	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.0%)	0 (0.0%)
**************************************	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)
RETINAL ARTERY EMBOLISM	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	1 (1.5%)	0 (0.0%)	1 (0.8%)
RETINAL DEPIGMENTATION	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	1 (1.5%)	0 (0.0%)	0 (0.0%)
№ STRABISMUS NEC	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
N	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.5%)
တ	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Note: Percentages based on the total number of patients of the given diabetic status within each dose group.

Type I Diabetes includes all insulin-dependent diabetics.

s:\dat\acs\iss2002\sas\programs\t_ocae_diab 06SEP2002 17:36

Table 23
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Diabetic Status
Safety Population

	Control						
System Organ Class / Preferred Term	Diabetic Status	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase	
VISUAL ACUITY REDUCED TRANSIENTLY	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
TOTAL MODELLA MANAGEMENT MANAGEME	DIABETIC: TYPE I	0 (0.0%)	1 (0.6%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
VITREOUS OPACITIES	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.3%)	
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
ANGLE CLOSURE GLAUCOMA	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.0%)	0 (0.0%)	
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
ANISEIKONIA	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	
ARCUS SENILIS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
BLEPHAROCONJUNCTIVITIS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.6%)	0 (0.0%)	
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
BLINDNESS NIGHT	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.8%)	
BLOODSHOT EYE	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.3%)	
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
CCONJUNCTIVAL EDEMA	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
CHALAZION	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.3%)	
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
CHORIORETINAL ATROPHY	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
C C C C C C C C C C C C C C C C C C C	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	
Ö	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	

s:\dat\acs\iss2002\sas\programs\t_ocae_diab 06SEP2002 17:36

Table 23
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Diabetic Status
Safety Population

System Organ Class / Preferred Term	Diabetic Status	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
CHORIORETINAL DISORDER NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	1 (1.5%)	0 (0.0%)	0 (0.0%)
CHOROIDAL HEMORRHAGE	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.3%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
COLOUR BLINDNESS NEC	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CORNEAL DEGENERATION	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)
CORNEAL SCAR	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CORNEAL ULCER NEC	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CYCLITIS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
ERYTHEMA NEC	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.6%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EXOPHTHALMOS ENDOCRINE	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	1 (0.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYE HEMORRHAGE NEC	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	1 (0.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYE INFECTION FUNGAL NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
SIB INFECTION FONGAL NOS	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
ဘ	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)

s:\dat\acs\iss2002\sas\programs\t_ocae_diab 06SEP2002 17:36

Table 23
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Diabetic Status
Safety Population

	Control					
System Organ Class / Preferred Term	Diabetic Status	<u>ww</u>	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
EYE INFECTION NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EIE INFECTION NOO	DIABETIC: TYPE I	0 (0.0%)	1 (0.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYE INFECTION STAPHYLOCOCCAL	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYE INFECTION TOXOPLASMAL	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.8%)
EYE INFLAMMATION NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYELID DISORDER NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYELID EDEMA	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.6%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
HERPES SIMPLEX OPHTHALMIC	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.3%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
IRIS NEVUS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	1 (0.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
LACRIMAL DUCT OBSTRUCTION NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
OCULAR HYPERAEMIA	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.3%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
J	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
OPTIC DISC HEMORRHAGE	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
5	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)
•	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

s:\dat\acs\iss2002\sas\programs\t_ocae_diab 06SEP2002 17:36

Table 23
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Diabetic Status
Safety Population

		Cont				
System Organ Class / Preferred Term	Diabetic Status	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
		0 / 0 08	0 (0 00)	0 (0 0%)	0 (0.0%)	0 (0.0%)
OPTIC NERVE INJURY NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%) 0 (0.0%)	1 (0.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.04)	I (0.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PAPILLEDEMA	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)
·	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
PINGUECULA	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
POST-OPERATIVE COMPLICATIONS NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.3%)
1001 010101111 00110 0110 1110	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
RETINAL DEGENERATION	NON-DIABETIC	0 (0.0%)	0 (0.0%)	1 (4.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
RETINAL EXUDATES	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	1 (0.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
RETINAL VASCULITIS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
RETINAL VEIN THROMBOSIS	NON-DIABETIC	0 (0,0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.8%)
SCLERITIS NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
TOPOGRAPHY CORNEAL ABNORMAL	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
V UVEITIS DIABETIC	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Pr.	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	1 (1.5%)	0 (0.0%)	0 (0.0%)
L. ,						

Note: Percentages based on the total number of patients of the given diabetic status within each dose group.

Type I Diabetes includes all insulin-dependent diabetics.

s:\dat\acs\iss2002\sas\programs\t_ocae_diab 06SEP2002 17:36

Table 23
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Diabetic Status
Safety Population

		Control						
System Organ Class / Preferred Term	Diabetic Status	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase		
VISION ABNORMAL NEC	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)		
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
VISUAL DISTURBANCE NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%) 0 (0.0%)		
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
INVESTIGATIONS	NON-DIABETIC	0 (0.0%)	8 (9.3%)	6 (24.0%)	12 (11.5%)	6 (7.5%)		
	DIABETIC: TYPE I	1 (20.0%)	18 (10.7%)	24 (22.6%)	23 (14.0%)	29 (15.5%)		
	DIABETIC: TYPE II	2 (18.2%)	18 (14.6%)	18 (26.9%)	15 (13.8%)	11 (8.9%)		
INTRAOCULAR PRESSURE INCREASED	NON-DIABETIC	0 (0.0%)	6 (7.0%)	6 (24.0%)	9 (8.7%)	4 (5.0%)		
	DIABETIC: TYPE I	1 (20.0%)	17 (10.1%)	20 (18.9%)	19 (11.6%)	25 (13.4%)		
	DIABETIC: TYPE II	2 (18.2%)	16 (13.0%)	14 (20.9%)	14 (12.8%)	11 (8.9%)		
CORNEAL STAINING	NON-DIABETIC	0 (0.0%)	2 (2.3%)	0 (0.0%)	3 (2.9%)	3 (3.8%)		
	DIABETIC: TYPE I	0 (0.0%)	1 (0.6%)	5 (4.7%)	4 (2.4%)	5 (2.7%)		
	DIABETIC: TYPE II	0 (0.0%)	3 (2.4%)	3 (4.5%)	2 (1.8%)	0 (0.0%)		
INTRAOCULAR PRESSURE ABNORMAL	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)		
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	1 (1.5%)	0 (0.0%)	0 (0.0%)		
SKIN & SUBCUTANEOUS TISSUE DISORDERS	NON-DIABETIC	0 (0.0%)	4 (4.7%)	3 (12.0%)	8 (7.7%)	6 (7.5%)		
	DIABETIC: TYPE I	0 (0.0%)	14 (8.3%)	11 (10.4%)	17 (10.4%)	14 (7.5%)		
	DIABETIC: TYPE II	0 (0.0%)	8 (6.5%)	5 (7.5%)	14 (12.8%)	18 (14.5%)		
EYELID EDEMA	NON-DIABETIC	0 (0.0%)	1 (1.2%)	2 (8.0%)	7 (6.7%)	4 (5.0%)		
	DIABETIC: TYPE I	0 (0.0%)	9 (5.3%)	8 (7.5%)	12 (7.3%)	8 (4.3%)		
	DIABETIC: TYPE II	0 (0.0%)	5 (4.1%)	2 (3.0%)	10 (9.2%)	13 (10.5%)		
ERYTHEMA NEC	NON-DIABETIC	0 (0.0%)	3 (3.5%)	0 (0.0%)	6 (5.8%)	3 (3.8%)		
	DIABETIC: TYPE I	0 (0.0%)	9 (5.3%)	6 (5.7%)	9 (5.5%)	7 (3.7%)		
	DIABETIC: TYPE II	0 (0.0%)	3 (2.4%)	2 (3.0%)	6 (5.5%)	10 (8.1%)		
OCULAR HYPEREMIA	NON-DIABETIC	0 (0.0%)	1 (1.2%)	1 (4.0%)	0 (0.0%)	0 (0.0%)		
	DIABETIC: TYPE I	0 (0.0%)	1 (0.6%)	0 (0.0%)	0 (0.0%)	1 (0.5%)		
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
CUTIS LAXA	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		
Ī	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)		
3	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	1 (1.5%)	0 (0.0%)	0 (0.0%)		

s:\dat\acs\iss2002\sas\programs\t_ocae_diab 06SEP2002 17:36

Table 23
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Diabetic Status
Safety Population

	Control						
System Organ Class / Preferred Term	Diabetic Status	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase	
PERIORBITAL EDEMA	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	1 (0.8%)	
DERMATITIS NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.3%)	
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
ECCHYMOSIS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
PRURITUS NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.6%)		
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
SURGICAL AND MEDICAL PROCEDURES	NON-DIABETIC	0 (0.0%)	3 (3.5%)	1 (4.0%)	2 (1.9%)	1 (1.3%)	
	DIABETIC: TYPE I	0 (0.0%)	8 (4.7%)	4 (3.8%)	4 (2.4%)	7 (3.7%)	
	DIABETIC: TYPE II	1 (9.1%)	3 (2.4%)	2 (3.0%)	7 (6.4%)	0 (0.0%)	
POST-OPERATIVE COMPLICATIONS NOS	NON-DIABETIC	0 (0.0%)	2 (2.3%)	1 (4.0%)	1 (1.0%)	0 (0.0%)	
	DIABETIC: TYPE I	0 (0.0%)	5 (3.0%)	2 (1.9%)	2 (1.2%)	4 (2.1%)	
	DIABETIC: TYPE II	1 (9.1%)	1 (0.8%)	1 (1.5%)	2 (1.8%)	0 (0.0%)	
UNSPECIFIED COMPLICATION OF PROCEDURE NEC	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	DIABETIC: TYPE I	0 (0.0%)	2 (1.2%)	2 (1.9%)	1 (0.6%)	2 (1.1%)	
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (2.8%)	0 (0.0%)	
VITRECTOMY	NON-DIABETIC	0 (0.0%)	1 (1.2%)	0 (0.0%)	0 (0.0%)	1 (1.3%)	
	DIABETIC: TYPE I	0 (0.0%)	1 (0.6%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	
	DIABETIC: TYPE II	0 (0.0%)	2 (1.6%)	1 (1.5%)	1 (0.9%)	0 (0.0%)	
EYE IRRITATION	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.6%)	0 (0.0%)	
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
LENS IMPLANT	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.3%)	
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
O POST-OPERATIVE HEMORRHAGE	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	

Note: Percentages based on the total number of patients of the given diabetic status within each dose group.

Type I Diabetes includes all insulin-dependent diabetics.

s:\dat\acs\iss2002\sas\programs\t_ocae_diab 06SEP2002 17:36

Table 23
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Diabetic Status
Safety Population

	Control						
System Organ Class / Preferred Term	Diabetic Status	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase	
SCLERAL OPERATION NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
SUTURE LINE PAIN	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.0%)	0 (0.0%)	
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
NERVOUS SYSTEM DISORDERS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.0%)	1 (1.3%)	
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	4 (3.8%)	0 (0.0%)	2 (1.1%)	
	DIABETIC: TYPE II	0 (0.0%)	1 (0.8%)	1 (1.5%)	3 (2.8%)	4 (3.2%)	
PUPILLARY DISORDER NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.0%)	1 (1.3%)	
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	2 (1.9%)	0 (0.0%)	1 (0.5%)	
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	1 (1.5%)	3 (2.8%)	1 (0.8%)	
VISUAL FIELD DEFECT NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.5%)	
	DIABETIC: TYPE II	0 (0.0%)	1 (0.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
FACIAL PALSY	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.8%)	
HEADACHE NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.8%)	
PUPILLARY REFLEX IMPAIRED	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.8%)	
VITH NERVE PARALYSIS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
IMMUNE SYSTEM DISORDERS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	1 (4.0%)	0 (0.0%)	0 (0.0%)	
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	1 (0.9%)	1 (0.6%)	0 (0.0%)	
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
hypersensitivity nos	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
3	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	1 (0.9%)	1 (0.6%)	0 (0.0%)	
3	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	

s:\dat\acs\iss2002\sas\programs\t_ocae_diab 06SEP2002 17:36

Table 23
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Diabetic Status
Safety Population

		Control					
DIRBETIC: TYPE I 0 (0.04) 0 (0.04) 0 (0.04) 0 (0.05) 0 (0.05) 0 (0.06) 0 (0	System Organ Class / Preferred Term	Diabetic Status	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
DIABETIC: TYPE II 0 (0.04) 0 (0.04) 0 (0.04) 0 (0.04) 0 (0.05) 0 (MULTIPLE ALLERGIES	NON-DIABETIC	0 (0.0%)	0 (0.0%)	1 (4.0%)	0 (0.0%)	0 (0.0%)
INJURY AND POISONING NON-DIABETIC O (0.0\$) O (···		0 (0.0%)		0 (0.0%)	0 (0.0%)	0 (0.0%)
DIABETIC: TYPE I 0 (0.04) 0 (0.04) 0 (0.04) 0 (0.04) 0 (0.05)		DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CHEMICAL BURNS OF EYE NON-DIABETIC: TYPE I 0 (0.0%) 1 (0.8%) 0 (0.0%) 0 (0	INJURY AND POISONING	NON-DIABETIC	0 (0.0%)	0 (0.0%)			
CHEMICAL BURNS OF EYE NON-DIABETIC O (0.0%) O							
DIABETIC: TYPE I 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.6%) 0 (0.0%) 0 (0		DIABETIC: TYPE II	0 (0.0%)	1 (0.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
HEAD INJURY	CHEMICAL BURNS OF EYE		·			•	
HEAD INJURY MON-DIABETIC O (0.0\$)					•		
DIABETIC: TYPE I 0 (0.0\$) 0 (0		DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
DIABETIC: TYPE II	HEAD INJURY					· · · · · · · · · · · · · · · · · · ·	· · ·
NEOPLASMS BENIGN AND MALIGNANT (INCLUDING CYSTS AND NON-DIABETIC 0 (0.0%) 1 (1.2%) 0 (0.0%) 0 (0.0%) 1 (1.3%) POLYPS) DIABETIC: TYPE I 0 (0.0%)							
POLYPS) DIABETIC: TYPE I		DIABETIC: TYPE II	0 (0.0%)	1 (0.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
DIABETIC: TYPE I 0 (0.0%) 1 (1.3%) 0 (0.0%)		NON-DIABETIC	0 (0.0%)	1 (1.2%)	0 (0.0%)	0 (0.0%)	1 (1.3%)
BENIGN NEOPLASM OF CHOROID NON-DIABETIC O (0.0%)		DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
DIABETIC: TYPE I 0 (0.0%) 0 (0		DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
DIABETIC: TYPE II O (0.0%) O (0.0	BENIGN NEOPLASM OF CHOROID	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.3%)
RADIOACTIVE IODINE THERAPY NON-DIABETIC O (0.0\$) 1 (1.2\$) O (0.0\$) O (0.0\$) O (0.0\$) O (0.0\$) DIABETIC: TYPE II O (0.0\$) GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS NON-DIABETIC TYPE II O (0.0\$) DIABETIC: TYPE II O (0.0\$) MECHANICAL COMPLICATION OF IMPLANT NON-DIABETIC TYPE II O (0.0\$) DIABETIC: TYPE II O (0.0\$) INFECTIONS AND INFESTATIONS NON-DIABETIC O (0.0\$) HYPOPYON NON-DIABETIC O (0.0\$) D (0.0\$) O (0.0\$) HYPOPYON NON-DIABETIC O (0.0\$) D (0.0\$) D (0.0\$) O (0.		DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
DIABETIC: TYPE I 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS NON-DIABETIC 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETIC: TYPE I 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.5%) DIABETIC: TYPE I 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.5%) MECHANICAL COMPLICATION OF IMPLANT NON-DIABETIC 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.5%) DIABETIC: TYPE I 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.5%) DIABETIC: TYPE I 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) INFECTIONS AND INFESTATIONS NON-DIABETIC 0 (0.0%) 1 (1.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETIC: TYPE I 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETIC: TYPE I 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) HYPOPYON NON-DIABETIC 0 (0.0%) 1 (1.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%)		DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
DIABETIC: TYPE II 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.5%) 0 (0.0%) 0 (RADIOACTIVE IODINE THERAPY	NON-DIABETIC	0 (0.0%)	1 (1.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS NON-DIABETIC DIABETIC: TYPE I DIABETIC: TYPE II		DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
DIABETIC: TYPE I 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.5%) DIABETIC: TYPE II 0 (0.0%) 0 (0		DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
DIABETIC: TYPE II 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) MECHANICAL COMPLICATION OF IMPLANT NON-DIABETIC 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.5%) DIABETIC: TYPE I 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.5%) DIABETIC: TYPE II 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) INFECTIONS AND INFESTATIONS NON-DIABETIC 0 (0.0%) 1 (1.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETIC: TYPE I 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETIC: TYPE II 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) HYPOPYON NON-DIABETIC 0 (0.0%) 1 (1.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
MECHANICAL COMPLICATION OF IMPLANT NON-DIABETIC DIABETIC: TYPE I O(0.0%)		DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)		
DIABETIC: TYPE I 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.5%) DIABETIC: TYPE II 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) INFECTIONS AND INFESTATIONS NON-DIABETIC 0 (0.0%) 1 (1.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETIC: TYPE II 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETIC: TYPE II 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETIC: TYPE II 0 (0.0%) 1 (1.2%) 0 (0.0%) 0 (0.0%) HYPOPYON NON-DIABETIC 0 (0.0%) 1 (1.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%)		DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
DIABETIC: TYPE II 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) INFECTIONS AND INFESTATIONS NON-DIABETIC 0 (0.0%) 1 (1.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETIC: TYPE I 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETIC: TYPE II 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) HYPOPYON NON-DIABETIC 0 (0.0%) 1 (1.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	MECHANICAL COMPLICATION OF IMPLANT	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	- , /
INFECTIONS AND INFESTATIONS NON-DIABETIC 0 (0.0%) 1 (1.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETIC: TYPE I 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETIC: TYPE II 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) HYPOPYON NON-DIABETIC 0 (0.0%) 1 (1.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%)		DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	· · · · · · · · · · · · · · · · · · ·
DIABETIC: TYPE I 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETIC: TYPE II 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) DIABETIC: TYPE II 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) HYPOPYON NON-DIABETIC 0 (0.0%) 1 (1.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%)		DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
DIABETIC: TYPE II 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) HYPOPYON NON-DIABETIC 0 (0.0%) 1 (1.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	INFECTIONS AND INFESTATIONS	NON-DIABETIC	0 (0.0%)	1 (1.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
MYPOPYON NON-DIABETIC 0 (0.0%) 1 (1.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%)		DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	·
		DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	\ HYPOPYON	NON-DIABETIC	0 (0.0%)	1 (1.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	7	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

s:\dat\acs\iss2002\sas\programs\t ocae_diab 06SEP2002 17:36

Page 17 of 17

ISTA Pharmaceuticals, Inc. Integrated Summary of Safety

Table 23
Incidence of Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Diabetic Status
Safety Population

		Contr	rol				
System Organ Class / Preferred Term	Diabetic Status	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase	
HYPOPYON	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
VASCULAR DISORDERS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.8%)	
PERIPHERAL ISCHEMIA NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.8%)	

Note: Percentages based on the total number of patients of the given diabetic status within each dose group.

Type I Diabetes includes all insulin-dependent diabetics.

Table 24
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Diabetic Status Safety Population

	Control					
System Organ Class / Preferred Term	Diabetic Status	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
NUMBER OF PATIENTS	NON-DIABETIC	2	86	25	104	80
NOTION OF THE PARTY	DIABETIC: TYPE I	5	169	106	164	187
	DIABETIC: TYPE II	11	123	67	109	124
NUMBER OF PATIENTS WITH AT LEAST ONE RELATED ADVERSE EVENT	NON-DIABETIC	1 (50.0%)	45 (52.3%)	22 (88.0%)	75 (72.1%)	66 (82.5%)
	DIABETIC: TYPE I	3 (60.0%)	110 (65.1%)	88 (83.0%)	118 (72.0%)	153 (81.8%)
	DIABETIC: TYPE II	7 (63.6%)	89 (72.4%)	58 (86.6%)	97 (89.0%)	107 (86.3%)
EYE DISORDERS	NON-DIABETIC	1 (50.0%)	45 (52.3%)	22 (88.0%)	75 (72.1%)	66 (82.5%)
	DIABETIC: TYPE I	3 (60.0%)	110 (65.1%)	88 (83.0%)	117 (71.3%)	153 (81.8%)
	DIABETIC: TYPE II	7 (63.6%)	88 (71.5%)	58 (86.6%)	96 (88.1%)	107 (86.3%)
IRITIS	NON-DIABETIC	0 (0.0%)	24 (27.9%)	14 (56.0%)	51 (49.0%)	41 (51.3%)
	DIABETIC: TYPE I	1 (20.0%)	41 (24.3%)	47 (44.3%)	81 (49.4%)	111 (59.4%)
	DIABETIC: TYPE II	0 (0.0%)	41 (33.3%)	39 (58.2%)	70 (64.2%)	79 (63.7%)
OCULAR HYPEREMIA	NON-DIABETIC	0 (0.0%)	23 (26.7%)	12 (48.0%)	41 (39.4%)	35 (43.8%)
	DIABETIC: TYPE I	1 (20.0%)	48 (28.4%)	49 (46.2%)	70 (42.7%)	84 (44.9%)
	DIABETIC: TYPE II	0 (0.0%)	42 (34.1%)	24 (35.8%)	47 (43.1%)	64 (51.6%)
EYE PAIN	NON-DIABETIC	0 (0.0%)	14 (16.3%)	6 (24.0%)	29 (27.9%)	23 (28.8%)
	DIABETIC: TYPE I	1 (20.0%)	20 (11.8%)	23 (21.7%)	41 (25.0%)	59 (31.6%)
	DIABETIC: TYPE II	0 (0.0%)	23 (18.7%)	19 (28.4%)	43 (39.4%)	46 (37.1%)
EYE IRRITATION	NON-DIABETIC	1 (50.0%)	13 (15.1%)	8 (32.0%)	18 (17.3%)	15 (18.8%)
	DIABETIC: TYPE I	2 (40.0%)	30 (17.8%)	35 (33.0%)	40 (24.4%)	54 (28.9%)
	DIABETIC: TYPE II	2 (18.2%)	36 (29.3%)	18 (26.9%)	38 (34.9%)	34 (27.4%)
LACRIMATION INCREASED	NON-DIABETIC	0 (0.0%)	8 (9.3%)	6 (24.0%)	22 (21.2%)	18 (22.5%)
	DIABETIC: TYPE I	1 (20.0%)	26 (15.4%)	25 (23.6%)	33 (20.1%)	47 (25.1%)
	DIABETIC: TYPE II	0 (0.0%)	22 (17.9%)	14 (20.9%)	39 (35.8%)	38 (30.6%)
ABNORMAL SENSATION IN EYE	NON-DIABETIC	0 (0.0%)	8 (9.3%)	9 (36.0%)	17 (16.3%)	23 (28.8%)
	DIABETIC: TYPE I	0 (0.0%)	19 (11.2%)	19 (17.9%)	37 (22.6%)	45 (24.1%)
	DIABETIC: TYPE II	1 (9.1%)	23 (18.7%)	15 (22.4%)	24 (22.0%)	24 (19.4%)
РНОТОРНОВІА	NON-DIABETIC	0 (0.0%)	6 (7.0%)	5 (20.0%)	12 (11.5%)	14 (17.5%)
	DIABETIC: TYPE I	1 (20.0%)	19 (11.2%)	22 (20.8%)	28 (17.1%)	43 (23.0%)
\circ	DIABETIC: TYPE II	2 (18.2%)	17 (13.8%)	14 (20.9%)	23 (21.1%)	28 (22.6%)
CONJUNCTIVAL EDEMA	NON-DIABETIC	0 (0.0%)	13 (15.1%)	2 (8.0%)	17 (16.3%)	13 (16.3%)
I	DIABETIC: TYPE I	1 (20.0%)	21 (12.4%)	17 (16.0%)	37 (22.6%)	32 (17.1%)

s:\dat\acs\iss2002\sas\programs\t_ocrae_diab 06SEP2002 17:36

Table 24
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Diabetic Status Safety Population

		Control					
System Organ Class / Preferred Term	Diabetic Status	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase	
CONJUNCTIVAL EDEMA	DIABETIC: TYPE II	0 (0.0%)	15 (12.2%)	11 (16.4%)	20 (18.3%)	32 (25.8%)	
VITREOUS FLOATERS	NON-DIABETIC DIABETIC: TYPE I	0 (0.0%) 1 (20.0%)	6 (7.0%) 22 (13.0%)	6 (24.0%) 21 (19.8%)	13 (12.5%) 26 (15.9%)	14 (17.5%) 45 (24.1%)	
	DIABETIC: TYPE II	2 (18.2%)	14 (11.4%)	13 (19.4%)	19 (17.4%)	15 (12.1%)	
VISUAL ACUITY REDUCED	NON-DIABETIC	0 (0.0%) 2 (40.0%)	4 (4.7%) 23 (13.6%)	3 (12.0%) 31 (29.2%)	17 (16.3%) 28 (17.1%)	6 (7.5%) 34 (18.2%)	
	DIABETIC: TYPE I DIABETIC: TYPE II	0 (0.0%)	16 (13.0%)	13 (19.4%)	21 (19.3%)	18 (14.5%)	
VITREOUS HEMORRHAGE	NON-DIABETIC	0 (0.0%)	3 (3.5%)	2 (8.0%)	6 (5.8%) 19 (11.6%)	3 (3.8%) 17 (9.1%)	
	DIABETIC: TYPE I DIABETIC: TYPE II	1 (20.0%) 0 (0.0%)	11 (6.5%) 11 (8.9%)	20 (18.9%) 10 (14.9%)	12 (11.0%)	9 (7.3%)	
PHOTOPSIA	NON-DIABETIC	0 (0.0%)	1 (1.2%)	1 (4.0%)	3 (2.9%)	3 (3.8%)	
	DIABETIC: TYPE I DIABETIC: TYPE II	0 (0.0%) 0 (0.0%)	8 (4.7%) 5 (4.1%)	11 (10.4%) 6 (9.0%)	7 (4.3%) 15 (13.8%)	16 (8.6%) 9 (7.3%)	
CATARACT SUBCAPSULAR	NON-DIABETIC	0 (0.0%)	0 (0.0%)	4 (16.0%)	8 (7.7%)	6 (7.5%)	
	DIABETIC: TYPE I DIABETIC: TYPE II	0 (0.0%) 0 (0.0%)	5 (3.0%) 6 (4.9%)	12 (11.3%) 4 (6.0%)	10 (6.1%) 2 (1.8%)	7 (3.7%) 4 (3.2%)	
RETINAL DETACHMENT	NON-DIABETIC	0 (0.0%)	0 (0.0%)	1 (4.0%)	9 (8.7%)	6 (7.5%) 10 (5.3%)	
	DIABETIC: TYPE I DIABETIC: TYPE II	0 (0.0%) 1 (9.1%)	4 (2.4%) 6 (4.9%)	7 (6.6%) 4 (6.0%)	5 (3.0%) 4 (3.7%)	6 (4.8%)	
CATARACT NUCLEAR	NON-DIABETIC	0 (0.0%)	3 (3.5%)	2 (8.0%)	6 (5.8%)	3 (3.8%)	
	DIABETIC: TYPE I DIABETIC: TYPE II	0 (0.0%) 1 (9.1%)	7 (4.1%) 6 (4.9%)	6 (5.7%) 4 (6.0%)	9 (5.5%) 7 (6.4%)	5 (2.7%) 2 (1.6%)	
CATARACT CORTICAL	NON-DIABETIC	0 (0.0%)	2 (2.3%)	0 (0.0%)	7 (6.7%)	4 (5.0%)	
	DIABETIC: TYPE I DIABETIC: TYPE II	1 (20.0%) 0 (0.0%)	6 (3.6%) 8 (6.5%)	3 (2.8%) 0 (0.0%)	7 (4.3%) 5 (4.6%)	12 (6.4%) 3 (2.4%)	
CORNEAL EROSION	NON-DIABETIC	0 (0.0%)	2 (2.3%)	0 (0.0%)	4 (3.8%)	3 (3.8%)	
	DIABETIC: TYPE I DIABETIC: TYPE II	0 (0.0%) 0 (0.0%)	8 (4.7%) 6 (4.9%)	4 (3.8%) 2 (3.0%)	6 (3.7%) 4 (3.7%)	5 (2.7%) 3 (2.4%)	
CORNEAL DISORDER NOS	NON-DIABETIC	0 (0.0%)	1 (1.2%)	0 (0.0%)	4 (3.8%)	4 (5.0%)	
	DIABETIC: TYPE I DIABETIC: TYPE II	0 (0.0%) 0 (0.0%)	2 (1.2%) 0 (0.0%)	2 (1.9%) 2 (3.0%)	8 (4.9%) 2 (1.8%)	11 (5.9%) 6 (4.8%)	
EYE DISCHARGE	NON-DIABETIC	0 (0.0%)	5 (5.8%)	1 (4.0%)	3 (2.9%)	5 (6.3%)	
*							

s:\dat\acs\iss2002\sas\programs\t_ocrae_diab 06SEP2002 17:36

Table 24
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Diabetic Status Safety Population

		Cont	rol			
System Organ Class / Preferred Term	Diabetic Status	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
EYE DISCHARGE	DIABETIC: TYPE I	0 (0.0%)	6 (3.6%)	0 (0.0%)	8 (4.9%)	6 (3.2%)
	DIABETIC: TYPE II	0 (0.0%)	2 (1.6%)	2 (3.0%)	1 (0.9%)	3 (2.4%)
			- ,,	- ,		
IRIS ADHESIONS	NON-DIABETIC	0 (0.0%)	1 (1.2%)	0 (0.0%)	5 (4.8%)	5 (6.3%)
	DIABETIC: TYPE I	1 (20.0%)	1 (0.6%)	2 (1.9%)	4 (2.4%)	7 (3.7%)
	DIABETIC: TYPE II	1 (9.1%)	1 (0.8%)	2 (3.0%)	1 (0.9%)	6 (4.8%)
CONJUNCTIVAL HEMORRHAGE	NON-DIABETIC	0 (0.0%)	4 (4.7%)	0 (0.0%)	1 (1.0%)	1 (1.3%)
CONG UNCTIVAD INDMONINACIO	DIABETIC: TYPE I	0 (0.0%)	3 (1.8%)	3 (2.8%)	1 (0.6%)	5 (2.7%)
	DIABETIC: TYPE II	0 (0.0%)	7 (5.7%)	3 (4.5%)	4 (3.7%)	2 (1.6%)
CORNEAL EDEMA	NON-DIABETIC	0 (0.0%)	4 (4.7%)	0 (0.0%)	4 (3.8%)	4 (5.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	3 (2.8%)	4 (2.4%)	3 (1.6%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	1 (1.5%)	0 (0.0%)	10 (8.1%)
RUBEOSIS IRIDIS	NON-DIABETIC	0 (0.0%)	1 (1.2%)	1 (4.0%)	2 (1.9%)	2 (2.5%)
***************************************	DIABETIC: TYPE I	0 (0.0%)	1 (0.6%)	4 (3.8%)	4 (2.4%)	3 (1.6%)
	DIABETIC: TYPE II	1 (9.1%)	3 (2.4%)	3 (4.5%)	0 (0.0%)	4 (3.2%)
НУРОРУОИ	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.0%)	4 (5.0%)
MIFOFION	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	1 (0.9%)	3 (1.8%)	5 (2.7%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.8%)	12 (9.7%)
HYPHEMA	NON-DIABETIC	0 (0.0%)	0 (0.0%)	1 (4.0%)	4 (3.8%)	1 (1.3%)
	DIABETIC: TYPE I	0 (0.0%)	2 (1.2%)	0 (0.0%)	0 (0.0%)	2 (1.1%)
	DIABETIC: TYPE II	0 (0.0%)	1 (0.8%)	2 (3.0%)	1 (0.9%)	3 (2.4%)
MACULAR EDEMA	NON-DIABETIC	0 (0.0%)	0 (0.0%)	1 (4.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	3 (1.8%)	1 (0.9%)	'3 (1.8%)	5 (2.7%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	1 (1.5%)	0 (0.0%)	3 (2.4%)
UVEITIS NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.3%)
	DIABETIC: TYPE I	1 (20.0%)	0 (0.0%)	1 (0.9%)	3 (1.8%)	2 (1.1%)
	DIABETIC: TYPE II	0 (0.0%)	1 (0.8%)	0 (0.0%)	2 (1.8%)	1 (0.8%)
VITREOUS DETACHMENT	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.5%)
VIIIMOOO BEIMCIMIBMI	DIABETIC: TYPE I	0 (0.0%)	1 (0.6%)	0 (0.0%)	2 (1.2%)	1 (0.5%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	1 (1.5%)	4 (3.7%)	0 (0.0%)
MACULOPATHY	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.0%)	0 (0.0%)
rinconvenini	DIABETIC: TYPE I	0 (0.0%)	2 (1.2%)	1 (0.9%)	2 (1.2%)	2 (1.1%)
\sim	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.6%)
7	DIMBELLC: TIPE II	0 (0.0%)	0 (0.0%)	0 (0.00)	0 (0.00)	2 (2.00)

s:\dat\acs\iss2002\sas\programs\t_ocrae_diab 06SEP2002 17:36

Table 24
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Diabetic Status
Safety Population

		Cont	rol			
System Organ Class / Preferred Term	Diabetic Status	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
VPD MYMY G NYO	NON DINDERIG	0 (0 0%)	0 (0 0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
KERATITIS NEC	NON-DIABETIC DIABETIC: TYPE I	0 (0.0%) 0 (0.0%)	0 (0.0%) 1 (0.6%)	3 (2.8%)	0 (0.0%)	2 (1.1%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.8%)	1 (0.8%)
CATARACT NEC	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.9%)	1 (1.3%)
CATAMCI NIC	DIABETIC: TYPE I	0 (0.0%)	1 (0.6%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
	DIABETIC: TYPE II	0 (0.0%)	1 (0.8%)	0 (0.0%)	0 (0.0%)	2 (1.6%)
CATARACT NOS AGGRAVATED	NON-DIABETIC	0 (0.0%)	1 (1.2%)	0 (0.0%)	1 (1.0%)	0 (0.0%)
	DIABETIC: TYPE I	1 (20.0%)	1 (0.6%)	0 (0.0%)	2 (1.2%)	1 (0.5%)
	DIABETIC: TYPE II	0 (0.0%)	1 (0.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
DRY EYE NEC	NON-DIABETIC	0 (0.0%)	1 (1.2%)	0 (0.0%)	0 (0.0%)	1 (1.3%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.6%)	2 (1.1%)
	DIABETIC: TYPE II	0 (0.0%)	1 (0.8%)	1 (1.5%)	1 (0.9%)	0 (0.0%)
DIPLOPIA	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	2 (1.2%)	1 (0.9%)	2 (1.2%)	1 (0.5%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
GLAUCOMA NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	4 (2.1%)
•	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.8%)
POSTERIOR CAPSULE OPACIFICATION	NON-DIABETIC	0 (0.0%)	1 (1.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	1 (0.6%)	0 (0.0%)	1 (0.6%)	1 (0.5%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	1 (0.8%)
VISION BLURRED	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.6%)	1 (0.5%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	1 (1.5%)	1 (0.9%)	1 (0.8%)
BLINDNESS NEC	NON-DIABETIC	0 (0.0%)	1 (1.2%)	0 (0.0%)	1 (1.0%)	1 (1.3%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.5%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
HYPOTONY OF EYE	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.3%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.6%)	1 (0.5%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.6%)
MYDRIASIS	NON-DIABETIC	0 (0.0%)	1 (1.2%)	0 (0.0%)	0 (0.0%)	1 (1.3%)
い	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.1%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.8%)

s:\dat\acs\iss2002\sas\programs\t_ocrae_diab 06SEP2002 17:36

Table 24
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Diabetic Status
Safety Population

	Control			_		
System Organ Class / Preferred Term	Diabetic Status	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
PHOTOPHOBIA AGGRAVATED	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	1 (0.6%)	0 (0.0%)	2 (1.2%)	1 (0.5%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)
CONJUNCTIVITIS NEC	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	2 (1.9%)	0 (0.0%)	2 (1.1%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CORNEAL EPITHELIUM DEFECT	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.6%)	0 (0.0%)
	DIABETIC: TYPE II	1 (9.1%)	0 (0.0%)	2 (3.0%)	0 (0.0%)	0 (0.0%)
FOREIGN BODY RETAINED IN EYE	NON-DIABETIC	0 (0.0%)	0 (0.0%)	1 (4.0%)	1 (1.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	1 (0.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
INTRAOCULAR PRESSURE INCREASED	NON-DIABETIC	0 (0.0%)	0 (0.0%)	1 (4.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.5%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)
RETINAL TEAR (EXC DETACHMENT)	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.9%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.6%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)
RETINOPATHY DIABETIC	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	1 (0.6%)	0 (0.0%)	1 (0.6%)	1 (0.5%)
	DIABETIC: TYPE II	0 (0.0%)	1 (0.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
VITREOUS DISORDER NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	1 (0.6%)	1 (0.9%)	0 (0.0%)	1 (0.5%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.8%)
CORNEAL ABRASION	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	1 (1.5%)	0 (0.0%)	0 (0.0%)
CORTICAL OPACITY	NON-DIABETIC	0 (0.0%)	0 (0.0%)	1 (4.0%)	0 (0.0%)	1 (1.3%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.6%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
INTRAOCULAR PRESSURE DECREASED	NON-DIABETIC	0 (0.0%)	1 (1.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	2 (1.9%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

s:\dat\acs\iss2002\sas\programs\t_ocrae_diab 06SEP2002 17:36

Table 24
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Diabetic Status Safety Population

		Cont	rol			
ystem Organ Class / Preferred Term	Diabetic Status	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitras
IRIDOCYCLITIS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	2 (3.0%)	1 (0.9%)	0 (0.0%
RETINAL HEMORRHAGE	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	DIABETIC: TYPE I	0 (0.0%)	1 (0.6%)	0 (0.0%)	1 (0.6%)	0 (0.0%
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	1 (1.5%)	0 (0.0%)	0 (0.0%
BLEPHARITIS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.9%)	0 (0.0%
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
CHOROIDAL DETACHMENT	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.0%)	0 (0.0%
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.59
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
CONJUNCTIVITIS (INFECTIVE) NEC	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.6%)	0 (0.0
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.8
EYE DEGENERATIVE DISORDER NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	1 (1.5%)	1 (0.9%)	0 (0.0
MACULAR DEGENERATION	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.6%)	0 (0.0
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	1 (1.5%)	0 (0.0%)	0 (0.0
OCULAR HYPERTENSION	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.6%)	0 (0.0
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.8
PSEUDOPHAKIA	NON-DIABETIC	0 (0.0%)	1 (1.2%)	0 (0.0%)	1 (1.0%)	0 (0.0
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
RETINAL DISORDER NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
	DIABETIC: TYPE I	0 (0.0%)	1 (0.6%)	0 (0.0%)	0 (0.0%)	1 (0.5
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
STRABISMUS NEC	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.5%
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%

s:\dat\acs\iss2002\sas\programs\t_ocrae_diab 06SEP2002 17:36

Table 24
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Diabetic Status Safety Population

	Control					
System Organ Class / Preferred Term	Diabetic Status	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
VITREOUS OPACITIES	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.3%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
APHAKIA	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	1 (0.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
BLINDNESS NIGHT	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.8%)
BLINDNESS TRANSIENT	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
BLOODSHOT EYE	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.3%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CCONJUNCTIVAL EDEMA	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CHORIORETINAL ATROPHY	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CHORIORETINAL DISORDER NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	1 (1.5%)	0 (0.0%)	0 (0.0%)
COLOUR BLINDNESS NEC	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
••••	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CONJUNCTIVITIS VIRAL NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.8%)
CORNEAL OPACITY	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
COMBAI OFACITI	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)
ÒC .	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

s:\dat\acs\iss2002\sas\programs\t_ocrae_diab 06SEP2002 17:36

Table 24
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Diabetic Status
Safety Population

		Cont	rol			
System Organ Class / Preferred Term	Diabetic Status	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
CYCLITIS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
ERYTHEMA NEC	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.6%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
DVD ALLEDOV	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.0%)	0 (0.0%)
EYE ALLERGY			0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	•	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYE INFECTION TOXOPLASMAL	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.8%)
					- />	- />
EYE INFLAMMATION NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYELID DISORDER NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EIBBID DISORDER NOS	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABBITC. TIPE II	0 (0.04)	0 (0.00)	0 (0.007	0 (0.00,	0 (0,000,
EYELID EDEMA	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.6%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MON BINDERIG	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
EYELID PTOSIS	NON-DIABETIC	- ,	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)			0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
KERATOCONJUNCTIVITIS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	1 (0.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
KERATOPATHY NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.6%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
LENTICULAR OPACITIES	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
O BRILLOWN OFNCILLED	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
X O	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.8%)
~	DIADELIC: LIPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.03)	1 (0.00)

s:\dat\acs\iss2002\sas\programs\t_ocrae_diab 06SEP2002 17:36

Table 24
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Diabetic Status Safety Population

		Cont	rol _			
stem Organ Class / Preferred Term	Diabetic Status	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitra
MEIBOMIAN CYST	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.0%)	0 (0.0%
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.05
OCULAR HYPERAEMIA	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.3
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
OPEN ANGLE GLAUCOMA NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	1 (1.5%)	0 (0.0%)	0 (0.0
OPTIC ATROPHY	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.6%)	0 (0.0
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
PAINFUL RED EYES	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
	DIABETIC: TYPE I	0 (0.0%)	1 (0.6%)	0 (0.0%)	0 (0.0%)	0 (0.0
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
PINGUECULA	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
POST-OPERATIVE PAIN	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.8
RETINAL DEPIGMENTATION	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	1 (1.5%)	0 (0.0%)	0 (0.
RETINAL ISCHEMIA	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
RETINAL MICROANEURYSMS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	1 (1.5%)	0 (0.0%)	0 (0.0
RETINAL SCAR	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.8

s:\dat\acs\iss2002\sas\programs\t_ocrae_diab 06SEP2002 17:36

Table 24
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Diabetic Status Safety Population

Control						
System Organ Class / Preferred Term	Diabetic Status	WW		7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
RETINAL VEIN THROMBOSIS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.8%)
TOPOGRAPHY CORNEAL ABNORMAL	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
UVEITIS DIABETIC	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	1 (1.5%)	0 (0.0%)	0 (0.0%)
VISUAL DISTURBANCE NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
INVESTIGATIONS	NON-DIABETIC	0 (0.0%)	6 (7.0%)	2 (8.0%)	7 (6.7%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	9 (5.3%)	11 (10.4%)	12 (7.3%)	12 (6.4%)
	DIABETIC: TYPE II	0 (0.0%)	9 (7.3%)	8 (11.9%)	5 (4.6%)	8 (6.5%)
INTRAOCULAR PRESSURE INCREASED	NON-DIABETIC	0 (0.0%)	4 (4.7%)	2 (8.0%)	5 (4.8%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	9 (5.3%)	7 (6.6%)	9 (5.5%)	8 (4.3%)
	DIABETIC: TYPE II	0 (0.0%)	7 (5.7%)	7 (10.4%)	4 (3.7%)	8 (6.5%)
CORNEAL STAINING	NON-DIABETIC	0 (0.0%)	2 (2.3%)	0 (0.0%)	2 (1.9%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	4 (3.8%)	3 (1.8%)	4 (2.1%)
	DIABETIC: TYPE II	0 (0.0%)	2 (1.6%)	1 (1.5%)	1 (0.9%)	0 (0.0%)
SKIN & SUBCUTANEOUS TISSUE DISORDERS	NON-DIABETIC	0 (0.0%)	2 (2.3%)	1 (4.0%)	6 (5.8%)	2 (2.5%)
	DIABETIC: TYPE I	0 (0.0%)	6 (3.6%)	5 (4.7%)	12 (7.3%)	10 (5.3%)
	DIABETIC: TYPE II	0 (0.0%)	7 (5.7%)	3 (4.5%)	11 (10.1%)	12 (9.7%)
EYELID EDEMA	NON-DIABETIC	0 (0.0%)	0 (0.0%)	1 (4.0%)	5 (4.8%)	2 (2.5%)
	DIABETIC: TYPE I	0 (0.0%)	2 (1.2%)	4 (3.8%)	10 (6.1%)	6 (3.2%)
	DIABETIC: TYPE II	0 (0.0%)	4 (3.3%)	1 (1.5%)	7 (6.4%)	11 (8.9%)
ERYTHEMA NEC	NON-DIABETIC	0 (0.0%)	1 (1.2%)	0 (0.0%)	5 (4.8%)	2 (2.5%)
	DIABETIC: TYPE I	0 (0.0%)	5 (3,0%)	2 (1.9%)	4 (2.4%)	4 (2.1%)
	DIABETIC: TYPE II	0 (0.0%)	3 (2.4%)	1 (1.5%)	5 (4.6%)	6 (4.8%)
CUTIS LAXA	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
$\overset{\sim}{\infty}$	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
₩	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	1 (1.5%)	0 (0.0%)	0 (0.0%)

Note: Percentages based on the total number of patients of the given diabetic status within each dose group.

Type I Diabetes includes all insulin-dependent diabetics.

s:\dat\acs\iss2002\sas\programs\t ocrae_diab 06SEP2002 17:36

Table 24 Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Diabetic Status Safety Population

Status TIC TYPE I TYPE II TYPE II TYPE II TYPE II TYPE II TYPE II TYPE I TYPE II TYPE II TYPE II	O (0.0%)	Saline 0 (0.0%) 0 (0.0%) 1 (1.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	7.5 IU Vitrase 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (2.8%)	0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.9%)	75 IU Vit 0 (0. 1 (0. 0 (0. 0 (0. 0 (0. 0 (0. 0 (0. 0 (0. 0 (0. 0 (0. 0 (0. 0 (0. 0 (0. 0 (0. 0 (0. 0 (0.
TYPE I TYPE II	0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%) 1 (1.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.6%)	0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.9%) 0 (0.0%)	1 (0. 0
TYPE I TYPE II	0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	0 (0.0%) 1 (1.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.9%) 0 (0.0%)	0 (0. 0 (0. 0 (0. 0 (0. 0 (0. 0 (0.
TYPE II TIC TYPE I TYPE II TYPE II TYPE II TYPE II TYPE II TYPE II	0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	0 (0.0%) 1 (1.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.9%)	0 (0. 0 (0. 0 (0. 0 (0. 0 (0.
TYPE I TYPE II TYPE I TYPE I TYPE I TYPE II TYPE II TYPE I TYPE I	0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.6%)	0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.9%)	0 (0. 0 (0. 0 (0. 0 (0. 0 (0.
TYPE II TYPE I TYPE I TYPE II TYPE II	0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.6%)	0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.9%) 0 (0.0%)	0 (0 .
ETIC TYPE I TYPE II ETIC TYPE I TYPE I	0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.6%)	0 (0.0%) 0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%) 1 (0.9%) 0 (0.0%)	0 (0 0 0 0 0 0 0 0 0 0
TYPE I TYPE II TYPE II TYPE I TYPE I	0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.6%)	0 (0.0%) 0 (0.0%) 0 (0.0%)	0 (0.0%) 1 (0.9%) 0 (0.0%)	0 (0 0 0 0 0 0 0 0 0 0
TYPE II TYPE I TYPE I TYPE II	0 (0.0%) 0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%) 1 (0.6%)	0 (0.0%)	1 (0.9%)	0 (0
ETIC : TYPE I : TYPE II	0 (0.0%) 0 (0.0%)	0 (0.0%) 1 (0.6%)	0 (0.0%)	0 (0.0%)	0 (0
TYPE I	0 (0.0%)	1 (0.6%)			
: TYPE II			3 (2.8%)		
	0 (0.0%)			1 (0.6%)	4 (2
TTC		0 (.0.0%)	1 (1.5%)	4 (3.7%)	0 (0
, a a C	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0
TYPE I	0 (0.0%)	1 (0.6%)	2 (1.9%)	0 (0.0%)	2 (1
TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (2.8%)	0 (0
ETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0
: TYPE I				· ·	0 (0
TYPE II	0 (0.0%)	0 (0.0%)	1 (1.5%)	0 (0.0%)	0 (0
ETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0
					0 (0
TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0
ETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0
					1 (0
TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0
ETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0
: TYPE I		,			0 (0
: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0
ETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0
: TYPE I					1 (0
: TYPE II	0 (0.0%)	0 (0.0%)	. 0 (0.0%)	O (0.0%)	0 (0
ETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.0%)	1 (1
: TYPE I				·	2 (1
	,		• • • •	1 (0.9%)	3 (2
ven diabetic	status within	each dose group).		
2 : : E : : E : : E : :	TYPE I TYPE II TYPE II	TIC 0 (0.0%) TYPE II 0 (0.0%)	TIC 0 (0.0%) 0 (0.0%) TYPE I 0 (0.0%) 0 (0.0%) TYPE II 0 (0.0%) 0 (0.0%) TYPE II 0 (0.0%) 0 (0.0%) TYPE I 0 (0.0%) 0 (0.0%) TYPE II 0 (0.0%) 0 (0.0%)	TIC	TIC

83

Table 24
Incidence of Related Ocular Adverse Events Affecting the Study Eye by System Organ Class Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Diabetic Status Safety Population

		Cont	rol			
System Organ Class / Preferred Term	Diabetic Status	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
	_			- (- 00)	. (
PUPILLARY DISORDER NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.0%)	1 (1.3%) 1 (0.5%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%) 0 (0.0%)	0 (0.0%) 1 (1.5%)	0 (0.0%) 1 (0.9%)	1 (0.8%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	1 (1.5%)	1 (0.9%)	1 (0.0%)
VISUAL FIELD DEFECT NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	1 (0.5%)
	DIABETIC: TYPE II	0 (0.0%)	1 (0.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
HEADACHE NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
***	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.8%)
PUPILLARY REFLEX IMPAIRED	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.8%)
INFECTIONS AND INFESTATIONS	NON-DIABETIC	0 (0.0%)	1 (1.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
НҮРОРУОМ	NON-DIABETIC	0 (0.0%)	1 (1.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
INJURY AND POISONING	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	1 (0.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
HEAD INJURY	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	० (०.०%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	1 (0.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
VASCULAR DISORDERS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.8%)
PERIPHERAL ISCHEMIA NOS	NON-DIABETIC	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE I	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	DIABETIC: TYPE II	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.8%)

Note: Percentages based on the total number of patients of the given diabetic status within each dose group.

Type I Diabetes includes all insulin-dependent diabetics.

s:\dat\acs\iss2002\sas\programs\t_ocrae_diab 06SEP2002 17:36

Table 25
Analysis of Selected Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

						p-Valu	es [1]	
	Saline					7.5 vs.	55 vs.	75 vs.
System Organ Class / Preferred Term	Control	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase	Overall	Saline	Saline	Saline
NUMBER OF PATIENTS	378	180	359	374				
NUMBER OF PATIENTS WITH AT LEAST ONE SELECTED ADVERSE EVENT	288 (76.2%)	174 (96.7%)	299 (83.3%)	327 (87.4%)				
EYE DISORDERS	287 (75.9%)	174 (96.7%)	298 (83.0%)	327 (87.4%)				
ABNORMAL SENSATION IN EYE	68 (18.0%)	54 (30.0%)	91 (25.3%)	105 (28.1%)	0.00203	0.00206	0.01576	0.00131
BLINDNESS NEC	4 (1.1%)	5 (2.8%)	5 (1.4%)	6 (1.6%)	0.48492	0.15614	0.74679	0.54419
BLINDNESS NIGHT	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0.70720	N/A	N/A	0.49734
BLINDNESS TRANSIENT	0 (0.0%)	1 (0.6%)	1 (0.3%)	0 (0.0%)	0.17412	0.32258	0.48711	N/A
CATARACT CORTICAL	27 (7.1%)	9 (5.0%)	26 (7.2%)	29 (7.8%)	0.70308	0.46093	1.00000	0.78241
CATARACT NEC	10 (2.6%)	1 (0.6%)	10 (2.8%)	8 (2.1%)	0.35474	0.11482	1.00000	0.81232
CATARACT NOS AGGRAVATED	8 (2.1%)	4 (2.2%)	5 (1.4%)	2 (0.5%)	0.19545	1.00000	0.57931	0.10708
CATARACT NUCLEAR	34 (9.0%)	20 (11.1%)	29 (8.1%)	27 (7.2%)	0.46070	0.44572	0.69389	0.42353
CATARACT SUBCAPSULAR	26 (6.9%)	30 (16.7%)	23 (6.4%)	32 (8.6%)	0.00106	0.00076	0.88269	0.41441
CONJUNCTIVAL EDEMA	59 (15.6%)	41 (22.8%)	86 (24.0%)	87 (23.3%)	0.01553	0.04476	0.00532	0.00970
EYE IRRITATION	111 (29.4%)	80 (44.4%)	121 (33.7%)	128 (34.2%)	0.00683	0.00058	0.23398	0.15923
EYE PAIN	84 (22.2%)	63 (35.0%)	129 (35.9%)	149 (39.8%)	<0.00001	0.00197	0.00005	<0.00001
HYPOPYON	0 (0.0%)	1 (0.6%)	6 (1.7%)	20 (5.3%)	<0.00001	0.32258	0.01307	<0.00001
INTRAOCULAR PRESSURE INCREASED	3 (0.8%)	6 (3.3%)	3 (0.8%)	4 (1.1%)	0.09359	0.03499	1.00000	0.72402
IRITIS	126 (33.3%)	110 (61.1%)	208 (57.9%)	230 (61.5%)	<0.00001	<0.00001	<0.00001	<0.00001
LACRIMATION INCREASED	87 (23.0%)	56 (31.1%)	114 (31.8%)	129 (34.5%)	0.00394	0.04857	0.00817	0.00053
OCULAR HYPEREMIA	140 (37.0%)	101 (56.1%)	192 (53.5%)	202 (54.0%)	<0.00001	0.00003	<0.00001	<0.00001
PHOTOPHOBIA	60 (15.9%)	52 (28.9%)	79 (22.0%)	94 (25.1%)	0.00130	0.00045	0.03814	0.00206
PHOTOPSIA	22 (5.8%)	21 (11.7%)	44 (12.3%)	37 (9.9%)	0.01302	0.02599	0.00279	0.04204
RETINAL DETACHMENT	26 (6.9%)	19 (10.6%)	31 (8.6%)	41 (11.0%)	0.21205	0.13817	0.40925	0.05500
VISUAL ACUITY REDUCED	74 (19.6%)	70 (38.9%)	92 (25.6%)	90 (24.1%)	0.00003	<0.00001	0.05259	0.15757
VITREOUS FLOATERS	67 (17.7%)	55 (30.6%)	79 (22.0%)	91 (24.3%)	0.00650	0.00095	0.16547	0.03150
VITREOUS HEMORRHAGE	66 (17.5%)	64 (35.6%)	84 (23.4%)	82 (21.9%)	0.00007	<0.00001	0.05440	0.14214
INVESTIGATIONS	39 (10.3%)	38 (21.1%)	39 (10.9%)	37 (9.9%)				
INTRAOCULAR PRESSURE INCREASED	39 (10.3%)	38 (21.1%)	39 (10.9%)	37 (9.9%)	0.00163	0.00093	0.81206	0.90390
INFECTIONS AND INFESTATIONS	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)				
HYPOPYON	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1.00000	1.00000	1.00000	1.00000

289

Note: Table only lists events related to Hypopyon, Retinal Detachment, Iritis, Hyperemia, Recurrent Vitreous Hemorrhage, Eye Pain, Intraocular Pressure
Increased, No Light Perception, or Cataract, or events occurring in 10% or more of patients in any one treatment group.

Does NOT include patients in any treatment group in the Watchful Waiting cohort in study VIT-02-08961X

^[1] p-Values for comparing across all treatment groups and for pairwise comparisons vs. Saline determined by Fisher's Exact Test.

s:\dat\acs\iss2002\sas\programs\t ocae pval 06SEP2002 17:37

Page 1 of 1

ISTA Pharmaceuticals, Inc.
Integrated Summary of Safety

29

Table 26
Analysis of Related Selected Ocular Adverse Events Affecting the Study Eye by System Organ Class
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

						p-Valu	es [1]	
	Saline					7.5 vs.	55 vs.	75 vs.
System Organ Class / Preferred Term	Control	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase	Overall	Saline	Saline	Saline
NUMBER OF PATIENTS	378	180	359	374				
NUMBER OF PATIENTS WITH AT LEAST ONE RELATED SELECTED ADVERSE EVENT	·	151 (83.9%)	265 (73.8%)	303 (81.0%)				
EYE DISORDERS	233 (61.6%)	151 (83.9%)	264 (73.5%)	303 (81.0%)				
ABNORMAL SENSATION IN EYE	50 (13.2%)	38 (21.1%)	73 (20.3%)	85 (22.7%)	0.00442	0.01865	0.01026	0.00084
BLINDNESS NEC	1 (0.3%)	1 (0.6%)	1 (0.3%)	1 (0.3%)	0.83480	0.54150	1.00000	1.00000
BLINDNESS NIGHT	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0.70720	N/A	N/A	0.49734
BLINDNESS TRANSIENT	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	0.41751	N/A	0.48711	N/A
CATARACT CORTICAL	16 (4.2%)	1 (0.6%)	16 (4.5%)	19 (5.1%)	0.03359	0.01657	1.00000	0.60762
CATARACT NEC	2 (0.5%)	0 (0.0%)	2 (0.6%)	3 (0.8%)	0.84779	1.00000	1.00000	0.68501
CATARACT NOS AGGRAVATED	3 (0.8%)	0 (0.0%)	3 (0.8%)	1 (0.3%)	0.55776	0.55469	1.00000	0.62402
CATARACT NUCLEAR	16 (4.2%)	9 (5.0%)	17 (4.7%)	10 (2.7%)	0.39552	0.66687	0.85895	0.31856
CATARACT SUBCAPSULAR	11 (2.9%)	17 (9.4%)	15 (4.2%)	17 (4.5%)	0.01336	0.00160	0.42578	0.25374
CONJUNCTIVAL EDEMA	49 (13.0%)	26 (14.4%)	69 (19.2%)	76 (20.3%)	0.02374	0.69061	0.02116	0.00803
EYE IRRITATION	79 (20.9%)	57 (31.7%)	90 (25.1%)	96 (25.7%)	0.05226	0.00818	0.18918	0.14223
EYE PAIN	57 (15.1%)	45 (25.0%)	105 (29.2%)	118 (31.6%)	<0.00001	0.00680	<0.00001	
HYPOPYON	0 (0.0%)	1 (0.6%)	6 (1.7%)	20 (5.3%)	<0.00001	0.32258		<0.00001
INTRAOCULAR PRESSURE INCREASED	0 (0.0%)	2 (1.1%)	1 (0.3%)	1 (0.3%)	0.11662	0.10367	0.48711	0.49734
IRITIS	106 (28.0%)	91 (50.6%)	188 (52.4%)	218 (58.3%)	<0.00001	<0.00001	<0.00001	
LACRIMATION INCREASED	56 (14.8%)	38 (21.1%)	89 (24.8%)	95 (25.4%)	0.00096	0.06991	0.00081	0.00036
OCULAR HYPEREMIA	113 (29.9%)	76 (42.2%)	151 (42.1%)	171 (45.7%)	0.00005	0.00543	0.00071	<0.00001
PHOTOPHOBIA	42 (11.1%)	37 (20.6%)	58 (16.2%)	80 (21.4%)	0.00075	0.00405	0.05261	0.00016
RETINAL DETACHMENT	10 (2.6%)	11 (6.1%)	16 (4.5%)	21 (5.6%)	0.12926	0.05633	0.23114	0.04452
VISUAL ACUITY REDUCED	43 (11.4%)	42 (23.3%)	60 (16.7%)	53 (14.2%)	0.00311	0.00038	0.04323	0.27512
VITREOUS FLOATERS	42 (11.1%)	34 (18.9%)	54 (15.0%)	68 (18.2%)	0.02213	0.01699	0.12564	0.00715
EYE DISORDERS ABNORMAL SENSATION IN EYE BLINDNESS NEC BLINDNESS NIGHT BLINDNESS TRANSIENT CATARACT CORTICAL CATARACT NEC CATARACT NOS AGGRAVATED CATARACT NUCLEAR CATARACT SUBCAPSULAR CONJUNCTIVAL EDEMA EYE IRRITATION EYE PAIN HYPOPYON INTRAOCULAR PRESSURE INCREASED IRITIS LACRIMATION INCREASED OCULAR HYPEREMIA PHOTOPHOBIA RETINAL DETACHMENT VISUAL ACUITY REDUCED VITREOUS FLOATERS VITREOUS HEMORRHAGE	25 (6.6%)	30 (16.7%)	33 (9.2%)	27 (7.2%)	0.00162	0.00039	0.21887	0.77520
INVESTIGATIONS	20 (5.3%)	16 (8.9%)	18 (5.0%)	16 (4.3%)				
INTRAOCULAR PRESSURE INCREASED	20 (5.3%)	16 (8.9%)	18 (5.0%)	16 (4.3%)	0.17723	0.13890	1.00000	0.60914
INFECTIONS AND INFESTATIONS	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)				
HYPOPYON	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1.00000	1.00000	1.00000	1.00000

Note: Table only lists events related to Hypopyon, Retinal Detachment, Iritis, Hyperemia, Recurrent Vitreous Hemorrhage, Eye Pain, Intraocular Pressure Increased, No Light Perception, or Cataract, or events occurring in 10% or more of patients in any one treatment group.

Does NOT include patients in any treatment group in the Watchful Waiting cohort in study VIT-02-08961X

^[1] p-Values for comparing across all treatment groups and for pairwise comparisons vs. Saline determined by Fisher's Exact Test.

s:\dat\acs\iss2002\sas\programs\t_ocrae_pval 06SEP2002 17:37

Table 27

Duration of Selected Ocular Adverse Events Affecting the Study Eye
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Cont	rol			
System Organ Class / Preferred Term	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
NUMBER OF PATIENTS	18	378	198	377	391
EYE DISORDERS					
BLINDNESS NEC	_		•	_	
NUMBER OF PATIENTS WITH EVENT	1	4	9	6	9
DURATION OF EVENTS (DAYS) [1]					
Number of events	1	4	8	5	10
Mean (SE)	18.0 (N/A)	72.0 (64.9)		82.0 (50.3)	
Min-Max	18.0 - 18.0	0.0 - 266.0	0.0 - 815.0	0.0 - 220.0	0.0 - 570.0
DURATION OF EVENTS WITH RESOLVED DATES (DAYS) [2]					
Number of events	1	0	1 27.0 (N/A) 27.0 - 27.0	0	2
Mean (SE)	18.0 (N/A)	N/A	27.0 (N/A)	N/A	171.5 (144)
Min-Max	18.0 - 18.0	N/A	27.0 - 27.0	N/A	28.0 - 315.0
DURATION OF MOST SEVERE EVENT (DAYS) [3][5]					
Number of patients	1	4	8	5	9
Mean (SE)	18.0 (N/A)			82.0 (50.3)	
Min-Max	18.0 - 18.0	0.0 - 266.0	0.0 - 815.0	0.0 - 220.0	0.0 - 570.0
DURATION OF LONGEST EVENT (DAYS) [4][5]					
Number of patients	1	4	8	5	9
Mean (SE)	18.0 (N/A)		238.3 (119)	82.0 (50.3)	248.3 (69.3)
Min-Max	18.0 - 18.0	0.0 - 266.0	0.0 - 815.0	0.0 - 220.0	0.0 - 570.0
BLINDNESS NIGHT					
NUMBER OF PATIENTS WITH EVENT	0	0	0	0	1
DURATION OF EVENTS (DAYS) [1]					
Number of events	0	0	0	0	1
Mean (SE)	N/A	N/A	N/A		27.0 (N/A)
Min-Max	N/A	N/A	N/A	N/A	
DURATION OF EVENTS WITH RESOLVED DATES (DAYS) [2]					
Number of events	0	0	0	0	0

^[1] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. Each event having the selected preferred term is counted.

^[2] Each event having the selected preferred term is counted unless the resolved date is missing.

^[3] For each patient the most severe event is used.

^[4] For each patient the longest event is used.

^[5] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. The number of patients may not be equal to the number of patients with the event if the start date is missing.

s:\dat\acs\iss2002\sas\programs\t ocae dur 06SEP2002 17:37

Table 27

Duration of Selected Ocular Adverse Events Affecting the Study Eye
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Con	trol			•
System Organ Class / Preferred Term	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
Mean (SE)	N/A	N/A	N/A	N/A	N/A
Min-Max	N/A	N/A	N/A	N/A	N/A
DURATION OF MOST SEVERE EVENT (DAYS) [3][5]					
Number of patients	0	0	0	0	1
Mean (SE)	N/A	N/A	N/A		27.0 (N/A)
Min-Max	N/A	N/A	N/A	N/A	27.0 - 27.0
DURATION OF LONGEST EVENT (DAYS) [4][5]					
Number of patients	0	0	0	0	1
Mean (SE)	N/A	N/A	N/A		27.0 (N/A)
Min-Max	N/A	N/A	N/A	N/A	27.0 - 27.0
BLINDNESS TRANSIENT					
NUMBER OF PATIENTS WITH EVENT	0	0	1	1	0
DURATION OF EVENTS (DAYS) [1]					
Number of events	0	0	1	1	0
Mean (SE)	N/A	N/A		49.0 (N/A)	N/A
Min-Max	N/A	N/A	1.0 - 1.0	49.0 - 49.0	N/A
DURATION OF EVENTS WITH RESOLVED DATES (DAYS) [2]					
Number of events	0	0	1	1 49.0 (N/A)	0
Mean (SE)	N/A	N/A	1.0 (N/A)	49.0 (N/A)	N/A
Min-Max	N/A	N/A	1.0 - 1.0	49.0 - 49.0	N/A
DURATION OF MOST SEVERE EVENT (DAYS) [3][5]					
Number of patients	0	0	1	1	0
Mean (SE)	N/A	N/A		49.0 (N/A)	N/A
Min-Max	N/A	N/A	1.0 - 1.0	49.0 - 49.0	N/A
DURATION OF LONGEST EVENT (DAYS) [4][5]					
Number of patients	0	0	1	1	0
Mean (SE)	N/A	N/A		49.0 (N/A)	N/A
Min-Max	N/A	N/A	1.0 - 1.0	49.0 - 49.0	N/A

CATARACT CORTICAL

^[1] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. Each event having the selected preferred term is counted.

^[2] Each event having the selected preferred term is counted unless the resolved date is missing.

^[3] For each patient the most severe event is used.

^[4] For each patient the longest event is used.

^[5] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. The number of patients may not be equal to the number of patients with the event if the start date is missing.

s:\dat\acs\iss2002\sas\programs\t_ocae dur 06SEP2002 17:37

29

ISTA Pharmaceuticals, Inc. Integrated Summary of Safety

Table 27

Duration of Selected Ocular Adverse Events Affecting the Study Eye
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Cont	rol			
em Organ Class / Preferred Term		Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitras
NUMBER OF PATIENTS WITH EVENT	5	27	14	30	31
DURATION OF EVENTS (DAYS) [1]					
Number of events	5	29	16	35 201.0 (41.8)	32
Mean (SE)	354.2 (155)	186.2 (28.9)	202.7 (57.9)	201.0 (41.8)	228.5 (32.4
Min-Max	42.0 - 875.0	0.0 - 549.0	0.0 - 714.0	0.0 - 942.0	0.0 - 658.
DURATION OF EVENTS WITH RESOLVED DATES (DAYS) [2]					
Number of events	2	9	8 164.0 (62.5)	15	14
Mean (SE)	47.0 (5.0)	161.7 (48.3)	164.0 (62.5)	143.9 (63.2)	169.2 (39.9
Min-Max	42.0 - 52.0	0.0 - 455.0	24.0 - 482.0	5.0 - 942.0	9.0 - 469.
DURATION OF MOST SEVERE EVENT (DAYS) [3][5]					
Number of patients	5 354.2 (155)	27	14	29	30
	354.2 (155)	193.0 (30.2)	205.6 (64.4)	199.1 (41.7)	232.9 (34.
Min-Max	42.0 - 875.0	0.0 - 549.0	0.0 - 714.0	0.0 - 735.0	0.0 - 658.
DURATION OF LONGEST EVENT (DAYS) [4][5]					
Number of patients	5 354.2 (155)	27	14	29	30
	354.2 (155)	199.9 (29.3)	231.1 (62.6)	240.9 (47.2)	242.5 (32.
Min-Max	42.0 - 875.0	0.0 - 549.0	0.0 - 714.0	0.0 - 942.0	0.0 - 658
ATARACT NEC					
NUMBER OF PATIENTS WITH EVENT	0	10	1	10	9
DURATION OF EVENTS (DAYS) [1]					
Number of events	0	9	1	8	9
Mean (SE)	N/A	96.4 (48.1)	0.0 (N/A)	59.0 (26.2)	54.8 (30.
Min-Max	N/A	0.0 - 345.0	0.0 - 0.0	0.0 - 220.0	0.0 - 224
DURATION OF EVENTS WITH RESOLVED DATES (DAYS) [2]					
Number of events	0	5	0.0 (N/A)	5	.6
Mean (SE)	N/A	76.2 (64.1)	0.0 (N/A)	40.6 (18.9)	11.2 (9.
Min-Max	N/A	0.0 - 330.0	0.0 - 0.0	2.0 - 103.0	0.0 - 59
DURATION OF MOST SEVERE EVENT (DAYS) [3][5]					
Number of patients	0	9	1	7	9

^[1] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. Each event having the selected preferred term is counted.

^[2] Each event having the selected preferred term is counted unless the resolved date is missing.

^[3] For each patient the most severe event is used.

^[4] For each patient the longest event is used.

^[5] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. The number of patients may not be equal to the number of patients with the event if the start date is missing.

s:\dat\acs\iss2002\sas\programs\t_ocae_dur 06SEP2002 17:37

Table 27

Duration of Selected Ocular Adverse Events Affecting the Study Eye
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

tem Organ Class / Preferred Term	ww N/A	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
	N7 / N				
Mean (SE)		96.4 (48.1)	0.0 (N/A)	67.1 (28.7)	54.8 (30.6)
Min-Max	N/A	0.0 - 345.0	0.0 - 0.0		
DURATION OF LONGEST EVENT (DAYS) [4][5]					
Number of patients	0	9	1	7	9
Mean (SE)	N/A		0.0 (N/A)		54.8 (30.6)
Min-Max	N/A	0.0 - 345.0	0.0 - 0.0	0.0 - 220.0	0.0 - 224.0
CATARACT NOS AGGRAVATED					
NUMBER OF PATIENTS WITH EVENT	ı	8	4	5	3
DURATION OF EVENTS (DAYS) [1]					
Number of events	1	9	4 107.5 (63.4)	6	3
Mean (SE)	121.0 (N/A)	130.2 (48.1)	107.5 (63.4)	63.7 (39.8)	0.0 (0.0)
Min-Max	121.0 - 121.0	0.0 - 372.0	0.0 - 247.0	0.0 - 245.0	0.0 - 0.0
DURATION OF EVENTS WITH RESOLVED DATES (DAYS) [2]	_	•	2		0
Number of events	1	50 0 (20 0)	215.0 (32.0)	4 05 5 (54 2)	N/A
Mean (SE) Min-Max	121.0 (N/A) 121.0 - 121.0		183.0 - 247.0	9 0 - 245 0	N/A
MIII-MAX	121.0 - 121.0	13.0 103.0	103.0 217.0	3.0 213.0	**/ **
DURATION OF MOST SEVERE EVENT (DAYS) [3][5]	1	۵	٨	E	3
Number of patients Mean (SE)	121.0 (N/A)	133 / (5/ /)	4 107.5 (63.4)	55 2 (47 6)	00(00)
Min-Max		0.0 - 372.0	0.0 - 247.0	0.0 - 245.0	0.0 - 0.0
	121.0 121.0	0.0 3,2.0	21.10	0,0	
DURATION OF LONGEST EVENT (DAYS) [4][5]	1	8	4	5	3
Number of patients Mean (SE)	121.0 (N/A)				
Min-Max	121.0 (N/A) 121 0 - 121 0	0.0 - 372.0	0.0 - 247.0	0.0 - 245.0	0.0 ~ 0.0
PIII-PIGA	121.0 121.0	0.0 3,2.0	0.0 21770	0.0	
CATARACT NUCLEAR	_		0.77	3.5	20
NUMBER OF PATIENTS WITH EVENT	5	34	27	37	29
DURATION OF EVENTS (DAYS) [1]					• •
Number of events	5	36	33	42 190.6 (31.3)	30 161.0 (27.1)
Mean (SE)	349.0 (125)	210.0 (24.8)	186.7 (30.7)	190.6 (31.3)	101.0 (2/.1)

Note: Table only lists events related to Hypopyon, Retinal Detachment, Iritis, Hyperemia, Recurrent Vitreous Hemorrhage, Eye Pain, Intraocular Pressure Increased, No Light Perception, or Cataract.

S

^[1] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. Each event having the selected preferred term is counted.

^[2] Each event having the selected preferred term is counted unless the resolved date is missing.

^[3] For each patient the most severe event is used.

^[4] For each patient the longest event is used.

^[5] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. The number of patients may not be equal to the number of patients with the event if the start date is missing.

s:\dat\acs\iss2002\sas\programs\t_ocae_dur 06SEP2002 17:37

Table 27

Duration of Selected Ocular Adverse Events Affecting the Study Eye
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Cont	rol			
System Organ Class / Preferred Term	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
Min-Max	0.0 - 674.0	0.0 - 518.0	0.0 - 698.0	0.0 - 888.0	0.0 - 535.0
DURATION OF EVENTS WITH RESOLVED DATES (DAYS) [2]	_			0.7	12
Number of events	2 407.0 (267)	14	15	21	13 110.2 (38.2)
Mean (SE) Min-Max		51.0 - 506.0		5.0 - 600.0	9.0 - 526.0
DURATION OF MOST SEVERE EVENT (DAYS) [3][5]					
Number of patients	5	34	27	37	29
	349.0 (125)	208.1 (24.1)	164.2 (34.2)	199.4 (35.0)	166.0 (27.5)
Min-Max	0.0 - 674.0	0.0 - 518.0	0.0 - 698.0	0.0 - 888.0	0.0 - 535.0
DURATION OF LONGEST EVENT (DAYS) [4][5] Number of patients	5	34	27	37	29
Mean (SE)	349.0 (125)	217.6 (25.4)	221.9 (33.7)	200.5 (34.8)	166.0 (27.5)
Min-Max		0.0 - 518.0	0.0 - 698.0	0.0 - 888.0	0.0 - 535.0
CATARACT SUBCAPSULAR					
NUMBER OF PATIENTS WITH EVENT	2	26	33	29	38
DURATION OF EVENTS (DAYS) [1]	_		2.0	7.4	39
Number of events	2	27	36 227.9 (31.4)	34 197 9 (29 4)	
Mean (SE) Min-Max			0.0 - 821.0		
	00.0 - 173.0	0.0 - 450.0	0.0 021.0	0.0 030.0	0.0 310.0
DURATION OF EVENTS WITH RESOLVED DATES (DAYS) [2] Number of events	1	8	18	17	17
Mean (SE)	60.0 (N/A)	172.4 (38.4)	206.2 (41.0)	188.3 (36.3)	184.2 (31.7)
Min-Max	60.0 - 60.0	54.0 - 364.0	6.0 - 553.0	2.0 - 656.0	0.0 - 409.0
DURATION OF MOST SEVERE EVENT (DAYS) [3][5]					
Number of patients Mean (SE)	2	25	33	29	38
Mean (SE)	117.5 (57.5)	190.2 (27.3)	228.0 (33.5) 0.0 - 821.0	199.4 (31.9) 0.0 - 656.0	
Min-Max	60.0 - 175.0	0.0 - 456.0	0.0 - 821.0	0.0 - 656.0	0.0 - 518.0
DURATION OF LONGEST EVENT (DAYS) [4][5]	•	0 "	2.2	20	3.6
Number of patients	2	25	33	29	38

Note: Table only lists events related to Hypopyon, Retinal Detachment, Iritis, Hyperemia, Recurrent Vitreous Hemorrhage, Eye Pain, Intraocular Pressure Increased, No Light Perception, or Cataract.

[2] Each event having the selected preferred term is counted unless the resolved date is missing.

[4] For each patient the longest event is used.

29

^[1] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. Each event having the selected preferred term is counted.

^[3] For each patient the most severe event is used.

^[5] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. The number of patients may not be equal to the number of patients with the event if the start date is missing.

s:\dat\acs\iss2002\sas\programs\t_ocae_dur 06SEP2002 17:37

Table 27

Duration of Selected Ocular Adverse Events Affecting the Study Eye
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Cont	Control			
System Organ Class / Preferred Term	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
Mean (SE)	117.5 (57.5)	190.2 (27.3)	228.0 (33.5)	205.2 (31.7)	
Min-Max	60.0 - 175.0	0.0 - 456.0	0.0 - 821.0	0.0 - 656.0	0.0 - 518.0
EYE PAIN					
NUMBER OF PATIENTS WITH EVENT	2	84	72	139	161
DURATION OF EVENTS (DAYS) [1]					
Number of events	1	119	99	183 33.6 (4.6)	203
Mean (SE)	2.0 (N/A)	36.5 (6.5)			39.7 (6.2)
Min-Max	2.0 - 2.0	0.0 - 393.0	0.0 - 462.0	0.0 - 422.0	0.0 - 573.0
DURATION OF EVENTS WITH RESOLVED DATES (DAYS) [2]					
Number of events	1	112	92	174	187
Mean (SE)	2.0 (N/A)	30.0 (5.7)	43.1 (8.1)	30.6 (4.4)	
Min-Max	2.0 - 2.0	0.0 - 372.0	0.0 - 462.0	0.0 - 422.0	0.0 - 573.0
DURATION OF MOST SEVERE EVENT (DAYS) [3][5]					
Number of patients	1	84	72	138	159
Mean (SE)	2.0 (N/A)	43.2 (8.8)	61.3 (11.7)	33.1 (5.6)	
Min-Max	2.0 - 2.0	0.0 - 393.0	0.0 - 462.0	0.0 - 422.0	0.0 - 573.0
DURATION OF LONGEST EVENT (DAYS) [4][5]					
Number of patients	1	84	72	138	159
Mean (SE)	2.0 (N/A)	48.1 (8.9)	61.9 (11.7)	39.5 (5.9)	
Min-Max	2.0 - 2.0	0.0 - 393.0	0.0 - 462.0	0.0 - 422.0	0.0 - 573.0
HYPOPYON					
NUMBER OF PATIENTS WITH EVENT	0	0	1	6	21
DURATION OF EVENTS (DAYS) [1]					
Number of events	0	0	1	6	21
Mean (SE)	N/A	N/A	19.0 (N/A)	7.8 (2.0)	
Min-Max	N/A	N/A	19.0 - 19.0	2.0 - 14.0	2.0 - 85.0
DURATION OF EVENTS WITH RESOLVED DATES (DAYS) [2]					
Number of events	0	0	1	6	21
Mean (SE)	N/A	N/A	19.0 (N/A)	7.8 (2.0)	10.3 (3.9)

^[1] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. Each event having the selected preferred term is counted.

^[2] Each event having the selected preferred term is counted unless the resolved date is missing.

^[3] For each patient the most severe event is used.

^[4] For each patient the longest event is used.

^[5] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. The number of patients may not be equal to the number of patients with the event if the start date is missing.

s:\dat\acs\iss2002\sas\programs\t_ocae_dur 06SEP2002 17:37

Table 27

Duration of Selected Ocular Adverse Events Affecting the Study Eye
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Cor	ntrol			
System Organ Class / Preferred Term	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
Min-Max	N/A	N/A	19.0 - 19.0	2.0 - 14.0	2.0 - 85.0
DURATION OF MOST SEVERE EVENT (DAYS) [3][5]					
Number of patients	0	0	1	6	21
Mean (SE)	N/A		19.0 (N/A)	7.8 (2.0)	
Min-Max	N/A	N/A	19.0 - 19.0	2.0 - 14.0	2.0 - 85.0
DURATION OF LONGEST EVENT (DAYS) [4][5]					
Number of patients	0	0	1	6	21
Mean (SE)	N/A		19.0 (N/A)	7.8 (2.0)	10.3 (3.9)
Min-Max	A\N	N/A	19.0 - 19.0	2.0 - 14.0	2.0 - 85.0
INTRAOCULAR PRESSURE INCREASED					
NUMBER OF PATIENTS WITH EVENT	0	3	6	3	6
DURATION OF EVENTS (DAYS) [1]					
Number of events	0	3	7	4	.6
Mean (SE)	N/A		69.1 (32.1)	18.8 (11.3)	19.0 (8.9)
Min-Max	N/A	1.0 - 10.0	0.0 - 225.0	4.0 - 52.0	0.0 - 61.0
DURATION OF EVENTS WITH RESOLVED DATES (DAYS) [2]					
Number of events	0	3	6	4	6
Mean (SE)		4.3 (2.8)	56.2 (34.8)	18.8 (11.3)	19.0 (8.9)
Min-Max	N/A	1.0 - 10.0	0.0 - 225.0	4.0 - 52.0	0.0 - 61.0
DURATION OF MOST SEVERE EVENT (DAYS) [3][5]					
Number of patients	.0	3	6	3	6
Mean (SE)	N/A	4.3 (2.8)			
Min-Max	N/A	1.0 - 10.0	0.0 - 225.0	4.0 - 52.0	0.0 - 61.0
DURATION OF LONGEST EVENT (DAYS) [4][5]					
Number of patients	.0	3	6	3	6
Mean (SE)	N/A	4.3 (2.8)	77.3 (36.7)	23.7 (14.4)	19.0 (8.9)
Min-Max	N/A	1.0 - 10.0	0.0 - 225.0	5.0 - 52.0	0.0 - 61.0
IRITIS		100	100	222	243
NUMBER OF PATIENTS WITH EVENT	4	126	123	222	243

^[1] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. Each event having the selected preferred term is counted.

^[2] Each event having the selected preferred term is counted unless the resolved date is missing.

^[3] For each patient the most severe event is used.

^[4] For each patient the longest event is used.

^[5] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. The number of patients may not be equal to the number of patients with the event if the start date is missing.

s:\dat\acs\iss2002\sas\programs\t ocae dur 06SEP2002 17:37

Table 27

Duration of Selected Ocular Adverse Events Affecting the Study Eye
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Control				
em Organ Class / Preferred Term	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitras
DURATION OF EVENTS (DAYS) [1]					
Number of events	4	229	255	454	496
Number of events Mean (SE)	106.3 (75.6)	39.5 (4.8)	52.1 (6.2)	31.0 (2.7)	26.8 (2.2
Min-Max	30.0 - 333.0	0.0 - 587.0	0.0 - 782.0	0.0 - 595.0	0.0 - 367.
DURATION OF EVENTS WITH RESOLVED DATES (DAYS) [2]					
Number of events	3 30.7 (0.3) 30.0 - 31.0	212	233	438	479
Mean (SE)	30.7 (0.3)	35.8 (4.8)	40.9 (4.2)	27.7 (2.3)	22.1 (1.6
Min-Max	30.0 - 31.0	1.0 - 587.0	2.0 - 465.0	3.0 - 595.0	0.0 - 363.
DURATION OF MOST SEVERE EVENT (DAYS) [3][5]		126	100	222	242
Number of patients	3 131.3 (101)	126	E2 1 (0 6)	27 / (2 9)	25 1 / 3 3
Mean (SE) Min-Max	30.0 - 333.0	0 0 - 542 0	0.0 - 782.0	0 0 - 595 0	0.0 - 367.
MIN-MAX	30.0 - 333.0	0.0 - 542.0	0.0 - 702.0	0.0 - 333.0	0.0 507.
DURATION OF LONGEST EVENT (DAYS) [4][5]	•	126	122	222	243
Number of patients Mean (SE)	3 131.3 (101)	45 4 (7 7)	66 1 (10 1)	37 9 (4 7)	32.1 (3.5
Min-Max	30.0 - 333.0	0.0 - 587.0	0.0 - 782.0	0.0 - 595.0	0.0 - 367.
FINAL DETACHMENT					
NUMBER OF PATIENTS WITH EVENT	3	26	22	35	45
DURATION OF EVENTS (DAYS) [1]					
Number of events	3	29	23 122.1 (52.0)	38	53
Mean (SE)	12.3 (10.4)	68.0 (19.1)	122.1 (52.0)	81.3 (20.8)	69.8 (15.7
Min-Max	0.0 - 33.0	0.0 - 331.0	0.0 - 861.0	0.0 - 538.0	0.0 - 468.
DURATION OF EVENTS WITH RESOLVED DATES (DAYS) [2]					
Number of events	3 12.3 (10.4)	22	17	2/	35
	12.3 (10.4)	34.6 (11.0)	0.0 - 120.0	24.8 (9.3) 0.0 - 248.0	0.0 - 126
Min-Max	0.0 - 33.0	0.0 - 189.0	0.0 - 120.0	0.0 - 240.0	0.0 - 126.
DURATION OF MOST SEVERE EVENT (DAYS) [3][5]	3	0.5	21	3.4	44
Number of patients Mean (SE)	12.3 (10.4)	45 70 0 /01 EV	122 1 (56 5)	34 99 1 (22 9)	73 9 (19 1
mean (SE) Min-Max	0.0 - 33.0	0.0 - 331 0	0.0 - 861.0	0.0 - 538.0	0.0 - 468.
nii-max	0.0 - 33.0	0.0 - 331.0	0.0 - 001.0	0.0 330.0	0.0 400

^[1] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. Each event having the selected preferred term is counted.

^[2] Each event having the selected preferred term is counted unless the resolved date is missing.

^[3] For each patient the most severe event is used.

^[4] For each patient the longest event is used.

^[5] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. The number of patients may not be equal to the number of patients with the event if the start date is missing.

s:\dat\acs\iss2002\sas\programs\t ocae dur 06SEP2002 17:37

Table 27

Duration of Selected Ocular Adverse Events Affecting the Study Eye

Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment

Safety Population

	Control				
System Organ Class / Preferred Term	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
DURATION OF LONGEST EVENT (DAYS) [4][5]					
Number of patients	3	25	21	34	44
Mean (SE)	12.3 (10.4)	78.6 (21.5)	133.1 (56.5)	89.1 (22.9)	81.1 (18.4)
Min-Max	0.0 - 33.0	0.0 - 331.0	0.0 - 861.0	0.0 - 538.0	0.0 - 468.0
INFECTIONS AND INFESTATIONS					
HYPOPYON					
NUMBER OF PATIENTS WITH EVENT	0	1	0	0	0
DURATION OF EVENTS (DAYS) [1]					
Number of events	0	1 .	.0	٥	0
Mean (SE)	N/A	175.0 (N/A)	n/A	N/A	N/A
Min-Max	N/A	175.0 - 175.0	N/A	N/A	N/A
DURATION OF EVENTS WITH RESOLVED DATES (DAYS) [2]					
Number of events	0	1	.0	.0	.0
Mean (SE)	N/A	175.0 (N/A)	N/A	N/A	N/A
Min-Max	N/A	175.0 - 175.0	N/A	N/A	N/A
DURATION OF MOST SEVERE EVENT (DAYS) [3][5]					
Number of patients	0	1	0	.0	0
Mean (SE)	N/A	175.0 (N/A)	N/A	N/A	N/A
Min-Max	A\N	175.0 - 175.0	A/N	A\N	И/A
DURATION OF LONGEST EVENT (DAYS) [4][5]					
Number of patients	0	1	0	0	0
Mean (SE)	N/A	175.0 (N/A)	N/A	N/A	N/A
Min-Max	N/A	175.0 - 175.0	N/A	N/A	N/A
INVESTIGATIONS					
INTRAOCULAR PRESSURE INCREASED					
NUMBER OF PATIENTS WITH EVENT	3	39	40	42	40
DURATION OF EVENTS (DAYS) [1]					
Number of events	3	44	50	49	56
number of evenes)	77	30	* 2	50

Note: Table only lists events related to Hypopyon, Retinal Detachment, Iritis, Hyperemia, Recurrent Vitreous Hemorrhage, Eye Pain, Intraocular Pressure Increased, No Light Perception, or Cataract.

29

^[1] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. Each event having the selected preferred term is counted.

^[2] Each event having the selected preferred term is counted unless the resolved date is missing.

^[3] For each patient the most severe event is used.

^[4] For each patient the longest event is used.

^[5] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. The number of patients may not be equal to the number of patients with the event if the start date is missing.

s:\dat\acs\iss2002\sas\programs\t_ocae_dur 065EP2002 17:37

Table 27 Duration of Selected Ocular Adverse Events Affecting the Study Eye Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment Safety Population

57.7 (31.9)	Saline 55.1 (13.7)		55 IU Vitrase	
	55.1 (13.7)	45 2 (10 9)		
		49.2 (10.7)	45.7 (9.6)	34.8 (8.7)
0.0 - 110.0	0.0 - 390.0	0.0 - 329.0	0.0 - 298.0	0.0 - 366.0
2	37	45	43	52
86.5 (23.5)	49.6 (14.3)	39.6 (10.2)	36.8 (7.4)	37.5 (9.3)
63.0 - 110.0	0.0 - 390.0	0.0 - 262.0	0.0 - 202.0	0.0 - 366.0
3	39	40	41	39
57.7 (31.9)	58.9 (15.4)	54.6 (13.2)	53.5 (11.0)	39.9 (11.3)
0.0 - 110.0	0.0 - 390.0	0.0 - 329.0	0.0 - 298.0	0.0 - 366.0
3	39	40	41	39
57.7 (31.9)	60.3 (15.3)	54.8 (13.2)	53.5 (11.0)	48.1 (11.9)
0.0 - 110.0	0.0 - 390.0	0.0 - 329.0	0.0 - 298.0	0.0 - 366.0
	0.0 - 110.0 2 86.5 (23.5) 63.0 - 110.0 3 57.7 (31.9) 0.0 - 110.0 3 57.7 (31.9)	0.0 - 110.0	0.0 - 110.0	0.0 - 110.0

^[1] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. Each event having the selected preferred term is counted.

^[2] Each event having the selected preferred term is counted unless the resolved date is missing.

^[3] For each patient the most severe event is used.

^[4] For each patient the longest event is used.

^[5] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. The number of patients may not be equal to the number of patients with the event if the start date is missing.

s:\dat\acs\iss2002\sas\programs\t_ocae_dur 06SEP2002 17:37

Table 28

Duration of Related Selected Ocular Adverse Events Affecting the Study Eye Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment Safety Population

	Control				
System Organ Class / Preferred Term	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
NUMBER OF PATIENTS	18	378	198	377	391
EYE DISORDERS					
BLINDNESS NEC NUMBER OF PATIENTS WITH RELATED EVENT	0	1	1	1	2
DURATION OF EVENTS (DAYS) [1]					
Number of events	0	1	1	1	2
Mean (SE)	N/A	266.0 (N/A)			368.0 (53.0)
Min-Max	N/A	266.0 - 266.0	0.0 - 0.0	0.0 - 0.0	315.0 - 421.0
DURATION OF EVENTS WITH RESOLVED DATES (DAYS) [2]					
Number of events	0	0	0	0	1
Mean (SE)	N/A	N/A	N/A	N/A	
Min-Max	N/A	N/A	N/A	N/A	315.0 - 315.0
DURATION OF MOST SEVERE EVENT (DAYS) [3][5]					
Number of patients	0	1	1	1	2
Mean (SE)	N/A	266.0 (N/A)		0.0 (N/A)	368.0 (53.0)
Min-Max	N/A	266.0 - 266.0	0.0 - 0.0	0.0 - 0.0	315.0 - 421.0
DURATION OF LONGEST EVENT (DAYS) [4][5]					
Number of patients	0	1	1	1	2
Mean (SE)	N/A		0.0 (N/A)		
Min-Max	N/A	266.0 - 266.0	0.0 - 0.0	0.0 - 0.0	315.0 - 421.0
BLINDNESS NIGHT					
NUMBER OF PATIENTS WITH RELATED EVENT	0	0	0	0	1
DURATION OF EVENTS (DAYS) [1]					
Number of events	0	0	0	0	1
Mean (SE)	N/A	N/A	N/A	N/A	27.0 (N/A)
Min-Max	N/A	N/A	N/A	N/A	27.0 - 27.0
DURATION OF EVENTS WITH RESOLVED DATES (DAYS) [2]					
Number of events	0	0	0	0	0

^[1] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. Each event having the selected preferred term is counted.

^[2] Each event having the selected preferred term is counted unless the resolved date is missing.

^[3] For each patient the most severe event is used.

^[4] For each patient the longest event is used.

^[5] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. The number of patients may not be equal to the number of patients with the event if the start date is missing.

s:\dat\acs\iss2002\sas\programs\t_ocrae_dur 06SEP2002 17:37

Table 28

Duration of Related Selected Ocular Adverse Events Affecting the Study Eye Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment Safety Population

	Control				
em Organ Class / Preferred Term	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitras
Mean (SE)	N/A	N/A	n/a	N/A	N/A
Min-Max	N/A	N/A	N/A	N/A	N/A
DURATION OF MOST SEVERE EVENT (DAYS) [3][5]					
Number of patients	0	0	0	0	1
Mean (SE)	N/A	N/A	N/A	N/A	27.0 (N/A
Min-Max	N/A	N/A	N/A	N/A	27.0 - 27.
DURATION OF LONGEST EVENT (DAYS) [4][5]					
Number of patients	0	0	0	0	1
Mean (SE)	N/A	N/A	N/A	N/A	27.0 (N/A
Min-Max	N/A	N/A	N/A	N/A	27.0 - 27.
LINDNESS TRANSIENT					
NUMBER OF PATIENTS WITH RELATED EVENT	0	0 ,	0	1	0
DURATION OF EVENTS (DAYS) [1]					
Number of events	0	.0	.0	1	0
Mean (SE)	N/A	N/A	N/A	49.0 (N/A)	N/A
Min-Max	N/A	N/A	N/A	49.0 - 49.0	N/A
DURATION OF EVENTS WITH RESOLVED DATES (DAYS) [2]					
Number of events	0	0	0	1	,0
Mean (SE)	N/A	N/A	N/A	49.0 (N/A)	N/A
Min-Max	N/A	N/A	N/A	49.0 - 49.0	N/A
DURATION OF MOST SEVERE EVENT (DAYS) [3][5]					
Number of patients	0	0	0	1	. 0
Mean (SE)	N/A	N/A		49.0 (N/A)	N/A
Min-Max	N/A	N/A	N/A	49.0 - 49.0	N/A
DURATION OF LONGEST EVENT (DAYS) [4][5]					
Number of patients	0	0	_. o	1	0
Mean (SE)	N/A	N/A	N/A	49.0 (N/A)	N/A
Min-Max	N/A	N/A	N/A	49.0 - 49.0	N/A

CATARACT CORTICAL

^[1] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. Each event having the selected preferred term is counted.

^[2] Each event having the selected preferred term is counted unless the resolved date is missing.

^[3] For each patient the most severe event is used.

^[4] For each patient the longest event is used.

^[5] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. The number of patients may not be equal to the number of patients with the event if the start date is missing.

s:\dat\acs\iss2002\sas\programs\t ocrae_dur 06SEP2002 17:37

Table 28

Duration of Related Selected Ocular Adverse Events Affecting the Study Eye Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment Safety Population

	Control				
System Organ Class / Preferred Term	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
NUMBER OF PATIENTS WITH RELATED EVENT	1	16	3	19	19
DURATION OF EVENTS (DAYS) [1] Number of events Mean (SE) Min-Max	1 42.0 (N/A) 42.0 - 42.0	17 209.2 (41.3) 0.0 - 549.0	4 174.0 (90.2) 8.0 - 336.0	21 172.6 (49.4) 0.0 - 942.0	21 246.0 (41.1) 0.0 - 658.0
DURATION OF EVENTS WITH RESOLVED DATES (DAYS) [2] Number of events Mean (SE) Min-Max	1 42.0 (N/A) 42.0 - 42.0	7 180.6 (57.6) 0.0 - 455.0	2 182.0 (154) 28.0 - 336.0	10 173.1 (93.7) 17.0 - 942.0	11 156.0 (43.8) 9.0 ~ 469.0
DURATION OF MOST SEVERE EVENT (DAYS) [3][5] Number of patients Mean (SE) Min-Max	1 42.0 (N/A) 42.0 - 42.0	16 222.3 (41.7) 0.0 - 549.0	3 222.7 (107) 8.0 - 336.0	18 193.8 (56.2) 0.0 - 942.0	19 254.7 (45.0) 0.0 - 658.0
DURATION OF LONGEST EVENT (DAYS) [4][5] Number of patients Mean (SE) Min-Max	1 42.0 (N/A) 42.0 - 42.0	16 222.3 (41.7) 0.0 - 549.0	3 229.3 (101) 28.0 - 336.0	18 199.0 (55.4) 0.0 - 942.0	19 269.9 (41.7) 9.0 - 658.0
CATARACT NEC NUMBER OF PATIENTS WITH RELATED EVENT	0	2	o	2	4
DURATION OF EVENTS (DAYS) [1] Number of events Mean (SE) Min-Max	0 N/A N/A	2 188.5 (142) 47.0 - 330.0		1 220.0 (N/A) 220.0 - 220.0	
DURATION OF EVENTS WITH RESOLVED DATES (DAYS) [2] Number of events Mean (SE) Min-Max	0 N/A N/A	2 188.5 (142) 47.0 - 330.0	0 N/A N/A	0 N/A N/A	4 16.8 (14.2) 0.0 - 59.0
DURATION OF MOST SEVERE EVENT (DAYS) [3][5] Number of patients	0	2	0	i	4

^[1] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. Each event having the selected preferred term is counted.

^[2] Each event having the selected preferred term is counted unless the resolved date is missing.

^[3] For each patient the most severe event is used.

^[4] For each patient the longest event is used.

^[5] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. The number of patients may not be equal to the number of patients with the event if the start date is missing.

s:\dat\acs\iss2002\sas\programs\t ocrae dur 06SEP2002 17:37

Table 28

Duration of Related Selected Ocular Adverse Events Affecting the Study Eye
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Control				
System Organ Class / Preferred Term	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
Mean (SE)	N/A	188.5 (142) 47.0 - 330.0	n/A n/A	220.0 (N/A) 220.0 - 220.0	16.8 (14.2) 0.0 - 59.0
Min-Max	N/A	47.0 - 330.0	N/A	220.0 - 220.0	0.0 - 39.0
DURATION OF LONGEST EVENT (DAYS) [4][5]					
Number of patients	.0	2 188.5 (142) 47.0 - 330.0	0	1 220.0 (N/A)	4
Mean (SE)	N/A	188.5 (142)	N/A	220.0 (N/A) 220.0 - 220.0	16.8 (14.2) 0.0 - 59.0
Min-Max	N/A	47.0 - 330.0	N/A	220.0 - 220.0	0.0 - 59.0
CATARACT NOS AGGRAVATED					
NUMBER OF PATIENTS WITH RELATED EVENT	1	3	0	3	1
DURATION OF EVENTS (DAYS) [1]					
Number of events	1	4	0	3	1
Mean (SE)	121.0 (N/A)	4 213.3 (84.8)	N/A	10.3 (6.4)	0.0 (N/A)
Min-Max	121.0 - 121.0	33.0 - 372.0	N/A	3 10.3 (6.4) 0.0 - 22.0	0.0 - 0.0
DURATION OF EVENTS WITH RESOLVED DATES (DAYS) [2]					
Number of events	1	1	0	2 15.5 (6.5)	0
Mean (SE)		105.0 (N/A)	N/A	15.5 (6.5)	N/A
Min-Max	121.0 - 121.0	105.0 - 105.0	N/A	9.0 - 22.0	N/A
DURATION OF MOST SEVERE EVENT (DAYS) [3][5]					
Number of patients	1	3	0 N/A	3	1
Mean (SE)	121.0 (N/A)				0.0 (N/A)
Min-Max	121.0 - 121.0	33.0 - 372.0	N/A	0.0 - 22.0	0.0 - 0.0
DURATION OF LONGEST EVENT (DAYS) [4][5]					
Number of patients		3		3	1
Mean (SE)		249.3 (108)		10.3 (6.4)	
Min-Max	121.0 - 121.0	33.0 - 372.0	N/A	0.0 - 22.0	0.0 - 0.0
CATARACT NUCLEAR					
NUMBER OF PATIENTS WITH RELATED EVENT	1	16	12	22	10
DURATION OF EVENTS (DAYS) [1]					
Number of events	1	16	14		
Mean (SE)	546.0 (N/A)	271.5 (34.8)	216.6 (41.5)	208.0 (50.8)	271.7 (58.3)

^[1] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. Each event having the selected preferred term is counted.

^[2] Each event having the selected preferred term is counted unless the resolved date is missing.

^[3] For each patient the most severe event is used.

^[4] For each patient the longest event is used.

^[5] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. The number of patients may not be equal to the number of patients with the event if the start date is missing.

s:\dat\acs\iss2002\sas\programs\t ocrae dur 06SEP2002 17:37

Table 28

Duration of Related Selected Ocular Adverse Events Affecting the Study Eye Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment Safety Population

	Control				
System Organ Class / Preferred Term	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
Min-Max	546.0 - 546.0	9.0 - 518.0	0.0 - 475.0	0.0 - 888.0	21.0 - 535.0
DURATION OF EVENTS WITH RESOLVED DATES (DAYS) [2]				_	
Number of events	0	8	6 239.0 (52.5)	9	4
Mean (SE)	N/A N/A	280.0 (45.0)	239.0 (52.5) 37.0 - 378.0	16/.9 (62.9)	21 0 - 526 0
Min-Max	N/A	112.0 - 506.0	37.0 - 378.0	5.0 - 600.0	21.0 - 328.0
DURATION OF MOST SEVERE EVENT (DAYS) [3][5]					• •
Number of patients	1 546.0 (N/A)	16	12	22	10
Mean (SE)	546.0 (N/A)	271.5 (34.8)	187.3 (42.8)	210.5 (53.1)	271.7 (58.3) 21.0 - 535.0
Min-Max	546.0 - 546.0	9.0 - 518.0	0.0 - 475.0	0.0 - 888.0	21.0 - 535.0
DURATION OF LONGEST EVENT (DAYS) [4][5]					
Number of patients	1	16	12 252.7 (39.4)	22	10
Mean (SE)	1 546.0 (N/A)				
Min-Max	546.0 - 546.0	9.0 - 518.0	37.0 - 475.0	0.0 - 888.0	21.0 - 535.0
CATARACT SUBCAPSULAR					
NUMBER OF PATIENTS WITH RELATED EVENT	0	11	20	20	17
DURATION OF EVENTS (DAYS) [1]					
Number of events	0	11	22	23 190.3 (38.9)	17
Mean (SE)	N/A	243.7 (34.6)	233.1 (46.3)	190.3 (38.9)	176.5 (23.8)
Min-Max	N/A	57.0 - 456.0	0.0 - 821.0	0.0 - 656.0	0.0 - 342.0
DURATION OF EVENTS WITH RESOLVED DATES (DAYS) [2]					
Number of events	0	2	10 205.2 (58.6)	11	8
Mean (SE)	N/A		205.2 (58.6)	182.6 (54.2)	206.9 (31.4)
Min-Max	N/A	57.0 - 364.0	18.0 - 553.0	2.0 - 656.0	105.0 - 342.0
DURATION OF MOST SEVERE EVENT (DAYS) [3][5]					
Number of patients	0	11	20 236.8 (49.6)	20	17
Mean (SE)		243.7 (34.6)	236.8 (49.6)	206.1 (42.5)	176.5 (23.8)
Min-Max	N/A	57.0 - 456.0	0.0 - 821.0	0.0 - 656.0	0.0 - 342.0
DURATION OF LONGEST EVENT (DAYS) [4][5]					
Number of patients	Q	11	20	20	17
-					

^[1] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. Each event having the selected preferred term is counted.

^[2] Each event having the selected preferred term is counted unless the resolved date is missing.

^[3] For each patient the most severe event is used.

^[4] For each patient the longest event is used.

^[5] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. The number of patients may not be equal to the number of patients with the event if the start date is missing.

s:\dat\acs\iss2002\sas\programs\t ocrae dur 06SEP2002 17:37

Table 28

Duration of Related Selected Ocular Adverse Events Affecting the Study Eye Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment Safety Population

	Co	ntrol			
System Organ Class / Preferred Term	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
Mean (SE)	N/A	243.7 (34.6)	236.8 (49.6)	214.4 (42.1)	176.5 (23.8)
Min-Max	N/A	57.0 - 456.0		0.0 - 656.0	
EYE PAIN					
NUMBER OF PATIENTS WITH RELATED EVENT	1	57	48	113	128
DURATION OF EVENTS (DAYS) [1]					
Number of events	0	61	56	135	144
Mean (SE)	N/A	30.4 (9.5)	36.3 (8.5)	27.8 (5.1)	
Min-Max	N/A	0.0 - 393.0	0.0 - 364.0	0.0 - 422.0	0.0 - 573.0
DURATION OF EVENTS WITH RESOLVED DATES (DAYS) [2]					
Number of events	0	58	53	131	138
Mean (SE)	N/A	18.7 (6.5)	28.0 (5.6)	25.6 (4.8)	
Min-Max	N/A	0.0 - 372.0	0.0 - 214.0	0.0 - 422.0	0.0 - 573.0
DURATION OF MOST SEVERE EVENT (DAYS) [3][5]					
Number of patients	0	57	48	113	127
Mean (SE)	N/A	31.9 (10.1)	37.5 (9.8)	27.4 (5.9)	
Min-Max	N/A	1.0 - 393.0	0.0 - 364.0	0.0 - 422.0	0.0 - 573.0
DURATION OF LONGEST EVENT (DAYS) [4][5]					
Number of patients	0	57	48	113	
Mean (SE)	N/A		37.8 (9.8)		
Min-Max	N/A	1.0 - 393.0	0.0 - 364.0	0.0 - 422.0	0.0 - 573.0
HYPOPYON					
NUMBER OF PATIENTS WITH RELATED EVENT	0	0	1	6	21
DURATION OF EVENTS (DAYS) [1]					
Number of events	0	0	1	6	21
Mean (SE)	N/A	N/A		7.8 (2.0)	
Min-Max	N/A	N/A	19.0 - 19.0	2.0 - 14.0	2.0 - 85.0
DURATION OF EVENTS WITH RESOLVED DATES (DAYS) [2]					
Number of events	0	0	1	6	21
Mean (SE)	N/A	N/A	19.0 (N/A)	7.8 (2.0)	10.3 (3.9)

^[1] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. Each event having the selected preferred term is counted.

^[2] Each event having the selected preferred term is counted unless the resolved date is missing.

^[3] For each patient the most severe event is used.

^[4] For each patient the longest event is used.

^[5] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. The number of patients may not be equal to the number of patients with the event if the start date is missing.

s:\dat\acs\iss2002\sas\programs\t ocrae_dur 06SEP2002 17:37

Table 28

Duration of Related Selected Ocular Adverse Events Affecting the Study Eye Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment Safety Population

	Con	trol			
System Organ Class / Preferred Term	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
Min-Max	N/A	N/A	19.0 - 19.0	2.0 - 14.0	2.0 - 85.0
DURATION OF MOST SEVERE EVENT (DAYS) [3][5]					
Number of patients	0	0	1	6	21
Mean (SE)	N/A	N/A	19.0 (N/A)	7.8 (2.0)	10.3 (3.9)
Min-Max	N/A	N/A	19.0 - 19.0	2.0 - 14.0	2.0 - 85.0
DURATION OF LONGEST EVENT (DAYS) [4][5]					
Number of patients	0	0	1	6	21
Mean (SE)	N/A	N/A	19.0 (N/A)	7.8 (2.0)	10.3 (3.9)
Min-Max	N/A	N/A	19.0 - 19.0	2.0 - 14.0	2.0 - 85.0
INTRAOCULAR PRESSURE INCREASED				_	
NUMBER OF PATIENTS WITH RELATED EVENT	0	0	2	1	1
DURATION OF EVENTS (DAYS) [1]					
Number of events	0	.0	2	2	1
Mean (SE)	N/A	N/A	73.5 (73.5)	4.5 (0.5)	0.0 (N/A)
Min-Max	N/A	N/A	0.0 - 147.0	4.0 - 5.0	0.0 - 0.0
DURATION OF EVENTS WITH RESOLVED DATES (DAYS) [2]					
Number of events	0	.0	1	2	1
Mean (SE)	N/A	N/A	0.0 (N/A)	4.5 (0.5)	
Min-Max	N/A	N/A	0.0 - 0.0	4.0 - 5.0	0.0 - 0.0
DURATION OF MOST SEVERE EVENT (DAYS) [3][5]					_
Number of patients	.0	<u>,</u> 0	2	1	1
Mean (SE)	N/A	N/A	73.5 (73.5)	4.0 (N/A)	0.0 (N/A)
Min-Max	N/A	N/A	0.0 - 147.0	4.0 - 4.0	0.0 - 0.0
DURATION OF LONGEST EVENT (DAYS) [4][5]					_
Number of patients	0	0	2	1	1
Mean (SE)	N/A	N/A	73.5 (73.5)	5.0 (N/A)	
Min-Max	N/A	N/A	0.0 - 147.0	5.0 - 5.0	0.0 - 0.0
IRITIS	2	100	100	202	231
NUMBER OF PATIENTS WITH RELATED EVENT	1	106	100	202	231

^[1] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. Each event having the selected preferred term is counted.

^[2] Each event having the selected preferred term is counted unless the resolved date is missing.

^[3] For each patient the most severe event is used.

^[4] For each patient the longest event is used.

^[5] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. The number of patients may not be equal to the number of patients with the event if the start date is missing.

s:\dat\acs\iss2002\sas\programs\t_ocrae_dur 06SEP2002 17:37

Table 28

Duration of Related Selected Ocular Adverse Events Affecting the Study Eye
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Conti	Control			
em Organ Class / Preferred Term	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitras
DURATION OF EVENTS (DAYS) [1]					
Number of events	0	175	182	381	436
Mean (SE)	N/A	30.1 (4.8)	182 34.3 (4.6)	25.1 (2.6)	21.5 (1.5
Min-Max	N/A	0.0 - 587.0	0.0 - 458.0	0.0 - 595.0	0.0 - 367.
DURATION OF EVENTS WITH RESOLVED DATES (DAYS) [2]					
Number of events	0	169	172 28.0 (3.1) 2.0 - 266.0	371	431
Mean (SE)	N/A	29.6 (4.8)	28.0 (3.1)	22.9 (2.1)	19.4 (1.5
Min-Max	N/A	1.0 - 587.0	2.0 - 266.0	3.0 - 595.0	0.0 - 363.
DURATION OF MOST SEVERE EVENT (DAYS) [3][5]					
Number of patients	.0	106	100	202	231
Mean (SE)	N/A	24.4 (4.0)	100 36.9 (5.8) 2.0 - 365.0	23.3 (3.6)	19.6 (2.6
Min-Max	N/A	0.0 - 324.0	2.0 - 365.0	0.0 - 595.0	1.0 - 367.
DURATION OF LONGEST EVENT (DAYS) [4][5]			•••	200	001
Number of patients	0	106	100	202	231
Mean (SE)	N/A	33.2 (7.0)	100 44.4 (7.7) 2.0 - 458.0	31.6 (4.6)	24.8 (2.5
Min-Max	N/A	3.0 - 587.0	2.0 - 458.0	0.0 - 595.0	1.0 - 367.
FINAL DETACHMENT		7.0	12	18	22
NUMBER OF PATIENTS WITH RELATED EVENT	1	10	12	18	22
DURATION OF EVENTS (DAYS) [1]	_		••	22	25
Number of events	1 (2)	12	12 91.3 (70.8)	57 2 (10 A)	04 6 100 6
Mean (SE)	4.0 (N/A) 4.0 - 4.0	0.0 - 301.0	0.0 - 861.0	0.0 - 301.0	0.0 - 445.
Min-Max	4.0 - 4.0	0.0 - 301.0	0.0 - 861.0	0.0 - 301.0	0.0 - 445.
DURATION OF EVENTS WITH RESOLVED DATES (DAYS) [2]	1	11	10	1 7	14
Number of events Mean (SE)	4.0 (N/A)		22 5 (13 2)	17 19.1 (5.3)	40.8 (10.9
Min-Max	4.0 (N/A) 4.0 - 4.0	0.0 - 189.0	0.0 - 120.0	0.0 - 70.0	0.0 - 126
	4.0 - 4.0	0.0 - 105.0	0.0 220.0	,,,,	
DURATION OF MOST SEVERE EVENT (DAYS) [3][5] Number of patients	1	10	11	18	22
Mean (SR)	4.0 (N/A)	70.2 (31.5)	11 99.5 (77.1)	64.9 (22.2)	94.8 (25.3
Mean (SE) Min-Max	4.0 - 4.0	0.0 - 301.0	0.0 - 861.0	0.0 - 301.0	0.0 - 445.
MIN-Max	±.0 ±.0	5.5 501.0	0.0 001.0	0.0 001.0	3.3 1.3.

^[1] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. Each event having the selected preferred term is counted.

^[2] Each event having the selected preferred term is counted unless the resolved date is missing.

^[3] For each patient the most severe event is used.

^[4] For each patient the longest event is used.

^[5] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. The number of patients may not be equal to the number of patients with the event if the start date is missing.

s:\dat\acs\iss2002\sas\programs\t ocrae dur 06SEP2002 17:37

Table 28

Duration of Related Selected Ocular Adverse Events Affecting the Study Eye Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment Safety Population

	_Control				
System Organ Class / Preferred Term	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
DURATION OF LONGEST EVENT (DAYS) [4][5]					
Number of patients	1	10	11	18	22
Mean (SE)	4.0 (N/A)	70.2 (31.5)	99.5 (77.1)	64.9 (22.2)	102.5 (26.3)
Min-Max	4.0 - 4.0	0.0 - 301.0	0.0 - 861.0	0.0 - 301.0	0.0 - 445.0
INFECTIONS AND INFESTATIONS					
HYPOPYON			_	_	_
NUMBER OF PATIENTS WITH RELATED EVENT	0	1	0	0	0
DURATION OF EVENTS (DAYS) [1]					
Number of events	.0	1	0	0	0
Mean (SE)	N/A	175.0 (N/A)	N/A	N/A	N/A
Min-Max	N/A	175.0 - 175.0	N/A	N/A	N/A
DURATION OF EVENTS WITH RESOLVED DATES (DAYS) [2]					
Number of events	0	1	,0	0	0
Mean (SE)	N/A	175.0 (N/A)	N/A	N/A	N/A
Min-Max	N/A	175.0 - 175.0	N/A	N/A	N/A
DURATION OF MOST SEVERE EVENT (DAYS) [3][5]					
Number of patients	0	1	.0	0	0
Mean (SE)	N/A	175.0 (N/A)	N/A	N/A	N/A
Min-Max	N/A	175.0 - 175.0	N/A	N/A	N/A
DURATION OF LONGEST EVENT (DAYS) [4][5]					
Number of patients	0	1	0	0	0
Mean (SE)	N/A	175.0 (N/A)	N/A	N/A	N/A
Min-Max	N/A	175.0 - 175.0	N/A	N/A	N/A
INVESTIGATIONS					
INTRAOCULAR PRESSURE INCREASED		0.0	16	1.0	3.0
NUMBER OF PATIENTS WITH RELATED EVENT	0	20	16	18	16
DURATION OF EVENTS (DAYS) [1]				4.0	
Number of events	0	23	19	20	20

^[1] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. Each event having the selected preferred term is counted.

^[2] Each event having the selected preferred term is counted unless the resolved date is missing.

^[3] For each patient the most severe event is used.

^[4] For each patient the longest event is used.

^[5] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. The number of patients may not be equal to the number of patients with the event if the start date is missing.

s:\dat\acs\iss2002\sas\programs\t ocrae dur 06SEP2002 17:37

Table 28

Duration of Related Selected Ocular Adverse Events Affecting the Study Eye Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment Safety Population

	Cor	ntrol			
stem Organ Class / Preferred Term	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
Mean (SE)	N/A	43.0 (15.2)	45.4 (14.9)	30.1 (8.1)	36.4 (18.7)
Min-Max	N/A	0.0 - 303.0	0.0 - 240.0	0.0 - 132.0	0.0 - 366.0
DURATION OF EVENTS WITH RESOLVED DATES (DAYS) [2]					
Number of events	0	20	18	16	19
Mean (SE)	N/A	32.5 (10.9)	45.6 (15.7)	31.4 (9.6)	38.3 (19.6)
Min-Max	N/A	0.0 - 210.0	0.0 - 240.0	0.0 - 132.0	0.0 - 366.0
DURATION OF MOST SEVERE EVENT (DAYS) [3][5]					
Number of patients	0	20	16	18	16
Mean (SE)	N/A	44.2 (17.4)	51.5 (17.3)	33.1 (8.8)	44.8 (23.0)
Min-Max	N/A	0.0 - 303.0	0.0 - 240.0	0.0 - 132.0	0.0 - 366.0
DURATION OF LONGEST EVENT (DAYS) [4][5]					
Number of patients	0	20	16	18	16
Mean (SE)	N/A	46.9 (17.3)	51.5 (17.3)	33.1 (8.8)	44.8 (23.0)
Min-Max	N/A	0.0 - 303.0	0.0 - 240.0	0.0 - 132.0	0.0 - 366.0

<u>س</u>

^[1] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. Each event having the selected preferred term is counted.

^[2] Each event having the selected preferred term is counted unless the resolved date is missing.

^[3] For each patient the most severe event is used.

^[4] For each patient the longest event is used.

^[5] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. The number of patients may not be equal to the number of patients with the event if the start date is missing.

s:\dat\acs\iss2002\sas\programs\t_ocrae_dur 06SEP2002 17:37

Table 29

Duration of Selected Ocular Adverse Events Affecting the Study Eye that Required Medication Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment Safety Population

	Cor	ntrol			
System Organ Class / Preferred Term	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
NUMBER OF PATIENTS	18	378	198	377	391
EYE DISORDERS					
BLINDNESS NEC					
NUMBER OF PATIENTS WITH EVENT	0	1	1	0	0
DURATION OF EVENTS (DAYS) [1]					
Number of events	0	1	1	0	0
Mean (SE)	N/A	0.0 (N/A)		N/A	N/A
Min-Max	N/A	0.0 - 0.0	257.0 - 257.0	N/A	N/A
DURATION OF EVENTS WITH RESOLVED DATES (DAYS) [2]					
Number of events	0	0	0	0	0
Mean (SE)	N/A	N/A	N/A	N/A	N/A
Min-Max	N/A	N/A	N/A	N/A	N/A
DURATION OF MOST SEVERE EVENT (DAYS) [3][5]					
Number of patients	0	1	1	0	0
Mean (SE)	N/A		257.0 (N/A)	N/A	N/A
Min-Max	N/A	0.0 - 0.0	257.0 - 257.0	N/A	N/A
DURATION OF LONGEST EVENT (DAYS) [4][5]					
Number of patients	0	1	1	0	0
Mean (SE)	N/A		257.0 (N/A)	N/A	N/A
Min-Max	N/A	0.0 - 0.0	257.0 - 257.0	N/A	N/A
EYE PAIN					
NUMBER OF PATIENTS WITH EVENT	0	23	21	44	38
DURATION OF EVENTS (DAYS) [1]					
Number of events	0	28	24	50	40
Mean (SE)	N/A	24.6 (7.6)	44.6 (20.8)	41.0 (11.5)	
Min-Max	N/A	0.0 - 191.0	0.0 - 462.0	0.0 - 380.0	0.0 - 141.0
DURATION OF EVENTS WITH RESOLVED DATES (DAYS) [2]					
Number of events	0	27	22	47	38

^[1] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. Each event having the selected preferred term is counted.

^[2] Each event having the selected preferred term is counted unless the resolved date is missing.

^[3] For each patient the most severe event is used.

^[4] For each patient the longest event is used.

^[5] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. The number of patients may not be equal to the number of patients with the event if the start date is missing.

s:\dat\acs\iss2002\sas\programs\t_ocae_reqmed 06SEP2002 17:37

Table 29

Duration of Selected Ocular Adverse Events Affecting the Study Eye that Required Medication Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment Safety Population

Control								
System Organ Class / Preferred Term	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase			
Mean (SE)	N/A	23.9 (7.9)						
Min-Max	N/A	0.0 - 191.0	0.0 - 462.0	0.0 - 380.0	0.0 - 141.0			
DURATION OF MOST SEVERE EVENT (DAYS) [3][5]								
Number of patients	0	23	21	44	36			
Mean (SE)	N/A	27.6 (9.2)		42.3 (12.6)				
Min-Max	N/A	0.0 - 191.0	0.0 - 462.0	0.0 - 380.0	0.0 - 141.0			
DURATION OF LONGEST EVENT (DAYS) [4][5]								
Number of patients	0	23	21	44	36			
Mean (SE)	N/A	29.0 (9.1)	47.9 (23.7)	42.9 (12.7)	21.4 (4.9)			
Min-Max	N/A	0.0 - 191.0	0.0 - 462.0	0.0 - 380.0	0.0 - 141.0			
HYPOPYON								
NUMBER OF PATIENTS WITH EVENT	0	0	1	5	16			
DURATION OF EVENTS (DAYS) [1]								
Number of events	0	0	1	5	16			
Mean (SE)	N/A	N/A	19.0 (N/A)	6.6 (2.0)				
Min-Max	N/A	N/A	19.0 - 19.0	2.0 - 14.0	2.0 - 28.0			
DURATION OF EVENTS WITH RESOLVED DATES (DAYS) [2]								
Number of events	0	0	1	5	16			
Mean (SE)	N/A	N/A		6.6 (2.0)				
Min-Max	N/A	N/A	19.0 - 19.0	2.0 - 14.0	2.0 - 28.0			
DURATION OF MOST SEVERE EVENT (DAYS) [3][5]								
Number of patients	0	0	1	5	16			
Mean (SE)	N/A	N/A		6.6 (2.0)				
Min-Max	N/A	N/A	19.0 - 19.0	2.0 - 14.0	2.0 - 28.0			
DURATION OF LONGEST EVENT (DAYS) [4][5]								
Number of patients	0	0	1	5	16			
Mean (SE)	N/A		19.0 (N/A)					
Min-Max	N/A	N/A	19.0 - 19.0	2.0 - 14.0	2.0 - 28.0			

INTRAOCULAR PRESSURE INCREASED

^[1] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. Each event having the selected preferred term is counted.

^[2] Each event having the selected preferred term is counted unless the resolved date is missing.

^[3] For each patient the most severe event is used.

^[4] For each patient the longest event is used.

^[5] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. The number of patients may not be equal to the number of patients with the event if the start date is missing.

s:\dat\acs\iss2002\sas\programs\t_ocae_reqmed 06SEP2002 17:37

Table 29

Duration of Selected Ocular Adverse Events Affecting the Study Eye that Required Medication Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment Safety Population

	Cor	ntrol					
m Organ Class / Preferred Term	<u>ww</u>	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitras		
NUMBER OF PATIENTS WITH EVENT	0	2	3	3	3		
DURATION OF EVENTS (DAYS) [1]							
Number of events	0	5.5 (4.5)	3	4	3		
Mean (SE)	N/A	5.5 (4.5)	58.0 (44.7)	18.8 (11.3)	16.0 (1.5		
Min-Max	N/A	1.0 - 10.0	7.0 - 147.0	4.0 - 52.0	13.0 - 18.		
DURATION OF EVENTS WITH RESOLVED DATES (DAYS) [2]							
Number of events	0	2	2	4	3		
Mean (SE)	N/A	5.5 (4.5)	13.5 (6.5)	18.8 (11.3)	16.0 (1.5		
Min-Max	N/A	2 5.5 (4.5) 1.0 - 10.0	7.0 - 20.0	4.0 - 52.0	13.0 - 18.		
DURATION OF MOST SEVERE EVENT (DAYS) [3][5]							
Number of patients	0	2	3	3	3		
Mean (SE)	N/A	5.5 (4.5)	3 58.0 (44.7) 7.0 - 147.0	23.3 (14.6)	16.0 (1.9		
Min-Max	N/A	1.0 - 10.0	7.0 - 147.0	4.0 - 52.0	13.0 - 18.		
DURATION OF LONGEST EVENT (DAYS) [4][5]							
Number of patients	0	2	3 58.0 (44.7)	3	3		
Mean (SE)	N/A	5.5 (4.5)	58.0 (44.7)	23.7 (14.4)	16.0 (1.5		
Min-Max	N/A	1.0 - 10.0	7.0 - 147.0	5.0 - 52.0	13.0 - 18.		
ITIS							
NUMBER OF PATIENTS WITH EVENT	1	53	46	129	124		
DURATION OF EVENTS (DAYS) [1]							
Number of events	0	95	80	225	231		
Mean (SE)	N/A	40.2 (10.0)	50.8 (9.1) 4.0 - 465.0	24.1 (3.1)	19.3 (1.8		
Min-Max	N/A	0.0 - 587.0	4.0 - 465.0	3.0 - 595.0	2.0 - 187		
DURATION OF EVENTS WITH RESOLVED DATES (DAYS) [2]		89 36.4 (10.2)					
Number of events	0	89	78 49.9 (9.2)	223	229		
Mean (SE)	N/A	36.4 (10.2)	49.9 (9.2)	24.0 (3.2)	18.2 (1.6		
Min-Max	N/A	1.0 - 587.0	4.0 - 465.0	3.0 - 595.0	2.0 - 187		
DURATION OF MOST SEVERE EVENT (DAYS) [3][5]				129			
Number of patients	0	53	46		124		

^[1] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. Each event having the selected preferred term is counted.

^[2] Each event having the selected preferred term is counted unless the resolved date is missing.

^[3] For each patient the most severe event is used.

^[4] For each patient the longest event is used.

^[5] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. The number of patients with the event if the start date is missing.

s:\dat\acs\iss2002\sas\programs\t ocae reqmed 06SEP2002 17:37

Table 29

Duration of Selected Ocular Adverse Events Affecting the Study Eye that Required Medication Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment Safety Population

	Cont:	Control			
System Organ Class / Preferred Term	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
Mean (SE) Min-Max	N/A N/A	39.2 (12.4) 1.0 - 542.0	41.4 (8.2) 4.0 - 204.0	24.8 (5.0) 3.0 - 595.0	
DURATION OF LONGEST EVENT (DAYS) [4][5] Number of patients Mean (SE) Min-Max	0 N/A N/A	53 51.4 (16.3) 1.0 - 587.0	46 57.2 (13.3) 4.0 - 465.0	129 28.1 (5.1) 3.0 - 595.0	
INVESTIGATIONS					
INTRAOCULAR PRESSURE INCREASED NUMBER OF PATIENTS WITH EVENT	3	31	32	34	35
DURATION OF EVENTS (DAYS) [1] Number of events Mean (SE) Min-Max	3 57. 7 (31.9) 0.0 - 110.0	34 67.3 (17.2) 0.0 - 390.0	37 45.8 (13.2) 0.0 - 329.0	39 40.4 (9.7) 0.0 - 298.0	
DURATION OF EVENTS WITH RESOLVED DATES (DAYS) [2] Number of events Mean (SE) Min-Max	2 86.5 (23.5) 63.0 - 110.0	28 60.7 (18.3) 0.0 - 390.0	34 37.0 (11.6) 0.0 - 262.0	35 34.6 (7.5) 0.0 - 168.0	
DURATION OF MOST SEVERE EVENT (DAYS) [3][5] Number of patients Mean (SE) Min-Max	3 57.7 (31.9) 0.0 - 110.0	31 70.8 (18.7) 0.0 - 390.0	32 51.4 (15.1) 0.0 - 329.0	33 46.8 (11.1) 0.0 - 298.0	
DURATION OF LONGEST EVENT (DAYS) [4][5] Number of patients Mean (SE) Min-Max	3 57.7 (31.9) 0.0 - 110.0	31 72.5 (18.6) 0.0 - 390.0	32 51.7 (15.1) 0.0 - 329.0	33 46.8 (11.1) 0.0 - 298.0	34 46.7 (12.3) 0.0 - 366.0

^[1] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. Each event having the selected preferred term is counted.

^[2] Each event having the selected preferred term is counted unless the resolved date is missing.

^[3] For each patient the most severe event is used.

^[4] For each patient the longest event is used.

^[5] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. The number of patients may not be equal to the number of patients with the event if the start date is missing.

s:\dat\acs\iss2002\sas\programs\t_ocae_reqmed 06SEP2002 17:37

Table 30

Duration of Related Selected Ocular Adverse Events Affecting the Study Eye that Required Medication

Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment

Safety Population

	Cor	itrol				
System Organ Class / Preferred Term	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase	
NUMBER OF PATIENTS	18	378	198	377	391	
EYE DISORDERS						
EYE PAIN NUMBER OF PATIENTS WITH RELATED EVENT	0	4	5	33	25	
NUMBER OF PATIENTS WITH RELATED EVENT	U	7	J	33	23	
DURATION OF EVENTS (DAYS) [1]						
Number of events	0	4	5	35	26	
Mean (SE)	N/A	21.3 (8.7)	13.4 (5.8) 0.0 - 30.0	28.8 (13.1)	19.4 (6.4)	
Min-Max	N/A	6.0 - 46.0	0.0 - 30.0	0.0 - 380.0	0.0 - 141.0	
DURATION OF EVENTS WITH RESOLVED DATES (DAYS) [2]						
Number of events	0	4	5	34	25	
Mean (SE)	N/A	21.3 (8.7)	13.4 (5.8)	21.4 (11.2)	17.6 (6.4)	
Min-Max	N/A	6.0 - 46.0	5 13.4 (5.8) 0.0 - 30.0	0.0 - 380.0	0.0 - 141.0	
DURATION OF MOST SEVERE EVENT (DAYS) [3][5]						
Number of patients	0	4	5	33	24	
Mean (SE)	N/A	21.3 (8.7)	5 13.4 (5.8)	30.3 (13.9)	19.7 (6.9)	
Min-Max	N/A	6.0 - 46.0	0.0 - 30.0		0.0 - 141.0	
DURATION OF LONGEST EVENT (DAYS) [4][5]						
Number of patients	0	4	5 13.4 (5.8)	33	24	
Mean (SE)	N/A	21.3 (8.7)	13.4 (5.8)	30.3 (13.9)	19.7 (6.9)	
Min-Max	N/A	6.0 - 46.0	0.0 - 30.0	0.0 - 380.0	0.0 - 141.0	
HYPOPYON						
NUMBER OF PATIENTS WITH RELATED EVENT	0	0	1	5	16	
DURATION OF EVENTS (DAYS) [1]						
Number of events	0	0	1	5	16	
Mean (SE)	N/A	N/A	19.0 (N/A)	6.6 (2.0)	7.2 (1.5)	
Min-Max	N/A	N/A	19.0 - 19.0	2.0 - 14.0	2.0 - 28.0	
DURATION OF EVENTS WITH RESOLVED DATES (DAYS) [2]						
Number of events	0	0	1	5	16	

^[1] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. Each event having the selected preferred term is counted.

^[2] Each event having the selected preferred term is counted unless the resolved date is missing.

^[3] For each patient the most severe event is used.

^[4] For each patient the longest event is used.

^[5] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. The number of patients with the event if the start date is missing.

s:\dat\acs\iss2002\sas\programs\t_ocrae_reqmed 06SEP2002 17:38

Table 30

Duration of Related Selected Ocular Adverse Events Affecting the Study Eye that Required Medication

Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment

Safety Population

	Cont	trol			
em Organ Class / Preferred Term	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
Mean (SE)	N/A	N/A	19.0 (N/A)	6.6 (2.0)	
Min-Max	N/A	N/A	19.0 - 19.0	2.0 - 14.0	2.0 - 28.0
DURATION OF MOST SEVERE EVENT (DAYS) [3][5]					
Number of patients	0	0	1	5	16
Mean (SE)	N/A	N/A		6.6 (2.0)	
Min-Max	N/A	N/A	19.0 - 19.0	2.0 - 14.0	2.0 - 28.
DURATION OF LONGEST EVENT (DAYS) [4][5]					
Number of patients	0	0	1	5	16
Mean (SE)	N/A	N/A		6.6 (2.0)	
Min-Max	N/A	N/A	19.0 - 19.0	2.0 - 14.0	2.0 - 28.0
TRAOCULAR PRESSURE INCREASED					
NUMBER OF PATIENTS WITH RELATED EVENT	0	0	1	1	0
DURATION OF EVENTS (DAYS) [1]					
Number of events	0	0	1	2	,0
Mean (SE)	N/A	N/A	147.0 (N/A)		N/A
Min-Max	N/A	N/A	147.0 - 147.0	4.0 - 5.0	N/A
DURATION OF EVENTS WITH RESOLVED DATES (DAYS) [2]					
Number of events	0	0	0	2	0
Mean (SE)	N/A	N/A	N/A	4.5 (0.5)	N/A
Min-Max	N/A	N/A	N/A	4.0 - 5.0	N/A
DURATION OF MOST SEVERE EVENT (DAYS) [3][5]					
Number of patients	0	0	1	1	.0
Mean (SE)	N/A	N/A		4.0 (N/A)	N/A
Min-Max	N/A	N/A	147.0 - 147.0	4.0 - 4.0	N/A
DURATION OF LONGEST EVENT (DAYS) [4][5]					
Number of patients	0	0	1	1	0
Mean (SE)	N/A	N/A	147.0 (N/A)	5.0 (N/A)	N/A
Min-Max	N/A	N/A	147.0 - 147.0	5.0 - 5.0	N/A

C) IRITIS

^[1] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. Each event having the selected preferred term is counted.

^[2] Each event having the selected preferred term is counted unless the resolved date is missing.

^[3] For each patient the most severe event is used.

^[4] For each patient the longest event is used.

^[5] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. The number of patients may not be equal to the number of patients with the event if the start date is missing.

s:\dat\acs\iss2002\sas\programs\t_ocrae_reqmed 06SEP2002 17:38

Table 30

Duration of Related Selected Ocular Adverse Events Affecting the Study Eye that Required Medication

Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment

Safety Population

	Co	ntrol			
System Organ Class / Preferred Term	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
NUMBER OF PATIENTS WITH RELATED EVENT	1	43	31	116	117
DURATION OF EVENTS (DAYS) [1]					
Number of events	0	76	50	195	210
Mean (SE)	N/A	32.6 (9.8)	25.6 (5.7)	21.7 (3.4)	18.1 (1.8)
Min-Max	N/A	0.0 - 587.0	4.0 - 204.0	3.0 - 595.0	2.0 - 187.0
DURATION OF EVENTS WITH RESOLVED DATES (DAYS) [2]					
Number of events	0	74 33.5 (10.1)	50	194	208
Mean (SE)	N/A	33.5 (10.1)	25.6 (5.7)	21.6 (3.4)	16.9 (1.6)
Min-Max	N/A	1.0 - 587.0	4.0 - 204.0	3.0 - 595.0	2.0 - 187.0
DURATION OF MOST SEVERE EVENT (DAYS) [3][5]					
Number of patients	0	43	31 26.9 (8.4)	116	117
Mean (SE)	N/A	24.0 (8.1)	26.9 (8.4)	22.5 (5.3)	15.8 (2.1)
Min-Max	N/A	1.0 - 324.0	4.0 - 204.0	3.0 - 595.0	2.0 - 187.0
DURATION OF LONGEST EVENT (DAYS) [4][5]					
Number of patients	0	43 39.0 (15.6)	31	116	117
Mean (SE)	N/A	39.0 (15.6)	26.9 (8.4)	25.6 (5.4)	19.6 (2.6)
Min-Max	N/A	1.0 - 587.0	4.0 - 204.0	3.0 - 595.0	2.0 - 187.0
INVESTIGATIONS					
INTRAOCULAR PRESSURE INCREASED					
NUMBER OF PATIENTS WITH RELATED EVENT	0	15	12	12	14
DURATION OF EVENTS (DAYS) [1]					
Number of events	0	17	13	14	17
Mean (SE)	N/A		54.4 (21.0)	33.5 (11.1)	41.5 (21.9)
Min-Max	N/A	0.0 - 303.0	0.0 - 240.0	0.0 - 132.0	0.0 - 366.0
DURATION OF EVENTS WITH RESOLVED DATES (DAYS) [2]					
Number of events	0	14	13	11	16
Mean (SE)	N/A		54.4 (21.0)		
Min-Max	N/A	0.0 - 210.0	0.0 - 240.0	2.0 - 132.0	0.0 - 366.0

^[1] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. Each event having the selected preferred term is counted.

^[2] Each event having the selected preferred term is counted unless the resolved date is missing.

^[3] For each patient the most severe event is used.

^[4] For each patient the longest event is used.

^[5] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. The number of patients may not be equal to the number of patients with the event if the start date is missing.

s:\dat\acs\iss2002\sas\programs\t_ocrae_reqmed 06SEP2002 17:38

Table 30

Duration of Related Selected Ocular Adverse Events Affecting the Study Eye that Required Medication

Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment

Safety Population

	Con	trol				
System Organ Class / Preferred Term	ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase	
DURATION OF MOST SEVERE EVENT (DAYS) [3][5]						
Number of patients	0	15	12	12	14	
Mean (SE)	N/A	53.9 (22.5)	56.8 (22.6)	38.5 (12.4)	49.6 (26.2)	
Min-Max	N/A	0.0 - 303.0	0.0 - 240.0	0.0 - 132.0	0.0 - 366.0	
DURATION OF LONGEST EVENT (DAYS) [4][5]						
Number of patients	0	15	12	12	14	
Mean (SE)	N/A	57.5 (22.3)	56.8 (22.6)	38.5 (12.4)	49.6 (26.2)	
Min-Max	N/A	0.0 - 303.0	0.0 - 240.0	0.0 - 132.0	0.0 - 366.0	

318

^[1] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. Each event having the selected preferred term is counted.

^[2] Each event having the selected preferred term is counted unless the resolved date is missing.

^[3] For each patient the most severe event is used.

^[4] For each patient the longest event is used.

^[5] The date of the patient's last visit is used for the resolved date of the event when the resolved date is missing. The number of patients may not be equal to the number of patients with the event if the start date is missing.

s:\dat\acs\iss2002\sas\programs\t ocrae_reqmed 06SEP2002 17:38

Table 31
Incidence of Cataract Affecting the Study Eye
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment and Time Period of Onset
Safety Population

	Contr				
	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
NUMBER OF PATIENTS	18	378	198	377	391
NUMBER OF PATIENTS WITH CATARACTS	9 (50.0%)	99 (26.2%)	69 (34.8%)	91 (24.1%)	95 (24.3%)
DAY 0 to DAY 1	0 (0.0%)	1 (0.3%)	1 (0.5%)	4 (1.1%)	6 (1.5%)
DAY 2 - DAY 7	1 (5.6%)	2 (0.5%)	3 (1.5%)	4 (1.1%)	3 (0.8%)
DAY 8 - DAY 30	1 (5.6%)	9 (2.4%)	4 (2.0%)	13 (3.4%)	6 (1.5%)
DAY 31 - DAY 60	1 (5.6%)	7 (1.9%)	11 (5.6%)	6 (1.6%)	10 (2.6%)
DAY 61 - DAY 90	1 (5.6%)	6 (1.6%)	5 (2.5%)	14 (3.7%)	13 (3.3%)
DAY 91 - DAY 180	1 (5.6%)	30 (7.9%)	19 (9.6%)	14 (3.7%)	20 (5.1%)
> DAY 180	4 (22.2%)	44 (11.6%)	26 (13.1%)	36 (9.5%)	37 (9.5%)

Table 32.1 Summary of Ocular Symptoms Post-Treatment All Studies by Treatment Safety Population

Hemorrhage Clearance Studies						Oth	Other Indications			
	Cont	rol			Vitrase					
Symptom	ww	Saline	7.5 IU	37.5 IU	55 IU	75 IU	Total Vitrase	Vitrase 50-500 IU	Saline Control	Other Active [1]
NUMBER OF PATIENTS	18	417	327	130	377	609	1443	84	21	70
PAIN BURNING / STINGING TEARING ITCHING FOREIGN BODY SENSATION PHOTOPHOBIA	3 (16.7%) 4 (22.2%) 8 (44.4%) 12 (66.7%) 6 (33.3%) 12 (66.7%)	146 (35.0%) 119 (28.5%) 191 (45.8%) 164 (39.3%) 149 (35.7%) 133 (31.9%)	140 (42.8%) 101 (30.9%) 177 (54.1%) 163 (49.8%) 149 (45.6%) 166 (50.8%)	100 (76.9%) 66 (50.8%) 79 (60.8%) 54 (41.5%) 78 (60.0%) 79 (60.8%)	174 (46.2%) 125 (33.2%) 200 (53.1%) 151 (40.1%) 166 (44.0%) 150 (39.8%)	366 (60.1%) 240 (39.4%) 374 (61.4%) 277 (45.5%) 290 (47.6%) 315 (51.7%)	780 (54.1%) 532 (36.9%) 830 (57.5%) 645 (44.7%) 683 (47.3%) 710 (49.2%) 274 (19.0%)	53 (63.1%) 37 (44.0%) 46 (54.8%) 40 (47.6%) 55 (65.5%) 56 (66.7%) 6 (7.1%)	11 (52.4%) 11 (52.4%) 8 (38.1%) 9 (42.9%) 13 (61.9%) 11 (52.4%) 7 (33.3%)	44 (62.9%) 25 (35.7%) 51 (72.9%) 39 (55.7%) 44 (62.9%) 53 (75.7%) 6 (8.6%)
PHOTOPSIA OTHER [2]	0 (0.0%) 16 (88.9%)	57 (13.7%) 253 (60.7%)	59 (18.0%) 173 (52.9%)	23 (17.7%) 25 (19.2%)	73 (19.4%) 262 (69.5%)	119 (19.5%) 316 (51.9%)	776 (53.8%)	67 (79.8%)	13 (61.9%)	59 (84.3%)

320

Note: One patient in study ACS201-HYA-002A received both 75 IU Vitrase and Saline. This patient is included in both groups here. Twelve patients in the "Probe Study" received two injections of 75 IU Vitrase. These patients are only counted once here.

^[1] Other Active treatments include SF6 (PVD-01-08961X) and ACS-101C (COR-01-08961X). Patients who received both Vitrase and another active study treatment are included in both groups

^[2] Other symptoms include any symptoms recorded in the individual studies not listed here, or those recorded as 'Other (specify)'. For studies VIT-02-08961X and VIT-03-08961X, the 'Other' symptom was floaters. See Table 32.3, for incidence of floaters.

Table 32.2
Summary of Ocular Symptoms Post-Treatment
All Studies by Study for Vitrase Groups Only
Safety Population

Symptom	Phase I [1]	V-01-VIT-08961X	ACS202-HYA-001US	ACS203-HYA-001MEX	VIT-02-08961X	VIT-03-08961X	Other Indications [2]
NUMBER OF PATIENTS	68	31	153	225	602	364	84
PAIN	45 (66.2%)	24 (77.4%)	98 (64.1%)	164 (72.9%)	304 (50.5%)	145 (39.8%)	53 (63.1%)
BURNING / STINGING	38 (55.9%)	15 (48.4%)	63 (41.2%)	97 (43.1%)	218 (36.2%)	101 (27.7%)	37 (44.0%)
TEARING	48 (70.6%)	26 (83.9%)	108 (70.6%)	123 (54.7%)	379 (63.0%)	146 (40.1%)	46 (54.8%)
ITCHING	47 (69.1%)	7 (22.6%)	79 (51.6%)	100 (44.4%)	303 (50.3%)	109 (29.9%)	40 (47.6%)
FOREIGN BODY SENSATION	47 (69.1%)	12 (38.7%)	89 (58.2%)	111 (49.3%)	306 (50.8%)	118 (32.4%)	55 (65.5%)
РНОТОРНОВІА	53 (77.9%)	10 (32.3%)	110 (71.9%)	109 (48.4%)	320 (53.2%)	108 (29.7%)	56 (66.7%)
PHOTOPSIA	20 (29.4%)	8 (25.8%)	34 (22.2%)	21 (9.3%)	140 (23.3%)	51 (14.0%)	6 (7.1%)
OTHER [3]	30 (44.1%)	3 (9.7%)	53 (34.6%)	3 (1.3%)	471 (78.2%)	216 (59.3%)	67 (79.8%)

ω 22 14

^[1] Includes ACS201-HYA-001A, ACS201-HYA-002A, Probe Study

^[2] Includes PVD-01-08961X, COR-01-08961X, COP-01-08961X

^[3] Other symptoms include any symptoms recorded in the individual studies not listed here, or those recorded as 'Other (specify)'. For studies VIT-02-08961X and VIT-03-08961X, the 'Other' symptom was floaters. See Table 32.3, for incidence of floaters.

Table 32.3

Summary of Ocular Symptoms Post-Treatment
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

		Control								
Symptom	WW		Sa	line	7.5 IU	J Vitrase	55 IU	Vitrase	75 IU	Vitrase
								· ·		
NUMBER OF PATIENTS	1	.8		378		198		377		391
PAIN	3 (1	.6.7%)	128	(33.9%)	77	(38.9%)	174	(46.2%)	198	(50.6%)
BURNING / STINGING	4 (2	2.2%)	108	(28.6%)	62	(31.3%)	125	(33.2%)	132	(33.8%)
TEARING	8 (4	4.4%)	162	(42.9%)	107	(54.0%)	200	(53.1%)	218	(55.8%)
ITCHING	12 (6	6.7%)	153	(40.5%)	102	(51.5%)	151	(40.1%)	159	(40.7%)
FOREIGN BODY SENSATION	6 (3	3.3%)	133	(35.2%)	85	(42.9%)	166	(44.0%)	173	(44.2%)
PHOTOPHOBIA	12 (6	6.7%)	126	(33.3%)	104	(52.5%)	150	(39.8%)	174	(44.5%)
PHOTOPSIA	•	0.0%)	55	(14.6%)	47	(23.7%)	73	(19.4%)	71	(18.2%)
FLOATERS	13 ((2.2%)	205	(54.2%)	128	(64.6%)	211	(56.0%)	233	(59.6%)

Table 32.4

Summary of Ocular Symptoms Post-Treatment
PVD Study (PVD-01-08961X) by Treatment
Safety Population

Symptom	Vitrase 75 IU	SF6	Vitrase 75 IU + SF6	Saline
NUMBER OF PATIENTS	15	15	14	16
PAIN	7 (46.7%)	4 (26.7%)	9 (64.3%)	8 (50.0%)
BURNING / STINGING	8 (53.3%)	4 (26.7%)	6 (42.9%)	9 (56.3%)
TEARING	9 (60.0%)	10 (66.7%)	6 (42.9%)	8 (50.0%)
ITCHING	6 (40.0%)	5 (33.3%)	6 (42.9%)	7 (43.8%)
FOREIGN BODY SENSATION	12 (80.0%)	6 (40.0%)	8 (57.1%)	10 (62.5%)
PHOTOPHOBIA PHOTOPSIA FLOATERS	9 (60.0%)	9 (60.0%)	10 (71.4%)	8 (50.0%)
	4 (26.7%)	4 (26.7%)	2 (14.3%)	7 (43.8%)
	11 (73.3%)	14 (93.3%)	9 (64.3%)	9 (56.3%)

Table 33
Summary of Ocular Symptoms Maximum Severity Post-Treatment
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Max. Severity	Cont:	rol				
Symptom	Post Treatment	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase	
NUMBER OF PATIENTS		18	378	198	377	391	
PAIN	MILD	2 (11.1%)	103 (27.2%)	65 (32.8%)	119 (31.6%)	135 (34.5%)	
	MODERATE	1 (5.6%)	22 (5.8%)	9 (4.5%)	38 (10.1%)	41 (10.5%)	
	SEVERE	0 (0.0%)	3 (0.8%)	3 (1.5%)	17 (4.5%)	22 (5.6%)	
BURNING / STINGING	MILD	4 (22.2%)	98 (25.9%)	54 (27.3%)	93 (24.7%)	99 (25.3%)	
•	MODERATE	0 (0.0%)	9 (2.4%)	6 (3.0%)	25 (6.6%)	27 (6.9%)	
	SEVERE	0 (0.0%)	1 (0.3%)	2 (1.0%)	7 (1.9%)	6 (1.5%)	
TEARING	MILD	6 (33.3%)	125 (33.1%)	77 (38.9%)	135 (35.8%)	139 (35.5%)	
	MODERATE	2 (11.1%)	28 (7.4%)	21 (10.6%)	46 (12.2%)	53 (13.6%)	
	SEVERE	0 (0.0%)	9 (2.4%)	9 (4.5%)	19 (5.0%)	26 (6.6%)	
ITCHING	MILD	11 (61.1%)	129 (34.1%)	88 (44.4%)	124 (32.9%)	122 (31.2%)	
TICHING	MODERATE	0 (0.0%)	21 (5.6%)	13 (6.6%)	21 (5.6%)	29 (7.4%)	
	SEVERE	1 (5.6%)	3 (0.8%)	1 (0.5%)	6 (1.6%)	8 (2.0%)	
FOREIGN BODY SENSATION	MILD	5 (27.8%)	113 (29.9%)	58 (29.3%)	125 (33.2%)	128 (32.7%)	
TORDICK DODI DEMONITION	MODERATE	0 (0.0%)	17 (4.5%)	21 (10.6%)	35 (9.3%)	33 (8.4%)	
	SEVERE	1 (5.6%)	3 (0.8%)	6 (3.0%)	6 (1.6%)	12 (3.1%)	
PHOTOPHOBIA	MILD	7 (38.9%)	82 (21.7%)	61 (30.8%)	73 (19.4%)	85 (21.7%)	
INCIGINOBIA	MODERATE	2 (11.1%)	27 (7.1%)	20 (10.1%)	52 (13.8%)	51 (13.0%)	
	SEVERE	3 (16.7%)	17 (4.5%)	23 (11.6%)	25 (6.6%)	38 (9.7%)	
PHOTOPSIA	MILD	0 (0.0%)	43 (11.4%)	34 (17.2%)	52 (13.8%)	45 (11.5%)	
11101010111	MODERATE	0 (0.0%)	9 (2.4%)	11 (5.6%)	19 (5.0%)	19 (4.9%)	
	SEVERE	0 (0.0%)	3 (0.8%)	2 (1.0%)	2 (0.5%)	7 (1.8%)	
FLOATERS	MILD	3 (16.7%)	98 (25.9%)	55 (27.8%)	108 (28.6%)	106 (27.1%)	
LDONIERS	MODERATE	5 (27.8%)	56 (14.8%)	41 (20.7%)	53 (14.1%)	67 (17.1%)	
	SEVERE	5 (27.8%)	51 (13.5%)	32 (16.2%)	50 (13.3%)	60 (15.3%)	

Table 34
Summary of Ocular Symptoms Maximum Severity Post-Treatment, Stratified by Baseline Severity
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Baseline		Cont:				
Symptom	Severity	Post Treatment	ww 	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
NUMBER OF PATIENTS			18	378	198	377	391
PAIN	NONE	NONE	15 (83.3%)	245 (64.8%)	115 (58.1%)	195 (51.7%)	190 (48.6%)
		MILD	1 (5.6%)	86 (22.8%)	55 (27.8%)	109 (28.9%)	120 (30.7%)
		MODERATE	1 (5.6%)	15 (4.0%)	6 (3.0%)	29 (7.7%)	33 (8.4%)
		SEVERE	0 (0.0%)	2 (0.5%)	2 (1.0%)	11 (2.9%)	15 (3.8%)
	MILD	NONE	0 (0.0%)	5 (1.3%)	5 (2.5%)	7 (1.9%)	2 (0.5%)
		MILD	1 (5.6%)	16 (4.2%)	8 (4.0%)	8 (2.1%)	15 (3.8%)
		MODERATE	0 (0.0%)	5 (1.3%)	2 (1.0%)	7 (1.9%)	8 (2.0%)
		SEVERE	0 (0.0%)	1 (0.3%)	1 (0.5%)	4 (1.1%)	5 (1.3%)
	MODERATE	NONE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
		MILD	0 (0.0%)	1 (0.3%)	2 (1.0%)	2 (0.5%)	0 (0.0%)
		MODERATE	0 (0.0%)	1 (0.3%)	0 (0.0%)	2 (0.5%)	0 (0.0%)
		SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
	SEVERE	NONE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		MODERATE	0 (0.0%)	1 (0.3%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
		SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
BURNING / STINGING	NONE	NONE	13 (72.2%)	264 (69.8%)	129 (65.2%)	246 (65.3%)	253 (64.7%)
		MILD	3 (16.7%)	77 (20.4%)	43 (21.7%)	78 (20.7%)	77 (19.7%)
		MODERATE	0 (0.0%)	7 (1.9%)	5 (2.5%)	18 (4.8%)	22 (5.6%)
		SEVERE	0 (0.0%)	1 (0.3%)	1 (0.5%)	4 (1.1%)	5 (1.3%)
	MILD	NONE	1 (5.6%)	5 (1.3%)	6 (3.0%)	6 (1.6%)	4 (1.0%)
		MILD	1 (5.6%)	17 (4.5%)	10 (5.1%)	15 (4.0%)	22 (5.6%)
		MODERATE	0 (0.0%)	2 (0.5%)	1 (0.5%)	2 (0.5%)	2 (0.5%)
		SEVERE	0 (0.0%)	0 (0.0%)	1 (0.5%)	3 (0.8%)	1 (0.3%)
	MODERATE	NONE	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	2 (0.5%)
		MILD	0 (0.0%)	3 (0.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (1.1%)	3 (0.8%)
		SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	NONE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		MILD	0 (0.0%)	1 (0.3%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
		MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
		SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Table 34
Summary of Ocular Symptoms Maximum Severity Post-Treatment, Stratified by Baseline Severity Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment Safety Population

	Baseline	Max. Severity	Conti	col			
Symptom	Severity	Post Treatment	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
				· • • • • • • • • • • • • • • • • • • •			
TEARING	NONE	NONE	10 (55.6%)	202 (53.4%)	86 (43.4%)	163 (43.2%)	162 (41.4%)
		MILD	1 (5.6%)	80 (21.2%)	46 (23.2%)	90 (23.9%)	90 (23.0%)
		MODERATE	1 (5.6%)	14 (3.7%)	6 (3.0%)	29 (7.7%)	30 (7.7%)
		SEVERE	0 (0.0%)	1 (0.3%)	5 (2.5%)	8 (2.1%)	14 (3.6%)
	MILD	NONE	0 (0.0%)	12 (3.2%)	5 (2.5%)	14 (3.7%)	10 (2.6%)
		MILD	5 (27.8%)	43 (11.4%)	29 (14.6%)	44 (11.7%)	44 (11.3%)
		MODERATE	1 (5.6%)	8 (2.1%)	10 (5.1%)	13 (3.4%)	17 (4.3%)
		SEVERE	0 (0.0%)	4 (1.1%)	3 (1.5%)	5 (1.3%)	6 (1.5%)
		SEVERE	0 (0.00)	1 (1.10)	3 (2.207	2 (2:+1,	,
	MODERATE	NONE	0 (0.0%)	2 (0.5%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
		MILD	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	3 (0.8%)
		MODERATE	0 (0.0%)	4 (1.1%)	5 (2.5%)	4 (1.1%)	6 (1.5%)
		SEVERE	0 (0.0%)	1 (0.3%)	1 (0.5%)	3 (0.8%)	2 (0.5%)
	SEVERE	NONE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		MILD	0 (0.0%)	2 (0.5%)	0 (0.0%)	0 (0.0%)	2 (0.5%)
		MODERATE	0 (0.0%)	2 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		SEVERE	0 (0.0%)	3 (0.8%)	0 (0.0%)	3 (0.8%)	4 (1.0%)
ITCHING	NONE	NONE	6 (33.3%)	218 (57.7%)	89 (44.9%)	218 (57.8%)	215 (55.0%)
110110110		MILD	9 (50.0%)	77 (20.4%)	62 (31.3%)	75 (19.9%)	78 (19.9%)
		MODERATE	0 (0.0%)	9 (2.4%)	9 (4.5%)	11 (2.9%)	12 (3.1%)
		SEVERE	0 (0.0%)	2 (0.5%)	0 (0.0%)	3 (0.8%)	3 (0.8%)
	MILD	NONE	0 (0.0%)	6 (1.6%)	7 (3.5%)	8 (2.1%)	16 (4.1%)
	HILDD	MILD	2 (11.1%)	50 (13.2%)	23 (11.6%)	48 (12.7%)	41 (10.5%)
		MODERATE	0 (0.0%)	3 (0.8%)	2 (1.0%)	5 (1.3%)	9 (2.3%)
		SEVERE	1 (5.6%)	1 (0.3%)	1 (0.5%)	3 (0.8%)	2 (0.5%)
		SEVERE	1 (3.0%)	1 (0.3%)	1 (0.5%)	3 (0.00)	2 (0.54)
	MODERATE	NONE	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
		MILD	0 (0.0%)	2 (0.5%)	2 (1.0%)	1 (0.3%)	2 (0.5%)
		MODERATE	0 (0.0%)	9 (2.4%)	1 (0.5%)	5 (1.3%)	8 (2.0%)
		SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)
	SEVERE	NONE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
		MODERATE	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
		SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)

Table 34

Summary of Ocular Symptoms Maximum Severity Post-Treatment, Stratified by Baseline Severity Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment Safety Population

	Baseline	Max, Severity	Cont:	rol			
Symptom	Severity		WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
FOREIGN BODY SENSATION	NONE	NONE	11 (61.1%)	239 (63.2%)	109 (55.1%)	202 (53.6%)	209 (53.5%)
		MILD	2 (11.1%)	85 (22.5%)	38 (19.2%)	92 (24.4%)	99 (25.3%)
		MODERATE	0 (0.0%)	13 (3.4%)	12 (6.1%)	23 (6.1%)	23 (5.9%)
		SEVERE	0 (0.0%)	2 (0.5%)	4 (2.0%)	3 (0.8%)	6 (1.5%)
	MILD	NONE	1 (5.6%)	5 (1.3%)	3 (1.5%)	9 (2.4%)	7 (1.8%)
		MILD	3 (16.7%)	27 (7.1%)	17 (8.6%)	33 (8.8%)	29 (7.4%)
		MODERATE	0 (0.0%)	0 (0.0%)	6 (3.0%)	9 (2.4%)	7 (1.8%)
		SEVERE	0 (0.0%)	1 (0.3%)	2 (1.0%)	1 (0.3%)	3 (0.8%)
	MODERATE	NONE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	MODERATE	MILD	0 (0.0%)	1 (0.3%)	3 (1.5%)	0 (0.0%)	0 (0.0%)
		MODERATE	0 (0.0%)	4 (1.1%)	3 (1.5%)	3 (0.8%)	2 (0.5%)
		SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	2 (0.5%)
		SEVERE	0 (0.0%)	0 (0.04)	0 (0.03)	1 (0.50)	2 (0.50/
	SEVERE	NONE	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
		MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
		SEVERE	1 (5.6%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
PHOTOPHOBIA	NONE	NONE	5 (27.8%)	242 (64.0%)	88 (44.4%)	220 (58.4%)	209 (53.5%)
		MILD	3 (16.7%)	48 (12.7%)	28 (14.1%)	39 (10.3%)	50 (12.8%)
		MODERATE	1 (5.6%)	12 (3.2%)	6 (3.0%)	22 (5.8%)	28 (7.2%)
		SEVERE	1 (5.6%)	3 (0.8%)	9 (4.5%)	6 (1.6%)	13 (3.3%)
		17017M	0 (0.0%)	8 (2.1%)	4 (2.0%)	6 (1.6%)	5 (1.3%)
	MILD	NONE	4 (22.2%)	29 (7.7%)	27 (13.6%)	30 (8.0%)	28 (7.2%)
		MILD MODERATE	1 (5.6%)	4 (1.1%)	6 (3.0%)	19 (5.0%)	17 (4.3%)
			· ·	2 (0.5%)	4 (2.0%)	7 (1.9%)	6 (1.5%)
		SEVERE	0 (0.0%)	2 (0.5%)	4 (2.08)	/ (1.96)	0 (1.5%)
	MODERATE	NONE	0 (0.0%)	2 (0.5%)	1 (0.5%)	0 (0.0%)	1 (0.3%)
		MILD	0 (0.0%)	4 (1.1%)	4 (2.0%)	4 (1.1%)	6 (1.5%)
		MODERATE	0 (0.0%)	9 (2.4%)	7 (3.5%)	10 (2.7%)	3 (0.8%)
		SEVERE	1 (5.6%)	3 (0.8%)	0 (0.0%)	5 (1.3%)	5 (1.3%)
	SEVERE	NONE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
		MILD	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
		MODERATE	0 (0.0%)	2 (0.5%)	1 (0.5%)	1 (0.3%)	2 (0.5%)
		SEVERE	1 (5.6%)	9 (2.4%)	10 (5.1%)	7 (1.9%)	14 (3.6%)
		OHVERE	1 (5.00)	2 (2.10)	(0.10,	. (=.,,	(2.27)

Table 34

Summary of Ocular Symptoms Maximum Severity Post-Treatment, Stratified by Baseline Severity Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment Safety Population

	Baseline	Max. Severity	Cont	rol			
Symptom	Severity	Post Treatment	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
PHOTOPSIA	NONE	NONE	6 (33.3%)	291 (77.0%)	115 (58.1%)	272 (72.1%)	274 (70.1%)
		MILD	0 (0.0%)	27 (7.1%)	18 (9.1%)	34 (9.0%)	31 (7.9%)
		MODERATE	0 (0.0%)	4 (1.1%)	8 (4.0%)	11 (2.9%)	13 (3.3%)
		SEVERE	0 (0.0%)	0 (0.0%)	2 (1.0%)	1 (0.3%)	5 (1.3%)
			•				
	MILD	NONE	0 (0.0%)	8 (2.1%)	2 (1.0%)	2 (0.5%)	6 (1.5%)
		MILD	0 (0.0%)	13 (3.4%)	9 (4.5%)	7 (1.9%)	10 (2.6%)
		MODERATE	0 (0.0%)	2 (0.5%)	1 (0.5%)	3 (0.8%)	1 (0.3%)
		SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
							0 (0 08)
	MODERATE	NONE	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		MILD	0 (0.0%)	0 (0.0%)	2 (1.0%)	0 (0.0%)	1 (0.3%)
		MODERATE	0 (0.0%)	2 (0.5%)	2 (1.0%)	4 (1.1%)	2 (0.5%)
		SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	NONE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		SEVERE	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
		SEVERE	0 (0.0%)	1 (0.50)	0 (0.00,	, , , , , ,	_ (,
FLOATERS	NONE	NONE	4 (22.2%)	162 (42.9%)	64 (32.3%)	155 (41.1%)	148 (37.9%)
		MILD	3 (16.7%)	36 (9.5%)	31 (15.7%)	60 (15.9%)	55 (14.1%)
		MODERATE	0 (0.0%)	18 (4.8%)	11 (5.6%)	11 (2.9%)	20 (5.1%)
		SEVERE	2 (11.1%)	3 (0.8%)	8 (4.0%)	8 (2.1%)	12 (3.1%)
	MILD	NONE	1 (5.6%)	7 (1.9%)	2 (1.0%)	6 (1.6%)	8 (2.0%)
	MILLO	MILD	0 (0.0%)	49 (13.0%)	20 (10.1%)	43 (11.4%)	38 (9.7%)
				4 (1.1%)	7 (3.5%)	7 (1.9%)	8 (2.0%)
		MODERATE	0 (0.0%)			4 (1.1%)	4 (1.0%)
		SEVERE	0 (0.0%)	5 (1.3%)	1 (0.5%)	4 (1.16)	4 (1.0%)
	MODERATE	NONE	0 (0.0%)	1 (0.3%)	4 (2.0%)	2 (0.5%)	2 (0.5%)
		MILD	0 (0.0%)	10 (2.6%)	4 (2.0%)	3 (0.8%)	10 (2.6%)
		MODERATE	4 (22.2%)	28 (7.4%)	16 (8.1%)	27 (7.2%)	36 (9.2%)
		SEVERE	0 (0.0%)	4 (1.1%)	5 (2.5%)	7 (1.9%)	4 (1.0%)
	SEVERE	NONE	0 (0.0%)	3 (0.8%)	0 (0.0%)	3 (0.8%)	0 (0.0%)
		MILD	0 (0.0%)	3 (0.8%)	0 (0.0%)	2 (0.5%)	3 (0.8%)
		MODERATE	1 (5.6%)	6 (1.6%)	6 (3.0%)	8 (2.1%)	3 (0.8%)
		SEVERE	3 (16.7%)	39 (10.3%)	18 (9.1%)	31 (8.2%)	40 (10.2%)

Table 35
Summary of Ocular Symptoms Change from Baseline at Specified Visits
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

				rol			
Symptom [1]	Visit		ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
		NUMBER OF PATIENTS	18	378	198	377	391
PAIN	DAY 1	DECREASE	0 (0.0%)	12 (3.2%)	10 (5.1%)	11 (2.9%)	5 (1.3%)
		NO CHANGE	17 (94.4%)	287 (75.9%)	147 (74.2%)	233 (61.8%)	235 (60.1%)
		INCREASE BY 1	0 (0.0%)	67 (17.7%)	35 (17.7%)	95 (25.2%)	108 (27.6%)
		INCREASE BY 2	0 (0.0%)	7 (1.9%)	1 (0.5%)	24 (6.4%)	27 (6.9%)
		INCREASE BY 3	0 (0.0%)	0 (0.0%)	1 (0.5%)	8 (2.1%)	10 (2.6%)
	WEEK 1	DECREASE	0 (0.0%)	21 (5.6%)	12 (6.1%)	22 (5.8%)	22 (5.6%)
		NO CHANGE	17 (94.4%)	327 (86.5%)	162 (81.8%)	309 (82.0%)	327 (83.6%)
		INCREASE BY 1	0 (0.0%)	14 (3.7%)	13 (6.6%)	25 (6.6%)	21 (5.4%)
		INCREASE BY 2	0 (0.0%)	2 (0.5%)	1 (0.5%)	2 (0.5%)	5 (1.3%)
		INCREASE BY 3	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	MONTH 1	DECREASE	0 (0.0%)	21 (5.6%)	13 (6.6%)	23 (6.1%)	19 (4.9%)
		NO CHANGE	14 (77.8%)	301 (79.6%)	145 (73.2%)	286 (75.9%)	300 (76.7%)
		INCREASE BY 1	0 (0.0%)	12 (3.2%)	4 (2.0%)	7 (1.9%)	18 (4.6%)
		INCREASE BY 2	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.8%)	2 (0.5%)
		INCREASE BY 3	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)
	MONTH 2	DECREASE	1 (5.6%)	16 (4.2%)	11 (5.6%)	19 (5.0%)	19 (4.9%)
		NO CHANGE	12 (66.7%)	256 (67.7%)	121 (61.1%)	246 (65.3%)	239 (61.1%)
		INCREASE BY 1	1 (5.6%)	8 (2.1%)	9 (4.5%)	6 (1.6%)	13 (3.3%)
		INCREASE BY 2	0 (0.0%)	2 (0.5%)	1 (0.5%)	3 (0.8%)	1 (0.3%)
		INCREASE BY 3	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	2 (0.5%)
	MONTH 3	DECREASE	1 (5.6%)	22 (5.8%)	15 (7.6%)	25 (6.6%)	26 (6.6%)
		NO CHANGE	12 (66.7%)	314 (83.1%)	154 (77.8%)	307 (81.4%)	317 (81.1%)
		INCREASE BY 1	0 (0.0%)	15 (4.0%)	7 (3.5%)	9 (2.4%)	15 (3.8%)
		INCREASE BY 2	1 (5.6%)	1 (0.3%)	1 (0.5%)	2 (0.5%)	2 (0.5%)
		INCREASE BY 3	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.5%)	1 (0.3%)

³²⁰

^[1] Symptoms were scored on the following scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe

s:\dat\acs\iss2002\sas\programs\t_ocsymp_change 06SEP2002 17:39

Table 35
Summary of Ocular Symptoms Change from Baseline at Specified Visits
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

				Cont	rol			
Symptom [1]	Visit			WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
							72 / 2 483	74 / 7 (%)
BURNING / STINGING	DAY 1	DECREASE		(5.6%)	16 (4.2%)	9 (4.5%)	13 (3.4%)	14 (3.6%)
		NO CHANGE		(88.9%)	305 (80.7%)	153 (77.3%)	295 (78.2%)	303 (77.5%)
		INCREASE BY 1		(0.0%)	46 (12.2%)	27 (13.6%)	48 (12.7%)	53 (13.6%)
		INCREASE BY 2		(0.0%)	5 (1.3%)	4 (2.0%)	12 (3.2%)	12 (3.1%)
		INCREASE BY 3	0	(0.0%)	1 (0.3%)	1 (0.5%)	3 (0.8%)	3 (0.8%)
	WEEK 1	DECREASE	1	(5.6%)	22 (5.8%)	14 (7.1%)	22 (5.8%)	20 (5.1%)
		NO CHANGE	15	(83.3%)	326 (86.2%)	167 (84.3%)	319 (84.6%)	332 (84.9%)
		INCREASE BY 1	1	(5.6%)	15 (4.0%)	7 (3.5%)	15 (4.0%)	22 (5.6%)
		INCREASE BY 2	0	(0.0%)	1 (0.3%)	0 (0.0%)	2 (0.5%)	2 (0.5%)
		INCREASE BY 3	0	(0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MONTH 1	DECREASE	1	(5.6%)	22 (5.8%)	17 (8.6%)	23 (6.1%)	19 (4.9%)
		NO CHANGE		(72.2%)	298 (78.8%)	144 (72.7%)	278 (73.7%)	302 (77.2%)
		INCREASE BY 1		(0.0%)	13 (3.4%)	2 (1.0%)	14 (3.7%)	17 (4.3%)
		INCREASE BY 2		(0.0%)	1 (0.3%)	0 (0.0%)	3 (0.8%)	1 (0.3%)
		INCREASE BY 3		(0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MONTH 2	DECREASE	2	(11.1%)	20 (5.3%)	10 (5.1%)	17 (4.5%)	17 (4.3%)
	2	NO CHANGE		(61.1%)	249 (65.9%)	129 (65.2%)	251 (66.6%)	244 (62.4%)
		INCREASE BY 1		(5.6%)	13 (3.4%)	3 (1.5%)	6 (1.6%)	9 (2.3%)
		INCREASE BY 2		(0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	4 (1.0%)
		INCREASE BY 3		(0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MONTH 3	DECREASE	2	(11.1%)	22 (5.8%)	14 (7.1%)	22 (5.8%)	20 (5.1%)
	HONIA 3	NO CHANGE		(61.1%)	312 (82.5%)	155 (78.3%)	310 (82.2%)	321 (82.1%)
		INCREASE BY 1		(5.6%)	16 (4.2%)	8 (4.0%)	11 (2.9%)	15 (3.8%)
		INCREASE BY 2		(0.0%)	1 (0.3%)	0 (0.0%)	2 (0.5%)	4 (1.0%)
				(0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
		INCREASE BY 3	U	(0.08)	U (U.U8)	0 (0.08)	0 (0.0%)	± (U.3%)

ري دري

^[1] Symptoms were scored on the following scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe

Table 35
Summary of Ocular Symptoms Change from Baseline at Specified Visits
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

			Cont	rol			
Symptom [1]	Visit		WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
TEARING	DAY 1	DECREASE	1 (5.6%)	37 (9.8%)	15 (7.6%)	29 (7.7%)	31 (7.9%)
		NO CHANGE	15 (83.3%)	284 (75.1%)	149 (75.3%)	244 (64.7%)	251 (64.2%)
		INCREASE BY 1	0 (0.0%)	44 (11.6%)	27 (13.6%)	67 (17.8%)	70 (17.9%)
		INCREASE BY 2	1 (5.6%)	8 (2.1%)	2 (1.0%)	24 (6.4%)	24 (6.1%)
		INCREASE BY 3	0 (0.0%)	0 (0.0%)	1 (0.5%)	7 (1.9%)	9 (2.3%)
	WEEK 1	DECREASE	2 (11.1%)	44 (11.6%)	33 (16.7%)	48 (12.7%)	45 (11.5%)
		NO CHANGE	14 (77.8%)	293 (77.5%)	144 (72.7%)	283 (75.1%)	296 (75.7%)
		INCREASE BY 1	1 (5.6%)	26 (6.9%)	8 (4.0%)	23 (6.1%)	31 (7.9%)
		INCREASE BY 2	0 (0.0%)	1 (0.3%)	2 (1.0%)	4 (1.1%)	2 (0.5%)
		INCREASE BY 3	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	2 (0.5%)
	MONTH 1	DECREASE	1 (5.6%)	42 (11.1%)	27 (13.6%)	42 (11.1%)	45 (11.5%)
		NO CHANGE	12 (66.7%)	268 (70.9%)	124 (62.6%)	254 (67.4%)	258 (66.0%)
		INCREASE BY 1	1 (5.6%)	20 (5.3%)	11 (5.6%)	20 (5.3%)	29 (7.4%)
		INCREASE BY 2	0 (0.0%)	4 (1.1%)	1 (0.5%)	3 (0.8%)	6 (1.5%)
		INCREASE BY 3	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	MONTH 2	DECREASE	2 (11.1%)	36 (9.5%)	23 (11.6%)	42 (11.1%)	41 (10.5%)
		NO CHANGE	10 (55.6%)	223 (59.0%)	112 (56.6%)	213 (56.5%)	207 (52.9%)
		INCREASE BY 1	2 (11.1%)	19 (5.0%)	6 (3.0%)	17 (4.5%)	21 (5.4%)
		INCREASE BY 2	0 (0.0%)	3 (0.8%)	1 (0.5%)	2 (0.5%)	4 (1.0%)
		INCREASE BY 3	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
	MONTH 3	DECREASE	1 (5.6%)	52 (13.8%)	24 (12.1%)	54 (14.3%)	57 (14.6%)
		NO CHANGE	11 (61.1%)	274 (72.5%)	141 (71.2%)	270 (71.6%)	276 (70.6%)
		INCREASE BY 1	2 (11.1%)	23 (6.1%)	9 (4.5%)	17 (4.5%)	24 (6.1%)
		INCREASE BY 2	0 (0.0%)	2 (0.5%)	3 (1.5%)	3 (0.8%)	3 (0.8%)
		INCREASE BY 3	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)

CU

^[1] Symptoms were scored on the following scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe

s:\dat\acs\iss2002\sas\programs\t_ocsymp_change 06SEP2002 17:39

Table 35
Summary of Ocular Symptoms Change from Baseline at Specified Visits
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

			Con	trol			
Symptom [1]	Visit		WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
·							
ITCHING	DAY 1	DECREASE	1 (5.6%)	30 (7.9%)	21 (10.6%)	37 (9.8%)	42 (10.7%)
		NO CHANGE	15 (83.3%)	304 (80.4%)	149 (75.3%)	294 (78.0%)	308 (78.8%)
		INCREASE BY 1	1 (5.6%)	38 (10.1%)	22 (11.1%)	34 (9.0%)	32 (8.2%)
		INCREASE BY 2	0 (0.0%)	1 (0.3%)	2 (1.0%)	3 (0.8%)	2 (0.5%)
		INCREASE BY 3	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.8%)	1 (0.3%)
	WEEK 1	DECREASE	1 (5.6%)	39 (10.3%)	20 (10.1%)	37 (9.8%)	44 (11.3%)
		NO CHANGE	15 (83.3%)	297 (78.6%)	150 (75.8%)	295 (78.2%)	297 (76.0%)
		INCREASE BY 1	1 (5.6%)	22 (5.8%)	17 (8.6%)	24 (6.4%)	34 (8.7%)
		INCREASE BY 2	0 (0.0%)	5 (1.3%)	1 (0.5%)	2 (0.5%)	1 (0.3%)
		INCREASE BY 3	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MONTH 1	DECREASE	1 (5.6%)	36 (9.5%)	20 (10.1%)	34 (9.0%)	42 (10.7%)
		NO CHANGE	12 (66.7%)	273 (72.2%)	129 (65.2%)	268 (71.1%)	275 (70.3%)
		INCREASE BY 1	1 (5.6%)	24 (6.3%)	12 (6.1%)	17 (4.5%)	20 (5.1%)
		INCREASE BY 2	0 (0.0%)	1 (0.3%)	2 (1.0%)	0 (0.0%)	1 (0.3%)
		INCREASE BY 3	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	MONTH 2	DECREASE	1 (5.6%)	40 (10.6%)	15 (7.6%)	27 (7.2%)	36 (9.2%)
		NO CHANGE	10 (55.6%)	216 (57.1%)	108 (54.5%)	227 (60.2%)	218 (55.8%)
		INCREASE BY 1	3 (16.7%)	25 (6.6%)	18 (9.1%)	19 (5.0%)	16 (4.1%)
		INCREASE BY 2	0 (0.0%)	1 (0.3%)	1 (0.5%)	2 (0.5%)	4 (1.0%)
		INCREASE BY 3	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MONTH 3	DECREASE	2 (11.1%)	47 (12.4%)	23 (11.6%)	35 (9.3%)	53 (13.6%)
		NO CHANGE	6 (33.3%)	283 (74.9%)	138 (69.7%)	290 (76.9%)	279 (71.4%)
		INCREASE BY 1	5 (27.8%)	18 (4.8%)	14 (7.1%)	18 (4.8%)	27 (6.9%)
		INCREASE BY 2	1 (5.6%)	3 (0.8%)	2 (1.0%)	2 (0.5%)	1 (0.3%)
		INCREASE BY 3	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	1 (0.3%)

³³ 73 73

^[1] Symptoms were scored on the following scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe

Table 35
Summary of Ocular Symptoms Change from Baseline at Specified Visits
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

			Cont	rol			
Symptom [1]	Visit		WW	Saline	7.5 IU Vitrase	5\$ IU Vitrase	75 IU Vitrase
FOREIGN BODY SENSATION	DAY 1	DECREASE	2 (11.1%)	14 (3.7%)	10 (5.1%)	14 (3.7%)	17 (4.3%)
		NO CHANGE	15 (83.3%)	293 (77.5%)	148 (74.7%)	261 (69.2%)	273 (69.8%)
		INCREASE BY 1	0 (0.0%)	55 (14.6%)	27 (13.6%)	78 (20.7%)	74 (18.9%)
		INCREASE BY 2	0 (0.0%)	10 (2.6%)	6 (3.0%)	16 (4.2%)	17 (4.3%)
		INCREASE BY 3	0 (0.0%)	1 (0.3%)	3 (1.5%)	2 (0.5%)	4 (1.0%)
	WEEK 1	DECREASE	2 (11.1%)	21 (5.6%)	21 (10.6%)	33 (8.8%)	24 (6.1%)
		NO CHANGE	15 (83.3%)	319 (84.4%)	157 (79.3%)	293 (77.7%)	315 (80.6%)
		INCREASE BY 1	0 (0.0%)	22 (5.8%)	8 (4.0%)	28 (7.4%)	33 (8.4%)
		INCREASE BY 2	0 (0.0%)	1 (0.3%)	2 (1.0%)	4 (1.1%)	2 (0.5%)
		INCREASE BY 3	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	2 (0.5%)
	MONTH 1	DECREASE	3 (16.7%)	19 (5.0%)	21 (10.6%)	35 (9.3%)	27 (6.9%)
		NO CHANGE	10 (55.6%)	290 (76.7%)	132 (66.7%)	261 (69.2%)	289 (73.9%)
		INCREASE BY 1	1 (5.6%)	24 (6.3%)	8 (4.0%)	21 (5.6%)	20 (5.1%)
		INCREASE BY 2	0 (0.0%)	1 (0.3%)	2 (1.0%)	2 (0.5%)	3 (0.8%)
		INCREASE BY 3	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MONTH 2	DECREASE	4 (22.2%)	21 (5.6%)	14 (7.1%)	29 (7.7%)	22 (5.6%)
		NO CHANGE	9 (50.0%)	244 (64.6%)	122 (61.6%)	233 (61.8%)	235 (60.1%)
		INCREASE BY 1	1 (5.6%)	14 (3.7%)	6 (3.0%)	13 (3.4%)	14 (3.6%)
		INCREASE BY 2	0 (0.0%)	2 (0.5%)	0 (0.0%)	0 (0.0%)	3 (0.8%)
		INCREASE BY 3	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MONTH 3	DECREASE	4 (22.2%)	28 (7,4%)	23 (11.6%)	37 (9.8%)	37 (9.5%)
		NO CHANGE	10 (55.6%)	307 (81.2%)	143 (72.2%)	292 (77.5%)	295 (75.4%)
		INCREASE BY 1	0 (0.0%)	15 (4.0%)	8 (4.0%)	14 (3.7%)	28 (7.2%)
		INCREASE BY 2	0 (0.0%)	2 (0.5%)	2 (1.0%)	2 (0.5%)	1 (0.3%)
		INCREASE BY 3	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	0 (0.0%)

⁽¹⁾ (1)

^[1] Symptoms were scored on the following scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe

s:\dat\acs\iss2002\sas\programs\t_ocsymp_change 06SEP2002 17:39

Table 35
Summary of Ocular Symptoms Change from Baseline at Specified Visits
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

			c	ontrol	_		
Symptom [1]	Visit		ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
					· 		
РНОТОРНОВІА	DAY 1	DECREASE	2 (11.1%	30 (7.9%)	28 (14.1%)	26 (6.9%)	33 (8.4%)
		NO CHANGE	11 (61.1%) 321 (84.9%)	151 (76.3%)	299 (79.3%)	286 (73.1%)
		INCREASE BY 1	2 (11.1%) 20 (5.3%)	10 (5.1%)	32 (8.5%)	39 (10.0%)
		INCREASE BY 2	1 (5.6%) 2 (0.5%)	1 (0.5%)	11 (2.9%)	17 (4.3%)
		INCREASE BY 3	0 (0.0%) 0 (0.0%)	2 (1.0%)	3 (0.8%)	7 (1.8%)
	WEEK 1	DECREASE	3 (16.7%) 29 (7.7%)	28 (14.1%)	42 (11.1%)	31 (7.9%)
		NO CHANGE	11 (61.1%) 310 (82.0%)	147 (74.2%)	279 (74.0%)	304 (77.7%)
		INCREASE BY 1	1 (5.6%) 24 (6.3%)	9 (4.5%)	35 (9.3%)	31 (7.9%)
		INCREASE BY 2	1 (5.6%) 1 (0.3%)	1 (0.5%)	2 (0.5%)	5 (1.3%)
		INCREASE BY 3	0 (0.0%) 0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.3%)
	MONTH 1	DECREASE	3 (16.7%) 30 (7.9%)	30 (15.2%)	41 (10.9%)	35 (9.0%)
		NO CHANGE	10 (55.6%) 277 (73.3%)	112 (56.6%)	253 (67.1%)	275 (70.3%)
		INCREASE BY 1	0 (0.0%) 20 (5.3%)	15 (7.6%)	17 (4.5%)	22 (5.6%)
		INCREASE BY 2	0 (0.0%) 4 (1.1%)	3 (1.5%)	7 (1.9%)	3 (0.8%)
		INCREASE BY 3	0 (0.0%) 3 (0.8%)	1 (0.5%)	1 (0.3%)	0 (0.0%)
	MONTH 2	DECREASE	3 (16.7%) 33 (8.7%)	25 (12.6%)	40 (10.6%)	30 (7.7%)
		NO CHANGE	8 (44.4%) 220 (58.2%)	99 (50.0%)	217 (57.6%)	218 (55.8%)
		INCREASE BY 1	1 (5.6%) 23 (6.1%)	13 (6.6%)	13 (3.4%)	15 (3.8%)
		INCREASE BY 2	1 (5.6%) 4 (1.1%)	2 (1.0%)	3 (0.8%)	6 (1.5%)
		INCREASE BY 3	0 (0.0%) 2 (0.5%)	1 (0.5%)	2 (0.5%)	2 (0.5%)
	MONTH 3	DECREASE	3 (16.7%	44 (11.6%)	30 (15.2%)	52 (13.8%)	53 (13.6%)
		NO CHANGE	10 (55.6%	288 (76.2%)	121 (61.1%)	266 (70.6%)	280 (71.6%)
		INCREASE BY 1	0 (0.0%	16 (4.2%)	17 (8.6%)	18 (4.8%)	20 (5.1%)
		INCREASE BY 2	0 (0.0%	4 (1.1%)	5 (2.5%)	5 (1.3%)	6 (1.5%)
		INCREASE BY 3	0 (0.0%	0 (0.0%)	2 (1.0%)	3 (0.8%)	0 (0.0%)

³³³

^[1] Symptoms were scored on the following scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe

Table 35
Summary of Ocular Symptoms Change from Baseline at Specified Visits
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

			Cont:	rol			
Symptom [1]	Visit		WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
PHOTOPSIA	DAY 1	DECREASE	0 (0.0%)	15 (4.0%)	5 (2.5%)	7 (1.9%)	12 (3.1%)
		NO CHANGE	5 (27.8%)	323 (85.4%)	142 (71.7%)	313 (83.0%)	313 (80.1%)
		INCREASE BY 1	0 (0.0%)	3 (0.8%)	5 (2.5%)	8 (2.1%)	8 (2.0%)
		INCREASE BY 2	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	3 (0.8%)
		INCREASE BY 3	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.8%)
	WEEK 1	DECREASE	0 (0.0%)	20 (5.3%)	9 (4.5%)	6 (1.6%)	11 (2.8%)
		NO CHANGE	5 (27.8%)	305 (80.7%)	134 (67.7%)	297 (78.8%)	302 (77.2%)
		INCREASE BY 1	0 (0.0%)	9 (2.4%)	6 (3.0%)	11 (2.9%)	10 (2.6%)
		INCREASE BY 2	0 (0.0%)	0 (0.0%)	1 (0.5%)	3 (0.8%)	4 (1.0%)
		INCREASE BY 3	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MONTH 1	DECREASE	0 (0.0%)	15 (4.0%)	8 (4.0%)	8 (2.1%)	11 (2.8%)
		NO CHANGE	3 (16.7%)	289 (76.5%)	117 (59.1%)	264 (70.0%)	274 (70.1%)
		INCREASE BY 1	0 (0.0%)	5 (1.3%)	4 (2.0%)	14 (3.7%)	13 (3.3%)
		INCREASE BY 2	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (1.3%)	4 (1.0%)
		INCREASE BY 3	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MONTH 2	DECREASE	0 (0.0%)	11 (2.9%)	5 (2.5%)	8 (2.1%)	12 (3.1%)
		NO CHANGE	4 (22.2%)	242 (64.0%)	101 (51.0%)	226 (59.9%)	225 (57.5%)
		INCREASE BY 1	0 (0.0%)	6 (1.6%)	7 (3.5%)	11 (2.9%)	6 (1.5%)
		INCREASE BY 2	0 (0.0%)	2 (0.5%)	1 (0.5%)	1 (0.3%)	3 (0.8%)
		INCREASE BY 3	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	MONTH 3	DECREASE	0 (0.0%)	19 (5.0%)	10 (5.1%)	12 (3.2%)	14 (3.6%)
		NO CHANGE	3 (16.7%)	296 (78.3%)	125 (63.1%)	283 (75.1%)	290 (74.2%)
		INCREASE BY 1	0 (0.0%)	8 (2.1%)	8 (4.0%)	10 (2.7%)	10 (2.6%)
		INCREASE BY 2	0 (0.0%)	1 (0.3%)	1 (0.5%)	0 (0.0%)	4 (1.0%)
		INCREASE BY 3	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	1 (0.3%)

³³⁵

^[1] Symptoms were scored on the following scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe

Table 35
Summary of Ocular Symptoms Change from Baseline at Specified Visits
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

			С	ontrol			
Symptom [1]	Visit		WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
		· • • • • • • • • • • • • • • • • • • •					
FLOATERS	DAY 1	DECREASE	5 (27.8%) 56 (14.8%)	25 (12.6%)	40 (10.6%)	45 (11.5%)
		NO CHANGE	11 (61.1%) 306 (81.0%)	147 (74.2%)	306 (81.2%)	301 (77.0%)
		INCREASE BY 1	1 (5.6%	9 (2.4%)	14 (7.1%)	21 (5.6%)	28 (7.2%)
		INCREASE BY 2	0 (0.0%) 2 (0.5%)	3 (1.5%)	4 (1.1%)	6 (1.5%)
		INCREASE BY 3	0 (0.0%	0 (0.0%)	5 (2.5%)	0 (0.0%)	5 (1.3%)
	WEEK 1	DECREASE	5 (27.8%) 60 (15.9%)	45 (22.7%)	68 (18.0%)	67 (17.1%)
		NO CHANGE	11 (61.1%) 277 (73.3%)	120 (60.6%)	255 (67.6%)	268 (68.5%)
		INCREASE BY 1	1 (5.6%) 20 (5.3%)	17 (8.6%)	27 (7.2%)	30 (7.7%)
		INCREASE BY 2	0 (0.0%	7 (1.9%)	3 (1.5%)	6 (1.6%)	7 (1.8%)
		INCREASE BY 3	0 (0.0%	0 (0.0%)	3 (1.5%)	2 (0.5%)	3 (0.8%)
	MONTH 1	DECREASE	6 (33.3%) 76 (20.1%)	35 (17.7%)	68 (18.0%)	72 (18.4%)
		NO CHANGE	7 (38.9%) 234 (61.9%)	95 (48.0%)	213 (56.5%)	220 (56.3%)
		INCREASE BY 1	0 (0.0%) 20 (5.3%)	23 (11.6%)	29 (7.7%)	34 (8.7%)
		INCREASE BY 2	0 (0.0%) 3 (0.8%)	7 (3.5%)	7 (1.9%)	13 (3.3%)
		INCREASE BY 3	1 (5.6%	1 (0.3%)	3 (1.5%)	2 (0.5%)	0 (0.0%)
	MONTH 2	DECREASE	4 (22.2%) 72 (19.0%)	37 (18.7%)	65 (17.2%)	58 (14.8%)
		NO CHANGE	8 (44.4%) 191 (50.5%)	80 (40.4%)	172 (45.6%)	187 (47.8%)
		INCREASE BY 1	1 (5.6%) 17 (4.5%)	23 (11.6%)	30 (8.0%)	21 (5.4%)
		INCREASE BY 2	0 (0.0%) 1 (0.3%)	2 (1.0%)	5 (1.3%)	8 (2.0%)
		INCREASE BY 3	1 (5.6%	1 (0.3%)	0 (0.0%)	3 (0.8%)	0 (0.0%)
	MONTH 3	DECREASE	7 (38.9%) 95 (25.1%)	52 (26.3%)	81 (21.5%)	91 (23.3%)
		NO CHANGE	7 (38.9%) 229 (60.6%)	104 (52.5%)	220 (58.4%)	232 (59.3%)
		INCREASE BY 1	0 (0.0%) 19 (5.0%)	15 (7.6%)	35 (9.3%)	29 (7.4%)
		INCREASE BY 2	0 (0.0%	7 (1.9%)	3 (1.5%)	6 (1.6%)	7 (1.8%)
		INCREASE BY 3	0 (0.0%	1 (0.3%)	3 (1.5%)	3 (0.8%)	2 (0.5%)

³³⁶

^[1] Symptoms were scored on the following scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe

Page 1 of 1

ISTA Pharmaceuticals, Inc. Integrated Summary of Safety

Table 36.1 Summary of Anterior Chamber Signs Post-Treatment All Studies by Treatment Safety Population

Hemorrhage Clearance Studies								Other Indications		
	Cont	rol			Vitrase			Vitrase	Saline	Other
Sign	ww	Saline	7.5 IU	37.5 IU	55 IU	75 IU	Total Vitrase	50-500 IU	Control	Active [1]
NUMBER OF PATIENTS	18	417	327	130	377	609	1443	84	21	70
CELLS FLARE	4 (22.2%) 4 (22.2%)	139 (33.3%) 119 (28.5%)	198 (60.6%) 176 (53.8%)	118 (90.8%) 103 (79.2%)	229 (60.7%) 184 (48.8%)	449 (73.7%) 361 (59.3%)	994 (68.9%) 824 (57.1%)	39 (46.4%) 30 (35.7%)	3 (14.3%) 4 (19.0%)	29 (41.4%) 24 (34.3%)

³³⁷

^[1] Other Active treatments include SF6 (PVD-01-08961X) and ACS-101C (COR-01-08961X). Patients who received both Vitrase and another active study treatment are included in both groups.

s:\dat\acs\iss2002\sas\programs\t_antchamb_treat 06SEP2002 17:39

Table 36.2 Summary of Anterior Chamber Signs Post-Treatment All Studies by Study for Vitrase Groups Only Safety Population

Sign	Phase I [1]	V-01-VIT-08961X	ACS202-HYA-001US	ACS203-HYA-001MEX	VIT-02-08961X	VIT-03-08961X	Other Indications [2]
NUMBER OF PATIENTS	68	31	153	225	602	364	84
CELLS FLARE	45 (66.2%) 45 (66.2%)	31 (100%) 28 (90.3%)	144 (94.1%) 136 (88.9%)	186 (82.7%) 143 (63.6%)	412 (68.4%) 352 (58.5%)	176 (48.4%) 120 (33.0%)	39 (46.4%) 30 (35.7%)

^[1] Includes ACS201-HYA-001A, ACS201-HYA-002A, Probe Study [2] Includes PVD-01-08961X, COR-01-08961X, COP-01-08961X



Table 36.3

Summary of Anterior Chamber Signs Post-Treatment
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

	Cont:	rol				
Sign	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase	
NUMBER OF PATIENTS	18	378	198	377	391	
CELLS	4 (22.2%)	110 (29.1%)	101 (51.0%)	229 (60.7%)	258 (66.0%)	
FLARE	4 (22.2%)	110 (29.1%)	93 (47.0%)	184 (48.8%)	195 (49.9%)	

Table 36.4 Summary of Anterior Chamber Signs Post-Treatment PVD Study (PVD-01-08961X) by Treatment Safety Population

Sign	Vitrase 75 IU	SF6	Vitrase 75 IU + SF6	Saline
NUMBER OF PATIENTS	15	15	14	16
CELLS FLARE	8 (53.3%) 12 (80.0%)	3 (20.0%) 6 (40.0%)	9 (64.3%) 11 (78.6%)	2 (12.5%) 4 (25.0%)

Table 37
Summary of Anterior Chamber Signs Maximum Severity Post-Treatment
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

Sign	Max. Severity Post Treatment	Contro WW	Saline	7.5 IU Vitrase	55 IV Vitrase	75 IU Vitrase
NUMBER OF PATIENTS		18	378	198	377	391
CELLS	MILD MODERATE SEVERE HYPOPYON	4 (22.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	76 (20.1%) 23 (6.1%) 10 (2.6%) 1 (0.3%)	71 (35.9%) 21 (10.6%) 8 (4.0%) 1 (0.5%)	104 (27.6%) 78 (20.7%) 42 (11.1%) 5 (1.3%)	95 (24.3%) 100 (25.6%) 41 (10.5%) 22 (5.6%)
FLARE	MILD MODERATE SEVERE HYPOPYON	3 (16.7%) 1 (5.6%) 0 (0.0%) 0 (0.0%)	90 (23.8%) 16 (4.2%) 4 (1.1%) 0 (0.0%)	71 (35.9%) 16 (8.1%) 6 (3.0%) 0 (0.0%)	121 (32.1%) 46 (12.2%) 17 (4.5%) 0 (0.0%)	112 (28.6%) 53 (13.6%) 29 (7.4%) 1 (0.3%)

Table 38

Summary of Anterior Chamber Signs Maximum Severity Post-Treatment Stratified by Baseline Severity Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment Safety Population

	Baseline	Max. Severity _ Post Treatment	Cont	rol			
Sign	Severity		ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
NUMBER OF PATIENTS			18	378	198	377	391
CELLS	NONE	NONE MILD MODERATE SEVERE HYPOPYON	13 (72.2%) 4 (22.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	267 (70.6%) 72 (19.0%) 18 (4.8%) 8 (2.1%) 1 (0.3%)	96 (48.5%) 68 (34.3%) 20 (10.1%) 8 (4.0%) 1 (0.5%)	148 (39.3%) 97 (25.7%) 75 (19.9%) 41 (10.9%) 5 (1.3%)	132 (33.8%) 90 (23.0%) 91 (23.3%) 37 (9.5%) 21 (5.4%)
	MII.D	NONE MILD MODERATE SEVERE HYPOPYON	1 (5.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	1 (0.3%) 4 (1.1%) 5 (1.3%) 2 (0.5%) 0 (0.0%)	0 (0.0%) 3 (1.5%) 1 (0.5%) 0 (0.0%) 0 (0.0%)	0 (0.0%) 7 (1.9%) 3 (0.8%) 1 (0.3%) 0 (0.0%)	1 (0.3%) 5 (1.3%) 9 (2.3%) 4 (1.0%) 0 (0.0%)
	MODERATE	NONE MILD MODERATE SEVERE HYPOPYON	0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%)
	SEVERE	NONE MILD MODERATE SEVERE HYPOPYON	0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	O (0.0%) O (0.0%) O (0.0%) O (0.0%) O (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)

Table 38

Summary of Anterior Chamber Signs Maximum Severity Post-Treatment Stratified by Baseline Severity Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment Safety Population

	Baseline	Max. Severity	Cont:	rol			
Sign	Severity	Post Treatment	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
	*******		10 (66 78)	267 (70.6%)	104 (52.5%)	193 (51.2%)	196 (50.1%)
FLARE	NONE	NONE	12 (66.7%)	84 (22.2%)	68 (34.3%)	118 (31.3%)	103 (26.3%)
		MILD	3 (16.7%)		•	43 (11.4%)	48 (12.3%)
		MODERATE	1 (5.6%)	13 (3.4%)	16 (8.1%)		27 (6.9%)
		SEVERE	0 (0.0%)	4 (1.1%)	6 (3.0%)	16 (4.2%)	
		HYPOPYON	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	MILD	NONE	2 (11.1%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		MILD	0 (0.0%)	6 (1.6%)	3 (1.5%)	3 (0.8%)	9 (2.3%)
		MODERATE	0 (0.0%)	3 (0.8%)	0 (0.0%)	2 (0.5%)	5 (1.3%)
		SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
		HYPOPYON	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MODERATE	NONE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	0 (0.0%)
		SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
		HYPOPYON	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	SEVERE	NONE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	**·	MILD	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		MODERATE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		SEVERE	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		HYPOPYON	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		HIFOFION	0 (0.00)	0 (0.00)	- (• • • • • • • • • • • • • • • • • •	- (

Table 39

Summary of Anterior Chamber Signs Change from Baseline at Specified Visits
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

			Cont	rol				
Sign	Visit	•	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase	
		NUMBER OF PATIENTS	18	378	198	377	391	
CELLS	DAY 1	DECREASE	1 (5.6%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	1 (0.3%)	
		NO CHANGE	16 (88.9%)	295 (78.0%)	118 (59.6%)	171 (45.4%)	142 (36.3%)	
		INCREASE BY 1	0 (0.0%)	59 (15.6%)	59 (29.8%)	88 (23.3%)	94 (24.0%)	
		INCREASE BY 2	0 (0.0%)	14 (3.7%)	13 (6.6%)	68 (18.0%)	94 (24.0%)	
		INCREASE BY 3	0 (0.0%)	4 (1.1%)	3 (1.5%)	40 (10.6%)	34 (8.7%)	
		INCREASE BY 4	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (0.8%)	20 (5.1%)	
	WEEK 1	DECREASE	1 (5.6%)	2 (0.5%)	1 (0.5%)	5 (1.3%)	8 (2.0%)	
		NO CHANGE	16 (88.9%)	325 (86.0%)	153 (77.3%)	277 (73.5%)	279 (71.4%)	
		INCREASE BY 1	0 (0.0%)	27 (7.1%)	24 (12.1%)	56 (14.9%)	74 (18.9%)	
		INCREASE BY 2	0 (0.0%)	5 (1.3%)	8 (4.0%)	18 (4.8%)	12 (3.1%)	
		INCREASE BY 3	0 (0.0%)	4 (1.1%)	2 (1.0%)	1 (0.3%)	2 (0.5%)	
		INCREASE BY 4	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	1 (0.3%)	
	MONTH 1	DECREASE	0 (0.0%)	6 (1.6%)	2 (1.0%)	4 (1.1%)	17 (4.3%)	
	••••	NO CHANGE	12 (66.7%)	310 (82.0%)	152 (76.8%)	291 (77.2%)	304 (77.7%)	
		INCREASE BY 1	2 (11.1%)	13 (3.4%)	7 (3.5%)	17 (4.5%)	16 (4.1%)	
		INCREASE BY 2	0 (0.0%)	3 (0.8%)	2 (1.0%)	6 (1.6%)	2 (0.5%)	
		INCREASE BY 3	0 (0.0%)	2 (0.5%)	0 (0.0%)	1 (0.3%)	0 (0.0%)	
		INCREASE BY 4	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	1 (0.3%)	
	MONTH 2	DECREASE	1 (5.6%)	8 (2.1%)	1 (0.5%)	1 (0.3%)	11 (2.8%)	
		NO CHANGE	10 (55.6%)	262 (69.3%)	134 (67.7%)	266 (70.6%)	253 (64.7%)	
		INCREASE BY 1	3 (16.7%)	9 (2.4%)	4 (2.0%)	5 (1.3%)	8 (2.0%)	
		INCREASE BY 2	0 (0.0%)	2 (0.5%)	1 (0.5%)	3 (0.8%)	2 (0.5%)	
		INCREASE BY 3	0 (0.0%)	1 (0.3%)	2 (1.0%)	0 (0.0%)	` 1 (0.3%)	
		INCREASE BY 4	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
	MONTH 3	DECREASE	1 (5.6%)	6 (1.6%)	2 (1.0%)	7 (1.9%)	14 (3.6%)	
		NO CHANGE	11 (61.1%)	331 (87.6%)	165 (83.3%)	328 (87.0%)	334 (85.4%)	
		INCREASE BY 1	2 (11.1%)	9 (2.4%)	7 (3.5%)	6 (1.6%)	8 (2.0%)	
		INCREASE BY 2	0 (0.0%)	4 (1.1%)	3 (1.5%)	4 (1.1%)	3 (0.8%)	
		INCREASE BY 3	0 (0.0%)	2 (0.5%)	0 (0.0%)	0 (0.0%)	1 (0.3%)	
		INCREASE BY 4	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	

³⁴⁴

^[1] Anterior Chamber signs were scored on the following scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Hypopyon

s:\dat\acs\iss2002\sas\programs\t_antchamb_change 06SEP2002 17:40

Table 39
Summary of Anterior Chamber Signs Change from Baseline at Specified Visits
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

			Cont:	rol			
Sign	Visit		ww	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
						·	
FLARE	DAY 1	DECREASE	2 (11.1%)	2 (0.5%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
		NO CHANGE	15 (83.3%)	298 (78.8%)	132 (66.7%)	207 (54.9%)	210 (53.7%)
		INCREASE BY 1	0 (0.0%)	64 (16.9%)	53 (26.8%)	110 (29.2%)	104 (26.6%)
		INCREASE BY 2	0 (0.0%)	7 (1.9%)	8 (4.0%)	37 (9.8%)	44 (11.3%)
		INCREASE BY 3	0 (0.0%)	1 (0.3%)	1 (0.5%)	15 (4.0%)	25 (6.4%)
		INCREASE BY 4	0 (0.0%)	0 (0.0%)		0 (0.0%)	1 (0.3%)
							- ()
	WEEK 1	DECREASE	- 1	2 (0.5%)		2 (0.5%)	6 (1.5%)
		NO CHANGE	15 (83.3%)	329 (87.0%)	158 (79.8%)	298 (79.0%)	308 (78.8%)
		INCREASE BY 1	0 (0.0%)	29 (7.7%)	24 (12.1%)	48 (12.7%)	52 (13.3%)
		INCREASE BY 2	0 (0.0%)	2 (0.5%)	6 (3.0%)	9 (2.4%)	8 (2.0%)
		INCREASE BY 3	0 (0.0%)	1 (0.3%)	0 (0.0%)	1 (0.3%)	1 (0.3%)
		INCREASE BY 4	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
	MONTH 1	DECREASE	1 (5.6%)	4 (1.1%)	1 (0.5%)	2 (0.5%)	13 (3.3%)
	HOWIN	NO CHANGE	13 (72.2%)	317 (83.9%)	156 (78.8%)	295 (78.2%)	316 (80.8%)
		INCREASE BY 1	0 (0.0%)	12 (3.2%)	4 (2.0%)	18 (4.8%)	9 (2.3%)
		INCREASE BY 2	0 (0.0%)	0 (0.0%)	3 (1.5%)	4 (1.1%)	2 (0.5%)
		INCREASE BY 3	0 (0.0%)	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		INCREASE BY 4	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		INCREASE DI 4	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.04)	0 (0.007
	MONTH 2	DECREASE	2 (11.1%)	7 (1.9%)	1 (0.5%)		11 (2.8%)
		NO CHANGE	9 (50.0%)	269 (71.2%)	133 (67.2%)	268 (71.1%)	255 (65.2%)
		INCREASE BY 1	3 (16.7%)	5 (1.3%)	5 (2.5%)	4 (1.1%)	6 (1.5%)
		INCREASE BY 2	0 (0.0%)	0 (0.0%)	1 (0.5%)	1 (0.3%)	3 (0.8%)
		INCREASE BY 3	0 (0.0%)	1 (0.3%)	2 (1.0%)	0 (0.0%)	0 (0.0%)
		INCREASE BY 4	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	MONTH 3	DECREASE	2 (11.1%)	6 (1.6%)	2 (1.0%)	5 (1.3%)	11 (2.8%)
		NO CHANGE	10 (55.6%)	338 (89.4%)	168 (84.8%)	334 (88.6%)	342 (87.5%)
		INCREASE BY 1	1 (5.6%)	7 (1.9%)	6 (3.0%)	5 (1.3%)	4 (1.0%)
		INCREASE BY 2	1 (5.6%)	1 (0.3%)	1 (0.5%)	1 (0.3%)	3 (0.8%)
		INCREASE BY 3	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		INCREASE BY 4	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		THOUGHOU DI 4	0 (0.00)	0 (0.00)	- (0.00)	- (0.00,	- (,

³⁴⁵

^[1] Anterior Chamber signs were scored on the following scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Hypopyon

Table 40.1

Summary of Minimum and Maximum Intraocular Pressure Post-Treatment
All Studies by Treatment

Safety Population

			Hemorrh	age Clearance	Studies			Ot	her Indicatio	ns
	Cor	trol			Vitrase					
IOP (mmHg)	ww	Saline	7.5 IU	37.5 IU	55 IU	75 IU	Total Vitrase	Vitrase 50-500 IU	Saline Control	Other Active [1]
NUMBER OF PATIENTS	18	417	327	130	377	609	1443	84	21	70
MINIMUM IOP										
<1	0 (0.0%)	2 (0.5%)	3 (0.9%)	0 (0.0%)	2 (0.5%)	3 (0.5%)	8 (0.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
1 - <3	0 (0.0%)		2 (0.6%)	0 (0.0%)	2 (0.5%)	4 (0.7%)	8 (0.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
3 - <6	1 (5.6%)	1 (0.2%)	7 (2.1%)	3 (2.3%)	3 (0.8%)	12 (2.0%)	25 (1.7%)	1 (1.2%)	0 (0.0%)	0 (0.0%)
>=6	17 (94.4%)	· ·	315 (96.3%)	127 (97.7%)	370 (98.1%)	552 (90.6%)	1364 (94.5%)	83 (98.8%)	21 (100%)	69 (98.6%)
n	18	417	327	130	377	571	1405	84	21	69
Mean (SE)	11.7 (0.8)	12.1 (0.1)	11.3 (0.2)	11.2 (0.3)	11.4 (0.1)	11.1 (0.1)	11.3 (0.1)	9.8 (0.3)	12.5 (0.6)	10.4 (0.3)
Range	3.0 - 16.0	0.0 - 27.0	0.0 - 29.0	4.0 - 24.0	0.0 - 20.0	0.0 - 38.0	0.0 - 38.0	5.0 - 16.0	8.0 - 16.0	6.0 - 16.0
MAXIMUM IOP										
<=23	17 (94.4%)	380 (91.1%)	292 (89.3%)	116 (89.2%)	349 (92.6%)	521 (85.6%)	1278 (88.6%)	84 (100%)	20 (95.2%)	69 (98.6%)
>23 - 30	1 (5.6%	24 (5.8%)	20 (6.1%)	10 (7.7%)	22 (5.8%)	36 (5.9%)	88 (6.1%)	0 (0.0%)	1 (4.8%)	0 (0.0%)
>30 - 35	0 (0.0%	5 (1.2%)	3 (0.9%)	1 (0.8%)	3 (0.8%)	4 (0.7%)	11 (0.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
>35 - 40	0 (0.0%	1 (0.2%)	4 (1.2%)	2 (1.5%)	2 (0.5%)	4 (0.7%)	12 (0.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
>40 - 50	0 (0.0%	3 (0.7%)	4 (1.2%)	0 (0.0%)	1 (0.3%)	2 (0.3%)	7 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
>50 - 60	0 (0.0%		2 (0.6%)	1 (0.8%)	0 (0.0%)	1 (0.2%)	4 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
>60	0 (0.0%			0 (0.0%)	0 (0.0%)	3 (0.5%)	5 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
n	18	417	327	130	377	571	1405	84	21	69
Mean (SE)	17.5 (0.9)	18.6 (0.3)	19.0 (0.4)	18.9 (0.5)	17.8 (0.2)	18.3 (0.2)	18.3 (0.2)	17.0 (0.2)	18.3 (0.5)	17.4 (0.2)
Range	10.0 - 26.0	5.0 - 63.0	10.0 - 68.0	10.0 - 52.0	9.0 - 50.0	5.0 - 65.0	5.0 - 68.0	12.0 - 23.0	14.0 - 24.0	12.0 - 21.0

³⁴⁶

^[1] Other Active treatments include SF6 (PVD-01-08961X) and ACS-101C (COR-01-08961X). Patients who received both Vitrase and another active study treatment are included in both groups.

s:\dat\acs\iss2002\sas\programs\t_iop_treat 06SEP2002 17:40

Table 40.2

Summary of Minimum and Maximum Intraocular Pressure Post-Treatment
All Studies by Study for Vitrase Groups Only
Safety Population

IOP (mmHg)	Phase I [1]	V-01-VIT-08961¥	ACS202-HYA-001US	ACS203-HYA-001MEX	VIT-02-08961X	VIT-03-08961X	Other Indications [2]
NUMBER OF PATIENTS	68	31	153	225	602	364	84
MINIMUM IOP							
<1	1 (1.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (1.0%)	1 (0.3%)	0 (0.0%)
1 - <3	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (1.0%)	2 (0.5%)	0 (0.0%)
3 - <6	0 (0.0%)	0 (0.0%)	4 (2.6%)	5 (2.2%)	11 (1.8%)	5 (1.4%)	1 (1.2%)
>=6	29 (42.6%)	31 (100%)	149 (97.4%)	220 (97.8%)	579 (96.2%)	356 (97.8%)	83 (98.8%)
n	30	31	153	225	602	364	84
Mean (SE)	12.5 (1.2)	10.6 (0.3)	10.9 (0.3)	11.2 (0.2)	11.1 (0.1)	11.6 (0.2)	9.8 (0.3)
Range	0.0 - 38.0	7.0 - 14.0	4.0 - 18.0	4.0 - 18.0	0.0 - 29.0	0.0 - 20.0	5.0 - 16.0
MAXIMUM IOP							
<=23	21 (30.9%)	28 (90.3%)	137 (89.5%)	211 (93.8%)	535 (88.9%)	346 (95.1%)	84 (100%)
>23 - 30	5 (7.4%)	2 (6.5%)	13 (8.5%)	12 (5.3%)	44 (7.3%)	12 (3.3%)	0 (0.0%)
>30 - 35	1 (1.5%)	0 (0.0%)	1 (0.7%)	1 (0.4%)	6 (1.0%)	2 (0.5%)	0 (0.0%)
>35 - 40	1 (1.5%)	1 (3.2%)	1 (0.7%)	1 (0.4%)	6 (1.0%)	2 (0.5%)	0 (0.0%)
>40 - 50	1 (1.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (0.8%)	1 (0.3%)	0 (0.0%)
>50 - 60	1 (1.5%)	0 (0.0%)	1 (0.7%)	0 (0.0%)	2 (0.3%)	0 (0.0%)	0 (0.0%)
>60	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (0.7%)	1 (0.3%)	0 (0.0%)
n	30	31	153	225	602	364	84
Mean (SE)	23.3 (1.8)	19.0 (0.9)	18.1 (0.4)	17.7 (0.3)	19.0 (0.3)	17.3 (0.2)	17.0 (0.2)
Range	11.0 - 58.0	12.0 - 40.0	10.0 - 52.0	10.0 - 37.0	5.0 - 68.0	8.0 - 62.0	12.0 - 23.0

³⁴⁷

^[1] Includes ACS201-HYA-001A, ACS201-HYA-002A, Probe Study

^[2] Includes PVD-01-08961X, COR-01-08961X, COP-01-08961X

Table 40.3

Summary of Minimum and Maximum Intraocular Pressure Post-Treatment

Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment

Safety Population

	Cont	rol				
IOP (mmHg)	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase	
NUMBER OF PATIENTS	18	378	198	377	391	
MINIMUM IOP						
<1	0 (0.0%)	2 (0.5%)	3 (1.5%)	2 (0.5%)	2 (0.5%)	
1 - <3	0 (0.0%)	0 (0.0%)	2 (1.0%)	2 (0.5%)	4 (1.0%)	
3 - <6	1 (5.6%)	1 (0.3%)	5 (2.5%)	3 (0.8%)	8 (2.0%)	
>=6	17 (94.4%)	375 (99.2%)	188 (94.9%)	370 (98.1%)	377 (96.4%)	
n	18	378	198	377	391	
Mean (SE)	11.7 (0.8)	12.1 (0.1)	11.3 (0.2)	11.4 (0.1)	11.2 (0.2)	
Range	3.0 - 16.0	0.0 - 27.0	0.0 - 29.0	0.0 - 20.0	0.0 - 23.0	
MAXIMUM IOP						
<=23	17 (94.4%)	349 (92.3%)	169 (85.4%)	349 (92.6%)	363 (92.8%)	
>23 - 30	1 (5.6%)	18 (4.8%)	15 (7.6%)	22 (5.8%)	19 (4.9%)	
>30 - 35	0 (0.0%)	4 (1.1%)	3 (1.5%)	3 (0.8%)	2 (0.5%)	
>35 - 40	0 (0.0%)	1 (0.3%)	3 (1.5%)	2 (0.5%)	3 (0.8%)	
>40 - 50	0 (0.0%)	3 (0.8%)	4 (2.0%)	1 (0.3%)	1 (0.3%)	
>50 - 60	0 (0.0%)	2 (0.5%)	2 (1.0%)	0 (0.0%)	0 (0.0%)	
>60	0 (0.0%)	1 (0.3%)	2 (1.0%)	0 (0.0%)	3 (0.8%)	
n	18	378	198	377	391	
Mean (SE)			20.2 (0.6)	17.8 (0.2)	18.0 (0.3)	
Range		5.0 - 62.0		9.0 - 50.0	5.0 - 65.0	

Table 40.4

Summary of Minimum and Maximum Intraocular Pressure Post-Treatment
PVD Study (PVD-01-08961X) by Treatment
Safety Population

IOP (mmHg)	Vitrase 75 IU	SF6	Vitrase 75 IU + SF6	Saline
NUMBER OF PATIENTS	15	15	14	16
MINIMUM IOP >=6	15 (100%)	15 (100%)	14 (100%)	16 (100%)
n Mean (SE) Range		15 12.7 (0.6) 9.0 - 16.0	14 11.7 (0.5) 8.0 - 16.0	
MAXIMUM IOP <=23	15 (100%)	15 (100%)	14 (100%)	16 (100%)
n Mean (SE) Range	15 18.1 (0.4) 16.0 - 23.0	15 18.1 (0.2) 17.0 - 21.0	14 18.6 (0.4) 16.0 ~ 21.0	

Table 41.1

Summary of Minimum and Maximum Intraocular Pressure Post-Treatment Change from Baseline
All Studies by Treatment
Safety Population

		_	Hemorrh	age Clearance	Studies			Ot	her Indicatio	ons
	Con	trol			Vitrase_					
IOP (mmHg)	ww	Saline	7.5 IU	37.5 IU	55 IU	75 IU	Total Vitrase	Vitrase 50-500 IU	Saline Control	Other Active [1]
NUMBER OF PATIENTS	18	417	327	130	377	609	1443	84	21	70
BASELINE IOP										
n	17	413	326	130	377	562	1395	84	21	70
Mean (SE)	16.2 (1.0)	15.0 (0.2)	15.0 (0.2)	14.8 (0.3)	14.9 (0.2)	14.8 (0.2)	14.9 (0.1)	14.6 (0.3)	15.2 (0.7)	14.5 (0.3)
Range		4.0 - 28.0		7.0 - 26.0				8.0 - 26.0	8.0 - 20.0	9.0 - 20.0
MINIMUM IOP CHANGE FROM BASELINE										
n	17	413	326	130	377	562	1395	84	21	69
Mean (SE)	-4.8 (0.8)	-2.9 (0.1)	-3.7 (0.2)	-3.6 (0.3)	-3.5 (0.2)	-3.7 (0.1)	-3.7 (0.1)	-4.8 (0.3)	-2.7 (0.9)	-4.1 (0.3)
Range	-12 - 2.0	-15 - 5.0	-22 - 11.0	-14 - 4.0	-19 - 9.0	-19 - 6.0	-22 - 11.0	-17 - 2.0	-9.0 - 4.0	-10 - 2.0
MAXIMUM IOP CHANGE FROM BASELINE										
n	17	413	326	130	377	562	1395	84	21	69
Mean (SE)	0.8 (1.1)	3.5 (0.3)	4.0 (0.4)	4.1 (0.5)	2.8 (0.2)	3.3 (0.2)	3.4 (0.1)	2.4 (0.4)	3.1 (0.8)	2.9 (0.3)
Range	-7.0 - 10.0	-7.0 - 44.0			-13 - 28.0	-10 - 55.0	-18 - 55.0	-11 - 10.9	-3.0 - 12.0	-5.0 - 9.0

³⁵⁰

^[1] Other Active treatments include SF6 (PVD-01-08961X) and ACS-101C (COR-01-08961X). Patients who received both Vitrase and another active study treatment are included in both groups.

Table 41.2

Summary of Minimum and Maximum Intraocular Pressure Post-Treatment Change from Baseline
All Studies by Study for Vitrase Groups Only
Safety Population

IOP (mmHg)	Phase I [1]	V-01-VIT-08961X	ACS202-HYA-001US	ACS203-HYA-001MEX	VIT-02-08961X	VIT-03-08961X	Other Indications [2]
NUMBER OF PATIENTS	68	31	153	225	602	364	84
BASELINE IOP							
n	21	31	153	225	601	364	84
Mean (SE)	18.8 (1.4)	14.4 (0.7)	15.2 (0.3)	14.2 (0.2)	15.0 (0.2)	14.8 (0.2)	14.6 (0.3)
Range	11.0 - 35.0	10.0 - 30.0	7.0 - 26.0	8.5 - 20.0	5.0 - 41.0	6.0 - 32.0	8.0 - 26.0
MINIMUM IOP CHANGE FROM BASELINE							
n	21	31	153	225	601	364	84
Mean (SE)	-6.9 (1.3)	-3.8 (0.6)	-4.3 (0.3)	-3.0 (0.2)	-3.9 (0.2)	-3.2 (0.2)	-4.8 (0.3)
Range	-19 - 4.0	-16 - 0.0	-14 - 3.0	-13 - 6.5	<i>-</i> 22 - 11.0	-18 - 9.0	-17 - 2.0
MAXIMUM IOP CHANGE FROM BASELINE							
n	21	31	153	225	601	364	84
Mean (SE)	3.9 (1.5)	4.6 (1.1)	3.0 (0.4)	3.5 (0.3)	4.0 (0.3)	2.5 (0.2)	2.4 (0.4)
Range	-10 - 19.0	-10 - 24.0	-6.0 - 36.0	-4.0 - 23.0	-18 - 55.0	-6.0 - 45.0	-11 - 10.9

³⁰

^[1] Includes ACS201-HYA-001A, ACS201-HYA-002A, Probe Study

^[2] Includes PVD-01-08961X, COR-01-08961X, COP-01-08961X

Table 41.3

Summary of Minimum and Maximum Intraocular Pressure Post-Treatment Change from Baseline Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment Safety Population

Control						
IOP (mmHg)	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase	
				· · · · · · · · · · · · · · · · · · ·		
NUMBER OF PATIENTS	18	378	198	377	391	
BASELINE IOP						
n	17	378	197	377	391	
Mean (SE)	16.2 (1.0)	15.0 (0.2)	15.4 (0.3)	14.9 (0.2)	14.7 (0.2)	
Range	9.0 - 28.0	4.0 - 28.0	5.0 - 41.0	7.0 - 33.0	5.0 - 32.0	
MINIMUM IOP CHANGE FROM BASELINE						
n	17	378	197	377	391	
Mean (SE)	-4.8 (0.8)	-2.9 (0.2)	-4.2 (0.3)	-3.5 (0.2)	-3.5 (0.2)	
Range	-12 - 2.0	- 15 - 5.0	-22 - 11.0	-19 - 9.0	-17 - 4.0	
MAXIMUM IOP CHANGE FROM BASELINE						
n	17	378	197	377	391	
Mean (SE)	0.8 (1.1)	3.4 (0.3)	4.8 (0.6)	2.8 (0.2)	3.3 (0.3)	
Range	-7.0 - 10.0	-7.0 - 44.0	-18 - 48.0	-13 - 28.0	-6.0 - 55.0	

Table 41.4 Summary of Minimum and Maximum Intraocular Pressure Post-Treatment Change from Baseline All Studies by Treatment Safety Population

IOP (mmHg)	Vitrase 75 IU		Vitrase 75 IU + SF6	Saline
NUMBER OF PATIENTS	15	15	14	16
BASELINE IOP				
n	15	15	14	16
Mean (SE)		15.5 (0.6)	14.4 (0.6)	16.0 (0.6)
Range			11.0 - 18.0	
MINIMUM IOP CHANGE FROM BASELINE				
n	15	15	14	16
Mean (SE)	-3.9 (0.7)	-2.8 (0.7)	-2.7 (0.7)	-2.6 (1.0)
Range	-8.0 - 2.0	-9.0 - 2.0	-8.0 - 0.0	-8.0 - 4.0
MAXIMUM IOP CHANGE FROM BASELINE				
n	15	15	14	16
Mean (SE)	2.1 (0.7)	2.7 (0.6)	4.2 (0.7)	2.5 (0.7)
	-1.0 - 7.0		0.0 - 9.0	

Table 42
Summary of Intraocular Pressure at Specified Visits
Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment
Safety Population

Control							
Visit	IOP (mmHg)	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase	
					·		
NUMBER OF PATIENTS		18	378	198	377	391	
BASELINE	n	17	378	197 15.4 (0.3)	37 7	391	
	Mean (SE)	16.2 (1.0)	15.0 (0.2)	15.4 (0.3)	14.9 (0.2)	14.7 (0.2)	
	Range	9.0 - 28.0	4.0 - 28.0	5.0 - 41.0	7.0 - 33.0	5.0 - 32.0	
DAY 1	n	17	372	194 14.3 (0.3)	371	385	
	Mean (SE)	13.4 (0.8)	14.6 (0.2)	14.3 (0.3)	14.0 (0.2)	14.1 (0.2)	
	Range					2.0 - 38.0	
WEEK 1	n	17	363	188 15.0 (0.4)	357	375	
	Mean (SE)	14.8 (1.0)	15.1 (0.2)	15.0 (0.4)	13.8 (0.2)	13.7 (0.2)	
	Range	6.0 - 21.0	5.0 - 62.0	8.0 - 61.0	6.0 - 29.0	4.0 - 37.0	
MONTH 1	n	14	335	163 15.7 (0.5)	318	339	
	Mean (SE)	14.6 (0.9)	15.1 (0.2)	15.7 (0.5)	14.6 (0.2)	14.0 (0.2)	
	Range	9.0 - 19.0	1.0 - 53.0	6.0 - 60.0	6.0 - 50.0	3.0 - 38.0	
MONTH 2	n	14	282	142	274	274	
	Mean (SE)	14.3 (0.7)		15.7 (0.5)	14.6 (0.2)	14.7 (0.2)	
	Range	10.0 - 18.0	1.0 - 35.0	2.0 - 56.0	4.0 - 36.0	4.0 - 33.0	
MONTH 3		14	353	178	344	361	
	Mean (SE)	13.6 (1.1)	14.9 (0.2)	15.6 (0.5)	14.9 (0.2)	14.6 (0.2)	
			4.0 - 38.0	3.0 - 68.0	6.0 - 40.0	4.0 - 40.0	

Table 43
Summary of Intraocular Pressure Change from Baseline at Specified Visits Primary Phase III Studies: VIT-02-08961X, VIT-03-08961X by Treatment Safety Population

		Cont	rol				
Visit	IOP (mmHg)	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase	
NUMBER OF PATIENTS		18	378	198	377	391	
BASELINE	n	17	378	197 15.4 (0.3)	377	391	
	Mean (SE)	16.2 (1.0)	15.0 (0.2)	15.4 (0.3)	14.9 (0.2)	14.7 (0.2)	
	Range	9.0 - 28.0	4.0 - 28.0	5.0 - 41.0	7.0 - 33.0	5.0 - 32.0	
CHANGE FROM BASELINE							
DAY 1	n	16	372	194	371	385	
	Mean (SE)	-3.2 (0.9)	-0.4 (0.2)	194 -1.2 (0.3)	-1.0 (0.2)	-0.6 (0.2)	
	Range	-9.0 - 2.0	-14 - 25.0	-21 - 15.0	-18 - 15.0	-12 - 21.0	
WEEK 1	n	16	363	188 -0.3 (0.4)	357	375	
	Mean (SE)	-1.6 (1.0)	0.1 (0.2)	-0.3 (0.4)	-1.1 (0.2)	-0.9 (0.2)	
	Range	-9.0 - 5.0	-12 - 44.0	-10 - 43.0	-17 - 9.0	-15 - 12.0	
MONTH 1	n	14	335	163 0.0 (0.5)	318	339	
	,		0.1 (0.2)	0.0 (0.5)	-0.4 (0.2)	-0.7 (0.2)	
	Range	-12 - 6.0	-10 - 41.0	-18 - 45.0	-18 - 20.0	-16 - 14.0	
		1.3	202	140	274	274	
MONTH 2	n Maan (CE)	1.0 / 3.1\	282	142 0.0 (0.5)	-0 3 (0 3)	-0 1 (0 2)	
	Mean (SE)	-1.8 (1.1)	-12 - 12 0	-21 - 34.0	-16 - 16 0	-11 - 21 0	
	kange	-10 - 4.0	-12 - 13.0	-21 - 24.0	-10 - 20.0	11 21.0	
MONTH 3	n	12	353	177	344	361	
PONTH 3	Mean (SR)	-1 7 (1.0)	-0.2 (0.2)	177 0.1 (0.5)	-0.2 (0.2)	-0.1 (0.2)	
	Range	-6.0 - 5.0	-12 - 24.0	-19 - 48.0	-17 - 28.0	-12 - 24.0	
	range.	0.0 5.0					

Table 44
Summary of Intraocular Pressure at Specified Visits
Study V-01-VIT-08961X by Treatment
Safety Population

Visit	IOP (mmHg)	Saline	75 IU Vitrase
NUMBER OF PATIENTS		30	31
BASELINE	n Mean (SE) Range	30 14.9 (0.6) 10.0 - 20.0	
DAY 1	n Mean (SE) Range	30 14.1 (0.6) 10.0 - 22.0	
WEEK 1	n Mean (SE) Range	30 13.6 (0.6) 10.0 - 24.0	31 12.6 (0.4) 10.0 - 18.0
MONTH 1	n Mean (SE) Range	30 14.4 (0.6) 10.0 - 20.0	
MONTH 2	Mean (SE)	29 14.0 (0.7) 8.0 - 28.0	13.4 (0.5)
MONTH 3	n Mean (SE) Range	30 14.3 (0.6) 10.0 - 20.0	13.6 (0.5)

Table 45
Summary of Intraocular Pressure Change from Baseline at Specified Visits
Study V-01-VIT-08961X by Treatment
Safety Population

=			
Visit		Saline	
NUMBER OF PATIENTS		30	31
BASELINE	n Mean (SE) Range	30 14.9 (0.6) 10.0 - 20.0	31 14.4 (0.7) 10.0 - 30.0
CHANGE FROM BASELINE DAY 1	n Mean (SE) Range	30 -0.8 (0.4) -8.0 - 2.0	30 0.8 (0.8) -8.0 - 15.0
WEEK 1		30 -1.2 (0.6) -8.0 - 4.0	
MONTH 1	n Mean (SE) Range	30 -0.5 (0.6) -8.0 - 4.0	31 -0.9 (0.6) -12 - 4.0
MONTH 2	n Mean (SE) Range	29 -0.7 (0.7) -8.0 - 8.0	-1.1 (0.7)
MONTH 3	n Mean (SE) Range	30 -0.5 (0.5) -8.0 - 4.0	31 -0.8 (0.6) -10 - 4.0

Page 1 of 1

Table 46
Incidence of Deaths
All Studies
Safety Population

Study	Number of Deaths	Safety Population	Incidence of Deaths	
	•			
ACS201-HYA-001A	О	14	0.0%	
ACS201-HYA-002A	0	28	0.0%	
PROBE STUDY	0	34	0.0%	
V-01-VIT-08961X	3	61	4.9%	
ACS202-HYA-001US	0	153	0.0%	
ACS203-HYA-001MEX	0	225	0.0%	
VIT-02-08961X (WW)	7	71	9.9%	
VIT-02-08961X	33	740	4.5%	
VIT-03-08961X	28	551	5.1%	
PVD-01-08961X	1	60	1.7%	
COR-01-08961X	0	41	0.0%	
COP-01-08961X	0	30	0.0%	

Page 1 of 1

ISTA Pharmaceuticals, Inc. Integrated Summary of Safety

Table 47
Incidence of Deaths by Treatment
Primary Phase III Studies: VIT-02-08961X and VIT-03-08961X
Safety Population

	Control				
	WW	Saline	7.5 IU Vitrase	55 IU Vitrase	75 IU Vitrase
NUMBER OF PATIENTS	18	378	198	377	391
INCIDENCE OF DEATHS	6 (33.3%)	16 (4.2%)	8 (4.0%)	17 (4.5%)	21 (5.4%)